FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Miller, YE
Keith, RL
AF Miller, York E.
Keith, Robert L.
TI Chemoprevention: EGFR targeted agents
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
C1 [Miller, York E.; Keith, Robert L.] Univ Colorado, Ctr Canc, Denver Vet Affairs Med Ctr, Denver, CO 80262 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD SEP
PY 2009
VL 4
IS 9
BP S190
EP S190
PG 1
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 490JC
UT WOS:000269496000187
ER
PT J
AU Opincariu, LI
Hudish, TM
Merrick, D
Malkoski, S
Cleaver, T
Mozer, AB
Keith, RL
AF Opincariu, Laura, I
Hudish, Tyler M.
Merrick, Daniel
Malkoski, Stephen
Cleaver, Tim
Mozer, Anthony B.
Keith, Robert L.
TI Characterization of pre-malignant dysplasia and squamous cell carcinoma
in the NTCU-induced murine model
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
C1 [Opincariu, Laura, I; Hudish, Tyler M.; Merrick, Daniel; Mozer, Anthony B.; Keith, Robert L.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Malkoski, Stephen; Cleaver, Tim; Keith, Robert L.] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD SEP
PY 2009
VL 4
IS 9
BP S632
EP S633
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 490JC
UT WOS:000269496002039
ER
PT J
AU Ostroff, RM
Brody, EN
Zichi, DA
Miller, Y
Wolf, H
Franklin, W
AF Ostroff, Rachel M.
Brody, Edward N.
Zichi, Dom A.
Miller, York
Wolf, Holly
Franklin, Wilbur
TI Highly multiplexed SLaptamer-based proteomics technology discovers
biomarkers in plasma for the detection of lung cancer
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
C1 [Ostroff, Rachel M.; Brody, Edward N.; Zichi, Dom A.] SomaLogic Inc, Boulder, CO USA.
[Miller, York] Univ Colorado, Ctr Canc, Denver Vet Affairs Med Ctr, Denver, CO 80262 USA.
[Wolf, Holly] Univ Colorado, Ctr Canc, Colorado Sch Publ Hlth, Denver, CO 80262 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD SEP
PY 2009
VL 4
IS 9
BP S511
EP S511
PG 1
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 490JC
UT WOS:000269496001385
ER
PT J
AU Inagami, S
Cohen, DA
Brown, AF
Asch, SM
AF Inagami, Sanae
Cohen, Deborah A.
Brown, Arleen F.
Asch, Steven M.
TI Body Mass Index, Neighborhood Fast Food and Restaurant Concentration,
and Car Ownership
SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE
LA English
DT Article
DE Multilevel; Fast food; BMI; Obesity; Mobility; Neighborhood; Restaurant
ID HEALTHY FOODS; UNITED-STATES; US ADULTS; INSULIN-RESISTANCE; ALCOHOL
OUTLETS; OBESITY; AVAILABILITY; WEIGHT; DISPARITIES; SCHOOLS
AB Eating away from home and particularly fast food consumption have been shown to contribute to weight gain. Increased geographic access to fast food outlets and other restaurants may contribute to higher levels of obesity, especially in individuals who rely largely on the local environment for their food purchases. We examined whether fast food and restaurant concentrations are associated with body mass index and whether car ownership might moderate this association. We linked the 2000 US Census data and information on locations of fast food and other restaurants with the Los Angeles Family and Neighborhood Study database, which consists of 2,156 adults sampled from 63 neighborhoods in Los Angeles County. Multilevel modeling was used to estimate associations between body mass index (BMI), fast food and restaurant concentration, and car ownership after adjustment for individual-level factors and socioeconomic characteristics of residential neighborhoods. A high concentration of local restaurants is associated with BMI. Car owners have higher BMIs than non-car owners; however, individuals who do not own cars and reside in areas with a high concentration of fast food outlets have higher BMIs than non-car owners who live in areas with no fast food outlets, approximately 12 lb more (p = 0.02) for an individual with a height of 5 ft. 5 in. Higher restaurant density is associated with higher BMI among local residents. The local fast food environment has a stronger association with BMI for local residents who do not have access to cars.
C1 [Inagami, Sanae] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA.
[Inagami, Sanae] Univ Pittsburgh, Pittsburgh, PA USA.
[Cohen, Deborah A.] RAND Corp, Santa Monica, CA USA.
[Brown, Arleen F.; Asch, Steven M.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Asch, Steven M.] VA Greater Angeles Healthcare Syst, HSR&D, Los Angeles, CA USA.
RP Inagami, S (reprint author), VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA.
EM sanae.inagami@va.gov; Deborah_Cohen@rand.org; abrown@mednet.ucla.edu;
Steven.Asch@va.gov
RI Loureiro, Nuno/I-6400-2012
OI Loureiro, Nuno/0000-0002-1166-3219
FU PHS HHS [R40MC00303]
NR 44
TC 67
Z9 67
U1 0
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1099-3460
J9 J URBAN HEALTH
JI J. Urban Health
PD SEP
PY 2009
VL 86
IS 5
BP 683
EP 695
DI 10.1007/s11524-009-9379-y
PG 13
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 486KP
UT WOS:000269195200004
PM 19533365
ER
PT J
AU Norton, MC
Piercy, KW
Rabins, PV
Green, RC
Breitner, JCS
Ostbye, T
Corcoran, C
Welsh-Bohmer, KA
Lyketsos, CG
Tschanz, JT
AF Norton, Maria C.
Piercy, Kathleen W.
Rabins, Peter V.
Green, Robert C.
Breitner, John C. S.
Ostbye, Truls
Corcoran, Christopher
Welsh-Bohmer, Kathleen A.
Lyketsos, Constantine G.
Tschanz, JoAnn T.
TI Caregiver-Recipient Closeness and Symptom Progression in Alzheimer
Disease. The Cache County Dementia Progression Study
SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL
SCIENCES
LA English
DT Article; Proceedings Paper
CT 21st Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 14-17, 2008
CL Orlando, FL
SP Amer Assoc Geriat Psychiat
DE Alzheimer's disease; Caregiving; Interpersonal relations
ID PROGNOSTIC-FACTORS; FAMILY CAREGIVERS; BEHAVIOR; DECLINE; IMPACT; CARE;
HOME; INTERVENTION; QUALITY; AD
AB Applying Rusbult's investment model of dyadic relationships, we examined the effect of caregiver-care recipient relationship closeness (RC) on cognitive and functional decline in Alzheimer's disease. After diagnosis, 167 participants completed up to six visits, observed over an average of 20 months. Participants were 64% women, had a mean age of 86 years, and mean dementia duration of 4 years. Caregiver-rated closeness was measured using a six-item scale. In mixed models adjusted for dementia severity, dyads with higher levels of closeness (p <.05) and with spouse caregivers (p =.01) had slower cognitive decline. Effect of higher RC on functional decline was greater with spouse caregivers (p =.007). These findings of attenuated Alzheimer's dementia (AD) decline with closer relationships, particularly with spouse caregivers, are consistent with investment theory. Future interventions designed to enhance the caregiving dyadic relationship may help slow decline in AD.
C1 [Norton, Maria C.; Piercy, Kathleen W.] Utah State Univ, Dept Family Consumer & Human Dev, Logan, UT 84322 USA.
[Norton, Maria C.; Tschanz, JoAnn T.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA.
[Norton, Maria C.; Piercy, Kathleen W.; Corcoran, Christopher; Tschanz, JoAnn T.] Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA.
[Rabins, Peter V.; Lyketsos, Constantine G.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.
[Green, Robert C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA.
[Green, Robert C.] Boston Univ, Sch Med, Dept Med Genet, Boston, MA 02215 USA.
[Green, Robert C.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
[Breitner, John C. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Breitner, John C. S.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98195 USA.
[Ostbye, Truls] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA.
[Corcoran, Christopher] Utah State Univ, Dept Math & Stat, Logan, UT 84322 USA.
[Welsh-Bohmer, Kathleen A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
[Welsh-Bohmer, Kathleen A.] Duke Univ, Med Ctr, Bryan Alzheimers Dis Res Ctr, Durham, NC USA.
RP Norton, MC (reprint author), Utah State Univ, Dept Family Consumer & Human Dev, 2905 Old Main Hill, Logan, UT 84322 USA.
EM maria.norton@usu.edu
RI Corcoran, Chris/F-2155-2010; piercy, kathleen/F-4808-2010; Tschanz,
JoAnn/E-5986-2010; Norton, Maria/E-6994-2013
FU NIA NIH HHS [AG011380, AG018712, AG021136, AG027841, AG031272, R01
AG021136, R01 AG021136-01, R01 AG021136-02, R01 AG021136-03, R01
AG021136-04, R01 AG021136-05, R01 AG021136-06A2]
NR 47
TC 39
Z9 39
U1 3
U2 12
PU GERONTOLOGICAL SOC AMER
PI WASHINGTON
PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA
SN 1079-5014
J9 J GERONTOL B-PSYCHOL
JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci.
PD SEP
PY 2009
VL 64
IS 5
BP 560
EP 568
DI 10.1093/geronb/gbp052
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology,
Multidisciplinary
SC Geriatrics & Gerontology; Psychology
GA 489RX
UT WOS:000269441100003
PM 19564210
ER
PT J
AU Jarvik, JG
Comstock, BA
Kliot, M
Turner, JA
Chan, L
Heagerty, PJ
Hollingworth, W
Kerrigan, CL
Deyo, RA
AF Jarvik, Jeffrey G.
Comstock, Bryan A.
Kliot, Michel
Turner, Judith A.
Chan, Leighton
Heagerty, Patrick J.
Hollingworth, William
Kerrigan, Carolyn L.
Deyo, Richard A.
TI Surgery versus non-surgical therapy for carpal tunnel syndrome: a
randomised parallel-group trial
SO LANCET
LA English
DT Article
ID WORKERS COMPENSATION; STEROID INJECTION; CLINICAL-TRIAL; HEALTH;
RESPONSIVENESS; QUESTIONNAIRE; POPULATION; ULTRASOUND; SYMPTOMS
AB Background A previous randomised controlled trial reported greater efficacy of surgery than of splinting for patients with carpal tunnel syndrome. Our aim was to compare surgical versus multi-modality, non-surgical treatment for patients with carpal tunnel syndrome without denervation. We hypothesised that surgery would result in improved functional and symptom outcomes.
Methods In this parallel-group randomised controlled trial, we randomly assigned 116 patients from eight academic and private practice centres, using computer-generated random allocation stratified by site, to carpal tunnel surgery (n=57) or to a well-defined, non-surgical treatment (including hand therapy and ultrasound; n=59). The primary outcome was hand function measured by the Carpal Tunnel Syndrome Assessment Questionnaire (CTSAQ) at 12 months assessed by research personnel unaware of group assignment. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00032227.
Findings 44 (77%) patients assigned to surgery underwent surgery. At 12 months, 101 (87%) completed follow-up and were analysed (49 of 57 assigned to surgery and 52 of 59 assigned to non-surgical treatment). Analyses showed a significant 12-month adjusted advantage for surgery in function (CTSAQ function score: Delta -0.40, 95% CI 0.11-0.70, p=0.0081) and symptoms (CTSAQ symptom score: 0.34, 0.02-0.65, p=0.0357). There were no clinically important adverse events and no surgical complications.
Interpretation Symptoms in both groups improved, but surgical treatment led to better outcome than did non-surgical treatment. However, the clinical relevance of this difference was modest. Overall, our study confirms that surgery is useful for patients with carpal tunnel syndrome without denervation.
Funding NIH/NIAMS 5P60AR048093 and the Intramural Research Program of the NIH Clinical Center.
C1 [Jarvik, Jeffrey G.] Univ Washington, Dept Radiol, Harborview Med Ctr, Sch Med, Seattle, WA 98104 USA.
[Jarvik, Jeffrey G.; Kliot, Michel] Univ Washington, Dept Neurol Surg, Sch Med, Seattle, WA 98104 USA.
[Turner, Judith A.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98104 USA.
[Jarvik, Jeffrey G.] Univ Washington, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98104 USA.
[Comstock, Bryan A.; Heagerty, Patrick J.] Univ Washington, Dept Biostat, Sch Publ Hlth, Seattle, WA 98104 USA.
[Jarvik, Jeffrey G.; Comstock, Bryan A.; Turner, Judith A.; Heagerty, Patrick J.] Univ Washington, Comparat Effectiveness Cost & Outcomes Res Ctr, Seattle, WA 98104 USA.
[Kliot, Michel] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Chan, Leighton] NIH, Intramural Res Program, Ctr Clin, Bethesda, MD 20892 USA.
[Kerrigan, Carolyn L.] Dartmouth Hitchcock Med Ctr, Sect Plast Surg, Lebanon, NH 03766 USA.
[Hollingworth, William] Univ Bristol, Dept Social Med, Bristol, Avon, England.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA.
RP Jarvik, JG (reprint author), Univ Washington, Dept Radiol, Harborview Med Ctr, Sch Med, Box 359728,325 Ninth Ave, Seattle, WA 98104 USA.
EM jarviks@comcast.net
FU NIH/NIAMS [SP60AR048093]; Intramural Research Program of the NIH
FX NIH/NIAMS SP60AR048093 and the Intramural Research Program of the NIH
Clinical Center.
NR 31
TC 31
Z9 33
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD SEP-OCT
PY 2009
VL 374
IS 9695
BP 1074
EP 1081
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 501HA
UT WOS:000270370900029
ER
PT J
AU Austin, DF
Konrad-Martin, D
Griest, S
McMillan, GP
McDermott, D
Fausti, S
AF Austin, Donald F.
Konrad-Martin, Dawn
Griest, Susan
McMillan, Garnett P.
McDermott, Daniel
Fausti, Stephen
TI Diabetes-Related Changes in Hearing
SO LARYNGOSCOPE
LA English
DT Article; Proceedings Paper
CT Combined Sections Meeting of the Southern/Middle Triological-Society
CY JAN 08-11, 2009
CL Bonita Springs, FL
SP Triol Soc
DE Audiologic monitoring; hearing loss; Veterans
ID IMPAIRMENT; MELLITUS
AB Objectives/Hypothesis: Determine the effects on hearing of diabetes mellitus (DM) severity.
Study Design: We conducted a cross-sectional study among Veterans to investigate the relationship of diabetes severity and hearing in randomly selected subjects with (165) and without (137) DM and who had no more than a moderate hearing loss.
Methods: Subjects were classified by three age tertiles (<50, 50-56, and 57+ years). Diabetes severity was classified as insulin-dependent (IDDM), non-insulin-dependent (NIDDM), or no DM. Other DM measures included concurrent serum glucose, serum HbA(1c), duration of disease, and several measures of DM-related complications. Pure-tone thresholds were measured in both ears of each subject at frequencies from 250 Hz through 14,000 Hz. Outcome measures were adjusted for age and frequency and analyzed for differences between subject groups using analysis of variance. Contrasts of the mean NIDDM and IDDM thresholds at each frequency to the DM group, and controlled for the effects of frequency, age, and interactions were modeled.
Results: There was greater hearing loss in younger tertile DM subjects compared to those without DM. Significant hearing differences were at all frequencies for NIDDM subjects, but for IDDM subjects, differences were at 1,000 Hz and below, and 10,000 Hz and above. Over age 50 years, there were significant associations between hearing at low frequencies and IDDM only. Self-report of prior noise exposure did not explain observed differences.
Conclusions: Diabetes is associated with an increased risk of hearing loss, and this difference is manifest particularly in adults <50 years old.
C1 [Austin, Donald F.; Konrad-Martin, Dawn; Griest, Susan; McMillan, Garnett P.; McDermott, Daniel; Fausti, Stephen] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, VA Rehabil Res & Dev Serv, Portland, OR 97239 USA.
[Austin, Donald F.] Oregon Hlth & Sci Univ, Sch Med, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
[Konrad-Martin, Dawn; Griest, Susan; Fausti, Stephen] Oregon Hlth & Sci Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA.
RP Konrad-Martin, D (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, VA Rehabil Res & Dev Serv, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM dawn.martin@va.gov
NR 12
TC 29
Z9 37
U1 1
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0023-852X
J9 LARYNGOSCOPE
JI Laryngoscope
PD SEP
PY 2009
VL 119
IS 9
BP 1788
EP 1796
DI 10.1002/lary.20570
PG 9
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA 491JB
UT WOS:000269573600019
PM 19593813
ER
PT J
AU Simon, K
Mukundan, A
Dewundara, S
Van Remmen, H
Dombkowski, AA
Cabelof, DC
AF Simon, Kirk
Mukundan, Anju
Dewundara, Samantha
Van Remmen, Holly
Dombkowski, Alan A.
Cabelof, Diane C.
TI Transcriptional profiling of the age-related response to genotoxic
stress points to differential DNA damage response with age
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE DNA repair; p53; Aging; DNA damage response; Cell cycle
ID BASE EXCISION-REPAIR; DOUBLE-STRAND BREAKS; OXIDATIVE STRESS; IN-VIVO;
SENESCENT CELLS; S-PHASE; CHECKPOINT; INDUCTION; EXPOSURE; MICE
AB The p53 DNA damage response attenuated with age and we have evaluated downstream factors in the DNA damage response. In old animals p21 protein accumulates in the whole cell fraction but significantly declines in the nucleus, which may after cell cycle and apoptotic programs in response to DNA damage. We evaluated the transcriptional response to DNA damage in young and old and find 2692 genes are differentially regulated in old compared to young in response to oxidative stress (p < 0.005). As anticipated, the transcriptional profile of young mice is consistent with DNA damage induced cell cycle arrest while the profile of old mice is consistent with cell cycle progression in the presence of DNA damage, suggesting the potential for catastrophic accumulation of DNA damage at the replication fork. Unique sets of DNA repair genes are induced in response to damage in old and young, suggesting the types of damage accumulating differs between young and old. The DNA repair genes upregulated in old animals point to accumulation of replication-dependent DNA double strand breaks (DSB). Expression data is consistent with loss of apoptosis following DNA damage in old animals. These data suggest DNA damage responses differ greatly in young and old animals. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Simon, Kirk; Cabelof, Diane C.] Wayne State Univ, Dept Nutr & Food Sci, Detroit, MI 48084 USA.
[Mukundan, Anju; Dombkowski, Alan A.] Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI 48084 USA.
[Dewundara, Samantha] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI 48084 USA.
[Van Remmen, Holly] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA.
[Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA.
[Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
RP Cabelof, DC (reprint author), Wayne State Univ, Dept Nutr & Food Sci, Detroit, MI 48084 USA.
EM d.cabelof@wayne.edu
FU NIH [1F32-ES013643]; American Federation for Aging Research (DCC);
Microarray and Bioinformatics Facility Core of the Environmental Health
Sciences Center at Wayne State University [P30 ES06639]
FX This work was supported by NIH 1F32-ES013643 (DCC) and American
Federation for Aging Research (DCC). Microarray and bioinformatics work
was facilitated by the Microarray and Bioinformatics Facility Core of
the Environmental Health Sciences Center at Wayne State University
(NIEHS Center Grant P30 ES06639). We would like to thank Dr. Thierry
Soussi for his input on p53-target genes. We would also like to thank
Anna Unnikrishnan, Sridevi Salagrama and Daniela Cukovic for their
technical assistance.
NR 50
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0047-6374
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD SEP
PY 2009
VL 130
IS 9
BP 637
EP 647
DI 10.1016/j.mad.2009.07.007
PG 11
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 504QL
UT WOS:000270632000008
PM 19679149
ER
PT J
AU Henke, RM
Zaslavsky, AM
McGuire, TG
Ayaian, JZ
Rubenstein, LV
AF Henke, Rachel M.
Zaslavsky, Alan M.
McGuire, Thomas G.
Ayaian, John Z.
Rubenstein, Lisa V.
TI Clinical Inertia in Depression Treatment
SO MEDICAL CARE
LA English
DT Article
DE depression; clinical inertia; evidence-based medicine; physician
practice patterns
ID PRIMARY-CARE CLINICIAN; QUALITY IMPROVEMENT; STATISTICAL DISCRIMINATION;
TREATING DEPRESSION; COLLABORATIVE CARE; COMPETING DEMANDS;
RANDOMIZED-TRIAL; COMMUNICATION; OUTCOMES; PATIENT
AB Objective: To explore reasons for clinical inertia in the management of persistent depression symptoms.
Research Design: We characterized patterns of treatment adjustment in primary care and their relation to the patient's clinical condition by modeling transition to a given treatment "state" conditional on the current state of treatment. We assessed associations of patient, clinician, and practice barriers with adjustment decisions.
Subjects: Survey data on patients in active care for major depression were collected at 6-month intervals over a 2-year period for the quality improvement for depression (QID) studies.
Measures: Patient and clinician characteristics were collected at baseline. Depression severity and treatment were measured at each interval.
Results: Approximately, one-third of the observation periods ending with less than a full response resulted in an adjustment recommendation. Clinicians often respond correctly to the combination of severe depression symptoms and less than maximal treatment by changing the treatment. Appropriate adjustment is less common, however, in management of less severely depressed patients who do not improve after starting treatment, particularly if their care already meets minimal treatment intensity guidelines.
Conclusions: Our findings suggest that quality improvement efforts should focus on promoting appropriate adjustments for patients with persistent depression symptoms, particularly those with less severe depression.
C1 [Henke, Rachel M.] Thomson Reuters Healthcare, Cambridge, MA USA.
[Zaslavsky, Alan M.; McGuire, Thomas G.; Ayaian, John Z.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Rubenstein, Lisa V.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Rubenstein, Lisa V.] VA Greater Los Angeles, Los Angeles, CA USA.
[Rubenstein, Lisa V.] RAND, Santa Monica, CA USA.
RP Henke, RM (reprint author), Thomson Reuters, 150 Cambridge Pk Dr, Cambridge, MA 02140 USA.
EM rachel.henke@thomsonreuters.com
FU F31 [F31 MH75719, R01 MH068260]
FX Supported by grants from the National Institute of Mental Health (F31
MH75719; R01 MH068260).
NR 48
TC 16
Z9 17
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD SEP
PY 2009
VL 47
IS 9
BP 959
EP 967
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 489GH
UT WOS:000269407700005
PM 19704353
ER
PT J
AU Marsteller, JA
Burton, L
Mader, SL
Naughton, B
Burl, J
Guido, S
Greenough, WB
Steinwachs, D
Clark, R
Leff, B
AF Marsteller, Jill A.
Burton, Lynda
Mader, Scott L.
Naughton, Bruce
Burl, Jeffrey
Guido, Susan
Greenough, William B., III
Steinwachs, Donald
Clark, Rebecca
Leff, Bruce
TI Health Care Provider Evaluation of a Substitutive Model of Hospital at
Home
SO MEDICAL CARE
LA English
DT Article
DE hospital care; home; provider evaluation; provider satisfaction
ID OLDER PATIENTS
AB Objective: To evaluate Hospital at Home (HaH), a substitute for inpatient care, from the perspectives of participating providers.
Research Design: Multivariate general estimating equations regression analyses of a patient-specific survey of providers delivering HaH care in a prospective, nonrandomized clinical trial.
Subjects: Eleven physicians and 26 nurses employed in 3 Medicare-Advantage plans and I Veterans Administration medical center.
Measures: Problems with care; benefits; problem-free index. Results: Case response rates were 95% and 82% for physicians and nurses, respectively. The overall problem-free index was high (mean 4.4, median 5, scale 1-5). "Major" problems were cited for 14 of 84 patients (17%), most relating to logistic issues without adverse patient outcomes. Positive effects included quicker patient functional recovery, greater opportunities for patient teaching, and increased communication with family caregivers. In multivariate analysis, the problem-free index was lower for nurses compared with physicians in one site; for patients with cellulitis; and for patients with a higher acuity (APACHE II) score. HaH physicians and nurses differed in their judgments of hours of continuous nursing required by patients.
Conclusions: The health care provider evaluation of substitutive HaH care was positive, providing support for the viability of this innovative model of care. Without provider support, no new model of care will survive. These findings also provide insight into areas to attend to in implementation. Organizations considering adoption of the HaH should monitor provider views to promote quality improvement in HaH.
C1 [Leff, Bruce] Johns Hopkins Univ, Sch Med, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Mader, Scott L.] Portland VA Med Ctr, Portland, OR USA.
[Mader, Scott L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Naughton, Bruce] SUNY Buffalo, Buffalo, NY 14260 USA.
[Burl, Jeffrey] Fallon Clin Inc, Worcester, MA USA.
RP Marsteller, JA (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, 624 N Broadway,Room 433 Hampton House, Baltimore, MD 21205 USA.
EM jmarstel@jhsph.edu
NR 12
TC 4
Z9 4
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD SEP
PY 2009
VL 47
IS 9
BP 979
EP 985
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 489GH
UT WOS:000269407700007
PM 19704355
ER
PT J
AU Hausmann, LRM
Ibrahim, SA
Mehrotra, A
Nsa, W
Bratzler, DW
Mor, MK
Fine, MJ
AF Hausmann, Leslie R. M.
Ibrahim, Said A.
Mehrotra, Ateev
Nsa, Wato
Bratzler, Dale W.
Mor, Maria K.
Fine, Michael J.
TI Racial and Ethnic Disparities in Pneumonia Treatment and Mortality
SO MEDICAL CARE
LA English
DT Article
DE health disparities; pneumonia; quality of care
ID COMMUNITY-ACQUIRED PNEUMONIA; QUALITY-OF-CARE; COST-EFFECTIVENESS;
HOSPITAL CHARACTERISTICS; HEALTH-CARE; ELDERLY-PATIENTS; WORKING ADULTS;
BLACK PATIENTS; VACCINATION; INFLUENZA
AB Background: The extent to which racial/ethnic disparities in pneumonia care occur within or between hospitals is unclear.
Objective: Examine within and between-hospital racial/ethnic disparities in quality indicators and mortality for patients hospitalized for pneumonia.
Research Design: Retrospective cohort Study. Subjects: A total of 1,183,753 non-Hispanic white, African American, and Hispanic adults hospitalized for pneumonia between January 2005 and June 2006.
Measures: Eight pneumonia care quality indicators and in-hospital mortality.
Results: Performance rates for the 8 quality indicators ranged from 99.4% (oxygenation assessment within 24 hours) to 60.2% (influenza vaccination). Overall hospital mortality was 4.1%. African American and Hispanic patients were less likely to receive pneumococcal and influenza vaccinations, smoking cessation counseling, and first dose of antibiotic within 4 hours than white patients at the same hospital (ORs = 0.65-0.95). Patients at hospitals with the racial composition of those attended by average African Americans and Hispanics were less likely to receive all indicators except blood culture within 24 hours than patients at hospitals with the racial composition of those attended by average whites. Hospital mortality was higher for African Americans (OR = 1.05; 95% Cl = 1.02, 1.09) and lower for Hispanics (OR = 0.85; 95% Cl = 0.81, 0.89) than for whites within the same hospital. Mortality for patients at hospitals with the racial composition of those attended by average African Americans (OR = 1.21; 95% Cl = 1.18, 1.25) or Hispanics (OR = 1.18; 95% Cl = 1.14, 1.23) was higher than for patients at hospitals with the racial composition of those attended by average whites.
Conclusions: Racial/ethnic disparities in pneumonia treatment and mortality are larger and more consistent between hospitals than within hospitals.
C1 [Hausmann, Leslie R. M.; Ibrahim, Said A.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Ibrahim, Said A.; Mehrotra, Ateev; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Ibrahim, Said A.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA USA.
[Mehrotra, Ateev] RAND Hlth, Pittsburgh, PA USA.
[Nsa, Wato; Bratzler, Dale W.] Oklahoma Fdn Med Qual, Oklahoma City, OK USA.
[Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
RP Hausmann, LRM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA.
EM leslie.hausmann@gmail.com
FU National Institutes of Musculoskeletal and Skin Disorders [RCD 06-287,
1K24AR055259-01]; National Center for Research Resources
[KL2-R-R024154-01]
FX Supported by resources and the use of facilities at the Veterans Affairs
Pittsburgh Healthcare System in Pittsburgh, PA and by VA Health Services
Research and Development Career Development Award RCD 06-287 (to
L.R.M.H.), K24 Award (1K24AR055259-01) from the National Institutes of
Musculoskeletal and Skin Disorders (to S.A.I., the recipient of a VA
Health Services Research and Development Award and the Harold Amos
Robert Wood Johnson Scholar Award). A.M.'s salary was supported by a
career development award from the National Center for Research
Resources, a component of the National Institutes of Health
(KL2-R-R024154-01).
NR 44
TC 17
Z9 17
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD SEP
PY 2009
VL 47
IS 9
BP 1009
EP 1017
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 489GH
UT WOS:000269407700011
PM 19648832
ER
PT J
AU Bismuth, J
Chai, H
Lin, PH
Yao, QZ
Chen, CY
AF Bismuth, Jean
Chai, Hong
Lin, Peter H.
Yao, Qizhi
Chen, Changyi
TI Lactosylceramide causes endothelial dysfunction in porcine coronary
arteries and human coronary artery endothelial cells
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE lactosylceramide; endothelial dysfunction; eNOS; coronary artery;
oxidative stress; NOX4; calatase
ID PROTEASE INHIBITOR RITONAVIR; NITRIC-OXIDE SYNTHASE; INDUCED VASCULAR
DYSFUNCTION; LOW-DENSITY-LIPOPROTEIN; SUPEROXIDE PRODUCTION;
PULMONARY-ARTERIES; CERAMIDE; SPHINGOMYELINASE; ATHEROSCLEROSIS;
ACTIVATION
AB Background: Lactosylceramide (LacCer) is a member of the glycosphingolipid family, which has been implicated in the atherogenic process. The goal of this study was to determine the effects and molecular mechanisms of LacCer on endothelial functions in porcine coronary arteries and human coronary endothelial cells (HCAECs).
Material/Methods: The vessel rings and HCAECs were treated with different concentrations of LacCer for 24 hours. Vasomotor function was studied using a myograph tension system in response to thromboxane A2 analog U46619, bradykinin and sodium nitroprusside (SNP). Superoxide anion production was determined using lucigenin-enhanced chemiluminescence. The expression of endothelial nitric oxide synthase (eNOS), NADPH oxidase subunit NOX4 and catalase was determined by real-time PCR.
Results: LacCer (0.1, 1 and 10 mu M) significantly decreased endothelium-dependent vasorelaxation (bradykinin) in porcine coronary artery rings in a concentration-dependent manner compared with untreated controls (P<0.05). High concentration of LacCer (10 mu M) also reduced endothelium-independent vasorelaxation (SNP). However, LacCer did not affect vessel contraction (U46619). Antioxidant selenomethionine (SeMet) effectively reversed LacCer-induced endothelial dysfunction in the vessel rings. Furthermore, LacCer significantly increased superoxide anion production in the vessel rings in a concentration-dependent manner compared with untreated controls (P<0.05). In response to LacCer treatment, NOX4 mRNA levels were significantly increased, while the expression of catalase and eNOS was significantly decreased in HCAECs compared with controls (P<0.05).
Conclusions: LacCer causes endothelial dysfunction with potential mechanisms of the down-regulation of eNOS and increase of oxidative stress due to the activation of NADPH oxidase and inhibition of internal antioxidant catalase. This study suggests that LacCer may represent a risk factor to the vascular system and antioxidant SeMet may have clinical applications for prevention of vascular disease.
C1 [Bismuth, Jean; Chai, Hong; Lin, Peter H.; Yao, Qizhi; Chen, Changyi] Baylor Coll Med, Michael E DeBakey Dept Surg, Mol Surg Res Ctr, Div Vasc Surg & Endovasc Therapy, Houston, TX 77030 USA.
[Lin, Peter H.; Yao, Qizhi; Chen, Changyi] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
RP Chen, CY (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, Mol Surg Res Ctr, Div Vasc Surg & Endovasc Therapy, 1 Baylor Plaza,Mail Stop BCM 390, Houston, TX 77030 USA.
EM jchen@bcm.tmc.edu
FU NHLBI NIH HHS [R01 HL072716-03, R01 HL072716, K08 HL076345, HL72716,
HL65916, HL076345, R01 HL065916, R01 HL065916-05, K08 HL076345-04]
NR 21
TC 10
Z9 10
U1 0
U2 1
PU INT SCIENTIFIC LITERATURE, INC
PI ALBERTSON
PA 1125 WILLIS AVE, ALBERTSON, NY 11507 USA
SN 1234-1010
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD SEP
PY 2009
VL 15
IS 9
BP BR270
EP BR274
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 502XP
UT WOS:000270494200005
PM 19721395
ER
PT J
AU Grady, D
Macer, J
Kristof, M
Shen, H
Tagliaferri, M
Creasman, J
AF Grady, Deborah
Macer, Judith
Kristof, Margaret
Shen, Hui
Tagliaferri, Mary
Creasman, Jennifer
TI Is a shorter hot flash diary just as good as a 7-day diary?
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Menopause; Hot flashes; Measurement; Diary
ID FLUSHES; TRIAL
AB Objective: In randomized trials, the most common way to measure the effect of treatment on the frequency and severity of menopausal hot flashes is a 7-day self-reported diary. However, adherence with completing the hot flash diary in real time may be poor, and completing a diary is cumbersome for study participants. Our objective was to determine if a shorter diary for recording self-reported hot flashes is as accurate and precise as the traditional 7-day diary.
Methods: Using cross-sectional data from a multicenter randomized clinical trial of an herbal preparation (MF101, an estrogen receptor beta-selective agonist for treatment of menopausal hot flashes), we compared findings based on shorter diaries with findings based on a 7-day diary.
Results: With 3 days of diary keeping, the mean number of hot flashes per day and mean severity were almost identical to the means based on the 7-day diary, the SDs of the means were almost identical, and the intraclass correlations were almost perfect. The difference in the mean number of hot flashes per day compared with the 7-day diary was only 12% of one hot flash. Data from a different clinical trial revealed similar correspondence between the findings of a 3- and 7-day diary.
Conclusions: In our study, the optimal duration of diary keeping to record menopausal hot flashes seems to be 3 days. In addition to being as good as a 7-day diary, a 3-day diary would be less burden on study participants and research staff and less expensive.
C1 [Grady, Deborah] Univ Calif San Francisco, Womens Hlth Clin Res Ctr, San Francisco, CA 94115 USA.
[Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA.
[Tagliaferri, Mary] Bionovo, Emeryville, CA USA.
RP Grady, D (reprint author), Univ Calif San Francisco, Womens Hlth Clin Res Ctr, 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA.
EM Deborah.Grady@ucsf.edu
FU Bionovo
FX Bionovo funded the phase 2 clinical trial from which the data was used
for this article.
NR 7
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1072-3714
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD SEP-OCT
PY 2009
VL 16
IS 5
BP 932
EP 936
DI 10.1097/gme.0b013e3181a4f558
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 493AZ
UT WOS:000269706800017
PM 19421075
ER
PT J
AU Conway, B
Evans, RW
Fried, L
Kelsey, S
Edmundowicz, D
Orchard, TJ
AF Conway, Baqiyyah
Evans, Rhobert W.
Fried, Linda
Kelsey, Sheryl
Edmundowicz, Daniel
Orchard, Trevor J.
TI Free fatty acids are associated with pulse pressure in women, but not
men, with type 1 diabetes mellitus
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
ID GENDER-RELATED DIFFERENCES; CORONARY-ARTERY-DISEASE; COUNTERREGULATORY
RESPONSES; AORTIC STIFFNESS; BLOOD-GLUCOSE; FOLLOW-UP; HYPOGLYCEMIA;
METABOLISM; RISK; GLUCONEOGENESIS
AB Cardiovascular disease (CVD) is the leading cause of death in type 1 diabetes mellitus (T1D). Pulse pressure, a measure of arterial stiffness, is elevated in T1D and associated with CVD. Free fatty acids (FFAs), elevated in women and abdominal adiposity, are also elevated in T1D and CVD. We thus examined the association of fasting FFAs with pulse pressure and coronary artery calcification (CAC, a marker of coronary atherosclerotic burden) in an adult population (n = 150) of childhood-onset T1D and whether any such associations varied by abdominal adiposity and sex. Mean age and diabetes duration were 42 and 33 years, respectively, when CAC, visceral abdominal adiposity (VAT), and subcutaneous abdominal adiposity (SAT) were determined by electron beam tomography. Free fatty acids were determined by in vitro colorimetry. Pulse pressure was calculated as systolic blood pressure minus diastolic blood pressure. Free fatty acids were log transformed before analyses, and all analyses were controlled for serum albumin. Free fatty acids were associated with pulse pressure in women (r = 0.24, P = .04), but not in men (r = 0.07, P = .55). An interaction for the prediction of pulse pressure was noted between FFAs and both VAT (P = .03) and SAT (P = .008) in women, but only a marginal interaction with SAT (P = .09) and no interaction for VAT (P = .40) with FFAs were observed in men. In multivariable linear regression analysis allowing for serum albumin, age, height, heart rate, albumin excretion rate, hemoglobin A(1c), high-density lipoprotein cholesterol, hypertension medication use, FFAs, SAT, and the interaction between FFAs and SAT, the interaction between FFAs and SAT remained associated with pulse pressure in women (FFAs, P = .04; interaction term, P = .03), but not: men (FFAs, P = .32; interaction term, P = .32). FFAs showed no association with log-transformed CAC. Although FFAs were not associated with CAC in either sex, they were associated with pulse pressure in women and their effect appeared to vary by abdominal adiposity, particularly SAT. This finding might help explain the loss of the sex difference in CVD in T1D. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Conway, Baqiyyah; Evans, Rhobert W.; Kelsey, Sheryl; Orchard, Trevor J.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA.
[Fried, Linda] VA Pittsburgh Healthcare Syst, Univ Drive Div, Pittsburgh, PA 15240 USA.
[Edmundowicz, Daniel] Univ Pittsburgh, Med Ctr, Cardiovasc Inst, Pittsburgh, PA 15213 USA.
RP Orchard, TJ (reprint author), Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA.
EM orchardt@edc.pitt.edu
OI orchard, trevor/0000-0001-9552-3215
FU National Institutes of Health [DK34818]
FX This research was supported by National Institutes of Health grant
DK34818. The authors would like to thank Beth Hauth for her help in
assaying the FFAs. Finally, we would like to thank the EDC study
participants for their dedicated participation in this research.
NR 45
TC 4
Z9 4
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
EI 1532-8600
J9 METABOLISM
JI Metab.-Clin. Exp.
PD SEP
PY 2009
VL 58
IS 9
BP 1215
EP 1221
DI 10.1016/j.metabol.2009.03.010
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 487XB
UT WOS:000269310300002
PM 19570556
ER
PT J
AU Meeran, SM
Katiyar, N
Singh, T
Katiyar, SK
AF Meeran, Syed M.
Katiyar, Nandan
Singh, Tripti
Katiyar, Santosh K.
TI Loss of Endogenous Interleukin-12 Activates Survival Signals in
Ultraviolet-Exposed Mouse Skin and Skin Tumors
SO NEOPLASIA
LA English
DT Article
ID NF-KAPPA-B; SKH-1 HAIRLESS MICE; GROWTH IN-VIVO; INDUCED APOPTOSIS;
HUMAN CANCER; PHOTOCARCINOGENESIS; PROANTHOCYANIDINS; INHIBITION;
EXPRESSION; PATHWAY
AB Interleukin-12 (IL-12)-deficiency promotes photocarcinogenesis in mice; however, the molecular mechanisms underlying this effect have not been fully elucidated. Here, we report that long-term exposure to ultraviolet (UV) radiation resulted in enhancement of the levels of cell survival kinases, such as phosphatidylinositol 3-kinase (PI3K), Akt (Ser(473)), p-ERK1/2, and p-p38 in the skin of IL-12p40 knockout (IL-12 KO) mice compared with the skin of wild-type mice. UV-induced activation of nuclear factor-kappa B (NF-kappa B)/p65 in the skin of IL-12 KO mice was also more prominent. The levels of NF-kappa B-targeted proteins, such as proliferating cell nuclear antigen (PCNA), cyclooxygenase-2, cyclin D1, and inducible nitric oxide synthase, were higher in the UV-exposed skin of IL-12 KO mice than the UV-exposed skin of wild types. In short-term UV irradiation experiments, subcutaneous treatment of IL-12 KO mice with recombinant IL-12 (rIL-12) or topical treatment with oridonin, an inhibitor of NF-kappa B,resulted in the inhibition of UV-induced increases in the levels of PCNA, cyclin D1, and NF-kappa B compared with non-rIL-12- or non-oridonin-treated IL-12 KO mice. UV-induced skin tumors of IL-12 KO mice had higher levels of PI3K, p-Akt (Ser(473)), p-ERK1/2, p-p38, NF-kappa B, and PCNA and fewer apoptotic cells than skin tumors of wild types. Together, these data suggest that the loss of endogenous IL-12 activates survival signals in UV-exposed skin and that may lead to the enhanced photocarcinogenesis in mice.
C1 [Meeran, Syed M.; Katiyar, Nandan; Singh, Tripti; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU National Center for Complementary and AlternativeMedicine/NIH [1 RO1
AT002536]; Veterans Administration Merit Review Award
FX This work was supported by grants from the National Center for
Complementary and AlternativeMedicine/NIH (1 RO1 AT002536; S.K.K.) and
the Veterans Administration Merit Review Award (S.K.K.). No conflict of
interest.
NR 34
TC 10
Z9 13
U1 0
U2 0
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
USA
SN 1522-8002
J9 NEOPLASIA
JI Neoplasia
PD SEP
PY 2009
VL 11
IS 9
BP 846
EP 855
DI 10.1593/neo.09528
PG 10
WC Oncology
SC Oncology
GA 497EJ
UT WOS:000270038200003
PM 19724678
ER
PT J
AU Holden, KF
Lindquist, K
Tylavsky, FA
Rosano, C
Harris, TB
Yaffe, K
AF Holden, Karen F.
Lindquist, Karla
Tylavsky, Frances A.
Rosano, Caterina
Harris, Tamara B.
Yaffe, Kristine
CA Hlth ABC Study
TI Serum leptin level and cognition in the elderly: Findings from the
Health ABC Study
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Leptin; Cognition; Learning; Memory; Elderly; Aging; Dementia;
Alzheimer's disease; Obesity; Hyperleptinemia; Leptin resistance;
Metabolic syndrome
ID HIPPOCAMPAL SYNAPTIC PLASTICITY; MICE OVEREXPRESSING LEPTIN; LONG-TERM
POTENTIATION; BLOOD-BRAIN-BARRIER; INSULIN SENSITIVITY;
GLUCOSE-METABOLISM; OLDER WOMEN; RESISTANCE; OBESITY; RATS
AB Leptin is a peptide hormone secreted by adipocytes. It has been shown to modulate production and clearance of amyloid beta (A beta) in rodent models. We sought to determine if serum leptin was associated with cognitive decline in the elderly.
We studied 2871 well-functioning elders, aged 70-79, who were enrolled in a prospective study. Serum leptin concentrations were measured at baseline and analyzed by mean +/- 1S.D. Clinically significantly cognitive decline over 4 years was defined as >= 5-point drop on the Modified Mini Mental State Exam (3MS).
Compared to those in the lower leptin groups, elders in the high leptin group had less cognitive decline, 20.5% versus 24.7% (OR=0.79; 95% CI 0.61-1.02, p = 0.07). After adjustment for demographic and clinical variables, including body mass index and total percent body fat, those in the high leptin group had significantly less likelihood of cognitive decline, OR = 0.66 (95% CI 0.48-0.91).
We conclude that in elderly individuals, higher serum leptin appears to protect against cognitive decline, independent of comorbidites and body fat. (C) 2007 Elsevier Inc. All rights reserved.
C1 [Holden, Karen F.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Lindquist, Karla] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Tylavsky, Frances A.] Univ Tennessee, Dept Prevent Med, Memphis, TN 38163 USA.
[Rosano, Caterina] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA.
[Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Holden, KF (reprint author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94143 USA.
EM karenholden@mac.com
OI Rosano, Caterina/0000-0002-0909-1506; Rosano,
Caterina/0000-0002-4271-6010
FU Paul Beeson Faculty Scholar in Aging Program; NIH [R01 AG021918-01]; NIA
[N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-21]
FX Dr. Yaffe is supported by the Paul Beeson Faculty Scholar in Aging
Program and NIH grant R01 AG021918-01. This research was supported in
part by the Intramural Research program of the NIA, National Institute
of Aging, as well as NIA contracts N01-AG-6-2101, N01-AG-6-2103 and
N01-AG-6-21.
NR 58
TC 88
Z9 90
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD SEP
PY 2009
VL 30
IS 9
BP 1483
EP 1489
DI 10.1016/j.neurobiolaging.2007.11.024
PG 7
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 481CA
UT WOS:000268783200014
PM 18358569
ER
PT J
AU Labus, JS
Naliboff, BD
Berman, SM
Suyenobu, B
Vianna, EP
Tillisch, K
Mayer, EA
AF Labus, Jennifer S.
Naliboff, Bruce D.
Berman, Steve M.
Suyenobu, Brandall
Vianna, Eduardo P.
Tillisch, Kirsten
Mayer, Emeran A.
TI Brain networks underlying perceptual habituation to repeated aversive
visceral stimuli in patients with irritable bowel syndrome
SO NEUROIMAGE
LA English
DT Article
ID PARTIAL LEAST-SQUARES; EFFECTIVE CONNECTIVITY; ATTENTIONAL NETWORKS;
PREFRONTAL CORTEX; NEURAL MECHANISMS; FEARFUL FACES; CHRONIC PAIN;
ANXIETY; AWARENESS; CONFLICT
AB Patients with irritable bowel syndrome (IBS) show decreased discomfort and pain thresholds to visceral stimuli, as well hypervigilance to gastrointestinal sensations, symptoms, and the context in which these visceral sensations and symptoms occur. Previous research demonstrated normalization of visceral hypersensitivity following repeated exposure to experimental rectal stimuli over a 12-month period that was associated with reduction in cortical regions functionally associated with attention and arousal. Building upon these functional analyses, multivariate functional and effective connectivity analyses were applied to [(15)O] water positron emission tomography (PET) data from 12 IBS patients (male = 4) Participating in a PET Study before and after 4 visceral sensory testing sessions involving rectal balloon distensions over a 1-year period. First, behavioral partial least squares was applied to test for networks related to reduced subjective ratings observed following repeated application of an aversive rectal stimulus. Next, path analysis within a structural equation modeling framework tested the hypothesis that perceptual habituation to the repeated visceral Stimuli resulted in part from the reduced connectivity within a selective attention to threat network over time. Two independent, perception-related networks comprised of interoceptive, attentional and arousal regions were engaged differentially during expectation and distension. In addition, changes in the effective connectivity of an attentional network as well as modulatory amygdala influence suggested that perceptual habituation associated with repeated stimulus delivery results both in an increase in top-down modulation of attentional circuits, as well as in a reduction of amygdala-related interference with attentional mechanisms. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Labus, Jennifer S.; Naliboff, Bruce D.; Berman, Steve M.; Suyenobu, Brandall; Vianna, Eduardo P.; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Los Angeles, CA 90095 USA.
[Berman, Steve M.; Suyenobu, Brandall; Vianna, Eduardo P.; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Labus, Jennifer S.; Naliboff, Bruce D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Labus, Jennifer S.; Berman, Steve M.; Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA.
[Naliboff, Bruce D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Labus, JS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Peter V Ueberroth Bldg,Rm 2338C2,10945 LeConte Av, Los Angeles, CA 90095 USA.
EM jlabus@ucla.edu
FU VA PET Center
FX We would like to acknowledge the invaluable support by the VA PET Center
under the direction of Dr. Mark Mandelkern.
NR 67
TC 37
Z9 39
U1 3
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD SEP
PY 2009
VL 47
IS 3
BP 952
EP 960
DI 10.1016/j.neuroimage.2009.05.078
PG 9
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 482YI
UT WOS:000268926200021
PM 19501173
ER
PT J
AU Tsai, PH
Mendez, MF
AF Tsai, Po-Heng
Mendez, Mario F.
TI AKINETOPSIA IN THE POSTERIOR CORTICAL VARIANT OF ALZHEIMER DISEASE
SO NEUROLOGY
LA English
DT Editorial Material
ID MOTION BLINDNESS; ATROPHY; DAMAGE
C1 [Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA 90073 USA.
[Tsai, Po-Heng] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Syst, Neurobehav Unit 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mmendez@ucla.edu
NR 7
TC 8
Z9 8
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD SEP 1
PY 2009
VL 73
IS 9
BP 731
EP +
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 489SY
UT WOS:000269444200014
PM 19720982
ER
PT J
AU Butler, MA
Corboy, JR
Filley, CM
AF Butler, Michelle A.
Corboy, John R.
Filley, Christopher M.
TI How the Conflict between American Psychiatry and Neurology Delayed the
Appreciation of Cognitive Dysfunction in Multiple Sclerosis
SO NEUROPSYCHOLOGY REVIEW
LA English
DT Review
DE Cognition; History of medicine; History of psychiatry/neurology;
Demyelinating disease; Schemas; Multiple sclerosis
ID DISABILITY STATUS SCALE; DIAGNOSTIC-CRITERIA; IMPAIRMENT; HISTORY;
DEMENTIA; PATTERNS; CONCEPTUALIZATION; MEDICINE; DISEASE; STATE
AB Whereas cognitive deficits in multiple sclerosis (MS) were documented in the original clinicopathological description by Charcot, the extent and nature of cognitive dysfunction was poorly understood in the U.S. until over a century later. Our objective was to discern reasons for this misunderstanding and to examine forces shifting this topic to center stage of research and increased awareness in clinical practice. We hypothesized that during the 19th century, conflict between psychiatrists and neurologists over control of treatment of the mentally ill fueled a misunderstanding of the nature of MS which led neurologists to treat diseases of the body, and psychiatrists, diseases of the mind. The importance of cognitive deficits in MS was thus minimized until scientific breakthroughs could once again bring them to light. As the rift between disciplines peaked, awareness of cognitive deficits diminished, and vice versa. This may have been one contributing factor affecting how MS was mistakenly conceptualized for a century.
C1 [Butler, Michelle A.] USAF Acad, HQ DFBL, Colorado Springs, CO 80840 USA.
[Corboy, John R.; Filley, Christopher M.] Univ Colorado, Denver Sch Med, Dept Neurol, Denver, CO 80202 USA.
[Filley, Christopher M.] Univ Colorado, Denver Sch Med, Dept Psychiat, Denver, CO 80202 USA.
[Corboy, John R.; Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Butler, MA (reprint author), USAF Acad, HQ DFBL, 2354 Fairchild Dr,Ste 6L101B, Colorado Springs, CO 80840 USA.
EM michelle.butler@usafa.edu
NR 89
TC 8
Z9 8
U1 0
U2 2
PU CONSULTANTS BUREAU/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1040-7308
J9 NEUROPSYCHOL REV
JI Neuropsychol. Rev.
PD SEP
PY 2009
VL 19
IS 3
BP 399
EP 410
DI 10.1007/s11065-009-9089-y
PG 12
WC Psychology, Clinical; Neurosciences
SC Psychology; Neurosciences & Neurology
GA 495SE
UT WOS:000269914500010
PM 19373561
ER
PT J
AU Dracheva, S
Lyddon, R
Barley, K
Marcus, SM
Hurd, YL
Byne, WM
AF Dracheva, Stella
Lyddon, Rebecca
Barley, Kevin
Marcus, Sue M.
Hurd, Yasmin L.
Byne, William M.
TI Editing of Serotonin 2C Receptor mRNA in the Prefrontal Cortex
Characterizes High-Novelty Locomotor Response Behavioral Trait
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE serotonin 2C receptor; mRNA editing; drug addiction; rat; high and low
responders; prefrontal cortex
ID VENTRAL TEGMENTAL AREA; SELF-ADMINISTRATION BEHAVIOR; RAT
NUCLEUS-ACCUMBENS; 5-HT2C RECEPTOR; DOPAMINE RELEASE; IN-VIVO;
INDIVIDUAL-DIFFERENCES; CONSTITUTIVE ACTIVITY; COCAINE; NEURONS
AB Serotonin 2C receptor (5-HT(2C)R) exerts a major inhibitory influence on dopamine (DA) neurotransmission within the mesocorticolimbic DA pathway that is implicated in drug reward and goal-directed behaviors. 5-HT(2C)R pre-mRNA undergoes adenosine-to-inosine editing, generating numerous receptor isoforms in brain. As editing influences 5-HT(2C)R activity, individual differences in editing might influence dopaminergic function and, thereby, contribute to interindividual vulnerability to drug addiction. Liability to drug-related behaviors in rats can be predicted by their level of motor activity in response to a novel environment. Rats with a high locomotor response (high responders; HRs) exhibit enhanced acquisition and maintenance of drug self-administration compared to rats with a low response (low responders; LRs). We here examined 5-HT(2C)R mRNA editing and expression in HR and LR phenotypes to investigate the relationship between 5-HT(2C)R function and behavioral traits relevant to drug addiction vulnerability. Three regions of the mesocorticolimbic circuitry (ventral tegmental area (VTA), nucleus accumbens (NuAc) shell, and medial prefrontal cortex (PFC)) were examined. 5-HT(2C)R mRNA expression and editing were significantly higher in the NuAc shell compared with both the PFC and VTA, implying significant differences in function (including constitutive activity) among 5-HT(2C)R neuronal populations within the circuitry. The regional differences in editing could, at least in part, arise from the variations in expression levels of the editing enzyme, ADAR2, and/or from the variations in the ADAR2/ADAR1 ratio observed in the study. No differences in the 5-HT(2C)R expression were detected between the behavioral phenotypes. However, editing was higher in the PFC of HRs vs LRs, implicating this region in the pathophysiology of drug abuse liability. Neuropsychopharmacology (2009) 34, 2237-2251; doi: 10.1038/npp.2009.51; published online 3 June 2009
C1 [Dracheva, Stella; Hurd, Yasmin L.; Byne, William M.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Dracheva, Stella; Lyddon, Rebecca; Barley, Kevin; Marcus, Sue M.; Hurd, Yasmin L.; Byne, William M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
RP Dracheva, S (reprint author), Bronx VA Med Ctr, Psychiat Res 4F-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Stella.Dracheva@mssm.edu
OI Barley, Kevin/0000-0003-1604-1694
FU National Institute on Drug Abuse [DA022264]; VISN3 Mental Illness
Research and Education Clinical Center
FX This work was supported by the National Institute on Drug Abuse grant
DA022264 (SD), the VISN3 Mental Illness Research and Education Clinical
Center (SD) and the use of facilities at the JJ Peters VA Medical
Center, Bronx, NY where SD and YH are Research Health Science
Specialists and WB is a Staff Physician. We are grateful to Ms Nayna
Patel and Mr Benjamin Chin for their superb technical assistance.
NR 81
TC 22
Z9 22
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD SEP
PY 2009
VL 34
IS 10
BP 2237
EP 2251
DI 10.1038/npp.2009.51
PG 15
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 482VY
UT WOS:000268919100005
PM 19494808
ER
PT J
AU Yang, YS
Koontz, AM
Triolo, RJ
Cooper, RA
Boninger, ML
AF Yang, Yu-Sheng
Koontz, Alicia M.
Triolo, Ronald J.
Cooper, Rory A.
Boninger, Michael L.
TI Biomechanical Analysis of Functional Electrical Stimulation on Trunk
Musculature During Wheelchair Propulsion
SO NEUROREHABILITATION AND NEURAL REPAIR
LA English
DT Article
DE Wheelchair; Spinal cord injury; Shoulder; Kinetics; Kinematics;
Electromyography; Functional electrical stimulation
ID SPINAL-CORD-INJURY; MECHANICAL EFFICIENCY; SHOULDER MUSCLES; UPPER
EXTREMITY; PUSHRIM FORCES; 2 SPEEDS; LEVEL; INDIVIDUALS; PHYSIOLOGY;
ENERGY
AB Background. The objective of this study was to examine how surface electrical stimulation of trunk musculature influences the kinematic, kinetic, and metabolic characteristics, as well as shoulder muscle activity, during wheelchair propulsion. Methods. Eleven participants with spinal cord injury propelled their own wheelchairs on a dynamometer at a speed of 1.3 m/s for three 5-minute trials. During a propulsion trial, 1 of 3 stimulation levels (HIGH, LOW, and OFF) was randomly applied to the participant's abdominal and back muscle groups with a surface functional electrical stimulation device. Propulsion kinetics, trunk kinematics, metabolic responses, and surface electromyographic (EMG) activity of 6 shoulder muscles were collected synchronously. Kinetic, kinematic, and EMG variables were recorded during 3 time intervals (30 seconds each) within a 5-minute trial. Metabolic variables were recorded through the entire 5-minute trial. Results. Participants with HIGH stimulation increased their gross mechanical efficiency (P = .05) during wheelchair propulsion. No differences were found in shoulder EMG activity, energy expenditure, and trunk motion between stimulation levels. Conclusion. Functional electrical stimulation on the trunk musculature has potential advantages in helping manual wheelchair users with spinal cord injury improve propulsion efficiency without placing additional demands on shoulder musculature.
C1 [Yang, Yu-Sheng; Koontz, Alicia M.; Cooper, Rory A.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA.
[Koontz, Alicia M.; Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
[Koontz, Alicia M.; Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA.
[Triolo, Ronald J.] Case Western Reserve Univ, Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA.
[Triolo, Ronald J.] Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA.
[Triolo, Ronald J.] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.
[Yang, Yu-Sheng] Kaohsiung Med Univ, Dept Occupat Therapy, Fac Occupat Therapy, Coll Hlth Sci, Kaohsiung, Taiwan.
[Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Med Ctr Hlth Syst, Pittsburgh, PA USA.
RP Koontz, AM (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr,151R1-H, Pittsburgh, PA 15206 USA.
EM akoontz@pitt.edu
RI Yang, Yu-Sheng/D-4525-2009
OI Yang, Yu-Sheng/0000-0002-2767-9354; Boninger,
Michael/0000-0001-6966-919X
FU US Department of Veterans Affairs, Rehabilitation Research and
Development [B3043-C]; American Society
FX This research was supported by the US Department of Veterans Affairs,
Rehabilitation Research and Development (B3043-C), and American Society
of Biomechanics Graduate Student Grant-In-Aid (2004).
NR 40
TC 7
Z9 7
U1 2
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1545-9683
J9 NEUROREHAB NEURAL RE
JI Neurorehabil. Neural Repair
PD SEP
PY 2009
VL 23
IS 7
BP 717
EP 725
DI 10.1177/1545968308331145
PG 9
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 487ZB
UT WOS:000269317100010
PM 19261768
ER
PT J
AU Connor, K
McNeese-Smith, D
van Servellen, G
Chang, B
Lee, M
Cheng, E
Hajar, A
Vickrey, BG
AF Connor, Karen
McNeese-Smith, Donna
van Servellen, Gwen
Chang, Betty
Lee, Martin
Cheng, Eric
Hajar, Abdulrahman
Vickrey, Barbara G.
TI Insight Into Dementia Care Management Using Social-Behavioral Theory and
Mixed Methods
SO NURSING RESEARCH
LA English
DT Article
DE care management; dementia; factor analysis
ID SERVICE USE; CAREGIVERS; INTERVENTION; STRAIN
AB Background. For health organizations (private and public) to advance their care-management programs, to use resources effectively and efficiently, and to improve patient outcomes, it is germane to isolate and quantify care-management activities and to identify overarching domains.
Objectives: The aims of this study were to identify and report on an application of mixed methods of qualitative statistical techniques, based on a theoretical framework, and to construct variables for factor analysis and exploratory factor analytic steps for identifying domains of dementia care management.
Methods: Care-management activity data were extracted from the care plans of 181 pairs of individuals (with dementia and their informal caregivers) who had participated in the intervention arm of a randomized controlled trial of a dementia care-management program. Activities were organized into types, using card-sorting methods, influenced by published theoretical constructs on self-efficacy and general strain theory. These activity types were mapped in the initial data set to construct variables for exploratory factor analysis. Principal components extraction with varimax and promax rotations was used to estimate the number of factors. Cronbach's alpha was calculated for the items in each factor to assess internal consistency reliability.
Results: The two-phase card-sorting technique yielded 45 activity types out of 450 unique activities. Exploratory factor analysis produced four care-management domains (factors): behavior management, clinical strategies and caregiver support, community agency, and safety. Internal consistency reliability (Cronbach's alpha) of items for each factor ranged from .63 for the factor "safety" to .89 for the factor "behavior management" (Factor 1).
Discussion: Applying a systematic method to a large set of care-management activities can identify a parsimonious number of higher order categories of variables and factors to guide the understanding of dementia care-management processes. Further application of this methodology in outcome analyses and to other data sets is necessary to test its practicality.
C1 [Connor, Karen; Cheng, Eric; Vickrey, Barbara G.] Vet Adm Greater Los Angeles Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Dept Neurol, Los Angeles, CA 90073 USA.
[Connor, Karen; Cheng, Eric; Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[McNeese-Smith, Donna; van Servellen, Gwen; Chang, Betty] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
[Lee, Martin] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
[Lee, Martin] Vet Adm Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA.
RP Connor, K (reprint author), Vet Adm Greater Los Angeles Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Dept Neurol, Los Angeles, CA 90073 USA.
EM kiconnor@ucla.edu
FU University of Los Angeles, School of Nursing, Audrienne H. Mosley
Scholarship
FX This work was supported by University of Los Angeles, School of Nursing,
Audrienne H. Mosley Scholarship.
NR 37
TC 4
Z9 4
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-6562
J9 NURS RES
JI Nurs. Res.
PD SEP-OCT
PY 2009
VL 58
IS 5
BP 348
EP 358
PG 11
WC Nursing
SC Nursing
GA 503HK
UT WOS:000270524100008
PM 19752675
ER
PT J
AU Wang, Z
Guo, YM
Bradesi, S
Labus, JS
Maarek, JMI
Lee, K
Winchester, WJ
Mayer, EA
Holschneider, DP
AF Wang, Zhuo
Guo, Yumei
Bradesi, Sylvie
Labus, Jennifer S.
Maarek, Jean-Michel I.
Lee, Kevin
Winchester, Wendy J.
Mayer, Emeran A.
Holschneider, Daniel P.
TI Sex differences in functional brain activation during noxious visceral
stimulation in rats
SO PAIN
LA English
DT Article
DE Visceral pain; Colorectal distension; Cerebral blood flow; Brain
mapping; Sex difference
ID IRRITABLE-BOWEL-SYNDROME; CORTICOTROPIN-RELEASING-FACTOR; COLORECTAL
DISTENSION; PREFRONTAL CORTEX; SEROTONERGIC ACTIVITY;
GENDER-DIFFERENCES; INSULAR CORTEX; RAPHE NUCLEUS; ESTROUS-CYCLE; IBS
PATIENTS
AB Studies in healthy human subjects and patients with irritable bowel syndrome suggest sex differences in cerebral nociceptive processing. Here we examine sex differences in functional brain activation in the rat during colorectal distention (CRD), a preclinical model of acute visceral pain. [(14)C]-iodoantipyrine was injected intravenously in awake, non-restrained female rats during 60- or 0-mmHg CRD while electromyographic abdominal activity (EMG) and pain behavior were recorded. Regional cerebral blood flow-related tissue radioactivity was analyzed by statistical parametric mapping from autoradiographic images of three-dimensionally reconstructed brains. Sex differences were addressed by comparing the current data with our previously published data collected from male rats. While sex differences in EMG and pain scores were modest, significant differences were noted in functional brain activation. Females showed widespread changes in limbic (amygdala, hypothalamus) and paralimbic structures (ventral striatum, nucleus accumbens, raphe), while males demonstrated broad cortical changes. Sex differences were apparent in the homeostatic afferent network (parabrachial nucleus, thalamus, insular and dorsal anterior cingulate cortices), in an emotional-arousal network (amygdala, locus coeruleus complex), and in cortical areas modulating these networks (prefrontal cortex). Greater activation of the ventromedial prefrontal cortex and broader limbic/paralimbic changes in females suggest greater engagement of affective mechanisms during visceral pain. Greater cortical activation in males is consistent with the concept of greater cortical inhibitory effects on limbic structures in males, which may relate to differences in attentional and cognitive attribution to visceral stimuli. These findings show remarkable similarities to reported sex differences in brain responses to visceral stimuli in humans. (C) 2009 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
C1 [Holschneider, Daniel P.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90089 USA.
[Holschneider, Daniel P.] Univ So Calif, Dept Neurol, Los Angeles, CA 90089 USA.
[Holschneider, Daniel P.] Univ So Calif, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA.
[Lee, Kevin; Winchester, Wendy J.] GlaxoSmithKline Inc, Neurol & GI Ctr Excellence Drug Discovery, Harlow, Essex, England.
[Maarek, Jean-Michel I.; Holschneider, Daniel P.] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA.
[Wang, Zhuo; Bradesi, Sylvie; Labus, Jennifer S.; Mayer, Emeran A.] Univ Calif Los Angeles, Ctr Neurobiol Stress, Los Angeles, CA USA.
[Bradesi, Sylvie; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Mayer, Emeran A.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA.
[Labus, Jennifer S.; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Labus, Jennifer S.; Mayer, Emeran A.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
[Wang, Zhuo; Bradesi, Sylvie; Mayer, Emeran A.; Holschneider, Daniel P.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Holschneider, DP (reprint author), Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, 1333 San Pablo St,BMT 403, Los Angeles, CA 90089 USA.
EM holschne@usc.edu
FU GlaxoSmithKIine; Animal Models Core; Neuroimaging Core of the Center for
Neurobiology of Stress, UCLA [NIDDK P50DK064539, NCCAM AT00268]
FX Grant support from GlaxoSmithKIine, and the Animal Models Core and the
Neuroimaging Core of the Center for Neurobiology of Stress, UCLA (NIDDK
P50DK064539, NCCAM AT00268) is acknowledged. There are no conflicts of
interest.
NR 55
TC 23
Z9 23
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3959
J9 PAIN
JI Pain
PD SEP
PY 2009
VL 145
IS 1-2
BP 120
EP 128
DI 10.1016/j.pain.2009.05.025
PG 9
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA 497YN
UT WOS:000270101400022
PM 19560270
ER
PT J
AU Miller, D
Richardson, D
Eisa, M
Bajwa, RJ
Jabbari, B
AF Miller, Diana
Richardson, Diana
Eisa, Mahmood
Bajwa, Rizma Jalees
Jabbari, Bahman
TI Botulinum Neurotoxin-A for Treatment of Refractory Neck Pain: A
Randomized, Double-Blind Study
SO PAIN MEDICINE
LA English
DT Article
DE Botulinum Neurotoxin-A; Neck; Persistent Pain; Placebo; Outcome Measures
ID TOXIN TYPE-A; NEUROPATHIC PAIN; CROSSOVER TRIAL; BACK-PAIN; INJECTION;
EFFICACY; SAFETY
AB Objective.
To investigate the efficacy and tolerability of Botulinum neurotoxin-A (BoNT-A) in the patients with refractory neck pain.
Background.
An analgesic effect is suggested for BoNT-A by a number of animal studies. Two blinded studies suggested efficacy of BoNT-A in a chronic neck pain.
Methods.
Forty-seven subjects were enrolled in a prospective, double-blind, placebo-controlled study. A total of 150 to 300 units of BoNT-A were injected into the neck and shoulder muscles based on pain localization. Subjects completed the visual analog scale (VAS), Pain Frequency Questionnaire and the Modified Oswestry Pain Questionnaire (MOPQ) at baseline, 3 and 8 weeks after the treatment. The primary outcomes consisted of: 1) >= 50% improvement on the VAS; and 2) >= 30% reduction in pain day frequency. The secondary outcome was an improvement of ADL in MOPQ. Excellent responders (ERs) were those who met all three outcomes.
Results.
At 2 months, a significant reduction in the mean VAS (pain intensity) was noted in the BoNT-A group compared with the placebo (P = 0.0018, CI 95% from 2.51 to 7.89). At 2 months, there were six ERs in the BoNT-A group and one ER in the placebo group (P = 0.0152).
Conclusion.
Administration of BoNT-A into the neck and shoulder muscles for treatment of chronic refractory neck pain met one of the two primary outcomes: reduction in pain intensity. More ERs were noted in the Botox group.
C1 [Miller, Diana; Richardson, Diana; Jabbari, Bahman] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.
[Eisa, Mahmood] Neurol Neurosurg Spine Ctr, Valdosta, GA USA.
[Bajwa, Rizma Jalees] James J Peters VA Med Ctr, Bronx, NY USA.
RP Miller, D (reprint author), Yale Univ, Sch Med, Dept Neurol, Temple Med Bldg,40 Temple St,Suite 6C, New Haven, CT 06510 USA.
EM diana.miller@yale.edu
NR 24
TC 13
Z9 13
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1526-2375
J9 PAIN MED
JI Pain Med.
PD SEP
PY 2009
VL 10
IS 6
BP 1012
EP 1017
DI 10.1111/j.1526-4637.2009.00658.x
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 495PU
UT WOS:000269906800008
PM 19594841
ER
PT J
AU Typpo, KV
Petersen, NJ
Hallman, M
Markovitz, BP
Mariscalco, M
AF Typpo, Katri V.
Petersen, Nancy J.
Hallman, Michael
Markovitz, Barry P.
Mariscalco, Michele
TI Day 1 multiple organ dysfunction syndrome is associated with poor
functional outcome and mortality in the pediatric intensive care unit
SO PEDIATRIC CRITICAL CARE MEDICINE
LA English
DT Article
DE multiple organ failure; pediatric; intensive care; critical care;
outcomes research; epidemiology
ID CRITICALLY-ILL CHILDREN; SYSTEM FAILURE; SEVERE SEPSIS; PELOD SCORE;
EPIDEMIOLOGY; RISK; IMPLEMENTATION; HYPERGLYCEMIA; MULTICENTER;
PREDICTORS
AB Objective. The epidemiology and outcomes of multiple organ dysfunction syndrome (MODS) are incompletely characterized in the pediatric population due to small sample size and conflicting diagnoses of organ failure. We sought to describe the epidemiology and outcomes of early MODS in a large clinical database of pediatric intensive care unit (PICU) patients based on consensus definitions of organ failure.
Design. Retrospective analysis of a contemporaneously collected clinical PICU database.
Setting: Virtual Pediatric Intensive Care Unit Performance System database patient admissions from January 2004 to December 2005 for 35 U.S. children's hospitals.
Patients. We evaluated 63,285 consecutive PICU admissions from January 2004 to December 2005 in the Virtual Pediatric Intensive Care Unit Performance System database. We excluded patients younger than 1 month or older than 18 years of age, and hospitals with >10% missing values for MODS variables. We identified day 1 MODS by International Pediatric Sepsis Consensus Conference criteria with day I laboratory and vital sign values. We evaluated functional status using Pediatric Overall Performance Category and Pediatric Cerebral Performance Category scores from PICU admission and discharge.
Interventions: Analysis: Student's t test, chi-square test Mann-Whitney rank sum, Kruskal-Wallis, and linear and logistic regression.
Measurements and Main Results. We analyzed 44,693 admissions from 28 hospitals meeting inclusion criteria. Overall PICU mortality was 2.8%. We identified day 1 MODS in 18.6% of admissions. Patients with day 1 MODS had higher mortality (10.0% vs. 1.2%, p < .001), longer PICU length of stay (3.6 vs. 1.3 days, p < .001), and larger change from baseline Pediatric Overall Performance Category and Pediatric Cerebral Performance Category scores at time of PICU discharge (p < .001). Infants had the highest incidence of day 1 MODS (25.2% vs. 16.5%, p < .001) compared with other age groups.
Conclusions. Using the largest clinical dataset to date and consensus definitions for organ failure, we found that children with MODS present on day 1 of intensive care unit admission have worse functional outcomes, higher mortality, and longer PICU length of stay than children who do not have MODS on day 1. Infants are disproportionally affected by MODS. (Pediatr Crit Care Med 2009; 10:562-570)
C1 [Typpo, Katri V.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Baylor Coll Med, Houston, TX USA.
[Hallman, Michael] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA.
[Markovitz, Barry P.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Markovitz, Barry P.] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA 90033 USA.
[Mariscalco, Michele] Baylor Coll Med, Dept Pediat, Sect Crit Care Med, Houston, TX 77030 USA.
RP Typpo, KV (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Baylor Coll Med, Houston, TX USA.
EM marym@bcm.tmc.edu
FU NIH [T32HL007939]; American Thoracic Society [ATS F-07-014]
FX Supported, in part, by grant NIH T32HL007939 (KVT) and American Thoracic
Society Fellow's Career Development Award ATS F-07-014 (KVT).
NR 37
TC 30
Z9 33
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1529-7535
J9 PEDIATR CRIT CARE ME
JI Pediatr. Crit. Care Med.
PD SEP
PY 2009
VL 10
IS 5
BP 562
EP 570
DI 10.1097/PCC.0b013e3181a64be1
PG 9
WC Critical Care Medicine; Pediatrics
SC General & Internal Medicine; Pediatrics
GA 496HF
UT WOS:000269959900005
PM 19741445
ER
PT J
AU Ross, JS
Mulvey, GK
Hines, EM
Nissen, SE
Krumholz, HM
AF Ross, Joseph S.
Mulvey, Gregory K.
Hines, Elizabeth M.
Nissen, Steven E.
Krumholz, Harlan M.
TI Trial Publication after Registration in ClinicalTrials.Gov: A
Cross-Sectional Analysis
SO PLOS MEDICINE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; OUTCOME REPORTING BIAS; CLINICAL-TRIALS;
ANTIINFLAMMATORY DRUGS; EMPIRICAL-EVIDENCE; OSTEOARTHRITIS; EFFICACY;
NABUMETONE; PROTOCOLS; COMMITTEE
AB Background: ClinicalTrials.gov is a publicly accessible, Internet-based registry of clinical trials managed by the US National Library of Medicine that has the potential to address selective trial publication. Our objectives were to examine completeness of registration within ClinicalTrials.gov and to determine the extent and correlates of selective publication.
Methods and Findings: We examined reporting of registration information among a cross-section of trials that had been registered at ClinicalTrials.gov after December 31, 1999 and updated as having been completed by June 8, 2007, excluding phase I trials. We then determined publication status among a random 10% subsample by searching MEDLINE using a systematic protocol, after excluding trials completed after December 31, 2005 to allow at least 2 y for publication following completion. Among the full sample of completed trials (n= 7,515), nearly 100% reported all data elements mandated by ClinicalTrials.gov, such as intervention and sponsorship. Optional data element reporting varied, with 53% reporting trial end date, 66% reporting primary outcome, and 87% reporting trial start date. Among the 10% subsample, less than half (311 of 677, 46%) of trials were published, among which 96 (31%) provided a citation within ClinicalTrials.gov of a publication describing trial results. Trials primarily sponsored by industry (40%, 144 of 357) were less likely to be published when compared with nonindustry/nongovernment sponsored trials (56%, 110 of 198; p < 0.001), but there was no significant difference when compared with government sponsored trials (47%, 57 of 122; p = 0.22). Among trials that reported an end date, 75 of 123 (61%) completed prior to 2004, 50 of 96 (52%) completed during 2004, and 62 of 149 (42%) completed during 2005 were published (p = 0.006).
Conclusions: Reporting of optional data elements varied and publication rates among completed trials registered within ClinicalTrials.gov were low. Without greater attention to reporting of all data elements, the potential for ClinicalTrials.gov to address selective publication of clinical trials will be limited.
C1 [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA.
[Ross, Joseph S.] James J Peters VA Med Ctr, HSR&D Res Enhancement Award Program, Bronx, NY USA.
[Ross, Joseph S.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Mulvey, Gregory K.; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA.
[Hines, Elizabeth M.] Amherst Coll, Amherst, MA 01002 USA.
[Nissen, Steven E.] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Sect Cardiolovasc Med, New Haven, CT 06510 USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA.
[Krumholz, Harlan M.] Yale Univ, Sch Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA.
RP Ross, JS (reprint author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA.
EM joseph.ross@mssm.edu
FU National Institute on Aging [K08 AG032886]; American Federation of Aging
Research; Department of Veterans Affairs Health Services Research and
Development [TRP-02-149]; Hartford Foundation
FX This project was not directly supported by any external grants or funds.
JSR is currently supported by the National Institute on Aging (K08
AG032886) and by the American Federation of Aging Research through the
Paul B. Beeson Career Development Award Program and had received support
from the Department of Veterans Affairs Health Services Research and
Development Service project no. TRP-02-149 and by the Hartford
Foundation during earlier periods in which this work was being
conducted. The views expressed in this article are those of the authors
and do not necessarily represent the views of the Department of Veterans
Affairs. The American Federation of Aging Research, the Department of
Veterans Affairs, and the Hartford Foundation had no role in the design
or conduct of the study; collection, management, analysis or
interpretation of the data; preparation, review or approval of the
manuscript.
NR 31
TC 161
Z9 162
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD SEP
PY 2009
VL 6
IS 9
AR e1000144
DI 10.1371/journal.pmed.1000144
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 506ZH
UT WOS:000270818100008
PM 19901971
ER
PT J
AU Goodman, DW
Thase, ME
AF Goodman, David W.
Thase, Michael E.
TI Recognizing ADHD in Adults with Comorbid Mood Disorders: Implications
for Identification and Management
SO POSTGRADUATE MEDICINE
LA English
DT Article
DE ADHD; mood disorders; comorbidity; adults
ID ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; DEFICIT HYPERACTIVITY
DISORDER; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND TRIAL; OROS
METHYLPHENIDATE; BIPOLAR DISORDER; PSYCHIATRIC COMORBIDITY; SURVEY
REPLICATION; EXTENDED-RELEASE; DEPRESSION
AB The objective of this study was to assist those in psychiatric clinical practice in the identification and management of attention-deficit/hyperactivity disorder (ADHD) in adults, with an emphasis on ADHD in the presence of comorbid mood disorders in adults. PubMed was searched to identify relevant studies and critical reviews published in English between 1988 and 2008 on the prevalence, persistence, and consequences of ADHD in adults. Additionally, relevant studies and critical reviews pertaining to the treatment of adults with ADHD and the relationships between ADHD and mood disorders with regard to overlapping symptom profiles, comorbidity, and treatment options were identified. The symptoms of ADHD persist into adulthood for a high proportion of children with this disorder. Among adults, the estimated prevalence of clinician-assessed ADHD in the general population is 4% to 5%. Untreated ADHD can adversely affect school and work achievements, diminish self-esteem, damage interpersonal relationships, and significantly reduce quality of life for adults. A significant proportion of adults with mood disorders have comorbid ADHD, and a significant proportion of adults with ADHD have comorbid mood disorders. Few reports have described the outcome of treatment of individuals with ADHD and concurrent mood disorders and no controlled trials were identified. Attention-deficit/hyperactivity disorder in adults can be identified despite resembling, or coexisting with, other psychiatric disorders. The complexities of comorbid psychiatric conditions require careful diagnostic prioritization when developing a comprehensive sequential treatment plan. The current research literature offers little clinical guidance for constructing treatment algorithms.
C1 [Goodman, David W.] Adult Attent Deficit Disorder Ctr Maryland, Johns Hopkins Green Spring Stn, Lutherville Timonium, MD USA.
[Goodman, David W.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.
[Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Goodman, DW (reprint author), Johns Hopkins Green Spring Stn, 10751 Falls Rd,Suite 306, Baltimore, MD 21093 USA.
EM dgoodma4@jhmi.edu
FU Shire US, Inc
FX Funding was provided by Shire US, Inc. The authors wish to thank Timothy
Coffey, Rosa Real, and William Perlman, Excerpta Medica, Bridgewater,
NJ, for their editorial assistance.
NR 67
TC 15
Z9 15
U1 0
U2 4
PU JTE MULTIMEDIA
PI BERWYN
PA 1235 WESTLAKES DR, STE 220, BERWYN, PA 19312 USA
SN 0032-5481
J9 POSTGRAD MED
JI Postgrad. Med.
PD SEP
PY 2009
VL 121
IS 5
BP 20
EP 30
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 506TL
UT WOS:000270799000003
PM 19820271
ER
PT J
AU Tice, JA
Kerlikowske, K
AF Tice, Jeffrey A.
Kerlikowske, Karla
TI Screening and Prevention of Breast Cancer in Primary Care
SO PRIMARY CARE
LA English
DT Review
DE Breast cancer screening; Breast cancer prevention; Mammography; Digital
mammography; Breast magnetic resonance imaging; Chemoprevention; Risk
assessment; Guidelines
ID FIELD DIGITAL MAMMOGRAPHY; CARCINOMA IN-SITU; BODY-MASS INDEX;
RECREATIONAL PHYSICAL-ACTIVITY; FALSE-POSITIVE MAMMOGRAMS; SURGICAL
ADJUVANT BREAST; HIGH GENETIC RISK; RANDOMIZED CONTROLLED-TRIALS;
ESTROGEN PLUS PROGESTIN; SWEDISH 2-COUNTY TRIAL
AB Mammography remains the mainstay of breast cancer screening. There is little controversy that mammography reduces the risk of dying from breast cancer by about 23% among women between the ages of 50 and 69 years, although the harms associated with false-positive results and overdiagnosis limit the net benefit of mammography. Women in their 70s may have a small benefit from screening mammography, but overdiagnosis increases in this age group as do competing causes of death. While new data support a 16% reduction in breast cancer mortality for 40- to 49-year-old women after 10 years of screening, the net benefit is less compelling in part because of the lower incidence of breast cancer in this age group and because mammography is less sensitive and specific in women younger than 50 years. Digital mammography is more sensitive than film mammography in young women with similar specificity, but no improvements in breast cancer outcomes have been demonstrated. Magnetic resonance imaging may benefit the highest risk women. Randomized trials suggest that self-breast examination does more harm than good. Primary prevention with currently approved medications will have a negligible effect on breast cancer incidence. Public health efforts aimed at increasing mammography screening rates, promoting regular exercise in all women, maintaining a healthy weight, limiting alcohol intake, and limiting postmenopausal hormone therapy may help to continue the recent trend of lower breast cancer incidence and mortality among American women.
C1 [Tice, Jeffrey A.] Univ Calif San Francisco, Div Gen Internal Med, Dept Med, San Francisco, CA 94143 USA.
[Kerlikowske, Karla] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA.
RP Tice, JA (reprint author), Univ Calif San Francisco, Div Gen Internal Med, Dept Med, 1701 Divisadero St,Suite 554, San Francisco, CA 94143 USA.
EM jeff.tice@ucsf.edu
NR 202
TC 13
Z9 15
U1 2
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0095-4543
J9 PRIMARY CARE
JI Primary Care
PD SEP
PY 2009
VL 36
IS 3
BP 533
EP +
DI 10.1016/j.pop.2009.04.003
PG 28
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 485PL
UT WOS:000269135800008
PM 19616154
ER
PT J
AU Lloyd, JC
Banez, LL
Aronson, WJ
Terris, MK
Presti, JC
Amling, CL
Kane, CJ
Freedland, SJ
AF Lloyd, J. C.
Banez, L. L.
Aronson, W. J.
Terris, M. K.
Presti, J. C., Jr.
Amling, C. L.
Kane, C. J.
Freedland, S. J.
TI Preoperative predictors of blood loss at the time of radical
prostatectomy: results from the SEARCH database
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Article
DE prostate neoplasm; blood loss; obesity; prostate weight; prostatectomy
ID BODY-MASS INDEX; RETROPUBIC PROSTATECTOMY; SINGLE-INSTITUTION; OUTCOMES;
CANCER; VOLUME; SURGEON; OBESITY; WEIGHT; IMPACT
AB The literature contains conflicting data on preoperative predictors of estimated blood loss (EBL) at radical retropubic prostatectomy (RRP). We sought to examine preoperative predictors of EBL at the time of RRP among patients from the SEARCH database to lend clarity to this issue. A total of 1154 patients were identified in the SEARCH database who underwent RRP between 1988 and 2008 and had EBL data available. We examined multiple preoperative factors for their ability to predict EBL using multivariate linear regression analysis. Median EBL was 900 ml (s.d. 1032). The 25th and 75th percentile for EBL were 600 and 1500 ml, respectively. EBL increased significantly with increasing body mass index (BMI) and increasing prostate size and decreased with more recent year of RRP (all P < 0.001). The mean-adjusted EBL in normal-weight men (BMI < 25 kg/m(2)) was 807 ml compared to 1067 ml among severely obese men (BMI >= 35 kg/m(2)). Predicted EBL for men with the smallest prostates (<20 g) was 721 ml, compared to 1326 ml for men with prostates >= 100 g. Finally, statistically significant differences between centers were observed, with mean- adjusted EBL ranging from 844 to 1094 ml. Both BMI and prostate size are predictors of increased EBL. Prostate size is of particular note, as a nearly twofold increased EBL was seen from the smallest (<20 g) to the largest prostates (>= 100 g). Over time, average EBL significantly decreased. Finally, significant differences in EBL were observed between centers. Patients with multiple risk factors should be forewarned they are at increased risk for higher EBL, which may translate into a greater need for blood transfusion. Prostate Cancer and Prostatic Diseases (2009) 12, 264-268; doi: 10.1038/pcan.2009.6; published online 24 March 2009
C1 [Lloyd, J. C.; Banez, L. L.; Freedland, S. J.] Duke Univ, Sch Med, Div Urol, Duke Prostate Ctr, Durham, NC 27710 USA.
[Lloyd, J. C.; Banez, L. L.; Freedland, S. J.] Duke Univ, Sch Med, Div Urol Surg, Dept Surg & Pathol, Durham, NC 27710 USA.
[Lloyd, J. C.; Banez, L. L.; Freedland, S. J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA.
[Aronson, W. J.] Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA.
[Aronson, W. J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
[Terris, M. K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA.
[Terris, M. K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA.
[Presti, J. C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA.
[Presti, J. C., Jr.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA.
[Amling, C. L.] Univ Alabama, Dept Urol, Birmingham, AL USA.
[Kane, C. J.] Vet Affairs Med Ctr, Urol Sect, San Diego, CA 92161 USA.
[Kane, C. J.] Univ Calif San Diego, Sch Med, Div Urol, San Diego, CA 92103 USA.
RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Div Urol, Duke Prostate Ctr, Box 2626 DUMC, Durham, NC 27710 USA.
EM steve.freedland@duke.edu
OI Terris, Martha/0000-0002-3843-7270
FU Department of Veterans Affairs, National Institute of Health
[R01CA100938]; NIH Specialized Programs of Research Excellence [P50
CA92131-01A1]; Georgia Cancer Coalition; Department of Defense, Prostate
Cancer Research Program; American Urological Association
Foundation/Astellas Rising Star in Urology Award; US Army or the
Department of Defense
FX This study was supported by the Department of Veterans Affairs, National
Institute of Health R01CA100938 (WJA), NIH Specialized Programs of
Research Excellence Grant P50 CA92131-01A1 (WJA), the Georgia Cancer
Coalition (MKT), the Department of Defense, Prostate Cancer Research
Program, (LLB, SJF) and the American Urological Association
Foundation/Astellas Rising Star in Urology Award (SJF). Views and
opinions of, and endorsements by the author(s) do not reflect those of
the US Army or the Department of Defense.
NR 20
TC 6
Z9 7
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1365-7852
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD SEP
PY 2009
VL 12
IS 3
BP 264
EP 268
DI 10.1038/pcan.2009.6
PG 5
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 490FD
UT WOS:000269483200009
PM 19322137
ER
PT J
AU Tabata, K
Watanabe, M
Naruishi, K
Edamura, K
Satoh, T
Yang, G
Fattah, EA
Wang, J
Goltsov, A
Floryk, D
Soni, SD
Kadmon, D
Thompson, TC
AF Tabata, K.
Watanabe, M.
Naruishi, K.
Edamura, K.
Satoh, T.
Yang, G.
Fattah, E. Abdel
Wang, J.
Goltsov, A.
Floryk, D.
Soni, S. D.
Kadmon, D.
Thompson, T. C.
TI Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified
macrophages in a mouse model of residual prostate cancer
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Article
DE adenoviral vectors; IL-12; matrix-embedded gene-modified cell therapy;
residual prostate cancer model
ID TUMOR-ASSOCIATED MACROPHAGES; RADICAL PROSTATECTOMY; INTERLEUKIN-12;
PROGRESSION; METASTASIS; SURGERY; GROWTH; AGENT
AB We evaluated the potential use of intraoperative gelatin matrix hemostatic sealant (GMHS; FloSeal; Baxter Healthcare) embedded with macrophages (M phi) transduced with murine interleukin (IL)-12 recombinant adenoviral vector (G/M phi/AdmIL-12) for prevention of recurrence of prostate cancer following radical prostatectomy. Application of G/M phi/AdmIL-12 resulted in significant suppression of tumor growth and spontaneous lung metastases, a statistically significant survival advantage of the G/M phi/AdmIL-12-treated animals, more efficient trafficking of M phi to lymph nodes draining from the prostate and generation of systemic natural killer cell activity and tumor-specific cytolytic T lymphocyte responses compared to the controls in a preclinical mouse model of residual prostate cancer. Our data recommend this treatment as a novel adjuvant for prevention of local recurrence of prostate cancer following radical prostatectomy. Prostate Cancer and Prostatic Diseases (2009) 12, 301-309; doi: 10.1038/pcan.2008.57; published online 23 December 2008
C1 [Tabata, K.; Watanabe, M.; Naruishi, K.; Edamura, K.; Satoh, T.; Yang, G.; Fattah, E. Abdel; Wang, J.; Goltsov, A.; Floryk, D.; Soni, S. D.; Kadmon, D.; Thompson, T. C.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.
[Kadmon, D.; Thompson, T. C.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Thompson, T. C.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA.
[Thompson, T. C.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
RP Thompson, TC (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM timthomp@mdanderson.org
NR 21
TC 2
Z9 2
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1365-7852
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD SEP
PY 2009
VL 12
IS 3
BP 301
EP 309
DI 10.1038/pcan.2008.57
PG 9
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 490FD
UT WOS:000269483200016
PM 19104507
ER
PT J
AU Kaplan, K
Kottsieper, P
Scott, J
Salzer, M
Solomon, P
AF Kaplan, Katy
Kottsieper, Petra
Scott, Jeniece
Salzer, Mark
Solomon, Phyllis
TI Adoption and Safe Families Act State Statutes Regarding Parents with
Mental Illnesses: A Review and Targeted Intervention
SO PSYCHIATRIC REHABILITATION JOURNAL
LA English
DT Article
DE parenting; psychiatric disability; disability policy; stigma
ID MOTHERS
AB Topic: This paper describes an intervention targeting states that list a parental mental illness/disability as an "aggravated circumstance" under the Adoption and Safe Families Act Of 1997 (ASFA), resulting in reasonable efforts not required to reunify a family. Purpose: This paper delineates the results from our review of ASFA state statutes, the development of a model ASFA statute, and strategies to educate legislators and the public about the impact of discrimination that parents with mental illnesses encounter because of ASFA legislation with the intent of modifying state ASFA legislation. Sources Used: The following sources were used for this educational initiative: a literature review and a review of ASFA state statutes. Conclusions: Adoption of the model ASFA state statute is simply a first step in an effort to end the discrimination that parents with psychiatric disabilities face; additional efforts are also noted.
C1 [Kaplan, Katy; Salzer, Mark; Solomon, Phyllis] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Salzer, Mark] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin 4, Philadelphia, PA USA.
[Scott, Jeniece] Villanova Law Sch, Villanova, PA USA.
[Kottsieper, Petra] Philadelphia Coll Osteopath Med, Philadelphia, PA USA.
[Solomon, Phyllis] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA.
RP Kaplan, K (reprint author), Univ Penn, Dept Psychiat, 3535 Market St,CMHPSR 3rd Floor, Philadelphia, PA 19104 USA.
EM katykap@mail.med.upenn.edu
NR 7
TC 7
Z9 7
U1 1
U2 5
PU CENTER PSYCHIATRIC REHABILITATION
PI BOSTON
PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA
SN 1095-158X
J9 PSYCHIATR REHABIL J
JI Psychiatr. Rehabil. J.
PD FAL
PY 2009
VL 33
IS 2
BP 91
EP 94
DI 10.2975/33.2.2009.91.94
PG 4
WC Psychiatry; Rehabilitation
SC Psychiatry; Rehabilitation
GA 507JZ
UT WOS:000270850700003
PM 19808203
ER
PT J
AU Freed, MC
Yeager, DE
Liu, X
Gore, KL
Engel, CC
Magruder, KM
AF Freed, Michael C.
Yeager, Derik E.
Liu, Xian
Gore, Kristie L.
Engel, Charles C.
Magruder, Kathryn M.
TI Preference-Weighted Health Status of PTSD Among Veterans: An Outcome for
Cost-Effectiveness Analysis Using Clinical Data
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; PRIMARY-CARE; UTILITY MEASURES;
METAANALYSIS; SYMPTOMS; PHARMACOTHERAPY; AFGHANISTAN; PREVALENCE;
VALIDATION; CHECKLIST
AB Objective: Posttraumatic stress disorder (PTSD) is a highly prevalent, chronic, disabling but treatable condition. Preference-based measures (for example, health utilities) are recommended for and useful in cost-effectiveness analyses and for policy decisions because they reflect a population's valuation of the desirability of disease states. However, no such measures exist for PTSD. This study aimed to estimate preference-weighted health status associated with PTSD and common co-occurring mental disorders in a sample of veterans by transforming health-related quality-of-life data into preference-weighted health status scores (PWHS scores), develop a usable regression model to predict PWHS scores from other data sets, and compare preference-weighted health status of PTSD with that of another chronic disorder, chronic obstructive pulmonary disease (COPD). Methods: A secondary analysis was performed on data from a random sample of 808 veterans (79% male; 12% met criteria for PTSD) in four primary care clinics. Veterans responded to the PTSD Checklist (PCL), Clinician-Administered PTSD Scale, Mini-International Neuropsychiatric Interview, and Medical Outcomes Survey Short Form-36. Results: PWHS scores were .029 lower among veterans with PTSD compared with veterans without PTSD, all else being equal. However, scores depended on PTSD severity, when the analysis controlled for other model variables. Specifically, PWHS scores dropped by .004 with a 1-unit increase in PCL scores among veterans without PTSD. Among veterans with PTSD, the reduction was .002. PTSD was associated with lower preference-weighted health status than COPD. Conclusions: This is the first study to estimate preference-weighted health status of persons with PTSD. These PWHS scores can be helpful in cost-effectiveness studies of PTSD treatments. (Psychiatric Services 60: 1230-1238, 2009)
C1 [Freed, Michael C.; Liu, Xian; Gore, Kristie L.; Engel, Charles C.] Walter Reed Army Med Ctr, Deployment Hlth Clin Ctr, Washington, DC 20307 USA.
[Freed, Michael C.; Liu, Xian; Gore, Kristie L.; Engel, Charles C.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA.
[Yeager, Derik E.; Magruder, Kathryn M.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA.
[Yeager, Derik E.; Magruder, Kathryn M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
RP Freed, MC (reprint author), Walter Reed Army Med Ctr, Deployment Hlth Clin Ctr, Bldg 2,Room 3E01,6900 Georgia Ave,NW, Washington, DC 20307 USA.
EM mc_freed@onebox.com
FU Veterans Affairs Health Services Research and Development [VCR-99-010-2]
FX This work was partly supported by grant VCR-99-010-2 (to Dr. Magruder)
funded by the Veterans Affairs Health Services Research and Development
program. The authors thank Phoebe Kuesters, B. A., and Leah Russell, M.
A., for their administrative support. The views expressed in this
manuscript are those of the authors and do not necessarily represent the
official policy or position of the Deployment Health Clinical Center,
Walter Reed Army Medical Center, Uniformed Services University of the
Health Sciences, Department of Defense, Department of Veterans Affairs,
United States Government, or Medical University of South Carolina.
NR 45
TC 7
Z9 7
U1 2
U2 6
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD SEP
PY 2009
VL 60
IS 9
BP 1230
EP 1238
PG 9
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 489RD
UT WOS:000269438700012
PM 19723738
ER
PT J
AU Zhang, XY
Chen, DC
Qi, LY
Wang, F
Xiu, MH
Chen, S
Wu, GY
Kosten, TA
Kosten, TR
AF Zhang, Xiang Yang
Chen, Da Chun
Qi, Ling Yan
Wang, Fang
Xiu, Mei Hong
Chen, Song
Wu, Gui Ying
Kosten, Therese A.
Kosten, Thomas R.
TI Gender differences in the prevalence, risk and clinical correlates of
tardive dyskinesia in Chinese schizophrenia
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Schizophrenia; Gender difference; Tardive dyskinesia; Prevalence; Risk
factor; Antipsychotic; Chinese
ID ATYPICAL ANTIPSYCHOTICS; PSYCHIATRIC-PATIENTS; NEGATIVE SYMPTOMS;
EXTRAPYRAMIDAL SYNDROMES; TYPICAL ANTIPSYCHOTICS; OLDER PATIENTS;
HONG-KONG; OUTPATIENTS; POPULATION; DRUGS
AB Despite extensive use of antipsychotic drug treatment, few studies address the prevalence of tardive dyskinesia (TD) in homogeneous ethnic groups such as the Chinese. This study examined gender-specific relationships between TD and symptom levels in schizophrenia among Han Chinese, which have previously received little systematic study.
Five hundred and twenty-two inpatients with schizophrenia receiving long-term treatment with antipsychotics were evaluated with the AIMS. The patient's psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS). Demographic and clinical data were collected from a detailed questionnaire and medical records.
The overall TD prevalence was 33.7% with rates of 39.2% (138/352) in males and 22.4% (38/170) in females (chi (2) = 14.6, df = 1, p < 0.0001; adjust odds ratio 2.06; CI, 1.32-3.16). The AIMS score in patients with TD was lower in females than males (5.3 +/- 3.9 vs 6.7 +/- 3.7, t = 2.52, p < 0.01) after adjustment for the significant covariates. TD was associated with the negative symptoms on the PANSS in both genders, and with age, PANSS total and positive symptoms in men, not women.
Our present findings suggest that there are gender differences in the prevalence, risk, and clinical correlates of TD in schizophrenia. Although this study is limited by cross-sectional designs, the magnitude of these gender-specific differences is substantial and deservers further prospective study.
C1 [Zhang, Xiang Yang; Kosten, Therese A.; Kosten, Thomas R.] VA Med Ctr, Houston, TX 77030 USA.
[Zhang, Xiang Yang; Chen, Da Chun; Qi, Ling Yan; Wang, Fang; Xiu, Mei Hong; Chen, Song] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing 100096, Peoples R China.
[Zhang, Xiang Yang; Wu, Gui Ying] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu; kosten@bcm.edu
FU Beijing Municipal Natural Science Foundation [ID: 7072035]; Stanley
Medical Research Institute [03T-459, 05T-726]; Department of Veterans
Affairs; United States National Institute of Health [K05-DA0454,
P50-DA18827, U01-MH79639]
FX Supported by grants from the Beijing Municipal Natural Science
Foundation (ID: 7072035), the Stanley Medical Research Institute
(03T-459 and 05T-726), and the Department of Veterans Affairs, VISN 16,
Mental Illness Research, Education and Clinical Center ( MIRECC), United
States National Institute of Health K05-DA0454, P50-DA18827, and
U01-MH79639.
NR 51
TC 14
Z9 15
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
EI 1432-2072
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD SEP
PY 2009
VL 205
IS 4
BP 647
EP 654
DI 10.1007/s00213-009-1590-8
PG 8
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 477JD
UT WOS:000268514400009
PM 19529921
ER
PT J
AU Hauser, P
Morasco, BJ
Linke, A
Bjornson, D
Ruimy, S
Matthews, A
Rifai, A
Indest, DW
Loftis, JM
AF Hauser, Peter
Morasco, Benjamin J.
Linke, Alex
Bjornson, Dannell
Ruimy, Samantha
Matthews, Annette
Rifai, Aly
Indest, David W.
Loftis, Jennifer M.
TI Antiviral Completion Rates and Sustained Viral Response in Hepatitis C
Patients With and Without Preexisting Major Depressive Disorder
SO PSYCHOSOMATICS
LA English
DT Article
ID ALPHA-INDUCED DEPRESSION; SUBSTANCE USE DISORDERS; INTERFERON-ALPHA;
PSYCHIATRIC-DISORDERS; VIRUS-INFECTION; PLUS RIBAVIRIN; THERAPY;
VETERANS; ILLNESS
AB Background: Despite evidence suggesting that the majority of patients with hepatitis C virus (HCV) have psychiatric and substance use disorders, patients with these comorbidities have historically been excluded from antiviral therapy for HCV. Objective: The authors compared antiviral completion and sustained virologic response (SVR) rates between hepatitis C ( HCV) patients with versus those without preexisting major depressive disorder (MDD). Method: The authors performed a chart review of HCV patients ( 30 with MDD and 25 control subjects) who attended an optional HCV education class and signed informed consent allowing collection of clinical data. Results: The MDD group had completion and SVR rates similar to those of control subjects. Neuropsychiatric side effects and reasons for discontinuation of treatment were not different between groups. Conclusion: Patients with MDD can be safely and effectively treated with antiviral therapy. (Psychosomatics 2009; 50: 500-505)
C1 [Hauser, Peter] Portland VA Med Ctr, NW Hepatitis Resource Ctr C, Portland, OR 97202 USA.
Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97202 USA.
Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA.
Portland VA Med Ctr, JENS Lab, Portland, OR 97202 USA.
Oregon Hlth & Sci Univ, Dept Internal Med, Div Gastroenterol, Portland, OR 97201 USA.
RP Hauser, P (reprint author), Portland VA Med Ctr, NW Hepatitis Resource Ctr C, 3710 SW US Vet Hosp Rd,POB 1035 V3MHC, Portland, OR 97202 USA.
EM peter.hauser2@med.va.gov
FU VA Merit Review Program, Northwest Hepatitis C Resource Center, Janssen
Pharmaceuticals; NIH [K23DA023467-01A1]; VA Clinical Sciences Research
Development
FX Dr. Hauser receives research/grant support from the VA Merit Review
Program, Northwest Hepatitis C Resource Center, Janssen Pharmaceuticals,
and is currently on the speaker's bureau for Astra Zeneca and Jazz
Pharmaceutical. Dr. Morasco receives support from the NIH
(K23DA023467-01A1). Drs. Matthews and Loftis are supported by VA
Clinical Sciences Research & Development career development awards.
NR 26
TC 14
Z9 14
U1 0
U2 2
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD SEP-OCT
PY 2009
VL 50
IS 5
BP 500
EP 505
PG 6
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA 510OY
UT WOS:000271100700010
PM 19855036
ER
PT J
AU Zhang, XY
Chen, DC
Xiu, MH
Wang, F
Qi, LY
Sun, HQ
Chen, S
He, SC
Wu, GY
Haile, CN
Kosten, TA
Lu, L
Kosten, TR
AF Zhang, Xiang Yang
Chen, Da Chun
Xiu, Mei Hong
Wang, Fan
Qi, Ling Yan
Sun, Hong Qang
Chen, Song
He, Shu Chang
Wu, Gui Ying
Haile, Colin N.
Kosten, Therese A.
Lu, Lin
Kosten, Thomas R.
TI The novel oxidative stress marker thioredoxin is increased in
first-episode schizophrenic patients
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Oxidative stress; Free radical; Thioredoxin;
Psychopathology
ID ATYPICAL ANTIPSYCHOTIC-DRUGS; ANTIOXIDANT DEFENSE SYSTEM; BLOOD
SUPEROXIDE-DISMUTASE; FREE-RADICAL PATHOLOGY; TARDIVE-DYSKINESIA;
LIPID-PEROXIDATION; THERAPEUTIC IMPLICATIONS; PLASMA THIOREDOXIN; REDOX
REGULATION; DIFFERENT FORMS
AB Excessive free radical production leading to oxidative stress may be involved in the pathophysiology of schizophrenia. oxidative stress increases serum thioredoxin (TRX), a redox-regulating protein with antioxidant activity recognized as an oxidative-stress marker. The aim of this study was to assess the clinical significance of serum TRX levels in various stages of schizophrenia. Serum TRX levels were determined using ELISA from 60 never-medicated first-episode and 66 medicated chronic schizophrenia patients and 66 healthy control subjects matched for age and gender. The psychopathology of schizophrenia was assessed by the Positive and Negative Syndrome Scale (PANSS). Our results showed that group comparison between first-episode and chronic patients and control groups revealed significantly increased serum TRX only in first-episode patients. Increased levels of TRX in patients experiencing an acute stage schizophrenic episode was also significantly higher compared to chronic schizophrenic patients on antipsychotic medication. Serum TRX was also positively correlated with positive symptoms of schizophrenia. Our results suggest oxidative stress occurs in an acute stage of schizophrenic episode and may have an important role in pathogenesis and symptomology of schizophrenia. Lower TRX levels in chronic patients treated with antipsychotics may have implications for treatment outcome. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Zhang, Xiang Yang] Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Zhang, Xiang Yang; Chen, Da Chun; Xiu, Mei Hong; Wang, Fan; Qi, Ling Yan; Sun, Hong Qang; Chen, Song] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing, Peoples R China.
[He, Shu Chang] Peking Univ, Dept Psychol, Beijing 100871, Peoples R China.
[Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100871, Peoples R China.
RP Zhang, XY (reprint author), Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu; kosten@bcm.edu
OI Haile, Colin/0000-0001-8293-7291
FU Stanley Medical Research Institute [03T-459, 05T-726]; Beijing Municipal
Natural Science Foundation [7072035]; Department of Veterans Affairs,
VISN 16; Mental Illness Research, Education and Clinical Center
(MIRECC); United States National Institute of Health [K05-DA0454,
P50-DA18827, U01-MH79639]
FX Funding for this study was provided by grants from the Stanley Medical
Research Institute (03T-459 and 05T-726), the Beijing Municipal Natural
Science Foundation (7072035) and the Department of Veterans Affairs,
VISN 16, Mental Illness Research, Education and Clinical Center
(MIRECC), United States National Institute of Health K05-DA0454,
P50-DA18827 and U01-MH79639. These sources had no further role in the
study design; in the collection, analysis and interpretation of data; in
the writing of the report; and in the decision to submit the paper for
publication.
NR 57
TC 42
Z9 42
U1 2
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD SEP
PY 2009
VL 113
IS 2-3
BP 151
EP 157
DI 10.1016/j.schres.2009.05.016
PG 7
WC Psychiatry
SC Psychiatry
GA 492CD
UT WOS:000269630800005
PM 19540723
ER
PT J
AU Bartzokis, G
Lu, PH
Stewart, SB
Oluwadara, B
Lucas, AJ
Pantages, J
Pratt, E
Sherin, JE
Altshuler, LL
Mintz, J
Gitlin, MJ
Subotnik, KL
Nuechterlein, KH
AF Bartzokis, George
Lu, Po H.
Stewart, Stephanie B.
Oluwadara, Bolanle
Lucas, Andrew J.
Pantages, Joanna
Pratt, Erika
Sherin, Jonathan E.
Altshuler, Lori L.
Mintz, Jim
Gitlin, Michael J.
Subotnik, Kenneth L.
Nuechterlein, Keith H.
TI In vivo evidence of differential impact of typical and atypical
antipsychotics on intracortical myelin in adults with schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article; Proceedings Paper
CT 47th Annual Meeting of the American-College-of-Neuropsychopharmacology
CY DEC 07-11, 2008
CL Scottsdale, AZ
SP Amer Coll Neuropsychopharmacol
DE Schizophrenia; Second generation antipsychotic medication; Atypical;
Intracortical myelin; White matter; Gray matter; Oligodendrocyte;
Trajectory; Development; Lipid; Age; Prevention
ID MAJOR DEPRESSIVE DISORDER; DORSOLATERAL PREFRONTAL CORTEX; INCREASES
CELL-PROLIFERATION; MATTER STRUCTURAL INTEGRITY; WHITE-MATTER; BIPOLAR
DISORDER; GRAY-MATTER; NEUROPSYCHIATRIC DISORDERS; DEVELOPMENTAL
DISORDERS; MORPHOMETRIC ANALYSIS
AB Context: Imaging and post-mortem studies provide converging evidence that patients with schizophrenia have a dysregulated developmental trajectory of frontal lobe myelination. The hypothesis that typical and atypical medications may differentially impact brain myelination in adults with schizophrenia was previously assessed with inversion recovery (IR) images. Increased white matter (WM) volume suggestive of increased myelination was detected in the patient group treated with an atypical antipsychotic compared to a typical one.
Objective: In a follow-up reanalysis of MRI images from the original study, we used a novel method to assess whether the difference in WM volumes could be caused by a differential effect of medications on the intracortical myelination process.
Design, setting, and participants: Two different male cohorts of healthy controls ranging in age from 18-35 years were compared to cohorts of subjects with schizophrenia who were treated with either oral risperidone (Ris) or fluphenazine decanoate (Fd).
Main outcome measure: A novel MRI method that combines the distinct tissue contrasts provided by IR and proton density (PD) images was used to estimate intracortical myelin (ICM) volume.
Results: When compared with their pooled healthy control comparison group, the two groups of schizophrenic patients differed in the frontal lobe ICM measure with the Ris group having significantly higher volume.
Conclusions: The data suggest that in adults with schizophrenia antipsychotic treatment choice may be specifically and differentially impacting later-myelinating intracortical circuitry. In vivo MRI can be used to dissect subtle differences in brain tissue characteristics and thus help clarify the effect of pharmacologic treatments on developmental and pathologic processes. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Bartzokis, George; Stewart, Stephanie B.; Oluwadara, Bolanle; Lucas, Andrew J.; Pantages, Joanna; Pratt, Erika; Sherin, Jonathan E.; Altshuler, Lori L.; Gitlin, Michael J.; Subotnik, Kenneth L.; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA.
[Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Div Brain Mapping,Lab Neuroimaging, Los Angeles, CA 90095 USA.
[Bartzokis, George; Oluwadara, Bolanle; Pantages, Joanna; Pratt, Erika; Sherin, Jonathan E.; Altshuler, Lori L.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
[Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
RP Bartzokis, G (reprint author), 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA.
EM gbar@ucla.edu
RI Bartzokis, George/K-2409-2013
FU NCRR NIH HHS [P41 RR013642-107155, P41 RR013642-116576, P41 RR013642,
P41 RR013642-125914, P41 RR013642-097338]; NIA NIH HHS [AG027342, R01
AG027342, R01 AG027342-02, R01 AG027342-03]; NIMH NIH HHS [MH0266029,
MH37705, MH51928, MH6357, P50 MH066286, P50 MH066286-01A19005, P50
MH066286-029005, P50 MH066286-039005, P50 MH066286-049005, P50
MH066286-059005, R01 MH037705, R01 MH037705-09S1, R01 MH037705-15A1, R01
MH037705-16, R01 MH037705-17, R01 MH037705-18, R01 MH037705-19, R01
MH037705-20A1, R01 MH037705-21, R01 MH037705-21S1, R01 MH037705-22, R01
MH037705-23, R01 MH037705-24, R01 MH066029, R01 MH066029-01A2, R01
MH066029-02, R01 MH066029-03, R01 MH066029-04, R01 MH066029-05]
NR 112
TC 45
Z9 46
U1 2
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD SEP
PY 2009
VL 113
IS 2-3
BP 322
EP 331
DI 10.1016/j.schres.2009.06.014
PG 10
WC Psychiatry
SC Psychiatry
GA 492CD
UT WOS:000269630800026
PM 19616412
ER
PT J
AU Vosler, PS
Graham, SH
Wechsler, LR
Chen, J
AF Vosler, Peter S.
Graham, Steven H.
Wechsler, Lawrence R.
Chen, Jun
TI Mitochondrial Targets for Stroke Focusing Basic Science Research Toward
Development of Clinically Translatable Therapeutics
SO STROKE
LA English
DT Article
DE cerebral ischemia; therapeutics; neuroprotection; mitochondria
ID ISCHEMIC BRAIN-INJURY; N-TERMINAL KINASE; FOCAL CEREBRAL-ISCHEMIA;
INDUCED CELL-DEATH; PEPTIDE INHIBITOR; SIGNALING PATHWAY; APOPTOSIS;
AUTOPHAGY; BIOGENESIS; ACTIVATION
AB Background and Purpose-Stroke is a major cause of death and disability, and it is imperative to develop therapeutics to mitigate stroke-related injury. Despite many promising prospects, attempts at translating neuroprotective agents that show success in animal models of stroke have resulted in very limited clinical success.
Summary of Review-This review discusses reasons for the lack of translational success based on the therapeutic targets tested and the pathophysiology of stroke. New recanalization therapies and alternative therapeutic strategies are discussed concerning mitochondria-mediated cell death. Mitochondrial death-regulation pathways are divided into 3 categories: Upstream signaling pathways, agents that target mitochondria directly, and downstream death-execution effectors. The apoptosis signal-related kinase/c-Jun-terminal kinase pathway is used as an example to provide rationale as to why inhibiting signaling pathway upstream of mitochondrial dysfunction is a promising therapeutic approach. Finally, the mechanisms of autophagy and mitochondrial biogenesis are discussed in relation to stroke.
Conclusions-Increasing evidence suggests that reperfusion is necessary for improved neurological outcomes after stroke. Development of improved recanalization methods with increased therapeutic windows will aid in improving clinical outcome. Adjunct neuroprotective interventions must also be developed to ensure maximal brain tissue salvage. Targeting prodeath signaling pathways upstream of mitochondrial damage is promising for potential clinically effective treatment. Further understanding of the roles of equilibrium of autophagy and mitochondrial biogenesis in the pathogenesis of stroke could also lead to novel therapeutics. (Stroke. 2009; 40: 3149-3155.)
C1 [Vosler, Peter S.; Graham, Steven H.; Wechsler, Lawrence R.; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
[Chen, Jun] Fudan Univ, Sch Med, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China.
[Graham, Steven H.; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-507,Biomed Sci Tower, Pittsburgh, PA 15213 USA.
EM chenj2@upmc.edu
FU NIH/NINDS [NS43802, NS45048, NS44178, NS56118, NS36736, NS37459]; NINDS
NRSA [F30NS057886]
FX This work was supported by NIH/NINDS grants (NS43802, NS45048, NS44178,
NS56118, NS36736, and NS37459), VA Merit Reviews to J. C. and S. H. G.,
and a NINDS NRSA predoctoral fellowship grant to P. S. V. (F30NS057886).
NR 39
TC 36
Z9 39
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD SEP
PY 2009
VL 40
IS 9
BP 3149
EP 3155
DI 10.1161/STROKEAHA.108.543769
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 487BB
UT WOS:000269244300038
PM 19478227
ER
PT J
AU Ehrenkranz, J
Davies, TF
AF Ehrenkranz, Joel
Davies, Terry F.
TI Why the History of Thyroid Disease Is Important
SO THYROID
LA English
DT Editorial Material
ID HORMONE; HYPERTHYROIDISM; INTERVIEW; THYROTROPIN; METABOLISM; IODINE; MD
C1 [Ehrenkranz, Joel] Intermt Hlth Care, Murrary, UT 84093 USA.
[Davies, Terry F.] Mt Sinai Hosp, Mt Sinai Sch Med, New York, NY 10029 USA.
[Davies, Terry F.] James J Peters VA Med Ctr, New York, NY USA.
RP Ehrenkranz, J (reprint author), Intermt Hlth Care, 5121 Cottonwood St, Murrary, UT 84093 USA.
EM joel.ehrenkranz@imail.org
NR 35
TC 1
Z9 1
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
J9 THYROID
JI Thyroid
PD SEP
PY 2009
VL 19
IS 9
BP 929
EP 931
DI 10.1089/thy.2009.1588
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 491KP
UT WOS:000269577900002
PM 19731975
ER
PT J
AU Davies, TF
Bianco, AC
AF Davies, Terry F.
Bianco, Antonio C.
TI Dr. John Maxwell "Max'' McKenzie (1928-2009) In Memoriam
SO THYROID
LA English
DT Biographical-Item
C1 [Davies, Terry F.] Mt Sinai Hosp, Mt Sinai Sch Med, New York, NY 10029 USA.
[Davies, Terry F.] James J Peters VA Med Ctr, New York, NY USA.
[Bianco, Antonio C.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
RP Davies, TF (reprint author), Mt Sinai Hosp, Mt Sinai Sch Med, New York, NY 10029 USA.
RI Bianco, Antonio/A-4965-2008
OI Bianco, Antonio/0000-0001-7737-6813
NR 0
TC 2
Z9 2
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
J9 THYROID
JI Thyroid
PD SEP
PY 2009
VL 19
IS 9
BP 1023
EP 1023
DI 10.1089/thy.2009.1587
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 491KP
UT WOS:000269577900020
ER
PT J
AU Joo, MJ
Au, DH
Lee, TA
AF Joo, Min J.
Au, David H.
Lee, Todd A.
TI Use of spirometry in the diagnosis of chronic obstructive pulmonary
disease and efforts to improve quality of care
SO TRANSLATIONAL RESEARCH
LA English
DT Article
ID INHALED CORTICOSTEROID USE; LUNG-FUNCTION; SALMETEROL/FLUTICASONE
PROPIONATE; FLUTICASONE PROPIONATE; GEOGRAPHIC-VARIATION; ACUTE
EXACERBATION; RANDOMIZED-TRIAL; AIR-FLOW; COPD; SALMETEROL
AB Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible. In a patient presenting with respiratory symptoms and risk factors, the recommendation is to perform spirometry to determine the presence of airflow obstruction. However, only about a third of patients with a diagnosis of COPD have spirometry along with their diagnosis, although studies have shown that history and physical examination alone are neither sensitive nor specific for diagnosing COPD. Thus, in current practice, many health care providers continue to diagnose and manage COPD without an accurate diagnosis and assessment of severity based on spirometry. This can contribute to inconsistent care and outcomes, as evidenced by findings of variation in spirometry use and acute exacerbation rates of COPD across geographic regions. As there is increasing evidence that pharmacotherapy for COPD has associated risks, including poor cardiovascular outcomes and pneumonia, it is pertinent to obtain an accurate diagnosis to determine appropriate risk-benefit ratios. Previous studies have shown that spirometry has an impact on COPD management; however, there seem to be barriers to the use of spirometry at the patient, provider, and health system level. Innovative quality improvement approaches, such as the application of the various components of the Chronic Care Model, could improve spirometry use in COPD. Only with accurate diagnosis can appropriate management and evidence-based treatment strategies be applied in practice. Therefore, it is important that we continue efforts to increase the use of spirometry in the diagnosis of COPD. (Translational Research 2009; 154:103-110)
C1 Hines VA Hosp, CMC3, Hines, IL USA.
Jesse Brown VA Hosp, CMC3, Chicago, IL USA.
Univ Illinois, Dept Med, Sect Pulm Crit Care & Sleep Med, Chicago, IL USA.
VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
Univ Illinois, Dept Pharm Practice, Ctr Pharmacoecon Res, Chicago, IL USA.
RP Joo, MJ (reprint author), 840 S Wood St,M-C 719, Chicago, IL 60612 USA.
EM joo@uic.edu
NR 70
TC 11
Z9 11
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1931-5244
J9 TRANSL RES
JI Transl. Res.
PD SEP
PY 2009
VL 154
IS 3
BP 103
EP 110
DI 10.1016/j.trsl.2009.06.003
PG 8
WC Medical Laboratory Technology; Medicine, General & Internal; Medicine,
Research & Experimental
SC Medical Laboratory Technology; General & Internal Medicine; Research &
Experimental Medicine
GA 486XZ
UT WOS:000269235600001
PM 19665686
ER
PT J
AU Ramsey, SD
Zeliadt, SB
Arora, NK
Potosky, AL
Blough, DK
Hamilton, AS
Van Den Eeden, SK
Oakley-Girvan, I
Penson, DF
AF Ramsey, Scott D.
Zeliadt, Steven B.
Arora, Neeraj K.
Potosky, Arnold L.
Blough, David K.
Hamilton, Ann S.
Van Den Eeden, Stephen K.
Oakley-Girvan, Ingrid
Penson, David F.
TI Access to Information Sources and Treatment Considerations Among Men
With Local Stage Prostate Cancer
SO UROLOGY
LA English
DT Article
ID EDUCATION MATERIALS; SEEKING BEHAVIORS; NEEDS; PREFERENCES; CARCINOMA;
PARTNERS; DECISION; INTERNET
AB OBJECTIVES To determine the role of information sources in the treatment decision-making process of men diagnosed with local stage prostate cancer. Diagnosed men have access to a large number of information sources about therapy, including print and broadcast media, the Internet, books, and friends with the disease.
METHODS Prospective survey of men with local stage prostate cancer in 3 geographically separate regions was carried out. Most men were surveyed after diagnosis but before starting therapy.
RESULTS On average, men with local prostate cancer consulted nearly 5 separate sources of information before treatment. The most common source of information was the patient's physician (97%), followed by lay-literature (pamphlets, videos) (76%), other health professionals (71%), friends with prostate cancer (67%), and the Internet (58%). Most men rated the Sources they consulted as helpful. Consulting the Internet was associated with considering more treatment options. Several information sources were significantly associated with considering particular treatments, but the magnitude of association was small in relation to patient age, comorbidity, and Gleason score. More than 70% of men stated that they were considering or planning only one type of therapy.
CONCLUSIONS Men with local stage prostate cancer consult a wide range of information sources. Nonphysician information sources appear to influence their treatment considerations, but to a smaller degree than clinical factors. UROLOGY 74: 509-516, 2009. (C) 2009 Elsevier Inc.
C1 [Ramsey, Scott D.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA.
NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
Georgetown Univ, Med Ctr, Canc Control Program, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
Univ Washington, Sch Pharm, Seattle, WA 98195 USA.
Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
Kaiser Permanente, Div Res, Oakland, CA USA.
No Calif Canc Cctr, Fremont, CA USA.
Univ So Calif, Dept Urol, Norris Canc Ctr, Los Angeles, CA USA.
Univ So Calif, Dept Prevent Med, Norris Canc Ctr, Los Angeles, CA 90089 USA.
RP Ramsey, SD (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,M3-B232, Seattle, WA 98109 USA.
EM sramsey@fhcrc.org
FU National Cancer Institute [N01-PC-35142, N01-PC-35139, N01-PC-35136];
Cancer Surveillance System; Fred Hutchinson Cancer Research Center
[N01-PC-35142]
FX Supported by the National Cancer Institute contracts N01-PC-35142,
N01-PC-35139, and N01-PC-35136 and by the Cancer Surveillance System of
the Fred Hutchinson Cancer Research Center, which is funded by Contract
No. N01-PC-35142 from the Surveillance, Epidemiology and End Results
(SEER) Program of the National Cancer Institute with additional support
from the Fred Hutchinson Cancer Research Center and the State of
Washington.
NR 25
TC 18
Z9 18
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
J9 UROLOGY
JI Urology
PD SEP
PY 2009
VL 74
IS 3
BP 509
EP 515
DI 10.1016/j.urology.2009.01.090
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 499GU
UT WOS:000270207100011
PM 19589564
ER
PT J
AU Olson, JM
Raugi, GJ
Nguyen, VQ
Yu, O
Reiber, GE
AF Olson, Jonathan M.
Raugi, Gregory J.
Nguyen, Viet Q.
Yu, Onchee
Reiber, Gayle E.
TI Guideline concordant venous ulcer care predicts healing in a tertiary
care Veterans Affairs Medical Center
SO WOUND REPAIR AND REGENERATION
LA English
DT Article
ID QUALITY-OF-LIFE; LEG ULCERS; INSUFFICIENCY
AB This study describes the impact of 80% adherence to guideline concordant care for compression therapy, moist wound-healing environment, and debridement on venous ulcer outcomes. The retrospective cohort design included patients from a tertiary care Veterans Affairs Medical Center from October 2003 to September 2007. During this 5-year interval, 155 patients with 400 venous ulcers met study inclusion. A majority of ulcers (n=362) healed, with an average time to healing of 18.1 weeks (range 2-209 weeks, median 10.4 weeks). From the multivariate Poisson regression, the likelihood of ulcer healing increased when compression therapy was provided during at least 80% of visits (relative risk [RR], 1.93; 95% confidence interval [CI], 1.27-2.92) or when a moist wound-healing environment was provided during at least 80% of visits (RR, 1.63; 95% CI, 1.09-2.42). Debridement alone was not significantly associated with ulcer healing (RR, 1.0; 95% CI, 0.61-1.64). Patients who received all three treatments during at least 80% of their visits were more likely to heal than those who received < 80% treatment (RR, 2.52; 95% CI, 1.53-4.16). Guideline concordant venous ulcer care was significantly associated with venous ulcer healing, when provided at 80% or more of patient visits.
C1 [Reiber, Gayle E.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Reiber, Gayle E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Yu, Onchee] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA.
[Nguyen, Viet Q.] Univ Washington, Sch Med, Seattle, WA USA.
[Raugi, Gregory J.] VA Puget Sound Healthcare Syst, Div Dermatol, Dept Vet Affairs, Seattle, WA USA.
[Olson, Jonathan M.; Raugi, Gregory J.; Nguyen, Viet Q.; Reiber, Gayle E.] Hlth Serv Res & Dev, Dept Vet Affairs, Seattle, WA USA.
RP Reiber, GE (reprint author), VA HSR&D, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM greiber@u.washington.edu
FU Department of Veterans Affairs; Veterans Health Administration; Health
Services Research and Development Service; Rehabilitation Research and
Development Service
FX The research reported here was supported by Department of Veterans
Affairs, Veterans Health Administration, Health Services Research and
Development Service, and Rehabilitation Research and Development
Service.
NR 18
TC 7
Z9 9
U1 0
U2 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1067-1927
J9 WOUND REPAIR REGEN
JI Wound Repair Regen.
PD SEP-OCT
PY 2009
VL 17
IS 5
BP 666
EP 670
DI 10.1111/j.1524-475X.2009.00524.x
PG 5
WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery
SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery
GA 493JM
UT WOS:000269732700005
PM 19769720
ER
PT J
AU Lipsky, BA
Polis, AB
Lantz, KC
Norquist, JM
Abramson, MA
AF Lipsky, Benjamin A.
Polis, Adam B.
Lantz, Keith C.
Norquist, Josephine M.
Abramson, Murray A.
TI The value of a wound score for diabetic foot infections in predicting
treatment outcome: A prospective analysis from the SIDESTEP trial
SO WOUND REPAIR AND REGENERATION
LA English
DT Article
ID CLASSIFICATION-SYSTEM; ULCER CLASSIFICATION; VALIDATION; MULTICENTER;
ISCHEMIA; RISK
AB Scoring the severity of a diabetic foot wound infection may help assess the severity, determine the type and urgency of antibiotic and surgical treatment needed, and predict clinical outcomes. We developed a 10-item diabetic foot infection wound score (results could range from 3 to 49 [least to most severe]) incorporating semi-quantitative grading of both wound measurements and various infection parameters. Using data from a prospective diabetic foot infection antibiotic trial (SIDESTEP), we evaluated the score's accuracy in predicting outcome, analyzed its components and tested it for consistency, construct, and validity. Wound scores for 371 patients significantly correlated with the clinical response; it was favorable at the follow-up assessment in 94.8% with a baseline score < 12 compared with 77.0% with a score > 19. Scores demonstrated good internal consistency (Cronbach's alpha > 0.70 to < 0.95). Patients with more severe wounds had higher scores, supporting construct validity. Excluding scores for wound discharge (purulent and nonpurulent), leaving an eight-item score, provided better measurement statistics. This easily performed wound score appears to be a reliable, valid, and useful tool for predicting clinical outcomes. Further validation studies in different patient populations should refine the items included.
C1 [Lipsky, Benjamin A.] Univ Washington, Sch Med, Primary Care Clin, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Polis, Adam B.; Lantz, Keith C.; Norquist, Josephine M.; Abramson, Murray A.] Merck Res Labs, West Point, PA USA.
RP Lipsky, BA (reprint author), Univ Washington, Sch Med, Primary Care Clin, VA Puget Sound Hlth Care Syst, S-111 PCC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM balipsky@u.washington.edu
OI Lipsky, Benjamin A./0000-0001-9886-5114
FU Merck Co.
FX We thank Dr. Edward Boyko for reviewing the manuscript and for his
suggestions on statistical analyses. The SIDESTEP study was supported by
Merck & Co., which also provided assistance with the study design, data
acquisition, and statistical and other analyses.
NR 26
TC 14
Z9 16
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1067-1927
J9 WOUND REPAIR REGEN
JI Wound Repair Regen.
PD SEP-OCT
PY 2009
VL 17
IS 5
BP 671
EP 677
DI 10.1111/j.1524-475X.2009.00521.x
PG 7
WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery
SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery
GA 493JM
UT WOS:000269732700006
PM 19671126
ER
PT J
AU Loganathan, G
Dawra, RK
Papas, KK
Pugazhenthi, S
Wiseman, A
Saluja, AK
Sutherland, DER
Hering, BJ
Appakalai, B
AF Loganathan, Gopalakrishnan
Dawra, Rajinder K.
Papas, Klearchos K.
Pugazhenthi, Subbiah
Wiseman, Alexander
Saluja, Ashok K.
Sutherland, David E. R.
Hering, Bernhard J.
Appakalai, Balamurugan
TI Culture of impure human islet fractions in the presence of
alpha-1-antitrypsin prevents insulin cleavage and improves islet
recovery
SO XENOTRANSPLANTATION
LA English
DT Meeting Abstract
CT Joint Meeting of the
International-Pancreas-and-Islet-Transplant-Association/International-Xe
notransplantation-Association
CY OCT 12-16, 2009
CL Venice, ITALY
SP Int Pancreas & Islet Transplant Assoc, Int Xenotransplantat Assoc
C1 [Loganathan, Gopalakrishnan; Papas, Klearchos K.; Sutherland, David E. R.; Hering, Bernhard J.; Appakalai, Balamurugan] Univ Minnesota, Dept Surg, Schulze Diabet Inst, Minneapolis, MN 55455 USA.
[Dawra, Rajinder K.; Saluja, Ashok K.] Dept Surg Basic & Transplantat Res, Minneapolis, MN 55455 USA.
[Pugazhenthi, Subbiah; Wiseman, Alexander] Univ Colorado, Denver VAMC, Denver, CO 80220 USA.
RI Loganathan, Gopalakrishnan/D-8762-2014
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0908-665X
J9 XENOTRANSPLANTATION
JI Xenotransplantation
PD SEP-OCT
PY 2009
VL 16
IS 5
BP 404
EP 404
PG 1
WC Medicine, Research & Experimental; Transplantation
SC Research & Experimental Medicine; Transplantation
GA 502CA
UT WOS:000270430500355
ER
PT J
AU Fihn, SD
Vaughan-Sarrazin, M
Lowy, E
Popescu, I
Maynard, C
Rosenthal, GE
Sales, AE
Rumsfeld, J
Pineros, S
McDonell, MB
Helfrich, CD
Rusch, R
Jesse, R
Almenoff, P
Fleming, B
Kussman, M
AF Fihn, Stephan D.
Vaughan-Sarrazin, Mary
Lowy, Elliott
Popescu, Ioana
Maynard, Charles
Rosenthal, Gary E.
Sales, Anne E.
Rumsfeld, John
Pineros, Sandy
McDonell, Mary B.
Helfrich, Christian D.
Rusch, Roxane
Jesse, Robert
Almenoff, Peter
Fleming, Barbara
Kussman, Michael
TI Declining mortality following acute myocardial infarction in the
Department of Veterans Affairs Health Care System
SO BMC CARDIOVASCULAR DISORDERS
LA English
DT Article
ID MEDICARE; QUALITY; US; TRANSFORMATION; ANGIOPLASTY; OUTCOMES; THERAPY;
DISEASE
AB Background: Mortality from acute myocardial infarction (AMI) is declining worldwide. We sought to determine if mortality in the Veterans Health Administration (VHA) has also been declining.
Methods: We calculated 30-day mortality rates between 2004 and 2006 using data from the VHA External Peer Review Program (EPRP), which entails detailed abstraction of records of all patients with AMI. To compare trends within VHA with other systems of care, we estimated relative mortality rates between 2000 and 2005 for all males 65 years and older with a primary diagnosis of AMI using administrative data from the VHA Patient Treatment File and the Medicare Provider Analysis and Review (MedPAR) files.
Results: Using EPRP data on 11,609 patients, we observed a statistically significant decline in adjusted 30-day mortality following AMI in VHA from 16.3% in 2004 to 13.9% in 2006, a relative decrease of 15% and a decrease in the odds of dying of 10% per year (p = .011). Similar declines were found for in-hospital and 90-day mortality.
Based on administrative data on 27,494 VHA patients age 65 years and older and 789,400 Medicare patients, 30-day mortality following AMI declined from 16.0% during 2000-2001 to 15.7% during 2004-June 2005 in VHA and from 16.7% to 15.5% in private sector hospitals. After adjusting for patient characteristics and hospital effects, the overall relative odds of death were similar for VHA and Medicare (odds ratio 1.02, 95% C.I. 0.96-1.08).
Conclusion: Mortality following AMI within VHA has declined significantly since 2003 at a rate that parallels that in Medicare-funded hospitals.
C1 [Fihn, Stephan D.; Lowy, Elliott; Maynard, Charles; Pineros, Sandy; Helfrich, Christian D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Fihn, Stephan D.] Univ Washington, Dept Med, Seattle, WA USA.
[Fihn, Stephan D.; Helfrich, Christian D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Vaughan-Sarrazin, Mary; Popescu, Ioana; Rosenthal, Gary E.; McDonell, Mary B.] VA Med Ctr, Iowa City, IA USA.
[Vaughan-Sarrazin, Mary; Popescu, Ioana; Rosenthal, Gary E.; McDonell, Mary B.] Univ Iowa, Dept Med, Iowa City, IA 52242 USA.
[Sales, Anne E.] Univ Alberta, Edmonton, AB, Canada.
[Rumsfeld, John] VA Med Ctr, Denver, CO USA.
[Rumsfeld, John] Univ Colorado, Dept Med, Denver, CO USA.
[Rusch, Roxane; Jesse, Robert; Almenoff, Peter; Fleming, Barbara; Kussman, Michael] Dept Vet Affairs, Washington, DC USA.
RP Fihn, SD (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA.
EM Stephan.Fihn@va.gov; Mary.Vaughan@va.gov; Elliott.Lowy@va.gov;
Ioanna.Popescu@va.gov; Charles.Maynard@va.gov; Gary-Rosenthal@uiowa.edu;
Anne.Sales@ualberta.ca; John.Rumsfeld@va.gov; vanbrit@hotmail.com;
Mary.McDonell@va.gov; Christian.Helfrich@va.gov; Roxane.Rusch@va.gov;
Jesse.Robert_r@richmond.va.gov; Peter.Almenoff@va.gov;
Barbflem@comcast.net; Michael.Kussman@va.gov
RI Sales, Anne/D-9678-2012; Maynard, Charles/N-3906-2015; Helfrich,
Christian/D-2382-2016
OI Maynard, Charles/0000-0002-1644-7814; Helfrich,
Christian/0000-0002-9827-4768; Vaughan Sarrazin,
Mary/0000-0001-8717-1061; Sales, Anne/0000-0001-9360-3334
FU Department of Veterans Affairs [MRC 03-334]
FX This work was supported by the Department of Veterans Affairs, grant MRC
03-334.
NR 27
TC 15
Z9 15
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2261
J9 BMC CARDIOVASC DISOR
JI BMC Cardiovasc. Disord.
PD AUG 31
PY 2009
VL 9
AR 44
DI 10.1186/1471-2261-9-44
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 500KA
UT WOS:000270296600001
PM 19719849
ER
PT J
AU Peluso, MAM
Glahn, DC
Matsuo, K
Monkul, ES
Najt, P
Zamarripa, F
Li, JQ
Lancaster, JL
Fox, PT
Gao, JH
Soares, JC
AF Peluso, Marco A. M.
Glahn, David C.
Matsuo, Koji
Monkul, E. Serap
Najt, Pablo
Zamarripa, Frank
Li, Jinqi
Lancaster, Jack L.
Fox, Peter T.
Gao, Jia-Hong
Soares, Jair C.
TI Amygdala hyperactivation in untreated depressed individuals
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article
DE Depressive disorder; Amygdala; Facial expression; Functional MRI
ID FACIAL EXPRESSIONS; ANTIDEPRESSANT TREATMENT; NEURAL RESPONSE; MOOD
DISORDERS; FACES; PERCEPTION; FMRI
AB The amygdala participates in the detection and control of affective states, and has been proposed to be a site of dysfunction in affective disorders. To assess amygdala processing in individuals with unipolar depression, we applied a functional MRI (fMRI) paradigm previously shown to be sensitive to amygdala function. Fourteen individuals with untreated DSM-IV major depression and 15 healthy subjects were studied using fMRI with a standardized emotion face recognition task. Voxel-level data sets were subjected to a multiple-regression analysis, and functionally defined regions of interest (ROI), including bilateral amygdala, were analyzed with MANOVA. Pearson correlation coefficients between amygdala activation and HAM-D score also were performed. While both depressed and healthy groups showed increased amygdala activity when viewing emotive faces compared to geometric shapes, patients with unipolar depression showed relatively more activity than healthy subjects, particularly on the left. Positive Pearson correlations between amygdala activation and HAM-D score were found for both left and right ROIs in the patient group. This study provides in vivo imaging evidence to support the hypothesis of abnormal amygdala functioning in depressed individuals. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Peluso, Marco A. M.] Univ Sao Paulo, Sect Psychiat Epidemiol, Dept Psychiat, CEAPESQ, BR-05403010 Sao Paulo, Brazil.
[Peluso, Marco A. M.; Glahn, David C.; Matsuo, Koji; Monkul, E. Serap; Najt, Pablo; Soares, Jair C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Peluso, Marco A. M.; Matsuo, Koji; Monkul, E. Serap; Najt, Pablo; Soares, Jair C.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
[Glahn, David C.; Zamarripa, Frank; Li, Jinqi; Lancaster, Jack L.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, San Antonio, TX 78229 USA.
[Monkul, E. Serap] Dokuz Eylul Univ, Dept Psychiat, Izmir, Turkey.
[Gao, Jia-Hong; Soares, Jair C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
RP Peluso, MAM (reprint author), Univ Sao Paulo, Sect Psychiat Epidemiol, Dept Psychiat, CEAPESQ, Av Dr Ovidio Pires de Campos 785,3O Andar,Sala 17, BR-05403010 Sao Paulo, Brazil.
EM mampeluso@hotmail.com
RI Lancaster, Jack/F-2994-2010; Fox, Peter/B-4725-2010; Li,
Jinqi/F-7778-2010; Frank, David/E-8213-2012
OI Fox, Peter/0000-0002-0465-2028;
FU UTHSCSA GCRC [M01-RR-01346]; Dana Founda-Administration (VA Merit
Review); CNPq ("Conselho Nacional de Desenvolvimento Cientifico e
Tecnologico", Brazil [200006/04-5]; [MH 01736]; [MH 068662];
[RR020571]
FX This research was partly supported by grants MH 01736, MH 068662,
RR020571, UTHSCSA GCRC (M01-RR-01346), Dana Founda-Administration (VA
Merit Review), and CNPq ("Conselho Nacional de Desenvolvimento
Cientifico e Tecnologico", Brazil - grant# 200006/04-5).
NR 23
TC 64
Z9 64
U1 0
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0925-4927
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD AUG 30
PY 2009
VL 173
IS 2
BP 158
EP 161
DI 10.1016/j.pscychresns.2009.03.006
PG 4
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 485HX
UT WOS:000269113000013
PM 19545982
ER
PT J
AU Chen, HY
Gao, SS
AF Chen, Hua Yun
Gao, Shasha
TI Estimation of average treatment effect with incompletely observed
longitudinal data: Application to a smoking cessation study
SO STATISTICS IN MEDICINE
LA English
DT Article
DE causal effect; potential outcomes; robust estimator; surrogate outcome
ID LINEAR MIXED MODELS; MARGINALIZED TRANSITION MODELS; IGNORABLE MISSING
DATA; CAUSAL INFERENCE; BINARY DATA; DROP-OUT; SEMIPARAMETRIC
REGRESSION; NONRESPONSE MODELS; LOCAL SENSITIVITY; REPEATED OUTCOMES
AB We stud the problem of estimation and inference oil the average treatment effect in a smoking, cessation trial where an outcome and some auxiliary information were measured longitudinally. and both were subject to missing Values. Dynamic generalized linear mixed effects models linking the outcome, the auxiliary information, and the covariates are proposed. The maximum likelihood approach is applied to the estimation and inference of the model Parameters. The average treatment effect is estimated by the G-computation approach. and the sensitivity of the treatment effect estimate to the nonignorable missing data mechanisms is investigated through the local sensitivity analysis approach. The Proposed approach call handle missing data that form arbitrary missing patterns over little. We applied the proposed method to the analysis of the smoking cessation trial. Copyright (C) 2009 John Wiley & Sons. Ltd.
C1 [Chen, Hua Yun] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL 60612 USA.
[Gao, Shasha] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
RP Chen, HY (reprint author), Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, 1603 W Taylor St, Chicago, IL 60612 USA.
EM hychen@uic.edu
FU NIH/NCI [R01 CA106355]
FX Contract/grant sponsor: NIH/NCI contract/grant number: R01 CA106355
NR 38
TC 3
Z9 3
U1 0
U2 4
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0277-6715
J9 STAT MED
JI Stat. Med.
PD AUG 30
PY 2009
VL 28
IS 19
BP 2451
EP 2472
DI 10.1002/sim.3617
PG 22
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA 475PY
UT WOS:000268373500003
PM 19462416
ER
PT J
AU Chen, YX
Gelfond, JAL
McManus, LM
Shireman, PK
AF Chen, Yongxin
Gelfond, Jonathan A. L.
McManus, Linda M.
Shireman, Paula K.
TI Reproducibility of quantitative RT-PCR array in miRNA expression
profiling and comparison with microarray analysis
SO BMC GENOMICS
LA English
DT Article
ID MICRORNA EXPRESSION; GENE-EXPRESSION; OLIGONUCLEOTIDE MICROARRAYS;
MAMMALIAN MICRORNAS; MESSENGER-RNA; IDENTIFICATION; CELLS;
DIFFERENTIATION; QUANTIFICATION; NEUROBLASTOMA
AB Background: MicroRNAs (miRNAs) have critical functions in various biological processes. MiRNA profiling is an important tool for the identification of differentially expressed miRNAs in normal cellular and disease processes. A technical challenge remains for high-throughput miRNA expression analysis as the number of miRNAs continues to increase with in silico prediction and experimental verification. Our study critically evaluated the performance of a novel miRNA expression profiling approach, quantitative RT-PCR array (qPCR-array), compared to miRNA detection with oligonucleotide microchip (microarray).
Results: High reproducibility with qPCR-array was demonstrated by comparing replicate results from the same RNA sample. Pre-amplification of the miRNA cDNA improved sensitivity of the qPCR-array and increased the number of detectable miRNAs. Furthermore, the relative expression levels of miRNAs were maintained after pre-amplification. When the performance of qPCR-array and microarrays were compared using different aliquots of the same RNA, a low correlation between the two methods (r = -0.443) indicated considerable variability between the two assay platforms. Higher variation between replicates was observed in miRNAs with low expression in both assays. Finally, a higher false positive rate of differential miRNA expression was observed using the microarray compared to the qPCR-array.
Conclusion: Our studies demonstrated high reproducibility of TaqMan qPCR-array. Comparison between different reverse transcription reactions and qPCR-arrays performed on different days indicated that reverse transcription reactions did not introduce significant variation in the results. The use of cDNA pre-amplification increased the sensitivity of miRNA detection. Although there was variability associated with pre-amplification in low abundance miRNAs, the latter did not involve any systemic bias in the estimation of miRNA expression. Comparison between microarray and qPCR-array indicated superior sensitivity and specificity of qPCR-array.
C1 [Chen, Yongxin; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA.
[Chen, Yongxin; Shireman, Paula K.] S Texas Vet Hlth Care Syst, Dept Surg, San Antonio, TX 78229 USA.
[Gelfond, Jonathan A. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA.
[Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
RP Chen, YX (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA.
EM cheny4@uthscsa.edu; gelfondjal@uthscsa.edu; mcmanus@uthscsa.edu;
shireman@uthscsa.edu
FU Veterans Administration Merit Review; National Institutes of Health
[R01HL074236, T32HL07446]; National Center for Research Resources [KL2
RR025766]
FX These studies were supported, in part, by a Veterans Administration
Merit Review grant and the National Institutes of Health (R01HL074236
and T32HL07446) from the National Heart, Lung, and Blood Institute and
CTSA Award (KL2 RR025766) from the National Center for Research
Resources. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National
Institutes of Health. The authors have no relationships that pose a
conflict of interest for these studies.
NR 41
TC 138
Z9 142
U1 1
U2 26
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD AUG 28
PY 2009
VL 10
AR 407
DI 10.1186/1471-2164-10-407
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 501PR
UT WOS:000270394300002
PM 19715577
ER
PT J
AU Cooper, M
Deering, KL
Slakey, DP
Harshaw, Q
Arcona, S
McCann, EL
Rasetto, FA
Florman, SS
AF Cooper, Matthew
Deering, Kathleen L.
Slakey, Douglas P.
Harshaw, Qing
Arcona, Stephen
McCann, Erin L.
Rasetto, Flavia A.
Florman, Sander S.
TI Comparing Outcomes Associated With Dose Manipulations of Enteric-Coated
Mycophenolate Sodium Versus Mycophenolate Mofetil in Renal Transplant
Recipients
SO TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 9th Joint Meeting of the
American-Society-of-Transplant-Surgeon/American-Society-of-Transplantati
on
CY MAY 30-JUN 03, 2009
CL Boston, MA
SP Amer Soc Transplant Surg, Amer Soc Transplantat
DE Gastrointestinal adverse events; Mycophenolate sodium; Mycophenolate
mofetil; Renal transplant; Rejection-risk
ID GASTROINTESTINAL COMPLICATIONS; CONVERSION; ACID; IMPACT; MMF
AB Background. This study assessed the incidence of reported gastrointestinal (GI) complications in patients treated with enteric-coated mycophenolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) and to examine the impact of dose manipulations on biopsy-proven acute rejection (BPAR).
Methods. A retrospective study was conducted in 379 renal transplant recipients initiated on EC-MPS or MMF through 3-months posttransplant between the years of 2001 to 2007. Descriptive univariate analyses were used for comparisons of baseline characteristics and outcome measures between the cohorts. A Cox proportional hazards model was used to evaluate the time to a first BPAR event.
Results. GI complications occurred at an incidence of 52.8% and 48.9% in the EC-MPS and MMF cohorts, respectively (NS). Patients requiring dose manipulations due to GI complications were 19.7% with EC-MPS and 25.3% with MMF (NS). The mean equimolar dose reduction below 2000 mg was 930 +/- 292.13 mg with EC-MPS and 933 +/- 173.95 mg with MMF (NS). Patients treated with EC-MPS experienced significantly fewer BPAR episodes than those treated with MMF (14% EC-MPS vs. 23.1% MMF; P=0.0221).
Conclusions. in this study, EC-MPS had a similar incidence of GI complications and dose manipulations compared with MMF. Despite similar GI complication rates and dose manipulations, treatment with EC-MPS seemed to result in a lower incidence of BPAR. Based on these observations, more studies need to be conducted to evaluate risks for BPAR relating to mycophenolic acid product.
C1 [Cooper, Matthew] Univ Maryland, Sch Med, Div Transplantat, Baltimore, MD 21201 USA.
[Deering, Kathleen L.; Harshaw, Qing] Hlth Econ & Outcomes Res, Oak Brook, IL USA.
[Slakey, Douglas P.; Florman, Sander S.] Tulane Univ Med Ctr Hosp & Clin, Div Transplantat, New Orleans, LA USA.
[Arcona, Stephen] Novartis Pharmaceut, Evidence Based Med, E Hanover, NJ USA.
[McCann, Erin L.] VA Pittsburgh Healthcare Syst, Dept Pharm, Pittsburgh, PA USA.
[McCann, Erin L.; Rasetto, Flavia A.] Univ Maryland, Med Syst, Dept Pharm, Baltimore, MD 21201 USA.
RP Cooper, M (reprint author), Univ Maryland, Sch Med, Div Transplantat, 29 S Greene St,Room 200, Baltimore, MD 21201 USA.
EM mcooper@smail.umaryland.edu
NR 19
TC 19
Z9 24
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD AUG 27
PY 2009
VL 88
IS 4
BP 514
EP 520
DI 10.1097/TP.0b013e3181b0e65e
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 487UT
UT WOS:000269303200011
PM 19696634
ER
PT J
AU Block, K
Gorin, Y
Abboud, HE
AF Block, Karen
Gorin, Yves
Abboud, Hanna E.
TI Subcellular localization of Nox4 and regulation in diabetes
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE kidney; mitochondria; oxidative stress
ID NADPH OXIDASE; NAD(P)H OXIDASE; ENDOTHELIAL-CELLS; MESANGIAL CELLS;
MITOCHONDRIA; EXPRESSION; SUPEROXIDE; IDENTIFICATION; NEPHROPATHY;
APOPTOSIS
AB Oxidative stress is implicated in human diseases. Some of the oxidative pathways are harbored in the mitochondria. NAD(P) H oxidases have been identified not only in phagocytic but also in somatic cells. Nox4 is the most ubiquitous of these oxidases and is a major source of reactive oxygen species (ROS) in many cell types and in kidney tissue of diabetic animals. We generated specific Nox4 antibodies, and found that Nox4 localizes to mitochondria. (i) Immunoblot analysis in cultured mesangial cells and kidney cortex revealed that Nox4 is present in crude mitochondria, in mitochondria-enriched heavy fractions, and in purified mitochondria; (ii) immunofluorescence confocal microscopy also revealed that Nox4 localizes with the mitochondrial marker Mitotracker; and (iii) the mitochondrial localization prediction program MitoProt indicated that the probability score for Nox4 is identical to mitochondrial protein cytochrome c oxidase subunit IV. We also show that in purified mitochondria, siRNA-mediated knockdown of Nox4 significantly reduces NADPH oxidase activity in pure mitochondria and blocks glucose-induced mitochondrial superoxide generation. In a rat model of diabetes, mitochondrial Nox4 expression is increased in kidney cortex. Our data provide evidence that a functional Nox4 is present and regulated in mitochondria, indicating the existence of a previously undescribed source of ROS in this organelle.
C1 [Block, Karen; Gorin, Yves; Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Abboud, Hanna E.] S Texas Vet Hlth Care Syst, Audie Leon Murphy Mem Hosp Div, San Antonio, TX 78229 USA.
RP Abboud, HE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
EM abboud@uthscsa.edu
OI Gorin, Yves/0000-0003-4048-6925
FU Juvenile Diabetes Research Foundation; South Central Affiliate of the
American Heart Association; American Diabetes Association; National
Institutes of Health [076923, R01 CA 131272, DK 43988, DK 33665];
National Institute of Diabetes and Digestive and Kidney
Diseases-National Institutes of Health George O'Brien Kidney Research
Center; Veterans Administration
FX We thank D.-Y. Lee and P. Hoover for technical contributions, and J.
Barnes for electron microscopy and rabbit immunization. This work was
supported by grants from the Juvenile Diabetes Research Foundation
Regular research (Y.G. and H.E.A.); a grant-in-aid from the South
Central Affiliate of the American Heart Association (Y.G.); the American
Diabetes Association (H.E.A.); the National Institutes of Health K01
Award DK 076923 and Grant R01 CA 131272 (K.B.); National Institutes of
Health Grants DK 43988 and DK 33665 (H.E.A.); the National Institute of
Diabetes and Digestive and Kidney Diseases-National Institutes of Health
George O'Brien Kidney Research Center (H.E.A. and Y.G.); and the
Veterans Administration (H.E.A. and K.B.).
NR 32
TC 197
Z9 197
U1 1
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 25
PY 2009
VL 106
IS 34
BP 14385
EP 14390
DI 10.1073/pnas.0906805106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 487SF
UT WOS:000269295100041
PM 19706525
ER
PT J
AU Tien, PC
Schneider, MF
Cole, SR
Cohen, MH
Glesby, MJ
Lazar, J
Young, M
Mack, W
Hodis, HN
Kaplan, RC
AF Tien, Phyllis C.
Schneider, Michael F.
Cole, Stephen R.
Cohen, Mardge H.
Glesby, Marshall J.
Lazar, Jason
Young, Mary
Mack, Wendy
Hodis, Howard N.
Kaplan, Robert C.
TI Association of hepatitis C virus and HIV infection with subclinical
atherosclerosis in the women's interagency HIV study
SO AIDS
LA English
DT Article
ID INTIMA-MEDIA THICKNESS; CORONARY-HEART-DISEASE; CAROTID-ARTERY;
RISK-FACTORS; INDIVIDUALS; PROGRESSION
AB Whether hepatitis C virus coinfection might accelerate atherosclerosis in HIV-infected individuals is unclear. We examined the relationship of HIV and hepatitis C virus with carotid artery intima media thickness and the presence of carotid plaques in the Women's Interagency HIV Study. Hepatitis C virus infection was not associated with greater carotid artery intima media thickness after adjustment for demographic and traditional cardiovascular risk factors. Further follow-up is needed to clarify whether HIV/hepatitis C virus coinfection may be associated with a greater risk of carotid plaque.
C1 [Tien, Phyllis C.] Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, San Francisco, CA 94121 USA.
[Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Schneider, Michael F.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Cole, Stephen R.] Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA.
[Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA.
[Cohen, Mardge H.] Rush Univ, Chicago, IL 60612 USA.
[Glesby, Marshall J.] Weill Cornell Med Coll, Dept Med, New York, NY USA.
[Lazar, Jason] SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA.
[Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA.
[Mack, Wendy] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
[Hodis, Howard N.] Univ So Calif, Atherosclerosis Res Unit, Los Angeles, CA USA.
[Kaplan, Robert C.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
RP Tien, PC (reprint author), Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, 111W,4150 Clement St, San Francisco, CA 94121 USA.
EM ptien@ucsf.edu
RI Kaplan, Robert/A-2526-2011
FU National Institute of Allergy Infectious Diseases [UO1-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UOI-AI-34993, UOI-AI-42590];
National Institute of Child Health and Human Development [UO1-HD-32632];
National Cancer Institute; National Institute on Drug Abuse; National
Institute Oil Deafness and Other Communication Disorders; National
Institute of Allergy and Infectious Diseases [R01-AI-052065,
R01-AI-0577006, K23 AI 66943, K24 AI 078884]
FX Data in this manuscript were collected by the Women's Interagency HIV
Study (WIHS) Collaborative Study Group with centers (Principal
Investigators) at New York City/Bronx Consortium (Kathryn Anastos);
Brooklyn, NY (Howard Minkoff); Washington DC Metropolitan Consortium
(Mary Young); The Connie Wofsy Study Consortium of Northern California
(Ruth Greenblatt); Los Angeles County/Southern California Consortium
(Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating
Center (Stephen Gauge). The WIHS is funded by the National Institute of
Allergy Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994,
UO1-AI-34989, UOI-AI-34993, and UOI-AI-42590) and by the National
Institute of Child Health and Human Development (UO1-HD-32632). The
study is co-funded by the National Cancer Institute, the National
Institute on Drug Abuse, and the National Institute Oil Deafness and
Other Communication Disorders. Funding is also provided by the National
Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). HCV
testing was supported by grants from the National Institute of Allergy
and Infectious Diseases (R01-AI-052065 and R01-AI-0577006). Dr P.C. Tien
and Dr M.J. Glesby are supported by the National Institute of Allergy
and Infectious Diseases through K23 AI 66943 and K24 AI 078884,
respectively. The contents of this publication are solely the
responsibility of the authors and do not necessarily represent the
official views of the National Institutes of Health.
NR 20
TC 23
Z9 24
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD AUG 24
PY 2009
VL 23
IS 13
BP 1781
EP 1784
DI 10.1097/QAD.0b013e32832d7aa8
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 488FF
UT WOS:000269333900019
PM 19553807
ER
PT J
AU Hook, VYH
Kindy, M
Reinheckel, T
Peters, C
Hook, G
AF Hook, Vivian Y. H.
Kindy, Mark
Reinheckel, Thomas
Peters, Christoph
Hook, Gregory
TI Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice
expressing human wild-type amyloid precursor protein
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Beta-amyloid; Cathepsin B; Gene knockout; Amyloid precursor protein;
Protease
ID REGULATED SECRETORY VESICLES; ALZHEIMERS-DISEASE; IN-VIVO; CHROMAFFIN
CELLS; GUINEA-PIGS; INHIBITORS; BACE; PATHWAYS; SEQUENCE; THERAPY
AB Neurotoxic beta-amyloid (A beta) peptides participate in Alzheimer's disease (AD); therefore, reduction of A beta generated from APP may provide a therapeutic approach for AD. Gene knockout studies in transgenic mice producing human A beta may identify targets for reducing A beta. This study shows that knockout of the cathepsin B gene in mice expressing human wild-type APP (hAPPwt) results in substantial decreases in brain A beta 40 and A beta 42 by 67% and decreases in levels of the C-terminal beta-secretase fragment (CTF beta) derived from APP. In contrast, knockout of cathepsin B in mice expressing hAPP with the rare Swedish (Swe) and Indiana (Ind) mutations had no effect on A beta. The difference in reduction of A beta in hAPPwt mice, but not in hAPPSwe/Ind mice, shows that the transgenic model can affect cathepsin B gene knockout results. Since most AD patients express hAPPwt, these data validate cathepsin B as a target for development of inhibitors to lower A beta in AD. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Hook, Vivian Y. H.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Dept Neurosci, La Jolla, CA 92093 USA.
[Hook, Vivian Y. H.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Dept Med & Pharmacol, La Jolla, CA 92093 USA.
[Kindy, Mark] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Dept Neurosci, Charleston, SC 29425 USA.
[Reinheckel, Thomas; Peters, Christoph] Univ Freiburg, Zentrum Biochem & Mol Zellforsch, Inst Mol Med & Zellforsch, D-79104 Freiburg, Germany.
[Hook, Gregory] Amer Life Sci Pharmaceut Inc, San Diego, CA 92109 USA.
RP Hook, VYH (reprint author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Dept Neurosci, 9500 Gilman Dr,MC 0744, La Jolla, CA 92093 USA.
EM vhook@ucsd.edu
FU NIA/NIH [R21 AG027446, 1R44AG032784]
FX We thank Dr. M.D. Pierschbacher for helpful review of the manuscript.
This research was supported by the NIA/NIH R21 Grant AG027446 and
1R44AG032784 (to American Life Science Pharmaceuticals (ALSP)). V.H.
holds equity in ALSP and serves on the Scientific Advisory Board of
ALSP. The terms of this agreement have been reviewed by the University
of California, San Diego, in accordance with its conflict of interest
policies. G.H. holds equity in and is employed by ALSP.
NR 32
TC 35
Z9 35
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 21
PY 2009
VL 386
IS 2
BP 284
EP 288
DI 10.1016/j.bbrc.2009.05.131
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 470FH
UT WOS:000267960100003
PM 19501042
ER
PT J
AU Krumholz, HM
Wang, Y
Chen, J
Drye, EE
Spertus, JA
Ross, JS
Curtis, JP
Nallamothu, BK
Lichtman, JH
Havranek, EP
Masoudi, FA
Radford, MJ
Han, LF
Rapp, MT
Straube, BM
Normand, SLT
AF Krumholz, Harlan M.
Wang, Yun
Chen, Jersey
Drye, Elizabeth E.
Spertus, John A.
Ross, Joseph S.
Curtis, Jeptha P.
Nallamothu, Brahmajee K.
Lichtman, Judith H.
Havranek, Edward P.
Masoudi, Frederick A.
Radford, Martha J.
Han, Lein F.
Rapp, Michael T.
Straube, Barry M.
Normand, Sharon-Lise T.
TI Reduction in Acute Myocardial Infarction Mortality in the United States
Risk-Standardized Mortality Rates From 1995-2006
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID QUALITY-OF-CARE; NATIONAL REGISTRY; HOSPITAL MORTALITY; TRENDS;
MEDICARE; IMPROVEMENT; ELEVATION; COMMUNITY; OUTCOMES; PROGRAM
AB Context During the last 2 decades, health care professional, consumer, and payer organizations have sought to improve outcomes for patients hospitalized with acute myocardial infarction (AMI). However, little has been reported about improvements in hospital short-term mortality rates or reductions in between-hospital variation in short-term mortality rates.
Objective To estimate hospital-level 30-day risk-standardized mortality rates (RSMRs) for patients discharged with AMI.
Design, Setting, and Patients Observational study using administrative data and a validated risk model to evaluate 3 195 672 discharges in 2 755 370 patients discharged from nonfederal acute care hospitals in the United States between January 1, 1995, and December 31, 2006. Patients were 65 years or older (mean, 78 years) and had at least a 12-month history of fee-for-service enrollment prior to the index hospitalization. Patients discharged alive within 1 day of an admission not against medical advice were excluded, because it is unlikely that these patients had sustained an AMI.
Main Outcome Measure Hospital-specific 30-day all-cause RSMR.
Results At the patient level, the odds of dying within 30 days of admission if treated at a hospital 1 SD above the national average relative to that if treated at a hospital 1 SD below the national average were 1.63 (95% CI, 1.60-1.65) in 1995 and 1.56 (95% CI, 1.53-1.60) in 2006. In terms of hospital-specific RSMRs, a decrease from 18.8% in 1995 to 15.8% in 2006 was observed (odds ratio, 0.76; 95% CI, 0.75-0.77). A reduction in between-hospital heterogeneity in the RSMRs was also observed: the coefficient of variation decreased from 11.2% in 1995 to 10.8%, the interquartile range from 2.8% to 2.1%, and the between-hospital variance from 4.4% to 2.9%.
Conclusion Between 1995 and 2006, the risk-standardized hospital mortality rate for Medicare patients discharged with AMI showed a significant decrease, as did between-hospital variation. JAMA. 2009;302(7):767-773
C1 [Krumholz, Harlan M.; Wang, Yun; Chen, Jersey; Drye, Elizabeth E.; Curtis, Jeptha P.] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06510 USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Hlth Policy & Adm, Sch Publ Hlth, New Haven, CT 06510 USA.
[Lichtman, Judith H.] Yale Univ, Sch Med, Sect Chron Dis Epidemiol, Sch Publ Hlth, New Haven, CT 06510 USA.
[Krumholz, Harlan M.; Wang, Yun] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA.
[Spertus, John A.] Univ Missouri Kansas City, Sch Med, Kansas City, MO USA.
[Spertus, John A.] Mid Amer Heart Inst, Kansas City, MO USA.
[Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA.
[Ross, Joseph S.] James J Peters VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA.
[Ross, Joseph S.] Hlth Serv Res Enhancement Award Program, Bronx, NY USA.
[Nallamothu, Brahmajee K.] Univ Michigan, Sch Med, Hlth Serv Res & Dev Ctr Excellence, Ann Arbor VA Med Ctr, Ann Arbor, MI USA.
[Nallamothu, Brahmajee K.] Univ Michigan, Sch Med, Div Cardiovasc Dis, Dept Internal Med, Ann Arbor, MI USA.
[Havranek, Edward P.; Masoudi, Frederick A.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA.
[Havranek, Edward P.; Masoudi, Frederick A.] Denver Hlth Med Ctr, Denver, CO USA.
[Radford, Martha J.] NYU, Sch Med, New York, NY USA.
[Han, Lein F.; Rapp, Michael T.; Straube, Barry M.] Ctr Medicare, Baltimore, MD USA.
[Han, Lein F.; Rapp, Michael T.; Straube, Barry M.] Ctr Medicaid Serv, Baltimore, MD USA.
[Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Krumholz, HM (reprint author), Yale Univ, Sch Med, Sect Cardiovasc Med, 1 Church St,Ste 200, New Haven, CT 06510 USA.
EM harlan.krumholz@yale.edu
FU Centers for Medicare & Medicaid Services (CMS); US Department of Health
and Human Services; [HHSM-500-2005-CO001C]
FX The analyses on which this article is based were performed under
contract HHSM-500-2005-CO001C, "Utilization and Quality Control Quality
Improvement Organization for the State (commonwealth) of Colorado,"
funded by the Centers for Medicare & Medicaid Services (CMS), an agency
of the US Department of Health and Human Services.
NR 21
TC 128
Z9 132
U1 1
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD AUG 19
PY 2009
VL 302
IS 7
BP 767
EP 773
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 484UT
UT WOS:000269073800025
PM 19690309
ER
PT J
AU Margolis, ML
AF Margolis, Mitchell L.
TI The PET and the Pendulum
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID CELL LUNG-CANCER; POSITRON-EMISSION-TOMOGRAPHY; RANDOMIZED-TRIAL;
VOLUME-REDUCTION; CT; MANAGEMENT; EMPHYSEMA; STANDARD
C1 [Margolis, Mitchell L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Margolis, Mitchell L.] Univ Penn, Philadelphia, PA 19104 USA.
RP Margolis, ML (reprint author), Philadelphia Vet Affairs Med Ctr, Room 8A112 Clin Addit, Philadelphia, PA 19104 USA.
EM mitchell.margolis@med.va.gov
NR 18
TC 1
Z9 1
U1 0
U2 0
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD AUG 18
PY 2009
VL 151
IS 4
BP 279
EP 280
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 484IW
UT WOS:000269038900009
PM 19581638
ER
PT J
AU Marder, S
AF Marder, Steven
TI Both typical and atypical antipsychotic agents were associated with
increased risk for sudden cardiac death Commentary
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
C1 US Dept Vet Affairs, Los Angeles, CA USA.
RP Marder, S (reprint author), US Dept Vet Affairs, Los Angeles, CA USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD AUG 18
PY 2009
VL 151
IS 4
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 484IW
UT WOS:000269038900041
ER
PT J
AU Dorph-Petersen, KA
Delevich, KM
Marcsisin, MJ
Zhang, W
Sampson, AR
Gundersen, HJG
Lewis, DA
Sweet, RA
AF Dorph-Petersen, Karl-Anton
Delevich, Kristen M.
Marcsisin, Michael J.
Zhang, Wei
Sampson, Allan R.
Gundersen, Hans Jorgen G.
Lewis, David A.
Sweet, Robert A.
TI Pyramidal neuron number in layer 3 of primary auditory cortex of
subjects with schizophrenia
SO BRAIN RESEARCH
LA English
DT Article
DE Auditory; Cerebral cortex; Schizophrenia; Pyramidal neuron; Stereology;
Post-mortem
ID DENDRITIC SPINE DENSITY; UNBIASED STEREOLOGICAL ESTIMATION; MISMATCH
NEGATIVITY GENERATION; SUPERIOR TEMPORAL GYRUS; PREFRONTAL CORTEX;
PLANUM TEMPORALE; MACAQUE MONKEYS; 1ST-EPISODE SCHIZOPHRENIA; CORTICAL
DYSFUNCTION; ALZHEIMERS-DISEASE
AB Individuals with schizophrenia demonstrate impairments of sensory processing within primary auditory cortex. We have previously identified lower densities of dendritic spines and axon boutons, and smaller mean pyramidal neuron somal volume, in layer 3 of the primary auditory cortex in subjects with schizophrenia, all of which might reflect fewer layer 3 pyramidal neurons in schizophrenia. To examine this hypothesis, we developed a robust stereological. method based upon unbiased principles for estimation of total volume and pyramidal neuron numbers for each layer of a cortical area. Our method generates both a systematic, uniformly random set of mapping sections as well as a set of randomly rotated sections cut orthogonal to the pial surface, within the region of interest. We applied our approach in twelve subjects with schizophrenia, each matched to a normal comparison subject. Primary auditory cortex volume was assessed using Cavalieri's method. The relative and absolute volume of each cortical layer and, within layer 3, the number and density of pyramidal neurons were estimated using our novel approach. Subject groups did not differ in regional volume, layer volumes, or pyramidal neuron number, although pyramidal neuron density was significantly greater in subjects with schizophrenia. These findings suggest that previously observed lower densities of dendritic spines and axon boutons reflect fewer numbers per neuron, and contribute to greater neuronal density via a reduced neuropil. Our approach represents a powerful new method for stereologic estimation of features of interest within individual layers of cerebral cortex, with applications beyond the current study. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Dorph-Petersen, Karl-Anton; Delevich, Kristen M.; Marcsisin, Michael J.; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Dorph-Petersen, Karl-Anton] Aarhus Univ Hosp, Ctr Psychiat Res, Risskov, Denmark.
[Zhang, Wei; Sampson, Allan R.] Univ Pittsburgh, Dept Stat, Pittsburgh, PA USA.
[Gundersen, Hans Jorgen G.] Univ Aarhus, Stereol & Electron Microscopy Res Lab, Aarhus, Denmark.
[Gundersen, Hans Jorgen G.] Univ Aarhus, MIND Ctr, Aarhus, Denmark.
[Lewis, David A.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA.
RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA.
EM sweetra@upmc.edu
RI Lewis, David/G-4053-2014; Dorph-Petersen, Karl-Anton/A-9039-2015
OI Lewis, David/0000-0002-3225-6778; Dorph-Petersen,
Karl-Anton/0000-0002-6676-034X; Delevich, Kristen/0000-0001-5698-0093
FU USPHS [MH 071533, MH 045156, MH 084053]
FX This work was supported by USPHS grants MH 071533, MH 045156 and MH
084053. The content is solely the responsibility of the authors and does
not necessarily represent the official views of the National institute
of Mental Health or the National Institutes of Health. The authors would
like to thank Professor Eva B.V. Jensen for consultation on the
calculation of the coefficients of error for our estimators, and Mrs.
Mary Brady for assistance with the figures. The authors gratefully
acknowledge the efforts of the research staff of the Translational
Neuroscience Program and the Conte Center for Neuroscience of Mental
Disorders at the 'University of Pittsburgh.
NR 76
TC 20
Z9 20
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD AUG 18
PY 2009
VL 1285
BP 42
EP 57
DI 10.1016/j.brainres.2009.06.019
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA 487MB
UT WOS:000269277300005
PM 19524554
ER
PT J
AU Guardado-Mendoza, R
Davalli, AM
Chavez, AO
Hubbard, GB
Dick, EJ
Majluf-Cruz, A
Tene-Perez, CE
Goldschmidt, L
Hart, J
Perego, C
Comuzzie, AG
Tejero, ME
Finzi, G
Placidi, C
La Rosa, S
Capella, C
Halff, G
Gastaldelli, A
DeFronzo, RA
Folli, F
AF Guardado-Mendoza, Rodolfo
Davalli, Alberto M.
Chavez, Alberto O.
Hubbard, Gene B.
Dick, Edward J.
Majluf-Cruz, Abraham
Tene-Perez, Carlos E.
Goldschmidt, Lukasz
Hart, John
Perego, Carla
Comuzzie, Anthony G.
Tejero, Maria Elizabeth
Finzi, Giovanna
Placidi, Claudia
La Rosa, Stefano
Capella, Carlo
Halff, Glenn
Gastaldelli, Amalia
DeFronzo, Ralph A.
Folli, Franco
TI Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell
proliferation are determinants of islet remodeling in type-2 diabetic
baboons
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE amyloid deposits; non-human primates; insulin resistance; islet of
Langerhans; type-2 diabetes mellitus
ID ENDOPLASMIC-RETICULUM STRESS; INSULIN-RESISTANCE; ENDOCRINE-CELLS;
TRANSGENIC MICE; POLYPEPTIDE; MELLITUS; GLUCOSE; INSIGHTS; EXPRESSION;
IAPP
AB beta-Cell dysfunction is an important factor in the development of hyperglycemia of type-2 diabetes mellitus, and pancreatic islet amyloidosis (IA) has been postulated to be one of the main contributors to impaired insulin secretion. The aim of this study was to evaluate the correlation of IA with metabolic parameters and its effect on islets of Langerhans remodeling and relative endocrine-cell volume in baboons. We sequenced the amylin peptide, determined the fibrillogenic propensities, and evaluated pancreatic histology, clinical and biochemical characteristics, and endocrine cell proliferation and apoptosis in 150 baboons with different metabolic status. Amylin sequence in the baboon was 92% similar to humans and showed superimposable fibrillogenic propensities. IA severity correlated with fasting plasma glucose (FPG) (r = 0.662, P < 0.001) and HbA1c (r = 0.726, P < 0.001), as well as with free fatty acid, glucagon values, decreased homeostasis model assessment (HOMA) insulin resistance, and HOMA-B. IA severity was associated with a decreased relative beta-cell volume, and increased relative alpha-cell volume and hyperglucagonemia. These results strongly support the concept that IA and beta-cell apoptosis in concert with alpha-cell proliferation and hypertrophy are key determinants of islets of Langerhans "dysfunctional remodeling'' and hyperglycemia in the baboon, a nonhuman primate model of type-2 diabetes mellitus. The most important determinants of IA were age and FPG (R(2) = 0.519, P < 0.0001), and different FPG levels were sensitive and specific to predict IA severity. Finally, a predictive model for islet amyloid severity was generated with age and FPG as required variables.
C1 [Guardado-Mendoza, Rodolfo; Chavez, Alberto O.; Gastaldelli, Amalia; DeFronzo, Ralph A.; Folli, Franco] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, Dept Med, San Antonio, TX 78229 USA.
[Davalli, Alberto M.] Ist Sci San Raffaele, I-20132 Milan, Italy.
[Hubbard, Gene B.; Dick, Edward J.] SW Fdn Biomed Res, San Antonio, TX 78227 USA.
[Hubbard, Gene B.; Dick, Edward J.] SW Natl Primate Res Ctr, San Antonio, TX 78227 USA.
[Majluf-Cruz, Abraham; Comuzzie, Anthony G.; Tejero, Maria Elizabeth] Unidad Invest Med Trombosis & Aterogenesis, Mexico City, DF, Mexico.
[Tene-Perez, Carlos E.] Univ Colima, Sch Med, Colima 28040, Mexico.
[Goldschmidt, Lukasz] Univ Calif Los Angeles, Dept Energy, Inst Genom & Proteom, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.
[Hart, John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Hart, John] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie Murphy Div, Dept Vet Affairs, San Antonio, TX 78229 USA.
[Perego, Carla] Univ Milan, Dept Mol Sci Appl Biosyst, I-20134 Milan, Italy.
[Finzi, Giovanna; Placidi, Claudia; La Rosa, Stefano; Capella, Carlo] Univ Insubria, Dept Human Morphol, Osped Circolo, Dept Pathol, I-21100 Varese, Italy.
[Finzi, Giovanna; Placidi, Claudia; La Rosa, Stefano; Capella, Carlo] Ctr Insubre Biotecnol Salute Umana, I-21100 Varese, Italy.
[Halff, Glenn] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA.
[Gastaldelli, Amalia] CNR, Fdn G Monasterio, I-56126 Pisa, Italy.
[Gastaldelli, Amalia] CNR, Inst Clin Physiol, I-56126 Pisa, Italy.
RP Folli, F (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, Dept Med, San Antonio, TX 78229 USA.
EM folli@uthscsa.edu
RI Gastaldelli, Amalia/H-3319-2014; Perego, Carla/L-6147-2015
OI Gastaldelli, Amalia/0000-0003-2594-1651; Perego,
Carla/0000-0003-3027-1779
FU Mexican Endocrine Society/Sanofi-Aventis; Consejo Nacional de Ciencia y
Tecnologia (CONACYT, Mexico); National Institutes of Health/National
Center for Research Resources [P51 RR013986]; Research Facilities
Improvement Program [C06 RR014578, C06 RR013556, C06 RR015456, C06
RR017515]; Robert A. Welch Foundation [AQ-1399]
FX We thank Iram P. Rodriguez-Sanchez for technical help in the sequencing
of IAPP, Dr. David Eisenberg (Howard Hughes Institute and University of
California at Los Angeles) for critical discussion, and Dr. Leslie David
Hillis for enthusiastic support and critical reading of the manuscript.
This work was supported by start-up funds from the University of Texas
Health Science Center (F.F.). R.G.-M. was supported by a Ralph A.
DeFronzo Postdoctoral Fellowship from Mexican Endocrine
Society/Sanofi-Aventis and the Consejo Nacional de Ciencia y Tecnologia
(CONACYT, Mexico). This work is part of the PhD requirements for R.G.-M.
at the University of Colima, Mexico, and was partially supported by the
National Institutes of Health/National Center for Research Resources
Grant P51 RR013986 to the Southwest National Primate Center; the
investigation was conducted in part in facilities constructed with
support from the Research Facilities Improvement Program under Grant
numbers C06 RR014578, C06 RR013556, C06 RR015456, C06 RR017515 (to
G.B.H., E.J.D., A.G.C.). J.H. was supported by Robert A. Welch
Foundation Grant AQ-1399.
NR 52
TC 79
Z9 79
U1 0
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 18
PY 2009
VL 106
IS 33
BP 13992
EP 13997
DI 10.1073/pnas.0906471106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 484WE
UT WOS:000269078700067
PM 19666551
ER
PT J
AU Walter, NAR
Bottomly, D
Laderas, T
Mooney, MA
Darakjian, P
Searles, RP
Harrington, CA
McWeeney, SK
Hitzemann, R
Buck, KJ
AF Walter, Nicole A. R.
Bottomly, Daniel
Laderas, Ted
Mooney, Michael A.
Darakjian, Priscila
Searles, Robert P.
Harrington, Christina A.
McWeeney, Shannon K.
Hitzemann, Robert
Buck, Kari J.
TI High throughput sequencing in mice: a platform comparison identifies a
preponderance of cryptic SNPs
SO BMC GENOMICS
LA English
DT Article
ID MOUSE; EXPRESSION
AB Background: Allelic variation is the cornerstone of genetically determined differences in gene expression, gene product structure, physiology, and behavior. However, allelic variation, particularly cryptic (unknown or not annotated) variation, is problematic for follow up analyses. Polymorphisms result in a high incidence of false positive and false negative results in hybridization based analyses and hinder the identification of the true variation underlying genetically determined differences in physiology and behavior. Given the proliferation of mouse genetic models (e. g., knockout models, selectively bred lines, heterogeneous stocks derived from standard inbred strains and wild mice) and the wealth of gene expression microarray and phenotypic studies using genetic models, the impact of naturally-occurring polymorphisms on these data is critical. With the advent of next-generation, high-throughput sequencing, we are now in a position to determine to what extent polymorphisms are currently cryptic in such models and their impact on downstream analyses.
Results: We sequenced the two most commonly used inbred mouse strains, DBA/2J and C57BL/6J, across a region of chromosome 1 (171.6-174.6 megabases) using two next generation high-throughput sequencing platforms: Applied Biosystems (SOLiD) and Illumina (Genome Analyzer). Using the same templates on both platforms, we compared realignments and single nucleotide polymorphism (SNP) detection with an 80 fold average read depth across platforms and samples. While public datasets currently annotate 4,527 SNPs between the two strains in this interval, thorough high-throughput sequencing identified a total of 11,824 SNPs in the interval, including 7,663 new SNPs. Furthermore, we confirmed 40 missense SNPs and discovered 36 new missense SNPs.
Conclusion: Comparisons utilizing even two of the best characterized mouse genetic models, DBA/2J and C57BL/6J, indicate that more than half of naturally-occurring SNPs remain cryptic. The magnitude of this problem is compounded when using more divergent or poorly annotated genetic models. This warrants full genomic sequencing of the mouse strains used as genetic models.
C1 [Walter, Nicole A. R.; Hitzemann, Robert; Buck, Kari J.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR USA.
[Walter, Nicole A. R.; Darakjian, Priscila; McWeeney, Shannon K.; Hitzemann, Robert; Buck, Kari J.] Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97201 USA.
[Walter, Nicole A. R.; Darakjian, Priscila; Hitzemann, Robert; Buck, Kari J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA.
[Bottomly, Daniel; Mooney, Michael A.; McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
[Bottomly, Daniel; Laderas, Ted; McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Oregon Clin & Translat Res Inst, Portland, OR 97201 USA.
[Laderas, Ted; Harrington, Christina A.; McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Div Biostat, Portland, OR 97201 USA.
RP Buck, KJ (reprint author), Portland VA Med Ctr, Res & Dev Serv, Portland, OR USA.
EM waltern@ohsu.edu; bottomly@ohsu.edu; laderast@ohsu.edu;
mooneymi@ohsu.edu; darakjia@ohsu.edu; searlesr@ohsu.edu;
harringc@ohsu.edu; mcweeney@ohsu.edu; hitzeman@ohsu.edu; buckk@ohsu.edu
OI McWeeney, Shannon/0000-0001-8333-6607; Laderas, Ted/0000-0002-6207-7068;
Mooney, Michael/0000-0003-1372-8722
FU [5R01AA011114]; [5R01DA005228]; [5P60AA10760]; [5R01AA11034];
[5R01AA13484]; [5T15LM007088]; [5P30CA069533]; [UL1RR024140]
FX This work is supported by 5R01AA011114, 5R01DA005228, 5P60AA10760,
5R01AA11034, 5R01AA13484, 5T15LM007088, 5P30CA069533, UL1RR024140, and
the VA. We thank Illumina and Applied Biosystems for their assistance in
the generation and realignment of these sequencing data.
NR 22
TC 18
Z9 19
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD AUG 17
PY 2009
VL 10
AR 379
DI 10.1186/1471-2164-10-379
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 501PI
UT WOS:000270393400001
PM 19686600
ER
PT J
AU Schittenhelm, MM
Kampa, KM
Yee, KWH
Heinrich, MC
AF Schittenhelm, Marcus M.
Kampa, Kerstin M.
Yee, Kevin W. H.
Heinrich, Michael C.
TI The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent
synergistic effects with cytarabine and daunorubicin
SO CELL CYCLE
LA English
DT Article
DE AML; FLT3 ITD; tandutinib; synergy; chemotherapy
ID ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; ACUTE MYELOGENOUS
LEUKEMIA; TYROSINE KINASE INHIBITOR; WILD-TYPE; IN-VITRO;
MYELODYSPLASTIC SYNDROME; CONSTITUTIVE ACTIVATION; LESTAURTINIB CEP701;
POOR-PROGNOSIS
AB AML remains a difficult disease to treat. Despite response to induction chemotherapy, most patients ultimately relapse. Further, among elderly patients, aggressive therapy options are often limited due to other medical conditions and decreased tolerance of these patients to conventional chemotherapy.
Internal tandem duplications (ITD) of the FLT3 juxtamembrane domain occur in 20-30% of AML patients and predict poor outcome. First clinical data with the FLT3 inhibitor tandutinib demonstrated antileukemic activity in approximately half of the patients-predominantly with FLT3 ITD positive AML. But the data also show that optimal use of tandutinib will require combination therapy with cytotoxic agents. Notably, single agent tandutinib has not been associated with myelosuppression, mucositis or cardiac toxicity-the dose limiting toxicities of AML chemotherapy.
We determined the feasibility of combining tandutinib with the standard "3 + 7" induction regimen in AML and show that, in contrast to other structurally unrelated FLT3 inhibitors recently evaluated in clinical trials, the use of tandutinib displayed application sequence independent synergistic antileukemic effects in combination with cytarabine and daunorubicin. Strong synergistic antiproliferative and proapoptotic effects were thereby predominantly seen on FLT3 ITD positive blasts. Further we demonstrate, that addition of tandutinib may allow dose reduction of chemotherapy without loss of overall antileukemic activity-resulting in a potential decrease of side effects. This approach might be an interesting novel strategy especially in the treatment of elderly/comorbid patients.
Our data provide a rationale for combining tandutinib with induction chemotherapy in intensified as well as in dose reduction protocols for FLT3 ITD positive AML.
C1 [Schittenhelm, Marcus M.; Kampa, Kerstin M.] Univ Tubingen, Med Univ Klin, Dept Hematol Oncol Rheumatol Immunol & Pulmol, Tubingen, Germany.
[Schittenhelm, Marcus M.; Kampa, Kerstin M.; Yee, Kevin W. H.; Heinrich, Michael C.] Oregon Hlth & Sci Univ, Dept Med, Portland VA Med Ctr, Knight Canc Inst, Portland, OR 97201 USA.
[Schittenhelm, Marcus M.; Kampa, Kerstin M.; Yee, Kevin W. H.; Heinrich, Michael C.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland VA Med Ctr, Knight Canc Inst, Portland, OR 97201 USA.
[Schittenhelm, Marcus M.; Kampa, Kerstin M.; Yee, Kevin W. H.; Heinrich, Michael C.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Div Hematol Oncol, Knight Canc Inst, Portland, OR 97201 USA.
[Schittenhelm, Marcus M.; Kampa, Kerstin M.; Yee, Kevin W. H.; Heinrich, Michael C.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol Oncol, Knight Canc Inst, Portland, OR 97201 USA.
RP Schittenhelm, MM (reprint author), Otfried Mueller Str 10, D-72076 Tubingen, Germany.
EM marcus.schittenhelm@med.uni-tuebingen.de
FU Department of Veterans Affairs; Doris Duke Charitable Foundation;
Leukemia and Lymphoma Society; Deutsche Krebshilfe Foundation; Tubingen
Medical School [F14900-0]
FX We thank the core facilities of the OHSU Cancer Institute and Mrs. Alida
Theil at the Medizinische Universitatsklinik Tubingen for excellent
technical assistance.; Supported in part by a Merit Review Grant from
the Department of Veterans Affairs (MCH), and grants from the Doris Duke
Charitable Foundation (MCH), the Leukemia and Lymphoma Society (MCH),
the Deutsche Krebshilfe Foundation (MMS) and Fortune-Program of the
Tubingen Medical School (Nr. F14900-0; MMS).
NR 40
TC 17
Z9 19
U1 0
U2 2
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD AUG 15
PY 2009
VL 8
IS 16
BP 2621
EP 2630
DI 10.4161/cc.8.16.9355
PG 10
WC Cell Biology
SC Cell Biology
GA 483QY
UT WOS:000268983900030
PM 19625780
ER
PT J
AU Restrepo, MI
AF Restrepo, Marcos I.
TI Efficacy of Intravenous Infusion of Doripenem
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID INADEQUATE ANTIMICROBIAL TREATMENT; VENTILATOR-ASSOCIATED PNEUMONIA;
NOSOCOMIAL PNEUMONIA; MULTICENTER; INFECTIONS; SAFETY
AB Initial treatment of nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), is usually empirical. The use of a broad-spectrum antibiotic regimen to treat NP-VAP that is active against suspected multidrug-resistant pathogens maximizes the likelihood of a favorable outcome. In a post hoc analysis of pooled data from 2 prospective, randomized, open-label, phase 3 NP-VAP trials, doripenem, a new broad-spectrum carbapenem with antipseudomonal activity, demonstrated noninferiority to standard comparator regimens (imipenem and piperacillin-tazobactam) with regard to clinical and microbiological outcomes. In subgroup analyses, doripenem continued to show noninferiority to the comparator drugs in achieving clinical and microbiological cures in populations at high risk of multidrug-resistant infection, such as patients with late-onset VAP (defined as patients who develop VAP > 5 days after intubation) or those with NP-VAP caused by Pseudomonas aeruginosa or complicated by bacteremia. Overall, the clinical data indicate that doripenem has the potential to be an important option in the treatment of NP, including VAP.
C1 [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Restrepo, Marcos I.] VERDICT S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
RP Restrepo, MI (reprint author), VERDICT Ctr 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM restrepom@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
FU Ortho-McNeil-Janssen Scientific Affairs
FX Financial support. Ortho-McNeil-Janssen Scientific Affairs.; Supplement
sponsorship. This article was published as part of a supplement entitled
"Doripenem: A New Carbapenem in the Treatment of Nosocomial Infection,"
sponsored by Ortho-McNeil-Janssen Scientific Affairs.
NR 21
TC 2
Z9 2
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2009
VL 49
SU 1
BP S17
EP S27
DI 10.1086/599812
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 472MJ
UT WOS:000268135600004
PM 19619018
ER
PT J
AU Anis, AH
Nosyk, B
Sun, HY
Guh, DP
Bansback, N
Li, X
Barnett, PG
Joyce, V
Swanson, KM
Kyriakides, TC
Holodniy, M
Cameron, DW
Brown, ST
AF Anis, Aslam H.
Nosyk, Bohdan
Sun, Huiying
Guh, Daphne P.
Bansback, Nick
Li, Xin
Barnett, Paul G.
Joyce, Vilija
Swanson, Kathleen M.
Kyriakides, Tassos C.
Holodniy, Mark
Cameron, D. William
Brown, Sheldon T.
CA OPTIMA Team
TI Quality of Life of Patients With Advanced HIV/AIDS: Measuring the Impact
of Both AIDS-Defining Events and Non-AIDS Serious Adverse Events
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article; Proceedings Paper
CT 48th Annual Interscience Conference on Antimicrobial Agents and
Chemotherapy/46th Annual Meeting of the
Infectious-Diseases-Society-of-America
CY OCT 25, 2008
CL Washington, DC
SP Infect Dis Soc Amer
DE AIDS-defining events; HIV/AIDS; HRQoL; non-AIDS serious adverse events
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH UTILITIES INDEX; HIV-INFECTED
PATIENTS; MEDICAL OUTCOMES; CLINICAL-TRIAL; HAART ERA; VALIDITY;
DISEASE; MULTIATTRIBUTE; INSTRUMENTS
AB Objective: To investigate the relative magnitude and duration of impact of AIDS-defining events (ADEs) and non-AIDS serious adverse events (SAEs) on health-related quality of life (HRQoL) among patients with advanced HIV/AIDS.
Methods: We use data from OPTIMA (OPTions In Management with Antiretrovirals), a multinational, randomized, open, control, clinical management trial of treatment strategies for patients with multidrug-resistant HIV and advanced immune disease. Longitudinal models were used to determine the effects of ADEs and SAEs oil HRQoL across periods before, during, and after event onset. The Medical Outcomes Study HIV Health Survey (MOS-HIV) physical and mental health summary scores (MOS-PHS and MOS-MHS), EQ-5D, and the Health Utilities Index Mark 3 HRQoL measures were all assessed at regular follow-up intervals during the trial.
Results: ADEs occurred much less frequently than SAEs (n = 147 vs. n = 821) in the study sample population of 368 patients, during median follow-up of 3.96 years. Although both ADEs and SAEs had significant negative impacts on HRQoL, SAEs had at least as large an impact upon HRQoL as ADEs when both were included in a multivariate linear regression model, controlling for other covariates. However, the effect of ADEs on HRQoL was more persistent, with larger magnitude of effect across all instruments in time intervals further from the onset of the event.
Conclusions: Non-AIDS SAEs occurring in patients with late-stage HIV/AIDS seem to have at least as important an immediate impact on patient HRQoL as ADEs; however, the impact of ADEs seems to be more persistent. Our findings call for a greater emphasis oil the detection and active prevention of non-AIDS SAEs in patients with late-stage HIV/AIDS.
C1 [Anis, Aslam H.; Nosyk, Bohdan; Sun, Huiying; Guh, Daphne P.; Bansback, Nick; Li, Xin] Canadian HIV Trials Network, Vancouver, BC, Canada.
[Anis, Aslam H.] Univ British Columbia, Fac Med, Sch Populat & Publ Hlth, Vancouver, BC, Canada.
[Barnett, Paul G.; Joyce, Vilija] Off Res & Dev, US Dept Vet Affairs, Cooperat Studies Program, VA Hlth Econ Resource Ctr, Menlo Pk, CA USA.
[Swanson, Kathleen M.] Clin Res Pharm Coordinating Ctr, Cooperat Studies Program, Regulatory Affairs & Clin Compliance Sect, Albuquerque, NM USA.
[Kyriakides, Tassos C.] VA Cooperat Studies Program Coordinating Ctr, West Haven, CT USA.
[Holodniy, Mark] VA Med Ctr, Palo Alto, CA USA.
[Cameron, D. William] Univ Ottawa, Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada.
[Brown, Sheldon T.] Mt Sinai Sch Med, James J Peters VA Med Ctr, Dept Med, Infect Dis Sect, New York, NY USA.
RP Anis, AH (reprint author), St Pauls Hosp, Canadian HIV Trials Network, 620-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM aslam.anis@ubc.ca
RI Joyce, Vilija/A-2578-2013
OI Joyce, Vilija/0000-0002-2484-4625; Cameron, Bill/0000-0002-0090-3539
FU Medical Research Council
NR 42
TC 27
Z9 27
U1 4
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 15
PY 2009
VL 51
IS 5
BP 631
EP 639
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 475GM
UT WOS:000268346600018
PM 19430303
ER
PT J
AU Meyer, JS
Li, Y
Chowdhury, MH
Thornby, J
AF Meyer, J. S.
Li, Y.
Chowdhury, M. H.
Thornby, J.
TI Combined mild diabetes with hypertension during aging increases white
matter atrophy
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Meeting Abstract
CT 5th International Congress on Vascular Dementia
CY NOV 08-11, 2007
CL Budapest, HUNGARY
C1 [Meyer, J. S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Li, Y.; Chowdhury, M. H.; Thornby, J.] Baylor Coll Med, Michael E Debakey Vet Adm Med Ctr, Dept Neurol, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD AUG 15
PY 2009
VL 283
IS 1-2
BP 258
EP 258
DI 10.1016/j.jns.2009.02.076
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 478SU
UT WOS:000268609400120
ER
PT J
AU Little, KY
Ramssen, E
Welchko, R
Volberg, V
Roland, CJ
Cassin, B
AF Little, Karley Y.
Ramssen, Eric
Welchko, Ryan
Volberg, Vitaly
Roland, Courtney J.
Cassin, Bader
TI Decreased brain dopamine cell numbers in human cocaine users
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Cocaine; Dopamine; Neurotoxicity; Dopamine transporter; Cocaine
dependence; Parkinson's Disease
ID VESICULAR MONOAMINE TRANSPORTER; SUBSTANTIA-NIGRA; PARKINSONS-DISEASE;
STRIATAL DOPAMINE; BINDING-SITES; METHAMPHETAMINE USERS; RADIOLIGAND
BINDING; OVERDOSE VICTIMS; MPTP TREATMENT; NEURONS
AB Cocaine use diminishes striatal and midbrain dopamine neuronal components in both post-mortem and in vivo human experiments. The diffuse nature of these declines suggests the possibility that cocaine use might cause a loss of dopamine neurons in humans. Previous rodent studies have not detected cocaine-induced dopamine cell damage. The present experiment involved counting midbrain dopamine neurons utilizing both melanin and tyrosine hydroxylase immunoreactivity. Well-preserved blocks ranging from + 38 torn obex to +45 mm obex were examined in 10 cocaine users and 9 controls. Sections were also examined for signs of acute pathological injury by counting activated macrophages and microglia. Melanized cells at six midbrain levels were significantly reduced in cocaine users by both drug exposures. The estimated total number of melanized dopamine cells in the anterior midbrain was significantly reduced in cocaine users by 16%. Results with tyrosine hydroxylase immunoreactivity were less conclusive because of variability in staining. Both activated macrophages and activated microglia were significantly increased among cocaine users. Cocaine exposure may have neurotoxic effects on dopamine neurons in humans. The infiltration of phagocytic cells suggests that the lower number of dopamine cells found in cocaine users was a relatively recent effect. The loss of dopamine cells could contribute to and intensify cocaine dependence, as well as anhedonic and depressive symptoms, in some cocaine users. Further efforts at clarifying the pathophysiological mechanisms involved may help explain treatment refractoriness, and identify targets for therapeutic intervention. Published by Elsevier Ireland Ltd.
C1 [Little, Karley Y.; Ramssen, Eric; Welchko, Ryan; Volberg, Vitaly; Roland, Courtney J.] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA.
[Little, Karley Y.] Houston VAMC, Houston, TX USA.
[Cassin, Bader] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
RP Little, KY (reprint author), Michael E Debakey Vet Adm Med Ctr, Lab Affect Neuropharmacol 151, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM karleyl@bcm.edu
FU NIH [DA15509]
FX The research reported was supported by NIH DA15509.
NR 71
TC 34
Z9 35
U1 2
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD AUG 15
PY 2009
VL 168
IS 3
BP 173
EP 180
DI 10.1016/j.psychres.2008.10.034
PG 8
WC Psychiatry
SC Psychiatry
GA 485KB
UT WOS:000269118700001
PM 19233481
ER
PT J
AU Idkowiak-Baldys, J
Baldys, A
Raymond, JR
Hannun, YA
AF Idkowiak-Baldys, Jolanta
Baldys, Aleksander
Raymond, John R.
Hannun, Yusuf A.
TI Sustained Receptor Stimulation Leads to Sequestration of Recycling
Endosomes in a Classical Protein Kinase C- and Phospholipase D-dependent
Manner
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID GROWTH-FACTOR RECEPTORS; COUPLED RECEPTORS; PLASMA-MEMBRANE;
5-HYDROXYTRYPTAMINE(2A) RECEPTOR; DOPAMINE TRANSPORTER; ACTIVATED
RECEPTOR-1; 5-HT2A RECEPTORS; BETA-II; DESENSITIZATION; ENDOCYTOSIS
AB Considerable insight has been garnered on initial mechanisms of endocytosis of plasma membrane proteins and their subsequent trafficking through the endosomal compartment. It is also well established that ligand stimulation of many plasma membrane receptors leads to their internalization. However, stimulus-induced regulation of endosomal trafficking has not received much attention. In previous studies, we showed that sustained stimulation of protein kinase C(PKC) with phorbol esters led to sequestration of recycling endosomes in a juxtanuclear region. In this study, we investigated whether G-protein-coupled receptors that activate PKC exerted effects on endosomal trafficking. Stimulation of cells with serotonin (5-hydroxytryptamine (5-HT)) led to sequestration of the 5-HT receptor(5-HT(2A)R) into a Rab11-positive juxtanuclear compartment. This sequestration coincided with translocation of PKC as shown by confocal microscopy. Mechanistically the observed sequestration of 5-HT2AR was shown to require continuous PKC activity because it was inhibited by pretreatment with classical PKC inhibitor Go6976 and could be reversed by posttreatment with this inhibitor. In addition, classical PKC autophosphorylation was necessary for receptor sequestration. Moreover inhibition of phospholipase D (PLD) activity and inhibition of PLD1 and PLD2 using dominant negative constructs also prevented this process. Functionally this sequestration did not affect receptor desensitization or resensitization as measured by intracellular calcium increase. However, the PKC- and PLD-dependent sequestration of receptors resulted in co-sequestration of other plasma membrane proteins and receptors as shown for epidermal growth factor receptor and protease activated receptor-1. This led to heterologous desensitization of those receptors and diverted their cellular fate by protecting them from agonist-induced degradation. Taken together, these results demonstrate a novel role for sustained receptor stimulation in regulation of intracellular trafficking, and this process requires sustained stimulation of PKC and PLD.
C1 [Idkowiak-Baldys, Jolanta; Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Baldys, Aleksander; Raymond, John R.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
[Baldys, Aleksander; Raymond, John R.] Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC 29401 USA.
RP Hannun, YA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.
EM hannun@musc.edu
FU National Institutes of Health [HL43707, R01 GM-63909]; Veterans Affairs
Merit and Research Enhancement Award Program Awards; American Heart
Association [0725358U]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants HL43707 (to Y. A. H.) and R01 GM-63909 (to J.R.R.). This
work was also supported by Veterans Affairs Merit and Research
Enhancement Award Program Awards (to J.R.R.), and American Heart
Association Mid-Atlantic Affiliate Grant 0725358U (to A. B.).
NR 48
TC 24
Z9 25
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 14
PY 2009
VL 284
IS 33
BP 22322
EP 22331
DI 10.1074/jbc.M109.026765
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 481CE
UT WOS:000268783700055
PM 19525236
ER
PT J
AU Hoda, MN
Singh, I
Singh, AK
Khan, M
AF Hoda, Md Nasrul
Singh, Inderjit
Singh, Avtar K.
Khan, Mushfiquddin
TI Reduction of lipoxidative load by secretory phospholipase A2 inhibition
protects against neurovascular injury following experimental stroke in
rat
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
ID FOCAL CEREBRAL-ISCHEMIA; NF-KAPPA-B; BLOOD-BRAIN-BARRIER;
ARACHIDONIC-ACID; FATTY-ACIDS; CELL-DEATH; GROUP IIA; REDUCES
INFLAMMATION; MEDIATED ACTIVATION; OXIDATIVE STRESS
AB Background: In animal models, ischemia reperfusion (IR) injury triggers membrane lipid degradation and accumulation of lipoxidative exacerbations in neurovascular unit, leading to blood brain barrier (BBB) damage and neurologic deficits. In this study, we investigated whether impeding membrane lipid breakdown by inhibiting secretory phospholipase A2 (sPLA2) activity reduces BBB leakage, leading to neuroprotection and functional recovery.
Methods: Focal cerebral IR injury was induced by middle cerebral artery occlusion (MCAO) in adult male rats. A sPLA2 inhibitor, 7,7-dimethyleicosadienoic acid (DEDA), was administered following IR injury. DEDA-treated animals were compared with vehicle-treated in terms of BBB leakage, edema, infarct volume, and neurological deficit. Membrane lipid degradation and the expression/activity of sPLA2 were also assessed. The role of one of the sPLA2 products, arachidonic acid (AA), on the morphology of the differentiated neuronal cell PC12 was examined by light microscopy.
Results: Treatment with DEDA after IR injury not only reduced BBB leakage but also decreased infarct volume and improved neurologic function. The treatment attenuated both the activity of sPLA2 and the levels of sPLA2-derived oxidized products. The metabolites of lipid oxidation/peroxidation, including the protein carbonyl, were reduced as well. The treatment also restored the levels of glutathione, indicating attenuation of oxidative stress. In vitro treatment of PC12 cells with DEDA did not restore the AA-mediated inhibition of neurite formation and the levels of glutathione, indicating that effect of DEDA is up stream to AA release.
Conclusion: sPLA2-derived oxidative products contribute to significant neurovascular damage, and treatment with sPLA2 inhibitor DEDA ameliorates secondary injury by reducing exacerbations from lipoxidative stress.
C1 [Hoda, Md Nasrul; Singh, Inderjit; Khan, Mushfiquddin] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Singh, Avtar K.] Ralph J Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
RP Khan, M (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.
EM hoda@musc.edu; singhi@musc.edu; singha@musc.edu; khanm@musc.edu
FU NIH [NS-22576, NS-34741, NS37766]; State of South Carolina Spinal Cord
Injury Research Fund Board [SCIRF 0406, SCIRF 0506]; National Center for
Research Resources [C06 RR018823, C06 RR015455]
FX These studies were supported by grants (NS-22576, NS-34741 and NS37766)
from the NIH, Veteran Administration merit award and (SCIRF 0406 and
SCIRF 0506) from State of South Carolina Spinal Cord Injury Research
Fund Board. This work was also supported by the NIH, Grants C06 RR018823
and No C06 RR015455 from the Extramural Research Facilities Program of
the National Center for Research Resources. We are grateful to Dr Tom
Smith from the MUSC Writing Center for his valuable editing and
correction of the manuscript. We would like to thank Ms. Joyce Bryan for
procurement of animals and chemicals used in this study. We would also
like to thank Dr Shailendra Giri and Anandakumar Shunmugavel for their
valuable assistance with the in vitro work
NR 63
TC 13
Z9 16
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD AUG 13
PY 2009
VL 6
AR 21
DI 10.1186/1742-2094-6-21
PG 11
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 495DD
UT WOS:000269869200001
PM 19678934
ER
PT J
AU Kernisan, LP
Dudley, RA
AF Kernisan, Leslie P.
Dudley, R. Adams
TI Hospital Mortality and Leapfrog Hospital Survey Results Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Kernisan, Leslie P.] San Francisco VA Med Ctr, Natl VA Qual Scholars Program, San Francisco, CA USA.
[Dudley, R. Adams] Univ Calif San Francisco, Phillip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA.
RP Kernisan, LP (reprint author), San Francisco VA Med Ctr, Natl VA Qual Scholars Program, San Francisco, CA USA.
EM lkernisan@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD AUG 12
PY 2009
VL 302
IS 6
BP 626
EP 626
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 481ZI
UT WOS:000268852300018
ER
PT J
AU Tanhehco, YC
Palmer, OMP
Derrico, LS
Blair, HC
Tanhehco, YC
Sepulveda, JL
AF Tanhehco, Yvette C.
Palmer, Octavia M. Peck
Derrico, Linda S.
Blair, Harry C.
Tanhehco, Yvette C.
Sepulveda, Jorge L.
TI Biases in antibody-based single-phase assays for free thyroxine due to
protein-bound analyte
SO CLINICA CHIMICA ACTA
LA English
DT Letter
ID TANDEM MASS-SPECTROMETRY; CAPACITY-DEPENDENT BIAS; NONTHYROIDAL ILLNESS;
FREE HORMONES; IMMUNOASSAYS; TRIIODOTHYRONINE; RADIOIMMUNOASSAYS;
PREGNANCY; ACCURACY; T4
C1 [Tanhehco, Yvette C.; Tanhehco, Yvette C.; Sepulveda, Jorge L.] Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA.
[Tanhehco, Yvette C.; Palmer, Octavia M. Peck; Derrico, Linda S.; Blair, Harry C.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15243 USA.
[Tanhehco, Yvette C.; Palmer, Octavia M. Peck; Derrico, Linda S.; Blair, Harry C.] Vet Affairs Med Ctr, Pittsburgh, PA 15243 USA.
[Tanhehco, Yvette C.; Sepulveda, Jorge L.] Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Tanhehco, YC (reprint author), Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA.
EM yvette.tanhehco@uphs.upenn.edu
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD AUG 11
PY 2009
VL 406
IS 1-2
BP 176
EP 178
DI 10.1016/j.cca.2009.05.021
PG 3
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 482XM
UT WOS:000268923900038
PM 19500559
ER
PT J
AU Billings, CJ
Tremblay, KL
Stecker, GC
Tolin, WM
AF Billings, Curtis J.
Tremblay, Kelly L.
Stecker, G. Christopher
Tolin, Wendy M.
TI Human evoked cortical activity to signal-to-noise ratio and absolute
signal level
SO HEARING RESEARCH
LA English
DT Article
DE Cortical auditory evoked potentials (CAEPs); Event-related potentials
(ERPs); Signals in noise; Signal-to-noise ratio (SNR); N1; Auditory
cortex; Hearing aids
ID SENSORINEURAL HEARING-LOSS; EVENT-RELATED POTENTIALS; BROAD-BAND NOISE;
NEURAL REPRESENTATION; AUDITORY-CORTEX; BEHAVIORAL MEASURES;
STIMULUS-INTENSITY; AMPLIFIED SPEECH; RESPONSES; SOUND
AB The purpose of this study was to determine the effect of signal level and signal-to-noise ratio (SNR) on the latency and amplitude of evoked cortical activity to further our understanding of how the human central auditory system encodes signals in noise. Cortical auditory evoked potentials (CAEPs) were recorded from 15 young normal-hearing adults in response to a 1000 Hz tone presented at two tone levels in quiet and while continuous background noise levels were varied in five equivalent SNR steps. These 12 conditions were used to determine the effects of signal level and SNR level on CAEP components P1, N1, P2, and N2. Based on prior signal-in-noise experiments conducted in animals, we hypothesized that SNR, would be a key contributor to human CAEP characteristics. As hypothesized, amplitude increased and latency decreased with increasing SNR; in addition, there was no main effect of tone level across the two signal levels tested (60 and 75 dB SPL). Morphology of the P1-N1-P2 complex was driven primarily by SNR, highlighting the importance of noise when recording CAEPs. Results are discussed in terms of the current interest in recording CAEPs in hearing aid users. Published by Elsevier B.V.
C1 [Billings, Curtis J.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA.
[Billings, Curtis J.; Tremblay, Kelly L.; Stecker, G. Christopher; Tolin, Wendy M.] Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98105 USA.
RP Billings, CJ (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA.
EM curtis.billings2@va.gov; tremblay@u.washington.edu;
cstecker@u.washington.edu; wendyt3@u.washington.edu
FU National Institutes of Health through the National Institute on Deafness
and Other Communication Disorders [F31-DC007296, R01-DC007705,
P30DC004661]
FX The authors thank Richard Folsom and Pamela Souza who contributed to
this work through many helpful discussions and as dissertation committee
members of the first author. The authors are also grateful to the
reviewers for their helpful comments. This work was supported by the
National Institutes of Health through the National Institute on Deafness
and Other Communication Disorders (F31-DC007296, CJ.B.; R01-DC007705,
K.L.T.; P30DC004661).
NR 59
TC 37
Z9 43
U1 2
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5955
J9 HEARING RES
JI Hear. Res.
PD AUG 11
PY 2009
VL 254
IS 1-2
BP 15
EP 24
DI 10.1016/j.heares.2009.04.002
PG 10
WC Audiology & Speech-Language Pathology; Neurosciences;
Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Neurosciences & Neurology;
Otorhinolaryngology
GA 476KH
UT WOS:000268438500002
PM 19364526
ER
PT J
AU Moreno, SG
Sutton, AJ
Turner, EH
Abrams, KR
Cooper, NJ
Palmer, TM
Ades, AE
AF Moreno, Santiago G.
Sutton, Alex J.
Turner, Erick H.
Abrams, Keith R.
Cooper, Nicola J.
Palmer, Tom M.
Ades, A. E.
TI Novel methods to deal with publication biases: secondary analysis of
antidepressant trials in the FDA trial registry database and related
journal publications
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID OUTCOME REPORTING BIAS; INTENTION-TO-TREAT; RANDOMIZED
CONTROLLED-TRIALS; MISLEADING FUNNEL PLOT; EMPIRICAL-EVIDENCE;
CLINICAL-TRIALS; EFFECT SIZE; FILL METHOD; METAANALYSIS; HETEROGENEITY
AB Objective To assess the performance of novel contour enhanced funnel plots and a regression based adjustment method to detect and adjust for publication biases.
Design Secondary analysis of a published systematic literature review.
Data sources Placebo controlled trials of antidepressants previously submitted to the US Food and Drug Administration (FDA) and matching journal publications.
Methods Publication biases were identified using novel contour enhanced funnel plots, a regression based adjustment method, Egger's test, and the trim and fill method. Results were compared with a meta-analysis of the gold standard data submitted to the FDA.
Results Severe asymmetry was observed in the contour enhanced funnel plot that appeared to be heavily influenced by the statistical significance of results, suggesting publication biases as the cause of the asymmetry. Applying the regression based adjustment method to the journal data produced a similar pooled effect to that observed by a meta-analysis of the FDA data. Contrasting journal and FDA results suggested that, in addition to other deviations from study protocol, switching from an intention to treat analysis to a per protocol one would contribute to the observed discrepancies between the journal and FDA results. Conclusion Novel contour enhanced funnel plots and a regression based adjustment method worked convincingly and might have an important part to play in combating publication biases.
C1 [Moreno, Santiago G.; Sutton, Alex J.; Abrams, Keith R.] Univ Leicester, Dept Hlth Sci, Leicester LE1 7RH, Leics, England.
[Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA.
[Palmer, Tom M.] Univ Bristol, MRC Ctr Causal Anal Translat Epidemiol, Dept Social Med, Bristol BS8 1TH, Avon, England.
[Ades, A. E.] Univ Bristol, Dept Community Based Med, Bristol BS8 1TH, Avon, England.
RP Moreno, SG (reprint author), Univ Leicester, Dept Hlth Sci, Leicester LE1 7RH, Leics, England.
EM sgm8@le.ac.uk
OI Turner, Erick/0000-0002-3522-3357; Abrams, Keith/0000-0002-7557-1567
FU Medical Research Council Health Services Research Collaboration
FX SGM was supported by a Medical Research Council Health Services Research
Collaboration studentship in the UK. AEA was funded by the Medical
Research Council Health Services Research Collaboration. The funding
agreement ensured the authors' independence in designing the study,
interpreting the data, and writing and publishing the report. The
corresponding author as well as the other authors had access to all the
data and take responsibility for the integrity of the data and the
accuracy of the data analysis.
NR 70
TC 72
Z9 72
U1 1
U2 10
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-8146
J9 BRIT MED J
JI Br. Med. J.
PD AUG 7
PY 2009
VL 339
AR b2981
DI 10.1136/bmj.b2981
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 481KF
UT WOS:000268808200002
PM 19666685
ER
PT J
AU Margaretten, ME
Tierney, LM
Dhaliwal, G
AF Margaretten, Mary E.
Tierney, Lawrence M., Jr.
Dhaliwal, Gurpreet
TI A Hard Diagnosis
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID SCLERODERMA RENAL CRISIS; SCLEROSIS SINE SCLERODERMA; SYSTEMIC-SCLEROSIS
C1 [Margaretten, Mary E.] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94118 USA.
[Tierney, Lawrence M., Jr.; Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA 94118 USA.
[Tierney, Lawrence M., Jr.; Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Margaretten, ME (reprint author), Univ Calif San Francisco, Div Rheumatol, 3333 Calif St,Suite 270, San Francisco, CA 94118 USA.
EM mary.margaretten@ucsf.edu
NR 10
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD AUG 6
PY 2009
VL 361
IS 6
BP 613
EP 617
DI 10.1056/NEJMcps0804137
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 479NR
UT WOS:000268667300013
PM 19657126
ER
PT J
AU Ramachandran, D
Luo, CA
Ma, TS
Clark, JW
AF Ramachandran, Deepa
Luo, Chuan
Ma, Tony S.
Clark, John W., Jr.
TI Using a human cardiovascular-respiratory model to characterize cardiac
tamponade and pulsus paradoxus
SO THEORETICAL BIOLOGY AND MEDICAL MODELLING
LA English
DT Article
ID PERICARDIAL CONSTRAINT; STROKE VOLUME; GAS-EXCHANGE; BLOOD-FLOW;
PRESSURE; INTERDEPENDENCE; DYNAMICS; EFFUSION; COLLAPSE; STATE
AB Background: Cardiac tamponade is a condition whereby fluid accumulation in the pericardial sac surrounding the heart causes elevation and equilibration of pericardial and cardiac chamber pressures, reduced cardiac output, changes in hemodynamics, partial chamber collapse, pulsus paradoxus, and arterio-venous acid-base disparity. Our large-scale model of the human cardiovascular-respiratory system (H-CRS) is employed to study mechanisms underlying cardiac tamponade and pulsus paradoxus. The model integrates hemodynamics, whole-body gas exchange, and autonomic nervous system control to simulate pressure, volume, and blood flow.
Methods: We integrate a new pericardial model into our previously developed H-CRS model based on a fit to patient pressure data. Virtual experiments are designed to simulate pericardial effusion and study mechanisms of pulsus paradoxus, focusing particularly on the role of the interventricular septum. Model differential equations programmed in C are solved using a 5(th)-order Runge-Kutta numerical integration scheme. MATLAB is employed for waveform analysis.
Results: The H-CRS model simulates hemodynamic and respiratory changes associated with tamponade clinically. Our model predicts effects of effusion-generated pericardial constraint on chamber and septal mechanics, such as altered right atrial filling, delayed leftward septal motion, and prolonged left ventricular pre-ejection period, causing atrioventricular interaction and ventricular desynchronization. We demonstrate pericardial constraint to markedly accentuate normal ventricular interactions associated with respiratory effort, which we show to be the distinct mechanisms of pulsus paradoxus, namely, series and parallel ventricular interaction. Series ventricular interaction represents respiratory variation in right ventricular stroke volume carried over to the left ventricle via the pulmonary vasculature, whereas parallel interaction (via the septum and pericardium) is a result of competition for fixed filling space. We find that simulating active septal contraction is important in modeling ventricular interaction. The model predicts increased arterio-venous CO(2) due to hypoperfusion, and we explore implications of respiratory pattern in tamponade.
Conclusion: Our modeling study of cardiac tamponade dissects the roles played by septal motion, atrioventricular and right-left ventricular interactions, pulmonary blood pooling, and the depth of respiration. The study fully describes the physiological basis of pulsus paradoxus. Our detailed analysis provides biophysically-based insights helpful for future experimental and clinical study of cardiac tamponade and related pericardial diseases.
C1 [Ramachandran, Deepa; Luo, Chuan; Clark, John W., Jr.] Rice Univ, Dept Elect & Comp Engn, Houston, TX 77005 USA.
[Ma, Tony S.] VA Med Ctr, Div Cardiol, Houston, TX 77030 USA.
[Ma, Tony S.] Baylor Coll Med, Houston, TX 77030 USA.
RP Clark, JW (reprint author), Rice Univ, Dept Elect & Comp Engn, Houston, TX 77005 USA.
EM dpr2@rice.edu; urania@rice.edu; ma.tonys@va.gov; jwc@rice.edu
FU Keck Center for Interdisciplinary Bioscience Training of the Gulf Coast
Consortia [5T15LM07093]
FX This work was supported by a training fellowship from the Keck Center
for Interdisciplinary Bioscience Training of the Gulf Coast Consortia
(NLM Grant No. 5T15LM07093).
NR 50
TC 6
Z9 8
U1 2
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4682
J9 THEOR BIOL MED MODEL
JI Theor. Biol. Med. Model.
PD AUG 6
PY 2009
VL 6
AR 15
DI 10.1186/1742-4682-6-15
PG 28
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA 498WU
UT WOS:000270177300001
PM 19656411
ER
PT J
AU Stanley, MA
Rhoades, HM
Kunik, ME
AF Stanley, Melinda A.
Rhoades, Howard M.
Kunik, Mark E.
TI Cognitive Behavior Therapy for Older Patients With Generalized Anxiety
Disorder Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Stanley, Melinda A.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Rhoades, Howard M.] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA.
[Kunik, Mark E.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
RP Stanley, MA (reprint author), Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
EM mstanley@bcm.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD AUG 5
PY 2009
VL 302
IS 5
BP 487
EP 487
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 479DS
UT WOS:000268640500007
ER
PT J
AU Turenius, CI
Charles, JR
Tsai, DH
Ebersole, PL
Htut, MH
Ngo, PT
Lara, RN
Stanley, BG
AF Turenius, Christine I.
Charles, Jonathan R.
Tsai, Donna H.
Ebersole, Priscilla L.
Htut, Myat H.
Ngo, Phuong T.
Lara, Raul N.
Stanley, B. Glenn
TI The tuberal lateral hypothalamus is a major target for GABA(A)- but not
GABA(B)-mediated control of food intake
SO BRAIN RESEARCH
LA English
DT Article
DE Feeding; Inhibition; GABA; Receptor; Lateral Hypothalamus; Rat
ID BODY-WEIGHT; INGESTIVE BEHAVIOR; LOCOMOTOR-ACTIVITY; DORSOMEDIAL
HYPOTHALAMUS; FEEDING-BEHAVIOR; RAT HYPOTHALAMUS; ARCUATE NUCLEUS;
NEURONS; RECEPTORS; ACID
AB The lateral hypothalamus (LH) is a site of integration for control mechanisms of feeding behavior as it has extensive reciprocal connections with multiple intrahypothalamic and extrahypothalamic brain areas. Evidence suggests that blockade of ionotropric gamma-aminobutyric acid (GABA) receptors in the LH elicits eating in satiated rats. To determine whether this GABA(A) receptor antagonist effect is specific to the LH, the antagonist picrotoxin was injected into one of six nearby sites and food intake was measured. Picrotoxin at 133 pmol elicited eating in the LH, but not in surrounding sites (thalamus, lateral preoptic area, ventral tegmental area, dorsomedial hypothalamus, and entopeduncular nucleus). More specifically, picrotoxin injected into the tuberal LH (tLH) elicited eating, but was ineffective when injected into the anterior or posterior LH. We also investigated whether GABA(B) receptors in the LH participated in the control of food intake and found that neither blockade nor activation of these receptors under multiple conditions changed food intake. Collectively, our findings suggest that GABAA but not GABAB receptors in the tLH act to suppress feeding behavior. Published by Elsevier B.V.
C1 [Turenius, Christine I.; Charles, Jonathan R.; Stanley, B. Glenn] Univ Calif Riverside, Interdepartmental Neurosci Grad Program, Riverside, CA 92521 USA.
[Tsai, Donna H.; Ebersole, Priscilla L.; Htut, Myat H.; Ngo, Phuong T.; Lara, Raul N.; Stanley, B. Glenn] Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA.
[Stanley, B. Glenn] Univ Calif Riverside, Dept Psychol, Riverside, CA 92521 USA.
RP Turenius, CI (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,R-151, Seattle, WA 98108 USA.
EM turenius@u.washington.edu
OI Charles, Jonathan/0000-0002-1598-0801
NR 51
TC 16
Z9 18
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD AUG 4
PY 2009
VL 1283
BP 65
EP 72
DI 10.1016/j.brainres.2009.05.064
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 484FQ
UT WOS:000269029700008
PM 19501070
ER
PT J
AU Davis, BR
Simpson, LM
Ford, CE
Kostis, JB
Black, HR
Cushman, WC
Einhorn, PT
Farber, MA
Levy, D
Massie, BM
Nawaz, S
AF Davis, Barry R.
Simpson, Lara M.
Ford, Charles E.
Kostis, John B.
Black, Henry R.
Cushman, William C.
Einhorn, Paula T.
Farber, Michael A.
Levy, Daniel
Massie, Barry M.
Nawaz, Shah
CA ALLHAT Collaborative Res Grp
TI Letter by Barrios et al Regarding Article, "Heart Failure With Preserved
and Reduced Left Ventricular Ejection Fraction in the Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial" Response
SO CIRCULATION
LA English
DT Letter
ID CARDIOVASCULAR EVENTS; BLOCKER; ALLHAT
C1 [Davis, Barry R.; Simpson, Lara M.; Ford, Charles E.] Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Houston, TX USA.
[Kostis, John B.] UMDNJ Robert Wood Johnson Med Sch, New Brunswick, NJ USA.
[Black, Henry R.] NYU, Sch Med, New York, NY USA.
[Cushman, William C.] Memphis Vet Affairs Med Ctr, Memphis, TN USA.
[Einhorn, Paula T.] NHLBI, Div Prevent & Populat Sci, Bethesda, MD 20892 USA.
[Farber, Michael A.] Crozer Keystone Hlth Network, Upland, PA USA.
[Levy, Daniel] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Davis, BR (reprint author), Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Houston, TX USA.
NR 4
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD AUG 4
PY 2009
VL 120
IS 5
BP E32
EP E32
DI 10.1161/CIRCULATIONAHA.109.854562
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 479DA
UT WOS:000268638700020
ER
PT J
AU Jasti, H
Hanusa, BH
Switzer, GE
Granieri, R
Elnicki, M
AF Jasti, Harish
Hanusa, Barbara H.
Switzer, Galen E.
Granieri, Rosanne
Elnicki, Michael
TI Residents' perceptions of a night float system
SO BMC MEDICAL EDUCATION
LA English
DT Article
ID INTERNAL-MEDICINE RESIDENTS; PATIENT-CARE; HOUSE STAFF;
SLEEP-DEPRIVATION; CALL STRUCTURE; WORKING HOURS; IMPACT;
RESPONSIBILITY; SATISFACTION; PERFORMANCE
AB Background: A Night Float (NF) system has been implemented by many institutions to address increasing concerns about residents' work hours. The purpose of our study was to examine the perceptions of residents towards a NF system.
Methods: A 115-item questionnaire was developed to assess residents' perceptions of the NF rotation as compared with a regular call month. The categories included patient care, education, medical errors, and overall satisfaction. Internal Medicine housestaff (post-graduate years 1-3) from three hospital settings at the University of Pittsburgh completed the questionnaire.
Results: The response rate was 90% (n = 149). Of these, 74 had completed the NF rotation. The housestaff felt that the quality of patient care was improved because of NF (41% agreed and 18% disagreed). A majority also felt that better care was provided by a rested physician in spite of being less familiar with the patient (46% agreed and 21% disagreed). Most felt that there was less emphasis on education (65%) and more emphasis on service (52%) during NF. Overall, the residents felt more rested during their call months (83%) and strongly supported the 80-hour workweek requirement (77%).
Conclusion: Housestaff felt that the overall quality of patient care was improved by a NF system. The perceived improved quality of care by a rested physician coupled with a perceived decrease in the emphasis on education may have significant implications in housestaff training.
C1 [Jasti, Harish; Granieri, Rosanne; Elnicki, Michael] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA.
[Hanusa, Barbara H.; Switzer, Galen E.] Univ Pittsburgh, VA Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Hanusa, Barbara H.; Switzer, Galen E.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Switzer, Galen E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Switzer, Galen E.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA.
RP Jasti, H (reprint author), Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA.
EM jastih@upmc.edu; hanusab@upmc.edu; switzerg@upmc.edu;
granierir@upmc.edu; elnickim@upmc.edu
NR 26
TC 15
Z9 15
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6920
J9 BMC MED EDUC
JI BMC Med. Educ.
PD AUG 3
PY 2009
VL 9
AR 52
DI 10.1186/1472-6920-9-52
PG 6
WC Education & Educational Research; Education, Scientific Disciplines
SC Education & Educational Research
GA 686RB
UT WOS:000284712300001
PM 19650924
ER
PT J
AU Ladiges, W
Van Remmen, H
Strong, R
Ikeno, Y
Treuting, P
Rabinovitch, P
Richardson, A
AF Ladiges, Warren
Van Remmen, Holly
Strong, Randy
Ikeno, Yuji
Treuting, Piper
Rabinovitch, Peter
Richardson, Arlan
TI Lifespan extension in genetically modified mice
SO AGING CELL
LA English
DT Review
ID NEMATODE CAENORHABDITIS-ELEGANS; FATAL NEOPLASTIC DISEASES; AMES DWARF
MICE; OXIDATIVE STRESS; DETERMINANT P66(SHC); DIETARY RESTRICTION;
EXTENDED LONGEVITY; DELAYED OCCURRENCE; KNOCKOUT MICE; F1 HYBRIDS
AB P>Major advances in aging research have been made by studying the effect of genetic modifications on the lifespan of organisms, such as yeast, invertebrates (worms and flies) and mice. Data from yeast and invertebrates have been the most plentiful because of the ease in which genetic manipulations can be made and the rapidity by which lifespan experiments can be performed. With the ultimate focus on advancing human health, testing genetic interventions in mammals is crucial, and the mouse has proven to be the mammal most amenable to this task. Lifespan studies in mice are resource intensive, requiring up to 4 years to complete. Therefore, it is critical that a set of scientifically-based criteria be followed to assure reliable results and establish statistically significant findings so other laboratories can replicate and build on the data. Only then will it be possible to confidently determine that the genetic modification extends lifespan and alters aging.
C1 [Ladiges, Warren; Treuting, Piper] Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA.
[Van Remmen, Holly; Strong, Randy; Ikeno, Yuji; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78245 USA.
[Van Remmen, Holly; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA.
[Van Remmen, Holly; Strong, Randy; Ikeno, Yuji; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78245 USA.
[Ikeno, Yuji] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78245 USA.
[Rabinovitch, Peter] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.
RP Ladiges, W (reprint author), Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA.
EM wladiges@u.washington.edu
NR 53
TC 53
Z9 53
U1 0
U2 7
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1474-9718
J9 AGING CELL
JI Aging Cell
PD AUG
PY 2009
VL 8
IS 4
BP 346
EP 352
DI 10.1111/j.1474-9726.2009.00491.x
PG 7
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 473NH
UT WOS:000268213300001
PM 19485964
ER
PT J
AU Beste, LA
Straits-Troster, K
Zickmund, S
Larson, M
Chapko, M
Dominitz, JA
AF Beste, L. A.
Straits-Troster, K.
Zickmund, S.
Larson, M.
Chapko, M.
Dominitz, J. A.
TI Specialty care and education associated with greater disease-specific
knowledge but not satisfaction with care for chronic hepatitis C
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID INJECTION-DRUG USERS; QUALITY-OF-LIFE; VIRUS-INFECTION; UNITED-STATES;
MANAGEMENT; VETERANS; IMPACT; IDENTIFICATION; PREVALENCE; PHYSICIANS
AB Background
Little is known about differences among hepatitis C virus (HCV) patients managed by generalists vs. specialists with respect to patient-centred outcomes, such as disease-specific knowledge, health-related quality of life (HRQoL) and satisfaction with care.
Aim
To examine selected patient-centred outcomes of HCV-related care provided in primary care, specialty care or both.
Methods
A total of 629 chronic HCV patients completed a survey including an HCV knowledge assessment and validated instruments for satisfaction and HRQoL. Multivariable linear regression was used to compare outcomes between groups.
Results
Adjusted total HCV knowledge score was lower among patients who did not attend specialty care (P < 0.01). Primary care and specialty patients did not differ in adjusted general HRQoL or satisfaction. Sixty percent of specialty patients underwent formal HCV education, which was associated with 5% higher knowledge score (P = 0.01). General HRQoL and patient satisfaction did not differ between primary care and specialty groups. Disease-specific knowledge and care satisfaction were independent of mental illness, substance abuse, socio-economic variables, history of antiviral treatment, formal HCV education and duration of time between last visit and survey completion.
Conclusions
Primary care patients with chronic HCV have lower adjusted disease-specific knowledge than specialty patients, but no difference in general HRQoL or patient satisfaction.
C1 [Beste, L. A.; Chapko, M.; Dominitz, J. A.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98101 USA.
[Beste, L. A.; Chapko, M.] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA.
[Straits-Troster, K.] VA Midatlantic Reg Mental Illness Res Educ & Clin, Durham, NC USA.
[Zickmund, S.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Larson, M.; Chapko, M.; Dominitz, J. A.] VA Puget Sound Hlth Care Syst, NW Hepatitis C Resource Ctr, Seattle, WA 98101 USA.
RP Beste, LA (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM Lauren.beste@va.gov
OI Dominitz, Jason/0000-0002-8070-7086
FU VA Puget Sound Health Care System, Seattle, Washington; Department of
Veterans Affairs Health Services Research and Development research
[IAC-06-021]; Schering-Plough
FX This study was funded in part by the VA Puget Sound Health Care System,
Seattle, Washington. The primary author was supported by Department of
Veterans Affairs Health Services Research and Development research and
training funds (IAC-06-021). The views expressed in this article are
those of the authors and do not necessarily reflect the position or
policy of the Department of Veterans Affairs. This study protocol was
supported by an unrestricted grant from Schering-Plough. This sponsor
had no role in the study design, analysis or interpretation of study
results. The authors thank the staff and patients of the Northwest
Hepatitis C Resource Center, VA Puget Sound for their contributions to
this project.
NR 28
TC 10
Z9 10
U1 1
U2 6
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD AUG 1
PY 2009
VL 30
IS 3
BP 275
EP 282
DI 10.1111/j.1365-2036.2009.04036.x
PG 8
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 469DB
UT WOS:000267874600009
PM 19438425
ER
PT J
AU Rosendorff, C
Dubiel, R
Xu, JB
Chavanu, KJ
AF Rosendorff, Clive
Dubiel, Robert
Xu, Jianbo
Chavanu, Kathleen J.
TI Comparison of Olmesartan Medoxomil Versus Amlodipine Besylate on
Regression of Ventricular and Vascular Hypertrophy
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID HYPERTENSIVE PATIENTS; ANGIOTENSIN-II; RECEPTOR ANTAGONIST; BLACK
PATIENTS; MASS; REDUCTION; LIFE
AB Reversal of left ventricular (LV) hypertrophy is an important goal of anti hypertensive therapy. This phase 3b study compared the ability of the angiotensin receptor blocker olmesartan medoxomil with the calcium channel blocker amlodipine besylate to induce regression of LV hypertrophy and vascular hypertrophy after achieving blood pressure (BP) goal. After a washout phase, 102 patients with hypertension and LV hypertrophy were randomized to olmesartan medoxomil 20 mg/day, up titrated to 40 mg/day, or amlodipine 5 mg/day, up titrated to 10 mg/day, for up to 4 weeks until a BP goal of <140/90 mm Hg (<130/85 mm Hg for diabetes) was achieved (hydrochlorothiazide 25 mg/day and terazosin 1 to 5 mg/day 2 times/day could be added if needed). Upon achieving the BP goal or by week 8, and again at weeks 26 and 52, assessments of LV mass and compliance and arterial structure and function were performed by echocardiography, Doppler flow, and arterial ultrasonography, respectively. There was no statistically significant percent change in LV mass at 52 weeks in either treatment group (11.6% with olmesartan medoxomil vs 2.9% with amlodipine) and no statistically significant difference between treatment groups. There were no significant changes in LV compliance or carotid or femoral artery wall-to-lumen ratios in either treatment group at 52 weeks. In conclusion, there did not appear to be a clinically significant BP-independent effect with olmesartan medoxomil or amlodipine on LV mass decrease, diastolic function or vascular structure., and compliance in patients with hypertension and LV hypertrophy. Published by Elsevier Inc. (Am J Cardiol 2009; 104:359-365)
C1 [Rosendorff, Clive] Mt Sinai Sch Med, Dept Med, Bronx, NY USA.
[Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY USA.
[Dubiel, Robert; Xu, Jianbo; Chavanu, Kathleen J.] Daiichi Sankyo Inc, Parsippany, NJ USA.
RP Rosendorff, C (reprint author), Mt Sinai Sch Med, Dept Med, Bronx, NY USA.
EM clive.rosendorff@med.va.gov
FU Daiichi Sankyo, Inc., Parsippany, New Jersey
FX This study was supported by Daiichi Sankyo, Inc., Parsippany, New
Jersey.
NR 12
TC 5
Z9 5
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD AUG 1
PY 2009
VL 104
IS 3
BP 359
EP 365
DI 10.1016/j.amjcard.2009.03.042
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 480KI
UT WOS:000268733000011
PM 19616668
ER
PT J
AU Clark, JI
Eisner, RM
Hofmeister, C
Norton, J
Thomas, S
Choudhury, A
Petruzzelli, G
Lathers, D
Young, MRI
Lau, A
Emami, B
AF Clark, Joseph I.
Eisner, Robert M.
Hofmeister, Craig
Norton, John
Thomas, Sachdev
Choudhury, Abdul
Petruzzelli, Guy
Lathers, Deanne
Young, M. Rita I.
Lau, Ann
Emami, Bahman
TI Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck
Cancer
SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
LA English
DT Article
DE phase I; radiochemotherapy; docetaxel; high risk; head and neck cancer
ID SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; ACTIVE-DRUG;
CHEMOTHERAPY; FLUOROURACIL; CISPLATIN; INFUSION; TRIAL
AB Background: This phase I study was designed to determine the maximum tolerated dose (MTD) and preliminary efficacy of docetaxel with concurrent radiotherapy (RT), in high-risk squamous cell carcinoma of the head and neck.
Patients and Methods: Eligible patients had resected squamous cell carcinoma of the head and neck, histologically involved lymph nodes, and/or extranodal disease, and/or involved surgical margins and performance status 0 to 1. Treatment included weekly docetaxel with concurrent RT in a dose-finding study; a subsequent small cohort of patients was treated using the MTD of docetaxel.
Results: Twenty patients were enrolled. Planned accrual was 25, but the study was closed prematurely because of slow accrual. The MTD was 15 mg/m(2). Dose-limiting toxicity was oral stomatitis. Therapy was well tolerated. Five patients experienced locoregional relapse at a median follow-up of 32 months.
Conclusion: Docetaxel with concurrent RT has acceptable toxicity. This approach warrants further investigation in a phase II trial.
C1 [Clark, Joseph I.; Eisner, Robert M.; Norton, John; Thomas, Sachdev; Lau, Ann] Loyola Univ, Med Ctr, Dept Med, Div Hematol Oncol,Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA.
[Clark, Joseph I.; Choudhury, Abdul] Jr Hines VA Hosp, Med Serv, Hines, IL USA.
[Hofmeister, Craig] Ohio State Univ, Dept Hematol, Columbus, OH 43210 USA.
[Petruzzelli, Guy] Rush Univ, Med Ctr, Dept Otolaryngol, Chicago, IL 60612 USA.
[Lathers, Deanne; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Dept Otolaryngol, Res Serv, Charleston, SC USA.
[Young, M. Rita I.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Emami, Bahman] Loyola Univ, Med Ctr, Dept Radiat Oncol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA.
RP Clark, JI (reprint author), Loyola Univ, Med Ctr, Dept Med, Div Hematol Oncol,Cardinal Bernardin Canc Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA.
EM jclark@lumc.edu
RI Hofmeister, Craig/E-3256-2011
OI Hofmeister, Craig/0000-0003-4816-1607
FU Aventis
FX The authors thank Aventis for support with an unrestricted educational
grant for this trial.
NR 18
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3732
J9 AM J CLIN ONCOL-CANC
JI Am. J. Clin. Oncol.-Cancer Clin. Trials
PD AUG
PY 2009
VL 32
IS 4
BP 396
EP 400
DI 10.1097/COC.0b013e31818da9c7
PG 5
WC Oncology
SC Oncology
GA 480UF
UT WOS:000268761600012
PM 19415031
ER
PT J
AU Karlamangla, AS
Miller-Martinez, D
Aneshensel, CS
Seeman, TE
Wight, RG
Chodosh, J
AF Karlamangla, Arun S.
Miller-Martinez, Dana
Aneshensel, Carol S.
Seeman, Teresa E.
Wight, Richard G.
Chodosh, Joshua
TI Trajectories of Cognitive Function in Late Life in the United States:
Demographic and Socioeconomic Predictors
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE aged; cognition; health status disparities; longitudinal studies; social
class
ID ALZHEIMERS-DISEASE; OLDER-ADULTS; INDIVIDUAL-DIFFERENCES;
MARITAL-STATUS; INTELLECTUAL-DEVELOPMENT; METHODOLOGICAL ISSUES;
LONGITUDINAL FINDINGS; BRAIN RESERVE; FOLLOW-UP; AGE
AB This study used mixed-effects modeling of data from a national sample of 6,476 US adults born before 1924, who were tested 5 times between 1993 and 2002 on word recall, serial 7's, and other mental status items to determine demographic and socioeconomic predictors of trajectories of cognitive function in older Americans. Mean decline with aging in total cognition score (range, 0-35; standard deviation, 6.00) was 4.1 (0.68 standard deviations) per decade (95% confidence interval: 3.8, 4.4) and in recall score (range, 0-20; standard deviation, 3.84) was 2.3 (0.60 standard deviations) per decade (95% confidence interval: 2.1, 2.5). Older cohorts (compared with younger cohorts), women (compared with men), widows/widowers, and those never married (both compared with married individuals) declined faster, and non-Hispanic blacks (compared with non-Hispanic whites) and those in the bottom income quintile (compared with the top quintile) declined slower. Race and income differences in rates of decline were not sufficient to offset larger differences in baseline cognition scores. Educational level was not associated with rate of decline in cognition scores. The authors concluded that ethnic and socioeconomic disparities in cognitive function in older Americans arise primarily from differences in peak cognitive performance achieved earlier in the life course and less from declines in later life.
C1 [Karlamangla, Arun S.; Miller-Martinez, Dana; Seeman, Teresa E.; Chodosh, Joshua] Univ Calif Los Angeles, Div Geriatr, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Aneshensel, Carol S.; Wight, Richard G.] Univ Calif Los Angeles, Dept Community Hlth Sci, Sch Publ Hlth, Los Angeles, CA 90095 USA.
[Chodosh, Joshua] VA Greater Los Angeles Hlth Syst, Hlth Serv Res, Los Angeles, CA USA.
RP Karlamangla, AS (reprint author), Univ Calif Los Angeles, Div Geriatr, David Geffen Sch Med, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA.
EM akarlamangla@mednet.ucla.edu
OI Chodosh, Joshua/0000-0001-7784-4306
FU NIA NIH HHS [R01 AG022537]
NR 75
TC 73
Z9 73
U1 6
U2 35
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD AUG 1
PY 2009
VL 170
IS 3
BP 331
EP 342
DI 10.1093/aje/kwp154
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 475BH
UT WOS:000268330300009
PM 19605514
ER
PT J
AU Spiegel, B
Harris, L
Lucak, S
Mayer, E
Naliboff, B
Bolus, R
Esrailian, E
Chey, WD
Lembo, A
Karsan, H
Tillisch, K
Dulai, G
Talley, J
Chang, L
AF Spiegel, Brennan
Harris, Lucinda
Lucak, Susan
Mayer, Emeran
Naliboff, Bruce
Bolus, Roger
Esrailian, Eric
Chey, William D.
Lembo, Anthony
Karsan, Hetal
Tillisch, Kirsten
Dulai, Gareth
Talley, Jennifer
Chang, Lin
TI Developing Valid and Reliable Health Utilities in Irritable Bowel
Syndrome: Results From the IBS PROOF Cohort
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; WORK PRODUCTIVITY; ILLNESS SEVERITY; IMPACT; INDEX
AB OBJECTIVES: A "utility" is a measure of health-related quality of life (HRQOL) that ranges between 0 (death) and 1 (perfect health). Disease-targeted utilities are mandatory to conduct cost-utility analyses. Given the economic and healthcare burden of irritable bowel syndrome (IBS), cost-utility analyses will play an important role in guiding health economic decision-making. To inform future cost-utility analyses in IBS, we measured and validated the IBS utilities.
METHODS: We analyzed data from Rome III IBS patients in the Patient Reported Observed Outcomes and Function (PROOF) Cohort-a longitudinal multi-center IBS registry. At entry, the patients completed a multi-attribute utility instrument (EuroQOL), bowel symptom items, IBS severity measurements (IBS Severity Scale (IBSSS), Functional Bowel Disease Severity Index (FBDSI)), HRQOL indexes (IBS quality-of-life instrument (IBS-QOL), Center for disease control-4 (CDC-4)), and the Worker Productivity Activity Index for IBS (WPAI). We repeated assessments at 3 months.
RESULTS: There were 257 patients (79% women; age = 43 +/- 15 years) at baseline and 85 at 3 months. The mean utilities in patients with severe vs. non-severe IBS were 0.70 and 0.80, respectively (P<0.001). There were no differences in utilities among IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed IBS (IBS-M) subgroups. EuroQOL utilities correlated with FBDSI (r=0.31; P<0.01), IBSSS (r=0.36; P<0.01), IBS-QOL (r=0.36; P<0.01), CDC-4 (r=0.44; P<0.01), WPAI presenteeism (r=0.16; P<0.01), abdominal pain (r=0.43; P<0.01), and distension (r=0.18; P=0.01). The utilities in patients reporting "considerable relief" of symptoms at 3 months vs. those without considerable relief were 0.78 and 0.73, respectively (P=0.02).
CONCLUSIONS: EuroQOL utilities are valid and reliable in IBS. The utility of severe IBS (0.7) is similar to Class III congestive heart failure and rheumatoid arthritis. These validated utilities can be employed in future IBS cost-utility analyses.
C1 [Spiegel, Brennan; Talley, Jennifer] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Spiegel, Brennan; Mayer, Emeran; Naliboff, Bruce; Bolus, Roger; Esrailian, Eric; Tillisch, Kirsten; Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Gastroenterol, Los Angeles, CA 90073 USA.
[Spiegel, Brennan; Mayer, Emeran; Naliboff, Bruce; Bolus, Roger; Tillisch, Kirsten; Chang, Lin] Univ Calif Los Angeles, Ctr Neurobiol Stress, Los Angeles, CA USA.
[Spiegel, Brennan] Columbia Univ, Dept Gastroenterol, New York, NY USA.
[Spiegel, Brennan; Bolus, Roger; Esrailian, Eric; Talley, Jennifer; Chang, Lin] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA 90073 USA.
[Harris, Lucinda; Lucak, Susan] Mayo Clin, Scottsdale, AZ USA.
[Chey, William D.] Univ Michigan, Dept Gastroenterol, Ann Arbor, MI 48109 USA.
[Lembo, Anthony] Harvard Univ, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Karsan, Hetal] Emory Univ, Dept Gastroenterol, Atlanta, GA 30322 USA.
[Karsan, Hetal] Atlanta Gastroenterol Associates, Atlanta, GA USA.
[Dulai, Gareth] Kaiser So Calif, Los Angeles, CA USA.
RP Spiegel, B (reprint author), Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 11,Room 21E, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ucla.edu
FU Veteran's Affairs Health Services Research and Development Career
Development Award [RCD 03-179-2]; CURE Digestive Disease Research Center
[2P30 DK 041301-17]; NIH [P50 DK64539, 1 R24 AT002681-NCCAM]
FX Spiegel is supported by a Veteran's Affairs Health Services Research and
Development Career Development Award (RCD 03-179-2), and the CURE
Digestive Disease Research Center (NIH 2P30 DK 041301-17). Chang,
Naliboff, and Mayer are supported by NIH grant no. P50 DK64539, and
Spiegel, Mayer, and Naliboff are supported by NIH Center Grant 1 R24
AT002681-NCCAM from the UCLA Center for Neurobiology of Stress.
NR 29
TC 25
Z9 26
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD AUG
PY 2009
VL 104
IS 8
BP 1984
EP 1991
DI 10.1038/ajg.2009.232
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 483KW
UT WOS:000268965300014
PM 19491835
ER
PT J
AU Jutabha, R
Jensen, DM
Chavalitdhamrong, D
AF Jutabha, Rome
Jensen, Dennis M.
Chavalitdhamrong, Disaya
TI Randomized Prospective Study of Endoscopic Rubber Band Ligation Compared
With Bipolar Coagulation for Chronically Bleeding Internal Hemorrhoids
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID INFRARED COAGULATION; SCLEROSANT INJECTION; OUTPATIENT TREATMENT; SINGLE
SESSION; SCLEROTHERAPY; ELECTROCOAGULATION; COMPLICATIONS; DIATHERMY;
IMPOTENCE; THERAPY
AB OBJECTIVES: Our purpose was to compare the efficacy, complications, success rate, recurrence rate at 1 year, and crossovers of rubber band ligation (RBL) with those of bipolar electrocoagulation (BPEC) treatment for chronically bleeding internal hemorrhoids.
METHODS: A total of 45 patients of mean age 51.5 years, who had rectal bleeding from grade II or III hemorrhoids and in whom intensive medical therapy failed, were randomized in a prospective study comparing RBL with BPEC. Treatment failure was predefined as continued bleeding, occurrence of a major complication, or failure to reduce the size of all internal hemorrhoidal segments to grade 1 in <= 3 treatments. Patients were followed up for 1 year.
RESULTS: With similar patients, rectal bleeding and other symptoms were controlled with significantly fewer treatments of RBL than of BPEC (2.3 +/- 0.2 vs. 3.8 +/- 0.4, P<0.05), and RBL had a significantly higher success rate (92% vs. 62%, P<0.05). RBL had more cases of severe pain during treatment (8% vs. 0%, P>0.05), but significantly fewer failures and crossovers (8% vs. 38%). Symptomatic recurrence at 1 year was 10% RBL and 15% BPEC.
CONCLUSIONS: For patients with chronically bleeding grade II or III internal hemorrhoids that are unresponsive to medical therapy, safety and complication rates of banding and BPEC were similar. The success rate was significantly higher with RBL than with BPEC. Symptom recurrence rates at 1 year were similar.
C1 [Jensen, Dennis M.] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, David Geffen Sch Med, Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA 90073 USA.
RP Jensen, DM (reprint author), Univ Calif Los Angeles, CURE Digest Dis Res Ctr, David Geffen Sch Med, Greater Los Angeles VA Healthcare Ctr, Blg 115,RM 318,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM djensen@mednet.ucla.edu
FU American Digestive Health Foundation Endoscopy Research Award; NIH [GCRC
M01-RR00865, IK24DK02650]; [NIH DK41301]
FX This research study was funded in part by NIH DK41301 ( CURE DDRC Human
Studies Core), the American Digestive Health Foundation Endoscopy
Research Award (Dr Jutabha), NIH-GCRC M01-RR00865, and NIH-IK24DK02650 (
Dr Jensen).
NR 32
TC 10
Z9 10
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD AUG
PY 2009
VL 104
IS 8
BP 2057
EP 2064
DI 10.1038/ajg.2009.292
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 483KW
UT WOS:000268965300023
PM 19513028
ER
PT J
AU Hou, JK
El-Serag, H
Thirumurthi, S
AF Hou, Jason K.
El-Serag, Hashem
Thirumurthi, Selvi
TI Distribution and Manifestations of Inflammatory Bowel Disease in Asians,
Hispanics, and African Americans: A Systematic Review
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
ID CROHNS-DISEASE; ULCERATIVE-COLITIS; CLINICAL CHARACTERISTICS; MONTREAL
CLASSIFICATION; FAMILIAL OCCURRENCE; CHINESE POPULATION;
RACIAL-DIFFERENCES; EPIDEMIOLOGY; PREVALENCE; RACE
AB OBJECTIVES: Although inflammatory bowel disease (IBD) has been reported worldwide, most studies have focused on Caucasian populations. Our aim was to summarize the existing epidemiological literature, identify temporal trends, and highlight areas for future research.
METHODS: We carried out a systematic review following standard guidelines to evaluate the incidence, prevalence, temporal trends, disease characteristics, and extra-intestinal manifestations (EIMs) of IBD in African American, Hispanic, and Asian adult patients. Two investigators independently identified eligible studies through 2008 using structured keyword searches in PubMed, applied several inclusion and exclusion criteria, and abstracted the data.
RESULTS: Twenty-eight publications were included, encompassing 1,272 Hispanic, 547 African American, and 35,844 Asian patients with IBD. Greater proportions of Hispanic (36.7-84.3%) and Asian (30.6-74.7%) patients were diagnosed with ulcerative colitis (UC) than with Crohn's disease (CD) compared with African Americans (27.6-40.6%). The prevalence rates of IBD in Hispanics in Puerto Rico varied between 5 (rural) and 62 (urban) per 100,000. Crude prevalence rates in Asia varied between 6 (Singapore) and 136 (South Asians in UK) per 100,000 for UC, and between 3 (Singapore) and 33 (South Asians in UK) per 100,000 for CD. Three studies reported a rising annual incidence rate among Hispanics (from 2.6 to 7.5 per 100,000) and Asians (from 0.22 to 3.62 per 100,000). Fistulizing CD was reported in nearly one-third of Hispanic patients, up to one-quarter of African-American patients, and up to one-half of Asian patients. Ileocolonic disease was the most common site of CD among the three racial/ethnic groups, with skin and joint manifestations noted as the most common EIMs.
CONCLUSIONS: Prevalence and incidence rates in Hispanics and Asians have recently increased. There are many similarities and differences in disease location and behavior among racial/ethnic groups. There is a paucity of literature on all aspects of the disease in Hispanics, in the incidence and prevalence of IBD in African Americans, and in Asians with IBD outside Asia.
C1 [Thirumurthi, Selvi] Baylor Coll Med, Gastroenterol Sect, Houston, TX 77030 USA.
[Hou, Jason K.; El-Serag, Hashem; Thirumurthi, Selvi] Michael E DeBakey Vet Adm Med Ctr, Gastroenterol Sect, Houston, TX USA.
[Hou, Jason K.; El-Serag, Hashem; Thirumurthi, Selvi] Michael E DeBakey Vet Adm Med Ctr, Sect Hlth Serv Res, Houston, TX USA.
RP Thirumurthi, S (reprint author), Baylor Coll Med, Gastroenterol Sect, 1709 Dryden Rd,Suite 8-35, Houston, TX 77030 USA.
EM jkhou@bcm.tmc.edu
NR 43
TC 82
Z9 83
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD AUG
PY 2009
VL 104
IS 8
BP 2100
EP 2109
DI 10.1038/ajg.2009.190
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 483KW
UT WOS:000268965300029
PM 19471256
ER
PT J
AU Mehrotra, R
Khawar, O
Duong, U
Fried, L
Norris, K
Nissenson, A
Kalantar-Zadeh, K
AF Mehrotra, Rajnish
Khawar, Osman
Duong, Uyen
Fried, Linda
Norris, Keith
Nissenson, Allen
Kalantar-Zadeh, Kamyar
TI Ownership Patterns of Dialysis Units and Peritoneal Dialysis in the
United States: Utilization and Outcomes
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Peritoneal dialysis; hemodialysis; end-stage renal disease; modality
selection; mortality; technique failure; leading dialysis organizations;
chains
ID MORTALITY
AB Background: Peritoneal dialysis (PD) provides outcomes similar to hemodialysis, but its use has decreased in the United States despite its potential for substantial taxpayer savings. We undertook this study to determine the relationship between dialysis unit ownership with PD use and outcomes.
Study Design: Observational study.
Setting & Participants: All incident dialysis patients (1996 to 2004) from the US Renal Data System.
Predictor: Large dialysis organization (LDO), defined as corporations owning 20 or more freestanding dialysis units located in more than 1 state.
Outcomes & Measurements: Odds for an incident dialysis patient undergoing PD and hazards for death on follow-up in incident PD patients for each of the 5 LDOs (non-LDO as reference).
Results: During the 9-year period, 785,531 patients started maintenance dialysis therapy; the proportion receiving care in LDOs increased from 39% to 63%. There were consistent differences in PD use. It was significantly lower in LDO 2 (adjusted odds ratio [OR], 0.66; 95% confidence interval [CI], 0.64 to 0.68), LDO 3 (OR, 0.82; 95% CI, 0.80 to 0.85), and LDO 4 (OR, 0.96; 95% CI, 0.92 to 0.995) and higher in LDO 1 (adjusted OR, 1.06; 95% CI, 1.02 to 1.11) and LDO 5 (adjusted OR, 1.09; 95% Cl, 1.06 to 1.12). Between 2000 and 2004, LDO 2 had the least use and greatest risk of death (hazard ratio, 1.08; 95% CI, 1.02 to 1.14); LDO 1 had greater use and the lowest death risk (hazard ratio, 0.87; 95% CI, 0.78 to 0.96).
Limitations: Only cross-sectional associations can be described.
Conclusions: Three of the 5 LDOs had consistently lower PD use. Patients treated in the LIDO with the lowest use of PD had the greatest risk of death. Understanding relationships among providers, physicians, and dialysis modality use may help devise strategies for increasing PD use in appropriate patients. This has the potential to reduce the cost of renal replacement therapy and further improve outcomes. Am J Kidney Dis 54:289-298. (C) 2009 by the National Kidney Foundation, Inc.
C1 [Mehrotra, Rajnish; Khawar, Osman; Duong, Uyen; Kalantar-Zadeh, Kamyar] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA.
[Mehrotra, Rajnish; Khawar, Osman; Duong, Uyen; Norris, Keith; Nissenson, Allen; Kalantar-Zadeh, Kamyar] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Fried, Linda] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA.
[Norris, Keith] Charles Drew Univ, Los Angeles, CA USA.
RP Mehrotra, R (reprint author), 1124 W Carson St, Torrance, CA 90502 USA.
EM rmehrotra@labiomed.org
OI Kalantar-Zadeh, Kamyar/0000-0002-8666-0725
FU National Institutes of Health (NIH) [RR18298, RR019234, MD00182,
DK078106]
FX Dr Mehrotra is supported by Grant RR18298 from the National Institutes
of Health (NIH) and grants from Satellite Health and DaVita Inc. Dr
Norris is supported by NIH Grants RR019234 and MD00182. Dr Nissenson
reports support from the Richard Rosenthal Dialysis Fund. Dr
Kalantar-Zadeh is supported by grants from DaVita Inc and NIH
(DK078106).
NR 13
TC 28
Z9 29
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD AUG
PY 2009
VL 54
IS 2
BP 289
EP 298
DI 10.1053/j.ajkd.2009.01.262
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA 492FL
UT WOS:000269640200014
PM 19359081
ER
PT J
AU Barrett-Connor, E
Cox, DA
Song, JL
Mitlak, B
Mosca, L
Grady, D
AF Barrett-Connor, Elizabeth
Cox, David A.
Song, Jingli
Mitlak, Bruce
Mosca, Lori
Grady, Deborah
TI Raloxifene and Risk for Stroke Based on the Framingham Stroke Risk Score
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Framingham; Raloxifene; SERM; Stroke
ID POSTMENOPAUSAL WOMEN; BREAST-CANCER; CARDIOVASCULAR EVENTS; CEREBRAL
INFARCTION; PRIMARY PREVENTION; RANDOMIZED-TRIAL; POPULATION;
RECURRENCE; PREDICTION; REDUCTION
AB PURPOSE: Raloxifene reduces vertebral fracture and invasive breast cancer risks, but increases fatal strokes in postmenopausal women at increased coronary risk. We assessed whether this risk is concentrated in postmenopausal women already at high stroke risk.
METHODS: Raloxifene Use for The Heart (RUTH) enrolled 10,101 postmenopausal women (mean age 67 years) with or at increased coronary heart disease risk; Multiple Outcomes of Raloxifene Evaluation ( MORE) enrolled 7705 osteoporotic postmenopausal women ( mean age 66 years). A Framingham Stroke Risk Score (FSRS) was calculated for all women with no prior cerebrovascular events (n = 16,858). The validity of the FSRS was assessed in the placebo groups, and then raloxifene-associated stroke risk was analyzed by FSRS subgroups.
RESULTS: FSRS predicted an increased stroke risk in the placebo group of both clinical trials. There was no difference in the incidence of nonfatal strokes between the raloxifene and placebo groups in MORE or RUTH, regardless of baseline Framingham stroke risk. In RUTH, women with FSRS <13 showed no increase in raloxifene-associated fatal stroke risk ( hazard ratio [HR] 1.08; 95% confidence interval [CI], 0.49-2.37). Those with FSRS >= 13 had a 75% increased risk of raloxifene-associated fatal stroke (HR 1.75; 95% CI, 1.01-3.02; interaction P = .33). In MORE, where 80% of women had a FSRS <13, no increase in fatal (HR 0.57; 95% CI, 0.19-1.68) stroke risk was observed.
DISCUSSION: Risk of fatal stroke associated with raloxifene was greater in women at high stroke risk. These results might be useful for identifying postmenopausal women at high risk of first stroke who should avoid raloxifene therapy. (C) 2009 Elsevier Inc. All rights reserved. The American Journal of Medicine (2009) 122, 754-761
C1 [Barrett-Connor, Elizabeth] Univ Calif San Diego, Dept Family & Prevent Med, Div Epidemiol, La Jolla, CA 92093 USA.
[Cox, David A.; Song, Jingli; Mitlak, Bruce] Lilly Res Labs, Indianapolis, IN USA.
[Mosca, Lori] Columbia Univ, Med Ctr, New York, NY USA.
[Grady, Deborah] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Barrett-Connor, E (reprint author), Univ Calif San Diego, Dept Family & Prevent Med, Div Epidemiol, 9500 Gilman Dr 0607, La Jolla, CA 92093 USA.
EM ebarrettconnor@ucsd.edu
FU Lilly Research Laboratories; Eli Lilly and Company (Indianapolis, IN)
FX The RUTH and MORE trials were both supported by Eli Lilly and Company
(Indianapolis, IN). We thank the investigators, staff, and the 17,806
women who participated in the RUTH and MORE trials. Complete lists of
the investigators and sub-investigators of both trials have been
published previously.1,3 We also are indebted to Steve Zheng
for statistical programming.
NR 19
TC 19
Z9 20
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD AUG
PY 2009
VL 122
IS 8
BP 754
EP 761
DI 10.1016/j.amjmed.2009.01.033
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 474PD
UT WOS:000268295500014
PM 19540454
ER
PT J
AU Gee, RE
Mitra, N
Wan, F
Chavkin, DE
Long, JA
AF Gee, Rebekah E.
Mitra, Nandita
Wan, Fei
Chavkin, Diana E.
Long, Judith A.
TI Power over parity: intimate partner violence and issues of fertility
control
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE abortion; contraception; intimate partner violence; multiparity
ID WOMEN SEEKING ABORTION; DOMESTIC VIOLENCE; RISK-FACTORS; PREVALENCE;
PREGNANCY; INTERVENTIONS
AB OBJECTIVE: The purpose of this study was to examine the association between intimate partner violence (IPV), abortion, parity, and contraception use.
STUDY DESIGN: We recruited 1463 women for this written questionnaire study of IPV. Patient demographics, contraceptive history, and reproductive history were obtained in the waiting room from patients presenting for gynecologic care.
RESULTS: Seventy percent of those eligible participated. Twenty-one percent reported a history of IPV. Partner unwillingness to use birth control, partner desirous of conception, partner creating difficulty for subject's use of birth control, and subjects expressing inability to afford contraception were all positively associated with report of IPV. Each additional pregnancy was associated with 10% greater odds of IPV (95% confidence interval, 1.03-1.17).
CONCLUSION: Contraception is more difficult to navigate for women experiencing IPV. Providers should consider prescribing contraceptive methods for IPV victims that are not partner dependent.
C1 [Gee, Rebekah E.] Univ Penn, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA.
[Gee, Rebekah E.; Long, Judith A.] Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Mitra, Nandita; Wan, Fei] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Chavkin, Diana E.] Univ Penn, Sch Med, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA.
[Long, Judith A.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Long, Judith A.] Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, Philadelphia, PA USA.
RP Gee, RE (reprint author), 423 Guardian Dr,13th Floor Blockley Hall 1303A, Philadelphia, PA 19104 USA.
EM rebekahgeemd@gmail.com
FU Pennsylvania Department of Health
FX This study was supported by the Robert Wood Johnson Clinical Scholars
Program and the Institute for Translational Medicine and Therapeutics,
both at the University of Pennsylvania and under a Grant from the
Pennsylvania Department of Health. The Department specifically disclaims
responsibility for any analysis, interpretations, or conclusions.
NR 26
TC 19
Z9 19
U1 1
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD AUG
PY 2009
VL 201
IS 2
AR 148.e1
DI 10.1016/j.ajog.2009.04.048
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 476RI
UT WOS:000268460900007
PM 19564020
ER
PT J
AU Chan, L
Jette, AM
Ottenbacher, KJ
Robinson, LR
Tietsworth, ML
Ricker, JH
Boninger, ML
AF Chan, Leighton
Jette, Alan M.
Ottenbacher, Kenneth J.
Robinson, Lawrence R.
Tietsworth, Monica L.
Ricker, Joseph H.
Boninger, Michael L.
TI Building a Research Program in Rehabilitation Sciences, Part II Case
Studies: University of Texas Medical Branch, Boston University,
University of Pittsburgh, and University of Washington
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Research; Research Activities; Academic Medical Center
AB This article presents four case studies of rehabilitation science programs that have created enduring research efforts: one in physical therapy, one in interdisciplinary rehabilitation sciences, and two in physical medicine and rehabilitation. Several themes emerge from these case studies. First, building an enduring research program takes time and significant foundational work. Most importantly, it is crucial to have the support of the dean, academic institution, and medical center. This seems to be a prerequisite for success in this area.
C1 [Jette, Alan M.] Boston Univ, Sch Publ Hlth, Hlth & Disabil Res Inst, Boston, MA USA.
[Ottenbacher, Kenneth J.] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX USA.
[Robinson, Lawrence R.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA.
[Tietsworth, Monica L.; Ricker, Joseph H.; Boninger, Michael L.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
[Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Ctr Excellence Wheelchairs & Related Technol, Pittsburgh, PA USA.
RP Chan, L (reprint author), 5511 Lambeth Rd, Bethesda, MD 20814 USA.
OI Jette, Alan/0000-0002-2117-9973; Boninger, Michael/0000-0001-6966-919X
FU Foundation for PMR
FX This study was supported through the Foundation for PM&R. Authors
received a small honorarium for their contributions.
NR 6
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD AUG
PY 2009
VL 88
IS 8
BP 667
EP 678
DI 10.1097/PHM.0b013e3181aeab55
PG 12
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 476VW
UT WOS:000268475400008
PM 19620833
ER
PT J
AU Aplin, AC
Zhu, WH
Fogel, E
Nicosia, RF
AF Aplin, A. C.
Zhu, W. H.
Fogel, E.
Nicosia, R. F.
TI Vascular regression and survival are differentially regulated by MT1-MMP
and TIMPs in the aortic ring model of angiogenesis
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE neovascularization; matrix metalloproteinase-14; collagen; endothelial
cells; aorta; rarefaction; membrane type 1 matrix metalloproteinase;
tissue inhibitors of matrix metalloproteinases
ID 3-DIMENSIONAL EXTRACELLULAR-MATRIX; HUMAN ENDOTHELIAL-CELLS; TISSUE
INHIBITOR; RAT AORTA; 1-MATRIX METALLOPROTEINASE; QUANTITATIVE ASSAY;
INVASIVE CELLS; TUMOR INVASION; IN-VITRO; MEMBRANE
AB Aplin AC, Zhu WH, Fogel E, Nicosia RF. Vascular regression and survival are differentially regulated by MT1-MMP and TIMPs in the aortic ring model of angiogenesis. Am J Physiol Cell Physiol 297: C471-C480, 2009. First published June 3, 2009; doi:10.1152/ajpcell.00019.2009.-This study was designed to investigate the role of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) in the reabsorption of neovessels in collagen gel cultures of rat and mouse aortic rings. Aortic angiogenesis was associated with collagen lysis and production of the matrix-degrading enzymes MMP-2, MMP-9, and membrane-type MMP (MT1-MMP, or MMP-14). Vascular growth and regression were not affected by disruption of MMP-2 or MMP-9. In addition, no effect on vascular regression was observed by blocking plasmin, a protease implicated in the activation of MMPs, with epsilon-aminocaproic acid or by adding plasminogen, which caused a modest increase in vascular proliferation. Conversely, angiogenesis was blocked and vessels stabilized by inhibiting MT1-MMP with neutralizing antibodies, TIMP-2, TIMP-3, or TIMP-4. TIMP-1, which blocks MMP-2 and MMP-9 but is a poor inhibitor of MT1-MMP, had no antiangiogenic effect. However, TIMP-1 prolonged the survival of neovessels following angiogenesis. Vascular regression was accelerated in aortic cultures from TIMP-1-and TIMP-2-deficient mice. The vascular survival effect of anti-MT1-MMP antibodies and TIMPs with MT1-MMP inhibitory activity was associated with complete inhibition of collagen lysis. In contrast, TIMP-1 had no anticollagenolytic effect. These results indicate that MT1-MMP plays a critical role not only in angiogenesis but also in vascular regression and demonstrate that TIMPs with anti-MT1-MMP activity have opposite effects on angiogenic outcomes depending on the stage of the angiogenic process. This study also suggests the existence of a TIMP-1-mediated alternate pathway of vascular survival that is unrelated to MT1-MMP inhibitory activity.
C1 [Fogel, E.; Nicosia, R. F.] Vet Affairs Puget Sound Hlth Care Syst, Pathol & Lab Med Serv, Seattle, WA 98108 USA.
[Aplin, A. C.; Zhu, W. H.; Nicosia, R. F.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
RP Nicosia, RF (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Pathol & Lab Med Serv S Lab 113, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM roberto.nicosia@va.gov
FU National Heart, Lung, and Blood Institute [HL52585]; Medical Research
Service, Department of Veterans Affairs
FX This work was supported by National Heart, Lung, and Blood Institute
Grant HL52585 ( R. F. Nicosia) and the Medical Research Service,
Department of Veterans Affairs ( R. F. Nicosia).
NR 63
TC 25
Z9 26
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD AUG
PY 2009
VL 297
IS 2
BP C471
EP C480
DI 10.1152/ajpcell.00019.2009
PG 10
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 477CI
UT WOS:000268494800026
PM 19494241
ER
PT J
AU Wray, C
Mao, Y
Pan, J
Chandrasena, A
Piasta, F
Frank, JA
AF Wray, Charlie
Mao, Ying
Pan, Jue
Chandrasena, Anita
Piasta, Frank
Frank, James A.
TI Claudin-4 augments alveolar epithelial barrier function and is induced
in acute lung injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE alveolar epithelium; ion transport; paracellular transport; tight
junction; pulmonary edema; acute respiratory distress syndrome
ID CLOSTRIDIUM-PERFRINGENS ENTEROTOXIN; JUNCTIONAL PERMEABILITY; DECREASES
EXPRESSION; FLUID TRANSPORT; CELLS; SODIUM; KINASE; EDEMA; ACTIVATION;
RESOLUTION
AB Wray C, Mao Y, Pan J, Chandrasena A, Piasta F, Frank JA. Claudin-4 augments alveolar epithelial barrier function and is induced in acute lung injury. Am J Physiol Lung Cell Mol Physiol 297: L219-L227, 2009. First published May 15, 2009; doi:10.1152/ajplung.00043.2009.-Intact alveolar barrier function is associated with better outcomes in acute lung injury patients; however, the regulation of alveolar epithelial paracellular transport during lung injury has not been extensively investigated. This study was undertaken to determine whether changes in tight junction claudin expression affect alveolar epithelial barrier properties and to determine the mechanisms of altered expression. In anesthetized mice exposed to ventilator-induced lung injury, claudin-4 was specifically induced among tight junction structural proteins. Real-time PCR showed an eightfold increase in claudin-4 expression in the lung injury model. To examine the role of this protein in barrier regulation, claudin-4 function was inhibited with small interfering RNA (siRNA) and a blocking peptide derived from the binding domain of Clostridium perfringens enterotoxin (CPE(BD)). Inhibition of claudin-4 decreased transepithelial electrical resistance but did not alter macromolecule permeability in primary rat and human epithelial cells. In mice, CPEBD decreased air space fluid clearance >33% and resulted in pulmonary edema during moderate tidal volume ventilation that did not induce edema in control peptide-treated mice. In vitro phorbol ester induced a ninefold increase in claudin-4 expression that was dependent on PKC activation and the JNK MAPK pathway. These data establish that changes in alveolar epithelial claudin expression influence paracellular transport, alveolar fluid clearance rates, and susceptibility to pulmonary edema. We hypothesize that increased claudin-4 expression early in acute lung injury represents a mechanism to limit pulmonary edema and that the regulation of alveolar epithelial claudin expression may be a novel target for acute lung injury therapy.
C1 [Pan, Jue; Chandrasena, Anita; Frank, James A.] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA.
[Chandrasena, Anita; Piasta, Frank; Frank, James A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Wray, Charlie; Mao, Ying; Frank, James A.] Vet Hlth Res Inst, NCIRE, San Francisco, CA USA.
RP Frank, JA (reprint author), 4150 Clement St,Box 111D, San Francisco, CA 94121 USA.
EM james.frank@ucsf.edu
FU National Heart, Lung, and Blood Institute [HL-88440]
FX This work was funded by National Heart, Lung, and Blood Institute Grant
HL-88440 ( J. A. Frank).
NR 37
TC 72
Z9 77
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD AUG
PY 2009
VL 297
IS 2
BP L219
EP L227
DI 10.1152/ajplung.00043.2009
PG 9
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA 474IE
UT WOS:000268276200004
PM 19447895
ER
PT J
AU Alexopoulos, GS
Reynolds, CF
Bruce, ML
Katz, IR
Raue, PJ
Mulsant, BH
Oslin, DW
Ten Have, T
AF Alexopoulos, George S.
Reynolds, Charles F., III
Bruce, Martha L.
Katz, Ira R.
Raue, Patrick J.
Mulsant, Benoit H.
Oslin, David W.
Ten Have, Thomas
CA Prospect Grp
TI Reducing Suicidal Ideation and Depression in Older Primary Care
Patients: 24-Month Outcomes of the PROSPECT Study
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID LATE-LIFE DEPRESSION; RANDOMIZED CONTROLLED-TRIAL; ADULTS; MANAGEMENT;
REMISSION; MORTALITY; DISEASE; MODELS; SCALE; AGE
AB OBJECTIVE: The Prevention of Suicide in Primary Care Elderly: Collaborative Trial (PROSPECT) evaluated the impact of a care management intervention on suicidal ideation and depression in older primary care patients. This is the first report of outcomes over a 2-year period. METHOD: Study participants were patients 60 years of age or older (N=599) with major or minor depression selected after screening 9,072 randomly identified patients of 20 primary care practices randomly assigned to provide either the PROSPECT intervention or usual care. The intervention consisted of services of 15 trained care managers, who offered algorithm-based recommendations to physicians and helped patients with treatment adherence over 24 months. RESULTS: Compared with patients receiving usual care, those receiving the intervention had a higher likelihood of receiving antidepressants and/or psychotherapy (84.9%-89% versus 49%-62%) and had a 2.2 times greater decline in suicidal ideation over 24 months. Treatment response occurred earlier on average in the intervention group and increased from months 18 to 24, while no appreciable increase in treatment response occurred in the usual care group during the same period. Among patients with major depression, a greater number achieved remission in the intervention group than in the usual-care group at 4 months (26.6% versus 15.2%), 8 months (36% versus 22.5%), and 24 months (45.4% versus 31.5%). Patients with minor depression had favorable outcomes regardless of treatment assignment. CONCLUSIONS: Sustained collaborative care maintains high utilization of depression treatment, reduces suicidal ideation, and improves the outcomes of major depression over 2 years.
C1 [Alexopoulos, George S.] Weill Cornell Med Coll, Dept Psychiat, White Plains, NY 10605 USA.
Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON M5S 1A1, Canada.
Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada.
RP Alexopoulos, GS (reprint author), Weill Cornell Med Coll, Dept Psychiat, 21 Bloomingdale Rd, White Plains, NY 10605 USA.
EM gsalexop@med.cornell.edu
OI Alexopoulos, George/0000-0001-5677-7001
FU NIMH [RO1 MH59366, R01 MH059380, RO37 MH51842, RO1 MH59318, P30 MH68638,
P30 MH52247, P30 MH066270]; Hartford Foundation; Forest Pharmaceuticals;
[R01 MH59366]; [R01 MH59380]; [P30 MH52129]; [R01 MH59381]
FX The Prevention of Suicide in Primary Care Elderly: Collaborative Trial
(PROSPECT) was a collaborative research study funded by NIMH. The three
groups included the Advanced Centers for Intervention and Services
Research of the following: Cornell University (PROSPECT Coordinating
Center; principal investigator, George S. Alexopoulos, M. D.;
co-principal investigators, Martha L. Bruce, Ph. D., M. P. H., and
Herbert C. Schulberg, Ph. D.; grants R01 MH59366, P30 MH68638);
University of Pennsylvania (principal investigator, Ira Katz, M. D., Ph.
D.; co-principal investigators: Thomas Ten Have, Ph. D., and Gregory K.
Brown, Ph. D.; grants R01 MH59380, P30 MH52129); and University of
Pittsburgh (principal investigator, Charles F. Reynolds III, M. D.;
co-principal investigator, Benoit H. Mulsant, M. D.; grants R01 MH59381,
P30 MH52247). PROSPECT was supported by NIMH grants RO1 MH59366, R01
MH059380, RO37 MH51842, RO1 MH59318, P30 MH68638, P30 MH52247, and P30
MH066270; the Hartford Foundation; and Forest Pharmaceuticals.
NR 30
TC 119
Z9 121
U1 2
U2 20
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD AUG
PY 2009
VL 166
IS 8
BP 882
EP 890
DI 10.1176/appi.ajp.2009.08121779
PG 9
WC Psychiatry
SC Psychiatry
GA 479DC
UT WOS:000268638900010
PM 19528195
ER
PT J
AU Randall, GJ
Zald, PB
Cohen, JI
Hamilton, BE
AF Randall, Geneva J.
Zald, Philip B.
Cohen, James I.
Hamilton, Bronwyn E.
TI Contrast-Enhanced MDCT Characteristics of Parathyroid Adenomas
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article; Proceedings Paper
CT 46th Annual Meeting of the American-Society-of-Neuroradiology
CY MAY 31-JUN 05, 2008
CL New Orleans, LA
SP Amer Soc Neuroradiol
DE adenoma; hypercalcemia; hyperparathyroidism; parathyroid
ID MINIMALLY INVASIVE SURGERY; PRIMARY HYPERPARATHYROIDISM; PREOPERATIVE
ULTRASOUND; COMPUTED-TOMOGRAPHY; SUPPLEMENTAL CT; LOCALIZATION; TUMORS;
US
AB OBJECTIVE. Minimally invasive directed parathyroidectomy has replaced conventional surgical techniques aimed at exploring all four glands in the bilateral neck. These changes have created the need for better preoperative imaging localization techniques. In this article, we describe the CT imaging characteristics of surgically confirmed adenomas and review anatomy and embryology to aid the radiologist in successfully identifying adenomas using contrast-enhanced CT.
CONCLUSION. Knowledge of normal CT appearance, contrast enhancement, and expected location are critical to correct interpretation of parathyroid adenoma at CT.
C1 [Randall, Geneva J.; Hamilton, Bronwyn E.] Oregon Hlth & Sci Univ, Dept Diagnost Radiol, Portland, OR 97239 USA.
[Zald, Philip B.] Oregon Hlth & Sci Ctr, Dept Otolaryngol Head & Neck Surg, Portland, OR USA.
[Cohen, James I.] Portland VA Med Ctr, Dept Otolaryngol Head & Neck Surg, Portland, OR USA.
RP Randall, GJ (reprint author), Oregon Hlth & Sci Univ, Dept Diagnost Radiol, Mail Code CR 135,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
NR 13
TC 20
Z9 21
U1 0
U2 1
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD AUG
PY 2009
VL 193
IS 2
BP W139
EP W143
DI 10.2214/AJR.08.2098
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 472RB
UT WOS:000268148600053
PM 19620416
ER
PT J
AU McGory, ML
Kao, KK
Shekelle, PG
Rubenstein, LZ
Leonardi, MJ
Parikh, JA
Fink, A
Ko, CY
AF McGory, Marcia. L.
Kao, Kenneth K.
Shekelle, Paul G.
Rubenstein, Laurence Z.
Leonardi, Michael J.
Parikh, Janak A.
Fink, Arlene
Ko, Clifford Y.
TI Developing Quality Indicators for Elderly Surgical Patients
SO ANNALS OF SURGERY
LA English
DT Article
ID CORONARY REVASCULARIZATION; VULNERABLE ELDERS; ASSESSING CARE; OF-CARE;
SURGERY; CRITERIA; POPULATION; UNDERUSE; CANCER; PANEL
AB Objective: To develop process-based quality indicators to improve perioperative care for elderly surgical patients.
Background: The population is aging and expanding, and physicians must continue to optimize elderly surgical care to meet the anticipated increase in surgical services. We sought to develop process-based quality indicators applicable to virtually all disciplines of surgery to identify necessary and meaningful ways to improve surgical care and outcomes in the elderly.
Methods: We identified candidate perioperative quality indicators for elderly patients undergoing ambulatory, or major elective or nonelective inpatient surgery through structured interviews with thought leaders and systematic reviews of the literature. An expert panel of physicians in surgery, geriatrics, anesthesia, critical care, internal, and rehabilitation medicine formally rated the indicators using a modification of the RAND/UCLA Appropriateness Methodology.
Results: Ninety-one of 96 candidate indicators were rated as valid. They were categorized into 8 domains: comorbidity assessment, elderly issues, medication use, patient-provider discussions, intraoperative care, postoperative management, discharge planning, and ambulatory surgery. Of note, 71 (78%) of the indicators rated as valid address processes of care not routinely performed in younger surgical populations.
Conclusions: Attention to the quality of care in elderly patients is of great importance due to the increasing numbers of elderly undergoing surgery. This project used a validated methodology to identify and rate process measures to achieve high quality perioperative care for elderly surgical patients.
C1 [McGory, Marcia. L.; Kao, Kenneth K.; Leonardi, Michael J.; Parikh, Janak A.; Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Rubenstein, Laurence Z.] VA Greater Los Angeles Healthcare Syst, Dept Med, David Geffen Sch Med, Los Angeles, CA USA.
[Fink, Arlene] VA Greater Los Angeles Healthcare Syst, Dept Gen Internal Med & Hlth Serv Res, David Geffen Sch Med, Los Angeles, CA USA.
RP McGory, ML (reprint author), Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, 72-215 Ctr Hlth Sci,Box 956904,10833 Conte Ave, Los Angeles, CA 90095 USA.
EM mmcgory@mednet.ucla.edu
FU NIA NIH HHS [5R21AG028121-02]
NR 23
TC 48
Z9 48
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-4932
J9 ANN SURG
JI Ann. Surg.
PD AUG
PY 2009
VL 250
IS 2
BP 338
EP 347
DI 10.1097/SLA.0b013e3181ae575a
PG 10
WC Surgery
SC Surgery
GA 482GS
UT WOS:000268873400027
PM 19638913
ER
PT J
AU Singh, JA
Hodges, JS
Asch, SM
AF Singh, J. A.
Hodges, J. S.
Asch, S. M.
TI Opportunities for improving medication use and monitoring in gout
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID QUALITY-OF-CARE; ACUTE CORONARY SYNDROMES; DRUG-THERAPY; MANAGED CARE;
III GUIDELINES; ALLOPURINOL; HYPERURICEMIA; COLCHICINE; ADHERENCE;
VETERANS
AB Purpose: To study patterns and predictors of medication use and laboratory monitoring in gout.
Methods: In a cohort of veterans with a diagnosis of gout prescribed allopurinol, colchicine or probenecid, quality of care was assessed by examining adherence to the following evidence-based recommendations: (1) whether patients starting a new allopurinol prescription (a) received continuous allopurinol, (b) received colchicine prophylaxis, (c) achieved the target uric acid level of <= 6 mg/dl; and (2) whether doses were adjusted for renal insufficiency. The association of sociodemographic characteristics, healthcare utilisation and comorbidity with the recommendations was examined by logistic/Poisson regression.
Results: Of the 643 patients with gout receiving a new allopurinol prescription, 297 (46%) received continuous allopurinol, 66 (10%) received colchicine prophylaxis and 126 (20%) reached the target uric acid level of <= 6 mg/dl. During episodes of renal insufficiency, appropriate dose reduction/discontinuation of probenecid was done in 24/31 episodes (77%) and of colchicine in 36/52 episodes (69%). Multivariable regression showed that higher outpatient utilisation, more rheumatology care and lower comorbidity were associated with better quality of care; more rheumatology clinic or primary care visits were associated with less frequent allopurinol discontinuation; more total outpatient visit days or most frequent visits to a rheumatology clinic were associated with a higher likelihood of receiving colchicine prophylaxis; and a lower Charlson Comorbidity Index or more outpatient visit days were associated with higher odds of reaching the target uric acid level of <= 6 mg/dl.
Conclusions: Important variations were found in patterns of medication use and monitoring in patients with gout with suboptimal care. A concerted effort is needed to improve the overall care of gout.
C1 [Singh, J. A.] VA Med Ctr, Rheumatol Sect, Med Serv, Minneapolis, MN USA.
[Singh, J. A.; Hodges, J. S.] VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Singh, J. A.] Univ Minnesota, Dept Med, Div Rheumatol, Minneapolis, MN 55455 USA.
[Hodges, J. S.] Univ Minnesota, Div Biostat, Minneapolis, MN USA.
[Asch, S. M.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Asch, S. M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Singh, JA (reprint author), Minneapolis VA Med Ctr, Rheumatol 111R,1 Vet Dr, Minneapolis, MN 55417 USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Center for Epidemiological and Clinical Research, Minneapolis VA Medical
Center, Minneapolis, MN; TAP Pharmaceuticals
FX We thank Ms Ann Emery, administrative assistant, Minneapolis VA Medical
Center for her help in typing the manuscript. This was
investigator-initiated research supported by VA Scholar Grant from the
Center for Epidemiological and Clinical Research, Minneapolis VA Medical
Center, Minneapolis, MN and a research grant from TAP Pharmaceuticals.
TAP Pharmaceuticals or its representatives did not contribute to the
design, conduct or data analyses or to writing, editing or approving the
manuscript.
NR 40
TC 46
Z9 47
U1 1
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD AUG
PY 2009
VL 68
IS 8
BP 1265
EP 1270
DI 10.1136/ard.2008.092619
PG 6
WC Rheumatology
SC Rheumatology
GA 470VS
UT WOS:000268010500006
PM 18701554
ER
PT J
AU Nguyen, KT
Ta, P
Hoang, BT
Cheng, S
Hao, BH
Nguyen, MH
Clancy, CJ
AF Nguyen, Katherine T.
Ta, Philip
Hoang, Bich Thu
Cheng, Shaoji
Hao, Binghua
Nguyen, M. Hong
Clancy, Cornelius J.
TI Anidulafungin Is Fungicidal and Exerts a Variety of Postantifungal
Effects against Candida albicans, C. glabrata, C. parapsilosis, and C.
krusei isolates
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID DOUBLE-BLIND TRIAL; TIME-KILL METHODS; AMPHOTERICIN-B; INVASIVE
CANDIDIASIS; CASPOFUNGIN; MICAFUNGIN; ECHINOCANDIN; FLUCONAZOLE; SPP.;
SUSCEPTIBILITY
AB Anidulafungin targets the cell walls of Candida species by inhibiting beta-1,3-glucan synthase, thereby killing isolates and exerting prolonged postantifungal effects (PAFEs). We performed time-kill and PAFE experiments on Candida albicans (n = 4), C. glabrata (n = 3), C. parapsilosis (n = 3), and C. krusei (n = 2) isolates and characterized the PAFEs in greater detail. MICs were 0.008 to 0.125 mu g/ml against C. albicans, C. glabrata, and C. krusei and 1.0 to 2.0 mu g/ml against C. parapsilosis. During time-kill experiments, anidulafungin caused significant kills at 16x MIC (range, log 2.68 to 3.89) and 4x MIC (log 1.87 to 3.19), achieving fungicidal levels (>= log 3) against nine isolates. A 1-hour drug exposure during PAFE experiments resulted in kills ranging from log 1.55 to 3.47 and log 1.18 to 2.89 (16x and 4x MIC, respectively), achieving fungicidal levels against four isolates. Regrowth of all 12 isolates was inhibited for >= 12 h after drug washout. Isolates of each species collected 8 h after a 1-hour exposure to anidulafungin (16x and 4x MIC) were hypersusceptible to sodium dodecyl sulfate (0.01 to 0.04%) and calcofluor white (40 mu g/ml). Moreover, PAFEs were associated with major cell wall disturbances, as evident in electron micrographs of viable cells, and significant reductions in adherence to buccal epithelial cells (P <= 0.01). Finally, three of four PAFE isolates tested were hypersusceptible to killing by J774 macrophages (P <= 0.007). Our data suggest that the efficacy of anidulafungin in the treatment of candidiasis might stem from both direct fungicidal activity and indirect PAFEs that lessen the ability of Candida cells to establish invasive disease and to persist within infected hosts.
C1 [Hao, Binghua; Nguyen, M. Hong; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA.
[Nguyen, Katherine T.; Ta, Philip; Hoang, Bich Thu; Cheng, Shaoji; Hao, Binghua; Nguyen, M. Hong; Clancy, Cornelius J.] Univ Florida, Coll Med, Dept Med, Gainesville, FL USA.
[Nguyen, M. Hong] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL USA.
[Nguyen, M. Hong; Clancy, Cornelius J.] N Florida S Georgia Vet Hlth Syst, Gainesville, FL USA.
[Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, 867 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM cjc76@pitt.edu
FU Pfizer, Inc.; Medical Research Service of the Department of Veterans
Affairs; Astellas Pharmaceuticals; Merck Co., Inc.
FX This project was funded by a research grant to C. J. C. from Pfizer,
Inc. C. J. C. and M. H. N. were supported by the Medical Research
Service of the Department of Veterans Affairs. Their research was
conducted as part of the University of Florida Mycology Research Unit.
C. J. C. has received research funding from Astellas Pharmaceuticals,
Pfizer, Inc., and Merck & Co., Inc. C. J. C. and M. H. N. have received
funds to speak at a symposium organized on behalf of Three Rivers
Pharmaceuticals, Inc.
NR 25
TC 24
Z9 25
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD AUG
PY 2009
VL 53
IS 8
BP 3347
EP 3352
DI 10.1128/AAC.01480-08
PG 6
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 471ZW
UT WOS:000268098300024
PM 19364856
ER
PT J
AU Thalacker-Mercer, AE
Petrella, JK
Bamman, MM
AF Thalacker-Mercer, Anna E.
Petrella, John K.
Bamman, Marcas M.
TI Does habitual dietary intake influence myofiber hypertrophy in response
to resistance training? A cluster analysis
SO APPLIED PHYSIOLOGY NUTRITION AND METABOLISM-PHYSIOLOGIE APPLIQUEE
NUTRITION ET METABOLISME
LA English
DT Article
DE diet; amino acids; exercise; muscle hypertrophy
ID MUSCLE PROTEIN-SYNTHESIS; ESSENTIAL AMINO-ACIDS; SKELETAL-MUSCLE; OLDER
MEN; MYONUCLEAR ADDITION; BODY-COMPOSITION; ENERGY-INTAKE; YOUNG MEN;
EXERCISE; INGESTION
AB Although resistance exercise training (RT) is a common intervention to stimulate muscle protein synthesis and increase skeletal muscle mass, the optimal daily protein and total energy intakes sufficient to support RT-mediated muscle growth are as yet unclear. Further, the efficacy of RT varies widely among adults of all ages and whether this is attributable to interindividual differences in nutrition is not known. To determine if self-selected daily intake of macronutrients and specific components of dietary protein and fat are predictive of the magnitude of RT-mediated muscle growth, detailed 4-day dietary records were analyzed on 60 subjects previously clustered (K-means cluster analysis) as non-, modest, and extreme responders (non, n = 16; mod, n = 29; xtr, n = 15), based on the magnitudes of change in vastus lateralis myofiber cross-sectional area following a 16-week, 3-day-per-week, high-intensity RT. Despite the marked contrast between 60% myofiber hypertrophy in xtr and zero growth in non, we found no differences among response clusters in daily intakes of energy (mean +/- SEM: non 102 +/- 8; mod 111 +/- 6; xtr 109 +/- 5 kJ.kg(-1).day(-1)), protein (non 0.97 +/- 0.08; mod 1.07 +/- 0.07; xtr 1.05 +/- 0.06 g.kg(-1).day(-1)), carbohydrate (non 3.02 +/- 0.24; mod 3.18 +/- 0.20; xtr 3.14 +/- 0.17 g.kg(-1).day(-1)), and fat (non 0.95 +/- 0.09; mod 1.05 +/- 0.08; xtr 1.03 +/- 0.08 g.kg(-1).day(-1)), which generally met or exceeded dietary recommendations. There were no cluster differences in intakes of branched chain amino acids known to stimulate muscle protein synthesis. Using the novel K-means clustering approach, we conclude from this preliminary study that protein and energy intakes were sufficient to facilitate modest and extreme muscle growth during RT and intrinsic or extrinsic factors other than nutrient ingestion apparently impaired the anabolic response in nonresponders.
C1 [Thalacker-Mercer, Anna E.; Petrella, John K.; Bamman, Marcas M.] UAB, Dept Physiol & Biophys, Birmingham, AL 35294 USA.
[Thalacker-Mercer, Anna E.; Petrella, John K.; Bamman, Marcas M.] UAB, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Bamman, Marcas M.] Birmingham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Birmingham, AL 35294 USA.
RP Bamman, MM (reprint author), UAB, Dept Physiol & Biophys, Birmingham, AL 35294 USA.
EM mbamman@uab.edu
FU National Institutes of Health/National Institute [1R01 AG017896];
Veterans Affairs Merit Grant; General Clinical Research Center
[M01-RR-0032]; National Institutes of Health/National Institute of
Diabetes and Digestive and Kidney Diseases [5T32 DK062710-01A1]
FX We are indebted to the research subjects for their invaluable
contributions to this work. We thank S. C. Tuggle and S. Hall for
conducting RT sessions and the staff of the Pittman General Clinical
Research Center at UAB for entering dietary food records. Funding for
this work was provided by National Institutes of Health/National
Institute on Aging Grant 1R01 AG017896 (M. M. B.), Veterans Affairs
Merit Grant (M. M. B.), General Clinical Research Center Grant
M01-RR-0032, and National Institutes of Health/National Institute of
Diabetes and Digestive and Kidney Diseases 5T32 DK062710-01A1 (A. E.
T.-M.).
NR 48
TC 16
Z9 16
U1 2
U2 2
PU NATL RESEARCH COUNCIL CANADA-N R C RESEARCH PRESS
PI OTTAWA
PA BUILDING M 55, OTTAWA, ON K1A 0R6, CANADA
SN 1715-5312
J9 APPL PHYSIOL NUTR ME
JI Appl. Physiol. Nutr. Metab.
PD AUG
PY 2009
VL 34
IS 4
BP 632
EP 639
DI 10.1139/H09-038
PG 8
WC Nutrition & Dietetics; Physiology; Sport Sciences
SC Nutrition & Dietetics; Physiology; Sport Sciences
GA 496KP
UT WOS:000269972200010
PM 19767798
ER
PT J
AU Tyler, KL
AF Tyler, Kenneth L.
TI Emerging Viral Infections of the Central Nervous System Part 1
SO ARCHIVES OF NEUROLOGY
LA English
DT Article; Proceedings Paper
CT 132nd Annual Meeting of the American-Neurological-Association
CY OCT 07-10, 2007
CL Washington, DC
SP Amer Neurol Assoc
ID WEST-NILE-VIRUS; VACCINE-DERIVED POLIOVIRUS; 4 TRANSPLANT RECIPIENTS;
MR-IMAGING FINDINGS; JAPANESE ENCEPHALITIS; TOSCANA VIRUS;
UNITED-STATES; NEUROINVASIVE DISEASE; LIMBIC ENCEPHALITIS; HUMAN
HERPESVIRUS-6
AB In this 2-part review, I will focus on emerging virus infections of the central nervous system (CNS). Part 1 will introduce the basic features of emerging infections, including their definition, epidemiology, and the frequency of CNS involvement. Important mechanisms of emergence will be reviewed, including viruses spreading into new host ranges as exemplified by West Nile virus (WNV), Japanese encephalitis (JE) virus, Toscana virus, and enterovirus 71 (EV71). Emerging infections also result from opportunistic spread of viruses into known niches, often resulting from attenuated host resistance to infection. This process is exemplified by transplant-associated cases of viral CNS infection caused by WNV, rabies virus, lymphocytic choriomeningitis, and lymphocytic choriomeningitis-like viruses and by the syndrome of human herpesvirus 6 (HHV6)-associated posttransplantation acute limbic encephalitis. The second part of this review begins with a discussion of JC virus and the occurrence of progressive multifocal leukoencephalopathy in association with novel immunomodulatory therapies and then continues with an overview of the risk of infection introduced by imported animals (eg, monkeypox virus) and examples of emerging diseases caused by enhanced competence of viruses for vectors and the spread of vectors (eg, chikungunya virus) and then concludes with examples of novel viruses causing CNS infection as exemplified by Nipah and Hendra viruses and bat lyssaviruses. Arch Neurol. 2009;66(8):939-948
C1 [Tyler, Kenneth L.] Univ Colorado Denver, Hlth Sci Ctr, Dept Neurol, Aurora, CO 80045 USA.
[Tyler, Kenneth L.] Univ Colorado Denver, Hlth Sci Ctr, Dept Med Infect Dis, Aurora, CO 80045 USA.
[Tyler, Kenneth L.] Univ Colorado Denver, Hlth Sci Ctr, Dept Microbiol, Aurora, CO 80045 USA.
[Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Neurol Serv, Denver, CO USA.
RP Tyler, KL (reprint author), Univ Colorado Denver, Hlth Sci Ctr, Dept Neurol, Neurol B-182,Res Complex 2,12700 E 19th Ave, Aurora, CO 80045 USA.
EM ken.tyler@ucdenver.edu
OI Tyler, Kenneth/0000-0003-3294-5888
FU NINDS NIH HHS [R01 NS050138, R01 NS050138-05, R01 NS050138-05S1, R01
NS051403, R01 NS051403-05]
NR 76
TC 61
Z9 64
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD AUG
PY 2009
VL 66
IS 8
BP 939
EP 948
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 481YA
UT WOS:000268848100003
PM 19667214
ER
PT J
AU Wecht, JM
Radulovic, M
LaFountaine, MF
Rosado-Rivera, D
Zhang, RL
Bauman, WA
AF Wecht, Jill M.
Radulovic, Miroslav
LaFountaine, Michael F.
Rosado-Rivera, Dwindally
Zhang, Run-Lin
Bauman, William A.
TI Orthostatic Responses to Nitric Oxide Synthase Inhibition in Persons
With Tetraplegia
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Hypotension, orthostatic; Rehabilitation; Spinal cord injuries;
Tilt-table test
ID SPINAL-CORD-INJURY; SYMPATHETIC PREGANGLIONIC NEURONS; PLASMA-RENIN
ACTIVITY; SIMULATED MICROGRAVITY; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE;
HYPOTENSION; MECHANISMS; RISK; EXPRESSION
AB Wecht JM, Radulovic M, LaFountaine MF, Rosado-Rivera D, Zhang R-L, Bauman WA. Orthostatic responses to nitric oxide synthase inhibition in persons with tetraplegia. Arch Phys Med Rehabil 2009;90:1428-34.
Objectives: To determine the effects of 1.0mg/kg nitro-L-arginine methyl ester (L-NAME) on orthostatic mean arterial pressure (MAP), serum aldosterone, and plasma renin concentrations in persons with chronic tetraplegia compared with nonspinal cord-injured controls.
Design: Prospective placebo-controlled intervention study.
Setting: James J. Peters Veterans Affairs Medical Center.
Participants: Patients (n=5) with tetraplegia and controls (n=7) participated. The groups were matched for age, height, and weight; the average duration of injury in the tetraplegia group was 22 +/- 14 years.
Intervention: Subjects with tetraplegia visited the laboratory twice, receiving placebo on day 1 and L-NAME (1.0mg/kg) on day 2. The agents were infused via an intravenous catheter over 60 minutes with the patient in the supine position. Data were collected during the infusion and then during head-up tilt to 45 degrees for 30 minutes. Control subjects visited the laboratory once for placebo infusion and the head-up tilt maneuver.
Main Outcome Measure: Orthostatic MAP.
Results: Orthostatic MAP was reduced after placebo infusion in subjects with tetraplegia compared with controls (69 +/- 11 vs 89 +/- 9mmHg, respectively; P <.01) and compared with L-NAME infusion (90 +/- 16mmHg; P <.01). Orthostatic MAP did not differ when comparing the tetraplegia group with controls after L-NAME infusion. Orthostatic aldosterone levels were increased after placebo compared with L-NAME infusion in persons with tetraplegia; plasma renin levels did not differ among the groups.
Conclusions: These data suggest that nitric oxide synthase inhibition may have clinical potential for treatment of orthostatic hypotension in persons with chronic tetraplegia.
C1 [Wecht, Jill M.; Radulovic, Miroslav; LaFountaine, Michael F.; Rosado-Rivera, Dwindally; Zhang, Run-Lin; Bauman, William A.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA.
[Wecht, Jill M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.
[Wecht, Jill M.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM jm.wecht@VA.gov
FU Veterans Affairs Rehabilitation Research and Development Service
[B3203R, B4162C]; United Spinal Association
FX Supported by the Veterans Affairs Rehabilitation Research and
Development Service (grant no. B3203R and B4162C) and by the United
Spinal Association.
NR 41
TC 9
Z9 9
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD AUG
PY 2009
VL 90
IS 8
BP 1428
EP 1434
DI 10.1016/j.apmr.2009.02.004
PG 7
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 483PY
UT WOS:000268981000022
PM 19651280
ER
PT J
AU Gleysteen, JJ
AF Gleysteen, John J.
TI Mesh-Reinforced Ventral Hernia Repair Preference for 2 Techniques
SO ARCHIVES OF SURGERY
LA English
DT Article
ID INCISIONAL HERNIA; SUTURE REPAIR; EXPERIENCE; HERNIOPLASTY; OUTCOMES
AB Hypothesis: Long-term (5-year) recurrence rates are comparable between onlay vs retrorectus mesh-reinforced ventral hernia repairs.
Design: Retrospective study of prospective data collection.
Setting: University and Veterans Affairs hospitals.
Patients: One hundred twenty-five patients treated between February 1988 and September 2001. Ninety-four patients were male. The mean patient age was 56 years (age range, 29-80 years). Fifty percent of patients were smokers, and 32.0% were obese; comorbidities were similar in the 2 cohorts studied.
Interventions: Open surgical extraperitoneal prosthetic mesh reinforcement of the incisional closure among 75 patients (onlay repair [cohort OR]) or in the retrorectus position among 50 patients (retrorectus repair [cohort RR]).
Main Outcome Measures: Recurrent hernia, wound infection, and intestinal fistulas.
Results: Nine patients in cohort OR and 2 patients in cohort RR (8.8%) had wound infections; no fistulas occurred. Complications were similar in the 2 cohorts. One mortality occurred. All hernias recurred at the cranial or caudal edge of the mesh. The median recurrence rates were 20.0% at 15 months in the OR cohort and 4.0% at 9 months in cohort RR (P < .02). Follow-up periods averaged 64 months. Three other patients in cohort OR developed subsequent hernia adjacent to their mesh reinforcement at 72, 73, and 86 months.
Conclusions: Extraperitoneal mesh reinforcement avoids intestinal complications and subsequent operations to remove mesh. Recurrence is more frequent after onlay mesh reinforcement and usually occurs at the cranial or caudal edge of the mesh within the first 2 years after hernia repair. Retrorectus repair is the preferred open surgical treatment of incisional hernia, but it has not been universally applicable. Hernias developing 6 to 7 years after surgery are not the result of failed earlier repairs.
C1 [Gleysteen, John J.] Birmingham Vet Affairs Med Ctr, Surg Serv, Birmingham, AL 35233 USA.
[Gleysteen, John J.] Univ Alabama, Sch Med, Dept Surg, Gastrointestinal Sect, Birmingham, AL USA.
RP Gleysteen, JJ (reprint author), Birmingham Vet Affairs Med Ctr, Surg Serv, Room 4343,700 S 19th St, Birmingham, AL 35233 USA.
EM jgleyst@bellsouth.net
NR 19
TC 13
Z9 13
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0004-0010
J9 ARCH SURG-CHICAGO
JI Arch. Surg.
PD AUG
PY 2009
VL 144
IS 8
BP 740
EP 745
PG 6
WC Surgery
SC Surgery
GA 484RD
UT WOS:000269063800010
PM 19687378
ER
PT J
AU Hagopian, K
Ramsey, JJ
Weindruch, R
AF Hagopian, Kevork
Ramsey, Jon J.
Weindruch, Richard
TI Caloric restriction counteracts age-related changes in the activities of
sorbitol metabolizing enzymes from mouse liver
SO BIOGERONTOLOGY
LA English
DT Article
DE Aldose reductase; Sorbitol dehydrogenase; Polyol; Glucose; Fructose;
Redox state
ID INDUCED DIABETIC-RATS; ALDOSE REDUCTASE; OXIDATIVE STRESS;
GENE-EXPRESSION; POLYOL PATHWAY; DEHYDROGENASE; COMPLICATIONS; LENS;
INHIBITION; MICE
AB The influence of caloric restriction (CR) on hepatic sorbitol-metabolizing enzyme activities was investigated in young and old mice. Aldose reductase and sorbitol dehydrogenase activities were significantly lower in old CR mice than in old controls. Young CR mice showed decreased aldose reductase activity and a trend towards decreased sorbitol dehydrogenase when compared to controls. Metabolites of the pathway, namely sorbitol, glucose and fructose were decreased by CR in young and old mice. Pyruvate levels were decreased by CR in both young and old mice, while lactate decreased only in old CR. Malate levels increased in old CR but remained unchanged in young CR, when compared with controls. Accordingly, the lactate/pyruvate and malate/pyruvate ratios in young and old CR mice were increased, indicating increased NADH/NAD and NADPH/NADP redox couples, respectively. The results indicate that decreased glucose levels under CR conditions lead to decreased sorbitol pathway enzyme activities and metabolite levels, and could contribute to the beneficial effects of long-term CR through decreased sorbitol levels and NADPH sparing.
C1 [Hagopian, Kevork; Ramsey, Jon J.] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA.
[Weindruch, Richard] Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA.
[Weindruch, Richard] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA.
RP Hagopian, K (reprint author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, 1 Shields Ave, Davis, CA 95616 USA.
EM khagopian@ucdavis.edu
FU National Institutes of Health [PO1 AG11915, RO1 AG028125]
FX The work was supported by the National Institutes of Health grants PO1
AG11915 and RO1 AG028125.
NR 37
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-5729
J9 BIOGERONTOLOGY
JI Biogerontology
PD AUG
PY 2009
VL 10
IS 4
BP 471
EP 479
DI 10.1007/s10522-008-9191-1
PG 9
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 461TC
UT WOS:000267293400009
PM 18953666
ER
PT J
AU Loberiza, FR
Lee, SJ
Freytes, CO
Giralt, SA
Van Besien, K
Kurion, S
del Cerro, P
Toro, JJ
Williams, LA
Ketelsen, SW
Navarro, WH
Rizzo, JD
AF Loberiza, Fausto R., Jr.
Lee, Stephanie J.
Freytes, Cesar O.
Giralt, Sergio A.
Van Besien, Koen
Kurion, Seira
del Cerro, Paula
Toro, Juan J.
Williams, Loretta A.
Ketelsen, Seth W.
Navarro, Willis H.
Rizzo, J. Douglas
TI Methodological and Logistical Considerations to Study Design and Data
Collection in Racial/Ethnic Minority Populations Evaluating Outcome
Disparity in Hematopoietic Cell Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Review
DE Hematopoietic cell transplantation; Racial/ethnic disparity
ID BONE-MARROW-TRANSPLANTATION; BREAST-CANCER SURVIVAL; ETHNIC-MINORITIES;
CHRONIC LEUKEMIA; UNITED-STATES; HEALTH-CARE; SERVICES; INCOME; RACE;
MORTALITY
AB Outcome disparity associated with race or ethnicity in the United States has been observed in hematopoietic cell transplantation (HCT). The underlying reasons for such disparity are not known. In the United States, an optimal study of health care disparity by race or ethnicity involves consideration of both biologic and psychosocial determinants, which requires an adequately powered, prospective cohort study design. To better characterize the nature and quantify the magnitude of the many impediments relevant to conducting a successful prospective study involving racial or ethnic minorities in HCT, we conducted a feasibility study to help guide planning of a larger scale outcome and disparity study in HCT The primary questions to be addressed in the study were: (1) can we establish a racially or ethnically diverse patient sample that will respond to a survey focused on sociodemographic, economic, health insurance, cultural, spiritual, and religious well-being, and social support information? (2) What is the retention rate in the study over time? (3) What is the quality of the data collected from the patients over time? The challenges we faced in conducting this multicenter feasibility study are summarized in this report. Despite the difficulty in conducting disparity studies in racial and ethnic minorities, such studies are essential to ensure that people of all ethnic and racial backgrounds have the best chance possible of benefiting from HCT Biol Blood Marrow Transplant 15: 903-909 (2009) (C) 2009 Elsevier Inc. All rights reserved.
C1 [Loberiza, Fausto R., Jr.] Univ Nebraska, Med Ctr, Onc Hem Sect, Omaha, NE 68198 USA.
[Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Freytes, Cesar O.; Toro, Juan J.] S Texas Vet Healthcare Syst, San Antonio, TX USA.
[Freytes, Cesar O.; Toro, Juan J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Giralt, Sergio A.; Williams, Loretta A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Van Besien, Koen; del Cerro, Paula] Univ Chicago, Chicago, IL 60637 USA.
[Kurion, Seira] Dept Publ Hlth, Los Angeles, CA USA.
[Ketelsen, Seth W.; Rizzo, J. Douglas] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Navarro, Willis H.] Natl Marrow Donor Program, Phoenix, AZ USA.
RP Loberiza, FR (reprint author), Univ Nebraska, Med Ctr, Onc Hem Sect, 600 S 42nd St, Omaha, NE 68198 USA.
EM floberiza@unmc.edu
RI van Besien, Koen/G-4221-2012
OI van Besien, Koen/0000-0002-8164-6211
FU Medical College of Wisconsin Cancer Center Institutional Research Fund
FX This work was supported by the Medical College of Wisconsin Cancer
Center Institutional Research Fund.
NR 25
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD AUG
PY 2009
VL 15
IS 8
BP 903
EP 909
DI 10.1016/j.bbmt.2009.04.005
PG 7
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 477PH
UT WOS:000268530500002
PM 19589479
ER
PT J
AU Feng, P
Yee, KK
Rawson, NE
Feldman, LM
Feldman, RS
Breslin, PAS
AF Feng, Pu
Yee, Karen K.
Rawson, Nancy E.
Feldman, Lauren M.
Feldman, Roy S.
Breslin, Paul A. S.
TI Immune cells of the human peripheral taste system: Dominant dendritic
cells and CD4 T cells
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE Taste tissue; Taste bud; Dendritic cell; Langerhans cell; Lymphocyte;
Fungiform papillae; Cell population
ID UNILATERAL NERVE INJURY; HIV-INFECTED PATIENTS; ORAL LICHEN-PLANUS;
UP-REGULATION; TISSUE SPECIMENS; LANGERHANS CELLS; SMELL; MUCOSA;
DISORDERS; SUBSETS
AB Taste loss or alterations can seriously impact health and quality of life due to the resulting negative influence on eating habits and nutrition. Infection and inflammation are thought to be some of the most common causes of taste perception disorders. Supporting this view, neuro-immune interactions in the peripheral gustatory system have been identified, underlying the importance of this tissue in mucosal immunity, but we have little understanding of how these interactions influence taste perception directly or indirectly. This limited understanding is evident by the lack of even a basic knowledge of the resident immune cell populations in or near taste tissues. The present study characterized the distribution and population of the major immune cells and their subsets in healthy human anterior, lingual, fungiform papillae (FP) using immunohistochemistry. Dendritic cells (DCs) were the predominant innate immune cells in this tissue, including four subtypes: CD11c(+) DCs, DC-SIGN+ immature DCs, CD83(+) mature DCs, and CD1a(+) DCs (Langerhans cells). While most DCs were localized beneath the lamina propria and only moderately in the epithelium, CD1a(+) Langerhans cells were exclusively present within the epithelium and not in sub-strata. A small number of macrophages were observed. T lymphocytes were present throughout the FP with CD4(+) T cells more prevalent than CD8(+)T cells. Very few CD19(+) B lymphocytes were detected. The results show that DCs, macrophages, and T lymphocytes are the constitutive guardians of human FP taste tissue, with DCs and CD4 T cells being dominant, while B lymphocytes are rare under normal, healthy conditions. These observations provide a basic anatomical foundation for the immune response in the healthy human tongue as a basis for subsequent disease-related studies, but none of the present data indicate that the immune cell populations identified are, in fact, altered in individuals with abnormal taste perception. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Feng, Pu; Yee, Karen K.; Rawson, Nancy E.; Feldman, Roy S.; Breslin, Paul A. S.] Monell Chem Senses Ctr, Philadelphia, PA 19104 USA.
[Feng, Pu] Acad Med Sci Gansu Prov, Lanzhou 730050, Gansu, Peoples R China.
[Rawson, Nancy E.] WellGen Inc, N Brunswick, NJ USA.
[Feldman, Lauren M.] Barnard Coll, New York, NY USA.
[Feldman, Roy S.] Philadelphia Vet Affairs Med Ctr, Dent Serv, Philadelphia, PA USA.
[Feldman, Roy S.; Breslin, Paul A. S.] Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA.
RP Breslin, PAS (reprint author), Monell Chem Senses Ctr, 3500 Market St, Philadelphia, PA 19104 USA.
EM breslin@monell.org
FU NIH [DC 02995, P50DC 06760]
FX This work was supported by NIH DC 02995 to PASB and P50DC 06760 to PASB
and NER. We thank Biostatistician Jesse Chittams for data analysis,
Linda Wysocki for her technical help in histology, and Luba Dankulich,
Suzanne Alarcon, and Anne Ledyard for their invaluable assistance.
NR 37
TC 15
Z9 15
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD AUG
PY 2009
VL 23
IS 6
BP 760
EP 766
DI 10.1016/j.bbi.2009.02.016
PG 7
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 474SR
UT WOS:000268304800007
PM 19268521
ER
PT J
AU Sloan, KA
Marquez, HA
Li, J
Cao, YX
Hinds, A
O'Hara, CJ
Kathuria, S
Ramirez, MI
Williams, MC
Kathuria, H
AF Sloan, Karin A.
Marquez, Hector A.
Li, Jun
Cao, Yuxia
Hinds, Anne
O'Hara, Carl J.
Kathuria, Satinder
Ramirez, Maria I.
Williams, Mary C.
Kathuria, Hasmeena
TI Increased PEA3/E1AF and decreased Net/Elk-3, both ETS proteins,
characterize human NSCLC progression and regulate caveolin-1
transcription in Calu-1 and NCI-H23 NSCLC cell lines
SO CARCINOGENESIS
LA English
DT Article
ID D7S522 LOCUS 7Q31.1; LUNG-CANCER; PROSTATE-CANCER; GENE-TRANSCRIPTION;
MOUSE LUNG; EXPRESSION; ADENOCARCINOMA; PROMOTER; METASTASIS; NET
AB Caveolin-1 protein has been called a 'conditional tumor suppressor' because it can either suppress or enhance tumor progression depending on cellular context. Caveolin-1 levels are dynamic in non-small-cell lung cancer, with increased levels in metastatic tumor cells. We have shown previously that transactivation of an erythroblastosis virus-transforming sequence (ETS) cis-element enhances caveolin-1 expression in a murine lung epithelial cell line. Based on high sequence homology between the murine and human caveolin-1 promoters, we proposed that ETS proteins might regulate caveolin-1 expression in human lung tumorigenesis. We confirm that caveolin-1 is not detected in well-differentiated primary lung tumors. Polyoma virus enhancer activator 3 (PEA3), a pro-metastatic ETS protein in breast cancer, is expressed at low levels in well-differentiated tumors and high levels in poorly differentiated tumors. Conversely, Net, a known ETS repressor, is expressed at high levels in the nucleus of well-differentiated primary tumor cells. In tumor cells in metastatic lymph node sites, caveolin-1 and PEA3 are highly expressed, whereas Net is now expressed in the cytoplasm. We studied transcriptional regulation of caveolin-1 in two human lung cancer cell lines, Calu-1 (high caveolin-1 expressing) and NCI-H23 (low caveolin-1 expressing). Chromatin immunoprecipitation-binding assays and small interfering RNA experiments show that PEA3 is a transcriptional activator in Calu-1 cells and that Net is a transcriptional repressor in NCI-H23 cells. These results suggest that Net may suppress caveolin-1 transcription in primary lung tumors and that PEA3 may activate caveolin-1 transcription in metastatic lymph nodes.
C1 [Sloan, Karin A.; Li, Jun; Cao, Yuxia; Hinds, Anne; Ramirez, Maria I.; Williams, Mary C.; Kathuria, Hasmeena] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA.
[Marquez, Hector A.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[O'Hara, Carl J.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA.
[Kathuria, Satinder] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Pathol, Hines, IL 60141 USA.
RP Sloan, KA (reprint author), Boston Univ, Sch Med, Ctr Pulm, 72 E Concord St,R304, Boston, MA 02118 USA.
EM kasloan@bu.edu
OI Kathuria, Hasmeena/0000-0002-9062-409X; Sloan, Karin/0000-0003-0733-927X
FU American Cancer Society [IRG-72-001-34-IRG]; American Lung Association
Lungevity; National Institute of Health/National Heart, Lung, and Blood
Institute
FX American Cancer Society (IRG-72-001-34-IRG) to H. K.; American Lung
Association Lungevity to H. K.; National Institute of Health/National
Heart, Lung, and Blood Institute Training Grant to K. A. S.
NR 53
TC 18
Z9 19
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD AUG
PY 2009
VL 30
IS 8
BP 1433
EP 1442
DI 10.1093/carcin/bgp129
PG 10
WC Oncology
SC Oncology
GA 478KG
UT WOS:000268586400023
PM 19483189
ER
PT J
AU Wecht, JM
Weir, JP
DeMeersman, RE
Schilero, GJ
Handrakis, JP
LaFountaine, MF
Cirnigliaro, CM
Kirshblum, SC
Bauman, WA
AF Wecht, Jill M.
Weir, Joseph P.
DeMeersman, Ronald E.
Schilero, Gregory J.
Handrakis, John P.
LaFountaine, Michael F.
Cirnigliaro, Christopher M.
Kirshblum, Steven C.
Bauman, William A.
TI Cold face test in persons with spinal cord injury: age versus inactivity
SO CLINICAL AUTONOMIC RESEARCH
LA English
DT Article
DE Heart rate variability; Bradycardia; Facial cooling; Sympathetic
activity; Vagal activity; Spinal cord injury
ID HEART-RATE-VARIABILITY; CARDIOVASCULAR-RESPONSES; VAGAL FUNCTION; DIVING
REFLEX; FITNESS; HUMANS; IMMERSION; STRESS; TETRAPLEGIA; BRADYCARDIA
AB Persons with spinal cord injury (SCI) reflect a model of precocious aging and inactivity; as such, these individuals manifest well-appreciated cardiovascular abnormalities. We aimed to determine the influence of inactivity in persons with SCI, and the influence of age in healthy controls, on cardiovascular autonomic responses to the cold face test (CFT).
Subjects recruited (n = 42) included 18 controls: 10 young (25 +/- A 2 years) and 8 old (50 +/- A 6 years), and 24 subjects with chronic SCI: 17 with tetraplegia (C3-C8 44 +/- A 7 years) and 7 with paraplegia (T5-T10 36 +/- A 8 years). Heart rate (HR) and blood pressure were collected continuously: 2-min pre-CFT, 1-min CFT and 2-min post-CFT. Time-frequency (wavelet) analysis of HR (HFln) was used as an estimate of vagal cardiac modulation.
The HR response to the CFT differed significantly among the SCI group (4.1 +/- A 8.8 bpm) and the young (-7.7 +/- A 5.9 bpm; P < 0.001) and old (-6.8 +/- A 10.7 bpm; P < 0.01). The HFln response was reduced in the SCI (0.01 +/- A 1.59) as compared with the young controls (1.50 +/- A 1.50; P < 0.05), but was not different from the old controls (0.69 +/- A 1.39). The bradycardia did not differ among the young and old controls; however, the vagal response was attenuated in the old compared with the young. These data suggest that age does not significantly alter the heart rate response to the CFT, but attenuates the vagal response.
In the SCI group, the paradoxical heart rate response to facial cooling and the lack of vagal activation suggest that abnormal autonomic cardiovascular reflexive control may result from profound inactivity and/or from the spinal cord injury per se.
C1 [Wecht, Jill M.; Schilero, Gregory J.; LaFountaine, Michael F.; Cirnigliaro, Christopher M.; Bauman, William A.] James J Peters VA Med Ctr, Rehabil Res & Dev Ctr Excellence Med Consequences, Bronx, NY 10468 USA.
[Wecht, Jill M.; Schilero, Gregory J.; Bauman, William A.] James J Peters VA Med Ctr, Med & Spinal Cord Injury Serv, Bronx, NY 10468 USA.
[Wecht, Jill M.; Schilero, Gregory J.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Wecht, Jill M.; Schilero, Gregory J.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.
[Weir, Joseph P.] Des Moines Univ, Osteopath Med Ctr, Des Moines, IA USA.
[Handrakis, John P.] Sch Hlth Profess Behav & Life Sci, NYIT, Old Westbury, NY USA.
[Cirnigliaro, Christopher M.; Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA.
[DeMeersman, Ronald E.] Columbia Univ Teachers Coll, New York, NY 10027 USA.
RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Rehabil Res & Dev Ctr Excellence Med Consequences, Rm 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM jm.wecht@va.gov
FU Veteran Affairs Rehabilitation Research & Development Service; Center of
Excellence for the Medical Consequences of SCI; Vidda Foundation; United
Spinal Association
FX We acknowledge financial and institutional support from the Veteran
Affairs Rehabilitation Research & Development Service, Center of
Excellence for the Medical Consequences of SCI, James J. Peters VAMC,
the Vidda Foundation, and United Spinal Association. We recognize Joel
T. Crammer, Ph.D., for his development of the time frequency analysis
program.
NR 38
TC 8
Z9 8
U1 0
U2 2
PU DR DIETRICH STEINKOPFF VERLAG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, 69121 HEIDELBERG, GERMANY
SN 0959-9851
J9 CLIN AUTON RES
JI Clin. Auton. Res.
PD AUG
PY 2009
VL 19
IS 4
BP 221
EP 229
DI 10.1007/s10286-009-0009-2
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 483OR
UT WOS:000268977600004
PM 19418115
ER
PT J
AU Aqel, R
Dorfman, TA
AF Aqel, Raed
Dorfman, Todd A.
TI The Brain First or the Heart: The Approach to Revascularizing Severe
Co-Existing Carotid and Coronary Artery Disease
SO CLINICAL CARDIOLOGY
LA English
DT Review
ID SINGLE-CENTER; BYPASS; ENDARTERECTOMY; IMMEDIATE; SURGERY; RISK;
ANGIOPLASTY; STENOSIS; STRATEGY
AB Combined symptomatic severe cerebralvascular disease and significant obstructive coronary artery disease frequently exist.(1,2) For the past few decades, clinicians have debated the various treatment strategies for these high-risk patients including staged procedures and hybrid revascularization. While some recommend addressing the more unstable vascular territory first, others prefer to intervene on the carotids prior to performing coronary revascularization. Both surgical and percutaneous options have been explored in various clinical settings, but there are no treatment guidelines to date. Given the frequency and magnitude of this problem, we performed an extensive review of the literature in an attempt to add some much needed clarity. An illustrative case and recommendations are provided.
C1 [Aqel, Raed] Birmingham Vet Affairs Med Ctr, Div Cardiovasc Dis, Birmingham, AL 35233 USA.
Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
RP Aqel, R (reprint author), Birmingham Vet Affairs Med Ctr, Div Cardiovasc Dis, 700 19th St S, Birmingham, AL 35233 USA.
EM RaedAqel@med.va.gov
NR 20
TC 3
Z9 3
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0160-9289
J9 CLIN CARDIOL
JI Clin. Cardiol.
PD AUG
PY 2009
VL 32
IS 8
BP 418
EP 425
DI 10.1002/clc.20443
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 491GM
UT WOS:000269566500002
PM 19685511
ER
PT J
AU Aspinall, SL
Good, CB
Jiang, R
McCarren, M
Dong, D
Cunningham, FE
AF Aspinall, Sherrie L.
Good, Chester B.
Jiang, Rong
McCarren, Madeline
Dong, Diane
Cunningham, Francesca E.
TI Severe Dysglycemia with the Fluoroquinolones: A Class Effect?
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID GATIFLOXACIN-INDUCED HYPERGLYCEMIA; RESISTANT HYPOGLYCEMIA;
HOSPITALIZED-PATIENTS; LEVOFLOXACIN; THERAPY; CIPROFLOXACIN
AB Background. Although gatifloxacin is no longer available, other fluoroquinolones may significantly interfere with glucose homeostasis. The objective of the present study was to compare the risk of severe hypo-and hyperglycemia in a cohort of patients treated with gatifloxacin, levofloxacin, ciprofloxacin, or azithromycin.
Methods. This was a retrospective inception cohort study of outpatients with a new prescription for gatifloxacin, levofloxacin, ciprofloxacin, or azithromycin from 1 October 2000 through 30 September 2005 in the Veterans Affairs health care system. For patients who received one of these antibiotics, we identified outcomes of hospitalization with a primary diagnosis of hypo-or hyperglycemia. Multivariable logistic regression was used to determine the odds of hypo-and hyperglycemia with the individual fluoroquinolones versus azithromycin.
Results. The crude incidence rates for severe hypo-and hyperglycemia among those who received gatifloxacin, levofloxacin, ciprofloxacin, and azithromycin were 0.35 and 0.45, 0.19 and 0.18, 0.10 and 0.12, and 0.07 and 0.10 cases per 1000 patients, respectively. Among patients with diabetes, the odds ratios for hypoglycemia compared with azithromycin were 4.3 (95% confidence interval [CI], 2.7-6.6) for gatifloxacin, 2.1 (95% CI, 1.4-3.3) for levofloxacin, and 1.1 (95% CI, 0.6-2.0) for ciprofloxacin. The odds ratios for hyperglycemia were 4.5 (95% CI, 3.0-6.9) for gatifloxacin, 1.8 (95% CI, 1.2-2.7) for levofloxacin, and 1.0 (95% CI, 0.6-1.8) for ciprofloxacin.
Conclusions. The odds of severe hypo-and hyperglycemia were significantly greater with gatifloxacin and levofloxacin, but not ciprofloxacin, than with azithromycin. Thus, the risk of a clinically relevant dysglycemic event appears to vary among the fluoroquinolones.
C1 [Aspinall, Sherrie L.; Good, Chester B.; Jiang, Rong; McCarren, Madeline; Dong, Diane; Cunningham, Francesca E.] Vet Affairs Ctr Medicat Safety, Hines, IL USA.
[Aspinall, Sherrie L.; Good, Chester B.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Aspinall, Sherrie L.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA.
[Good, Chester B.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
RP Cunningham, FE (reprint author), Pharm Benefits Management Serv 119D, Vet Hlth Adm, Hines, IL 60141 USA.
EM fran.cunningham@va.gov
FU Veterans Affairs Center for Medication Safet
FX In-kind support for this project was provided by the Veterans Affairs
Center for Medication Safety. S. L. A. was a Veterans Affairs Health
Services Research and Development Research Career Development awardee
when the project was conducted. The contents of this article do not
represent the views of the Department of Veterans Affairs or the US
Government.
NR 34
TC 33
Z9 36
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2009
VL 49
IS 3
BP 402
EP 408
DI 10.1086/600294
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 468LK
UT WOS:000267819700014
PM 19545207
ER
PT J
AU Sun, HY
Singh, N
AF Sun, Hsin-Yun
Singh, Nina
TI Are Statins Applicable for the Prevention and Treatment of Zygomycosis?
Reply
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
ID ORGAN TRANSPLANT RECIPIENTS; CASPOFUNGIN; ATTRIBUTES
C1 [Sun, Hsin-Yun; Singh, Nina] Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Singh, Nina] Univ Pittsburgh, Div Infect Dis, Dept Med, Pittsburgh, PA USA.
[Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan.
[Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
RP Singh, N (reprint author), Vet Affairs Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA.
EM nis5@pitt.edu
OI SUN, HSIN-YUN/0000-0003-0074-7721
NR 7
TC 0
Z9 0
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2009
VL 49
IS 3
BP 484
EP 484
DI 10.1086/600826
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 468LK
UT WOS:000267819700034
ER
PT J
AU Abdel-Kader, K
Palevsky, PM
AF Abdel-Kader, Khaled
Palevsky, Paul M.
TI Acute Kidney Injury in the Elderly
SO CLINICS IN GERIATRIC MEDICINE
LA English
DT Review
DE Acute kidney injury; Acute renal failure; Elderly; Geriatric
ID ACUTE-RENAL-FAILURE; ACUTE INTERSTITIAL NEPHRITIS; CONTRAST-INDUCED
NEPHROPATHY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
CONVERTING-ENZYME-INHIBITORS; RANDOMIZED CONTROLLED-TRIAL;
CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; AORTIC-ANEURYSM SURGERY;
VOID RESIDUAL URINE
AB The aging kidney undergoes several important anatomic and physiologic changes that increase the risk of acute kidney injury (formerly acute renal failure) in the elderly. This article reviews these changes and discusses the diagnoses frequently encountered in the elderly patient with acute kidney injury. The incidence, staging, evaluation, management, and prognosis of acute kidney injury are also examined with special focus given to older adults.
C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA.
[Abdel-Kader, Khaled; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA.
RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Room 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA.
EM palevsky@pitt.edu
OI Abdel-Kader, Khaled/0000-0002-6412-8498; Palevsky,
Paul/0000-0002-7334-5400
FU Ruth L. Kirschstein National Research Service Award Institutional
Research Training Grants [T32-DK061296]
FX This work was supported by a Ruth L. Kirschstein National Research
Service Award Institutional Research Training Grants, T32-DK061296
(Abdel-Kader).
NR 189
TC 32
Z9 33
U1 1
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0690
J9 CLIN GERIATR MED
JI Clin. Geriatr. Med.
PD AUG
PY 2009
VL 25
IS 3
BP 331
EP +
DI 10.1016/j.cger.2009.04.001
PG 29
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 506IW
UT WOS:000270769500004
PM 19765485
ER
PT J
AU London, MJ
AF London, Martin J.
TI Cardiovascular problems in noncardiac surgery
SO CURRENT OPINION IN CRITICAL CARE
LA English
DT Review
DE beta-adrenergic blockade; guidelines; myocardial infarction; natriuretic
peptides; postoperative complications; troponins
ID PERIOPERATIVE BETA-BLOCKADE; PERCUTANEOUS CORONARY INTERVENTION; MAJOR
VASCULAR-SURGERY; RANDOMIZED CONTROLLED-TRIALS; PLACEBO-CONTROLLED
TRIAL; HEART-RATE CONTROL; MYOCARDIAL-INFARCTION; ARTERY STENTS; CARDIAC
RISK; STRESS ECHOCARDIOGRAPHY
AB Purpose of review
Perioperative cardiac complications remain a major area of concern as our surgical population increases in volume, age and frequency of comorbidity. A variety of strategies can be used to optimize patients and potentially reduce the incidence of these serious complications.
Recent findings
Recent literature suggests a trend towards less invasive testing for detection and quantification of coronary artery disease and greater interest in pharmacologic 'cardioprotection' using beta-blockers, statins and other agents targeting heart rate control and other mechanisms (e.g. reducing inflammatory responses). The recent Perioperative Ischemic Evaluation study has substantially altered this approach at least towards widespread application to lower/intermediate risk cohorts. Considerable attention has been focused on ensuring optimal standardized perioperative management of patients with a recent percutaneous coronary intervention, particularly those with an intracoronary stent. Widespread surveillance of postoperative troponin release and increasing recognition of the prognostic potential of elevated preoperative brain natriuretic peptides point towards changing strategies for long-term risk stratification.
Summary
The complexity of a particular patient's physiologic responses to a wide variety of surgical procedures, which are undergoing constant technological refinement generally associated with lesser degrees of invasivity and stress make calculation of patients' perioperative risk very challenging. At the present time, adequate information is available for the clinician to screen patients with high-risk preoperative predictors, delay elective surgery for patients with recent intracoronary stents and continue chronic beta-blockade in appropriate patients. New large-scale database and subanalyses of major trials (e.g. Perioperative Ischemic Evaluation and Coronary Artery Revascularization Prophylaxis) should provide additional information to minimize perioperative cardiac risk.
C1 [London, Martin J.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA.
[London, Martin J.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP London, MJ (reprint author), Anesthesia 129,4150 Clement St, San Francisco, CA 94121 USA.
EM londonm@anesthesia.ucsf.edu
NR 61
TC 5
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1070-5295
J9 CURR OPIN CRIT CARE
JI Curr. Opin. Crit. Care
PD AUG
PY 2009
VL 15
IS 4
BP 333
EP 341
DI 10.1097/MCC.0b013e32832e4795
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA 480ME
UT WOS:000268738100010
PM 19553809
ER
PT J
AU Sun, HY
Singh, N
AF Sun, Hsin-Yun
Singh, Nina
TI Immune reconstitution inflammatory syndrome in non-HIV immunocompromised
patients
SO CURRENT OPINION IN INFECTIOUS DISEASES
LA English
DT Review
DE immune reconstitution inflammatory syndrome; immunocompromised hosts;
non-HIV
ID REGULATORY T-CELLS; ORGAN TRANSPLANT RECIPIENTS; RENAL-ALLOGRAFT
REJECTION; NECROSIS-FACTOR-ALPHA; INVASIVE PULMONARY ASPERGILLOSIS;
ACTIVE ANTIRETROVIRAL THERAPY; MYCOBACTERIUM-TUBERCULOSIS; CRYPTOCOCCAL
MENINGITIS; PARADOXICAL RESPONSE; AUTOIMMUNE-DISEASE
AB Purpose of review
In the era of highly active antiretroviral therapy, immune reconstitution inflammatory syndrome has become well recognized in the HIV-infected population. However, little is known about its occurrence in non-HIV immunocompromised hosts. The present review aims to propose the pathogenesis of immune reconstitution inflammatory syndrome, summarize its occurrence in immunocompromised patients without HIV infection, and suggest potential treatment options.
Recent findings
Immune reconstitution inflammatory syndrome is exuberant and dysregulated inflammatory responses to invading microorganisms. It manifests when an abrupt shift of host immunity from an anti-inflammatory and immunrosuppressive status towards a pathogenic proinflammatory state occurs as a result of rapid decreases or removal of factors promoting immunosuppression or inhibiting inflammation. In addition to HIV-infected patients, immune reconstitution inflammatory syndrome has also been observed in solid organ transplant recipients, women during the postpartum period, neutropenic patients, and tumor necrosis factor antagonist recipients. Corticosteroids are the most commonly employed treatment, whereas other potential agents based on its pathogenesis deserve further investigation.
Summary
Non-HIV immunocompromised hosts develop immune reconstitution inflammatory syndrome when the sudden change in the dominant T helper responses to inflammation is not well balanced by anti-inflammatory responses. Judicious manipulation of host immunity and timely recognition of immune reconstitution inflammatory syndrome as we deal with the infections in these populations is critical to limit or avoid the harm by immune reconstitution inflammatory syndrome.
C1 [Sun, Hsin-Yun; Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
[Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan.
[Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA.
RP Singh, N (reprint author), Vet Adm Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA.
EM nis5@pitt.edu
OI SUN, HSIN-YUN/0000-0003-0074-7721
NR 112
TC 35
Z9 38
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0951-7375
J9 CURR OPIN INFECT DIS
JI Curr. Opin. Infect. Dis.
PD AUG
PY 2009
VL 22
IS 4
BP 394
EP 402
DI 10.1097/QCO.0b013e32832d7aff
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 470IS
UT WOS:000267969000010
PM 19483618
ER
PT J
AU Ellis, BC
Gattoni-Celli, S
Mancia, A
Kindy, MS
AF Ellis, Blake C.
Gattoni-Celli, Sebastiano
Mancia, Annalaura
Kindy, Mark S.
TI The vitamin D3 transcriptomic response in skin cells derived from the
Atlantic bottlenose dolphin
SO DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY
LA English
DT Review
DE Vitamin D; Immunity; Keratinocyte; Gene expression; Transcription
factors; Dolphin
ID SINGLE-NUCLEOTIDE POLYMORPHISM; LYMPHOID TYROSINE PHOSPHATASE;
ANTIMICROBIAL PROTEIN HCAP18; UVB-INDUCED CONVERSION;
TUMOR-NECROSIS-FACTOR; BREAST-CANCER CELLS; TURSIOPS-TRUNCATUS;
D-RECEPTOR; GENE-EXPRESSION; 1,25-DIHYDROXYVITAMIN D-3
AB The Atlantic bottlenose dolphin has attracted attention due to the evident impact that environmental stressors have taken on its health. In order to better understand the mechanisms linking environmental health with dolphin health, we have established cell cultures from dolphin skin as in vitro tools for molecular evaluations. The vitamin D3 pathway is one mechanism of interest because of its well established chemopreventative and immunomodulatory properties in terrestrial mammals. On the other hand, little is known of the physiological role of this molecule in aquatic animals. 1,25-dihydroxyvitamin D3 (1,25D3), the bioactive and hormonal form of vitamin D3, exerts its biological function by binding to the vitamin D receptor (VDR), a ligand-activated regulator of gene transcription. Therefore, we investigated the transcriptomic changes induced by 1,25D3 administration in dolphin skin cells. Identification of specific genes activated by 1,25D3 has provided clues to the physiological function of the vitamin D3 pathway in the dolphin. We found that exposure of the cells to 1,25D3 upregulated transactivation of a vitamin D-sensitive promoter. cDNA microarray analysis, using a novel dolphin array, identified specific gene targets within this pathway, and real-time PCR (qPCR) confirmed the enhanced expression of select genes of interest. These transcriptional changes correlated with an increase in VDR levels. This is the first report of the presence and activation of the vitamin D3 pathway in a marine mammal, and our experimental results demonstrate a number of similarities to terrestrial animals. Conservation of this pathway in the Atlantic bottlenose dolphin is consistent with the importance of nonclassic functions of vitamin D3, such as its role in innate immunity, similar to what has been demonstrated in other mammals. Published by Elsevier Ltd.
C1 [Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Ellis, Blake C.; Gattoni-Celli, Sebastiano] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA.
[Mancia, Annalaura] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Ellis, Blake C.; Gattoni-Celli, Sebastiano; Mancia, Annalaura; Kindy, Mark S.] Med Univ S Carolina, Marine Biomed & Environm Sci Program, Charleston, SC 29425 USA.
[Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC 29403 USA.
RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
EM kindyms@musc.edu
RI mancia, annalaura/F-9706-2013
OI mancia, annalaura/0000-0001-8680-3530
FU National Science Foundation EPSCoR grant [EPS-0132573, EPS-0447660];
Veterans Administration Merit Review (MSK); National Oceanic and
Atmospheric Administration grant [MOA-2004-168/1259]; SC Sea Grant
[MOA-2006-025/7182]; Marine Biomedicine and Environmental Sciences
Center, Oceans and Human Health Training Program
FX This work was partially supported by a National Science Foundation
EPSCoR grant (MSK, EPS-0132573 and EPS-0447660), Veterans Administration
Merit Review (MSK) and a National Oceanic and Atmospheric Administration
grant to Center for Coastal Environmental Health and Biomolecular
Research (NOAA Biotech Contract, MOA-2004-168/1259), SC Sea Grant
(MOA-2006-025/7182) and the Marine Biomedicine and Environmental
Sciences Center, Oceans and Human Health Training Program.
NR 104
TC 9
Z9 9
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0145-305X
J9 DEV COMP IMMUNOL
JI Dev. Comp. Immunol.
PD AUG
PY 2009
VL 33
IS 8
BP 901
EP 912
DI 10.1016/j.dci.2009.02.008
PG 12
WC Immunology; Zoology
SC Immunology; Zoology
GA 458GW
UT WOS:000267004700003
PM 19454332
ER
PT J
AU Phelan, S
Kanaya, AM
Subak, LL
Hogan, PE
Espeland, MA
Wing, RR
Burgio, KL
DiLillo, V
Gorin, AA
West, DS
Brown, JS
AF Phelan, Suzanne
Kanaya, Alka M.
Subak, Leslee L.
Hogan, Patricia E.
Espeland, Mark A.
Wing, Rena R.
Burgio, Kathryn L.
DiLillo, Vicki
Gorin, Amy A.
West, Delia S.
Brown, Jeanette S.
CA Action Hlth Diabet Look AHEAD Res
TI Prevalence and Risk Factors for Urinary Incontinence in Overweight and
Obese Diabetic Women Action for Health in Diabetes (Look AHEAD) study
SO DIABETES CARE
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL
WOMEN; EPIDEMIOLOGIC SURVEY; NATIONAL-HEALTH; WEIGHT-LOSS; COMMUNITY;
STRESS; TRIAL
AB OBJECTIVE - To determine the prevalence and risk factors for Urinary incontinence among different racial/ethnic groups of overweight. and obese women with type 2 diabetes.
RESEARCH DESIGN AND METHODS - Cross-sectional analysis of baseline data from the Action for Health in Diabetes (Look AHEAD) study, a randomized clinical trial with 2,994 overweight/obese women with type 2 diabetes.
RESULTS - Weekly Incontinence (27%) was reported more Often than other diabetes-associated complications, including retinopathy (7.5%), microalbuminuria (2.2%), and neuropathy (1.5%). The prevalence of weekly incontinence was highest among non-Hispanic whites (32%) and lowest among African Americans (18%), and Asians (12%) (P < 0,001). Asian and African American women had lower odds of weekly incontinence compared with non-Hispanic whites (75 and 55% lower, respectively; P < 0.001). Women with a BMI of >= 35 kg/m(2) had a higher odds of overall and stress incontinence (55-85% higher P < 0.03) compared with that for nonobese women. Risk factors for overall incontinence, as well as for Stress and Urgency incontinence, included prior hysterectomy (40-80% increased risks P < 0.01) and urinary tract infection in the prior year (5-90% increased risk, P < 0.001).
CONCLUSIONS - Among overweight and obese women with type 2 diabetes, urinary incontinence is highly prevalent and far exceeds the prevalence of other diabetes complications. Racial/ethnic differences in incontinence prevalence are similar to those in women without diabetes, affecting non-Hispanic whites more than Asians and African Americans. Increasing obesity (BMI >= 35 kg/m(2)) was the strongest modifiable risk factor for overall incontinence and stress incontinence ill this diverse cohort.
C1 [Phelan, Suzanne] Calif Polytech State Univ San Luis Obispo, Dept Kinesiol, San Luis Obispo, CA 93407 USA.
[Kanaya, Alka M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Gen Internal Med, San Francisco, CA 94143 USA.
[Subak, Leslee L.; Brown, Jeanette S.] Univ Calif San Francisco, Womens Hlth Clin Res Ctr, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
[Subak, Leslee L.; Brown, Jeanette S.] Univ Calif San Francisco, Womens Hlth Clin Res Ctr, Dept Urol, San Francisco, CA 94143 USA.
[Subak, Leslee L.; Brown, Jeanette S.] Univ Calif San Francisco, Womens Hlth Clin Res Ctr, Dept Epidemiol, San Francisco, CA 94143 USA.
[Hogan, Patricia E.; Espeland, Mark A.] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat Sci, Winston Salem, NC USA.
[Wing, Rena R.] Miriam Hosp, Dept Psychiat & Human Behav, Brown Med Sch, Providence, RI 02906 USA.
[Burgio, Kathryn L.] Univ Alabama, Birmingham, AL USA.
[Burgio, Kathryn L.] Dept Vet Affairs, Birmingham, AL USA.
[DiLillo, Vicki] Ohio Wesleyan Univ, Dept Psychol, Delaware, OH 43015 USA.
[Gorin, Amy A.] Univ Connecticut, Dept Psychol, Ctr Hlth Intervent & Prevent, Storrs, CT USA.
[West, Delia S.] Univ Arkansas Med Sci, Fay W Boozman Coll Publ Hlth, Little Rock, AR 72205 USA.
RP Phelan, S (reprint author), Calif Polytech State Univ San Luis Obispo, Dept Kinesiol, San Luis Obispo, CA 93407 USA.
EM sphelan@calpoly.edu
FU National Institutes of Health [DK57136, DK57149, DK56990, DK57177,
DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178,
DK57219, DK57008, DK57135, DK56992]; National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK); National Heart, Lung, and Blood
Institute; National Institute of Nursing Research; National Center on
Minority Health and Health Disparities; Office of Research on Women's
Health; Centers for Disease Control and Prevention; The Johns Hopkins
Medical Institutions Bayview General Clinical Research [M01-RR-02719];
Massachusetts General Hospital Mallinckrodt General Clinical Research
Center [M01RR-01066]; University of Colorado Health Sciences Center
General Clinical Research Center [M01 RR00051]; Clinical Nutrition
Research Unit [P30 DK48520]; University Award in Patient Oriented
Research [(PA-98053]; NIDDK
FX This study was supported by the Department of Health and Human Services
through the following cooperative agreements from the National
Institutes of Health: DK57136, DK57149, DK56990, DK57177, DK57171,
DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219,
DK57008, DK57135, and DK56992. The following federal agencies have
contributed support: National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK), National Heart, Lung, and Blood Institute,
National Institute of Nursing Research, National Center on Minority
Health and Health Disparities, Office of Research on Women's Health, and
the Centers for Disease Control and Prevention. Additional support was
received from The Johns Hopkins Medical Institutions Bayview General
Clinical Research Center (M01-RR-02719), the Massachusetts General
Hospital Mallinckrodt General Clinical Research Center (M01RR-01066),
the University of Colorado Health Sciences Center General Clinical
Research Center (M01 RR00051) and Clinical Nutrition Research Unit (P30
DK48520), the University Award in Patient Oriented Research (PA-98053)
from the NIDDK.
NR 25
TC 32
Z9 37
U1 0
U2 6
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD AUG
PY 2009
VL 32
IS 8
BP 1391
EP 1397
DI 10.2337/dc09-0516
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 479UX
UT WOS:000268687800006
PM 19487639
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI Hospitalization for Achalasia in the United States 1997-2006
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Environmental risk factors; Epidemiology of achalasia; Geographic
variation; Hospital statistics; Socio-economic status; Time trends
ID CLINICAL-FEATURES; EPIDEMIOLOGY; POPULATION; PREVALENCE
AB The Nationwide Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP) was used to study the demographic characteristics of achalasia patients.
HCUP data from 1997 to 2006 were stratified by categories pertaining to patient demographics, such as age, sex, race, income, residence in metropolitan area, and region of the United States, as well as categories pertaining to hospital characteristics, such teaching status, location, and bed size. The distributions of inpatients among different categories were compared between achalasia and all other diagnoses, using odds ratios and their 95% confidence intervals for comparison.
The annual hospitalization rates of achalasia revealed a clear-cut age-dependent rise between the youngest age group less than 18 years old (0.25/100,000) and the oldest age group over 85 years old (37.35/100,000). Between 1997 and 2007, the rates of hospitalization remained largely unchanged for all age groups alike. Achalasia was equally distributed among men and women and among various ethnic groups. Compared with other diagnoses, achalasia was more frequent among hospitalized patients from zip codes associated with a higher average income (1.26, 1.23-1.29), living in metropolitan areas (1.12, 1.09-1.15), and living in the northeast region of the United States (1.27, 1.25-1.30). Achalasia patients were mostly seen in large hospitals (1.22, 1.19-1.26), teaching hospitals (1.73, 1.70-1.76), and hospitals located in metropolitan areas (1.15, 1.14-1.15).
With exception of its striking age-dependence, the epidemiology of achalasia does not reveal any clues about its yet unsolved etiology.
C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA.
RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 19
TC 14
Z9 17
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD AUG
PY 2009
VL 54
IS 8
BP 1680
EP 1685
DI 10.1007/s10620-009-0863-8
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 464DM
UT WOS:000267485400011
PM 19517232
ER
PT J
AU Kovacs, TO
Freston, JW
Haber, MM
Hunt, B
Atkinson, S
Peura, DA
AF Kovacs, Thomas O.
Freston, James W.
Haber, Marian M.
Hunt, Barbara
Atkinson, Stuart
Peura, David A.
TI Long-Term Efficacy of Lansoprazole in Preventing Relapse of Erosive
Reflux Esophagitis
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Lansoprazole; Erosive esophagitis; Gastroesophageal reflux disease;
GERD; Efficacy; Long-term maintenance therapy
ID PROTON PUMP INHIBITORS; ESOMEPRAZOLE 20 MG; LIFE-STYLE ADVICE;
MAINTENANCE TREATMENT; DOSE LANSOPRAZOLE; CONTROLLED TRIAL; DISEASE;
OMEPRAZOLE; ARTICLE; MEDICATION
AB In a phase III study of lansoprazole treatment, patients with healed or unhealed erosive esophagitis entered a titrated open-label treatment period and received lansoprazole for a parts per thousand currency sign6 years to assess long-term maintenance therapy. Doses were adjusted depending on symptom response. Endoscopy was performed yearly. One hundred ninety-five subjects received lansoprazole for < 1 to 72 months; most received daily doses of a parts per thousand currency sign30 mg. Lansoprazole maintained erosive esophagitis remission in 75% of subjects receiving treatment for a parts per thousand currency sign72 months, with 39 subjects experiencing 50 recurrences. Most subjects (94-95%) had no or mild symptoms of day or night heartburn at study end, and 77% were asymptomatic at first erosive esophagitis recurrence. The most common treatment-related adverse events included diarrhea (10%), headache (8%), and abdominal pain (6%), and were mild or moderate in severity. Long-term lansoprazole is effective and well tolerated when used to maintain erosive esophagitis remission for a parts per thousand currency sign6 years.
C1 [Kovacs, Thomas O.] CURE Digest Dis Res Ctr, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Freston, James W.] Univ Connecticut, Ctr Hlth, Farmington, CT USA.
[Haber, Marian M.] Drexel Univ, Coll Med, Dept Pathol, Philadelphia, PA 19104 USA.
[Hunt, Barbara; Atkinson, Stuart] Takeda Global Res & Dev Ctr Inc, Deerfield, IL USA.
[Peura, David A.] Univ Virginia Hlth Syst, Charlottesville, VA USA.
RP Kovacs, TO (reprint author), CURE Digest Dis Res Ctr, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
EM TKovacs@mednet.ucla.edu
FU Takeda Global Research & Development Center, Inc.
FX This study (M94-140) was funded in full by Takeda Global Research &
Development Center, Inc. (TAP Pharmaceutical Products Inc. is now a part
of Takeda Global Research & Development Center, Inc.) Dr. Kovacs
confirms that he has no conflicts of interest or disclosures. Dr.
Freston has served as a consultant for Takeda Global Research &
Development Center, Inc., Takeda Pharmaceuticals North America, Inc.,
GlaxoSmithKline, and EnteroMedics, Inc. Dr. Haber serves as a consultant
for Takeda Global Research & Development Center, Inc. Dr. Peura serves
as a consultant for Takeda Global Research & Development Center, Inc.
and as a member of the speaker's bureau for Takeda Pharmaceuticals North
America, Inc. Ms. Hunt and Dr. Atkinson are employees of Takeda Global
Research & Development Center, Inc.
NR 25
TC 7
Z9 7
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD AUG
PY 2009
VL 54
IS 8
BP 1693
EP 1701
DI 10.1007/s10620-009-0769-5
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 464DM
UT WOS:000267485400013
PM 19267194
ER
PT J
AU Sonnenberg, A
Richardson, PA
Abraham, NS
AF Sonnenberg, Amnon
Richardson, Peter A.
Abraham, Neena S.
TI Hospitalizations for Inflammatory Bowel Disease Among US Military
Veterans 1975-2006
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Crohn's disease; Epidemiology; Incidence; Prevalence; Ethnicity; Time
trends; Ulcerative colitis; Veterans population
ID ULCERATIVE-COLITIS; CROHNS-DISEASE; UNITED-STATES; TIME TRENDS;
INCIDENCE RATES; EPIDEMIOLOGY; PREVALENCE; MORTALITY
AB Background The Department of Veterans Affairs (VA) is the largest healthcare system in the United States. The VA database was used to analyze patterns of hospitalization for inflammatory bowel disease (IBD) among US military veterans. Methods The study used the VA Patient Treatment File (PTF) between 1975 and 2006. Each hospital record extracted from the PTF included diagnosis, patient age, and ethnicity. Patient age was analyzed in three age groups: 0-44, 45-64, and 65+. Patient ethnicity was analyzed by two broad categories as white and nonwhite. Results Among veterans, Crohn's disease was more common than ulcerative colitis and both diseases were more common in whites than in nonwhites. During the past 30 years, the age distributions of both diseases have shifted towards older patients who have come to represent an increasingly larger fraction of patients with Crohn's disease, as well as ulcerative colitis. Hospitalization rates for inflammatory bowel disease among whites recently declined, while most rates among nonwhites continued to rise throughout the observation period. Conclusion The present study revealed a time-dependent shift towards older ages in the age distribution of IBD among hospitalized veterans. These changes, which have been observed similarly in other US statistics, may reflect a birth-cohort phenomenon underlying the long-term time trends of IBD.
C1 [Sonnenberg, Amnon; Richardson, Peter A.; Abraham, Neena S.] Portland VA Med Ctr, Portland, OR 97239 USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Richardson, Peter A.; Abraham, Neena S.] Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA.
[Richardson, Peter A.; Abraham, Neena S.] Baylor Coll Med, Houston, TX 77030 USA.
[Sonnenberg, Amnon; Richardson, Peter A.; Abraham, Neena S.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
FU Houston VA HSR&D Center of Excellence, Houston Center for Quality of
Care & Utilization Studies [HFP90-020]
FX This work was supported in part by the Houston VA HSR&D Center of
Excellence, Houston Center for Quality of Care & Utilization Studies
[HFP90-020].
NR 17
TC 11
Z9 11
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD AUG
PY 2009
VL 54
IS 8
BP 1740
EP 1745
DI 10.1007/s10620-009-0764-x
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 464DM
UT WOS:000267485400021
PM 19259815
ER
PT J
AU Baca, CB
Cheng, EM
Spencer, SS
Vassar, S
Vickrey, BG
AF Baca, Christine Bower
Cheng, Eric M.
Spencer, Susan S.
Vassar, Stefanie
Vickrey, Barbara G.
CA Multictr Study Epilepsy Surg
TI Racial differences in patient expectations prior to resective epilepsy
surgery
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Epilepsy surgery; Expectations; Race/ethnicity
ID TEMPORAL-LOBE EPILEPSY; INTRACTABLE EPILEPSY; MULTICENTER
AB We assessed the nature and frequency of preoperative expectations among patients with refractory epilepsy who were enrolled in a seven-center observational study of epilepsy surgery outcomes. At enrollment, patients responded to open-ended questions about expectations for surgical outcome. With the use of an iterative cutting-and-sorting technique, expectation themes were identified and rank-ordered. Associations of expectations with race/ethnicity were evaluated. Among 391 respondents, the two most frequently endorsed expectations (any rank order) were driving (62%) and job/school (43%). When only the most important (first-ranked) expectation was analyzed, driving (53%) and cognition (17%) were most frequently offered. Nonwhites endorsed job/school and cognition more frequently and driving less frequently than whites (all P <= 0.05), whether expectations of any order or only first-ranked expectations were included. Elucidating the reason for these differences can aid in the clinical decision-making process for resective surgery and potentially address disparities in its utilization. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Baca, Christine Bower] Univ Calif Los Angeles, Dept Neurol, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA 90024 USA.
[Cheng, Eric M.; Vassar, Stefanie; Vickrey, Barbara G.] VA Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA.
[Spencer, Susan S.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.
RP Baca, CB (reprint author), Univ Calif Los Angeles, Dept Neurol, Robert Wood Johnson Fdn, Clin Scholars Program, 911 Braxton Ave,3rd Floor, Los Angeles, CA 90024 USA.
EM cbower@mednet.ucla.edu
FU NINDS [RO1 NS 32375, K23NS058571]; Robert Wood Johnson Foundation
Clinical Scholars Program [59982]
FX This work was supported by RO1 NS 32375 NINDS. Dr. Bowel, Baca was
supported by the Robert Wood Johnson Foundation Clinical Scholars
Program (Grant 59982). Dr. Cheng was supported by a Career Development
Award from NINDS (K23NS058571).
NR 11
TC 11
Z9 11
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD AUG
PY 2009
VL 15
IS 4
BP 452
EP 455
DI 10.1016/j.yebeh.2009.05.010
PG 4
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA 484GV
UT WOS:000269033000010
PM 19541545
ER
PT J
AU Vosler, PS
Sun, DD
Wang, SP
Gao, YQ
Kintner, DB
Signore, AP
Cao, GD
Chen, J
AF Vosler, Peter S.
Sun, Dandan
Wang, Suping
Gao, Yanqin
Kintner, Douglas B.
Signore, Armando P.
Cao, Guodong
Chen, Jun
TI Calcium dysregulation induces apoptosis-inducing factor release:
Cross-talk between PARP-1-and calpain- signaling pathways
SO EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE NMDA toxicity; Calpain; PARP-1; Apoptosis-inducing factor; Ischemia;
Mitochondria; Calcium homeostasis
ID MEDIATED PROGRAMMED NECROSIS; POLY(ADP-RIBOSE) PAR POLYMER; TRANSIENT
CEREBRAL-ISCHEMIA; OXYGEN-GLUCOSE DEPRIVATION; NEURONAL CELL-DEATH;
NITRIC-OXIDE; CORTICAL CULTURES; MU-CALPAIN; GLUTAMATE; ACTIVATION
AB Recent discoveries show that caspase-independent cell death pathways are a pervasive mechanism in neurodegenerative diseases, and apoprosis-inducing factor (AIF) is an important effector of this mode of neuronal death. There are currently two known mechanisms underlying AIF release following excitotoxic stress, PARP-1 and calpain. To test whether there is an interaction between PARP-1 and calpain in triggering AIF release, we used the NMDA toxicity model in rat primary cortical neurons. Exposure to NMIDA resulted in AIF truncation and nuclear translocation, and shRNA-mediated knockdown of AIF resulted in neuroprotection. Both calpain and PARM are involved with AIF processing as AIF truncation, nuclear translocation and neuronal death were attenuated by calpain inhibition using adeno-associated virus-mediated overexpression of the endogenous calpain inhibitor, calpastatin, or treatment with the PARP-1 inhibitor 3-ABA. Activation of PARP-1 is necessary for calpain activation as PARP-1 inhibition blocked mitochondrial calpain activation. Finally, NMDA toxicity induces mitochondrial Ca(2+) dysregulation in a PARP-1 dependent manner. Thus, PARP-1 and mitochondrial calpain activation are linked via PARP-1-induced alterations in mitochondrial Ca(2+) homeostasis. Collectively, these findings link the two seemingly independent mechanisms triggering AIF-induced neuronal death. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Vosler, Peter S.; Wang, Suping; Signore, Armando P.; Cao, Guodong; Chen, Jun] Univ Pittsburgh, Dept Neurol, Sch Med, Pittsburgh, PA 15213 USA.
[Vosler, Peter S.; Wang, Suping; Signore, Armando P.; Cao, Guodong; Chen, Jun] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Sch Med, Pittsburgh, PA 15213 USA.
[Gao, Yanqin; Cao, Guodong; Chen, Jun] Fudan Univ, Sch Med, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.
[Sun, Dandan; Kintner, Douglas B.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53792 USA.
[Wang, Suping; Cao, Guodong; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst Pittsburgh, Geriatr Res, Educ & Clin Ctr, Pittsburgh, PA 15261 USA.
RP Chen, J (reprint author), Univ Pittsburgh, Dept Neurol, 507 S Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.
EM chenj2@upmc.edu
RI Gao, Yanqin/I-6790-2016
OI Gao, Yanqin/0000-0002-4915-9819
FU National Institutes of Health/NINDS [NS43802, NS45048, NS36736, NS
56118, NS38118, NS48216]; NIH NRSA [1F30NS057886]; Chinese Natural
Science Foundation [30470592, 30670642]
FX This project was supported by the National Institutes of Health/NINDS
grants NS43802, NS45048, NS36736, and NS 56118 (to J.C.) and NS38118 and
NS48216 (to D.S.), and VA Merit Review grant (to J.C.). P. S.V. is
supported by an NIH NRSA pre-doctoral fellowship (1F30NS057886). YG was
supported by the Chinese Natural Science Foundation (grants 30470592 and
30670642).
NR 36
TC 47
Z9 52
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
J9 EXP NEUROL
JI Exp. Neurol.
PD AUG
PY 2009
VL 218
IS 2
BP 213
EP 220
DI 10.1016/j.expneurol.2009.04.032
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 472GE
UT WOS:000268117400006
PM 19427306
ER
PT J
AU Johnston, RK
Balasubramanian, S
Kasiganesan, H
Baicu, CF
Zile, MR
Kuppuswamy, D
AF Johnston, Rebecca K.
Balasubramanian, Sundaravadivel
Kasiganesan, Harinath
Baicu, Catalin F.
Zile, Michael R.
Kuppuswamy, Dhandapani
TI beta(3) Integrin-mediated ubiquitination activates survival signaling
during myocardial hypertrophy
SO FASEB JOURNAL
LA English
DT Article
DE NF-kappa B; cIAP1; pressure overload
ID NF-KAPPA-B; RAT VENTRICULAR MYOCYTES; FOCAL COMPLEX-FORMATION;
CARDIAC-MUSCLE-CELLS; HEART-FAILURE; DILATED CARDIOMYOPATHY;
PRESSURE-OVERLOAD; E3 LIGASES; IN-VIVO; C-SRC
AB Identifying the molecular mechanisms activated in compensatory hypertrophy and absent during decompensation will provide molecular targets for prevention of heart failure. We have previously shown enhanced ubiquitination (Ub) during the early growth period of pressure overload (PO) hypertrophy near intercalated discs of cardiomyocytes, where integrins are important for mechanotransduction. In this study, we tested the role of integrins upstream of Ub, whether enhanced Ub contributes to survival signaling in early PO, and if loss of this mechanism could lead to decreased ventricular function. The study used a beta(3) integrin (-/-) mouse and a wild-type mouse as a control for in vivo PO by transverse aortic constriction (TAC) and for cultured cardiomyocytes in vitro, stimulated with the integrin-activating peptide RGD. We demonstrate beta(3) integrin mediates transient Ub of targeted proteins during PO hypertrophy, which is necessary for cardiomyocyte survival and to maintain ventricular function. Prosurvival signaling proceeds by initiation of NF-kappa B transcription of the E3 ligase, cIAP1. In PO beta(-/-)(3) mice, absence of this mechanism correlates with increased TUNEL staining and decreased ventricular mass and function by 4 wk. This is the first study to show that a beta(3) integrin/Ub/NF-kappa B pathway contributes to compensatory hypertrophic growth.-Johnston, R. K., Balasubramanian, S., Kasiganesan, H., Baicu, C. F., Zile, M. R., Kuppuswamy, D. beta(3) Integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. FASEB J. 23, 2759-2771 ( 2009)
C1 [Johnston, Rebecca K.; Balasubramanian, Sundaravadivel; Kasiganesan, Harinath; Baicu, Catalin F.; Zile, Michael R.; Kuppuswamy, Dhandapani] Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, Charleston, SC 29425 USA.
[Zile, Michael R.; Kuppuswamy, Dhandapani] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA.
RP Kuppuswamy, D (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, 114 Doughty St, Charleston, SC 29425 USA.
EM kuppusd@musc.edu
FU National Institutes of Health (NIH) [HL-48788, RO1 HL-092124,
T32HL07260]; American Heart Association predoctoral fellowship
[0615468U]
FX This study was supported by National Institutes of Health (NIH) grant
PPG HL-48788, by a Merit Award from the Research Service of the
Department of Veterans Affairs, by NIH grant RO1 HL-092124 ( to D. K.),
by American Heart Association predoctoral fellowship 0615468U ( to R. K.
J.), and by NIH predoctoral fellowship NIH T32HL07260 ( to R. K. J.). We
thank An Van Laer for proficiency with the TAC model. We also thank Dr.
Robin Muise-Helmericks, Dr. Amy Bradshaw, and Phillip Moschella for
thoughtful comments and useful discussions, and Dr. Francis G. Spinale
for help with the measurement of myocyte cross-sectional area.
NR 49
TC 26
Z9 29
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD AUG
PY 2009
VL 23
IS 8
BP 2759
EP 2771
DI 10.1096/fj.08-127480
PG 13
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 481UE
UT WOS:000268836700044
PM 19364763
ER
PT J
AU Liang, HY
Ran, QT
Jang, YC
Holstein, D
Lechleiter, J
McDonald-Marsh, T
Musatov, A
Song, W
Van Remmen, H
Richardson, A
AF Liang, Hanyu
Ran, Qitao
Jang, Youngmok Charles
Holstein, Deborah
Lechleiter, James
McDonald-Marsh, Tiffany
Musatov, Andrej
Song, Wook
Van Remmen, Holly
Richardson, Arlan
TI Glutathione peroxidase 4 differentially regulates the release of
apoptogenic proteins from mitochondria
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article; Proceedings Paper
CT 16th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine
CY NOV 18-22, 2009
CL San Francisco, CA
SP Soc Free Rad Biol & Med
DE Gpx4; Phospholipid hydroperoxide glutathione peroxidase 4; Apoptosis;
Cardiolipin; Lipid peroxidation; Oxidative stress; Free radicals
ID RAT-LIVER MITOCHONDRIA; CYTOCHROME-C RELEASE; NF-KAPPA-B; CELL-DEATH;
OXIDATIVE STRESS; INDUCED APOPTOSIS; CARDIOLIPIN; INJURY; OXYGEN;
MEMBRANES
AB Glutathione peroxidase 4 (Gpx4) is a unique antioxidant enzyme that repairs oxidative damage to biomembranes. In this study, we examined the effects of Gpx4 on the release of various apoptogenic proteins from mitochondria using transgenic mice overexpressing Gpx4 [Tg(GPX(+/0))] and mice deficient in Gpx4 (Gpx4(+/-) mice). Diquat exposure triggered apoptosis that occurred through an intrinsic pathway and resulted in the mitochondrial release of cytochrome c (Cyt c), Smac/DIABLO, and Omi/HtrA2 in the liver of wild-type (Wt) mice. Liver apoptosis and Cyt c release were Suppressed in Tg(GPX(+/0)) mice but exacerbated in Gpx4(+/-) mice: however, neither the Tg(GPX4(+/0)) nor the Gpx4(+/-) mice showed any alterations in the levels of Smac/DIABLO or Omi/HtrA2 released from mitochondria. Submitochondrial fractionation data showed that Smac/DIABLO and Omi/HtrA2 existed primarily in the intermembrane space and matrix, whereas Cyt c and Gpx4 were both associated with the inner membrane. In addition, diquat exposure induced cardiolipin peroxidation in the liver of Wt mice; the levels of cardiolipin peroxidation were reduced in Tg(GPX4(+/0)) mice but elevated in Gpx4(+/-) mice. These data suggest that Gpx4 differentially regulates apoptogenic protein release owing to its inner membrane location in mitochondria and its ability to repair cardiolipin peroxidation. Published by Elsevier Inc.
C1 [Liang, Hanyu; Ran, Qitao; Jang, Youngmok Charles; Holstein, Deborah; Lechleiter, James; Van Remmen, Holly; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA.
[Ran, Qitao; Lechleiter, James; Van Remmen, Holly; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Ran, Qitao; Van Remmen, Holly; Richardson, Arlan] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
[McDonald-Marsh, Tiffany; Musatov, Andrej] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78245 USA.
[Song, Wook] Seoul Natl Univ, Dept Phys Educ, Seoul 151742, South Korea.
RP Richardson, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA.
EM richardsona@uthscsa.edu
RI Liang, Hanyu/A-1066-2010; Musatov, Andrej/K-8963-2012
FU NIA NIH HHS [P01 AG020591, 1P30-AG13319, P30 AG013319-15, P01 AG019316,
P01 AG019316-080008, R37 AG026557-04, P01AG19316, P01AG020591, R37
AG026557, P30 AG013319, P01 AG020591-079004]
NR 53
TC 31
Z9 33
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD AUG 1
PY 2009
VL 47
IS 3
BP 312
EP 320
DI 10.1016/j.freeradbiomed.2009.05.012
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 464UI
UT WOS:000267532800014
PM 19447173
ER
PT J
AU Spiegel, BMR
AF Spiegel, Brennan M. R.
TI Endoscopy for acute upper GI tract hemorrhage: sooner is better
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Editorial Material
ID UPPER GASTROINTESTINAL HEMORRHAGE; CONTROLLED-TRIAL; THERAPY; QUALITY;
LENGTH; OXYGEN; STAY; CARE
C1 Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr,VA Ctr Outcomes Res & Edu, Los Angeles, CA 90095 USA.
RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr,VA Ctr Outcomes Res & Edu, Los Angeles, CA 90095 USA.
NR 25
TC 10
Z9 12
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD AUG
PY 2009
VL 70
IS 2
BP 236
EP 239
DI 10.1016/j.gie.2008.12.053
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 480OJ
UT WOS:000268745200007
PM 19631802
ER
PT J
AU Artifon, ELA
Couto, D
Sakai, P
da Silveira, EB
AF Artifon, Everson L. A.
Couto, Decio, Jr.
Sakai, Paulo
da Silveira, Eduardo B.
TI Prospective evaluation of EUS versus CT scan for staging of ampullary
cancer
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID ENDOSCOPIC ULTRASOUND; COMPUTED-TOMOGRAPHY; PANCREATIC TUMORS;
ANGIOGRAPHY; SONOGRAPHY; CARCINOMA
AB Background: Malignancies of the biliary and pancreatic systems are associated with a poor prognosis. However, ampullary cancer carries a better prognosis and is often diagnosed when curative treatment is still possible. Accurate staging is important for the determination of the most appropriate treatment option.
Objectives: (1) To determine the test performance characteristics of EUS and CT in loco-regional staging of ampullary neoplasms, and (2) to determine the impact of CT scan results on the test performance characteristics of EUS.
Design and Setting: Prospective single-arm intervention study performed in 2 academic hospitals.
Results and Main Outcome Measurements: Thirty-seven patients were screened and 33 staged with EUS and CT A total of 27 patients (13 men; mean age, 69.5 years; mean serum bilirubin level, 12.6 mg/dL) with locally advanced disease completed the protocol with EUS and CT and underwent surgical resection. Tumor classifications were as follows: 2 patients (7.4%), T1 tumors; 13 patients (48.1%), T2 tumors; and 12 patients (44.4%), T3 tumors, as per surgical pathology. Seventeen tumors (62.9%) were classified as NO and 10 (37.1%) as NI. The difference in proportion of correct tumor (74.1% vs 51.8%; P =.15, 95% CI, -0.06-0-50) and lymph node (81.4% vs; 55.5%; P =.07, 95% Cl, -0.01-0.53) staging by EUS and CT, respectively, was not statistically significantly different. However, the strength of tumor (kappa 0.51 vs 0.11) and nodal (kappa 0.59 vs 0.05) agreement with pathology was statistically significantly higher for EUS than for CT (P <.05). EUS was more sensitive and specific than CT for tumor and nodal staging, and the association of CT to EUS data did not improve the final test accuracy
Limitation: Low number of T1 tumors.
Conclusions: EUS is in accurate diagnostic test and exhibits a high level of agreement with surgical pathology. CT findings do not improve the test performance characteristics of EUS. Therefore, the evaluation for metastatic disease should not be compromised by CT protocols that aim to perform tumor and nodal staging. Further studies to determine the role of specialized CT protocols in patients with ampullary malignancies are needed. (Gastrointest Endosc 2009;70:290-6.)
C1 [Artifon, Everson L. A.; Couto, Decio, Jr.; Sakai, Paulo] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
[da Silveira, Eduardo B.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Gastroenterol, Portland, OR 97201 USA.
RP da Silveira, EB (reprint author), 3710 SW US Vet Hosp Rd,MC P3GI, Portland, OR 97239 USA.
EM eda_silveira@hotmail.com
NR 18
TC 26
Z9 26
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD AUG
PY 2009
VL 70
IS 2
BP 290
EP 296
DI 10.1016/j.gie.2008.11.045
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 480OJ
UT WOS:000268745200016
PM 19523619
ER
PT J
AU Phillips, LL
Paukert, AL
Stanley, MA
Kunik, ME
AF Phillips, Laura L.
Paukert, Amber L.
Stanley, Melinda A.
Kunik, Mark E.
TI Incorporating religion and spirituality to improve care for anxiety and
depression in older adults
SO GERIATRICS
LA English
DT Article
DE anxiety; depression; religion; spirituality
ID ILL ELDERLY-PATIENTS; HEALTH; INVOLVEMENT; PREDICTOR; SYMPTOMS;
MEDICINE; OUTCOMES
AB Recent research has suggested that religion/spirituality may be linked to improved physical and emotional health, although the patients motivation and method of using religious/spiritual beliefs appear to be a key factor in obtaining benefit. Studies have shown that there is a high level of religion/spirituality among older adults in the United States and significant patient-reported desire to include such beliefs in health care settings. This article provides a brief overview of the support for considering religion/spirituality in the health care of older adults and reviews potential drawbacks and methods for providers to assess and use patient beliefs to improve anxiety/depression. Phillips LL, Paukert AL, Stanley MA, Kunik ME. Incorporating religion and spirituality to improve care for anxiety and depression in older adults. Geriatrics. 2009;64(8):15-18.
C1 [Phillips, Laura L.] Olin E Teague VA Med Ctr, Temple, TX USA.
[Paukert, Amber L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Stanley, Melinda A.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Stanley, Melinda A.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA.
[Stanley, Melinda A.; Kunik, Mark E.] VA S Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA.
[Kunik, Mark E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
RP Phillips, LL (reprint author), Olin E Teague VA Med Ctr, Temple, TX USA.
NR 20
TC 9
Z9 9
U1 1
U2 8
PU ADVANSTAR COMMUNICATIONS INC
PI WOODLAND HILLS
PA 6200 CANOGA AVE, 2ND FLR, WOODLAND HILLS, CA 91367 USA
SN 0016-867X
J9 GERIATRICS
JI Geriatrics
PD AUG
PY 2009
VL 64
IS 8
BP 15
EP +
PG 4
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 483LX
UT WOS:000268969400003
PM 20722312
ER
PT J
AU Primack, BA
Fine, D
Yang, CK
Wickett, D
Zickmund, S
AF Primack, Brian A.
Fine, Danielle
Yang, Christopher K.
Wickett, Dustin
Zickmund, Susan
TI Adolescents' impressions of antismoking media literacy education:
qualitative results from a randomized controlled trial
SO HEALTH EDUCATION RESEARCH
LA English
DT Article
ID MASTER SETTLEMENT AGREEMENT; SMOKING-CESSATION METHODS; 6-YEAR
FOLLOW-UP; TOBACCO USE; NORMATIVE BELIEFS; CIGARETTE-SMOKING;
UNITED-STATES; YOUTH SMOKING; PREVENTION; INITIATION
AB Although media literacy represents an innovative venue for school-based antismoking programming, studies have not systematically compared student impressions of these and traditional programs. This study utilized data from a randomized trial comparing these two types of programs. After each program, students responded to three open-ended questions related to their assigned curriculum. Two coders, blinded to student assignments, independently coded these data. Coders had strong inter-rater agreement (kappa = 0.77). Our primary measures were spontaneously noted overall assessment, enjoyment/interest and the likelihood of changing smoking behavior. Of the 531 participants, 255 (48.0%) were randomized to the intervention (media literacy) group. Intervention participants had more net positive responses [rate ratio (RR) = 1.27, 95% confidence interval (CI) = 1.05, 1.54], more responses rating the program as compelling (RR = 1.63, 95% CI = 1.16, 2.29) and fewer responses rating the program as non-compelling (RR = 0.62, 95% CI = 0.39, 0.97). However, the intervention group was not more likely to suggest that the curriculum was likely to change behavior positively (RR = 0.57, 95% CI = 0.30, 1.06). Findings suggest that although media literacy provides a compelling format for the delivery of antitobacco programming, integration of components of traditional programming may help media literacy programs achieve maximal efficacy.
C1 [Primack, Brian A.; Yang, Christopher K.; Wickett, Dustin] Univ Pittsburgh, Div Gen Internal Med, Dept Med, Pittsburgh, PA 15213 USA.
[Primack, Brian A.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA.
[Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15213 USA.
[Fine, Danielle] Univ Colorado, Boulder, CO 80302 USA.
[Zickmund, Susan] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15213 USA.
RP Primack, BA (reprint author), Univ Pittsburgh, Div Gen Internal Med, Dept Med, Pittsburgh, PA 15213 USA.
EM bprimack@pitt.edu
FU NCI NIH HHS [K07 CA114315, K07-CA114315]
NR 72
TC 16
Z9 16
U1 5
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1153
J9 HEALTH EDUC RES
JI Health Educ. Res.
PD AUG
PY 2009
VL 24
IS 4
BP 608
EP 621
DI 10.1093/her/cyn062
PG 14
WC Education & Educational Research; Public, Environmental & Occupational
Health
SC Education & Educational Research; Public, Environmental & Occupational
Health
GA 469IA
UT WOS:000267888500006
PM 19052155
ER
PT J
AU Werner, RM
Konetzka, RT
Stuart, EA
Norton, EC
Polsky, D
Park, J
AF Werner, Rachel M.
Konetzka, R. Tamara
Stuart, Elizabeth A.
Norton, Edward C.
Polsky, Daniel
Park, Jeongyoung
TI Impact of Public Reporting on Quality of Postacute Care
SO HEALTH SERVICES RESEARCH
LA English
DT Article; Proceedings Paper
CT Annual Research Meeting of the Academy-Health
CT Academy Health Annual Research Meeting
CY JUN 09-10, 2008
CY JUN 08-10, 2008
CL Washington, DC
CL Washington, DC
SP Acad Hlth
SP Acad Hlth
DE Quality of care; postacute care; nursing home quality; public reporting
ID NEW-YORK-STATE; RESIDENT ASSESSMENT INSTRUMENT; ARTERY-BYPASS-SURGERY;
PROPENSITY SCORE; OF-CARE; CARDIAC-SURGERY; NURSING-HOMES; MARKET SHARE;
INFORMATION; MORTALITY
AB Objective
Evidence supporting the use of public reporting of quality information to improve health care quality is mixed. While public reporting may improve reported quality, its effect on quality of care more broadly is uncertain. This study tests whether public reporting in the setting of nursing homes resulted in improvement of reported and broader but unreported quality of postacute care.
Data Sources/Study Setting
1999-2005 nursing home Minimum Data Set and inpatient Medicare claims.
Study Design
We examined changes in postacute care quality in U.S. nursing homes in response to the initiation of public reporting on the Centers for Medicare and Medicaid Services website, Nursing Home Compare. We used small nursing homes that were not subject to public reporting as a contemporaneous control and also controlled for patient selection into nursing homes. Postacute care quality was measured using three publicly reported clinical quality measures and 30-day potentially preventable rehospitalization rates, an unreported measure of quality.
Principal Findings
Reported quality of postacute care improved after the initiation of public reporting for two of the three reported quality measures used in Nursing Home Compare. However, rates of potentially preventable rehospitalization did not significantly improve and, in some cases, worsened.
Conclusions
Public reporting of nursing home quality was associated with an improvement in most postacute care performance measures but not in the broader measure of rehospitalization.
C1 [Werner, Rachel M.] Univ Penn, Sch Med, Div Gen Internal Med, Ctr Hlth Equ Res & Promot,Philadelphia VAMC, Philadelphia, PA 19104 USA.
[Werner, Rachel M.; Polsky, Daniel] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA.
[Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
[Norton, Edward C.] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA.
[Norton, Edward C.] Univ Michigan, Dept Econ, Ann Arbor, MI 48109 USA.
RP Werner, RM (reprint author), 1230 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM rwerner@mail.med.upenn.edu
RI Norton, Edward/B-2211-2009
OI Norton, Edward/0000-0003-4555-0631; Stuart,
Elizabeth/0000-0002-9042-8611
FU AHRQ HHS [R01 HS016478, R01 HS016478-01]
NR 49
TC 59
Z9 59
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-9124
EI 1475-6773
J9 HEALTH SERV RES
JI Health Serv. Res.
PD AUG
PY 2009
VL 44
IS 4
BP 1169
EP 1187
DI 10.1111/j.1475-6773.2009.00967.x
PG 19
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 469FX
UT WOS:000267882400005
PM 19490160
ER
PT J
AU Mitchell, J
Sullam, PM
AF Mitchell, Jennifer
Sullam, Paul M.
TI Streptococcus mitis Phage-Encoded Adhesins Mediate Attachment to alpha
2-8-Linked Sialic Acid Residues on Platelet Membrane Gangliosides
SO INFECTION AND IMMUNITY
LA English
DT Article
ID SURFACE GLYCOPROTEINS GSPB; CLUMPING FACTOR-A; HAEMOPHILUS-INFLUENZAE;
INFECTIVE ENDOCARDITIS; STAPHYLOCOCCUS-AUREUS; NEISSERIA-MENINGITIDIS;
PROTEINS PBLA; IB-ALPHA; BINDING; GORDONII
AB The direct binding of bacteria to human platelets contributes to the pathogenesis of infective endocarditis. Platelet binding by Streptococcus mitis strain SF100 is mediated in part by two bacteriophage-encoded proteins, PblA and PblB. However, the platelet membrane receptor for these adhesins has been unknown. In this study, we demonstrate that these proteins mediate attachment of bacterial cells to sialylated gangliosides on the platelet cell surface. Desialylation of human platelet monolayers reduced adherence of SF100, whereas treatment of the platelets with N- or O-glycanases did not affect platelet binding. Treatment of platelets with sialidases having different linkage specificities showed that removal of alpha 2-8-linked sialic acids resulted in a marked reduction in bacterial binding. Preincubation of SF100 with ganglioside GD3, a glycolipid containing alpha 2-8-linked sialic acids that is present on platelet membranes, blocked subsequent binding of this strain to these cells. In contrast, GD3 had no effect on the residual binding of platelets by strain PS344, an isogenic Delta pblA Delta pblB mutant. Preincubating platelets with specific monoclonal antibodies to ganglioside GD3 also inhibited binding of SF100 to platelets, but again, they had no effect on binding by PS344. When the direct binding of S. mitis strains SF100 and PS344 to immobilized gangliosides was tested, binding of PS344 to GD3 was reduced by 70% compared to the parent strain. These results indicated that platelet binding by SF100 is mediated by the interaction of PblA and PblB with alpha 2-8-linked sialic acids on ganglioside GD3.
C1 San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
Univ Calif San Francisco, San Francisco, CA 94121 USA.
RP Sullam, PM (reprint author), VA Med Ctr 111W, Div Infect Dis, 4150 Clement St, San Francisco, CA 94121 USA.
EM paul.sullam@ucsf.edu
FU Department of Veterans Affairs; National Institutes of Health [R01
AI041513, R01 AI057433]
FX This study was supported by the Department of Veterans Affairs and by
grants R01 AI041513 and R01 AI057433 from the National Institutes of
Health.
NR 29
TC 21
Z9 21
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD AUG
PY 2009
VL 77
IS 8
BP 3485
EP 3490
DI 10.1128/IAI.01573-08
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 471ZX
UT WOS:000268098400040
PM 19506011
ER
PT J
AU Melrose, RJ
Campa, OM
Harwood, DG
Osato, S
Mandelkern, MA
Sultzer, DL
AF Melrose, Rebecca J.
Campa, Olivia M.
Harwood, Dylan G.
Osato, Sheryl
Mandelkern, Mark A.
Sultzer, David L.
TI The neural correlates of naming and fluency deficits in Alzheimer's
disease: an FDG-PET study
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article; Proceedings Paper
CT 12th Biennial Cognitive Aging Conference
CY APR, 2008
CL Atlanta, GA
DE Alzheimer's disease; language; naming; temporal lobe; inferior frontal
gyrus; PET imaging
ID SEMANTIC MEMORY LOSS; GLUCOSE-UTILIZATION; VERBAL FLUENCY; DEMENTIA;
LANGUAGE; IMPAIRMENT; RETRIEVAL; KNOWLEDGE; BATTERY; SYSTEMS
AB Objective To examine the neural processes associated with language deficits in Alzheimer's disease (AD), and in particular to elucidate the correlates of confrontation naming and word retrieval impairments.
Methods Sixty patients with probable AD were included. Confrontation naming was assessed using the number of words spontaneously named correctly on the Boston Naming Test. We recorded the number of additional words stated following phonemic cuing. We also assessed phonemic (FAS) and semantic (supermarket items) fluency. We then correlated performance on each measure with resting cortical metabolic activity using FDG-PET images.
Results We found that poorer ability to spontaneously name an object was associated with hypometabolism of bilateral inferior temporal lobes. In contrast, when a phonemic cue was provided, successful naming under this condition was associated with higher metabolic activity in bilateral inferior frontal gyrus (IFG), right superior frontal gyrus (SFG), left temporal, and occipital regions. Consistent with these findings, we found that poorer semantic fluency was associated with hypometabolism in regions including both IFG and temporal regions, and poorer phonemic fluency was associated with hypometabolism in only left IFG. Across analyses, measures that required cued retrieval were associated with metabolism in the left IFG, whereas measures taxing semantic knowledge were associated with metabolic rate of left temporal cortex.
Conclusions Naming deficits in AD reflect compromise to temporal regions involved in the semantic knowledge network, and frontal regions involved in the controlled retrieval of information from that network. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Melrose, Rebecca J.; Campa, Olivia M.; Harwood, Dylan G.; Osato, Sheryl; Sultzer, David L.] VA Greater Angeles Healthcare Syst, Clin Neurosci Res Lab, Los Angeles, CA USA.
[Melrose, Rebecca J.; Harwood, Dylan G.; Osato, Sheryl; Sultzer, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Mandelkern, Mark A.] VA Greater Angeles Healthcare Syst, Nucl Med Serv, Irvine, CA USA.
[Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.
RP Melrose, RJ (reprint author), 11301 Wilshire Blvd,116AE, Los Angeles, CA 90073 USA.
EM rjmelrose@ucla.edu
FU NIMH NIH HHS [MH56301, R01 MH056031-03]
NR 39
TC 33
Z9 33
U1 2
U2 7
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0885-6230
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD AUG
PY 2009
VL 24
IS 8
BP 885
EP 893
DI 10.1002/gps.2229
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 477XM
UT WOS:000268552300012
PM 19296551
ER
PT J
AU Mathalon, DH
Jorgensen, KW
Roach, BJ
Ford, JM
AF Mathalon, Daniel H.
Jorgensen, Kasper W.
Roach, Brian J.
Ford, Judith M.
TI Error detection failures in schizophrenia: ERPs and FMRI
SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY
LA English
DT Article; Proceedings Paper
CT 14th World Congress of Psychophysiology the Olympics of the Brain
CY SEP 08-13, 2008
CL St Petersburg, RUSSIA
SP Int Org Psychophysiol
DE Error detection; Schizophrenia; NoGo task; ERN; ERPs; FMRI
ID ANTERIOR CINGULATE CORTEX; EVENT-RELATED FMRI; MEDIAL FRONTAL-CORTEX;
BRAIN POTENTIALS; NEURAL SYSTEM; CORRECTING BEHAVIOR; RESPONSE
SELECTION; PERFORMANCE; DOPAMINE; TASK
AB Self-monitoring of actions, critical for guiding goal-directed behavior, is deficient in schizophrenia. Defective error-monitoring may reflect more general self-monitoring deficiencies. Prior studies have shown that the error-related negativity (ERN) component of the event-related potential (ERP) is smaller in patients with schizophrenia. Other studies using functional magnetic resonance imaging (FMRI) have shown the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC), both critical for error detection, to be less responsive to errors in patients with schizophrenia.
In the present study, both ERP and FMRI data were collected while 11 patients with schizophrenia and 10 healthy controls performed a Go-NoGo task requiring a button press to Xs (p = .88) while withholding responses to Ks (p = .12). We measured the ERN and ACC and DLPFC activations to false alarms.
The task elicited a robust ERN and modest activations in ACC and DLPFC to false alarms. As expected, ERN was larger in controls than patients. However, ACC and DLPFC activations were not greater in controls than patients. Surprisingly, DLPFC was more activated by errors in patients than controls.
ERPs may be superior to fMRI for assessing error processing abnormalities in schizophrenia because (1) ERNs can be measured precisely without needing to control for the multiple comparisons of FMRI, and (2) ERPs have the temporal precision to detect transient activity necessary for error detection and on-the-fly behavioral adjustments. Published by Elsevier B.V.
C1 San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA.
Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
RP Mathalon, DH (reprint author), San Francisco VA Med Ctr, Psychiat Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA.
EM daniel.mathalon@ucsf.edu
OI Roach, Brian/0000-0002-3264-1465; Mathalon, Daniel/0000-0001-6090-4974
FU NIMH NIH HHS [R01 MH040052, K02 MH067967, K02 MH067967-08, MH 40052, MH
58262, R01 MH058262, R01 MH058262-08A1]
NR 79
TC 29
Z9 31
U1 8
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-8760
J9 INT J PSYCHOPHYSIOL
JI Int. J. Psychophysiol.
PD AUG
PY 2009
VL 73
IS 2
BP 109
EP 117
DI 10.1016/j.ijpsycho.2009.02.005
PG 9
WC Psychology, Biological; Neurosciences; Physiology; Psychology;
Psychology, Experimental
SC Psychology; Neurosciences & Neurology; Physiology
GA 478YW
UT WOS:000268625700009
PM 19414043
ER
PT J
AU Lewis, DR
Clegg, LX
Johnson, NJ
AF Lewis, D. R.
Clegg, L. X.
Johnson, N. J.
TI Lung disease mortality in the United States: the Nationa Longitudinal
Mortality Study
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE cancer; mortality; lung diseases; health disparities; income; education
ID OBSTRUCTIVE PULMONARY-DISEASE; GLOBAL BURDEN; CANCER; SMOKING;
RACE/ETHNICITY; EPIDEMIOLOGY; DEATHS; TRENDS; AREA
AB SETTING: The National Longitudinal Mortality Study (NLMS) offers the advantage of assessing mortality in a representative population of the United States.
OBJECTIVE: To evaluate health disparities associated with lung cancer and chronic obstructive pulmonary disease (COPD) mortality in the United States and whether these associations are similar between these outcomes.
DESIGN: The NLMS is a prospective study. Data from NLMS cohort years 1985, 1992, 1993, 1995 and 1.996 were included, representing nearly 1.5 million person-years. Lung cancer and COPD mortality relative risks (RRs) from Cox regression analysis, including residential characteristics, marital status, education, health insurance and family income, were evaluated.
RESULTS: By 1998, 1273 lung cancer deaths and 772 COPD deaths occurred. Lung cancer mortality rates were approximately two times higher than COPD mortality rates among race and ethnic groups. Cox regression analysis revealed that low education (RR = 1.77, significant, P = 0.01) and low family income (RR = 1.50, significant, P = 0.01) are associated with lung cancer and COPD mortality, controlling for age, race/ethnicity, sex and smoking status.
CONCLUSIONS: COPD and lung cancer mortality have similar associations with health disparity indicators in the NLMS data, with some differences in the magnitude of the effect.
C1 [Lewis, D. R.] NCI, Surveillance Res Program, NIH, US Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Clegg, L. X.] US Dept Vet Affairs, Off Healthcare Inspect, Off Inspector Gen, Washington, DC USA.
[Johnson, N. J.] US Bur Census, Suitland, MD USA.
RP Lewis, DR (reprint author), NCI, Surveillance Res Program, NIH, US Dept Hlth & Human Serv, 6116 Execut Blvd,Room 504,MSC 8316, Bethesda, MD 20892 USA.
EM lewisde@mail.nih.gov
FU Intramural NIH HHS [Z99 CA999999]
NR 35
TC 13
Z9 13
U1 1
U2 5
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
EI 1815-7920
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD AUG
PY 2009
VL 13
IS 8
BP 1008
EP 1014
PG 7
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 477JW
UT WOS:000268516300014
PM 19723382
ER
PT J
AU Lilly, MM
Pole, N
Best, SR
Metzler, T
Marmar, CR
AF Lilly, Michelle M.
Pole, Nnamdi
Best, Suzanne R.
Metzler, Thomas
Marmar, Charles R.
TI Gender and PTSD: What can we learn from female police officers?
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Gender; PTSD; Peritraumatic distress; Police; Somatization
ID POSTTRAUMATIC-STRESS-DISORDER; SOCIAL DESIRABILITY SCALE;
SEX-DIFFERENCES; PSYCHOMETRIC PROPERTIES; TRAUMATIC EVENTS;
RISK-FACTORS; SYMPTOMS; ADULTS; METAANALYSIS; PREDICTORS
AB Studies of civilians typically find that female gender is a risk factor for posttraurnatic stress disorder (PTSD). Police and military studies often find no gender differences in PTSD. We compared 157 female police officers and 124 female civilians on several variables including trauma exposure, peritraumatic emotional distress, current somatization, and cumulative PTSD symptoms. We found that despite greater exposure to assaultive violence in the officer group, female civilians reported significantly more severe PTSD symptoms. Elevated PTSD symptoms in female civilians were explained by significantly more intense peritraurnatic emotional distress among female civilians. We also found that female officers showed a stronger direct relationship between peritraurnatic emotional distress and current somatization. Our findings suggest that apparent gender differences in PTSD may result from differences in peritraurnatic emotionality, which influence subsequent PTSD and somatization symptoms. Emotionality may be more important than biological sex in understanding gender differences in PTSD. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Lilly, Michelle M.; Pole, Nnamdi] Univ Michigan, Dept Psychol, Ann Arbor, MI USA.
[Best, Suzanne R.; Metzler, Thomas; Marmar, Charles R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Best, Suzanne R.; Metzler, Thomas; Marmar, Charles R.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Pole, N (reprint author), Smith Coll, Dept Psychol, Bass Hall, Northampton, MA 01060 USA.
EM npole@email.smith.edu
FU NIMH NIH HHS [R01 MH056350, R01 MH056350-03, R01-MH056350-01A1]
NR 68
TC 30
Z9 33
U1 2
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD AUG
PY 2009
VL 23
IS 6
BP 767
EP 774
DI 10.1016/j.janxdis.2009.02.015
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 452XL
UT WOS:000266574400006
PM 19345556
ER
PT J
AU Mani, G
Chandrasekar, B
Feldman, MD
Patel, D
Agrawal, CM
AF Mani, Gopinath
Chandrasekar, Bysani
Feldman, Marc D.
Patel, Devang
Agrawal, C. Mauli
TI Interaction of Endothelial Cells with Self-Assembled Monolayers for
Potential Use in Drug-Eluting Coronary Stents
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS
LA English
DT Article
DE stents; endothelial cells; cell-material interactions
ID TITANIUM-OXIDE SURFACES; 316L STAINLESS-STEEL; BALLOON ANGIOPLASTY;
PROTEIN ADSORPTION; ARTERY DISEASE; GOLD; FLUORESCENCE; ORIENTATION;
THROMBOSIS; BINDING
AB Drug-eluting stents (DES) are implanted in patients to treat in-stent restenosis. Commercially available DES use polymers for coating and releasing drugs. Several studies have showed that polymer coatings cause adverse reactions. Delayed endothelialization of polymer-coated DES leads to late stent thrombosis. Recently, the potential for using self-assembled monolayers (self-assembled monolayers (SAMs)-organic constructs composed of (a) chemical groups which attach to metal surfaces, (b) long hydrocarbon chains, and (c) terminal functional groups) as an alternate drug delivery system for coronary stents has been demonstrated. In this study, the interaction of human aortic endothelial cells (HAECs) with SAMs and therapeutic SAMs (therapeutic self-assembled monolayers (TSAMs)-SAMs derivatized with the drug, flufenamic acid) was investigated. HAECs were cultured on plain glass, control, SAW, and TSAMs-coated titanium (Ti) and gold (Au) specimens. The viability and proliferation of HAECs were investigated using MTT colorimetric assay. The adhesion of HAECs on SAMs and TSAMs was equivalent to that of control metal surfaces and superior to that of plain glass surfaces. The cells continued to proliferate on both SAMs and TSAMs even though the rate of proliferation was slower than plain glass or control-Ti. The spreading of HAECs on TSAMs with typical polygonal shape indicated that these surfaces are conducive to endothelialization. The expression of surface adhesion protein, platelet endothelial cell adhesion molecule-1, on TSAMs indicated that the endothelial cells preserved their phenotype on these surfaces. Thus, this study demonstrated that SAMs and TSAMs do not elicit an adverse response from endothelial cells in in vitro conditions. (C) 2009 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 90B: 789-801, 2009
C1 [Mani, Gopinath; Feldman, Marc D.; Agrawal, C. Mauli] Univ Texas San Antonio, Coll Engn, Dept Biomed Engn, San Antonio, TX 78249 USA.
[Chandrasekar, Bysani; Feldman, Marc D.; Patel, Devang] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Cardiol, San Antonio, TX 78229 USA.
[Feldman, Marc D.] Dept Vet Affairs S Texas Hlth Care Syst, San Antonio, TX 78229 USA.
RP Agrawal, CM (reprint author), Univ Texas San Antonio, Coll Engn, Dept Biomed Engn, San Antonio, TX 78249 USA.
EM Mauli.Agrawal@utsa.edu
NR 62
TC 20
Z9 20
U1 2
U2 6
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1552-4973
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD AUG
PY 2009
VL 90B
IS 2
BP 789
EP 801
DI 10.1002/jbm.b.31348
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 472FD
UT WOS:000268114200037
PM 19274726
ER
PT J
AU Miyamoto, SD
Brown, RD
Robinson, BA
Tyler, KL
Long, CS
Debiasi, RL
AF Miyamoto, Shelley D.
Brown, R. D.
Robinson, Bridget A.
Tyler, Kenneth L.
Long, Carlin S.
Debiasi, Roberta L.
TI Cardiac Cell-specific Apoptotic and Cytokine Responses to Reovirus
Infection: Determinants of Myocarditic Phenotype
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Viral myocarditis; myocytes; fibroblasts
ID LEFT-VENTRICULAR FUNCTION; VIRAL CORE PROTEINS; DILATED CARDIOMYOPATHY;
GENE-EXPRESSION; BETA-INTERFERON; IMMUNOSUPPRESSIVE THERAPY; INHIBITION
PROTECTS; MYOCYTE CULTURES; CLINICAL-TRIAL; MICE
AB Background: The pathophysiologic mechanisms underlying viral myocarditis are not well defined. As a result, effective treatments do not exist and viral myocarditis remains a potentially lethal infection of the heart.
Methods and Results: We used Cultured rat cardiac myocytes and fibroblasts to investigate apoptosis and cytokine production in response to infection by myocarditic vs. non-myocarditic strains Of reovirus. Myocarditic reovirus strain 8B and non-myocarditic strain DB188 replicate comparably ill each cardiac cell type. However, strain 8B and related myocarditic reoviruses preferentially increase apoptosis of myocytes relative to fibroblasts, whereas DB188 and nonmyocarditic strains preferentially increase fibroblast apoptosis. Infection of cardiac fibroblasts with the nonmyocarditic strain DB188 elicits, substantial increases ill a panel of cytokines compared to fibroblasts infected with strain 8B or mock-infected controls. Analysis of culture supernatants using cytometric bead arrays revealed that DB188 enhanced release of interleukin (IL)-1 beta, IL-4, IL-6, IL-10, IL-12(p70), GRO-KC, tumor necrosis factor-alpha, and MCP-1 relative to 8B or mock-infected controls (all P < .05).
Conclusion: We hypothesize that differential cytokine production and cell-specific apoptosis are important determinants of myocarditic potential of reoviral strains. Therapies that target the beneficial effects of cytokines in limiting cytopathic damage may offer an effective and novel treatment approach to viral myocarditis. (J Cardiac Fail 2009;15;529-539)
C1 [Miyamoto, Shelley D.; Robinson, Bridget A.; Debiasi, Roberta L.] Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA.
[Brown, R. D.; Tyler, Kenneth L.; Long, Carlin S.] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA.
[Tyler, Kenneth L.] Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA.
[Tyler, Kenneth L.] Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO USA.
[Debiasi, Roberta L.] George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20052 USA.
[Debiasi, Roberta L.] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Neurol Serv, Denver, CO USA.
RP Miyamoto, SD (reprint author), Childrens Hosp, 13123 E l6th Ave,B100, Aurora, CO 80045 USA.
EM Miyamoto.shelley@tchden.org
OI Tyler, Kenneth/0000-0003-3294-5888
FU Children's Hospital. Denver, CO; VA MERIT; NIH [R01 NS051403, NS050139,
HL59428, HL79160, K08 A1052261-05]
FX Supported by the Research Scholar Award. The Children's Hospital.
Denver, CO (S.M.) VA MERIT and NIH R01 NS051403 and NS050139 (K.T.) NIH
HL59428 and HL79160 (C.L.): NIH K08 A1052261-05 (R.D.).
NR 71
TC 5
Z9 5
U1 0
U2 0
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD AUG
PY 2009
VL 15
IS 6
BP 529
EP 539
DI 10.1016/j.cardfail.2009.01.004
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 482OA
UT WOS:000268897300010
PM 19643365
ER
PT J
AU Metra, M
Teerlink, JR
Weatherley, BD
Greenberg, BH
Felker, GM
Ponikowski, P
Voors, AA
Filippatos, G
Feaganes, J
Unemori, E
Teichman, SL
Cotter, G
AF Metra, Marco
Teerlink, John R.
Weatherley, Beth D.
Greenberg, Barry H.
Felker, G. Michael
Ponikowski, Piotr
Voors, Adrian A.
Filippatos, Gerasimos
Feaganes, John
Unemori, Elaine
Teichman, Sam L.
Cotter, Gad
TI Changes in Dyspnea during Treatment of Acute Heart Failure Are
Correlated with Clinical Signs. Rehospitalizations and Mortality.
Results from the Pre-RELAX-AHF Trial
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Meeting Abstract
CT 13th Annual Scientific Meeting of the Heart-Failure-Society-of-America
CY SEP 13-16, 2009
CL Boston, MA
SP Heart Failure Soc Amer
C1 [Metra, Marco] Univ Brescia, Brescia, BS, Italy.
[Teerlink, John R.] UCSF, San Francisco VAMC, San Francisco, CA USA.
[Felker, G. Michael] Duke Univ, Duke Clin Res Inst, Durham, NC USA.
[Weatherley, Beth D.; Feaganes, John; Cotter, Gad] Momentum Res Inc, Durham, NC USA.
[Greenberg, Barry H.] Univ Calif San Diego, UCSD Med Ctr, Adv Heart Failure Program, San Diego, CA 92103 USA.
[Ponikowski, Piotr] Med Univ, Mil Hosp, Dept Hlth Sci, Wroclaw, Poland.
[Voors, Adrian A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
[Unemori, Elaine; Teichman, Sam L.] Corthera Inc, San Mateo, CA USA.
[Filippatos, Gerasimos] Univ Athens, Hosp Attikon, Athens, Greece.
RI Teerlink, John/D-2986-2012; Lainscak, Mitja/F-3237-2015; Ponikowski,
Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064
NR 0
TC 1
Z9 3
U1 0
U2 0
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD AUG
PY 2009
VL 15
IS 6
SU 1
MA 203
BP S62
EP S63
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 482OC
UT WOS:000268897500202
ER
PT J
AU Teerlink, JR
Metra, M
Felker, GM
Voors, AA
Greenberg, BH
Ponikowski, P
Teichman, SL
Cotter, G
AF Teerlink, John R.
Metra, Marco
Felker, G. Michael
Voors, Adriaan A.
Greenberg, Barry H.
Ponikowski, Piotr
Teichman, Sam L.
Cotter, Gad
TI Vasodilators in Acute Heart Failure (AHF): Does Blood Pressure Matter?
Results from Pre-Relax-AHF
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Meeting Abstract
CT 13th Annual Scientific Meeting of the Heart-Failure-Society-of-America
CY SEP 13-16, 2009
CL Boston, MA
SP Heart Failure Soc Amer
C1 [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Metra, Marco] Univ Brescia, Brescia, BS, Italy.
[Felker, G. Michael] Duke Clin Res Inst, Durham, NC USA.
[Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
[Greenberg, Barry H.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Ponikowski, Piotr] Med Univ, Dept Hlth Sci, Mil Hosp, Wroclaw, Poland.
[Teichman, Sam L.] Corthera Inc, San Mateo, CA USA.
[Cotter, Gad] Momentum Res Inc, Durham, NC USA.
RI Teerlink, John/D-2986-2012; Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD AUG
PY 2009
VL 15
IS 6
SU 1
MA 243
BP S74
EP S74
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 482OC
UT WOS:000268897500241
ER
PT J
AU Eyman, D
Damodarasamy, M
Plymate, SR
Reed, MJ
AF Eyman, D.
Damodarasamy, M.
Plymate, S. R.
Reed, M. J.
TI CCL5 Secreted by Senescent Aged Fibroblasts Induces Proliferation of
Prostate Epithelial Cells and Expression of Genes that Modulate
Angiogenesis
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID GROWTH-FACTOR; TUMOR ANGIOGENESIS; PATHOLOGICAL ANGIOGENESIS; PARACRINE
INDUCER; CHEMOKINE RANTES; HYPERPLASIA; CANCER; PLEIOTROPHIN;
CCL5/RANTES; PROGRESSION
AB There is increased interest in the effects of secretory products from aged cells on promoting both benign and malignant cell growth. We identified a human fibroblast line, AG04382, from an aged donor that naturally demonstrated senescence-associated features and whose conditioned media significantly induced proliferation of benign prostatic hyperplasia (BPHI) cells. Candidate cytokines mediating this effect were identified with protein arrays and validated by ELISA. We found that the AG04382 fibroblast line secreted high levels of CXCL5, CCL5, and CCL2, but relative to the other lines, its conditioned media was unique in its increased expression of CCL5. Blocking studies using specific antibodies against CXCL5, CCL5, and CCL2 in the conditioned media of AG04382 showed that only CCL5 contributed significantly to BPHI proliferation. Stimulation of BPHI cells with rhuCCL5 resulted in increased proliferation and migration, as well as significant changes in the expression of genes that influence angiogenesis. These data suggest that CCL5 is a candidate chemokine secreted by aged cells that promotes prostate growth and regulates angiogenesis. J. Cell. Physiol. 220: 376-381, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Eyman, D.; Damodarasamy, M.; Reed, M. J.] Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA.
[Plymate, S. R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Reed, MJ (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, Harborview Res & Training Bldg 325,9th Ave, Seattle, WA 98104 USA.
EM mjr@u.washington.edu
FU NIH [U54 CA12654C, R0 AG 15887]
FX Contract grant numbers: U54 CA12654C, R0 AG 15887
NR 55
TC 16
Z9 17
U1 0
U2 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD AUG
PY 2009
VL 220
IS 2
BP 376
EP 381
DI 10.1002/jcp.21776
PG 6
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 465BG
UT WOS:000267555000013
PM 19360811
ER
PT J
AU Marcocci, C
Chanson, P
Shoback, D
Bilezikian, J
Fernandez-Cruz, L
Orgiazzi, J
Henzen, C
Cheng, SF
Sterling, LR
Lu, J
Peacock, M
AF Marcocci, Claudio
Chanson, Philippe
Shoback, Dolores
Bilezikian, John
Fernandez-Cruz, Laureano
Orgiazzi, Jacques
Henzen, Christoph
Cheng, Sunfa
Sterling, Lulu Ren
Lu, John
Peacock, Munro
TI Cinacalcet Reduces Serum Calcium Concentrations in Patients with
Intractable Primary Hyperparathyroidism
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID QUALITY-OF-LIFE; ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; SF-36 HEALTH
SURVEY; SECONDARY HYPERPARATHYROIDISM; POSTMENOPAUSAL WOMEN;
PARATHYROIDECTOMY FAILURES; CALCIMIMETIC AGENT; CONTROLLED-TRIAL;
DOUBLE-BLIND; FOLLOW-UP
AB Context: Patients with persistent primary hyperparathyroidism (PHPT) after parathyroidectomy or with contraindications to parathyroidectomy often require chronic treatment for hypercalcemia.
Objective: The objective of the study was to assess the ability of the calcimimetic, cinacalcet, to reduce serum calcium in patients with intractable PHPT.
Design: This was an open-label, single-arm study comprising a titration phase of variable duration (2-16 wk) and a maintenance phase of up to 136 wk.
Setting: The study was conducted at 23 centers in Europe, the United States, and Canada.
Patients: The study included 17 patients with intractable PHPT and serum calcium greater than 12.5 mg/dl (3.1 mmol/liter).
Intervention: During the titration phase, cinacalcet dosages were titrated every 2 wk (30 mg twice daily to 90 mg four times daily) for 16 wk until serum calcium was 10 mg/dl or less (2.5 mmol/liter). If serum calcium increased during the maintenance phase, additional increases in the cinacalcet dose were permitted.
Main Outcome Measure: The primary end point was the proportion of patients experiencing a reduction in serum calcium of 1 mg/dl or greater (0.25 mmol/liter) at the end of the titration phase.
Results: Mean +/- SD baseline serum calcium was 12.7 +/- 0.8 mg/dl (3.2 +/- 0.2 mmol/liter). At the end of titration, a 1 mg/dl or greater reduction in serum calcium was achieved in 15 patients (88%). Fifteen patients (88%) experienced treatment-related adverse events, none of which were serious. The most common adverse events were nausea, vomiting, and paresthesias.
Conclusions: In patients with intractable PHPT, cinacalcet reduces serum calcium, is generally well tolerated, and has the potential to fulfill an unmet medical need. (J Clin Endocrinol Metab 94: 2766-2772, 2009)
C1 [Marcocci, Claudio] Univ Pisa, Dept Endocrinol & Metab, I-56124 Pisa, Italy.
[Chanson, Philippe] Univ Paris 11, F-94275 Le Kremlin Bicetre, France.
[Chanson, Philippe] Hop Bicetre, APHP, Dept Endocrinol & Reprod Dis, F-94275 Le Kremlin Bicetre, France.
[Shoback, Dolores] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Shoback, Dolores] San Francisco VA Med Ctr, Endocrine Res Unit, San Francisco, CA 94143 USA.
[Bilezikian, John] Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA.
[Fernandez-Cruz, Laureano] Univ Barcelona, E-08028 Barcelona, Spain.
[Orgiazzi, Jacques] Univ Lyon 1, Ctr Hosp Lyon Sud, Serv Endocrinol Diabetol, F-69495 Pierre Benite, France.
[Henzen, Christoph] Endokrinol Diabetol Kantonsspital, Luzern, Switzerland.
[Cheng, Sunfa; Sterling, Lulu Ren; Lu, John] Amgen Inc, Thousand Oaks, CA 91320 USA.
[Peacock, Munro] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
RP Marcocci, C (reprint author), Univ Pisa, Dept Endocrinol & Metab, Via Paradisa 2, I-56124 Pisa, Italy.
EM c.marcocci@endoc.med.unipi.it
RI Chanson, Philippe/F-8511-2013
FU Amgen Inc; Amgen Europe; Antonia Panayi
FX Disclosure Summary: C. M., J. B., L. F.-C., J. O., and C. H. have
nothing to declare. P. C. has received a research grant from and
consults for Amgen. D. S. is a consultant for Amgen and a speaker for
Novartis, and has received honoraria from both. S. C., L. R. S., and J.
L. are employed by Amgen. M. P. is a consultant for Amgen, Deltanoid,
Genzyme, and Kirin.
NR 33
TC 62
Z9 64
U1 0
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD AUG
PY 2009
VL 94
IS 8
BP 2766
EP 2772
DI 10.1210/jc.2008-2640
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 479UW
UT WOS:000268687700014
PM 19470620
ER
PT J
AU Mitra, J
Glover, JR
Ktonas, PY
Kumar, AT
Mukherjee, A
Karayiannis, NB
Frost, JD
Hrachovy, RA
Mizrahi, EM
AF Mitra, Joyeeta
Glover, John R.
Ktonas, Periklis Y.
Kumar, Arun Thitai
Mukherjee, Amit
Karayiannis, Nicolaos B.
Frost, James D., Jr.
Hrachovy, Richard A.
Mizrahi, Eli M.
TI A Multistage System for the Automated Detection of Epileptic Seizures in
Neonatal Electroencephalography
SO JOURNAL OF CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE EEG; Neonatal; Epileptic; Seizure; Detection; Automated
ID WAVELET TRANSFORM; EEG; ALGORITHM; INFANTS
AB This paper describes the design and test results of it three-stage automated system for neonatal EEG seizure detection. Stage I of the system is the initial detection stage and identifies overlapping 5-second segments of suspected seizure activity in each EEG channel. In stage II, the detected segments from stage I are spatiotemporally clustered to produce multichannel candidate Seizures. In stage III, the candidate seizures are processed further using measures of quality and context-based rules to eliminate false candidates. False candidates because of artifacts and commonly Occurring EEG background patterns such as bifrontal delta activity are also rejected. Seizures at least 10 seconds in duration are considered for reporting results. The testing data consisted of recordings of 28 seizure Subjects (34 hours of data) and 48 nonseizure subjects (87 hours of data) obtained in the neonatal intensive care unit. The data were not edited to remove artifacts and were identical in every way to data normally processed visually. The system was able to detect seizures Of widely varying morphology with an average detection sensitivity of almost 80% and a subject sensitivity of 96%, in comparison with a team of clinical neurophysiologists who had scored the same recordings. The average false detection rate obtained in nonseizure subjects was 0.74 per hour.
C1 [Glover, John R.; Ktonas, Periklis Y.; Karayiannis, Nicolaos B.] Univ Houston, Dept Elect & Comp Engn, Houston, TX 77204 USA.
[Mitra, Joyeeta] Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA USA.
[Kumar, Arun Thitai] Univ Texas MD Anderson Canc Ctr, Dept Expt Diagnost Imaging, Houston, TX 77030 USA.
[Mukherjee, Amit] Rensselaer Polytech Inst, ECSE Dept, Troy, NY USA.
[Frost, James D., Jr.] Baylor Coll Med, Dept Neurol, Peter Kellaway Sect Neurophysiol, Houston, TX 77030 USA.
[Hrachovy, Richard A.; Mizrahi, Eli M.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA.
[Hrachovy, Richard A.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
RP Glover, JR (reprint author), Univ Houston, Dept Elect & Comp Engn, N308 Engn Bldg 1, Houston, TX 77204 USA.
EM glover@uh.edu
FU National Institutes of Health [R01-NS40577]
FX Supported by National Institutes of Health grant R01-NS40577.
NR 16
TC 36
Z9 36
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0736-0258
J9 J CLIN NEUROPHYSIOL
JI J. Clin. Neurophysiol.
PD AUG
PY 2009
VL 26
IS 4
BP 218
EP 226
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 480OQ
UT WOS:000268746000002
PM 19602985
ER
PT J
AU Fox, BD
Smitherman, SM
Amhaz, H
Ruiz, MI
Rouah, E
Radaideh, M
Ehni, BL
AF Fox, Benjamin D.
Smitherman, Sheila M.
Amhaz, Hassan
Ruiz, Monica I.
Rouah, Emilie
Radaideh, Majdi
Ehni, Bruce L.
TI A supratentorial, hemorrhagic, intraparenchymal epidermoid cyst
SO JOURNAL OF CLINICAL NEUROSCIENCE
LA English
DT Article
DE Epidermoid cyst; Hemorrhage; Intraparenchymal; Supratentorial; Tumor
ID CENTRAL-NERVOUS-SYSTEM; TUMORS CHOLESTEATOMAS; POSTERIOR-FOSSA;
PATHOGENESIS
AB Epidermoid cysts are Slow growing benign tumors that represent < 1-2% of all intracranial tumors and rarely present as supratentorial, intraparenchymal masses. We present the first report of a supratentorial, hemorrhagic, intraparenchymal epidermoid cyst with its presentation. our operative approach, postoperative course, radiographic features, and a literature review. Published by Elsevier Ltd.
C1 [Fox, Benjamin D.; Smitherman, Sheila M.; Ehni, Bruce L.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
[Amhaz, Hassan] Baylor Coll Med, Off Student Affairs, Houston, TX 77030 USA.
[Rouah, Emilie; Radaideh, Majdi; Ehni, Bruce L.] Michael E Debakey Vet Affairs Med Ctr, Houston, TX USA.
[Ruiz, Monica I.; Rouah, Emilie] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.
[Radaideh, Majdi] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA.
RP Ehni, BL (reprint author), Baylor Coll Med, Dept Neurosurg, 1709 Dryden Rd,Suite 750, Houston, TX 77030 USA.
EM bruce.ehni@va.gov
NR 28
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0967-5868
J9 J CLIN NEUROSCI
JI J. Clin. Neurosci.
PD AUG
PY 2009
VL 16
IS 8
BP 1101
EP 1105
DI 10.1016/j.jocn.2008.04.033
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 478SG
UT WOS:000268608000033
PM 19428259
ER
PT J
AU Anton, RF
Myrick, H
Baros, AM
Latham, PK
Randall, PK
Wright, TM
Stewart, SH
Waid, R
Malcolm, R
AF Anton, Raymond F.
Myrick, Hugh
Baros, Alicia M.
Latham, Patricia K.
Randall, Patrick K.
Wright, Tara M.
Stewart, Scott H.
Waid, Randy
Malcolm, Robert
TI Efficacy of a Combination of Flumazenil and Gabapentin in the Treatment
of Alcohol Dependence Relationship to Alcohol Withdrawal Symptoms
SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
LA English
DT Article
DE alcoholism; treatment; flumazenil; gabapentin; alcohol withdrawal
ID CHRONIC INTERMITTENT ETHANOL; GAMMA-AMINOBUTYRIC-ACID; DOUBLE-BLIND;
GABA(A) RECEPTORS; CONTROLLED-TRIAL; GENE-EXPRESSION; OPEN-LABEL;
PLACEBO; SCALE; PHARMACOLOGY
AB Improved treatment of alcohol dependence is a high priority, including defining subtypes that might respond differently. We evaluated a medication combination of intravenous flumazenil (FMZ) and oral gabapentin (GBP) in alcoholics who did and did not exhibit pretreatment alcohol withdrawal (AW) symptoms. Sixty alcohol-dependent individuals (44 with low AW and 16 with high AW) were randomized to receive FMZ (2 mg of incremental bolus for 20 minutes for 2 consecutive days) and GBP (up to 1200 mg nightly for 39 days) or their inactive placebos. Alcohol withdrawal was measured for the first 2 days, and drinking, sleep parameters, and adverse events were monitored during weekly evaluations, along with behavioral counseling sessions. Percent days abstinent (PDA) during treatment and time to first heavy drinking (TFHD) day were primary outcome variables. There was an interaction between the pretreatment AW status and the medication group on PDA (P = 0.0006) and TFHD (P = 0.06). Those in the high AW group had more PDA and more TFHD if treated with active medications, whereas those in the low AW group had more PDA and more TFHD if treated with placebo. This interaction remained for those totally abstinent (P = 0.03) and was confirmed by percent carbohydrate-deficient transferrin values. In addition, the pattern of response remained up to 8 weeks after treatment. In addition, in those with high AW, greater improvement in AW symptoms was observed in the active medication group compared with the placebo group. These results suggest a differential response to FMZ/GBP treatment, depending on pretreatment AW status that should be taken into account during future treatment trials.
C1 [Anton, Raymond F.; Myrick, Hugh; Baros, Alicia M.; Latham, Patricia K.; Randall, Patrick K.; Wright, Tara M.; Stewart, Scott H.; Waid, Randy; Malcolm, Robert] Med Univ S Carolina, Charleston, SC 29425 USA.
[Myrick, Hugh; Wright, Tara M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Anton, RF (reprint author), Med Univ S Carolina, MSC 861,67 President St, Charleston, SC 29425 USA.
EM antonr@musc.edu
FU Hythiam, Inc.
FX This study was conducted under air unrestricted grant from Hythiam, Inc.
NR 48
TC 31
Z9 31
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0271-0749
J9 J CLIN PSYCHOPHARM
JI J. Clin. Psychopharmacol.
PD AUG
PY 2009
VL 29
IS 4
BP 334
EP 342
DI 10.1097/JCP.0b013e3181aba6a4
PG 9
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA 470QX
UT WOS:000267995200004
PM 19593171
ER
PT J
AU Hall, YN
Rodriguez, RA
Boyko, EJ
Chertow, GM
O'Hare, AM
AF Hall, Yoshio N.
Rodriguez, Rudolph A.
Boyko, Edward J.
Chertow, Glenn M.
O'Hare, Ann M.
TI Characteristics of Uninsured Americans with Chronic Kidney Disease
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE chronic kidney disease; uninsured; risk factors; end-stage renal
disease; race-ethnicity
ID STAGE RENAL-DISEASE; JOINT NATIONAL COMMITTEE; HIGH BLOOD-PRESSURE; 7TH
REPORT; OUTCOMES; PROGRESSION; RISK; MEN; POPULATION; PREVENTION
AB In the United States, public health insurance is available for nearly all persons with end-stage renal disease (ESRD). Little is known about the extent of health insurance coverage for persons with non-dialysis dependent chronic kidney disease (CKD).
To describe patterns of health insurance coverage for adults with non-dialysis dependent CKD and to examine risk factors for progression of CKD to ESRD and management of hypertension among those lacking insurance.
Cross-sectional analysis of data from a nationally representative sample of 16,148 US adults aged 20 years or older who participated in the National Health and Nutrition Examination Survey 1999-2006.
National prevalence estimates of health insurance coverage, ESRD risk factors, and treatment of hypertension.
An estimated 10.0% (95% CI, 8.3%-12.0%) of US adults with non-dialysis dependent CKD were uninsured, 60.9% (95% CI, 58.2%-63.7%) had private insurance and 28.7% (95% CI, 26.4%-31.1%) had public insurance alone. Uninsured persons with non-dialysis dependent CKD were more likely to be under the age of 50 (62.8% vs. 23.0%, P < 0.001) and nonwhite (58.7%, vs. 21.8%, P < 0.001) compared with their insured counterparts. Approximately two-thirds of uninsured adults with non-dialysis dependent CKD had at least one modifiable risk factor for CKD progression, including 57% with hypertension, 40% who were obese, 22% with diabetes, and 13% with overt albuminuria. In adjusted analyses, uninsured persons with non-dialysis dependent CKD were less likely to be treated for their hypertension (OR, 0.59; 95% CI, 0.40-0.85) and less likely to be receiving recommended therapy with angiotensin inhibitors (OR, 0.45; 95% CI, 0.26-0.77) compared with those with insurance coverage.
Uninsured persons with non-dialysis dependent CKD are at higher risk for progression to ESRD than their insured counterparts but are less likely to receive recommended interventions to slow disease progression. Lack of public health insurance for patients with non-dialysis dependent CKD may result in missed opportunities to slow disease progression and thereby reduce the public burden of ESRD.
C1 [Hall, Yoshio N.; Rodriguez, Rudolph A.; Boyko, Edward J.; O'Hare, Ann M.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Hall, Yoshio N.; Rodriguez, Rudolph A.; Boyko, Edward J.; O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA USA.
[Chertow, Glenn M.] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA.
RP Hall, YN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM ynhall@u.washington.edu
OI Boyko, Edward/0000-0002-3695-192X
FU Satellite Healthcare's Norman S. Coplon [N01-DK-75007-01,
U01-DK066481-05]; [K23-AG-028980-02]
FX Dr. Hall received support from Satellite Healthcare's Norman S. Coplon
extramural grant program. Dr. Chertow received support from
N01-DK-75007-01 and U01-DK066481-05. Dr. O'Hare received support from
K23-AG-028980-02. The findings and conclusions in this report are those
of the authors and do not represent the views of the US government.
NR 33
TC 20
Z9 22
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD AUG
PY 2009
VL 24
IS 8
BP 917
EP 922
DI 10.1007/s11606-009-1028-3
PG 6
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 471PC
UT WOS:000268069500005
PM 19506974
ER
PT J
AU Niu, N
Laufer, T
Homer, RJ
Cohn, L
AF Niu, Naiqian
Laufer, Terri
Homer, Robert J.
Cohn, Lauren
TI Cutting Edge: Limiting MHC Class II Expression to Dendritic Cells Alters
the Ability to Develop Th2-Dependent Allergic Airway Inflammation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID T-CELLS; IN-VIVO; MICE; RESPONSES; CYTOKINE; ANTIGEN;
HYPERRESPONSIVENESS; BASOPHILS; IMMUNITY; DISEASE
AB In allergic airway inflammation, dendritic cells (DCs) are required for Th2 generation, recruitment, and activation in the respiratory tract. DCs have been shown to be necessary and sufficient for the induction of Th1 immune responses. In Th2 immunity and allergic airway inflammation, the ability of a DC to function as the sole APC has not been tested. We show that CD11c/A(beta)(b) mice with MHC class II expression restricted to CD11c-expressing DCs develop airway neutrophilia rather than allergic airway inflammation. Although CD11c/A(beta)(b) mice are capable of Th2 recruitment and activation in the lung, Th2 priming in CD11c/A(beta)(b) mice results in IFN-gamma production. Effective Th2 generation and allergic airway inflammation was achieved in CD11c/A(beta)(b) mice after treatment with anti-IFN-gamma. These studies show that DCs alone cannot drive the development of Th2 cells but require an additional MHC class II signal to stimulate effective Th2 immunity. The Journal of Immunology, 2009, 183: 1523-1527.
C1 [Niu, Naiqian; Cohn, Lauren] Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA.
[Homer, Robert J.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA.
[Laufer, Terri] Univ Penn, Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA.
[Laufer, Terri] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA 19104 USA.
RP Cohn, L (reprint author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, 333 Cedar St,POB 208057, New Haven, CT 06520 USA.
EM lauren.cohn@yale.edu
FU National Institutes of Health [ROI-64040]
FX This work was supported by National Institutes of Health Grant ROI-64040
(to L.C.) and the Seltzer Family Translational Research Fund (to L.C.).
NR 25
TC 12
Z9 12
U1 1
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD AUG 1
PY 2009
VL 183
IS 3
BP 1523
EP 1527
DI 10.4049/jimmunol.0901349
PG 5
WC Immunology
SC Immunology
GA 477LB
UT WOS:000268519500006
PM 19596982
ER
PT J
AU Guan, SX
Fan, JH
Han, A
Chen, M
Woodley, DT
Li, W
AF Guan, Shengxi
Fan, Jianhua
Han, Arum
Chen, Mei
Woodley, David T.
Li, Wei
TI Non-Compensating Roles between Nck alpha and Nck beta in PDGF-BB
Signaling to Promote Human Dermal Fibroblast Migration
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE CELLS; SH2/SH3 ADAPTERS; ACTIN
POLYMERIZATION; KINASE ACTIVATION; KIDNEY PODOCYTES; PROTEIN;
PHOSPHORYLATION; INTERACTS; MECHANISM
AB Platelet-derived growth factor BB (PDGF-BB) is a Food and Drug Administration (FDA)-approved growth factor, acting as a mitogen and motogen of dermal fibroblasts (DFs), for skin wound healing. The two closely related SH2/SH3 adapter proteins, Nck alpha and Nck beta, connect PDGF-BB signaling to the actin cytoskeleton and cell motility. The mechanism has not been fully understood. In this study, we investigated, side by side, the roles of Nck alpha and Nck beta in PDGF-BB-stimulated DF migration. We found that cells expressing the PDGFR beta-Y751F mutant (preventing Ncka binding) or PDGFR beta-Y1009F mutant (preventing Nckb binding), DF cells isolated from Nck alpha- or Nck beta-knockout mice, and primary human DF cells with RNA interference (RNAi) knockdown of the endogenous Nck alpha or Nck beta all failed to migrate in response to PDGF-BB. Overexpression of the middle SH3 domain of Nck alpha or Nck beta alone in human DFs also blocked PDGF-BB-induced cell migration. However, neither Ncka nor Nck beta was required for the activation of the PDGF receptor, p21-activated protein kinase (Pak1), AKT, extracellular signal-regulated kinase (ERK) 1/2, or p38MAP by PDGF-BB. Although PDGF-BB stimulated the membrane translocation of both Nck alpha and Nck beta, Nck alpha appeared to mediate Cdc42 signaling for filopodium formation, whereas Nck beta mediated Rho signaling to induce stress fibers. Thus, this study has elucidated the independent roles and mechanisms of action of Nck alpha and Nck beta in DF migration, which is critical for wound healing.
C1 [Li, Wei] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Dermatol, Los Angeles, CA 90033 USA.
[Fan, Jianhua; Chen, Mei; Woodley, David T.; Li, Wei] Greater Los Angles Vet Adm Hlth Syst, Los Angeles, CA USA.
RP Li, W (reprint author), Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Dermatol, 1441 Eastlake Ave Rd, Los Angeles, CA 90033 USA.
EM wli@usc.edu
FU National Institutes of Health [GM/AR67100-01]
FX We thank Tony Pawson for Nck alpha+/- and Nck
beta+/- mice and Jonathon Cooper for TRUMP cells expressing
the PDGFR mutants. This study was supported by the National Institutes
of Health Grant GM/AR67100-01 (to W. L.).
NR 57
TC 9
Z9 9
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD AUG
PY 2009
VL 129
IS 8
BP 1909
EP 1920
DI 10.1038/jid.2008.457
PG 12
WC Dermatology
SC Dermatology
GA 479FC
UT WOS:000268644100011
PM 19242519
ER
PT J
AU Opel, DJ
Wilfond, BS
Brownstein, D
Diekema, DS
Pearlman, RA
AF Opel, D. J.
Wilfond, B. S.
Brownstein, D.
Diekema, D. S.
Pearlman, R. A.
TI Characterisation of organisational issues in paediatric clinical ethics
consultation: a qualitative study
SO JOURNAL OF MEDICAL ETHICS
LA English
DT Article; Proceedings Paper
CT 10th Annual Meeting of the American-Society-for-Bioethics-and-Humanities
CY 2008
CL Cleveland, OH
SP Amer Soc Bioethics & Humanities
AB Background: The traditional approach to resolving ethics concerns may not address underlying organisational issues involved in the evolution of these concerns. This represents a missed opportunity to improve quality of care "upstream''. The purpose of this study was to understand better which organisational issues may contribute to ethics concerns.
Methods: Directed content analysis was used to review ethics consultation notes from an academic children's hospital from 1996 to 2006 (N = 71). The analysis utilised 18 categories of organisational issues derived and modified from published quality improvement protocols.
Results: Organisational issues were identified in 68 of the 71 (96%) ethics consult notes across a range of patient settings and reasons for consultation. Thirteen of the 18 categories of organisational issues were identified and there was a median of two organisational issues per consult note. The most frequently identified organisational issues were informal organisational culture (eg, collective practices and approaches to situations with ethical dimensions that are not guided by policy), policies and procedures (eg, staff knows policy and/or procedural guidelines for an ethical concern but do not follow it) and communication (eg, communication about critical information, orders, or hand-offs repeatedly does not occur among services).
Conclusions: Organisational issues contribute to ethical concerns that result in clinical ethics consults. Identifying and addressing organisational issues such as informal culture and communication may help decrease the recurrence of future similar ethics concerns.
C1 [Opel, D. J.; Wilfond, B. S.; Diekema, D. S.] Seattle Childrens Hosp, Treuman Katz Ctr Pediat Bioeth, Seattle, WA USA.
[Pearlman, R. A.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Opel, D. J.; Wilfond, B. S.; Brownstein, D.; Diekema, D. S.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA.
[Pearlman, R. A.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
RP Opel, DJ (reprint author), Metropolitan Pk W,M-S MPW 8-2,1100 Olive Way,Suit, Seattle, WA 98101 USA.
EM djopel@u.washington.edu
NR 32
TC 3
Z9 3
U1 1
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-6800
J9 J MED ETHICS
JI J. Med. Ethics
PD AUG
PY 2009
VL 35
IS 8
BP 477
EP 482
DI 10.1136/jme.2008.027896
PG 6
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
Biomedical Social Sciences
GA 477HB
UT WOS:000268508700007
PM 19644005
ER
PT J
AU Levin, H
Wilde, E
Troyanskaya, M
Petersen, N
Scheibel, R
AF Levin, Harvey
Wilde, Elisabeth
Troyanskaya, Maya
Petersen, Nancy
Scheibel, Randall
TI DIFFUSION TENSOR IMAGING OF MILD TO MODERATE BLAST RELATED TBI IN
RELATION TO POST-CONCUSSION AND POSTTRAUMATIC STRESS DISORDER SYMPTOMS
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 2nd Joint Symposium of the
National-and-International-Neurotrauma-Societies
CY SEP 07-11, 2009
CL Santa Barbara, CA
SP Natl & Int Neurotrauma Soc
C1 [Levin, Harvey; Wilde, Elisabeth; Troyanskaya, Maya; Scheibel, Randall] Baylor Coll Med, Houston, TX 77030 USA.
[Petersen, Nancy] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD AUG
PY 2009
VL 26
IS 8
MA P267
BP A69
EP A69
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 479AF
UT WOS:000268629900287
ER
PT J
AU Wallis, RA
Panizzon, K
AF Wallis, Roi Ann
Panizzon, Kimberly
TI TREATMENT WITH BCL-2(20-34) PROVIDES LONG-TERM PROTECTION AGAINST THE
DECREASED SEIZURE THRESHOLD OF CA1 HIPPOCAMPAL NEURONS AFTER CONTROLLED
CORTICAL IMPACT
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 2nd Joint Symposium of the
National-and-International-Neurotrauma-Societies
CY SEP 07-11, 2009
CL Santa Barbara, CA
SP Natl & Int Neurotrauma Soc
C1 [Panizzon, Kimberly] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Wallis, Roi Ann] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD AUG
PY 2009
VL 26
IS 8
MA P243
BP A63
EP A63
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 479AF
UT WOS:000268629900263
ER
PT J
AU Fromme, EK
Rosenfeld, KE
Brokaw, FC
Hughes, MT
Arnold, RM
AF Fromme, Erik K.
Rosenfeld, Kenneth E.
Brokaw, Francis C.
Hughes, Mark T.
Arnold, Robert M.
TI Update in Palliative Medicine
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Review
ID PAIN CLINICAL-TRIALS; IMMPACT RECOMMENDATIONS
C1 [Fromme, Erik K.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA.
[Rosenfeld, Kenneth E.] VA Greater Angeles Healthcare Syst, Palliat Care Sect, Div Gen Med, Los Angeles, CA USA.
[Brokaw, Francis C.] Dartmouth Hitchcock Med Ctr, Div Gen Internal Med, Lebanon, NH 03766 USA.
[Hughes, Mark T.] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA.
[Arnold, Robert M.] Univ Pittsburgh, Sect Palliat Care & Med Eth, Div Gen Internal Med, Pittsburgh, PA USA.
RP Fromme, EK (reprint author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, L586 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM frommee@ohsu.edu
FU National Cancer Institute [K07CA109511]
FX Dr. Fromme is supported by a Career Development Award from the National
Cancer Institute K07CA109511. Six of these papers were presented at the
Society of General Internal Medicine 31st Annual Meeting on April 12,
2008 in Pittsburgh, Pennsylvania.
NR 5
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD AUG
PY 2009
VL 12
IS 8
BP 731
EP 736
DI 10.1089/jpm.2009.0019
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 480XG
UT WOS:000268770000016
ER
PT J
AU McCloskey, MS
New, AS
Siever, LJ
Goodman, M
Koenigsberg, HW
Flory, JD
Coccaro, EF
AF McCloskey, Michael S.
New, Antonia S.
Siever, Larry J.
Goodman, Marianne
Koenigsberg, Harold W.
Flory, Janine D.
Coccaro, Emil F.
TI Evaluation of behavioral impulsivity and aggression tasks as
endophenotypes for borderline personality disorder
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Borderline personality disorder; Endophenotype; Aggression; Impulsivity
ID INTERMITTENT EXPLOSIVE DISORDER; AXIS-II DISORDERS; DSM-IV CRITERIA;
RESPONSE-INHIBITION; PREFRONTAL CORTEX; BIPOLAR DISORDER;
SELF-MUTILATION; TRAITS; SCHIZOPHRENIA; PREVALENCE
AB Borderline personality disorder (BIRD) is marked by aggression and impulsive, often self-destructive behavior. Despite the severe risks associated with BPD, relatively little is known about the disorder's etiology. Identification of genetic correlates (endophenotypes) of BPD would improve the prospects of targeted interventions for more homogeneous subsets of borderline patients characterized by specific genetic vulnerabilities. The current study evaluated behavioral measures of aggression and impulsivity as potential endophenotypes for BPD. Subjects with BPD (N = 127), a non cluster B personality disorder (OPD N = 122), or healthy volunteers (HV N = 112) completed self report and behavioral measures of aggression, motor impulsivity and cognitive impulsivity. Results showed that BPD subjects demonstrated more aggression and motor impulsivity than HV (but not OPD) subjects on behavioral tasks. In contrast, BPD subjects self-reported more impulsivity and aggression than either comparison group. Subsequent analyses showed that among BPD subjects behavioral aggression was associated with self-reported aggression, while behavioral and self-report impulsivity measures were more modestly associated. Overall I, the results provide partial support for the use of behavioral measures of aggression and motor impulsivity as endophenotypes for BPD, with stronger support for behavioral aggression measures as an endophenotype for aggression within BPD samples. (c) 2009 Elsevier Ltd. All rights reserved.
C1 [McCloskey, Michael S.; Coccaro, Emil F.] Univ Chicago, Pritzker Sch Med, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA.
[New, Antonia S.; Siever, Larry J.; Goodman, Marianne; Koenigsberg, Harold W.] Mt Sinai Sch Med, Psychiat Serv, Bronx, NY 10468 USA.
[New, Antonia S.; Siever, Larry J.; Goodman, Marianne; Koenigsberg, Harold W.] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Flory, Janine D.] CUNY Queens Coll, Dept Psychol, Flushing, NY 11367 USA.
RP McCloskey, MS (reprint author), Univ Chicago, Pritzker Sch Med, Dept Psychiat & Behav Neurosci, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM mmcclosk@yoda.bsd.uchicago.edu
FU national institute of health (NIH) [RO1 MH63875]; Veterans
Administration (VA); Borderline Personality Disorder Research Foundation
(Siever, Coccaro); VA (MERIT award, New)
FX The authors would like to thank Bing Chen and Shauna Weinstein for their
invaluable assistance with data management and analysis. Funding for
this study was provided by the Borderline Personality Disorder Research
Foundation (Siever, Coccaro), VA (MERIT award, New) and the NIH (RO1
MH63875, Siever).
NR 97
TC 47
Z9 48
U1 4
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD AUG
PY 2009
VL 43
IS 12
BP 1036
EP 1048
DI 10.1016/j.jpsychires.2009.01.002
PG 13
WC Psychiatry
SC Psychiatry
GA 487JS
UT WOS:000269269900006
PM 19232640
ER
PT J
AU Pratt, SR
Kuller, L
Talbott, EO
McHugh-Pemu, K
Buhari, AM
Xu, XH
AF Pratt, Sheila R.
Kuller, Lewis
Talbott, Evelyn O.
McHugh-Pemu, Kathleen
Buhari, Alhaji M.
Xu, Xiaohui
TI Prevalence of Hearing Loss in Black and White Elders: Results of the
Cardiovascular Health Study
SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH
LA English
DT Article
DE hearing loss; aging; gender; race
ID OLDER-ADULTS; OTOACOUSTIC EMISSIONS; STRIA VASCULARIS; SEX-DIFFERENCES;
POSTMENOPAUSAL WOMEN; CIGARETTE-SMOKING; ACOUSTIC TRAUMA; RISK-FACTORS;
GUINEA-PIGS; AID USE
AB Purpose: The goal of this study was to determine the impact of age, gender, and race on the prevalence and severity of hearing loss in elder adults, aged 72-96 years, after accounting for income, education, smoking, and clinical and subclinical cardiovascular disease.
Methods: Air-conduction thresholds for standard and extended high-frequency pure-tones were obtained from a cohort of 548 (out of 717) elderly adults (ages 72-96 years) who were recruited during the Year 11 clinical visit (1999-2000) of the Cardiovascular Health Study (CHS) at the Pittsburgh, Pennsylvania site. Participant smoking, income, education, and cardiovascular disease histories were obtained from the CHS database and were included as factors.
Results: Hearing loss was more common and more severe for the participants in their 80s than for those in their 70s-the men more than the women and the White participants more than the Black participants. The inclusion of education, income, smoking, and cardiovascular disease (clinical and subclinical) histories as factors did not substantively impact the overall results.
Conclusion: Although the data reported in this article were cross-sectional and a cohort phenomenon might have been operational, they suggested that hearing loss is more substantive in the 8th than the 7th decade of life and that race and gender influence this decline in audition. Given the high prevalence in the aging population and the differences across groups, there is a clear need to understand the nature and causes of hearing loss across various groups in order to improve prevention and develop appropriate interventions.
C1 [Pratt, Sheila R.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA.
[Pratt, Sheila R.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
RP Pratt, SR (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorders, 4033 Forbes Tower, Pittsburgh, PA 15260 USA.
EM spratt@pitt.edu
RI Pratt, Sheila/H-7139-2013
OI Talbott, Evelyn/0000-0002-5198-7939
FU NHLBI NIH HHS [N01 HC015103, N01 HC035129, N01 HC085086, N01-HC-85079,
N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084,
N01-HC-85085, N01-HC-85086, N01HC085082, N01HC85079, N01HC85082,
N01HC85086]
NR 86
TC 15
Z9 18
U1 2
U2 6
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA
SN 1092-4388
J9 J SPEECH LANG HEAR R
JI J. Speech Lang. Hear. Res.
PD AUG
PY 2009
VL 52
IS 4
BP 973
EP 989
DI 10.1044/1092-4388(2009/08-0026)
PG 17
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA 476JB
UT WOS:000268434900012
PM 19380605
ER
PT J
AU Bauman, WA
Zhang, RL
Morrison, N
Spungen, AM
AF Bauman, William A.
Zhang, Run-Lin
Morrison, Nancy
Spungen, Ann M.
TI Acute Suppression of Bone Turnover With Calcium Infusion in Persons With
Spinal Cord Injury
SO JOURNAL OF SPINAL CORD MEDICINE
LA English
DT Article
DE Immobilization; Tetraplegia; Paraplegia; Vitamin D; Calcium; Parathyroid
hormone; N-telopeptide; Bone resorption; Osteoporosis
ID VITAMIN-D SUPPLEMENTATION; LOWER-EXTREMITY FRACTURES;
PARATHYROID-HORMONE; ANTICONVULSANT THERAPY; POSTMENOPAUSAL WOMEN;
ELDERLY-WOMEN; D METABOLISM; AGE; DENSITY; MEN
AB Background: Some people with chronic spinal cord injury (SCI) have low vitamin D levels and secondary hyperparathyroidism.
Objective: To determine whether, and to what extent, an acute calcium infusion decreased levels of N-telopeptide (NTx), a marker of osteoclastic activity, in individuals with chronic SCI.
Study Design: Case series.
Subjects: Eight men with chronic SCI. A relatively low serum 25 hydroxyvitamin D concentration (25[ OH] D <= 20 ng/mL) and/or a high parathyroid hormone (PTH) (> 55 pg/mL) was a prerequisite for study inclusion.
Methods: Calcium gluconate bolus 0.025 mmol elemental calcium/kg over 20 minutes followed by a constant infusion of 0.025 mmol/kg per hour for 6 hours was infused; blood samples were collected every 2 hours for measurement of serum total calcium, creatinine, NTx, and PTH.
Results: All results are expressed as means (+/- SDs). Baseline serum 25-hydroxyvitamin D level was 14.5 +/- 3.5 ng/mL (range: 10.2-19.6 ng/mL); PTH, 70 +/- 25 pg/mL (range: 37-100 pg/mL); and NTx, 21 +/- 7 nM bone collagen equivalents (BCE) (range: 14-34 nM). At 2, 4, and 6 hours after the calcium infusion, serum calcium rose from 9.3 +/- 0.2 to 10.8 +/- 0.9, 10.5 +/- 0.8, and 10.6 +/- 0.6 mg/d; PTH was suppressed from 70 +/- 25 pg/mL to 18 +/- 12, 16 +/- 9, and 15 +/- 9 pg/mL, respectively; NTx fell from 21 +/- 8 nM BCE to 17 +/- 5, 12 +/- 4, and 12 +/- 3 nM BCE, respectively.
Conclusions: Serum NTx is a marker for bone collagen catabolism, and its reduction suggests that bone turnover was decreased. A relative deficiency of vitamin D associated with chronically elevated levels of PTH would be expected to increase bone turnover and to worsen the bone loss associated with immobilization.
C1 [Bauman, William A.] James J Peters Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Med & Res Serv, Bronx, NY 10468 USA.
[Bauman, William A.; Zhang, Run-Lin; Spungen, Ann M.] James J Peters Med Ctr, Vet Affairs Rehabil Res & Dev Ctr Excellence, Bronx, NY 10468 USA.
[Bauman, William A.; Zhang, Run-Lin; Spungen, Ann M.] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA.
[Bauman, William A.; Zhang, Run-Lin; Spungen, Ann M.] Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA.
RP Bauman, WA (reprint author), James J Peters Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Med & Res Serv, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM william.bauman@va.gov
FU Department of Veterans Affairs; Center of Excellence for the Medical
Consequences of Spinal Cord Injury [B4162C]; United Spinal Association;
James J. Peters Veterans Affairs Medical Center, Bronx, NY
FX This work was supported by the Department of Veterans Affairs
Rehabilitation Research and Development (RR&D) Service, the Center of
Excellence for the Medical Consequences of Spinal Cord Injury (B4162C),
United Spinal Association, and the James J. Peters Veterans Affairs
Medical Center, Bronx, NY.
NR 36
TC 8
Z9 9
U1 0
U2 0
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 1079-0268
EI 2045-7723
J9 J SPINAL CORD MED
JI J. Spinal Cord. Med.
PD AUG
PY 2009
VL 32
IS 4
BP 398
EP 403
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA V16HX
UT WOS:000207861800005
PM 19777860
ER
PT J
AU Weinstock, MA
Lee, KC
Chren, MM
Marcolivio, K
AF Weinstock, Martin A.
Lee, Kachiu C.
Chren, Mary-Margaret
Marcolivio, Kimberly
CA VATTC Trial Grp
TI Quality of life in the actinic neoplasia syndrome: The VA Topical
Tretinoin Chemoprevention (VATTC) Trial
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
ID NONMELANOMA SKIN-CANCER; SUN SENSITIVITY; INDEX; PREDICTORS; CARCINOMA;
MORTALITY; DISEASES; THERAPY; SCALE
AB Background: Keratinocyte carcinomas (KCs) are the most common malignancies of the skin. As lesions have a low mortality rate, understanding quality-of-life (QoL) factors is necessary in their management.
Objective. To assess QoL and associated patient characteristics in those with a history of keratinocyte carcinomas.
Methods. We conducted a cross-sectional Study of veterans with a history of KCs enrolled in a randomized controlled trial for chemoprevention of keratinocyte carcinomas. Study dermatologists Counted actinic keratoses (AKs) and assessed for skin photodamage. QoL was assessed using Skindex-29 and KC-specific questions. Demographics were self-reported.
Results: Participants (n = 931) enrolled at 5 clinical sites had worse QoL on all subscales (emotions, functioning, and symptoms) compared to a reference group of patients without skin disease. Univariate analysis demonstrated worse QoL associated with higher AK count, past 5-fluorouracil (5-FU) use, and greater Sun sensitivity. Multivariate analysis demonstrated that higher AK count and past 5-FU use were independently related to diminished QoL. Higher comorbidities showed modest associations on the symptoms and functioning subscales. Number of previous KCs was not independently associated with any QoL differences.
Limitations: Study Population may not be generalizable to the general population. Counting of AKs is of limited reliability. Previous 5-FU use is self reported.
Conclusions: A history Of ever use Of 5-FU and present AKs was strongly associated with worse QoL. We find it more useful to consider these patients as having the chronic condition "actinic neoplasia syndrome," whose burden may be best measured by factors other than their history of KCs. (J Am Acad Dermatol 2009;61:207-15.)
C1 [Weinstock, Martin A.; Lee, Kachiu C.; Marcolivio, Kimberly] Vet Adm Med Ctr, Dermatoepidemiol Unit, Providence, RI 02908 USA.
[Weinstock, Martin A.] Rhode Isl Hosp, Dept Dermatol, Providence, RI USA.
[Weinstock, Martin A.] Brown Univ, Dept Community Hlth, Providence, RI 02912 USA.
[Lee, Kachiu C.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Chren, Mary-Margaret] Univ Calif San Francisco, Dermatol Serv, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
RP Weinstock, MA (reprint author), Vet Adm Med Ctr, Dermatoepidemiol Unit, 830 Chalkstone Ave,Med Serv 111D, Providence, RI 02908 USA.
EM maw@brown.edu
FU VA Cooperative Studies Program [402]; Office of Research and
Development, Department of Veterans Affairs; American Cancer Society;
OrthoNeutrogena division of Ortho-McNeil Pharmaceutical, Inc.; National
Institutes of Health [R01CA106592, R01CA106807, R25CA087972,
R01AR49342]; National Institute of Arthritis and Musculoskeletal and
Skin Diseases, National Institutes of Health [K24-AR052667]
FX This trial was supported by the VA Cooperative Studies Program
(CSP#402), Office of Research and Development, Department of Veterans
Affairs. Additional support was received from the American Cancer
Society. The study medication was donated by the OrthoNeutrogena
division of Ortho-McNeil Pharmaceutical, Inc. Dr Weinstock is also
supported by grants R01CA106592, R01CA106807, R25CA087972, and
R01AR49342 from the National Institutes of Health. Dr Chren's work is
supported by a Midcareer Investigator Award (K24-AR052667) from the
National Institute of Arthritis and Musculoskeletal and Skin Diseases,
National Institutes of Health.
NR 22
TC 28
Z9 28
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD AUG
PY 2009
VL 61
IS 2
BP 207
EP 215
DI 10.1016/j.jaad.2009.02.022
PG 9
WC Dermatology
SC Dermatology
GA 480ZH
UT WOS:000268775500003
PM 19398145
ER
PT J
AU Framson, C
Kristal, AR
Schenk, JM
Littman, AJ
Zeliadt, S
Benitez, D
AF Framson, Celia
Kristal, Alan R.
Schenk, Jeannette M.
Littman, Alyson J.
Zeliadt, Steve
Benitez, Denise
TI Development and Validation of the Mindful Eating Questionnaire
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION
LA English
DT Article
ID SELF-REPORT; MEDITATION; SCALE
AB "Mindful eating" describes a nonjudgmental awareness of physical and emotional sensations associated with eating. This article reports the development of a mindful eating questionnaire (MEQ) to support rigorous scientific inquiry into this concept. An item pool was developed based on hypothesized domains of mindful eating. A cross-sectional survey examined associations of MEQ scores with demographic and health-related characteristics. The MEQ was distributed to seven convenience samples between January and May 2007, with an overall response rate of 62% (n = 303). Participants were mostly women (81%) and white (90%), and had a mean age of 42 +/- 14.4 years (range 18 to 80 years). Exploratory factor analysis was used to identify factors, which were defined as the mean of items scored one to four, where four indicated higher mindfulness; the mean of all factors was the summary MEQ score. Multiple regression analysis was used to measure associations of demographic characteristics, obesity, yoga practice, and physical activity with MEQ scores. Domains of the final 28-item questionnaire were: disinhibition, awareness, external cues, emotional response, and distraction. The mean MEQ score was 2.92 +/- 0.37, with a reliability (Chronbach's alpha) of .64. The covariate-adjusted MEQ score was inversely associated with body mass index (3.02 for body mass index <25 vs 2.54 for body mass index >30, P<0.001). Yoga practice, but neither walking nor moderate/intense physical activity, was associated with higher MEQ score. In this study sample, the MEQ had good measurement characteristics. Its negative association with body mass index and positive association with yoga provide evidence of construct validity. Further evaluation in more diverse populations is warranted. J Am Diet Assoc. 2009;109:1439-1444.
C1 [Framson, Celia] Seattle Childrens Hosp, Seattle, WA USA.
[Framson, Celia; Kristal, Alan R.] Univ Washington, Interdisciplinary Program Nutr Sci, Seattle, WA 98195 USA.
[Kristal, Alan R.; Schenk, Jeannette M.; Littman, Alyson J.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA.
[Schenk, Jeannette M.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
[Littman, Alyson J.] Epidemiol Res & Informat Ctr, Dept Vet Affairs, Seattle, WA USA.
[Zeliadt, Steve] VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA.
[Benitez, Denise] Seattle Yoga Arts, Seattle, WA USA.
RP Kristal, AR (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,M4 B402,POB 19024, Seattle, WA 98109 USA.
EM akristal@fhcre.org
OI Kristal, Alan/0000-0002-7329-1617
FU institutional new development programs at the Fred Hutchinson Cancer
Research Center
FX Funding for this study was provided by institutional new development
programs at the Fred Hutchinson Cancer Research Center, through the
Nutrition Assessment Shared Resource and Cancer Prevention Program.
NR 18
TC 54
Z9 55
U1 5
U2 30
PU AMER DIETETIC ASSOC
PI CHICAGO
PA 216 W JACKSON BLVD #800, CHICAGO, IL 60606-6995 USA
SN 0002-8223
J9 J AM DIET ASSOC
JI J. Am. Diet. Assoc.
PD AUG
PY 2009
VL 109
IS 8
BP 1439
EP 1444
DI 10.1016/j.jada.2009.05.006
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 480AD
UT WOS:000268702800020
PM 19631053
ER
PT J
AU Huang, AJ
Subak, LL
Thom, DH
Van den Eeden, SK
Ragins, AI
Kuppermann, M
Shen, H
Brown, JS
AF Huang, Alison J.
Subak, Leslee L.
Thom, David H.
Van den Eeden, Stephen K.
Ragins, Arona I.
Kuppermann, Miriam
Shen, Hui
Brown, Jeanette S.
TI Sexual Function and Aging in Racially and Ethnically Diverse Women
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article; Proceedings Paper
CT 40th Annual Meeting of the American-Association-for-Cancer-Education
CY OCT 12-14, 2006
CL San Diego, CA
SP Amer Assoc Canc Educ
DE female sexual function; aging; race; ethnicity; sexual activity
ID SELF-RATED HEALTH; URINARY-INCONTINENCE; POSTMENOPAUSAL WOMEN; OLDER
WOMEN; DYSFUNCTION; HORMONES; IMPACT; CARE
AB OBJECTIVES
To examine factors influencing sexual activity and functioning in racially and ethnically diverse middle-aged and older women.
DESIGN
Cross-sectional cohort study.
SETTING
Integrated healthcare delivery system.
PARTICIPANTS
One thousand nine hundred seventy-seven women aged 45 to 80.
MEASUREMENTS
Self-administered questionnaires assessed sexual desire, activity, satisfaction, and problems.
RESULTS
Of the 1,977 participants (876 white, 388 African American, 347 Latina, and 351 Asian women), 43% reported at least moderate sexual desire, and 60% had been sexually active in the previous 3 months. Half of sexually active participants (n=969) described their overall sexual satisfaction as moderate to high. Among sexually inactive women, the most common reason for inactivity was lack of interest in sex (39%), followed by lack of a partner (36%), physical problem of partner (23%), and lack of interest by partner (11%); only 9% were inactive because of personal physical problems. In multivariable analysis, African-American women were more likely than white women to report at least moderate desire (odds ratio (OR)=1.65, 95% confidence interval (CI)=1.25-2.17) but less likely to report weekly sexual activity (OR=0.68, 95% CI=0.48-0.96); sexually active Latina women were more likely than white women to report at least moderate sexual satisfaction (OR=1.75, 95% CI=1.20-2.55).
CONCLUSION
A substantial proportion of community-dwelling women remain interested and engaged in sexual activity into older age. Lack of a partner capable of or interested in sex may contribute more to sexual inactivity than personal health problems in this population. Racial and ethnic differences in self-reported sexual desire, activity, and satisfaction may influence discussions about sexual difficulties in middle-aged and older women.
C1 [Huang, Alison J.; Shen, Hui] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Huang, Alison J.; Kuppermann, Miriam] Univ Calif San Francisco, Med Effectiveness Res Ctr Diverse Populat, San Francisco, CA 94143 USA.
[Subak, Leslee L.; Kuppermann, Miriam; Brown, Jeanette S.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
[Subak, Leslee L.; Kuppermann, Miriam; Brown, Jeanette S.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Subak, Leslee L.; Brown, Jeanette S.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA.
[Thom, David H.] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.
[Van den Eeden, Stephen K.; Ragins, Arona I.] Kaiser Permanente, Div Res, Oakland, CA USA.
[Shen, Hui] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Huang, AJ (reprint author), 1635 Div St,Ste 600, San Francisco, CA 94115 USA.
EM ahuang@ucsfmed.org
FU NCRR NIH HHS [KL2 RR024130]; NIDDK NIH HHS [K24 DK080775, R01 DK053335,
P50 DK064538-067114, P50 DK064538, DK53335]
NR 25
TC 28
Z9 32
U1 0
U2 6
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD AUG
PY 2009
VL 57
IS 8
BP 1362
EP 1368
DI 10.1111/j.1532-5415.2009.02353.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 477QH
UT WOS:000268533100004
PM 19558473
ER
PT J
AU Bean-Mayberry, B
Yano, EM
Mor, MK
Bayliss, NK
Xu, XY
Fine, MJ
AF Bean-Mayberry, Bevanne
Yano, Elizabeth M.
Mor, Maria K.
Bayliss, Nichole K.
Xu, Xiangyan
Fine, Michael J.
TI Does Sex Influence Immunization Status for Influenza and Pneumonia in
Older Veterans?
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE immunizations; preventive health services; women; veterans; elderly
ID WOMENS HEALTH-CARE; ELDERLY-PEOPLE; VACCINATION; QUALITY; SYSTEM;
INNOVATION; DELIVERY; CLINICS
AB OBJECTIVES
To compare the prevalence of influenza and pneumococcal immunization rates according to sex in a national sample of older veterans in the Department of Veterans Affairs (VA) healthcare system.
DESIGN
Retrospective, cross-sectional.
SETTING
VA healthcare system.
PARTICIPANTS
Current VA healthcare system users aged 65 and older eligible for immunization in fiscal years 2001 to 2003 (N=48,424 patient records).
MEASUREMENTS
Generalized estimating equations were performed to analyze combined chart review and administrative data to determine effect of sex on receipt of influenza and pneumococcal immunizations.
RESULTS
Unadjusted immunization rates were higher for men than women for influenza (73% vs 69%) and pneumococcal (87% vs 83%) vaccine. Adjusting for demographics, clinical comorbidities, use, and region, women had significantly lower odds of influenza (odds ratio (OR)=0.85, 95% confidence interval (CI=0.79-0.92) and pneumococcal (OR=0.77, 95% CI=0.71-0.84) immunization.
CONCLUSION
Older female veterans have lower rates of immunization than older male veterans in VA settings. Although VA remains above community levels for immunization, older female veterans will benefit from targeted efforts to increase immunization prevalence.
C1 [Bean-Mayberry, Bevanne] VA Greater Angeles HSR&D Ctr Excellence, Sepulveda Ambulatory Care Ctr & Nursing Home, Ctr Study Hlth Care Provider Behav, Sepulveda, CA 91343 USA.
[Bean-Mayberry, Bevanne] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA.
[Yano, Elizabeth M.] Univ Calif Los Angeles, Dept Hlth Serv, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Mor, Maria K.; Bayliss, Nichole K.; Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Bayliss, Nichole K.] Univ Pittsburgh, Dept Sociol, Pittsburgh, PA USA.
[Xu, Xiangyan] Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA.
[Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA.
RP Bean-Mayberry, B (reprint author), VA Greater Angeles HSR&D Ctr Excellence, Sepulveda Ambulatory Care Ctr & Nursing Home, Ctr Study Hlth Care Provider Behav, 16111 Plummer St, Sepulveda, CA 91343 USA.
EM bevanne.bean-mayberry@va.gov
FU VA Career Development Award; VA Health Services Research and Development
Services (HSR&D) Research Career Development Award [RCD-02-039];
National Institutes of Allergy and Infectious Disease [K24-AIO1769]; VA
HSR&D Research Career Scientist Award [RCS 05-195]; VA Investigator
Initiated Research [IIR 04-036]
FX Conflict of Interest: All of the authors are employed by the VA. This
work is supported by a VA Career Development Award to the principal
investigator (Bean-Mayberry). None of the authors have a personal or
potential conflict of interest in the design, analyses, interpretation
of results, or the development of this research. Dr. Bean-Mayberry is
funded by a VA Health Services Research and Development Services (HSR&D)
Research Career Development Award (RCD-02-039), Dr. Fine was supported
in part by a Mid-Career Development Award (K24-AIO1769) from the
National Institutes of Allergy and Infectious Disease, and Dr. Yano was
supported in part by a VA HSR&D Research Career Scientist Award (RCS
05-195) and in part by a VA Investigator Initiated Research Grant (IIR
04-036).
NR 30
TC 14
Z9 14
U1 0
U2 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD AUG
PY 2009
VL 57
IS 8
BP 1427
EP 1432
DI 10.1111/j.1532-5415.2009.02316.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 477QH
UT WOS:000268533100012
PM 19515114
ER
PT J
AU Federman, AD
Sano, M
Wolf, MS
Siu, AL
Halm, EA
AF Federman, Alex D.
Sano, Mary
Wolf, Michael S.
Siu, Albert L.
Halm, Ethan A.
TI Health Literacy and Cognitive Performance in Older Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE health literacy; cognition; older adults
ID MENTAL-STATE-EXAMINATION; VERBAL FLUENCY; IMPAIRMENT; PREVALENCE;
MORTALITY; EDUCATION; EXAMPLE; DISEASE; AGE
AB OBJECTIVES
To study the relationship between health literacy and memory and verbal fluency in older adults.
DESIGN
Cross-sectional cohort.
SETTING
Twenty senior centers and apartment buildings in New York, New York.
PARTICIPANTS
Independently living, English- and Spanish-speaking adults aged 60 and older (N=414).
MEASUREMENTS
Health literacy was measured using the Short Test of Functional Health Literacy in Adults (S-TOFHLA). The associations between S-TOFHLA scores and immediate and delayed recall (Wechsler Memory Scale II), verbal fluency (Animal Naming), and global cognitive function (Mini-Mental State Examination, MMSE) were modeled using multivariable logistic and linear regression.
RESULTS
Health literacy was inadequate in 24.3% of participants. Impairment of immediate recall occurred in 20.4%; delayed recall, 15.0%; verbal fluency, 9.9%; and MMSE, 17.4%. Abnormal cognitive function was strongly associated with inadequate health literacy: immediate recall (adjusted odds ratio (AOR)=3.44, 95% confidence interval (CI)=1.71-6.94, P <.001), delayed recall (AOR=3.48, 95% CI=1.58-7.67, P=.002), and verbal fluency (AOR=3.47, 95% CI=1.44-8.38, P=.006). These associations persisted in subgroups that excluded individuals with normal age-adjusted MMSE scores.
CONCLUSION
Memory and verbal fluency are strongly associated with health literacy, independently of education and health status, even in those with subtle cognitive dysfunction. Reducing the cognitive burden of health information might mitigate the detrimental effects of limited health literacy in older adults. Research that examines the effect of materials modified to older adults' cognitive limitations on health literacy and health outcomes is needed.
C1 [Federman, Alex D.] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA.
[Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Siu, Albert L.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA.
[Sano, Mary; Siu, Albert L.] Bronx Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Wolf, Michael S.] Northwestern Univ, Hlth Literacy & Learning Program, Div Gen Internal Med, Chicago, IL 60611 USA.
[Halm, Ethan A.] Univ Texas Dallas, Div Gen Internal Med, Dallas, TX 75230 USA.
RP Federman, AD (reprint author), Mt Sinai Sch Med, Div Gen Internal Med, 1 Gustave L Levy Pl,Box 1087, New York, NY 10029 USA.
EM alex.federman@mssm.edu
FU National Institute on Aging [1K23AG028955-01]; Robert Wood Johnson
Generalist Physician Faculty Scholars Program; Veterans Affairs Health
Services Research and Development Service; Mount Sinai School of
Medicine Alzheimer's Disease Research Center [NIH AG0051318]
FX This study was supported by a Paul B. Beeson Career Development Award in
Aging from the National Institute on Aging (Dr. Federman,
1K23AG028955-01). Dr. Federman received additional support from the
Robert Wood Johnson Generalist Physician Faculty Scholars Program during
the period of data collection. Dr. Siu is supported by a Mid-career
Investigator Award in Patient-oriented Research from the National
Institute on Aging. Additional support was provided by the Veterans
Affairs Health Services Research and Development Service to the Bronx
Veterans Affairs Medical Center Program of Research on Serious Physical
and Mental Illness and the Mount Sinai School of Medicine Alzheimer's
Disease Research Center (NIH AG0051318).
NR 30
TC 52
Z9 54
U1 2
U2 9
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD AUG
PY 2009
VL 57
IS 8
BP 1475
EP 1480
DI 10.1111/j.1532-5415.2009.02347.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 477QH
UT WOS:000268533100020
PM 19515101
ER
PT J
AU DeLisser, HM
Keirns, CC
Clinton, EA
Margolis, ML
AF DeLisser, Horace M.
Keirns, Carla C.
Clinton, Esther A.
Margolis, Mitchell L.
TI "The Air Got to It:" Exploring a Belief About Surgery for Lung Cancer
SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
LA English
DT Article
DE lung; cancer; surgery; cultural competence; health disparities; folk
beliefs
ID POSITRON-EMISSION-TOMOGRAPHY; MICROMETASTATIC TUMOR-CELLS; STAGE-I;
AFRICAN-AMERICANS; THORACOSCOPIC RESECTION; BRONCHOGENIC-CARCINOMA;
RACIAL DISPARITY; BONE-MARROW; HEALTH-CARE; METASTASIS
AB Background: The belief that exposure of lung cancer to air during surgery causes tumor spread is prevalent but poorly understood.
Purpose: The purpose of the study was to summarize the published literature on the potential historical origins of this belief, study the recurrence rates of surgically treated stage I non-small cell lung cancer, research the mechanisms by which surgery might promote tumor growth and metastasis, and examine the social and cultural implications of this belief.
Data Sources: Various databases, reference lists, and expert contacts were the sources of data.
Findings: Although the origin of this belief is ooscure, Its emergence may have been due to early debates within the medical community about the risks of lung biopsies, the significant surgical morbidity initially associated with thoracic surgery, and the difficulty early on of staging lung cancer patients before surgery. Approximately one-third of patients undergoing curative surgery for stage I lung cancer experience a recurrence of the tumor. Most recurrences are detected in the first 24 months after resection and likely reflect the presence of undetected, occult metastases at the time of surgery. Mechanisms by which surgery could promote tumor growth and worsen prognosis include direct seeding of tumor at local sites, tumor manipulation, stimulation of subclinical tumor by postsurgical inflammation, and accelerated metastatic tumor growth due to loss of inhibitory factors derived from the primary tumor. These beliefs are more likely to be prevalent, and resistant to change, in minority and disadvantaged groups.
Conclusions: These findings provide the basis for an approach to patients who fear the spread of their cancer by surgery.
C1 [DeLisser, Horace M.] Univ Penn, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA.
[Keirns, Carla C.] Univ Michigan, Div Gen Med, Ann Arbor, MI 48109 USA.
[Clinton, Esther A.] Bowling Green State Univ, Dept Popular Culture, Bowling Green, OH 43403 USA.
[Margolis, Mitchell L.] Philadelphia Vet Affairs Med Ctr, Pulm Sect, Philadelphia, PA USA.
RP DeLisser, HM (reprint author), Univ Penn, Pulm Allergy & Crit Care Div, SVM Hill Pavil,Rm 410B,380 S Univ Ave, Philadelphia, PA 19104 USA.
EM delisser@mail.med.upenn.edu
FU National Institutes of Health [K07HLO7921]; Veterans Administration
Center for Health Equity and Promotion [72-011]
FX This paper was supported by funding from the National Institutes of
Health (K07HLO7921, to HMD) and the Veterans Administration Center for
Health Equity and Promotion (LIP 72-011, to MLM).
NR 83
TC 12
Z9 12
U1 0
U2 1
PU NATL MED ASSOC
PI WASHINGON
PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA
SN 0027-9684
J9 J NATL MED ASSOC
JI J. Natl. Med. Assoc.
PD AUG
PY 2009
VL 101
IS 8
BP 765
EP 771
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 482PJ
UT WOS:000268900900004
PM 19715038
ER
PT J
AU Chu, D
Bakaeen, FG
AF Chu, Danny
Bakaeen, Faisal G.
TI IMPACT OF MULTIPLE GRAFTS TO EACH MYOCARDIAL TERRITORY ON LONG-TERM
SURVIVAL Reply
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Letter
ID REVASCULARIZATION
C1 [Chu, Danny; Bakaeen, Faisal G.] Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Chu, D (reprint author), Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD AUG
PY 2009
VL 138
IS 2
BP 513
EP 514
DI 10.1016/j.jtcvs.2009.04.013
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 472UM
UT WOS:000268157800045
ER
PT J
AU Pipavath, SNJ
Schmidt, RA
Takasugi, JE
Godwin, JD
AF Pipavath, Sudhakar N. J.
Schmidt, Rodney A.
Takasugi, Julie E.
Godwin, J. David
TI Chronic Obstructive Pulmonary Disease: Radiology-Pathology Correlation
SO JOURNAL OF THORACIC IMAGING
LA English
DT Article
DE emphysema; high-resolution computed tomography; bronchitis; secondary
pulmonary lobule
ID RESOLUTION COMPUTED-TOMOGRAPHY; EMPHYSEMA; CT; LUNG; STANDARDS; RITALIN
AB Chronic obstructive pulmonary disease is defined as a preventable and treatable disease state characterized by airflow limitation that is not fully reversible. This review will discuss the relevant anatomy of the secondary pulmonary lobule, the subtypes of emphysema, and their imaging appearances and corresponding pathologic findings.
C1 [Pipavath, Sudhakar N. J.; Godwin, J. David] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA.
[Schmidt, Rodney A.] Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA.
[Takasugi, Julie E.] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA USA.
RP Godwin, JD (reprint author), Univ Washington, Med Ctr, Dept Radiol, Box 357115,1959 NE Pacific St, Seattle, WA 98195 USA.
EM godwin@u.washington.edu
NR 25
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0883-5993
J9 J THORAC IMAG
JI J. Thorac. Imaging
PD AUG
PY 2009
VL 24
IS 3
BP 171
EP 180
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 489AK
UT WOS:000269391600004
PM 19704320
ER
PT J
AU Jakupcak, M
Cook, J
Imel, Z
Fontana, A
Rosenheck, R
McFall, M
AF Jakupcak, Matthew
Cook, Jessica
Imel, Zac
Fontana, Alan
Rosenheck, Robert
McFall, Miles
TI Posttraumatic Stress Disorder as a Risk Factor for Suicidal Ideation in
Iraq and Afghanistan War Veterans
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID VIETNAM VETERANS; US VETERANS; SCALE; MODEL
AB Posttraumatic stress disorder (PTSD) was examined as a risk factor for suicidal ideation in Iraq and Afghanistan War veterans (N = 407) referred to Veterans Affairs mental health care. The authors also examined if risk for suicidal ideation was increased by the presence of comorbid mental disorders in veterans with PTSD. Veterans who screened positive for PTSD were more than 4 times as likely to endorse suicidal ideation relative to non-PTSD veterans. Among veterans who screened positive for PTSD (n = 202), the risk for suicidal ideation was 5.7 times greater in veterans who screened positive for two or more comorbid disorders relative to veterans with PTSD only. Findings are relevant to identifying risk for suicide behaviors in Iraq and Afghanistan War veterans.
C1 [Jakupcak, Matthew; Cook, Jessica; Imel, Zac; McFall, Miles] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA.
[Jakupcak, Matthew; Cook, Jessica; McFall, Miles] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Imel, Zac] Univ Wisconsin, Dept Counseling Psychol, Madison, WI USA.
[Fontana, Alan; Rosenheck, Robert] VA Natl Ctr PTSD, NEPEC, West Haven, CT USA.
[Fontana, Alan; Rosenheck, Robert] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
RP Jakupcak, M (reprint author), Puget Sound Hlth Care Syst, Deployment Hlth Clin, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM matthew.jakupcak@va.gov
OI imel, zachary/0000-0001-9645-7184
NR 13
TC 127
Z9 127
U1 0
U2 11
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD AUG
PY 2009
VL 22
IS 4
BP 303
EP 306
DI 10.1002/jts.20423
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 489AH
UT WOS:000269391300007
PM 19626682
ER
PT J
AU Banez, LL
Sun, L
Trock, BJ
Han, M
Partin, AW
Aronson, WJ
Terris, MK
Presti, JC
Kane, CJ
Amling, CL
Moul, JW
Freedland, SJ
AF Banez, Lionel L.
Sun, Leon
Trock, Bruce J.
Han, Misop
Partin, Alan W.
Aronson, William J.
Terris, Martha K.
Presti, Joseph C., Jr.
Kane, Christopher J.
Amling, Christopher L.
Moul, Judd W.
Freedland, Stephen J.
TI Body Mass Index and Prostate Specific Antigen as Predictors of Adverse
Pathology and Biochemical Recurrence After Prostatectomy
SO JOURNAL OF UROLOGY
LA English
DT Article
DE prostate; prostatic neoplasms; obesity; prostate-specific antigen;
hemodilution
ID RADICAL PROSTATECTOMY; CANCER; OBESITY; MEN; PSA; RISK; ASSOCIATION;
MORTALITY; PROGRESSION; POPULATION
AB Purpose: Preoperative prostate specific antigen is widely used to predict unfavorable pathological features and biochemical relapse after radical prostatectomy. Recent reports that hemodilution may be responsible for lower prostate specific antigen in obese men led to concerns that prostate specific antigen may be less effective for prognosticating in men with increased body mass index. We determined whether the clinical usefulness of prostate specific antigen is negatively impacted by obesity by examining its operating characteristics and predictive accuracy as a function of body mass index.
Materials and Methods: We performed a multicenter retrospective analysis of the records of 11,705 men who underwent radical prostatectomy from 1988 to 2007 from Veterans Affairs hospitals of the Shared Equal Access Regional Cancer Hospital Database, the Duke Prostate Center and Johns Hopkins Hospital. ROC curve analysis, the concordance index and the test for interaction were used to compare the ability of prostate specific antigen to predict unfavorable tumor characteristics and biochemical recurrence across body mass index categories.
Results: There were no significant differences in the area under ROC curves across increasing body mass index categories for prostate specific antigen to predict pathological Gleason sum (7 or greater, 7 [4 + 3] or greater, or 8 or greater), positive surgical margins, extracapsular extension or seminal vesicle invasion in all 3 cohorts. There was no significant difference in prostate specific antigen accuracy to predict biochemical failure across increasing body mass index categories.
Conclusions: In 3 cohorts of men treated with radical prostatectomy the ability of preoperative prostate specific antigen to predict adverse pathological features and posttreatment biochemical recurrence is not significantly affected by obesity. However, adjusting for obesity related hemodilution may still be required to properly interpret prostate specific antigen results in men with increased body mass index.
C1 [Banez, Lionel L.; Sun, Leon; Moul, Judd W.; Freedland, Stephen J.] Duke Univ, Med Ctr, Div Urol Surg, Dept Surg, Durham, NC 27710 USA.
[Banez, Lionel L.; Sun, Leon; Moul, Judd W.; Freedland, Stephen J.] Duke Univ, Med Ctr, Duke Prostate Ctr, Durham, NC 27710 USA.
[Freedland, Stephen J.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
[Banez, Lionel L.; Freedland, Stephen J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA.
[Trock, Bruce J.; Han, Misop; Partin, Alan W.] Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD 21205 USA.
[Aronson, William J.] Univ Calif Los Angeles, Sch Med, Urol Sect, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
[Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA.
[Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA.
[Kane, Christopher J.] Vet Affairs Med Ctr, Urol Sect, San Diego, CA 92161 USA.
[Kane, Christopher J.] Univ Calif San Diego, Dept Urol, San Diego, CA 92103 USA.
[Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA.
[Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA.
[Amling, Christopher L.] Univ Alabama, Urol Sect, Vet Affairs Med Ctr, Birmingham, AL USA.
[Amling, Christopher L.] Univ Alabama, Dept Urol, Birmingham, AL USA.
RP Banez, LL (reprint author), Duke Univ, Med Ctr, Div Urol Surg, Dept Surg, Box 2626,MSRB I,Suite 455,571 Res Dr, Durham, NC 27710 USA.
EM lionel.banez@duke.edu
OI Terris, Martha/0000-0002-3843-7270
FU NCI NIH HHS [P50 CA58236, P50 CA92131-01A1, R01CA100938]
NR 27
TC 14
Z9 14
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD AUG
PY 2009
VL 182
IS 2
BP 491
EP 496
DI 10.1016/j.juro.2009.04.007
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 468UW
UT WOS:000267850300029
PM 19524974
ER
PT J
AU Bergman, J
Gore, JL
Pension, DF
Kwan, L
Litwin, MS
AF Bergman, Jonathan
Gore, John L.
Pension, David F.
Kwan, Lorna
Litwin, Mark S.
TI Erectile Aid Use by Men Treated for Localized Prostate Cancer
SO JOURNAL OF UROLOGY
LA English
DT Article
DE penis; prostatic neoplasms; erectile dysfunction; penile erection;
sildenafil
ID QUALITY-OF-LIFE; RADICAL PROSTATECTOMY; DYSFUNCTION; SURVIVORS;
BRACHYTHERAPY; RADIATION; EVOLUTION; AMERICAN; OUTCOMES; THERAPY
AB Purpose: We evaluated associations between demographic and clinical characteristics, quality of life outcome measures and erectile aids in men treated for localized prostate cancer.
Materials and Methods: Patients had clinically localized prostate cancer, were not using erectile aids at baseline and chose treatment with radical prostatectomy (275), external beam radiotherapy (70) or brachytherapy (80). Patient characteristics and health related quality of life outcomes were prospectively assessed at baseline and at regular intervals up to 48 months after treatment. Outcomes were assessed with SF-36 (TM), the American Urological Association symptom index and UCLA-PCI. We categorized use of a phosphodiesterase type 5 inhibitor, urethral alprostadil suppositories, penile injection therapy or a vacuum erection device after treatment as erectile aid use. We created a multivariate model examining baseline demographic, clinical and health related quality of life covariates associated with erectile aid use.
Results: Of the 425 patients 237 (56%) used an erectile aid at some point during the posttreatment period. In our multivariate model patients treated with external beam radiation were less likely to use an aid (OR 0.34, 95% CI 0.16-0.69) and men with significant sexual bother (OR 2.68, 95% CI 1.37-5.23), or with 1 or more comorbidities (OR 1.80, 95% CI 1.08-2.93) were more likely to use an aid. Patient demographic characteristics were not associated with erectile aids.
Conclusions: After treatment for localized prostate cancer more than half of men use erectile aids, especially when they are significantly bothered by dysfunction. This is most pronounced after radical prostatectomy and in men with significant comorbidity.
C1 [Bergman, Jonathan; Gore, John L.; Litwin, Mark S.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA.
[Litwin, Mark S.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA 90095 USA.
[Kwan, Lorna; Litwin, Mark S.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Gore, John L.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90095 USA.
[Gore, John L.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Pension, David F.] Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90033 USA.
RP Bergman, J (reprint author), Univ Calif Los Angeles, Dept Urol, Box 951738, Los Angeles, CA 90095 USA.
EM jbergman@mednet.ucla.edu
OI Gore, John/0000-0002-2847-5062
NR 20
TC 20
Z9 20
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD AUG
PY 2009
VL 182
IS 2
BP 649
EP 654
DI 10.1016/j.juro.2009.04.001
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 468UW
UT WOS:000267850300093
PM 19535108
ER
PT J
AU Hirata, H
Hinoda, Y
Nakajima, K
Kikuno, N
Suehiro, Y
Tabatabai, ZL
Ishii, N
Dahiya, R
AF Hirata, Hiroshi
Hinoda, Yuji
Nakajima, Koichi
Kikuno, Nobuyuki
Suehiro, Yutaka
Tabatabai, Z. Laura
Ishii, Nobuhisa
Dahiya, Rajvir
TI The bcl2-938CC Genotype Has Poor Prognosis and Lower Survival in Renal
Cancer
SO JOURNAL OF UROLOGY
LA English
DT Article
DE kidney; carcinoma, renal cell; polymorphism, single nucleotide;
apoptosis; genotype
ID CHRONIC-LYMPHOCYTIC-LEUKEMIA; BCL-2 EXPRESSION; CELL CARCINOMA; P53;
PHARMACOGENOMICS; POLYMORPHISM; RECURRENCE; APOPTOSIS; PROMOTER; THERAPY
AB Purpose: A single nucleotide polymorphism (-938C/A, rs2279115) was found in the bcl2 gene, whose -938A allele is significantly associated with increased Bcl2 expression compared with that of the C allele. Bcl2 up-regulation was reported to be associated with longer survival in patients with renal cancer. However, to our knowledge there is currently no information on the role of the bcl2-938C/A single nucleotide polymorphism in renal cell carcinoma cases. Therefore, we investigated the polymorphism at the bcl2 -938C/A site and its effects on clinical characteristics in patients with renal cell carcinoma.
Materials and Methods: We genotyped the bcl2-938C/A single nucleotide polymorphism in 216 patients with renal cancer, and in 209 healthy age and gender matched controls. We also investigated the relationship between the bcl2 -938C/A polymorphism, Bcl2 expression, proliferation and apoptosis status in renal cell carcinoma tissues using immunohistochemistry and TUNEL assay. The association of the bcl2 -938C/A single nucleotide polymorphism with survival in patients with renal cell carcinoma was also analyzed by Kaplan-Meier curves.
Results: Survival in Bcl2 positive cases was significantly longer than in negative cases. On univariate and multivariate analyses the bc12 -938CC genotype was independently associated with poor prognosis. Kaplan-Meier analysis showed that survival in patients with CC genotypes was significantly worse than in those with CA+AA genotypes. CC genotype carriers had significantly lower Bcl2 expression and higher proliferative activity in renal cancer tissues than CA+AA genotype carriers.
Conclusions: To our knowledge this is the first report to show that the bc12 -938C/C genotype has worse prognosis and lower survival in patients with renal cell carcinoma. In addition, the bc12 -938C/A single nucleotide polymorphism was shown to be an independent adverse prognostic factor for renal cell carcinoma.
C1 [Hirata, Hiroshi; Kikuno, Nobuyuki; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA.
[Tabatabai, Z. Laura] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hinoda, Yuji; Suehiro, Yutaka] Yamaguchi Univ, Grad Sch Med, Dept Oncol, Yamaguchi, Japan.
[Hinoda, Yuji; Suehiro, Yutaka] Yamaguchi Univ, Grad Sch Med, Lab Med, Yamaguchi, Japan.
[Nakajima, Koichi; Kikuno, Nobuyuki] Toho Univ, Dept Urol, Fac Med, Tokyo, Japan.
RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Urol Res Ctr, 112F,4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU NCI NIH HHS [R01CA101844, R01CA111470]; NIDDK NIH HHS [T32-DK07790]
NR 25
TC 22
Z9 25
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD AUG
PY 2009
VL 182
IS 2
BP 721
EP 727
DI 10.1016/j.juro.2009.03.081
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 468UW
UT WOS:000267850300125
PM 19539330
ER
PT J
AU Veena, MS
Qin, M
Andersson, A
Sharma, S
Batra, RK
AF Veena, Mysore S.
Qin, Min
Andersson, Asa
Sharma, Sherven
Batra, Raj K.
TI CAR mediates efficient tumor engraftment of mesenchymal type lung cancer
cells
SO LABORATORY INVESTIGATION
LA English
DT Article
DE lung cancer; tumorigenesis; EMT; CAR; adhesion molecules
ID ADENOVIRUS RECEPTOR CAR; AIRWAY EPITHELIAL-CELLS; ADHESION MOLECULE JAM;
HUMAN BLADDER-CANCER; TIGHT-JUNCTION; GENE-TRANSFER; E-CADHERIN;
MATRIX-METALLOPROTEINASE; CARCINOMA-CELLS; COXSACKIEVIRUS
AB The coxsackie-adenovirus receptor (CAR) is a developmentally regulated intercellular adhesion molecule that was previously observed to be required for efficient tumor formation. To confirm that observation, we compared the tumorigenicity of clonally derived test and control cell subsets that were genetically modified for CAR. Silencing CAR in lung cancer cells with high constitutive expression reduced engraftment efficiency. Conversely, overexpressing CAR in lung cancer cells with low constitutive expression did not affect tumor formation or growth kinetics. A blocking antibody to the extracellular domain of CAR inhibited tumor engraftment, implicating that domain as being important to this process. However, differences in adhesion properties attributable to this domain (barrier function and aggregation) could not be distinguished in the test groups in vitro, and the mechanisms underlying CAR's contribution to tumor engraftment remain elusive. Because high CAR cells displayed a spindle-shaped morphology at baseline, we considered whether this expression was an accompaniment of other mesenchymal features in these lung cancer cells. Molecular correlates of CAR were compared in model epithelial and mesenchymal type lung cancer cells. CAR expression is associated with an absence of E-cadherin, diminished expression of alpha- and gamma-catenin, and increased Zeb1, Snail, and vimentin expression in lung cancer cells. In contrast, epithelial type (NCI-H292, Calu3) lung cancer cells show comparatively low CAR expression. These data suggest that if the mesenchymal cell phenotype is an accurate measure of an undifferentiated and invasive state, then CAR expression may be more closely aligned with this phenotype of lung cancer cells. Laboratory Investigation (2009) 89, 875-886; doi:10.1038/labinvest.2009.56; published online 8 June 2009
C1 [Veena, Mysore S.; Batra, Raj K.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90073 USA.
[Qin, Min; Andersson, Asa; Sharma, Sherven; Batra, Raj K.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA USA.
[Batra, Raj K.] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA.
RP Batra, RK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 11301 Wilshire Blvd 111Q, Los Angeles, CA 90073 USA.
EM rbatra@ucla.edu
OI Batra, Raj K./0000-0002-1126-543X
FU Veterans Administration Medical Research Funds
FX This project was supported from the Veterans Administration Medical
Research Funds. We thank Dr Ling Zhang for the outstanding technical
support.
NR 74
TC 10
Z9 10
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD AUG
PY 2009
VL 89
IS 8
BP 875
EP 886
DI 10.1038/labinvest.2009.56
PG 12
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 476JI
UT WOS:000268435900004
PM 19506548
ER
PT J
AU Kunisaki, KM
Janoff, EN
AF Kunisaki, Ken M.
Janoff, Edward N.
TI Influenza in immunosuppressed populations: a review of infection
frequency, morbidity, mortality, and vaccine responses
SO LANCET INFECTIOUS DISEASES
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SYSTEMIC-LUPUS-ERYTHEMATOSUS;
LUNG-TRANSPLANT RECIPIENTS; HUMORAL IMMUNE-RESPONSE; STEM-CELL
TRANSPLANTATION; RESPIRATORY VIRAL-INFECTIONS; SERUM ANTIBODY-RESPONSE;
BRONCHIOLITIS OBLITERANS SYNDROME; AMBULATORY PERITONEAL-DIALYSIS;
ACTIVE ANTIRETROVIRAL THERAPY
AB Patients that are immunosuppressed might be at risk of serious influenza-associated complications. As a result, multiple guidelines recommend influenza vaccination for patients infected with HIV, who have received solid-organ transplants, who have received haemopoietic stem-cell transplants, and patients on haemodialysis. However, immunosuppression might also limit vaccine responses. To better inform policy, we reviewed the published work relevant to incidence, outcomes, and prevention of influenza infection in these patients, and in patients being treated chemotherapy and with systemic corticosteroids. Available data suggest that most immunosuppressed populations are indeed at higher risk of influenza-associated complications, have a general trend toward impaired humoral vaccine responses (although these data are mixed), and can be safely vaccinated-although longitudinal data are largely lacking. Randomised clinical trial data were limited to one study of HIV-infected patients with high vaccine efficacy. Better trial data would inform vaccination recommendations on the basis of efficacy and cost in these at-risk populations.
C1 [Kunisaki, Ken M.] Minneapolis VA Med Ctr, Pulm Sect, Minneapolis, MN 55417 USA.
[Kunisaki, Ken M.] Univ Minnesota, Div Pulm Allergy Crit Care & Sleep Med, Minneapolis, MN USA.
[Janoff, Edward N.] Univ Colorado Denver, Mucosal & Vaccine Res Ctr, Div Infect Dis, Sch Med, Aurora, CO USA.
[Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Kunisaki, KM (reprint author), Minneapolis VA Med Ctr, Pulm Sect, 1 Vet Dr,Pulm 111N, Minneapolis, MN 55417 USA.
EM kunis001@umn.edu
RI Kunisaki, Ken/A-6950-2009
OI Kunisaki, Ken/0000-0001-8644-2827
FU NCRR NIH HHS [K12 RR023247, K12 RR023247-02]; NHLBI NIH HHS [T32
HL007741-10, T32 HL007741, T32 HL07741]; NIAID NIH HHS [R21 AI077069,
R21 AI077069-01]
NR 168
TC 255
Z9 263
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD AUG
PY 2009
VL 9
IS 8
BP 493
EP 504
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA 478YT
UT WOS:000268625400017
PM 19628174
ER
PT J
AU Putt, M
Long, JA
Montagnet, C
Silber, JH
Chang, VW
Liao, KJ
Schwartz, JS
Pollack, CE
Wong, YN
Armstrong, K
AF Putt, Mary
Long, Judith A.
Montagnet, Chantal
Silber, Jeffrey H.
Chang, Virginia W.
Liao, Kaijun
Schwartz, J. Sanford
Pollack, Craig Evan
Wong, Yu-Ning
Armstrong, Katrina
TI Racial Differences in the Impact of Comorbidities on Survival Among
Elderly Men With Prostate Cancer
SO MEDICAL CARE RESEARCH AND REVIEW
LA English
DT Article
DE administrative data; comorbidity; disparities; Medicare; prostate
cancer; social epidemiology; survival analysis
ID CORONARY-ARTERY-DISEASE; ALL-CAUSE MORTALITY; RACIAL/ETHNIC DIFFERENCES;
SOCIOECONOMIC-STATUS; RADICAL PROSTATECTOMY; BREAST-CANCER; BLACK; AGE;
DISABILITY; HEALTH
AB This study investigates differences in the effects of comorbidities on survival in Medicare beneficiaries with prostate cancer. Medicare data were used to assemble a cohort of 65- to 76-year-old Black (n = 6,402) and White (n = 47,458) men with incident localized prostate cancer in 1999 who survived >= 1 year postdiagnosis. Comorbidities were more prevalent among Blacks than among Whites. For both races, greater comorbidity was associated with decreasing survival rates; however, the effect among Blacks was smaller than in Whites. After adjusting for age, socioeconomic status, and community characteristics, the association between increasing comorbidities and survival remained weaker for Blacks than for Whites, and racial disparity in survival decreased with increasing number of comorbidities. Differential effects of comorbidities on survival were also evident when examining different classes of comorbid conditions. Adjusting for treatment had little impact on these results, despite variation in the racial difference in receipt of prostatectomy with differing comorbidity levels.
C1 [Schwartz, J. Sanford; Armstrong, Katrina] Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Long, Judith A.; Chang, Virginia W.; Pollack, Craig Evan] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Silber, Jeffrey H.] Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA USA.
[Silber, Jeffrey H.; Schwartz, J. Sanford] Univ Penn, Wharton Sch Business, Philadelphia, PA 19104 USA.
[Pollack, Craig Evan] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA.
[Wong, Yu-Ning] Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19111 USA.
[Wong, Yu-Ning] Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA.
[Armstrong, Katrina] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Putt, Mary] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
RP Armstrong, K (reprint author), Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, 1204 Blockley Hall, Philadelphia, PA 19104 USA.
EM karmstro@mail.med.upenn.edu
FU Center for Population Health and Health Disparities at the University of
Pennsylvania under Public Health Services [P50-CA105641]
FX This research was sponsored by the Center for Population Health and
Health Disparities at the University of Pennsylvania under Public Health
Services Grant P50-CA105641. The funding agencies had no role in the
design and conduct of the study; collection, management, analysis, and
interpretation of the data; and preparation, review, or approval of the
manuscript. The interpretation and reporting of these data are the sole
responsibility of the authors. The authors acknowledge the efforts of
the Applied Research Program, NCI; the Office of Research, Development
and Information, CMS; and the Research Data Assistance Center (ResDAC),
University of Minnesota. Please address correspondence to Katrina
Armstrong, 1204 Blockley Hall, University of Pennsylvania, Philadelphia,
PA 19104; e-mail: karmstro@ mail. med. upenn. edu.
NR 42
TC 13
Z9 13
U1 8
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1077-5587
J9 MED CARE RES REV
JI Med. Care Res. Rev.
PD AUG
PY 2009
VL 66
IS 4
BP 409
EP 435
DI 10.1177/1077558709333996
PG 27
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 468FG
UT WOS:000267801600002
PM 19357389
ER
PT J
AU Liu, JY
Park, SH
Morisseau, C
Hwang, SH
Hammock, BD
Weiss, RH
AF Liu, Jun-Yan
Park, See-Hyoung
Morisseau, Christophe
Hwang, Sung Hee
Hammock, Bruce D.
Weiss, Robert H.
TI Sorafenib has soluble epoxide hydrolase inhibitory activity, which
contributes to its effect profile in vivo
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID RENAL-CELL CARCINOMA; REFRACTORY SOLID TUMORS; ARACHIDONIC-ACID;
EPOXYEICOSATRIENOIC ACIDS; EPOXYGENASE METABOLITES; BLOOD-PRESSURE;
KIDNEY CANCER; PHASE-I; HYPERTENSION; SUNITINIB
AB The advent of multikinase inhibitors targeting the vascular endothelial growth factor (VEGF) receptor has revolutionized the treatment of highly angiogenic malignancies such as renal cell carcinoma. Interestingly, several such inhibitors are commercially available, and they each possess diverse specific beneficial and adverse effect profiles. In examining the structure of sorafenib, it was hypothesized that this compound would possess inhibitory effects on the soluble epoxide hydrolase, an enzyme with pleiotropic effects on inflammation and vascular disease. We now show that sorafenib but not another VEGF receptor targeted inhibitor sunitinib is a potent inhibitor of the human soluble epoxide hydrolase in vitro (K(1) = 17 +/- 4 nmol/L). Furthermore, sorafenib causes the expected in vivo shift in oxylipid profile resulting from soluble epoxide hydrolase inhibition, evidence of a reduction in the acute inflammatory response. Lipopolysaccharide-induced hypotension was reversed with sorafenib but not sunitinib treatment, suggesting that soluble epoxide hydrolase inhibition accounts for at least part of the anti-inflammatory effect of sorafenib. The pharmacokinetic studies presented here in light of the known potency of sorafenib as a soluble epoxide hydrolase inhibitor indicate that the soluble epoxide hydrolase will be largely inhibited at therapeutic doses of sorafenib. Thus, it is likely that soluble epoxide hydrolase inhibition contributes to the beneficial effects from the inhibition of the VEGF receptor and other kinases during treatment with sorafenib. [Mol Cancer Ther 2009;8(8):2193-203]
C1 [Weiss, Robert H.] Univ Calif Davis, Div Nephrol, Dept Internal Med, Genome & Biomed Sci Facil, Davis, CA 95616 USA.
[Liu, Jun-Yan; Morisseau, Christophe; Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA.
[Morisseau, Christophe; Hammock, Bruce D.; Weiss, Robert H.] Univ Calif Davis, Canc Res Ctr, Davis, CA 95616 USA.
[Park, See-Hyoung; Weiss, Robert H.] Univ Calif Davis, Comparat Pathol Grad Grp, Davis, CA 95616 USA.
[Weiss, Robert H.] Med Ctr, US Dept Vet Affairs, Sacramento, CA USA.
RP Weiss, RH (reprint author), Univ Calif Davis, Div Nephrol, Dept Internal Med, Genome & Biomed Sci Facil, Room 6312,1 Shields Ave, Davis, CA 95616 USA.
EM rhweiss@ucdavis.edu
RI LIU, JUNYAN/B-2515-2010
FU National Institute of Environmental Health Sciences (NIEHS) [R37
ES02710]; NIEHS SBRP [P42 ES04699]; NIH [HL85727]; Early Detection
Research Network, National Cancer Institute, U.S. NIH [5UO1CA86402];
Morris Animal Foundation [D06CA-065]
FX National Institute of Environmental Health Sciences (NIEHS) grant R37
ES02710, NIEHS SBRP grant P42 ES04699, and NIH HL85727 (J-Y. Liu, C.
Morisseau, and B.D. Hammock), and grant 5UO1CA86402 (Early Detection
Research Network, National Cancer Institute, U.S. NIH) and grant
D06CA-065 from the Morris Animal Foundation (S-H. Park and R.H. Weiss).
NR 53
TC 39
Z9 39
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD AUG
PY 2009
VL 8
IS 8
BP 2193
EP 2203
DI 10.1158/1535-7163.MCT-09-0119
PG 11
WC Oncology
SC Oncology
GA 484FM
UT WOS:000269029300014
PM 19671760
ER
PT J
AU Sheffler, DJ
Williams, R
Bridges, TM
Xiang, ZX
Kane, AS
Byun, NE
Jadhav, S
Mock, MM
Zheng, F
Lewis, LM
Jones, CK
Niswender, CM
Weaver, CD
Lindsley, CW
Conn, PJ
AF Sheffler, Douglas J.
Williams, Richard
Bridges, Thomas M.
Xiang, Zixiu
Kane, Alexander S.
Byun, Nellie E.
Jadhav, Satyawan
Mock, Mathew M.
Zheng, Fang
Lewis, L. Michelle
Jones, Carrie K.
Niswender, Colleen M.
Weaver, Charles D.
Lindsley, Craig W.
Conn, P. Jeffrey
TI A Novel Selective Muscarinic Acetylcholine Receptor Subtype 1 Antagonist
Reduces Seizures without Impairing Hippocampus-Dependent Learning
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID N-DESMETHYLCLOZAPINE; PYRAMIDAL CELLS; MUTANT MICE; ACTIVATION;
ANTIBODIES; DISORDERS; CLOZAPINE; PROTEINS; AGONISTS; DISEASE
AB Previous studies suggest that selective antagonists of specific subtypes of muscarinic acetylcholine receptors (mAChRs) may provide a novel approach for the treatment of certain central nervous system (CNS) disorders, including epileptic disorders, Parkinson's disease, and dystonia. Unfortunately, previously reported antagonists are not highly selective for specific mAChR subtypes, making it difficult to definitively establish the functional roles and therapeutic potential for individual subtypes of this receptor subfamily. The M 1 mAChR is of particular interest as a potential target for treatment of CNS disorders. We now report the discovery of a novel selective antagonist of M(1) mAChRs, termed VU0255035 [N-(3-oxo-3-(4-(pyridine-4-yl)piperazin-1-yl)propyl)benzo[c][1,2,5]thiadiazole-4-sulfonamide]. Equilibrium radioligand binding and functional studies demonstrate a greater than 75-fold selectivity of VU0255035 for M(1) mAChRs relative to M(2)-M(5). Molecular pharmacology and mutagenesis studies indicate that VU0255035 is a competitive orthosteric antagonist of M(1) mAChRs, a surprising finding given the high level of M(1) mAChR selectivity relative to other orthosteric antagonists. Whole-cell patch-clamp recordings demonstrate that VU0255035 inhibits potentiation of N-methyl-D-aspartate receptor currents by the muscarinic agonist carbachol in hippocampal pyramidal cells. VU0255035 has excellent brain penetration in vivo and is efficacious in reducing pilocarpine-induced seizures in mice. We were surprised to find that doses of VU0255035 that reduce pilo-carpine-induced seizures do not induce deficits in contextual freezing, a measure of hippocampus-dependent learning that is disrupted by nonselective mAChR antagonists. Taken together, these data suggest that selective antagonists of M(1) mAChRs do not induce the severe cognitive deficits seen with nonselective mAChR antagonists and could provide a novel approach for the treatment certain of CNS disorders.
C1 [Sheffler, Douglas J.; Williams, Richard; Bridges, Thomas M.; Xiang, Zixiu; Kane, Alexander S.; Jadhav, Satyawan; Jones, Carrie K.; Niswender, Colleen M.; Conn, P. Jeffrey] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
[Lindsley, Craig W.] Vanderbilt Univ, Med Ctr, Dept Chem, Nashville, TN 37232 USA.
[Byun, Nellie E.] Vanderbilt Univ, Med Ctr, Dept Radiol & Radiol Sci, Nashville, TN 37232 USA.
[Williams, Richard; Jadhav, Satyawan; Jones, Carrie K.; Niswender, Colleen M.; Weaver, Charles D.; Lindsley, Craig W.; Conn, P. Jeffrey] Vanderbilt Univ, Med Ctr, Vanderbilt Program Drug Discovery, Nashville, TN 37232 USA.
[Lewis, L. Michelle; Weaver, Charles D.; Lindsley, Craig W.; Conn, P. Jeffrey] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA.
[Jones, Carrie K.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN USA.
[Mock, Mathew M.; Zheng, Fang] Univ Arkansas, Med Ctr, Dept Pharmacol & Toxicol, Little Rock, AR 72204 USA.
RP Conn, PJ (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Light Hall MRB 4,Room 1215D,2215 B Garland Ave, Nashville, TN 37232 USA.
EM jeff.conn@vanderbilt.edu
RI Conn, Peter/D-7848-2012; Zheng, Fang/J-1400-2016
OI Zheng, Fang/0000-0002-6626-1938; Xiang, Zixiu/0000-0002-1678-209X
FU NIBIB NIH HHS [T32 EB001628]; NIMH NIH HHS [1 U54-MH084659, 1
X01-MH077606-01, 3 U54-MH074427, 3 U54-MH074427-02S1]
NR 40
TC 45
Z9 46
U1 1
U2 7
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD AUG
PY 2009
VL 76
IS 2
BP 356
EP 368
DI 10.1124/mol.109.056531
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 472SV
UT WOS:000268153400012
PM 19407080
ER
PT J
AU Smith, EN
Bloss, CS
Badner, JA
Barrett, T
Belmonte, PL
Berrettini, W
Byerley, W
Coryell, W
Craig, D
Edenberg, HJ
Eskin, E
Foroud, T
Gershon, E
Greenwood, TA
Hipolito, M
Koller, DL
Lawson, WB
Liu, C
Lohoff, F
McInnis, MG
McMahon, FJ
Mirel, DB
Murray, SS
Nievergelt, C
Nurnberger, J
Nwulia, EA
Paschall, J
Potash, JB
Rice, J
Schulze, TG
Scheftner, W
Panganiban, C
Zaitlen, N
Zandi, PP
Zollner, S
Schork, NJ
Kelsoe, JR
AF Smith, E. N.
Bloss, C. S.
Badner, J. A.
Barrett, T.
Belmonte, P. L.
Berrettini, W.
Byerley, W.
Coryell, W.
Craig, D.
Edenberg, H. J.
Eskin, E.
Foroud, T.
Gershon, E.
Greenwood, T. A.
Hipolito, M.
Koller, D. L.
Lawson, W. B.
Liu, C.
Lohoff, F.
McInnis, M. G.
McMahon, F. J.
Mirel, D. B.
Murray, S. S.
Nievergelt, C.
Nurnberger, J.
Nwulia, E. A.
Paschall, J.
Potash, J. B.
Rice, J.
Schulze, T. G.
Scheftner, W.
Panganiban, C.
Zaitlen, N.
Zandi, P. P.
Zoellner, S.
Schork, N. J.
Kelsoe, J. R.
TI Genome-wide association study of bipolar disorder in European American
and African American individuals
SO MOLECULAR PSYCHIATRY
LA English
DT Article
DE ANK3; Bipolar Genome Study; genetic background; allelic heterogeneity;
GAIN
ID FAMILY-BASED ASSOCIATION; NEUROTROPHIC FACTOR GENE; BRAIN; TRANSMISSION;
LINKAGE; SUSCEPTIBILITY; SCHIZOPHRENIA; METAANALYSIS; DISEASE; MODELS
AB To identify bipolar disorder (BD) genetic susceptibility factors, we conducted two genome-wide association (GWA) studies: one involving a sample of individuals of European ancestry (EA; n=1001 cases; n=1033 controls), and one involving a sample of individuals of African ancestry (AA; n=345 cases; n=670 controls). For the EA sample, single-nucleotide polymorphisms (SNPs) with the strongest statistical evidence for association included rs5907577 in an intergenic region at Xq27.1 (P=1.6 x 10(-6)) and rs10193871 in NAP5 at 2q21.2 (P=9.8 x 10(-6)). For the AA sample, SNPs with the strongest statistical evidence for association included rs2111504 in DPY19L3 at 19q13.11 (P=1.5 x 10(-6)) and rs2769605 in NTRK2 at 9q21.33 (P=4.5 x 10(-5)). We also investigated whether we could provide support for three regions previously associated with BD, and we showed that the ANK3 region replicates in our sample, along with some support for C15Orf53; other evidence implicates BD candidate genes such as SLITRK2. We also tested the hypothesis that BD susceptibility variants exhibit genetic background-dependent effects. SNPs with the strongest statistical evidence for genetic background effects included rs11208285 in ROR1 at 1p31.3 (P=1.4 x 10(-6)), rs4657247 in RGS5 at 1q23.3 (P=4.1 x 10(-6)), and rs7078071 in BTBD16 at 10q26.13 (P=4.5 x 10(-6)). This study is the first to conduct GWA of BD in individuals of AA and suggests that genetic variations that contribute to BD may vary as a function of ancestry. Molecular Psychiatry (2009) 14, 755-763; doi:10.1038/mp.2009.43; published online 2 June 2009
C1 [Smith, E. N.; Murray, S. S.; Schork, N. J.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.
[Smith, E. N.; Bloss, C. S.; Murray, S. S.; Schork, N. J.] Scripps Translat Sci Inst, La Jolla, CA USA.
[Bloss, C. S.; Murray, S. S.; Schork, N. J.] Scripps Hlth, La Jolla, CA USA.
[Badner, J. A.; Gershon, E.; Liu, C.] Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA.
[Barrett, T.] Portland VA Med Ctr, Dept Psychiat, Portland, OR USA.
[Belmonte, P. L.; Potash, J. B.; Zandi, P. P.] Johns Hopkins Sch Med, Dept Psychiat, Baltimore, MD USA.
[Berrettini, W.; Lohoff, F.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Byerley, W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Coryell, W.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA.
[Craig, D.; Panganiban, C.] Translat Genom Res Inst, Neurogenom Div, Phoenix, AZ USA.
[Edenberg, H. J.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN USA.
[Edenberg, H. J.; Foroud, T.] Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
[Eskin, E.; Zaitlen, N.] Univ Calif Los Angeles, Dept Comp Sci, Los Angeles, CA 90024 USA.
[Greenwood, T. A.; Nievergelt, C.; Kelsoe, J. R.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Hipolito, M.; Lawson, W. B.; Nwulia, E. A.] Howard Univ, Dept Psychiat, Washington, DC 20059 USA.
[Koller, D. L.; Nurnberger, J.] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA.
[McInnis, M. G.; Zoellner, S.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
[McMahon, F. J.; Schulze, T. G.] NIMH, Genet Basis Mood & Anxiety Disorders Unit, Intramural Res Program, NIH,US Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Mirel, D. B.] Harvard Univ, Broad Inst, Cambridge, MA 02138 USA.
[Mirel, D. B.] MIT, Cambridge, MA 02139 USA.
[Paschall, J.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA.
[Rice, J.] Washington Univ, Div Biostat, St Louis, MO USA.
[Scheftner, W.] Rush Univ, Dept Psychiat, Chicago, IL 60612 USA.
[Kelsoe, J. R.] VA San Diego Healthcare Syst, Dept Psychiat, La Jolla, CA USA.
RP Schork, NJ (reprint author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Ave,MEM 275, La Jolla, CA 92037 USA.
EM nschork@scripps.edu
RI ; Smith, Erin/E-5933-2011; Liu, Chunyu/G-7561-2012; McInnis,
Melvin/F-6963-2012; Eskin, Eleazar/J-9187-2012; Greenwood,
Tiffany/F-6356-2012; Schulze, Thomas/H-2157-2013; Lohoff,
Falk/M-7951-2016
OI Edenberg, Howard/0000-0003-0344-9690; Liu, Chunyu/0000-0002-5986-4415;
McInnis, Melvin/0000-0002-0375-6247; Eskin, Eleazar/0000-0003-1149-4758;
Greenwood, Tiffany/0000-0002-6080-6503; Lawson,
William/0000-0002-9324-7090; Nurnberger, John/0000-0002-7674-1767;
Nievergelt, Caroline/0000-0001-5766-8923; McMahon,
Francis/0000-0002-9469-305X
FU NIMH [R01 MH59553, U01 MH46282, R01 MH59545, U01 MH46280, R01 MH059534,
U01 MH46274, R01 MH59533, R01 MH60068, R01 MH059548, R01 MH59535, R01
MH59567, R01 MH059556]; NHGRI [MH078151, MH081804, MH059567]; Genetic
Association Information Network ( GAIN; NIH [R01 MH59553, K08 MH080372,
1U54RR025204-01]; NIMH Intramural Research Program, Clinical
Neurogenetics Branch, Bethesda, MD; NIMH Intramural Research Program,
Bethesda, MD [1Z01MH00281001]
FX We thank the participants in the study, as without them this work would
not have been possible. For best estimate diagnostic work, we thank
Vegas Coleman, Robert Schweitzer, N Leela Rau and Kelly Rhoadarmer. For
data management, we thank Mariano Erpe and for study coordination Carre
Fisher RN. This work was supported by grants from the NIMH and NHGRI to
JRK (MH078151, MH081804, MH059567 supplement), and by the Genetic
Association Information Network ( GAIN). This work was additionally
supported by the NIMH Intramural Research Program (FJM and TGS). WHB was
supported by a grant from the Tzedakah Foundation, a grant from NIH (R01
MH59553) and a grant from Philip and Marcia Cohen. Falk Lohoff was
supported by the Daland Fellowship Award from the American Philosophical
Society and by NIH grant K08 MH080372. David Craig and Corrie Panganiban
acknowledge the Stardust foundation. Follow-up genotyping was performed
in the laboratory of HE at Indiana University School of Medicine. This
research was also supported, in part, by the Intramural Research Program
of the NIH, National Library of Medicine. Dr Smith, Dr Bloss, Dr Murray
and Dr Schork are supported in part by National Institutes of Health
grant NIH 1U54RR025204-01. Data and biomaterials were collected in four
projects that participated in the National Institute of Mental Health
(NIMH) Bipolar Disorder Genetics Initiative. From 1991 to 1998, the
principal investigators and coinvestigators were: Indiana University,
Indianapolis, IN, U01 MH46282, John Nurnberger, Marvin Miller and
Elizabeth Bowman; Washington University, St Louis, MO, U01 MH46280,
Theodore Reich, Allison Goate and John Rice; Johns Hopkins University,
Baltimore, MD U01 MH46274, J Raymond DePaulo, Jr, Sylvia Simpson and
Colin Stine; NIMH Intramural Research Program, Clinical Neurogenetics
Branch, Bethesda, MD, Elliot Gershon, Diane Kazuba and Elizabeth
Maxwell. Data and biomaterials were collected as part of 10 projects
that participated in the National Institute of Mental Health ( NIMH)
Bipolar Disorder Genetics Initiative. From 1999 to 2007, the principal
investigators and coinvestigators were: Indiana University,
Indianapolis, IN, R01 MH59545, John Nurnberger, Marvin J Miller,
Elizabeth S Bowman, N Leela Rau, P Ryan Moe, Nalini Samavedy, Rif
El-Mallakh ( at University of Louisville), Husseini Manji ( at Wayne
State University), Debra A Glitz ( at Wayne State University), Eric T
Meyer, Carrie Smiley, Tatiana Foroud, Leah Flury, Danielle M Dick,
Howard Edenberg; Washington University, St Louis, MO, R01 MH059534, John
Rice, Theodore Reich, Allison Goate, Laura Bierut; Johns Hopkins
University, Baltimore, MD, R01 MH59533, Melvin McInnis, J Raymond
DePaulo, Jr, Dean F MacKinnon, Francis M Mondimore, James B Potash,
Peter P Zandi, Dimitrios Avramopoulos and Jennifer Payne; University of
Pennsylvania, PA, R01 MH59553, Wade Berrettini; University of California
at Irvine, CA, R01 MH60068, William Byerley and Mark Vawter; University
of Iowa, IA, R01 MH059548, William Coryell and Raymond Crowe; University
of Chicago, IL, R01 MH59535, Elliot Gershon, Judith Badner, Francis
McMahon, Chunyu Liu, Alan Sanders, Maria Caserta, Steven Dinwiddie, Tu
Nguyen, Donna Harakal; University of California at San Diego, CA, R01
MH59567, John Kelsoe, Rebecca McKinney; Rush University, IL, R01
MH059556, William Scheftner, Howard M Kravitz, Diana Marta, Annette
VaughnBrown and Laurie Bederow; NIMH Intramural Research Program,
Bethesda, MD, 1Z01MH00281001, Francis J McMahon, Layla Kassem, Sevilla
DeteraWadleigh, Lisa Austin, Dennis L Murphy.
NR 32
TC 198
Z9 201
U1 2
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1359-4184
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
PD AUG
PY 2009
VL 14
IS 8
BP 755
EP 763
DI 10.1038/mp.2009.43
PG 9
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA 473VR
UT WOS:000268239200005
PM 19488044
ER
PT J
AU Goedecke, JH
Levitt, NS
Lambert, EV
Utzschneider, KM
Faulenbach, MV
Dave, JA
West, S
Victor, H
Evans, J
Olsson, T
Walker, BR
Seckl, JR
Kahn, SE
AF Goedecke, Julia H.
Levitt, Naomi S.
Lambert, Estelle V.
Utzschneider, Kristina M.
Faulenbach, Mirjam V.
Dave, Joel A.
West, Sacha
Victor, Hendriena
Evans, Juliet
Olsson, Tommy
Walker, Brian R.
Seckl, Jonathan R.
Kahn, Steven E.
TI Differential Effects of Abdominal Adipose Tissue Distribution on Insulin
Sensitivity in Black and White South African Women
SO OBESITY
LA English
DT Article
ID FAT DISTRIBUTION; BODY-FAT; RESISTANCE; OBESITY; RISK; DETERMINANTS;
COMPARTMENTS; AMERICANS; DISEASE; WEIGHT
AB Black South African women are more insulin resistant than BMI-matched white women. The objective of the study was to characterize the determinants of insulin sensitivity in black and white South African women matched for BMI. A total of 57 normal-weight (BMI 18-25 kg/m(2)) and obese (BMI > 30 kg/m(2)) black and white premenopausal South African women underwent the following measurements: body composition (dual-energy X-ray absorptiometry), body fat distribution (computerized tomography (CT)), insulin sensitivity (S(1), frequently sampled intravenous glucose tolerance test), dietary intake (food frequency questionnaire), physical activity (Global Physical Activity Questionnaire), and socioeconomic status (SES, demographic questionnaire). Black women were less insulin sensitive (4.4 +/- 0.8 vs. 9.5 +/- 0.8 and 3.0 +/- 0.8 vs. 6.0 +/- 0.8 x 10(-5)/min/(pmol/l), for normal-weight and obese women, respectively, P < 0.001), but had less visceral adipose tissue (VAT) (P = 0.051), more abdominal superficial subcutaneous adipose tissue (SAT) (P = 0.003), lower SES (P < 0.001), and higher dietary fat intake (P = 0.001) than white women matched for BMI. S I correlated with deep and superficial SAT in both black (R = -0.594, P = 0.002 and R = 0.495, P = 0.012) and white women (R = -0.554, P = 0.005 and R = -0.546, P = 0.004), but with VAT in white women only (R = -0.534, P = 0.005). In conclusion, body fat distribution is differentially associated with insulin sensitivity in black and white women. Therefore, the different abdominal fat depots may have varying metabolic consequences in women of different ethnic origins.
C1 [Goedecke, Julia H.; Lambert, Estelle V.; West, Sacha; Victor, Hendriena; Evans, Juliet] Univ Cape Town, Dept Human Biol, UCT MRC Res Unit Exercise Sci & Sports Med, ZA-7925 Cape Town, South Africa.
[Goedecke, Julia H.] S African MRC, Cape Town, South Africa.
[Levitt, Naomi S.; Dave, Joel A.] Univ Cape Town, Dept Med, Endocrine Unit, ZA-7925 Cape Town, South Africa.
[Utzschneider, Kristina M.; Faulenbach, Mirjam V.; Kahn, Steven E.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Evans, Juliet; Olsson, Tommy] Umea Univ, Dept Med, Dept Publ Hlth & Clin Med, Umea, Sweden.
[Walker, Brian R.; Seckl, Jonathan R.] Univ Edinburgh, Ctr Cardiovasc Sci, Endocrinol Unit, Edinburgh, Midlothian, Scotland.
RP Goedecke, JH (reprint author), Univ Cape Town, Dept Human Biol, UCT MRC Res Unit Exercise Sci & Sports Med, ZA-7925 Cape Town, South Africa.
EM julia.goedecke@uct.ac.za
RI Seckl, Jonathan/C-3555-2013; Goedecke, Julia/J-8628-2013; Goedecke,
Julia/E-1820-2016
OI Goedecke, Julia/0000-0001-6795-4771; Goedecke,
Julia/0000-0001-6795-4771; Olsson, Tommy/0000-0001-7768-1076; Kahn,
Steven/0000-0001-7307-9002
FU Medical Research Council of South Africa; National Research Foundation
of South Africa; Royal Society SA-UK Science Networks Programme;
University of Cape Town; British Heart Foundation; Wellcome Trust;
United States Department of Veterans Affairs
FX We thank the research volunteers for their participation in this study,
Nandipha Sinyanya for her excellent field work, Judy Belonje for her
expert technical assistance and Madelaine Carstens for performing the
dietary analyses. Jack Bergman, Naomi Fenton of Symington Radiology, and
Linda Bewerunge are thanked for performing the CT and dual-energy X-ray
absorptiometry scans. This study was funded by the Medical Research
Council of South Africa (Career Development Award to J. H. G.), the
International Atomic Energy Agency, the National Research Foundation of
South Africa, and Royal Society SA-UK Science Networks Programme, the
University of Cape Town, the British Heart Foundation, the Wellcome
Trust and the United States Department of Veterans Affairs.
NR 33
TC 38
Z9 38
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1930-7381
J9 OBESITY
JI Obesity
PD AUG
PY 2009
VL 17
IS 8
BP 1506
EP 1512
DI 10.1038/oby.2009.73
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 475QD
UT WOS:000268374200007
PM 19300428
ER
PT J
AU Phuong, L
Garg, S
Duda, JE
Stern, MB
Weintraub, D
AF Phuong, Lisa
Garg, Shalini
Duda, John E.
Stern, Matthew B.
Weintraub, Daniel
TI Involuntary emotional expression disorder (IEED) in Parkinson's disease
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Article
DE Involuntary emotional expression disorder; Pseudobulbar affect;
Emotional lability; Depression; Parkinson's disease
ID PSEUDOBULBAR AFFECT; MULTIPLE-SCLEROSIS; DEXTROMETHORPHAN/QUINIDINE;
LABILITY; TRIAL; SCALE
AB Objective: To estimate the frequency and correlates Of involuntary emotional expression disorder (IEED) in Parkinson's disease (PD) using the Center for Neurologic Study-Lability Scale (CNS-LS) and recently-proposed diagnostic criteria for IEED.
Background: IEED is characterized by uncontrollable emotional episodes, typically unrelated to or in excess of the underlying mood, and occurring with minimal or no stimulus. IEED has been reported to occur in many neurological disorders and neurodegenerative diseases, but its prevalence and correlates in PD have not been well studied. Additionally, there is no published research using recently-proposed IEED diagnostic criteria in any population.
Methods: 193 patients with idiopathic PD were assessed with a neuropsychiatric battery, including the CNS-LS and the 15-item Geriatric Depression Scale (GDS-15). A subset (N = 100) was also administered a diagnostic interview by a blinded rater that applied criteria for both IEED and Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) depressive disorders.
Results: Applying formal diagnostic criteria, 7.0% of patients were diagnosed with IEED, and an additional 7.0% had subsyndromal IEED symptoms. Applying recommended CNS-LS cutoff scores from other populations, either 42.5% (cutoff >= 13) or 16.6% (cutoff >= 17) screened positive for IEED. Depressive symptoms were associated with higher CNS-LS scores (B[SE] = 0.27[.08], P=.001) but not with a diagnosis of IEED (odds ratio = 1.1, [95% CI=1.0-1.31, P=.16). The CNS-LS had Poor discriminant validity for an IEED diagnosis (AUC=.79, no cutoff value with sensitivity and specificity both >60%).
Conclusions: IEED and depression are overlapping but distinct disorders in PD. IEED symptoms may occur in up to 15% of PD patients, but a disorder occurs in only half of those, suggesting that often IEED symptoms are not clinically significant in this population. The CNS-LS does not appear to be a good screening instrument for IEED in PD, in part due to its high correlation with depressive symptoms. Published by Elsevier Ltd.
C1 [Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Duda, John E.; Stern, Matthew B.; Weintraub, Daniel] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Phuong, Lisa; Garg, Shalini; Duda, John E.; Stern, Matthew B.; Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, PADRECC, Philadelphia, PA USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA.
RP Weintraub, D (reprint author), Univ Penn, Dept Psychiat, 3615 Chestnut St,330,3535 Market St,Room 3003, Philadelphia, PA 19104 USA.
EM weintrau@mail.med.upenn.edu
FU National Institute of Mental Health [K23 067894]
FX Supported by a grant from the National Institute of Mental Health
(K23#067894).
NR 15
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD AUG
PY 2009
VL 15
IS 7
BP 511
EP 515
DI 10.1016/j.parkreldis.2009.01.001
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 483US
UT WOS:000268994500006
PM 19181560
ER
PT J
AU McDonald, JR
Pittman, C
Zeringue, AL
Eisen, SA
Cunningham, F
Wehmeier, K
Caplan, L
AF McDonald, Jay R.
Pittman, Cory
Zeringue, Angelique L.
Eisen, Seth A.
Cunningham, Fran
Wehmeier, Kent
Caplan, Liron
TI Atrial Fibrillation in US Veteran Fracture Patients Treated with
Bisphosphonates
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [McDonald, Jay R.; Pittman, Cory; Zeringue, Angelique L.] St Louis VAMC, St Louis, MO USA.
[McDonald, Jay R.; Zeringue, Angelique L.] Washington Univ, Sch Med, St Louis, MO USA.
[Pittman, Cory] Mercy Med Ctr, Des Moines, IA USA.
[Eisen, Seth A.] Dept Vet Affairs, HSR&D Serv, Washington, DC USA.
[Cunningham, Fran] Dept Vet Affairs, Hines, IL USA.
[Wehmeier, Kent] Univ Florida, Sch Med, Jacksonville, FL USA.
[Caplan, Liron] Denver VAMC, Denver, CO USA.
[Caplan, Liron] Univ Colorado, Hlth Sci Ctr, Denver, CO USA.
RI Zeringue, Angelique/I-1755-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1053-8569
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD AUG
PY 2009
VL 18
BP S220
EP S220
PG 1
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA 483YQ
UT WOS:000269009900502
ER
PT J
AU Howard, G
Cushman, M
Prineas, RJ
Howard, VJ
Moy, CS
Sullivan, LM
D'Agostino, RB
McClure, LA
Pulley, L
Safford, MM
AF Howard, George
Cushman, Mary
Prineas, Ronald J.
Howard, Virginia J.
Moy, Claudia S.
Sullivan, Lisa M.
D'Agostino, Ralph B., Sr.
McClure, Leslie A.
Pulley, LeaVonne
Safford, Monika M.
TI Advancing the hypothesis that geographic variations in risk factors
contribute relatively little to observed geographic variations in heart
disease and stroke mortality
SO PREVENTIVE MEDICINE
LA English
DT Article
DE Stroke; Coronary heart disease; Geography; Risk factors; Mortality
ID SOUTHEASTERN UNITED-STATES; HYPERTENSION; PREDICTION; PROFILE; BELT
AB Purpose. Geographic variation in risk factors may underlie geographic disparities in coronary heart disease (CHD) and stroke mortality.
Methods. Framingham CHD Risk Score (FCRS) and Stroke Risk Score (FSRS) were calculated for 25,770 stroke-free and 22,247 CHD-free participants from the REasons for Geographic And Racial Differences in Stroke cohort. Vital statistics provided age-adjusted CHD and stroke mortality rates. In an ecologic analysis, the age-adjusted, race-sex weighted, average state-level risk factor levels were compared to state-level mortality rates.
Results. There was no relationship between CHD and stroke mortality rates (r=0.04; p=0.78), but there was between CHD and stroke risk scores at the individual (r=0.68: p<0.0001) and state (r=0.64, p<0.0001) level. There was a stronger (p<0.0001) association between state-level FCRS and state-level CHD mortality (r=0.28, p=0.18), than between FSRS and stroke mortality (r=0.12, p=0.56).
Conclusions. weak associations between CHD and stroke mortality and strong associations between CHD and stroke risk scores suggest that geographic variation in risk factors may not underlie geographic variations in stroke and CHID mortality. The relationship between risk factor scores and mortality was stronger for CHID than stroke. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Howard, George; McClure, Leslie A.] Univ Alabama, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA.
[Cushman, Mary] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA.
[Prineas, Ronald J.] Wake Forest Univ, Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27109 USA.
[Howard, Virginia J.] Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
[Moy, Claudia S.; D'Agostino, Ralph B., Sr.] NINDS, NIH, Bethesda, MD 20892 USA.
[Sullivan, Lisa M.] Dept Biostat & Framingham Study, Boston, MA USA.
[Pulley, LeaVonne] Univ Arkansas Hlth Sci Univ, Dept Hlth Behav, Little Rock, AR USA.
[Safford, Monika M.] Univ Alabama, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA.
[Safford, Monika M.] Birmingham VA Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA.
RP Howard, G (reprint author), Univ Alabama, Sch Publ Hlth, Dept Biostat, 1665 Univ Blvd, Birmingham, AL 35294 USA.
EM ghoward@uab.edu
RI McClure, Leslie/P-2929-2015
OI Sullivan, Lisa/0000-0003-0726-7149
FU National Institute of Neurological Disorders and Stroke [NS 041588]
FX The research reported in this article was supported by cooperative
agreement NS 041588 from the National Institute of Neurological
Disorders and Stroke.
NR 17
TC 22
Z9 23
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-7435
J9 PREV MED
JI Prev. Med.
PD AUG-SEP
PY 2009
VL 49
IS 2-3
BP 129
EP 132
DI 10.1016/j.ypmed.2009.03.004
PG 4
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 503TF
UT WOS:000270562200011
PM 19285103
ER
PT J
AU Magruder, KM
Yeager, DE
AF Magruder, Kathryn M.
Yeager, Derik E.
TI The Prevalence of PTSD across War Eras and the Effect of Deployment on
PTSD: a Systematic Review and Meta-analysis
SO PSYCHIATRIC ANNALS
LA English
DT Review
ID POSTTRAUMATIC-STRESS-DISORDER; PERSIAN-GULF-WAR; SELF-REPORTED SYMPTOMS;
HEALTH-STATUS; VIETNAM VETERANS; PHYSICAL HEALTH; PRISONERS; ILLNESS;
EPIDEMIOLOGY; RESERVISTS
C1 [Magruder, Kathryn M.; Yeager, Derik E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Magruder, Kathryn M.; Yeager, Derik E.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA.
RP Magruder, KM (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St, Charleston, SC 29425 USA.
EM magrudkm@musc.edu
NR 31
TC 26
Z9 26
U1 5
U2 12
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0048-5713
J9 PSYCHIAT ANN
JI Psychiatr. Ann.
PD AUG
PY 2009
VL 39
IS 8
BP 778
EP 788
DI 10.3928/00485713-20090728-04
PG 11
WC Psychiatry
SC Psychiatry
GA 483EP
UT WOS:000268945500003
ER
PT J
AU Milner, KK
Healy, D
Barry, KL
Blow, FC
Irmiter, C
De Chavez, P
AF Milner, Karen K.
Healy, Daniel
Barry, Kristen L.
Blow, Frederic C.
Irmiter, Cheryl
De Chavez, Peter
TI Implementation of Computerized Medication Prescribing Algorithms in a
Community Mental Health System
SO PSYCHIATRIC SERVICES
LA English
DT Editorial Material
ID PHASE-3 TMAP-3; PROJECT; RATIONALE; DISORDER; DESIGN
AB This column describes a Michigan initiative to implement medication prescribing algorithms for schizophrenia, bipolar disorder, and major depression. The algorithms were incorporated into the electronic medical records system of a four-county community mental health system. Guideline adherence of 30 providers who treated nearly 3,000 patients was measured at mid- and endpoints of the first year. They were adherent for about a third of their patients in the first six months (32%) and more than half in the second (52%). Scores on scales measuring providers' perceptions of algorithm ease of use and usefulness were in the midrange at both time points. (Psychiatric Services 60: 1010-1012, 2009)
C1 [Milner, Karen K.; Healy, Daniel; Barry, Kristen L.; Blow, Frederic C.; Irmiter, Cheryl; De Chavez, Peter] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
[Milner, Karen K.; Healy, Daniel] Washtenaw Community Hlth Org, Ypsilanti, MI USA.
[Barry, Kristen L.; Blow, Frederic C.] US Dept Vet Affairs, Serious Mental Illness Treatment Res & Evaluat Ct, Ann Arbor, MI USA.
[Irmiter, Cheryl] Amer Med Assoc, Chicago, IL 60610 USA.
RP Milner, KK (reprint author), Univ Michigan, Dept Psychiat, Rachel Upjohn Bldg,4250 Plymouth Rd,SPC 5740, Ann Arbor, MI 48109 USA.
EM kmilner@med.umich.edu
NR 10
TC 3
Z9 3
U1 1
U2 2
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD AUG 1
PY 2009
VL 60
IS 8
BP 1010
EP 1012
PG 3
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 477RU
UT WOS:000268537000002
PM 19648185
ER
PT J
AU Uomoto, JM
Williams, RM
AF Uomoto, Jay M.
Williams, Rhonda M.
TI Post-Acute Polytrauma Rehabilitation and Integrated Care of Returning
Veterans: Toward a Holistic Approach
SO REHABILITATION PSYCHOLOGY
LA English
DT Article
DE Operation Enduring Freedom; Operation Iraqi Freedom; war;
rehabilitation; brain injuries; stress disorders
ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; OPERATION IRAQI
FREEDOM; MENTAL-HEALTH PROBLEMS; MEDICALLY UNEXPLAINED SYMPTOMS;
RANDOMIZED CONTROLLED-TRIAL; OF-THE-LITERATURE; PEER SUPPORT; VIETNAM
VETERANS; SHELL-SHOCK
AB Throughout the history of war, exposure to combat has been associated with clusters of physical and psychological symptoms labeled in various ways, from "hysteria" to "shell shock" in World War I to "polytrauma" in Operations Enduring Freedom (OEF) and Iraqi Freedom (OIF). Objective: To describe the historical conceptualizations of combat injury and the ways they are relevant to developing current rehabilitation strategies, discuss the symptom complex presented by OEF/OIF veterans, and describe key elements and principles of holistic, integrated care for post-acute OEF/OIF veterans. Conclusions: A conceptualization of rehabilitation recognizing a final common pathway of functional disability and suffering is proposed, and both systematic and treatment-specific aspects at the core of a veteran-centered holistic approach are discussed.
C1 [Uomoto, Jay M.] VA Puget Sound Hlth Care Syst, VISN VHA Polytrauma Network Site 20, Ctr Polytrauma Care, Rehabil Care Serv, Seattle, WA USA.
[Williams, Rhonda M.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA.
RP Uomoto, JM (reprint author), VA Puget Sound Hlth Care Syst, VISN VHA Polytrauma Network Site 20, Ctr Polytrauma Care, Rehabil Care Serv, Seattle, WA USA.
EM jay.uomoto@va.gov
NR 84
TC 12
Z9 12
U1 2
U2 4
PU EDUCATIONAL PUBLISHING FOUNDATION
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0090-5550
J9 REHABIL PSYCHOL
JI Rehabil. Psychol.
PD AUG
PY 2009
VL 54
IS 3
BP 259
EP 269
DI 10.1037/a0016907
PG 11
WC Psychology, Clinical; Rehabilitation
SC Psychology; Rehabilitation
GA 488SW
UT WOS:000269371100003
PM 19702424
ER
PT J
AU Dausch, BM
Saliman, S
AF Dausch, Barbara M.
Saliman, Sheila
TI Use of Family Focused Therapy in Rehabilitation for Veterans With
Traumatic Brain Injury
SO REHABILITATION PSYCHOLOGY
LA English
DT Article
DE family therapy; TBI; rehabilitation; veterans; Iraq
ID RANDOMIZED CONTROLLED-TRIAL; POSTTRAUMATIC-STRESS-DISORDER;
MENTAL-HEALTH PROBLEMS; SPINAL-CORD INJURIES; BIPOLAR DISORDER;
EXPRESSED EMOTION; COMBAT DEPLOYMENT; IRAQ WAR; INTERVENTION; CAREGIVERS
AB Objective: Military personnel returning from Iraq and Afghanistan with traumatic brain injury (TBI) present with a complex array of stressors encountered during combat as well as upon re-entry, often with additional physical and mental health comorbidities. This requires an intensive approach to treatment that includes family intervention as a part of rehabilitation. There is a small but growing literature addressing the needs of families when a family member has sustained a TBI. An established treatment intervention for individuals with serious mental illness, such as family focused therapy (FFT), is uniquely suited to address the complexity of issues presented by returning military personnel, and may be adapted for moderate to severe TBI populations. In this article, we discuss the rationale for adapting this family intervention for this population and present a case vignette illustrating adaptations for TBI. Conclusions: The adaptation of an existing family intervention for a chronic condition that focuses on enhancing both individual and family functioning is a useful starting point. With further research to modify FFT for this unique population and establish feasibility, this approach may supplement existing models of family intervention.
C1 [Dausch, Barbara M.; Saliman, Sheila] Denver Vet Affairs Med Ctr, Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA.
[Dausch, Barbara M.] Univ Colorado, Sch Med, Boulder, CO 80309 USA.
RP Dausch, BM (reprint author), Denver Vet Affairs Med Ctr, Eastern Colorado Hlth Care Syst, 1055 Clermont St,116 Denver, Denver, CO 80220 USA.
EM Barbara.Dausch@va.gov
NR 54
TC 16
Z9 17
U1 6
U2 12
PU EDUCATIONAL PUBLISHING FOUNDATION
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0090-5550
J9 REHABIL PSYCHOL
JI Rehabil. Psychol.
PD AUG
PY 2009
VL 54
IS 3
BP 279
EP 287
DI 10.1037/a0016809
PG 9
WC Psychology, Clinical; Rehabilitation
SC Psychology; Rehabilitation
GA 488SW
UT WOS:000269371100005
PM 19702426
ER
PT J
AU Dougherty, CM
Thompson, EA
AF Dougherty, Cynthia M.
Thompson, Elaine A.
TI Intimate Partner Physical and Mental Health After Sudden Cardiac Arrest
and Receipt of an Implantable Cardioverter Defibrillator
SO RESEARCH IN NURSING & HEALTH
LA English
DT Article
DE sudden cardiac death; ICD; partner; psychological; physical health;
description
ID MYOCARDIAL-INFARCTION; SPOUSAL CAREGIVERS; ADJUSTMENT; QUALITY; PATIENT;
ANXIETY; SUPPORT; FAMILY; IMPACT; TRIAL
AB The purpose of this study was to describe the physical and mental health of the intimate Partners of persons receiving an implantable cardioverter defibrillator (ICD). A prospective longitudinal repeated measures design was used, with data collected at hospital discharge, and at 1, 3, 6, and 12 months after implantation. Intimate Partners' Physical health, symptoms, and depression significantly declined over the first year. Although anxiety was significantly reduced over time, it remained elevated in Partners after 1 year. The impact of implantation of the ICD on the intimate relationship and care demands was most dramatic at hospital discharge. Health care use was low throughout the year. Intimate partners could benefit from an intervention that would assist in their psychological adjustment and provide strategies for dealing with caregiving demands at home. (C) 2009 Wiley Periodicals, Inc. Res Nurs Health 32:432-442, 2009
C1 [Dougherty, Cynthia M.; Thompson, Elaine A.] Univ Washington, Sch Nursing, Psychosocial & Community Hlth, Seattle, WA 98195 USA.
[Dougherty, Cynthia M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
RP Dougherty, CM (reprint author), Univ Washington, Sch Nursing, Psychosocial & Community Hlth, Box 357266, Seattle, WA 98195 USA.
FU National Institutes of Health; National Institute for Nursing Research
[R03 NR008942]
FX Contract grant sponsor: National Institutes of Health, National
Institute for Nursing Research; Contract grant number: R03 NR008942.
NR 40
TC 11
Z9 11
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-6891
J9 RES NURS HEALTH
JI Res. Nurs. Health
PD AUG
PY 2009
VL 32
IS 4
BP 432
EP 442
DI 10.1002/nur.20330
PG 11
WC Nursing
SC Nursing
GA 472RQ
UT WOS:000268150100007
PM 19434648
ER
PT J
AU Thannickal, TC
Nienhuis, R
Siegel, JM
AF Thannickal, Thomas C.
Nienhuis, Robert
Siegel, Jerome M.
TI Localized Loss of Hypocretin (Orexin) Cells in Narcolepsy Without
Cataplexy
SO SLEEP
LA English
DT Article
DE Hypocretin; orexin; narcolepsy; cataplexy
ID OLFACTORY DYSFUNCTION; PARKINSONS-DISEASE; SLEEP BEHAVIOR; EPIDEMIOLOGY;
NEURONS
AB Study Objectives: Narcolepsy with cataplexy is characterized by a loss of approximately 90% of hypocretin (Hcrt) neurons. However, more than a quarter of narcoleptics do not have cataplexy and have normal levels of hypocretin in their cerebrospinal fluid, raising the possibility that their disease is caused by unrelated abnormalities. In this study we examined hypocretin pathology in narcolepsy without cataplexy.
Design: We examined postmortem brain samples, including the hypothalamus of 5 narcolepsy with cataplexy patients; one narcolepsy without cataplexy patient whose complete hypothalamus was available (patient 1); one narcolepsy without cataplexy patient with anterior hypothalamus available (patient 2); and 6 normal brains. The hypothalamic tissue was immunostained for Hcrt-1, melanin-concentrating hormone (MCH), and glial fibrillary acidic protein (GFAP).
Measurements and Results: Neither of the narcolepsy without cataplexy patients had a loss of Hcrt axons in the anterior hypothalamus. The narcolepsy without cataplexy patient whose entire brain was available for study had an overall loss of 33% of hypocretin cells compared to normals, with maximal cell loss in the posterior hypothalamus. We found elevated levels of gliosis with GFAP staining, with levels increased in the posterior hypothalamic nucleus by (295%), paraventricular (211%), periventricular (123%), arcuate (126%), and lateral (72%) hypothalamic nuclei, but not in the anterior, dorsomedial, or dorsal hypothalamus. There was no reduction in the number of MCH neurons in either patient.
Conclusions: Narcolepsy without cataplexy can be caused by a partial loss of hypocretin cells.
C1 [Thannickal, Thomas C.; Nienhuis, Robert; Siegel, Jerome M.] Vet Adm Greater Los Angeles Healthcare Syst, North Hills, CA USA.
[Thannickal, Thomas C.; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA.
[Thannickal, Thomas C.; Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
RP Siegel, JM (reprint author), Univ Calif Los Angeles, VAGLAHS Sepulveda, Neurobiol Res 151A3,16111 Plummer St, North Hills, CA 91343 USA.
EM jsiegel@ucla.edu
FU Human Brain and Spinal Fluid Resource Center, VAGLAHS, Los Angeles
[NS14610, HL41370, MH64109]; Medical Research Service of the Dept. of
Veterans Affairs
FX Tissues were obtained from the Human Brain and Spinal Fluid Resource
Center, VAGLAHS, Los Angeles. Supported by NS14610, HL41370, MH64109 and
the Medical Research Service of the Dept. of Veterans Affairs. A
preliminary version of these findings was submitted on May 12, 2008, for
presentation at the Society for Neuroscience Meeting.; The work was
performed at Veterans Administration Greater Los Angeles Healthcare
System, North Hills and U.C.L.A.
NR 20
TC 86
Z9 88
U1 0
U2 6
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD AUG 1
PY 2009
VL 32
IS 8
BP 993
EP 998
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 477ZN
UT WOS:000268557600006
PM 19725250
ER
PT J
AU Cannuscio, CC
Weiss, EE
Fruchtman, H
Schroeder, J
Weiner, J
Asch, DA
AF Cannuscio, Carolyn C.
Weiss, Eve E.
Fruchtman, Hannah
Schroeder, Jeannette
Weiner, Janet
Asch, David A.
TI Visual epidemiology: Photographs as tools for probing street-level
etiologies
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE USA; Urban health; Social epidemiology; Visual methods; Health
disparities; Neighborhoods; Food environment; Violence; Social
environment; Physical environment; Photovoice
ID HEALTH INEQUALITIES; LAY EPIDEMIOLOGY; PHOTOVOICE; PLACE;
DISCRIMINATION; ENVIRONMENT; PREVENTION; CONTEXT; FAMILY; ADULTS
AB Epidemiologists and social scientists agree that place shapes health. But the model of "risk factor" epidemiology faces limits in explaining how neighborhoods, as complex systems, produce health or disease. This paper describes how visual methods can advance epidemiological inquiry. Drawing from the work of The Health of Philadelphia Photo-documentation Project (HOPPP), this paper asks the following question: how can visual methods inform the work of epidemiologists?
The project was conducted in three contiguous neighborhoods that represent a steep socioeconomic gradient. Photographs served as a stimulus for probing the sources of health variation across neighborhoods. The project incorporated three visual data sources: 1) "outsider perspective" images gathered systematically by staff photographers on randomly sampled blocks; 2) "insider perspective" images taken by adult residents during their daily routines; and 3) collaborative images taken by staff photographers in partnership with local participants. During in-depth interviews, these photographs served as prompts to elicit residents' health concerns and beliefs regarding urban environmental causes of good and poor health ("street-level etiologies").
We found that visual methods generated etiologic insights regarding the production of urban health and illness. Photographs enabled systematic observation of urban neighborhoods by the research team; engaged urban residents as active agents in the search for the underlying causes of urban health disparities; and created a social bridge between researchers and urban residents. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Cannuscio, Carolyn C.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn C.; Schroeder, Jeannette] Univ Penn, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn C.; Weiner, Janet; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Asch, David A.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Cannuscio, CC (reprint author), Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
EM cannusci@wharton.upenn.edu
OI Asch, David/0000-0002-7970-286X; Weiner, Janet/0000-0001-5810-5807
NR 41
TC 17
Z9 18
U1 2
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD AUG
PY 2009
VL 69
IS 4
BP 553
EP 564
DI 10.1016/j.socscimed.2009.06.013
PG 12
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 489JR
UT WOS:000269416900012
PM 19573966
ER
PT J
AU Evans, CT
Hershow, RC
Chin, A
Foulis, PR
Burns, SP
Weaver, FM
AF Evans, C. T.
Hershow, R. C.
Chin, A.
Foulis, P. R.
Burns, S. P.
Weaver, F. M.
TI Bloodstream infections and setting of onset in persons with spinal cord
injury and disorder
SO SPINAL CORD
LA English
DT Article
DE bacteremia; spinal cord injuries; health care
ID ACUTE REHABILITATION UNIT; ACQUIRED INFECTIONS; RESISTANT ORGANISMS;
BACTEREMIA; EPIDEMIOLOGY; POPULATION; MORTALITY; VETERANS
AB Study Design: A retrospective cohort study.
Objective: Health-care-associated (HCA) bloodstream infection (BSI) has been shown to be a distinct epidemiologic category in the general adult population, but few studies have examined specific patient populations. The objective of this study was to assess characteristics associated with BSI that occurred in the hospital (hospital-acquired, HA BSI), from health-care contact outside the hospital (HCA BSI) or in the community (community-acquired, CA BSI) in veterans with spinal cord injury and disorder (SCI&D).
Setting: Two United States Department of Veterans Affairs hospitals.
Methods: All patients with SCI&D with a positive blood culture admitted to study hospitals over a 7-year period (1 October 1997 to 30 September 2004). Demographics, medical characteristics and causative organisms were collected.
Results: Four hundred and thirteen episodes of BSI occurred in 226 patients, with a rate of 7.2 BSI episodes per 100 admissions: 267 (64.7%) were HA BSI, 110 (26.6%) were HCA BSI and 36 (8.7%) were CA BSI. Antibiotic resistance was more common in those with HA BSI (65.5%) compared with that in those with HCA (49.1%, P = 0.001) and CA BSI (22.2%, P<0.0001). Methicillin resistance in Staphylococcus aureus was highly prevalent; HA BSI (84.5%), HCA BSI (60.6%) and CA BSI (33.3%).
Conclusion: HCA BSI comprises one-quarter of all BSIs in hospitalized patients with SCI&D. Although those with HCA and CA BSI share similarities, several differences in medical characteristics and causal microorganism are noted. Treatment and management strategies for HCA and CA infections need to vary. Spinal Cord (2009) 47, 610-615; doi: 10.1038/sc.2009.2; published online 24 February 2009
C1 [Evans, C. T.; Chin, A.; Weaver, F. M.] EJ Hines Jr VA Hosp 151H, Ctr Management Complex Chron Care, Dept Vet Affairs, Hines, IL 60141 USA.
[Evans, C. T.; Weaver, F. M.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA.
[Evans, C. T.; Hershow, R. C.] Univ Illinois, Sch Publ Hlth, Dept Epidemiol & Biostat, Chicago, IL USA.
[Foulis, P. R.] James A Haley VA Hosp, Pathol Lab Serv, Tampa, FL USA.
[Burns, S. P.] Univ Washington, Seattle, WA 98195 USA.
[Burns, S. P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Weaver, F. M.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA.
RP Evans, CT (reprint author), EJ Hines Jr VA Hosp 151H, Ctr Management Complex Chron Care, Dept Vet Affairs, 5th Ave & Roosevelt Rd, Hines, IL 60141 USA.
EM Charlesnika.Evans@va.gov
FU Department of Veterans Affairs; Office of Research and Development;
Health Services Research and Development Service
FX This paper is based upon study supported by the Department of Veterans
Affairs, Office of Research and Development, Health Services Research
and Development Service.
NR 20
TC 6
Z9 6
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
J9 SPINAL CORD
JI Spinal Cord
PD AUG
PY 2009
VL 47
IS 8
BP 610
EP 615
DI 10.1038/sc.2009.2
PG 6
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 479TT
UT WOS:000268684500008
PM 19238165
ER
PT J
AU Bauman, WA
Schwartz, E
Song, ISY
Kirshblum, S
Cirnigliaro, C
Morrison, N
Spungen, AM
AF Bauman, W. A.
Schwartz, E.
Song, I. S. Y.
Kirshblum, S.
Cirnigliaro, C.
Morrison, N.
Spungen, A. M.
TI Dual-energy X-ray absorptiometry overestimates bone mineral density of
the lumbar spine in persons with spinal cord injury
SO SPINAL CORD
LA English
DT Article
DE spinal cord injury; bone mineral density; vertebral body; quantitative
computerized tomography; dual-energy X-ray absorptiometry; degenerative
joint disease
ID QUANTITATIVE COMPUTED-TOMOGRAPHY; LOWER-EXTREMITY FRACTURES;
POSTMENOPAUSAL WOMEN; BODY-COMPOSITION; CLINICAL-USE; OSTEOPOROSIS;
DENSITOMETRY; DEMINERALIZATION; DIAGNOSIS; DISEASE
AB Background: Bone mineral density (BMD) of the lumbar spine (L-spine) has been reported to be normal or increased in persons with chronic spinal cord injury (SCI).
Objective: To determine BMD of the L-spine by dual-energy X-ray absorptiometry (DXA) and quantitative computerized tomography (qCT) in men with chronic SCI compared with able-bodied controls.
Design: Cross-sectional, comparative study.
Setting: Clinical research unit, Veterans Affairs Medical Center, Bronx, NY, USA and Kessler Institute of Rehabilitation, West Orange, NJ, USA.
Methods: Measurements of the L-spine were made in 20 men with SCI and compared with 15 able-bodied controls. The DXA images were acquired on a GE Lunar DPX-IQ. The qCT images of the L-spine were acquired on a Picker Q series computerized tomographic scanner.
Results: The mean ages for the SCI and control groups were 44 +/- 13 vs 42 +/- 9 years, and the duration of injury of the group with SCI was 14 +/- 11 years. There were no significant differences between the SCI and control groups for L-spine DXA BMD (1.391 +/- 0.210 vs 1.315 +/- 0.178 g/m(2)) or for L-spine DXA T-score (1.471 +/- 1.794 vs 0.782 +/- 1.481). L-spine qCT BMD was significantly lower in the SCI compared with the control group (1.296 +/- 0.416 vs 1.572 +/- 0.382 g/m(2), P=0.05); the T-score approached significance (-1.838 +/- 1.366 vs -0.963 +/- 1.227, P=0.059). Subjects with moderate degenerative joint disease (DJD) had significantly higher T-scores by DXA than those without or with mild DJD.
Conclusion: Individuals with SCI who have moderate to severe DJD may have bone loss of the L-spine that may be underestimated by DXA, reducing awareness of the risk of fracture. Spinal Cord (2009) 47, 628-633; doi: 10.1038/sc.2008.169; published online 20 January 2009
C1 [Bauman, W. A.; Schwartz, E.; Song, I. S. Y.; Cirnigliaro, C.; Morrison, N.; Spungen, A. M.] James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA.
[Bauman, W. A.; Spungen, A. M.] James J Peters Vet Affairs Med Ctr, Med Serv, Bronx, NY 10468 USA.
[Bauman, W. A.; Spungen, A. M.] James J Peters Vet Affairs Med Ctr, Spinal Cord Injury Serv, Bronx, NY 10468 USA.
[Bauman, W. A.; Spungen, A. M.] James J Peters Vet Affairs Med Ctr, Res Serv, Bronx, NY 10468 USA.
[Bauman, W. A.; Spungen, A. M.] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA.
[Bauman, W. A.; Spungen, A. M.] Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA.
[Kirshblum, S.] Kessler Inst Rehabil, W Orange, NJ USA.
[Kirshblum, S.] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA.
RP Bauman, WA (reprint author), James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM william.bauman@va.gov
FU United Spinal Association (formally Eastern Paralyzed Veterans
Association),; James J Peters Medical Center, Bronx, NY; Department of
Veterans Affairs Rehabilitation Research & Development Service; Kessler
Institute for Rehabilitation, West Orange, NJ,; Rehabilitation Research
& Development (RRD) Service [B98-1452]; RR&D Center of Excellence for
the Medical Consequences of Spinal Cord Injury [B2648C, B4162C]
FX The authors wish to thank United Spinal Association (formally Eastern
Paralyzed Veterans Association), The James J Peters Medical Center,
Bronx, NY, the Department of Veterans Affairs Rehabilitation Research &
Development Service, and the Kessler Institute for Rehabilitation, West
Orange, NJ, for their support. This work was funded by a Rehabilitation
Research & Development (RR&D) Service Merit Review entitled 'Bone Loss
in Acute and Chronic Spinal Cord Injury' (#B98-1452) & RR&D Center of
Excellence for the Medical Consequences of Spinal Cord Injury (#B2648C &
B4162C).
NR 25
TC 10
Z9 11
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
EI 1476-5624
J9 SPINAL CORD
JI Spinal Cord
PD AUG
PY 2009
VL 47
IS 8
BP 628
EP 633
DI 10.1038/sc.2008.169
PG 6
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 479TT
UT WOS:000268684500011
PM 19153590
ER
PT J
AU Baer, S
Baddley, JW
Gnann, JW
Pappas, PG
AF Baer, S.
Baddley, J. W.
Gnann, J. W.
Pappas, P. G.
TI Cryptococcal disease presenting as necrotizing cellulitis in transplant
recipients
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE Cryptococcus; necrotizing fasciitis; necrotizing vasculitis; myositis;
transplantation
ID NEOFORMANS; VASCULITIS; FASCIITIS
AB P>Disseminated cryptococcosis uncommonly presents with skin lesions in immunocompromised hosts. Necrotizing fasciitis, necrotizing vasculitis, myositis, or necrotizing soft tissue infection are even more rare presentations. We report 3 cases of cryptococcal necrotizing soft tissue infection, 2 in renal transplant patients, and 1 in a heart transplant patient, and discuss similar cases from the literature. Cryptococcus neoformans should be considered in the differential diagnosis of cellulitis or necrotizing soft tissue infections in immunocompromised patients.
C1 [Baer, S.] Augusta VA Med Ctr, Augusta, GA 30904 USA.
[Baer, S.] Med Coll Georgia, Dept Internal Med, Div Infect Dis, Augusta, GA 30912 USA.
[Baddley, J. W.; Gnann, J. W.; Pappas, P. G.] Univ Alabama, Dept Internal Med, Div Infect Dis, Birmingham, AL USA.
[Baddley, J. W.; Gnann, J. W.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Baer, S (reprint author), Augusta VA Med Ctr, 1 Freedom Way 235, Augusta, GA 30904 USA.
EM sbaer@mcg.edu
NR 19
TC 10
Z9 10
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD AUG
PY 2009
VL 11
IS 4
BP 353
EP 358
DI 10.1111/j.1399-3062.2009.00399.x
PG 6
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 480EI
UT WOS:000268714600014
PM 19422669
ER
PT J
AU Weintraub, D
Hoops, S
Shea, JA
Lyons, KE
Pahwa, R
Driver-Dunckley, ED
Adler, CH
Potenza, MN
Miyasaki, J
Siderowf, AD
Duda, JE
Hurtig, HI
Colcher, A
Horn, SS
Stem, MB
Voon, V
AF Weintraub, Daniel
Hoops, Staci
Shea, Judy A.
Lyons, Kelly E.
Pahwa, Rajesh
Driver-Dunckley, Erika D.
Adler, Charles H.
Potenza, Marc N.
Miyasaki, Janis
Siderowf, Andrew D.
Duda, John E.
Hurtig, Howard I.
Colcher, Amy
Horn, Stacy S.
Stem, Matthew B.
Voon, Valerie
TI Validation of the Questionnaire for Impulsive-Compulsive Disorders in
Parkinson's Disease
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson's disease; impulse control disorders; dopamine dysregulation
syndrome; punding; pathological gambling
ID HEDONISTIC HOMEOSTATIC DYSREGULATION; DOPAMINE AGONISTS; PREVALENCE;
BEHAVIOR; ASSOCIATION
AB As no comprehensive assessment instrument for impulse control disorders (ICDs) in Parkinson's disease (PD) exists, the aim of this study was to design and assess the psychometric properties of a self-administered screening questionnaire for ICDs and other compulsive behaviors in PD. The Questionnaire for Impulsive-compulsive Disorders in Parkinson's Disease (QUIP) has 3 sections: Section 1 assesses four ICDs (involving gambling, sexual, buying, and eating behaviors), Section 2 other compulsive behaviors (punding, hobbyism, and walkabout), and Section 3 Compulsive medication use. For validation, a convenience sample of 157 PD patients at 4 movement disorders centers first completed the QUIP, and then was administered a diagnostic interview by a trained rater blinded to the QUIP results. A shortened instrument (QUIP-S) was then explored. The discriminant validity of the QUIP was high for each disorder or behavior (receiver operating characteristic area under the curve [ROC AUC]: gambling = 0.95, sexual behavior = 0.97, buying = 0.87, eating = 0.88, punding = 0.78, hobbyism = 0.93, walkabout = 0.79). On post hoc analysis, the QUIP-S ICD section had similar properties (ROC AUC: gambling = 0.95, sexual behavior = 0.96, buying = 0.87, eating = 0.88). When disorders/behaviors were combined, the sensitivity of the QUIP and QUIP-S to detect an individual with any disorder was 96 and 94%, respectively. Scores on the QUIP appear to be valid as a self-assessment screening instrument for a range of ICDs and other compulsive behaviors that occur in PD, and a shortened version may perform as well as the full version. A positive screen should be followed by a comprehensive, clinical interview to determine the range and severity of symptoms, as well as need for clinical management. (C) 2009 Movement Disorder Society
C1 [Weintraub, Daniel; Hoops, Staci] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Weintraub, Daniel; Siderowf, Andrew D.; Duda, John E.; Hurtig, Howard I.; Colcher, Amy; Horn, Stacy S.; Stem, Matthew B.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Weintraub, Daniel; Duda, John E.; Stem, Matthew B.] Philadelphia Vet Affairs Med Ctr, PADRECC, Philadelphia, PA USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA.
[Shea, Judy A.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Shea, Judy A.] Philadelphia Vet Affairs Med, CHERP, Philadelphia, PA USA.
[Lyons, Kelly E.; Pahwa, Rajesh] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA.
[Driver-Dunckley, Erika D.; Adler, Charles H.] Mayo Clin Scottsdale, Dept Neurol, Scottsdale, AZ USA.
[Potenza, Marc N.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA.
[Miyasaki, Janis] Univ Toronto, Div Neurol, Toronto, ON, Canada.
[Voon, Valerie] NINDS, Bethesda, MD 20892 USA.
RP Weintraub, D (reprint author), 3615 Chestnut St,Room 330, Philadelphia, PA 19104 USA.
EM weintrau@mail.med.upenn.edu
OI Miyasaki, Janis/0000-0002-6372-6007
FU NIDA NIH HHS [R01 DA019039, R01 DA019039-05]; NIMH NIH HHS [K23
MH067894, K23 MH067894-05]
NR 31
TC 135
Z9 136
U1 3
U2 13
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD JUL 30
PY 2009
VL 24
IS 10
BP 1461
EP 1467
DI 10.1002/mds.22571
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 478UK
UT WOS:000268613600006
PM 19452562
ER
PT J
AU Steinman, MA
Rosenthal, GE
Landefeld, CS
Bertenthal, D
Kaboli, PJ
AF Steinman, Michael A.
Rosenthal, Gary E.
Landefeld, C. Seth
Bertenthal, Daniel
Kaboli, Peter J.
TI Agreement Between Drugs-to-Avoid Criteria and Expert Assessments of
Problematic Prescribing
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article; Proceedings Paper
CT 30th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 25-28, 2007
CL Toronto, CANADA
SP Soc Gen Internal Med
ID INAPPROPRIATE MEDICATION USE; EMERGENCY-DEPARTMENT VISITS; NURSING-HOME
RESIDENTS; BEERS CRITERIA; ELDERLY PATIENTS; CONSENSUS PANEL;
OLDER-ADULTS; QUALITY; OUTCOMES; EVENTS
AB Background: Drugs-to-avoid criteria are commonly used to evaluate prescribing quality in elderly persons. However, few studies have evaluated the concordance between these criteria and individualized patient assessments as measures of problem prescribing.
Methods: We used data on 256 outpatients from the Iowa City VA Medical Center who were 65 years or older and taking 5 or more medications. After a comprehensive patient interview, a study team composed of a physician and a pharmacist recommended that certain drugs be discontinued, substituted, or reduced in dose. We evaluated the degree to which drugs considered potentially inappropriate by the drugs-to-avoid criteria of Beers et al and Zhan et al (hereinafter, Beers criteria and Zhan criteria) were also considered problematic by the study team, and vice versa.
Results: In the study cohort, 256 patients were using 3678 medications. The physician-pharmacist team identified 563 drugs (15%) as problematic, while 214 drugs (6%) were flagged as potentially inappropriate by the Beers criteria and 91 drugs (2.5%) were flagged as potentially inappropriate using the Zhan criteria. The kappa statistics for concordance between drugs-to-avoid criteria and expert assessments were 0.10 to 0.14, indicating slight agreement between these measures. Sixty-one percent of drugs identified as potentially inappropriate by the Beers criteria and 49% of drugs flagged by the Zhan criteria were not judged to be problematic by the expert reviewers. Correspondence between drugs-to-avoid criteria and expert assessment varied widely across different types of drugs.
Conclusions: Drugs-to-avoid criteria have limited power to differentiate between drugs and patients with and without prescribing problems identified on individualized expert review. Although these criteria are useful as guides for initial prescribing decisions, they are insufficiently accurate to use as stand-alone measures of prescribing quality.
C1 [Steinman, Michael A.; Landefeld, C. Seth; Bertenthal, Daniel] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Steinman, Michael A.; Landefeld, C. Seth] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Rosenthal, Gary E.; Kaboli, Peter J.] Iowa City VA Healthcare Syst, Ctr Res Implementat Innovat Strategies Practice, Iowa City, IA USA.
[Rosenthal, Gary E.; Kaboli, Peter J.] Univ Iowa, Dept Internal Med, Div Gen Internal Med, Iowa City, IA 52242 USA.
RP Steinman, MA (reprint author), San Francisco VA Med Ctr, Box 181G,4150 Clement St, San Francisco, CA 94121 USA.
EM mike.steinman@ucsf.edu
FU AHRQ HHS [U18 HS016094]; NIA NIH HHS [AG 10418, K07 AG000912, Z01
AG000912, K23 AG030999-01A1, K23 AG030999, 1K23AG030999, AG 00912]; PHS
HHS [5 U18 HSO16094]
NR 30
TC 32
Z9 33
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
EI 1538-3679
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD JUL 27
PY 2009
VL 169
IS 14
BP 1326
EP +
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 475PT
UT WOS:000268373000011
PM 19636035
ER
PT J
AU Copeland, LA
Zeber, JE
Wang, CP
Parchman, ML
Lawrence, VA
Valenstein, M
Miller, AL
AF Copeland, Laurel A.
Zeber, John E.
Wang, Chen-Pin
Parchman, Michael L.
Lawrence, Valerie A.
Valenstein, Marcia
Miller, Alexander L.
TI Patterns of primary care and mortality among patients with schizophrenia
or diabetes: a cluster analysis approach to the retrospective study of
healthcare utilization
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
ID SERIOUS MENTAL-ILLNESS; OF-VETERANS-AFFAIRS; EXCESS MORTALITY; SYSTEM;
MANAGEMENT; RETENTION; QUALITY; RISK
AB Background: Patients with schizophrenia have difficulty managing their medical healthcare needs, possibly resulting in delayed treatment and poor outcomes. We analyzed whether patients reduced primary care use over time, differentially by diagnosis with schizophrenia, diabetes, or both schizophrenia and diabetes. We also assessed whether such patterns of primary care use were a significant predictor of mortality over a 4-year period.
Methods: The Veterans Healthcare Administration (VA) is the largest integrated healthcare system in the United States. Administrative extracts of the VA's all-electronic medical records were studied. Patients over age 50 and diagnosed with schizophrenia in 2002 were age-matched 1:4 to diabetes patients. All patients were followed through 2005. Cluster analysis explored trajectories of primary care use. Proportional hazards regression modelled the impact of these primary care utilization trajectories on survival, controlling for demographic and clinical covariates.
Results: Patients comprised three diagnostic groups: diabetes only (n = 188,332), schizophrenia only (n = 40,109), and schizophrenia with diabetes (Scz-DM, n = 13,025). Cluster analysis revealed four distinct trajectories of primary care use: consistent over time, increasing over time, high and decreasing, low and decreasing. Patients with schizophrenia only were likely to have low-decreasing use (73% schizophrenia-only vs 54% Scz-DM vs 52% diabetes). Increasing use was least common among schizophrenia patients (4% vs 8% Scz-DM vs 7% diabetes) and was associated with improved survival. Low-decreasing primary care, compared to consistent use, was associated with shorter survival controlling for demographics and case-mix. The observational study was limited by reliance on administrative data.
Conclusion: Regular primary care and high levels of primary care were associated with better survival for patients with chronic illness, whether psychiatric or medical. For schizophrenia patients, with or without comorbid diabetes, primary care offers a survival benefit, suggesting that innovations in treatment retention targeting at-risk groups can offer significant promise of improving outcomes.
C1 [Copeland, Laurel A.; Zeber, John E.; Wang, Chen-Pin; Parchman, Michael L.; Lawrence, Valerie A.] S Texas Vet Hlth Care Syst, VERDICT Res, San Antonio, TX USA.
[Copeland, Laurel A.; Zeber, John E.; Miller, Alexander L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Wang, Chen-Pin] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Parchman, Michael L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA.
[Lawrence, Valerie A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Valenstein, Marcia] Vet Adm Ann Arbor Healthcare Syst, SMITREC Res, Ann Arbor, MI USA.
[Valenstein, Marcia] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
RP Copeland, LA (reprint author), S Texas Vet Hlth Care Syst, VERDICT Res, San Antonio, TX USA.
EM copelandl@uthscsa.edu; zeber@uthscsa.edu; chen-pin.wang@va.gov;
parchman@uthscsa.edu; vlawrence@uthscsa.edu; marciav@umich.edu;
millera@uthscsa.edu
OI Copeland, Laurel/0000-0002-9478-0209
FU Department of Veterans Affairs; Veterans Health Administration, Health
Services Research and Development Service [IIR 05-326]; South Texas
Veterans Health Care System, San Antonio, TX; University of Texas Health
Science Center at San Antonio; Serious Mental Illness Treatment Research
& Evaluation Center; VA Ann Arbor Healthcare System, Ann Arbor, MI;
Merit Review Entry Program [MRP-05145]; VA Health Services Research and
Development program; VA HSRD [IIR05-326]
FX This research was supported by the Department of Veterans Affairs,
Veterans Health Administration, Health Services Research and Development
Service ( IIR 05-326; PI: Copeland). This work was completed with the
additional support of the VERDICT Research Program at the South Texas
Veterans Health Care System, San Antonio, TX, the University of Texas
Health Science Center at San Antonio, and the Serious Mental Illness
Treatment Research & Evaluation Center, VA Ann Arbor Healthcare System,
Ann Arbor, MI. LAC is funded by Merit Review Entry Program grant
MRP-05145 from the VA Health Services Research and Development program.
CPW, VAL, ALM, MV and JEZ are co-investigators on grant VA HSRD
IIR05-326 [Copeland-PI]. The authors gratefully acknowledge the
contributions of Brandon J Hosek in extracting, aggregating, and
managing the data.
NR 30
TC 35
Z9 36
U1 2
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD JUL 26
PY 2009
VL 9
AR 127
DI 10.1186/1472-6963-9-127
PG 11
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 490SW
UT WOS:000269525900001
PM 19630997
ER
PT J
AU Bains, M
Florez-McClure, ML
Heidenreich, KA
AF Bains, Mona
Florez-McClure, Maria L.
Heidenreich, Kim A.
TI Insulin-like Growth Factor-I Prevents the Accumulation of Autophagic
Vesicles and Cell Death in Purkinje Neurons by Increasing the Rate of
Autophagosome-to-lysosome Fusion and Degradation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CHAPERONE-MEDIATED AUTOPHAGY; CEREBELLAR GRANULE NEURONS;
PROTEIN-KINASE; ALZHEIMERS-DISEASE; SIGNALING PATHWAYS;
GLUTAMATE-RECEPTOR; TRANSGENIC MICE; LURCHER MICE; APOPTOSIS;
MACROAUTOPHAGY
AB Continuous macroautophagic activity is critical for the maintenance of neuronal homeostasis; however, unchecked or dysregulated autophagy can lead to cell death. Cultured Purkinje neurons die by an autophagy-associated cell death mechanism when deprived of trophic support. Here, we report that insulin-like growth factor-I ( IGF-I) completely blocked the autophagy-associated cell death of Purkinje neurons. To examine the mechanism by which IGF-I influences autophagy, neurons were infected with adeno-RFP-LC3 and subjected to trophic factor withdrawal, and the size and number of autophagosomes were analyzed by live-cell fluorescence imaging. In control neurons, autophagy occurred at a constitutive low level with most autophagosomes measuring less than 0.75 mu m. Trophic factor withdrawal increased the number and size of autophagosomes with most autophagosomes ranging between 0.75 and 1.5 mu m and some reaching 1.5-2.25 mu m. IGF-I added at the time of trophic factor withdrawal prevented the accumulation of the larger autophagosomes; however, it had no effect on the conversion of LC3, an indicator of autophagy induction. Instead, the rate of autophagosome-to-lysosome fusion measured by colocalization of RFP-LC3 and LysoSensor Green was accelerated by IGF-I. Treating the neurons with bafilomycin A(1) in the presence of IGF-I led to the accumulation of autophagosomes even larger than those induced by trophic factor withdrawal alone, indicating that IGF-I regulates autophagic vesicle turnover. Finally, the effect of IGF-I on autophagy was mediated by an Akt/mTOR-dependent and an ERK-independent pathway. These data suggest a novel role for IGF-I in protecting Purkinje neurons from autophagy-associated cell death by increasing autophagy efficiency downstream of autophagy induction.
C1 [Bains, Mona; Heidenreich, Kim A.] Univ Colorado Denver, Dept Pharmacol, Aurora, CO 80045 USA.
[Florez-McClure, Maria L.] Discovery Martek Biosci Corp, Neurosci Res, Boulder, CO 80301 USA.
[Heidenreich, Kim A.] Denver Vet Affairs Med Ctr, Denver, CO 80262 USA.
RP Heidenreich, KA (reprint author), Univ Colorado Denver, Dept Pharmacol, MS 8303,POB 6511, Aurora, CO 80045 USA.
EM Kim.Heidenreich@ucdenver.edu
FU National Institutes of Health [NS045560, 1F32NS062534-01A1]; Department
of Veterans Affairs merit awards; Department of Defense [03281009]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants NS045560 and 1F32NS062534-01A1 (NINDS). This work was also
supported by a Department of Veterans Affairs merit awards and
Department of Defense Grant 03281009 (United States Army Medical
Research and Material Command).
NR 55
TC 31
Z9 32
U1 3
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 24
PY 2009
VL 284
IS 30
BP 20398
EP 20407
DI 10.1074/jbc.M109.011791
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 471ZO
UT WOS:000268097400065
PM 19509289
ER
PT J
AU Vlopp, KG
Das, A
AF Vlopp, Kevin G.
Das, Anup
TI Comparative Effectiveness - Thinking beyond Medication A versus
Medication B
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID SMOKING-CESSATION
C1 [Vlopp, Kevin G.; Das, Anup] Univ Penn, Philadelphia, PA 19104 USA.
[Vlopp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Vlopp, KG (reprint author), Univ Penn, Philadelphia, PA 19104 USA.
NR 5
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUL 23
PY 2009
VL 361
IS 4
BP 331
EP 333
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 473DC
UT WOS:000268184500003
ER
PT J
AU Lipschutz, JH
AF Lipschutz, Josh H.
TI Electronic Health Records in Hospitals
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID CARE
C1 Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Lipschutz, JH (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
EM jhlipsch@mail.med.upenn.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUL 23
PY 2009
VL 361
IS 4
BP 421
EP 421
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 473DC
UT WOS:000268184500024
PM 19625724
ER
PT J
AU Werner, RM
McNutt, RA
AF Werner, Rachel M.
McNutt, Robert A.
TI Identifying and Improving Quality of Care Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID PERFORMANCE-MEASURES
C1 [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[McNutt, Robert A.] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA.
RP Werner, RM (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
EM rwerner@mail.med.upenn.edu
NR 3
TC 0
Z9 0
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUL 22
PY 2009
VL 302
IS 4
BP 383
EP 383
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 472NQ
UT WOS:000268139200020
ER
PT J
AU Volberding, P
AF Volberding, Paul
TI Cohorts, Trials, and Evidence: Expanding Our Confidence in Guidelines
for Antiretroviral Resistance Testing
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID HIV-INFECTED PATIENTS; SOCIETY-USA PANEL; 2008 RECOMMENDATIONS;
DRUG-RESISTANCE; THERAPY
C1 [Volberding, Paul] Univ Calif San Francisco, San Francisco, CA 94121 USA.
[Volberding, Paul] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Volberding, P (reprint author), Vet Affairs Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM paul.volberding@med.va.gov
NR 13
TC 1
Z9 1
U1 0
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JUL 21
PY 2009
VL 151
IS 2
BP 135
EP 136
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 478RH
UT WOS:000268605300008
PM 19620166
ER
PT J
AU Barnes, DE
Covinsky, KE
Whitmer, RA
Kuller, LH
Lopez, OL
Yaffe, K
AF Barnes, D. E.
Covinsky, K. E.
Whitmer, R. A.
Kuller, L. H.
Lopez, O. L.
Yaffe, K.
TI Predicting risk of dementia in older adults The late-life dementia risk
index
SO NEUROLOGY
LA English
DT Article
ID CARDIOVASCULAR HEALTH COGNITION; INCIDENT ALZHEIMER-DISEASE; PROGNOSTIC
INDEX; BREAST-CANCER; PREVALENCE; VALIDATION; MORTALITY; PEOPLE; SCORE
AB Objective: To develop a late-life dementia risk index that can accurately stratify older adults into those with a low, moderate, or high risk of developing dementia within 6 years.
Methods: Subjects were 3,375 participants in the Cardiovascular Health Cognition Study without evidence of dementia at baseline. We used logistic regression to identify those factors most predictive of developing incident dementia within 6 years and developed a point system based on the logistic regression coefficients.
Results: Subjects had a mean age of 76 years at baseline; 59% were women and 15% were African American. Fourteen percent (n = 480) developed dementia within 6 years. The final late-life dementia risk index included older age (1-2 points), poor cognitive test performance (2-4 points), body mass index <18.5 (2 points), >= 1 apolipoprotein E epsilon 4 alleles (1 point), cerebral MRI findings of white matter disease (1 point) or ventricular enlargement (1 point), internal carotid artery thickening on ultrasound (1 point), history of bypass surgery (1 point), slow physical performance (1 point), and lack of alcohol consumption (1 point) (c statistic, 0.81; 95% confidence interval, 0.79-0.83). Four percent of subjects with low scores developed dementia over 6 years compared with 23% of subjects with moderate scores and 56% of subjects with high scores.
Conclusions: The late-life dementia risk index accurately stratified older adults into those with low, moderate, and high risk of developing dementia. This tool could be used in clinical or research settings to target prevention and intervention strategies toward high-risk individuals. Neurology (R) 2009; 73: 173-179
C1 [Barnes, D. E.; Yaffe, K.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Covinsky, K. E.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA.
[Yaffe, K.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
[Yaffe, K.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
[Barnes, D. E.; Covinsky, K. E.; Whitmer, R. A.; Yaffe, K.] Kaiser Div Res, Oakland, CA USA.
[Kuller, L. H.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA.
[Lopez, O. L.] Univ Pittsburgh, Dept Neurol & Psychiat, Pittsburgh, PA 15260 USA.
RP Barnes, DE (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,151R, San Francisco, CA 94121 USA.
EM Deborah.Barnes@ucsf.edu
FU National Heart, Lung, and Blood Institute [N01-HC85079, N01-HC-85086,
N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133,
U01 HL080295]; National Institute on Aging [AG15928]; National Institute
of Neurological Disorders and Stroke; NIH [K01 AG024069]; NIH/NCRR [UL1
RR024131]
FX The research reported in this article was supported by contracts
N01-HC85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103,
N01-HC-55222, N01-HC-75150, N01-HC-45133, grant U01 HL080295 from the
National Heart, Lung, and Blood Institute, and grant AG15928 from the
National Institute on Aging with additional contribution from the
National Institute of Neurological Disorders and Stroke. A full list of
principal CHS investigators and institutions can be found at
http://www.chs-nhlbi.org/pi.htm. Dr. Barnes is funded through a K01
Career Development Award (K01 AG024069) from the NIH. This project also
was supported by NIH/NCRR UCSF-CTSI grant UL1 RR024131. The
Biostatistics, Research Design, Ethics and Data Management program of
UCSF's Clinical and Translational Sciences Institute (NIH/NCRR UCSF-CTSI
grant UL1 RR024131) provided preliminary data analyses and statistical
advice.
NR 35
TC 86
Z9 88
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUL 21
PY 2009
VL 73
IS 3
BP 173
EP 179
DI 10.1212/WNL.0b013e3181a81636
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 472QO
UT WOS:000268147100004
PM 19439724
ER
PT J
AU Britschgi, M
Olin, CE
Johns, HT
Takeda-Uchimura, Y
LeMieux, MC
Rufibach, K
Rajadas, J
Zhang, H
Tomooka, B
Robinson, WH
Clark, CM
Fagan, AM
Galasko, DR
Holtzman, DM
Jutel, M
Kaye, JA
Lemere, CA
Leszek, J
Li, G
Peskind, ER
Quinn, JF
Yesavage, JA
Ghiso, JA
Wyss-Coray, T
AF Britschgi, M.
Olin, C. E.
Johns, H. T.
Takeda-Uchimura, Y.
LeMieux, M. C.
Rufibach, K.
Rajadas, J.
Zhang, H.
Tomooka, B.
Robinson, W. H.
Clark, C. M.
Fagan, A. M.
Galasko, D. R.
Holtzman, D. M.
Jutel, M.
Kaye, J. A.
Lemere, C. A.
Leszek, J.
Li, G.
Peskind, E. R.
Quinn, J. F.
Yesavage, J. A.
Ghiso, J. A.
Wyss-Coray, T.
TI Neuroprotective natural antibodies to assemblies of amyloidogenic
peptides decrease with normal aging and advancing Alzheimer's disease
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID A-BETA ANTIBODIES; MOUSE MODEL; IN-VITRO; PROTEIN; AUTOANTIBODIES;
OLIGOMERS; PLAQUES; IMMUNOTHERAPY; MICROARRAYS; DEPOSITION
AB A number of distinct beta-amyloid (A beta) variants or multimers have been implicated in Alzheimer's disease (AD), and antibodies recognizing such peptides are in clinical trials. Humans have natural A beta-specific antibodies, but their diversity, abundance, and function in the general population remain largely unknown. Here, we demonstrate with peptide microarrays the presence of natural antibodies against known toxic A beta and amyloidogenic non-A beta species in plasma samples and cerebrospinal fluid of AD patients and healthy controls aged 21-89 years. Antibody reactivity was most prominent against oligomeric assemblies of A beta and pyroglutamate or oxidized residues, and IgGs specific for oligomeric preparations of A beta 1-42 in particular declined with age and advancing AD. Most individuals showed unexpected antibody reactivities against peptides unique to autosomal dominant forms of dementia (mutant A beta, ABri, ADan) and IgGs isolated from plasma of AD patients or healthy controls protected primary neurons from A beta toxicity. Aged vervets showed similar patterns of plasma IgG antibodies against amyloid peptides, and after immunization with A beta the monkeys developed high titers not only against A beta peptides but also against ABri and ADan peptides. Our findings support the concept of conformation-specific, cross-reactive antibodies that may protect against amyloidogenic toxic peptides. If a therapeutic benefit of A beta antibodies can be confirmed in AD patients, stimulating the production of such neuroprotective antibodies or passively administering them to the elderly population may provide a preventive measure toward AD.
C1 [Britschgi, M.; Olin, C. E.; Johns, H. T.; Takeda-Uchimura, Y.; Rajadas, J.; Zhang, H.; Yesavage, J. A.; Wyss-Coray, T.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.
[LeMieux, M. C.] Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.
[Rufibach, K.] Univ Zurich, Biostat Unit, Inst Social & Prevent Med, CH-8001 Zurich, Switzerland.
[Robinson, W. H.; Yesavage, J. A.; Wyss-Coray, T.] Vet Affairs Palo Alto Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA 94304 USA.
[Clark, C. M.] Univ Penn, Alzheimers Dis Ctr, Dept Neurol, Philadelphia, PA 19104 USA.
[Clark, C. M.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA.
[Fagan, A. M.; Holtzman, D. M.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA.
[Galasko, D. R.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[Jutel, M.] Wroclaw Med Univ, Dept Internal Med & Allergol, PL-50417 Wroclaw, Poland.
[Kaye, J. A.; Quinn, J. F.] Oregon Hlth & Sci Univ, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA.
[Lemere, C. A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Lemere, C. A.] Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.
[Leszek, J.] Wroclaw Med Univ, Dept Psychiat, PL-51622 Wroclaw, Poland.
[Li, G.; Peskind, E. R.] Univ Washington, Alzheimers Dis Res Ctr, Seattle, WA 98108 USA.
[Li, G.; Peskind, E. R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Ghiso, J. A.] NYU, Langone Med Ctr, Dept Pathol, New York, NY 10016 USA.
[Ghiso, J. A.] NYU, Langone Med Ctr, Dept Psychiat, New York, NY 10016 USA.
RP Wyss-Coray, T (reprint author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.
EM twc@stanford.edu
RI Rufibach, Kaspar/F-1163-2010
OI Kaye, Jeffrey/0000-0002-9971-3478
FU John Douglas French Alzheimer's Foundation; Department of Veterans
Affairs; National Institute on Aging [AG20603, AG10491, AG030539, P50
AG005136, AG08017]
FX We thank the patients who participated in this study; M. BenBarak and P.
Chandra for assistance with the peptide array; J. Frost for technical
assistance with the vervet samples; R. Palmour and F. Ervin for housing
the vervets at the Behavioral Science Foundation, St. Kitts, Eastern
Caribbean, and numerous unnamed staff at our institutions for their
effort in patient recruitment, clinical assessment, and sample
preparation. This work was supported by the John Douglas French
Alzheimer's Foundation (T. W.-C.), the Department of Veterans Affairs
(T. W.-C., E. R. P., G. L., and J. A. Y.), and National Institute on
Aging Grants AG20603 (to T. W.-C.), AG10491, AG030539 (to J. A. G.), P50
AG005136 (to E. R. P.), and AG08017 (to J. F. Q. and J. A. K.).
NR 62
TC 88
Z9 89
U1 1
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 21
PY 2009
VL 106
IS 29
BP 12145
EP 12150
DI 10.1073/pnas.0904866106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 473BI
UT WOS:000268178400059
PM 19581601
ER
PT J
AU Angelov, L
Doolittle, ND
Kraemer, DF
Siegal, T
Barnett, GH
Peereboom, DM
Stevens, G
McGregor, J
Jahnke, K
Lacy, CA
Hedrick, NA
Shalom, E
Ference, S
Bell, S
Sorenson, L
Tyson, RM
Haluska, M
Neuwelt, EA
AF Angelov, Lilyana
Doolittle, Nancy D.
Kraemer, Dale F.
Siegal, Tali
Barnett, Gene H.
Peereboom, David M.
Stevens, Glen
McGregor, John
Jahnke, Kristoph
Lacy, Cynthia A.
Hedrick, Nancy A.
Shalom, Edna
Ference, Sandra
Bell, Susan
Sorenson, Lisa
Tyson, Rose Marie
Haluska, Marianne
Neuwelt, Edward A.
TI Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based
Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional
Experience
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT 43rd Annual Meeting of the American-Society-of-Clinical-Oncology
CY JUN 01-05, 2007
CL Chicago, IL
SP Amer Soc Clin Oncol
ID CENTRAL-NERVOUS-SYSTEM; HIGH-DOSE METHOTREXATE; ENHANCED CHEMOTHERAPY
DELIVERY; TERM-FOLLOW-UP; PHASE-II; DEFERRED RADIOTHERAPY; EUROPEAN
ORGANIZATION; COGNITIVE FUNCTIONS; MULTICENTER; SURVIVAL
AB Purpose Primary CNS lymphoma (PCNSL) is confined to the CNS and/or the eyes at presentation and is usually initially treated with intravenous methotrexate-based chemotherapy and whole-brain radiotherapy (WBRT). However, the intact blood-brain barrier (BBB) can limit diffusion of methotrexate into brain and tumor. With BBB disruption (BBBD), enhanced drug delivery to the tumor can be achieved.
Patients and Methods This report summarizes the multi-institutional experience of 149 newly diagnosed (with no prior WBRT) patients with PCNSL treated with osmotic BBBD and intra-arterial (IA) methotrexate at four institutions from 1982 to 2005. In this series, 47.6% of patients were age >= 60 years, and 42.3% had Karnofsky performance score (KPS) less than 70 at diagnosis.
Results The overall response rate was 81.9% (57.8% complete; 24.2% partial). Median overall survival (OS) was 3.1 years (25% estimated survival at 8.5 years). Median progression-free survival (PFS) was 1.8 years, with 5-year PFS of 31% and 7-year PFS of 25%. In low-risk patients (age >= 60 years and KPS >= 70), median OS was approximately 14 years, with a plateau after approximately 8 years. Procedures were generally well tolerated; focal seizures (9.2%) were the most frequent side effect and lacked long-term sequelae.
Conclusion This large series of patients treated over a 23-year period demonstrates that BBBD/IA methotrexate-based chemotherapy results in successful and durable tumor control and outcomes that are comparable or superior to other PCNSL treatment regimens.
C1 Cleveland Clin, Brain Tumor & Neuro Oncol Ctr, Cleveland, OH USA.
Cleveland Clin, Dept Neurosurg, Cleveland, OH USA.
Cleveland Clin, Dept Hematol, Cleveland, OH USA.
Cleveland Clin, Dept Med Oncol, Cleveland, OH USA.
Ohio State Univ, Med Ctr, Dept Neurosurg, Columbus, OH 43210 USA.
Oregon Hlth & Sci Univ, Dept Neurol, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Dept Publ Hlth, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Dept Prevent Med, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
Oregon State Univ, Dept Pharm Practice, Corvallis, OR 97331 USA.
Portland VA Med Ctr, Portland, OR USA.
Hadassah Hebrew Univ Hosp, Leslie & Michael Gaffin Ctr Neurooncol, Jerusalem, Israel.
RP Neuwelt, EA (reprint author), 3181 SW Sam Jackson Pk Rd,Mailcode L603, Portland, OR 97239 USA.
EM neuwelte@ohsu.edu
RI McGregor, John/K-6870-2013
FU NCI NIH HHS [R13 CA086959, CA137488, R01 CA137488, R01 CA137488-15, R13
CA086959-10]; NINDS NIH HHS [NS34608, NS44687, R01 NS034608, R01
NS044687, R37 NS044687]
NR 47
TC 84
Z9 86
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUL 20
PY 2009
VL 27
IS 21
BP 3503
EP 3509
DI 10.1200/JCO.2008.19.3789
PG 7
WC Oncology
SC Oncology
GA 471II
UT WOS:000268049100016
PM 19451444
ER
PT J
AU Pryaslova, JP
Lyamin, OI
Siegel, JM
Mukhametov, LM
AF Pryaslova, Julia P.
Lyamin, Oleg I.
Siegel, Jerome M.
Mukhametov, Lev M.
TI Behavioral sleep in the walrus
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article
DE Quiet sleep; REM sleep; Behavioral sleep; Sleep variability; Continuous
swimming; Breathing pattern; Walrus; Pinnipeds
ID SEAL PAGOPHILUS-GROENLANDICA; MAMMALIAN SLEEP; FUR-SEAL; PATTERNS; PUPS;
WAKEFULNESS; ASYMMETRY; WAKE; EEG
AB In this study we examined behavioral sleep in the walrus, the only living species of the family Odobenidae. The behavior of four 1.5-2-year-old captive walruses was videotaped continuously for 7-17 days and scored in 1-min epochs. When walruses had access to water and land, behavioral sleep, the combined amount of quiet and rapid eye movement (REM) sleep, occupied on average 17 +/- 4% of 24 h (n = 4) with the majority of sleep occurring on land. All walruses alternated periods of almost continuous swimming lasting for 40-84 h with periods of rest on land lasting for 2-19 h. When in water they were predominantly awake (88-99% of the time). On land walruses were asleep on average 40-74% of the time. The total sleep time varied between 0 and 60% of 24 h with the daily amount of REM sleep ranging from 0 to 5% of 24 h. In water, walruses slept while floating at the surface, lying on the bottom or standing and leaning against the pool wall. REM sleep in water occurred in all positions. On land the breathing pattern was regular during quiet sleep (most pauses were <30s) and arrhythmic in REM sleep (apneas lasted up to 160s). While in water the irregularity of breathing further increased (apneas were >4 min) and all REM sleep episodes occurred during a single apnea. Data indicate that the pattern of sleep and breathing in walruses is similar to the Otariidae seats while on land and the Phocidae seats while in water. Published by Elsevier B.V.
C1 [Lyamin, Oleg I.; Siegel, Jerome M.] Vet Affairs Greater Los Angeles Healthcare Syst S, Neurobiol Res 151A3, North Hills, CA 91343 USA.
[Pryaslova, Julia P.; Lyamin, Oleg I.; Mukhametov, Lev M.] Utrish Dolphinarium Ltd, Moscow 119071, Russia.
[Lyamin, Oleg I.; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat, Sch Med, Los Angeles, CA USA.
RP Lyamin, OI (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst S, Neurobiol Res 151A3, 16111 Plummer St, North Hills, CA 91343 USA.
EM olyamin@ucla.edu
FU Utrish Dolphinarium Ltd. (Moscow, Russia); The Medical Research Service
of the Department of Veterans Affairs (USA)
FX This research was supported by Utrish Dolphinarium Ltd. (Moscow, Russia)
and The Medical Research Service of the Department of Veterans Affairs
(USA). The authors wish to thank the staff of the Utrish Dolphinarium
and the Utrish Marine Station (Severtsov Institute of the Russian
Academy of Sciences, Novorossiysk, Russia), for their help and
assistance during the observations. We are also thankful to J. Lapierre
for valuable comments on this manuscript.
NR 40
TC 5
Z9 5
U1 4
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD JUL 19
PY 2009
VL 201
IS 1
BP 80
EP 87
DI 10.1016/j.bbr.2009.01.033
PG 8
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 447ZV
UT WOS:000266231800012
PM 19428620
ER
PT J
AU Viel, KR
Kasper, CK
Howard, TE
AF Viel, Kevin R.
Kasper, Carol K.
Howard, Tom E.
TI Inhibitors of Factor VIII in Hemophilia REPLY
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID INVERSIONS; GENE
C1 [Viel, Kevin R.] St Josephs Translat Res Inst, Atlanta, GA 30342 USA.
[Kasper, Carol K.] Orthoped Hosp, Los Angeles, CA 90007 USA.
[Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Viel, KR (reprint author), St Josephs Translat Res Inst, Atlanta, GA 30342 USA.
EM tom.howard@va.gov
NR 4
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUL 16
PY 2009
VL 361
IS 3
BP 310
EP 310
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 470LL
UT WOS:000267976100030
ER
PT J
AU Zahid, M
Good, CB
Singla, I
Sonel, AF
AF Zahid, Maliha
Good, Chester B.
Singla, Ish
Sonel, Ali F.
TI Clinical Significance of Borderline Elevated Troponin I Levels Across
Different Assays in Patients With Suspected Acute Coronary Syndrome
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID CARDIAC TROPONIN; MYOCARDIAL-INFARCTION; MORTALITY; RISK; TERM
AB We aimed to elucidate the clinical significance of borderline troponin I (TnI) increases and see if such increases are of similar significance across different assays. Markedly increased TnI is a strong predictor of adverse cardiac events. It is not clear if borderline increases with different commercially available TnI assays provide similar prognostic information. From January 2001 to February 2004, 3 different TnI assays (Beckman Access TnI, Beckman Access AccuTnI, and Vitros ECI Troponin) were used to evaluate the peak TO value in 1,152 consecutive patients admitted with suspected acute coronary syndrome/non-ST-elevation myocardial infarction (MI). Recommended cutoffs were used to differentiate borderline from marked increases reported as consistent with MI. Clinical data and 30-day death/new MIs were determined by chart abstraction. Demographics and cardiac risk factors were similar for the 3 groups. Frequency of borderline TnI ranged widely among assays (18.7% to 42.1%) but was significantly less with the Vitros ECI Troponin assay (p < 0.0001). Prognostic significance of borderline increased TnI values also varied greatly by assay, with borderline Beckman Access AccuTnI increases being predictive of adverse 30-day outcomes (odds ratio 4.0, 95% confidence interval 1.46 to 10.97, p = 0.007), but not with the other 2 assays. Borderline increases were significantly associated with chronic renal insufficiency (CRI; serum creatine > 1.5); the relation to adverse 30-day outcomes and borderline increases persisted after correcting for CRI in a multivariate logistic regression model. In conclusion, although borderline increased TnI levels are common and significantly associated with CRI, they do not all portend the same clinical prognosis. This study highlights the need for standardization of TnI levels across different assays. (C) 2009 Published by Elsevier Inc. (Am J Cardiol 2009;104:164-168)
C1 [Zahid, Maliha; Good, Chester B.; Singla, Ish; Sonel, Ali F.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Good, Chester B.; Sonel, Ali F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Good, Chester B.; Sonel, Ali F.] Ctr Healthy Equ & Res Promot, Pittsburgh, PA USA.
RP Zahid, M (reprint author), Univ Pittsburgh, Pittsburgh, PA 15260 USA.
EM maz7@pitt.edu
NR 11
TC 10
Z9 10
U1 0
U2 1
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD JUL 15
PY 2009
VL 104
IS 2
BP 164
EP 168
DI 10.1016/j.amjcard.2009.03.012
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 477TB
UT WOS:000268540500003
PM 19576340
ER
PT J
AU Melloni, C
Alexander, KP
Ou, FS
LaPointe, NMA
Roe, MT
Newby, LK
Baloch, K
Ho, PM
Rumsfeld, JS
Peterson, ED
AF Melloni, Chiara
Alexander, Karen P.
Ou, Fang-Shu
LaPointe, Nancy M. Allen
Roe, Matthew T.
Newby, L. Kristin
Baloch, Khaula
Ho, P. Michael
Rumsfeld, John S.
Peterson, Eric D.
TI Predictors of Early Discontinuation of Evidence-Based Medicine After
Acute Coronary Syndrome
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; MEDICATION ADHERENCE; PATIENT
COMMUNICATION; SECONDARY PREVENTION; ADVERSE OUTCOMES; ARTERY-DISEASE;
THERAPY; MORTALITY; NONADHERENCE; ASSOCIATION
AB Use of evidence-based medicine (EBM) improves outcomes after acute coronary syndromes (ACS), yet patients often discontinue prescribed therapies after discharge. Although such discontinuation is well documented, patients' reasons for medication discontinuation have not been reported. MAINTAIN is a longitudinal follow-up registry of CRUSADE/ACTION, which enrolled patients during an ACS hospitalization from January 2006 to September 2007. All discharge medications were obtained from hospital charts. Patients were interviewed by telephone 3 months after discharge to determine if EBM classes prescribed at discharge were continued (aspirin, clopidogrel, beta blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and lipid-lowering medications). If discontinuation occurred, patients were asked if it was with provider knowledge/input or not (self-discontinuation). A multivariable logistic regression model was performed to identify factors associated with self-discontinuation of prescribed EBM. Of the 1,077 patients interviewed, 1,006 (93.4%) were discharged on aspirin, 816 (75.8%) on clopidogrel, 982 (91.2%) on beta blockers, 745 (69.2%) on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 968 (89.9%) on lipid-lowering medications. At 3-month follow-up, 304 patients (28.2%) had discontinued >= 1 of these prescribed EBM classes. Although many reported provider involvement, most discontinuation (61.5%) was self-determined. Factors independently associated with self-discontinuation were no pharmacy coinsurance, increasing number of medications, not using reminder tools (e.g., pillbox), lower education, and dialysis. In conclusion, 1/3 of patients with ACS discontinue >= 1 of their prescribed EBMs within 3 months of hospital discharge, and most of this discontinuation is without provider involvement. Patient education, better prescription drug coverage, and reminder strategies may improve use of EBMs at 3 months after discharge from ACS admission. (C) 2009 Published by Elsevier Inc. (Am J Cardiol 2009;104:175-181)
C1 [Melloni, Chiara; Alexander, Karen P.; Ou, Fang-Shu; Roe, Matthew T.; Newby, L. Kristin; Baloch, Khaula; Peterson, Eric D.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA.
[Melloni, Chiara; Alexander, Karen P.; Ou, Fang-Shu; Roe, Matthew T.; Newby, L. Kristin; Baloch, Khaula; Peterson, Eric D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27710 USA.
[LaPointe, Nancy M. Allen] Duke Univ, Med Ctr, Div Clin Pharmacol, Durham, NC 27710 USA.
[Ho, P. Michael; Rumsfeld, John S.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA.
[Ho, P. Michael; Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
RP Melloni, C (reprint author), Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA.
EM mello004@mc.duke.edu
FU Bristol-Myers Squibb/Sanoti-Aventis Pharmaceuticals; Merck
Schering-Plough Pharmaceutical
FX MAINTAIN is funded by Bristol-Myers Squibb/Sanoti-Aventis
Pharmaceuticals partnership and by Merck Schering-Plough Pharmaceutical.
NR 28
TC 52
Z9 57
U1 0
U2 4
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD JUL 15
PY 2009
VL 104
IS 2
BP 175
EP 181
DI 10.1016/j.amjcard.2009.03.013
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 477TB
UT WOS:000268540500005
PM 19576342
ER
PT J
AU Dhaliwal, AS
Habib, G
Deswal, A
Verduzco, M
Souchek, J
Ramasubbu, K
Aguilar, D
Ma, TS
Jneid, HM
Bolos, M
Bozkurt, B
AF Dhaliwal, Amandeep S.
Habib, Gabriel
Deswal, Anita
Verduzco, Melinda
Souchek, Julianne
Ramasubbu, Kumudha
Aguilar, David
Ma, Tony S.
Jneid, Hani M.
Bolos, Mariana
Bozkurt, Biykem
TI Impact of Alpha 1-Adrenergic Antagonist Use for Benign Prostatic
Hypertrophy on Outcomes in Patients With Heart Failure
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID LEFT-VENTRICULAR DYSFUNCTION; DOUBLE-BLIND; ALPHA(1)-ADRENERGIC
RECEPTORS; PLASMA NOREPINEPHRINE; HYPERTENSIVE PATIENTS;
ALPHA-ADRENOCEPTOR; PRAZOSIN THERAPY; CARVEDILOL; DOXAZOSIN; TRIAL
AB Previous clinical trials have shown that alpha(1)-adrenergic antagonists are not effective in subjects with heart failure (HF) and might increase HF rates when used for hypertension. However, alpha(1)-adrenergic antagonists may be prescribed to subjects with HF who have symptomatic benign prostatic hyperplasia. We sought to determine any association between alpha(1)-adrenergic antagonist use, commonly prescribed for benign prostatic hyperplasia, and the clinical outcomes of subjects with HF receiving contemporary therapy. An existing database of 388 subjects with decompensated HF admissions from 2002 to 2004 at the Veterans Affairs Hospital was analyzed according to the use of alpha(1)-adrenergic antagonists at discharge. Covariate-adjusted Cox proportional hazard models were used to examine any association with future admissions for decompensated HF and total mortality. Alpha-1-adrenergic antagonist therapy was prescribed in 25% of our HF population, predominantly for benign prostatic hyperplasia, and was not associated with significant increases in the combined risk of all-cause mortality and rehospitalization for HF (hazard ratio 1.24, 95% confidence interval 0.93 to 1.65, p = 0.14), HF hospitalization (hazard ratio 1.20, 95% confidence interval 0.85 to 1.70, p 0.31), or all-cause mortality (hazard ratio 1.10, 95% confidence interval 0.78 to 1.56, p 0.57). In patients not receiving beta-blocker therapy, alpha(1)-adrenergic antagonist therapy was significantly associated with increased HF hospitalizations (hazard ratio 1.94, 95% confidence interval 1.14 to 3.32, p = 0.015). In conclusion, in patients with chronic HF, the use of alpha(1)-adrenergic antagonists was significantly associated with more HF hospitalizations when prescribed without concomitant beta blockade. Thus, background beta-blocker therapy appears to be protective against the potential harmful effects of alpha(1)-adrenergic antagonist therapy in patients with HF. Published by Elsevier Inc. (Am J Cardiol 2009;104:270-275)
C1 [Dhaliwal, Amandeep S.; Habib, Gabriel; Deswal, Anita; Verduzco, Melinda; Souchek, Julianne; Ramasubbu, Kumudha; Ma, Tony S.; Jneid, Hani M.; Bozkurt, Biykem] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Cardiol Sect, Houston, TX USA.
[Deswal, Anita; Ramasubbu, Kumudha; Aguilar, David; Bolos, Mariana; Bozkurt, Biykem] Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA.
RP Bozkurt, B (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Cardiol Sect, Houston, TX USA.
EM bbozkurt@bcm.tmc.edu
FU Veterans Affairs Medical Research Service; National Institutes of
Health, Bethesda, Maryland [NIH-K12]
FX Dr. Bozkurt is a recipient of a Merit Entry Level grant support from the
Veterans Affairs Medical Research Service. Dr. Aguilar is a recipient of
the Mentored Clinical Scientist Development Program (NIH-K12 Award)
award from the National Institutes of Health, Bethesda, Maryland.
NR 29
TC 7
Z9 10
U1 0
U2 1
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD JUL 15
PY 2009
VL 104
IS 2
BP 270
EP 275
DI 10.1016/j.amjcard.2009.03.030
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 477TB
UT WOS:000268540500022
PM 19576359
ER
PT J
AU Hung, WW
Wisnivesky, JP
Siu, AL
Ross, JS
AF Hung, William W.
Wisnivesky, Juan P.
Siu, Albert L.
Ross, Joseph S.
TI Cognitive Decline among Patients with Chronic Obstructive Pulmonary
Disease
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE chronic obstructive pulmonary disease; cognitive impairment;
longitudinal survey
ID IMPAIRMENT; DEFICITS; COPD
AB Rationale: Prior research has suggested an association between chronic obstructive pulmonary disease (COPD) and the development of cognitive decline; however, these studies have been cross-sectional or small case series.
Objectives: To determine whether COPD increases the risk of cognitive decline among older adults surveyed in a large, population-based longitudinal cohort.
Methods: We included data from the 1996 to 2002 waves of the Health and Retirement Study, a biennial nationally representative survey. We studied respondents who completed cognitive testing in 1996 and at least one subsequent survey, and excluded those with unknown history of COPD. Clinical history of COPD was based on self-report; severity was categorized based on use of oxygen or disease-related activity limitations. Our primary outcome was cognitive performance, measured using a validated 35-point scale. We examined the effect of COPD on cognition using multivariable mixed linear models accounting for repeated measurements, adjusted for sociodemographic and clinical characteristics.
Measurements and Main Results: A total of 4,150 adults were included in our study. Among them, 12% reported a history of COPD (29% severe, 71% nonsevere disease). On repeated measurement, mean cognition scores of older adults with both severe and nonsevere COPD were significantly lower when compared with adults without COPD (2.6 points [P < 0.001] and 0.9 points [P < 0,001], respectively). After multivariable adjustment, mean scores of adults with severe COPD remained lower (0.9 point [P < 0.001]), whereas mean score of adults with nonsevere COPD was no longer different (P = 0.39) when compared with adults without COPD.
Conclusions. Severe COPD was associated with lower cognitive performance on standardized measurement over time.
C1 [Hung, William W.; Siu, Albert L.; Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA.
[Wisnivesky, Juan P.] Mt Sinai Sch Med, Dept Med, Div Gen Internal Med, New York, NY 10029 USA.
[Wisnivesky, Juan P.] Mt Sinai Sch Med, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA.
[Hung, William W.; Siu, Albert L.; Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA.
[Hung, William W.; Siu, Albert L.; Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Hlth Serv Res & Dev, Serv Res Enhancement Award Program, Bronx, NY USA.
RP Hung, WW (reprint author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA.
EM william.hung@mssm.edu
NR 23
TC 57
Z9 61
U1 0
U2 5
PU AMER THORACIC SOC
PI NEW YORK
PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD JUL 15
PY 2009
VL 180
IS 2
BP 134
EP 137
DI 10.1164/rccm.200902-0276OC
PG 4
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 472EP
UT WOS:000268112500007
PM 19423714
ER
PT J
AU Wong, K
Lyddon, R
Dracheva, S
AF Wong, Kevin
Lyddon, Rebecca
Dracheva, Stella
TI TaqMan-based, real-time quantitative polymerase chain reaction method
for RNA editing analysis
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE RNA editing; GluR5; Multiplex qPCR; Taqman
ID SEROTONIN 2C RECEPTOR; PCR DATA-ANALYSIS; MESSENGER-RNA; ADENOSINE;
TRANSMISSION; DEAMINASES; MECHANISM; CORTEX; GLUR2; BRAIN
AB Abnormal adenosine to inosine (A-to-1) messenger RNA (mRNA) editing has been linked to several disease states afflicting the central nervous system. Here we report an assay to determine RNA editing frequencies at specific sites that is based on quantitative polymerase chain reaction (qPCR) with TaqMan probes. The assay was tested by measuring the frequency of the A-to-1 mRNA editing at the Q/R site of the human kainate receptor Subunit GluR5 and was compared with two established methods of assessing RNA editing: sequencing of individual clones and restriction analysis. The qPCR assay displayed high sensitivity and reproducibility, demonstrated exceptional discrimination between edited and Unedited transcript variants, and proved to have several advantages over the other editing methods. Due to the fact that TaqMan-based qPCR technology can be easily adapted to different editing targets, the increased capabilities afforded by this new technique should facilitate various RNA editing studies that aim to elucidate the role of this process in normal physiology and in disease. Published by Elsevier Inc. Published by Elsevier Inc.
C1 [Wong, Kevin; Dracheva, Stella] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
[Lyddon, Rebecca; Dracheva, Stella] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
RP Dracheva, S (reprint author), Bronx VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM stella.dracheva@mssm.edu
FU VA Merit award; American Foundation for Suicide Prevention; VISN3 Mental
Illness Research and Education Clinical Center (MIRECC)
FX Postmortem brain tissue was donated by the Stanley Medical Research
Institute's array Collection Courtesy of Michael B. Knable, E. Fuller
Torrey, Maree J Webster, and Robert H. Yolken. This Study was supported
by a VA Merit award (S.D.), a grant from the American Foundation for
Suicide Prevention (S.D.), and the VISN3 Mental Illness Research and
Education Clinical Center (MIRECC).
NR 28
TC 6
Z9 6
U1 2
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD JUL 15
PY 2009
VL 390
IS 2
BP 173
EP 180
DI 10.1016/j.ab.2009.04.011
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 457QB
UT WOS:000266946000011
PM 19371717
ER
PT J
AU Butt, AA
Wang, XQ
Budoff, M
Leaf, D
Kuller, LH
Justice, AC
AF Butt, Adeel A.
Wang Xiaoqiang
Budoff, Matthew
Leaf, David
Kuller, Lewis H.
Justice, Amy C.
TI Hepatitis C Virus Infection and the Risk of Coronary Disease
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID FATTY LIVER-DISEASE; ARTERY-DISEASE; HEPATOCELLULAR-CARCINOMA;
HEMODIALYSIS-PATIENTS; ATHEROSCLEROSIS; VETERANS; HIV; INFLAMMATION;
ASSOCIATION; COCAINE
AB Background. The association between hepatitis C virus (HCV) infection and coronary artery disease (CAD) is controversial. We conducted this study to determine and quantify this association.
Methods. We used an established, national, observational cohort of all HCV-infected veterans receiving care at all Veterans Affairs facilities, the Electronically Retrieved Cohort of HCV Infected Veterans, to identify HCV-infected subjects and HCV-uninfected control subjects. We used the Cox proportional-hazards model to determine the risk of CAD among HCV-infected subjects and control subjects.
Results. We identified 82,083 HCV-infected and 89,582 HCV-uninfected subjects. HCV-infected subjects were less likely to have hypertension, hyperlipidemia, and diabetes but were more likely to abuse alcohol and drugs and to have renal failure and anemia. HCV-infected subjects had lower mean (+/- standard deviation) total plasma cholesterol (175 +/- 40.8 mg/dL vs. 198 +/- 41.0 mg/dL), low-density lipoprotein cholesterol (102 +/- 36.8 mg/dL vs. 119 +/- 38.2 mg/dL), and triglyceride (144 +/- 119 mg/dL vs. 179 +/- 151 mg/dL) levels, compared with HCV-uninfected subjects (P < .001 for all comparisons). In multivariable analysis, HCV infection was associated with a higher risk of CAD (hazard ratio, 1.25; 95% confidence interval, 1.20-1.30). Traditional risk factors (age, hypertension, chronic obstructive pulmonary disease, diabetes, and hyperlipidemia) were associated with a higher risk of CAD in both groups, whereas minority race and female sex were associated with a lower risk of CAD.
Conclusions. HCV-infected persons are younger and have lower lipid levels and a lower prevalence of hypertension. Despite a favorable risk profile, HCV infection is associated with a higher risk of CAD after adjustment for traditional risk factors.
C1 [Butt, Adeel A.] Univ Pittsburgh, Med Ctr, Sch Med, Pittsburgh, PA 15213 USA.
[Justice, Amy C.] Yale Univ, Sch Med & Publ Hlth, New Haven, CT USA.
[Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Kuller, Lewis H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA.
[Butt, Adeel A.; Wang Xiaoqiang] Univ Pittsburgh, Grad Sch Publ Hlth, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA.
[Butt, Adeel A.; Wang Xiaoqiang] Univ Pittsburgh, Grad Sch Publ Hlth, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15213 USA.
[Leaf, David] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Leaf, David] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[Budoff, Matthew] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Los Angeles, CA USA.
RP Butt, AA (reprint author), Univ Pittsburgh, Med Ctr, Sch Med, 3601 5th Ave,Ste 3A, Pittsburgh, PA 15213 USA.
EM butta@dom.pitt.edu
FU National Institutes of Health, National Institute on Drug Abuse [K23
DA016175-01A1]
FX National Institutes of Health, National Institute on Drug Abuse (K23
DA016175-01A1 to A. A. B.).
NR 44
TC 115
Z9 121
U1 1
U2 4
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUL 15
PY 2009
VL 49
IS 2
BP 225
EP 232
DI 10.1086/599371
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 460XU
UT WOS:000267226900011
PM 19508169
ER
PT J
AU Whitson, JM
Noonan, EJ
Pookot, D
Place, RF
Dahiya, R
AF Whitson, Jared M.
Noonan, Emily J.
Pookot, Deepa
Place, Robert F.
Dahiya, Rajvir
TI Double stranded-RNA-mediated activation of P21 gene induced apoptosis
and cell cycle arrest in renal cell carcinoma
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE renal cell carcinoma; RNAa; saRNA; p21WAF1/CIP1; apoptosis;
survivin/Birc5
ID BLADDER-CANCER CELLS; SURVIVIN EXPRESSION; DEPENDENT KINASE;
MAMMALIAN-CELLS; IN-VIVO; P21(WAF1/CIP1); INTERFERENCE; INHIBITION;
SIRNAS; DRUGS
AB Small double stranded RNAs (dsRNA) are a new class of molecules which regulate gene expression. Accumulating data suggest that some dsRNA can function as tumor suppressors. Here, we report further evidence on the potential of dsRNA mediated p21 induction. Using the human renal cell carcinoma cell line A498, we found that dsRNA targeting the p21 promoter significantly induced the expression of p21 mRNA and protein levels. As a result, dsP21 transfected cells had a significant decrease in cell viability with a concomitant G1 arrest. We also observed a significant increase in apoptosis. These findings were associated with a significant decrease in survivin mRNA and protein levels. This is the first report that demonstrates dsRNA mediated gene activation in renal cell carcinoma and suggests that forced over-expression of p21 may lead to an increase in apoptosis through a survivin dependent mechanism. (C) 2009 UICC
C1 [Whitson, Jared M.; Dahiya, Rajvir] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA.
[Noonan, Emily J.; Pookot, Deepa; Place, Robert F.; Dahiya, Rajvir] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU NIH [RO1CA111470, RO1CA101844, RO1CA130860, T32DK007790]
FX Grant sponsor: NIH; Grant numbers: RO1CA111470, RO1CA101844,
RO1CA130860. T32DK007790.
NR 33
TC 20
Z9 27
U1 1
U2 6
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD JUL 15
PY 2009
VL 125
IS 2
BP 446
EP 452
DI 10.1002/ijc.24370
PG 7
WC Oncology
SC Oncology
GA 460ZJ
UT WOS:000267231600026
PM 19384944
ER
PT J
AU Ma, QL
Yang, FS
Rosario, ER
Ubeda, OJ
Beech, W
Gant, DJ
Chen, PP
Hudspeth, B
Chen, CR
Zhao, YL
Vinters, HV
Frautschy, SA
Cole, GM
AF Ma, Qiu-Lan
Yang, Fusheng
Rosario, Emily R.
Ubeda, Oliver J.
Beech, Walter
Gant, Dana J.
Chen, Ping Ping
Hudspeth, Beverly
Chen, Cory
Zhao, Yongle
Vinters, Harry V.
Frautschy, Sally A.
Cole, Greg M.
TI beta-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of
Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling:
Suppression by Omega-3 Fatty Acids and Curcumin
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID GLYCOGEN-SYNTHASE KINASE-3-BETA; POLYUNSATURATED FATTY-ACIDS; DEPENDENT
DIABETES-MELLITUS; APOLIPOPROTEIN-E GENOTYPE; GROWTH-FACTOR EXPRESSION;
TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE AD; DOCOSAHEXAENOIC ACID;
OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES
AB Both insulin resistance (type II diabetes) and beta-amyloid (A beta) oligomers are implicated in Alzheimer's disease (AD). Here, we investigate the role of A beta oligomer-induced c-Jun N-terminal kinase (JNK) activation leading to phosphorylation and degradation of the adaptor protein insulin receptor substrate-1 (IRS-1). IRS-1 couples insulin and other trophic factor receptors to downstream kinases and neuroprotective signaling. Increased phospho-IRS-1 is found in AD brain and insulin-resistant tissues from diabetics. Here, we report A beta oligomers significantly increased active JNK and phosphorylation of IRS-1 (Ser616) and tau (Ser422) in cultured hippocampal neurons, whereas JNK inhibition blocked these responses. The omega-3 fatty acid docosahexaenoic acid (DHA) similarly inhibited JNK and the phosphorylation of IRS-1 and tau in cultured hippocampal neurons. Feeding 3xTg-AD transgenic mice a diet high in saturated and omega-6 fat increased active JNK and phosphorylated IRS-1 and tau. Treatment of the 3xTg-AD mice on high-fat diet with fish oil or curcumin or a combination of both for 4 months reduced phosphorylated JNK, IRS-1, and tau and prevented the degradation of total IRS-1. This was accompanied by improvement in Y-maze performance. Mice fed with fish oil and curcumin for 1 month had more significant effects on Y-maze, and the combination showed more significant inhibition of JNK, IRS-1, and tau phosphorylation. These data indicate JNK mediates A beta oligomer inactivation of IRS-1 and phospho-tau pathology and that dietary treatment with fish oil/DHA, curcumin, or a combination of both has the potential to improve insulin/trophic signaling and cognitive deficits in AD.
C1 [Ma, Qiu-Lan; Yang, Fusheng; Rosario, Emily R.; Ubeda, Oliver J.; Beech, Walter; Gant, Dana J.; Chen, Ping Ping; Hudspeth, Beverly; Chen, Cory; Zhao, Yongle; Frautschy, Sally A.; Cole, Greg M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA.
[Vinters, Harry V.; Frautschy, Sally A.; Cole, Greg M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA.
[Vinters, Harry V.] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Ma, Qiu-Lan; Yang, Fusheng; Rosario, Emily R.; Ubeda, Oliver J.; Beech, Walter; Gant, Dana J.; Chen, Ping Ping; Hudspeth, Beverly; Chen, Cory; Zhao, Yongle; Frautschy, Sally A.; Cole, Greg M.] Greater Los Angeles Vet Affairs Healthcare Syst, Geriatr Res & Clin Ctr, Vet Affairs Med Ctr, North Hills, CA 91343 USA.
RP Cole, GM (reprint author), Greater Los Angeles Healthcare Syst Res 151, Vet Affairs, Bldg 7,Room A101,16111 Plummer St, North Hills, CA 91343 USA.
EM gmcole@ucla.edu
FU National Institutes of Health (NIH) [R01 AT003008]; National Institute
on Aging-NIH [R01 AG16570, AG13471, U01 AG028583, R01 AG021975];
Alzheimer's Association [NIRG-07-59659]; Daljit S. and Elaine Sarkaria
Chair in Diagnostic Medicine
FX This work was supported by National Institutes of Health (NIH) Grant R01
AT003008 (G. M. C.); National Institute on Aging-NIH Grants R01 AG16570
(G. M. C., H. V. V.), AG13471 (G. M. C.), U01 AG028583 (S. A. F.), and
R01 AG021975 (S. A. F.); and Alzheimer's Association Grant NIRG-07-59659
(Q.-L. M.). H. V. V. was supported in part by the Daljit S. and Elaine
Sarkaria Chair in Diagnostic Medicine.
NR 99
TC 234
Z9 248
U1 3
U2 31
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUL 15
PY 2009
VL 29
IS 28
BP 9078
EP 9089
DI 10.1523/JNEUROSCI.1071-09.2009
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 470YI
UT WOS:000268018000022
PM 19605645
ER
PT J
AU Mizumori, M
Ham, M
Guth, PH
Engel, E
Kaunitz, JD
Akiba, Y
AF Mizumori, Misa
Ham, Maggie
Guth, Paul H.
Engel, Eli
Kaunitz, Jonathan D.
Akiba, Yasutada
TI Intestinal alkaline phosphatase regulates protective surface
microclimate pH in rat duodenum
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article
ID MUCUS-BICARBONATE BARRIER; CYSTIC-FIBROSIS; BRUSH-BORDER; ATP RELEASE;
ADENOSINE-TRIPHOSPHATASE; CARBONIC-ANHYDRASES; MOUSE DUODENUM; KNOCKOUT
MICE; P2X RECEPTORS; ACID
AB Regulation of localized extracellular pH (pH(o)) maintains normal organ function. An alkaline microclimate overlying the duodenal enterocyte brush border protects the mucosa from luminal acid. We hypothesized that intestinal alkaline phosphatase (IAP) regulates pH(o) due to pH-sensitive ATP hydrolysis as part of an ecto-purinergic pH regulatory system, comprised of cell-surface P2Y receptors and ATP-stimulated duodenal bicarbonate secretion (DBS). To test this hypothesis, we measured DBS in a perfused rat duodenal loop, examining the effect of the competitive alkaline phosphatase inhibitor glycerol phosphate (GP), the ecto-nucleoside triphosphate diphosphohydrolase inhibitor ARL67156, and exogenous nucleotides or P2 receptor agonists on DBS. Furthermore, we measured perfusate ATP concentration with a luciferin-luciferase bioassay. IAP inhibition increased DBS and luminal ATP output. Increased luminal ATP output was partially CFTR dependent, but was not due to cellular injury. Immunofluorescence localized the P2Y(1) receptor to the brush border membrane of duodenal villi. The P2Y(1) agonist 2-methylthio-ADP increased DBS, whereas the P2Y(1) antagonist MRS2179 reduced ATP- or GP-induced DBS. Acid perfusion augmented DBS and ATP release, further enhanced by the IAP inhibitor l-cysteine, and reduced by the exogenous ATPase apyrase. Furthermore, MRS2179 or the highly selective P2Y(1) antagonist MRS2500 co-perfused with acid induced epithelial injury, suggesting that IAP/ATP/P2Y signalling protects the mucosa from acid injury. Increased DBS augments IAP activity presumably by raising pH(o), increasing the rate of ATP degradation, decreasing ATP-mediated DBS, forming a negative feedback loop. The duodenal epithelial brush border IAP-P2Y-HCO3- surface microclimate pH regulatory system effectively protects the mucosa from acid injury.
C1 [Mizumori, Misa; Ham, Maggie; Kaunitz, Jonathan D.; Akiba, Yasutada] Univ Calif Los Angeles, Dept Med, Sch Med, Los Angeles, CA 90073 USA.
[Engel, Eli] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90073 USA.
[Guth, Paul H.; Kaunitz, Jonathan D.; Akiba, Yasutada] Greater Los Angles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA.
[Kaunitz, Jonathan D.; Akiba, Yasutada] Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA.
RP Kaunitz, JD (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jake@ucla.edu
FU Department of Veterans Affairs Merit Review Award; NIH-NIDDK [R01
DK54221, P30 DK0413]
FX We thank Jenifer Kugler for her assistance with manuscript preparation.
This work was supported by a Department of Veterans Affairs Merit Review
Award, NIH-NIDDK R01 DK54221 (J.D.K.), and the animal core of NIH-NIDDK
P30 DK0413 (J. E. Rozengurt).
NR 51
TC 48
Z9 48
U1 3
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD JUL 15
PY 2009
VL 587
IS 14
BP 3651
EP 3663
DI 10.1113/jphysiol.2009.172270
PG 13
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 471FF
UT WOS:000268040500029
PM 19451200
ER
PT J
AU Yeh, PH
Simpson, K
Durazzo, TC
Gazdzinski, S
Meyerhoff, DJ
AF Yeh, Ping-Hong
Simpson, Ken
Durazzo, Timothy C.
Gazdzinski, Stefan
Meyerhoff, Dieter J.
TI Tract-based spatial statistics (TBSS) of diffusion tensor imaging data
in alcohol dependence: Abnormalities of the motivational neurocircuitry
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article
DE Alcohol use disorder; Cognition; Brain MRI; Diffusion tensor imaging,
DTI; Tract-based spatial statistics, TBSS; Probabilistic tractography
ID NATIONAL EPIDEMIOLOGIC SURVEY; CHRONIC CIGARETTE-SMOKING; DSM-IV
ALCOHOL; WHITE-MATTER; WATER DIFFUSION; DRUG-ADDICTION; NEUROPSYCHIATRIC
DISORDERS; MULTIPLE-SCLEROSIS; GENE-EXPRESSION; UNITED-STATES
AB Previous diffusion tensor imaging (DTI) studies indicated microstructural disruption of white matter in alcohol dependence. To investigate the microstructure of primary neurocircuitry involved in alcohol use disorders, the present study used Tract-Based Spatial Statistics (TBSS) of DTI measures as well as probabilistic tractography. Eleven recovering alcoholics in their first week of abstinence from alcohol were compared with 10 light-drinking controls; diffusion measures were correlated with measures of neurocognition and drinking severity. Regions characterized by low fractional anisotropy and high mean diffusivity included cortico-striatal fibers and those in frontal white matter and limbic pathways. Greater diffusion abnormalities in sections of commissural fibers (inter-hemispheric connections) were associated with greater drinking severity, and lower fractional anisotropy measures in frontal and limbic fiber tracts correlated with lower visuospatial memory performance. These study findings provide direct evidence of compromised integrity of the motivational brain circuitry in alcohol use disorders. These abnormalities in fiber connections could be partially responsible for deficiencies in executive functions, behavioral regulation, and impulse control commonly described in alcohol dependence. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Yeh, Ping-Hong; Simpson, Ken; Durazzo, Timothy C.; Gazdzinski, Stefan; Meyerhoff, Dieter J.] San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA.
[Durazzo, Timothy C.; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.
RP Yeh, PH (reprint author), San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis, 4150 Clement St 114M, San Francisco, CA 94121 USA.
EM ping-hong_yeh@med.unc.edu
FU NIH [AA10788]
FX NIH AA10788 (DJM) and the Veteran's Administration research service
supported this project We thank Mary Rebecca Young and Bill Clift of the
San Francisco VA Substance Abuse Day Hospital, and Dr. David Pating,
Karen Moise, and their colleagues at the San Francisco Kaiser Permanente
Chemical Dependency Recovery Program for their valuable assistance in
recruiting research participants. We also thank Dr. Hemanth
Thayyullathil for assistance with data analyses, as well as Drs. Michael
W. Weiner, Norbert Schuff, Wang Zhan, and Yu Zhang for valuable
discussions. Last but not least, we thank our study volunteers, who made
this research possible.
NR 72
TC 50
Z9 52
U1 1
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0925-4927
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD JUL 15
PY 2009
VL 173
IS 1
BP 22
EP 30
DI 10.1016/j.pscychresns.2008.07.012
PG 9
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 463YF
UT WOS:000267469400004
PM 19442492
ER
PT J
AU van Tulder, MW
Suttorp, M
Morton, S
Bouter, LM
Shekelle, P
AF van Tulder, Maurits W.
Suttorp, Marika
Morton, Sally
Bouter, Lex M.
Shekelle, Paul
TI Empirical Evidence of an Association Between Internal Validity and
Effect Size in Randomized Controlled Trials of Low-Back Pain
SO SPINE
LA English
DT Article
DE Cochrane collaboration; randomized trials; low back pain; bias; effect
size
ID CLINICAL-TRIALS; SYSTEMATIC REVIEWS; QUALITY ASSESSMENT; METHOD
GUIDELINES; CRITERIA LIST; METAANALYSES
AB Study Design. We conducted a methodologic study. Objective. The objective of this study was to assess the validity of the criteria list recommended by the Cochrane Back Review Group Editorial Board by evaluating whether individual items and a total score are associated with effect sizes in randomized controlled trials of back-pain interventions.
Summary of Background Data. There is concern that studies of low methodologic quality may exaggerate the effectiveness of treatments for low back pain. We performed this study to examine the association between a common measure of internal validity and the reported magnitude of treatment effects.
Methods. We assessed the relationship between the 11 items contained in the Cochrane Back Review Group Internal Validity checklist and effect size in randomized trials of interventions for back pain. Of 267 trials in 15 Cochrane reviews that were eligible for inclusion, 51 were excluded, leaving 216 trials included in the analysis. The scores on the 11 items for each trial were taken from the original review. We extracted effect sizes from each low back pain trial.
Results. We found that trials that fulfilled a specific item had smaller effect sizes compared with trials that did not fulfill that item for 10 of the 11 items, and for 6 of the criteria, the absolute difference in effect sizes was 0.10 or greater. The 95% confidence interval of the difference in effect sizes crossed the null value in each case. The number of items fulfilled showed that trials with higher scores consistently reported smaller effect sizes than trials with lower scores. At the thresholds of 5 or 6 items fulfilled, the difference in effect sizes was 0.20 in each case (95% confidence intervals 0.05-0.35 and 0.06-0.34, respectively). Stratified analyses did not support confounding by intervention.
Conclusion. We conclude that the 11-item Internal Validity Checklist is associated with effect size in randomized trials of interventions for back pain, and that our data support the use of a sum score of the number of fulfilled items in this list.
C1 [van Tulder, Maurits W.] Vrije Univ Amsterdam, Dept Hlth Sci, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands.
[van Tulder, Maurits W.; Bouter, Lex M.] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands.
[Suttorp, Marika; Shekelle, Paul] RAND Hlth, Santa Monica, CA USA.
[Morton, Sally] RTI Int, Res Triangle Pk, NC USA.
[Shekelle, Paul] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
RP van Tulder, MW (reprint author), Vrije Univ Amsterdam, Dept Hlth Sci, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands.
EM maurits.van.tulder@falw.vu.nl
OI Bouter, Lex/0000-0002-2659-5482; van Tulder, Maurits/0000-0002-7589-8471
NR 39
TC 74
Z9 74
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0362-2436
J9 SPINE
JI SPINE
PD JUL 15
PY 2009
VL 34
IS 16
BP 1685
EP 1692
PG 8
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 527TX
UT WOS:000272390900004
PM 19770609
ER
PT J
AU Thinda, S
Tomlinson, JS
AF Thinda, Sumeer
Tomlinson, James S.
TI Mesenteric rheumatoid nodules masquerading as an intra-abdominal
malignancy: a case report and review of the literature
SO WORLD JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
ID ACCELERATED NODULOSIS; ARTHRITIS; THERAPY
AB Background: Rheumatoid nodules are the most common extra-articular findings in patients with rheumatoid arthritis. They occur most commonly at pressure points such as the extensor surfaces of the forearms, fingers, and occiput, but have also been reported to occur in unusual locations including the central nervous system, pericardium, pleura, and sclera. We present the unusual case of rheumatoid nodules in the small bowel mesentery masquerading as an intra-abdominal malignancy.
Case presentation: A 65-year-old-male with a known history of longstanding erosive, nodular, seropositive rheumatoid arthritis was incidentally found to have a mesenteric mass on computed tomography (CT) exam of the abdomen. This mass had not been present on prior imaging studies and was worrisome for a malignancy. Attempts at noninvasive biopsy were nondiagnostic but consistent with a "spindle" cell neoplasm. Laparotomy revealed extensive thickening and fibrosis of the small bowel mesentery along with large, firm nodules throughout the mesentery. A limited bowel resection including a large, partially obstructing, nodule was performed. Pathology was consistent with an unusual presentation of rheumatoid nodules in the mesentery of the small bowel.
Conclusion: Rheumatoid nodules should be considered in the differential diagnosis of a patient who presents with an intra-abdominal mass and a history of rheumatoid arthritis. Currently, no tests or imaging modality can discriminate with sufficient accuracy to rule out a malignancy in this difficult diagnostic delimma. Hopefully, this case will serve as impetus for further study and biomarker discovery to allow for improved diagnostic power.
C1 [Tomlinson, James S.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Thinda, Sumeer; Tomlinson, James S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
RP Tomlinson, JS (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
EM sumeer.thinda@ucla.edu; jtomlinson@mednet.ucla.edu
NR 13
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-7819
J9 WORLD J SURG ONCOL
JI World J. Surg. Oncol.
PD JUL 15
PY 2009
VL 7
AR 59
DI 10.1186/1477-7819-7-59
PG 5
WC Oncology; Surgery
SC Oncology; Surgery
GA 488DP
UT WOS:000269329600001
PM 19604347
ER
PT J
AU Helfrich, CD
Li, YF
Sharp, ND
Sales, AE
AF Helfrich, Christian D.
Li, Yu-Fang
Sharp, Nancy D.
Sales, Anne E.
TI Organizational readiness to change assessment (ORCA): Development of an
instrument based on the Promoting Action on Research in Health Services
(PARIHS) framework
SO IMPLEMENTATION SCIENCE
LA English
DT Article
ID TOTAL-QUALITY-MANAGEMENT; THEORETICAL PERSPECTIVES;
CONCEPTUAL-FRAMEWORK; IMPLEMENTATION; VETERANS; CONTEXT; IMPACT; CARE;
FACILITATION; IMPROVEMENT
AB Background: The Promoting Action on Research Implementation in Health Services, or PARIHS, framework is a theoretical framework widely promoted as a guide to implement evidence-based clinical practices. However, it has as yet no pool of validated measurement instruments that operationalize the constructs defined in the framework. The present article introduces an Organizational Readiness to Change Assessment instrument (ORCA), organized according to the core elements and sub-elements of the PARIHS framework, and reports on initial validation.
Methods: We conducted scale reliability and factor analyses on cross-sectional, secondary data from three quality improvement projects (n = 80) conducted in the Veterans Health Administration. In each project, identical 77-item ORCA instruments were administered to one or more staff from each facility involved in quality improvement projects. Items were organized into 19 subscales and three primary scales corresponding to the core elements of the PARIHS framework: (1) Strength and extent of evidence for the clinical practice changes represented by the QI program, assessed with four subscales, (2) Quality of the organizational context for the QI program, assessed with six subscales, and (3) Capacity for internal facilitation of the QI program, assessed with nine subscales.
Results: Cronbach's alpha for scale reliability were 0.74, 0.85 and 0.95 for the evidence, context and facilitation scales, respectively. The evidence scale and its three constituent subscales failed to meet the conventional threshold of 0.80 for reliability, and three individual items were eliminated from evidence subscales following reliability testing. In exploratory factor analysis, three factors were retained. Seven of the nine facilitation subscales loaded onto the first factor; five of the six context subscales loaded onto the second factor; and the three evidence subscales loaded on the third factor. Two subscales failed to load significantly on any factor. One measured resources in general (from the context scale), and one clinical champion role (from the facilitation scale).
Conclusion: We find general support for the reliability and factor structure of the ORCA. However, there was poor reliability among measures of evidence, and factor analysis results for measures of general resources and clinical champion role did not conform to the PARIHS framework. Additional validation is needed, including criterion validation.
C1 [Helfrich, Christian D.; Li, Yu-Fang; Sharp, Nancy D.] VA Puget Sound Healthcare Syst, NW HSR&D Ctr Excellence, Seattle, WA USA.
[Helfrich, Christian D.; Sharp, Nancy D.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[Helfrich, Christian D.; Sharp, Nancy D.] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA.
[Sales, Anne E.] Univ Alberta, Fac Nursing, Edmonton, AB, Canada.
RP Helfrich, CD (reprint author), VA Puget Sound Healthcare Syst, NW HSR&D Ctr Excellence, Seattle, WA USA.
EM christian.helfrich@va.gov; yufang.li@va.gov; nancy.sharp@va.gov;
anne.sales@ualberta.ca
RI Sales, Anne/D-9678-2012; Helfrich, Christian/D-2382-2016
OI Helfrich, Christian/0000-0002-9827-4768; Sales, Anne/0000-0001-9360-3334
FU Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development Service [RRP 07-280]
FX The views expressed in this article are the authors' and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs.
NR 41
TC 95
Z9 97
U1 2
U2 28
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
4LB, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD JUL 14
PY 2009
VL 4
AR 38
DI 10.1186/1748-5908-4-38
PG 13
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 482LY
UT WOS:000268891600001
PM 19594942
ER
PT J
AU Colman, RJ
Anderson, RM
Johnson, SC
Kastman, EK
Kosmatka, KJ
Beasley, TM
Allison, DB
Cruzen, C
Simmons, HA
Kemnitz, JW
Weindruch, R
AF Colman, Ricki J.
Anderson, Rozalyn M.
Johnson, Sterling C.
Kastman, Erik K.
Kosmatka, Kristopher J.
Beasley, T. Mark
Allison, David B.
Cruzen, Christina
Simmons, Heather A.
Kemnitz, Joseph W.
Weindruch, Richard
TI Caloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys
SO SCIENCE
LA English
DT Article
ID DIETARY RESTRICTION; ADULT MALE; LIFE-SPAN; MACAQUES
AB Caloric restriction (CR), without malnutrition, delays aging and extends life span in diverse species; however, its effect on resistance to illness and mortality in primates has not been clearly established. We report findings of a 20-year longitudinal adult-onset CR study in rhesus monkeys aimed at filling this critical gap in aging research. In a population of rhesus macaques maintained at the Wisconsin National Primate Research Center, moderate CR lowered the incidence of aging-related deaths. At the time point reported, 50% of control fed animals survived as compared with 80% of the CR animals. Furthermore, CR delayed the onset of age-associated pathologies. Specifically, CR reduced the incidence of diabetes, cancer, cardiovascular disease, and brain atrophy. These data demonstrate that CR slows aging in a primate species.
C1 [Colman, Ricki J.; Anderson, Rozalyn M.; Johnson, Sterling C.; Cruzen, Christina; Simmons, Heather A.; Kemnitz, Joseph W.; Weindruch, Richard] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.
[Johnson, Sterling C.; Kastman, Erik K.; Kosmatka, Kristopher J.; Kemnitz, Joseph W.; Weindruch, Richard] Univ Wisconsin, Dept Med, Madison, WI 53706 USA.
[Johnson, Sterling C.; Kastman, Erik K.; Kosmatka, Kristopher J.; Weindruch, Richard] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA.
[Beasley, T. Mark; Allison, David B.] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA.
[Kemnitz, Joseph W.] Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA.
RP Colman, RJ (reprint author), Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.
EM rcolman@primate.wisc.edu; rhweindr@wisc.edu
RI Kastman, Erik/N-6645-2016
OI Kastman, Erik/0000-0001-7221-9042; Allison, David/0000-0003-3566-9399
FU NIH [P01 AG-11915, P51 RR000167]; Research Facilities Improvement
Program [RR15459-01, RR020141-01]; William S. Middleton Memorial
Veterans Hospital
FX We acknowledge the excellent technical assistance provided by S. Baum,
J. Christensen, J. A. Adriansjach, C. E. Armstrong, D. G. McLaren, C.
Dizack, D. Shanmuganayagam, J. Root, and the Animal Care, Veterinary and
Pathology Staff of the WNPRC. R.W. is a cofounder and member of the
board of LifeGen Technologies, a company focused on nutritional
genomics, including the impact of dietary interventions on the aging
process. This work was supported by NIH grants P01 AG-11915 and P51
RR000167. This research was conducted in part at the WNPRC, which
received support from Research Facilities Improvement Program grant
numbers RR15459-01 and RR020141-01. This research was supported in part
by facilities and resources at the William S. Middleton Memorial
Veterans Hospital.
NR 19
TC 943
Z9 966
U1 24
U2 195
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD JUL 10
PY 2009
VL 325
IS 5937
BP 201
EP 204
DI 10.1126/science.1173635
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 468FK
UT WOS:000267802000047
PM 19590001
ER
PT J
AU Peterson, PN
Ambardekar, AV
Jones, PG
Krumholz, HM
Schelbert, E
Spertus, JA
Rumsfeld, JS
Masoudi, FA
AF Peterson, Pamela N.
Ambardekar, Amrut V.
Jones, Philip G.
Krumholz, Harlan M.
Schelbert, Erik
Spertus, John A.
Rumsfeld, John S.
Masoudi, Frederick A.
TI Increased Mortality among Survivors of Myocardial Infarction with Kidney
Dysfunction: the Contribution of Gaps in the use of Guideline-Based
Therapies
SO BMC CARDIOVASCULAR DISORDERS
LA English
DT Article
ID ACUTE CORONARY SYNDROMES; STAGE RENAL-DISEASE; CARDIOVASCULAR-DISEASE;
HEART-FAILURE; INSUFFICIENCY; OUTCOMES; ASSOCIATION; INHIBITORS;
ASPIRIN; EVENTS
AB Background: We assessed the degree to which differences in guideline-based medical therapy for acute myocardial infarction (AMI) contribute to the higher mortality associated with kidney disease.
Methods: In the PREMIER registry, we evaluated patients from 19 US centers surviving AMI. Cox regression evaluated the association between estimated glomerular filtration rate (GFR) and time to death over two years, adjusting for demographic and clinical variables. The contribution of variation in guideline-based medical therapy to differences in mortality was then assessed by evaluating the incremental change in the hazard ratios after further adjustment for therapy.
Results: Of 2426 patients, 26% had GFR >= 90, 44% had GFR = 60- < 90, 22% had GFR = 30- < 60, and 8% had GFR < 30 ml/min/1.73 m(2). Greater degrees of renal dysfunction were associated with greater 2-year mortality and lower rates of guideline-based therapy among eligible patients. For patients with severely decreased GFR, adjustment for differences in guideline-based therapy did not significantly attenuate the relationship with mortality (HR 3.82, 95% CI 2.39-6.11 partially adjusted; HR = 3.90, 95% CI 2.42-6.28 after adjustment for treatment differences).
Conclusion: Higher mortality associated with reduced GFR after AMI is not accounted for by differences in treatment factors, underscoring the need for novel therapies specifically targeting the pathophysiological abnormalities associated with kidney dysfunction to improve survival.
C1 [Peterson, Pamela N.; Masoudi, Frederick A.] Denver Hlth Med Ctr, Denver, CO USA.
[Peterson, Pamela N.; Ambardekar, Amrut V.; Rumsfeld, John S.; Masoudi, Frederick A.] Univ Colorado Denver, Aurora, CO USA.
[Jones, Philip G.; Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA.
[Schelbert, Erik] Natl Inst Hlth, Bethesda, MD USA.
[Spertus, John A.] Univ Missouri, Kansas City, MO 64110 USA.
[Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
RP Peterson, PN (reprint author), Denver Hlth Med Ctr, Denver, CO USA.
EM pamela.peterson@uchsc.edu; Amrut.Ambardekar@uchsc.edu;
pgjones@saint-lukes.org; Harlan.Krumholz@yale.edu;
Schelberteb@nhlbi.nih.gov; spertusj@umkc.edu; John.Rumsfeld@uchsc.edu;
Fred.Masoudi@uchsc.edu
OI Schelbert, Erik/0000-0003-0356-4437
NR 26
TC 4
Z9 4
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2261
J9 BMC CARDIOVASC DISOR
JI BMC Cardiovasc. Disord.
PD JUL 8
PY 2009
VL 9
AR 29
DI 10.1186/1471-2261-9-29
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 477AN
UT WOS:000268488400001
PM 19586550
ER
PT J
AU Ahmad, M
Zhang, YQ
Liu, H
Rose, ME
Graham, SH
AF Ahmad, Muzamil
Zhang, Yuquin
Liu, Hao
Rose, Marie E.
Graham, Steven H.
TI Prolonged opportunity for neuroprotection in experimental stroke with
selective blockade of cyclooxygenase-2 activity
SO BRAIN RESEARCH
LA English
DT Article
DE Cerebral ischemia; Therapeutic window; Clinical significance;
Valdecoxib; COX-2 inhibitor
ID FOCAL CEREBRAL-ISCHEMIA; BRAIN-DAMAGE; NEURONS; COX-2; INHIBITION;
RECEPTORS; RATS; NEUROTOXICITY; INFLAMMATION; CONTRIBUTES
AB The post-treatment effects of the selective cyclooxygenase (COX)-2 inhibitor, valdecoxib, were investigated in a rat model of temporary focal ischemia. Valdecoxib reduced basal brain prostaglandin E(2) concentrations at dosages that did not affect serum thromboxane B(2), consistent with a selective COX-2 effect. Temporary focal cerebral ischemia was produced in rats by middle cerebral artery occlusion for 90 min. There was increased expression of COX-2 protein detected by Western blot and immunocytochemistry within neurons in the ischemic cortex at 4 and 24 h after ischemia. Rats were treated with vehicle or valdecoxib IS min before or 1.5, 3 and 6 h after cerebral ischemia. Rats were sacrificed and brain infarction volume determined 24 h after ischemia. Valdecoxib treatment was associated with a decrease in infarction volume when administered 15 min before, and 1.5 or 3 h but not 6 h after cerebral ischemia, There were no differences in physiological parameters during the procedure. Valdecoxib administered at 1.5 h after ischemia significantly reduced the concentrations of prostaglandin E(2) in ischemic penumbral cortex as compared to the vehicle-treated group and contralateral non-ischemic cortex. These results suggest that COX-2 inhibition with valdecoxib is effective when initiated both before and after middle cerebral artery occlusion. Published by Elsevier B.V.
C1 VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
RP Graham, SH (reprint author), VA Pittsburgh Healthcare, Geriatr Res Educ & Clin Ctr 00GRH, Highland Dr, Pittsburgh, PA 15205 USA.
EM sgra@pitt.edu
FU NIH [R01 NS37459]
FX This work was supported by NIH R01 NS37459 (SHG).
NR 27
TC 20
Z9 22
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD JUL 7
PY 2009
VL 1279
BP 168
EP 173
DI 10.1016/j.brainres.2009.05.020
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 466PI
UT WOS:000267674100018
PM 19446533
ER
PT J
AU Lyss-Lerman, P
Teherani, A
Aagaard, E
Loeser, H
Cooke, M
Harper, GM
AF Lyss-Lerman, Pamela
Teherani, Arianne
Aagaard, Eva
Loeser, Helen
Cooke, Molly
Harper, G. Michael
TI What Training Is Needed in the Fourth Year of Medical School? Views of
Residency Program Directors
SO ACADEMIC MEDICINE
LA English
DT Article
ID 4TH-YEAR CURRICULUM; CLINICAL EDUCATION; FAMILY MEDICINE; STUDENTS;
SKILLS; SUBINTERNSHIP; PERCEPTIONS; OUTCOMES; PROJECT
AB Purpose
To identify common struggles of interns, determine residency program directors' (PDs') views of the competencies to be gained in the fourth year of medical school, and apply this information to formulate goals of curricular reform and student advising.
Method
In 2007, semistructured interviews were conducted with 30 PDs in the 10 most common specialty choices of students the University of California, San Francisco, School of Medicine to assess the PDs' priorities for knowledge, skills, and attitudes to be acquired in the fourth year. Interviews were coded to identify major themes.
Results
Common struggles of interns were lack of self-reflection and improvement, poor organizational skills, underdeveloped professionalism, and lack of medical knowledge. The Accreditation Council for Graduate Medical Education competencies of patient care, practice-based learning and improvement, interpersonal and communication skills, and professionalism were deemed fundamental to fourth-year students' development. Rotations recommended across specialties were a subinternship in a student's future field and in internal medicine (IM), rotations in an IM subspecialty, critical care, and emergency and ambulatory medicine. PDs encouraged minimizing additional time spent in the student's future field. Suggested coursework included an intensively coached transitional subinternship and courses to improve students' medical knowledge.
Conclusions
PDs deemed the fourth year to have a critical role in the curriculum. There was consensus about expected fourth-year competencies and the common clinical experiences that best prepare students for residency training. These findings support using the fourth year to transition students to graduate medical training and highlight areas for curricular innovation.
C1 [Harper, G. Michael] Univ Calif San Francisco, Sch Med, Dept Med, Div Geriatr, San Francisco, CA 94143 USA.
[Harper, G. Michael] San Francisco VA Med Ctr, San Francisco, CA USA.
[Aagaard, Eva] Univ Colorado, Dept Med, Denver Sch Med, Denver, CO USA.
[Teherani, Arianne] Univ Calif San Francisco, Sch Med, Off Med Educ, San Francisco, CA USA.
RP Harper, GM (reprint author), 4150 Clement St,Box 181G, San Francisco, CA 94121 USA.
EM Michael.harper3@med.va.gov
NR 33
TC 84
Z9 84
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD JUL
PY 2009
VL 84
IS 7
BP 823
EP 829
PG 7
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 466IT
UT WOS:000267655500007
PM 19550170
ER
PT J
AU Leo-Lieber, MA
AF Leo-Lieber, Maria Anna
TI Beyond Science: My Memories of Charles S. Lieber
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Biographical-Item
C1 [Leo-Lieber, Maria Anna] Mt Sinai Sch Med MALL, New York, NY USA.
[Leo-Lieber, Maria Anna] James J Peters VA Med Ctr, Sp Bronx, NY USA.
RP Leo-Lieber, MA (reprint author), Mt Sinai Sch Med MALL, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUL
PY 2009
VL 33
IS 7
BP 1123
EP 1124
DI 10.1111/j.1530-0277.2009.00999.x
PG 2
WC Substance Abuse
SC Substance Abuse
GA 461PR
UT WOS:000267281200004
ER
PT J
AU Barnes, DE
Yaffe, K
Belfor, N
Jagust, WJ
DeCarli, C
Reed, BR
Kramer, JH
AF Barnes, Deborah E.
Yaffe, Kristine
Belfor, Nataliya
Jagust, William J.
DeCarli, Charles
Reed, Bruce R.
Kramer, Joel H.
TI Computer-based Cognitive Training for Mild Cognitive Impairment Results
from a Pilot Randomized, Controlled Trial
SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS
LA English
DT Article; Proceedings Paper
CT 10th International Conference on Alzheimers Disease and Related
Disorders
CY JUL 16-18, 2006
CL Madrid, SPAIN
DE human; aged; cognition; cognitive rehabilitation; memory;
neuropsychologic tests; randomized controlled trial; mild cognitive
impairment
ID ALZHEIMERS-DISEASE PATIENTS; HEALTHY OLDER-ADULTS;
CHOLINESTERASE-INHIBITORS; MEMORY ENHANCEMENT; REHABILITATION; DEMENTIA;
STIMULATION; PROGRAM; PEOPLE; INTERVENTION
AB We performed a pilot randomized, controlled trial of intensive, computer-based cognitive training in 47 subjects with mild cognitive impairment. The intervention group performed exercises specifically designed to improve auditory processing speed and accuracy for 100 min/d, 5 d/wk for 6 weeks; the control group performed more passive computer activities (reading, listening, visuospatial game) for similar amounts of time. Subjects had a mean age of 74 years and 60% were men; 77% successfully completed training. On our primary outcome, Repeatable Battery for Assessment of Neuropsychological Status total scores improved 0.36 standard deviations (SD) in the intervention group (P = 0.097) compared with 0.03 SD in the control group (P = 0.88) for a nonsignificant difference between the groups of 0.33 SD (P = 0.26). On 12 secondary outcome measures, most differences between the groups were not statistically significant. However, we observed a pattern in which effect sizes for verbal learning and memory measures tended to favor the intervention group whereas effect sizes for language and visuospatial function measures tended to favor the control group, which raises the possibility that these training programs may have domain-specific effects. We conclude that intensive, computer-based mental activity is feasible in subjects with mild cognitive impairment and that larger trials are warranted.
C1 [Barnes, Deborah E.; Yaffe, Kristine; Belfor, Nataliya] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Yaffe, Kristine; Kramer, Joel H.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94121 USA.
[Barnes, Deborah E.; Yaffe, Kristine] San Francisco VA Med Ctr, Mental Hlth Res Serv, San Francisco, CA USA.
[DeCarli, Charles; Reed, Bruce R.] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA.
[Jagust, William J.] Univ Calif Berkeley, Dept Neurosci, Berkeley, CA 94720 USA.
[Jagust, William J.] Univ Calif Berkeley, Dept Publ Hlth, Berkeley, CA 94720 USA.
RP Barnes, DE (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St 151R, San Francisco, CA 94121 USA.
EM Deborah.Barnes@ucsf.edu
FU NIA NIH HHS [P30 AG010129, P30 AG010129-17, P30 AG010129-18, K01
AG024069, K01 AG 024069, K01 AG024069-04]
NR 37
TC 93
Z9 97
U1 5
U2 54
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0893-0341
J9 ALZ DIS ASSOC DIS
JI Alzheimer Dis. Assoc. Dis.
PD JUL-SEP
PY 2009
VL 23
IS 3
BP 205
EP 210
PG 6
WC Clinical Neurology; Pathology
SC Neurosciences & Neurology; Pathology
GA 495QO
UT WOS:000269909300005
PM 19812460
ER
PT J
AU Chao, LL
Pa, J
Duarte, A
Schuff, N
Weiner, MW
Kramer, JH
Miller, BL
Freeman, KM
Johnson, JK
AF Chao, Linda L.
Pa, Judy
Duarte, Audrey
Schuff, Norbert
Weiner, Michael W.
Kramer, Joel H.
Miller, Bruce L.
Freeman, Katie M.
Johnson, Julene K.
TI Patterns of Cerebral Hypoperfusion in Amnestic and Dysexecutive MCI
SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS
LA English
DT Article
DE mild cognitive impairment (MCI); memory; executive function; perfusion;
MRI
ID MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; BRAIN; PRECUNEUS;
DEMENTIA; MATTER; MRI
AB Although early studies on mild cognitive impairment (MCI) focused on memory dysfunction; more recent Studies suggest that MCI is clinically heterogeneous. The objective of this study is to examine patterns of cerebral perfusion in anmestic (N = 12) and nonamnestic (N = 12) single-domain MCI patients from 4 a priori regions of interest: middle and superior frontal cortex, posterior cingulate, and precuneus, to compare them relative to healthy controls (N = 12), and to correlate perfusion with neuropsychologic measures. Relative to controls, all MCI patients had hypoperfusion in the posterior cingulate, bilaterally. MCI patients with executive dysfunctions also showed hypoperfusion in bilateral middle frontal cortex and the left precuneus relative to controls and in the left middle frontal cortex, left posterior cingulate, and left precuneus relative to amnestic MCI patients. Perfusion in the posterior cingulate correlated positively with memory performance whereas perfusion in all 4 a priori regions of interest, predominately on the left side, correlated with executive function performance. The finding that single-domain MCI patients with prominent deficits in different cognitive domains exhibited different patterns of hypoperfusion relative to controls supports the existence of distinct subgroups of MCI. These data further Suggest that cognitive impairment in MCI is related to cerebral hypoperfusion.
C1 [Chao, Linda L.; Duarte, Audrey; Schuff, Norbert; Weiner, Michael W.] Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Chao, Linda L.; Schuff, Norbert; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94121 USA.
[Pa, Judy; Kramer, Joel H.; Miller, Bruce L.; Freeman, Katie M.; Johnson, Julene K.] Univ Calif San Francisco, Memory & Aging Ctr, Dept Neurol, San Francisco, CA 94121 USA.
[Duarte, Audrey] Georgia Inst Technol, Dept Psychol, Atlanta, GA 30332 USA.
RP Chao, LL (reprint author), Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, San Francisco VA Med Ctr, 4150 Clement St,114M, San Francisco, CA 94121 USA.
EM linda.chao@ucsf.edu
FU NIH NIA [R01 AG022538, R01 AG010897, P50 AG0300601]
FX Supported by NIH NIA R01 AG022538, R01 AG010897, P50 AG0300601.
NR 41
TC 41
Z9 43
U1 3
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0893-0341
J9 ALZ DIS ASSOC DIS
JI Alzheimer Dis. Assoc. Dis.
PD JUL-SEP
PY 2009
VL 23
IS 3
BP 245
EP 252
PG 8
WC Clinical Neurology; Pathology
SC Neurosciences & Neurology; Pathology
GA 495QO
UT WOS:000269909300012
PM 19812467
ER
PT J
AU Cavusoglu, E
Chopra, V
Gupta, A
Choksi, PU
Ruwende, C
Yanamadala, S
Frishman, WH
Pinsky, DJ
Marmur, JD
AF Cavusoglu, Erdal
Chopra, Vineet
Gupta, Amit
Choksi, Palak U.
Ruwende, Cyril
Yanamadala, Sunitha
Frishman, William H.
Pinsky, David J.
Marmur, Jonathan D.
TI Relation of Baseline Serum Potassium Levels to Angiographic Findings in
Patients With Known or Suspected Coronary Artery Disease
SO AMERICAN JOURNAL OF HYPERTENSION
LA English
DT Article
ID SPONTANEOUSLY HYPERTENSIVE RATS; ACUTE MYOCARDIAL-INFARCTION; BLOOD-CELL
COUNT; CARDIAC MORTALITY; PREDICTOR
AB BACKGROUND
In experimental animal studies, potassium has been demonstrated to protect against the development of atherosclerosis through a variety of mechanisms. Data regarding the role of potassium in the development of human atherosclerosis are sparse. The objective of this study was to determine the association between plasma potassium levels and angiographically defined coronary artery disease (CAD).
METHODS
In a cohort of 389 male patients undergoing coronary angiography for a variety of clinical indications, the association between baseline serum potassium levels and the extent of angiographically defined atherosclerosis was analyzed. Adjustments were made for clinical and laboratory variables (including inflammatory markers) known to be associated with atherosclerosis.
RESULTS
By multivariate logistic regression analysis, baseline serum potassium levels were an independent predictor of the presence of multivessel disease (odds ratio (OR) 1.31, 95% confidence interval (CI) 1.01-1.69; P<0.05). In addition, in the non-myocardial infarction subpopulation of patients, serum potassium was also an independent predictor of the presence of multivessel disease by multivariate logistic regression analysis (OR 1.34, 95% Cl, 1.02-1.76; P<0.05). In the myocardial infarction (MI) subpopulation, serum potassium was not a predictor of multivessel disease, possibly due to the confounding effect of hypokalemia known-to be present during MI.
CONCLUSIONS
These data demonstrate that a simple baseline serum potassium level is independently associated with the presence of multivessel disease, even in the context of clinical CAD risk factors and other established inflammatory markers.
C1 [Cavusoglu, Erdal; Gupta, Amit; Marmur, Jonathan D.] Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA.
[Cavusoglu, Erdal; Chopra, Vineet; Choksi, Palak U.] Bronx Vet Affairs Med Ctr, Dept Med, Bronx, NY USA.
[Ruwende, Cyril; Yanamadala, Sunitha; Pinsky, David J.] Univ Michigan, Dept Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA.
[Frishman, William H.] New York Med Coll, Dept Med, Westchester Med Ctr, Valhalla, NY 10595 USA.
RP Cavusoglu, E (reprint author), Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA.
EM ECavusoglu@aol.com
NR 12
TC 2
Z9 2
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0895-7061
J9 AM J HYPERTENS
JI Am. J. Hypertens.
PD JUL
PY 2009
VL 22
IS 7
BP 754
EP 762
DI 10.1038/ajh.2009.65
PG 9
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 462IX
UT WOS:000267346100012
PM 19373212
ER
PT J
AU Egan, BM
Basile, JN
Rehman, SU
Davis, PB
Grob, CH
Riehle, JF
Walters, CA
Lackland, DT
Merali, C
Sealey, JE
Laragh, JH
AF Egan, Brent M.
Basile, Jan N.
Rehman, Shakaib U.
Davis, Phillip B.
Grob, Curt H., III
Riehle, Jessica Flynn
Walters, Christine A.
Lackland, Daniel T.
Merali, Carmen
Sealey, Jean E.
Laragh, John H.
TI Plasma Renin Test-Guided Drug Treatment Algorithm for Correcting
Patients With Treated but Uncontrolled Hypertension: A Randomized
Controlled Trial
SO AMERICAN JOURNAL OF HYPERTENSION
LA English
DT Article
ID CONVERTING-ENZYME-INHIBITOR; BLOOD-PRESSURE RESPONSE; RESISTANT
HYPERTENSION; LARAGHS LESSONS; CLINICAL PEARLS; ANTIHYPERTENSIVE ACTION;
RENAL-FUNCTION; THERAPY; PATHOPHYSIOLOGY; DIAGNOSIS
AB BACKGROUND
Undefined pathophysiologic mechanisms likely contribute to unsuccessful anti hypertensive drug therapy. The renin test-guided therapeutic (RTGT) algorithm is based on the concept that, irrespective of current drug treatments, subnormal plasma renin activity (PRA) (<0.65 ng/ml/h) indicates sodium-volume excess "V" hypertension, whereas values >= 0.65 indicate renin-angiotensin vasoconstriction excess "R" hypertension.
METHODS
The RTGT algorithm was applied to treated, uncontrolled hypertensives and compared to clinical hypertension specialists' care (CHSC) without access to PRA. RTGT protocol: "V" patients received natriuretic anti-"V"drugs (diuretics, spironolactone, calcium antagonists, or alpha(1)-blockers) while withdrawing antirenin "R" drugs (converting enzyme inhibitors, angiotensin receptor antagonists, or beta-blockers). Converse strategies were applied to "R" patients. Eighty-four ambulatory hypertensives were randomized and 77 qualified for the intention-to-treat analysis including 38 in RTGT (63.9 +/- 1.8 years; baseline blood pressure (BP) 157.0 +/- 2.6/87.1 +/- 2.0 mm Hg; PRA 5.8 +/- 1.6; 3.1 +/- 0.3 antihypertensive drugs) and 39 in CHSC (58.0 +/- 2.0 years; BD 153.6 +/- 2.3/91.9 +/- 2.0; PRA 4.6 +/- 1.1; 2.7 +/- 0.2 drugs).
RESULTS
BP was controlled in 28/38 (74% (RTGT)) vs. 23/39 (59% (CHSC)), P=0.17, falling to 127.9 +/- 2.3/73.1 +/- 1.8 vs. 134.0 +/- 2.8/79.8 +/- 1.9 mm Hg, respectively. Systolic BP (SBP) fell more with RTGT (-29.1 +/- 3.2 vs. -19.2 +/- 3.2 mm Hg, P=0.03), whereas diastolic BP (DBP) declined similarly (P=0.32). Although final anti hypertensive drug numbers were similar (3.1 +/- 0.2 (RTGT) vs. 3.0 +/- 0.3 (CHSC), P=0.73) in "V" patients, 60% (RTGT) vs. 11% (CHSC) of "R" drugs were withdrawn and BP medications were reduced (-0.5 +/- 03 vs. +0.7 +/- 0.3, P=0.01).
CONCLUSIONS
In treated but uncontrolled hypertension, RTGT improves control and lowers BP equally well or better than CHSC, indicating that RTGT provides a reasonable strategy for correcting treated but uncontrolled hypertension.
C1 [Egan, Brent M.; Basile, Jan N.; Rehman, Shakaib U.; Davis, Phillip B.; Grob, Curt H., III; Lackland, Daniel T.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Basile, Jan N.; Rehman, Shakaib U.] Ralph H Johnson VA Med Ctr, Dept Med, Charleston, SC USA.
[Riehle, Jessica Flynn; Walters, Christine A.; Lackland, Daniel T.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA.
[Merali, Carmen; Laragh, John H.] Weill Cornell Med Coll, Dept Cardiothorac Surg, New York, NY USA.
[Sealey, Jean E.] Weill Cornell Med Coll, Dept Med, New York, NY USA.
RP Egan, BM (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
EM eganbm@musc.edu
RI Sealey, Jean/A-9562-2009
FU New York Presbyterian Hospital; National Institutes of Health [HL04290];
Ralph H. Johnson Veterans Affairs Hospital
FX This research was supported by grants from the New York Presbyterian
Hospital, National Institutes of Health HL04290, and the Ralph H.
Johnson Veterans Affairs Hospital.
NR 49
TC 60
Z9 61
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0895-7061
J9 AM J HYPERTENS
JI Am. J. Hypertens.
PD JUL
PY 2009
VL 22
IS 7
BP 792
EP 801
DI 10.1038/ajh.2009.63
PG 10
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 462IX
UT WOS:000267346100017
PM 19373213
ER
PT J
AU Flythe, JE
Rueda, JF
Riscoe, MK
Watnick, S
AF Flythe, Jennifer E.
Rueda, Jose F.
Riscoe, Michael K.
Watnick, Suzanne
TI Silicate Nephrolithiasis After Ingestion of Supplements Containing
Silica Dioxide
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Silicate; silica; nephrolithiasis; over-the-counter supplements
ID MAGNESIUM TRISILICATE; URINARY CALCULI; UROLITHIASIS
AB Silicate calculi are common in some mammals, such as dogs and sheep, but extremely rare in humans. We report a case of silicate calculi in a woman using oral over-the-counter Uncaria tomentosa, Digestive Advantage and FlexProtex supplements. All 3 contained the excipient silica dioxide. Stone analysis showed composition of 100% silicate. The nephrolithiasis promptly abated after discontinuation of the products containing silica, then returned when the patient restarted her supplements. This case emphasizes the importance of stone analysis when obvious causes of nephrolithiasis are unclear and highlights the concerns of using over-the-counter supplements without substantial oversight. Am J Kidney Dis 54:127-130. (c) 2009 by the National Kidney Foundation, Inc.
C1 [Watnick, Suzanne] Portland VA Med Ctr, P3NEPH, Div Hosp & Specialty Med, Portland, OR 97239 USA.
[Rueda, Jose F.; Watnick, Suzanne] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA.
[Riscoe, Michael K.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR USA.
RP Watnick, S (reprint author), Portland VA Med Ctr, P3NEPH, Div Hosp & Specialty Med, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM suzanne.watnick@va.gov
NR 27
TC 4
Z9 5
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD JUL
PY 2009
VL 54
IS 1
BP 127
EP 130
DI 10.1053/j.ajkd.2008.10.042
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA 499JC
UT WOS:000270214400020
PM 19100669
ER
PT J
AU Wilhelm-Leen, ER
Hall, YN
Tamura, MK
Chertow, GM
AF Wilhelm-Leen, Emilee R.
Hall, Yoshio N.
Tamura, Manjula K.
Chertow, Glenn M.
TI Frailty and Chronic Kidney Disease: The Third National Health and
Nutrition Evaluation Survey
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Body composition; Chronic kidney disease; Frailty
ID GLOMERULAR-FILTRATION-RATE; FUNCTIONAL DECLINE; DIALYSIS PATIENTS; SERUM
CREATININE; OLDER-ADULTS; PREDICTION; WOMEN
AB BACKGROUND: Frailty is common in the elderly and in persons with chronic diseases. Few studies have examined the association of frailty with chronic kidney disease.
METHODS: We used data from the Third National Health and Nutrition Examination Survey to estimate the prevalence of frailty among persons with chronic kidney disease. We created a definition of frailty based on established validated criteria, modified to accommodate available data. We used logistic regression to determine whether and to what degree stages of chronic kidney disease were associated with frailty. We also examined factors that might mediate the association between frailty and chronic kidney disease.
RESULTS: The overall prevalence of frailty was 2.8%. However, among persons with moderate to severe chronic kidney disease (estimated glomerular filtration rate < 45 mL/min/1.73 m(2)), 20.9% were frail. The odds of frailty were significantly increased among all stages of chronic kidney disease, even after adjustment for the residual effects of age, sex, race, and prevalent chronic diseases. The odds of frailty associated with chronic kidney disease were only marginally attenuated with additional adjustment for sarcopenia, anemia, acidosis, inflammation, vitamin D deficiency, hypertension, and cardiovascular disease. Frailty and chronic kidney disease were independently associated with mortality.
CONCLUSION: Frailty is significantly associated with all stages of chronic kidney disease and particularly with moderate to severe chronic kidney disease. Potential mechanisms underlying the chronic kidney disease and frailty connection remain elusive. (C) 2009 Elsevier Inc. All rights reserved. The American Journal of Medicine (2009) 122, 664-671
C1 [Wilhelm-Leen, Emilee R.; Tamura, Manjula K.; Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Dept Med, Palo Alto, CA 94304 USA.
[Hall, Yoshio N.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA.
[Hall, Yoshio N.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Wilhelm-Leen, ER (reprint author), Stanford Univ, Sch Med, Div Nephrol, Dept Med, 780 Welch Rd,Suite 106, Palo Alto, CA 94304 USA.
EM ewilhelm@stanford.edu
RI Kurella Tamura, Manjula/C-8284-2014
OI Kurella Tamura, Manjula/0000-0001-5227-2479
FU Stanford University School of Medicine Medical Scholars Program
FX This research was funded by a grant from the Stanford University School
of Medicine Medical Scholars Program.
NR 23
TC 106
Z9 110
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD JUL
PY 2009
VL 122
IS 7
BP 664
EP U86
DI 10.1016/j.amjmed.2009.01.026
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 462HF
UT WOS:000267341000014
PM 19559169
ER
PT J
AU Choi, AI
Rodriguez, RA
Bacchetti, P
Bertenthal, D
Hernandez, GT
O'Hare, AM
AF Choi, Andy I.
Rodriguez, Rudolph A.
Bacchetti, Peter
Bertenthal, Daniel
Hernandez, German T.
O'Hare, Ann M.
TI White/Black Racial Differences in Risk of End-stage Renal Disease and
Death
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Kidney disease; Mortality; Racial disparities
ID CHRONIC KIDNEY-DISEASE; OF-VETERANS-AFFAIRS; UNITED-STATES;
ETHNIC-DIFFERENCES; AFRICAN-AMERICAN; MORTALITY; PREVALENCE;
STRATIFICATION; BENEFICIARIES; ASCERTAINMENT
AB BACKGROUND: End-stage renal disease disproportionately affects black persons, but it is unknown when in the course of chronic kidney disease racial differences arise. Understanding the natural history of racial differences in kidney disease may help guide efforts to reduce disparities.
METHODS: We compared white/black differences in the risk of end-stage renal disease and death by level of estimated glomerular filtration rate (eGFR) at baseline in a national sample of 2,015,891 veterans between 2001 and 2005.
RESULTS: Rates of end-stage renal disease among black patients exceeded those among white patients at all levels of baseline eGFR. The adjusted hazard ratios for end-stage renal disease associated with black versus white race for patients with an eGFR >= 90, 60-89, 45-59, 30-44, 15-29, and <15 mL/min/1.73m(2), respectively, were 2.14 (95% confidence interval [CI], 1.72-2.65), 2.30 (95% CI, 2.02-2.61), 3.08 (95% CI, 2.74-3.46), 2.47 (95% CI, 2.26-2.70), 1.86 (95% CI, 1.75-1.98), and 1.23 (95% CI, 1.12-1.34). We observed a similar pattern for mortality, with equal or higher rates of death among black persons at all levels of eGFR. The highest risk of mortality associated with black race also was observed among those with an eGFR 45-59 mL/min/1.73m(2) (hazard ratio 1.32, 95% CI, 1.27-1.36).
CONCLUSION: Racial differences in the risk of end-stage renal disease appear early in the course of kidney disease and are not explained by a survival advantage among blacks. Efforts to identify and slow progression of chronic kidney disease at earlier stages may be needed to reduce racial disparities. Published by Elsevier Inc. The American Journal of Medicine (2009) 122, 672-678
C1 [Choi, Andy I.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA.
[Rodriguez, Rudolph A.; O'Hare, Ann M.] Univ Washington, Seattle, WA 98195 USA.
[Rodriguez, Rudolph A.; O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Dept Med, Seattle, WA USA.
[Choi, Andy I.; Bacchetti, Peter] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Bertenthal, Daniel] San Francisco VA Med Ctr, VA Res Enhancement Award Program, San Francisco, CA USA.
[Hernandez, German T.] Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Dept Med, El Paso, TX USA.
RP Choi, AI (reprint author), San Francisco VA Med Ctr, Dept Med, Box 111J,4150 Clement St, San Francisco, CA 94121 USA.
EM andy.choi@ucsf.edu
FU National Kidney Foundation; National Institutes of Health
[K23DK080645-01A1, K23AG028980-03, R01AI069952-03]; W. K. Kellogg
Scholars in Health Disparities Program; Paso del Norte Health
Foundation's Center for Border Health Research; San Francisco VA
Research Enhancement Award Program
FX This study was supported by a fellowship grant from the National Kidney
Foundation, grants from the National Institutes of Health
(K23DK080645-01A1, K23AG028980-03, R01AI069952-03), W. K. Kellogg
Scholars in Health Disparities Program, Paso del Norte Health
Foundation's Center for Border Health Research, and the San Francisco VA
Research Enhancement Award Program to Improve Care for Older Veterans.
These funding sources had no involvement in the design or execution of
this study.
NR 38
TC 52
Z9 52
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD JUL
PY 2009
VL 122
IS 7
BP 672
EP 678
DI 10.1016/j.amjmed.2008.11.021
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 462HF
UT WOS:000267341000015
PM 19559170
ER
PT J
AU Dicianno, BE
Gaines, A
Collins, DM
Lee, S
AF Dicianno, Brad E.
Gaines, Anna
Collins, Diane M.
Lee, Shannon
TI Mobility, Assistive Technology Use, and Social Integration Among Adults
with Spina Bifida
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Depression; Rehabilitation; Socialization; Spinal Dysraphism; Self-Help
Devices; Walking; Wheelchairs
ID QUALITY-OF-LIFE; YOUNG-ADULTS; FUNCTIONAL INDEPENDENCE; CORD-INJURY;
ADOLESCENTS; MENINGOMYELOCELE; HYDROCEPHALUS; DETERMINANTS; CHILDREN;
MYELOMENINGOCELE
AB Objective: Many individuals with spina bifida have impairments that limit mobility and functional independence. Sedentary lifestyles and social isolation are very prevalent. This study evaluated the association between the use of mobility devices and degree of socialization.
Design: A retrospective chart review was performed on 208 adults with spina bifida attending a university-based clinic. Data collected included the Craig Handicap Assessment Reporting Technique-Short Form, Beck Depression Inventory, and data on wheelchair and other assistive technology use. We hypothesized that community and home mobility and social Integration, as measured by the Craig Handicap Assessment Reporting Technique-Short Form, would be lower for manual and power wheelchair users than for ambulators, regardless of depression scores or shunt history.
Results: We found that individuals with spina bifida who used both manual and power wheelchairs do have lower daily home and community activity levels compared with ambulators, but that most individuals with spina bifida have low social integration and economic self-sufficiency scores, regardless of whether they can ambulate or use wheelchairs. These findings were not explained by wheelchair quality because most were prescribed high-quality devices. A high prevalence of depression was also found.
Conclusions: Special considerations for wheelchair provision are discussed. Additional research is needed to identify other barriers to social integration.
C1 [Dicianno, Brad E.; Gaines, Anna; Collins, Diane M.; Lee, Shannon] Univ Pittsburgh, Human Engn Res Labs, Pittsburgh, PA 15260 USA.
[Dicianno, Brad E.; Collins, Diane M.] Univ Pittsburgh, Adult Spina Bifida Clin, Pittsburgh, PA 15260 USA.
[Dicianno, Brad E.; Collins, Diane M.; Lee, Shannon] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA.
[Dicianno, Brad E.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA.
[Dicianno, Brad E.; Gaines, Anna] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
[Dicianno, Brad E.; Collins, Diane M.] Ctr Excellence Wheelchairs & Associated Rehabil E, VA Pittsburgh HealthCare Syst, Pittsburgh, PA USA.
RP Dicianno, BE (reprint author), Suite 202 Kaufmann Bldg,3471 5th Ave, Pittsburgh, PA 15213 USA.
OI Dicianno, Brad/0000-0003-0738-0192
NR 37
TC 20
Z9 20
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD JUL
PY 2009
VL 88
IS 7
BP 533
EP 541
DI 10.1097/PHM.0b013e3181aa41d4
PG 9
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 463CO
UT WOS:000267406400002
PM 19542778
ER
PT J
AU Larauche, M
Gourcerol, G
Wang, LX
Pambukchian, K
Brunnhuber, S
Adelson, DW
Rivier, J
Million, M
Tache, Y
AF Larauche, Muriel
Gourcerol, Guillaume
Wang, Lixin
Pambukchian, Karina
Brunnhuber, Stefan
Adelson, David W.
Rivier, Jean
Million, Mulugeta
Tache, Yvette
TI Cortagine, a CRF1 agonist, induces stresslike alterations of colonic
function and visceral hypersensitivity in rodents primarily through
peripheral pathways
SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
LA English
DT Article
DE CRF1 agonist; colonic motility; visceral pain; rat; mice; colonic
permeability; astressin; CP-154,526
ID CORTICOTROPIN-RELEASING-FACTOR; IRRITABLE-BOWEL-SYNDROME; FACTOR
SIGNALING PATHWAYS; FACTOR-RELATED PEPTIDES; ENTERIC NERVOUS-SYSTEM;
COLORECTAL DISTENSION; RECEPTOR ANTAGONIST; MOTOR FUNCTION; MAST-CELLS;
RAT COLON
AB Larauche M, Gourcerol G, Wang L, Pambukchian K, Brunnhuber S, Adelson DW, Rivier J, Million M, Tache Y. Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways. Am J Physiol Gastrointest Liver Physiol 297: G215-G227, 2009. First published April 30, 2009; doi:10.1152/ajpgi.00072.2009.-Corticotropin-releasing factor (CRF) 1 receptor (CRF1) activation in the brain is a core pathway orchestrating the stress response. Anatomical data also support the existence of CRF signaling components within the colon. We investigated the colonic response to intraperitoneal (ip) injection of cortagine, a newly developed selective CRF1 peptide agonist. Colonic motor function and visceral motor response (VMR) were monitored by using a modified miniaturized pressure transducer catheter in adult conscious male Sprague-Dawley rats and C57Bl/6 mice. Colonic permeability was monitored by the Evans blue method and myenteric neurons activation by Fos immunohistochemistry. Compared with vehicle, cortagine (10 mu g/kg ip) significantly decreased the distal colonic transit time by 45% without affecting gastric transit, increased distal and transverse colonic contractility by 35.6 and 66.2%, respectively, and induced a 7.1-fold increase in defecation and watery diarrhea in 50% of rats during the first hour postinjection whereas intracerebroventricular (icv) cortagine (3 mu g/rat) had lesser effects. Intraperitoneal (ip) cortagine also increased colonic permeability, activated proximal and distal colonic myenteric neurons, and induced visceral hypersensitivity to a second set of phasic colorectal distention (CRD). The CRF antagonist astressin (10 mu g/kg ip) abolished ip cortagine-induced hyperalgesia whereas injected icv it had no effect. In mice, cortagine (30 mu g/kg ip) stimulated defecation by 7.8-fold, induced 60% incidence of diarrhea, and increased VMR to CRD. Stresslike colonic alterations induced by ip cortagine in rats and mice through restricted activation of peripheral CRF1 receptors support a role for peripheral CRF1 signaling as the local arm of the colonic response to stress.
C1 [Larauche, Muriel; Gourcerol, Guillaume; Wang, Lixin; Pambukchian, Karina; Brunnhuber, Stefan; Adelson, David W.; Million, Mulugeta; Tache, Yvette] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA USA.
[Larauche, Muriel; Gourcerol, Guillaume; Wang, Lixin; Pambukchian, Karina; Brunnhuber, Stefan; Adelson, David W.; Million, Mulugeta; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Ctr Neurobiol Stress,Dept Med, Los Angeles, CA 90095 USA.
[Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Rivier, Jean] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA USA.
RP Larauche, M (reprint author), W Los Angeles VA Med Ctr, CURE Digest Dis Res Ctr, 11301 Wilshire Blvd,Bldg 115,Rm 111, Los Angeles, CA 90073 USA.
EM mlarauche@mednet.ucla.edu
OI Larauche, Muriel/0000-0003-3320-3675; Adelson, David/0000-0002-4623-6030
FU VA Career Scientist Award; National Institute of Diabetes and Digestive
and Kidney Diseases [R01 DK-57238, DK-33061, P50 DK-64539, DK AM 41301,
DK PO1-26741, DK-068155, T32 DK07180-3255]; French Society of
Gastroenterology (SNFGE)
FX The research was supported by a VA Career Scientist Award (Y. Tache),
National Institute of Diabetes and Digestive and Kidney Diseases Grants
R01 DK-57238 and DK-33061 (Y. Tache), P50 DK-64539 (Emeran Mayer), DK AM
41301 (Animal Model Core, Y. Tache), DK PO1-26741 (J. Rivier), DK-068155
(M. Million), T32 DK07180-32 (M. Larauche), and the French Society of
Gastroenterology (SNFGE; G. Gourcerol).
NR 67
TC 59
Z9 60
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1857
J9 AM J PHYSIOL-GASTR L
JI Am. J. Physiol.-Gastroint. Liver Physiol.
PD JUL
PY 2009
VL 297
IS 1
BP G215
EP G227
DI 10.1152/ajpgi.00072.2009
PG 13
WC Gastroenterology & Hepatology; Physiology
SC Gastroenterology & Hepatology; Physiology
GA 472RU
UT WOS:000268150500025
PM 19407218
ER
PT J
AU Nakano, T
Inoue, I
Alpers, DH
Akiba, Y
Katayama, S
Shinozaki, R
Kaunitz, JD
Ohshima, S
Akita, M
Takahashi, S
Koyama, I
Matsushita, M
Komoda, T
AF Nakano, Takanari
Inoue, Ikuo
Alpers, David H.
Akiba, Yasutada
Katayama, Shigehiro
Shinozaki, Rina
Kaunitz, Jonathan D.
Ohshima, Susumu
Akita, Masumi
Takahashi, Seiichiro
Koyama, Iwao
Matsushita, Makoto
Komoda, Tsugikazu
TI Role of lysophosphatidylcholine in brush-border intestinal alkaline
phosphatase release and restoration
SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
LA English
DT Article
DE Caco-2 cells; lipid absorption; small intestine; enzyme-labeled
fluorescence-97
ID SURFACTANT-LIKE PARTICLES; FAT; SECRETION; ABSORPTION; PROTEINS;
INHIBITION; PROTEASES; FISSION; SERUM; RATS
AB Nakano T, Inoue I, Alpers DH, Akiba Y, Katayama S, Shinozaki R, Kaunitz JD, Ohshima S, Akita M, Takahashi S, Koyama I, Matsushita M, Komoda T. Role of lysophosphatidylcholine in brush-border intestinal alkaline phosphatase release and restoration. Am J Physiol Gastrointest Liver Physiol 297: G207-G214, 2009. First published April 30, 2009; doi:10.1152/ajpgi.90590.2008.-Intestinal alkaline phosphatase (IAP) is a brush-border membrane ectoenzyme (BBM-IAP) that is released into the lumen (L-IAP) after a high-fat diet. We examined the effects of oil feeding and the addition of mixed-lipid micelles on the formation of L-IAP in oil-fed rat intestine, Caco-2 cell monolayers, and mouse intestinal loops. We localized IAP in the duodenum of rats fed corn oil using fluorescence microscopy with enzyme-labeled fluorescence-97 as substrate. Four hours after oil feeding, L-IAP increased similar to 10-fold accompanied by the loss of BBM-IAP, consistent with BBM-IAP release. Rat IAP isozyme mRNAs progressively increased 4-6 h after oil feeding, followed by the increase of IAP activity in the subapical location at 6 h, consistent with the restoration of IAP protein. Postprandial lipid-micelle components, sodium taurocholate with or without oleic acid, mono-oleylglycerol, cholesterol, or lysophosphatidylcholine (lysoPC) were applied singly or as mixed-lipid micelles to the apical surface of polarized Caco-2 cell monolayers. LysoPC increased L-IAP > 10-fold over basal release. LysoPC released IAP into the apical medium more than other intestinal brush-border enzymes, 5'-nucleotidase, sucrase, aminopeptidase N, and lactase, without comparable lactate dehydrogenase release or cell injury. LysoPC increased human IAP mRNA levels by 1.5-fold in Caco-2 cells. Luminally applied lysoPC also increased release of IAP preferentially in mouse intestinal loops. These data show that lysoPC accelerates the formation of L-IAP from BBM-IAP, followed by enhanced IAP synthesis, suggesting the role that lysoPC might play in the turnover of brush-border proteins.
C1 [Nakano, Takanari; Shinozaki, Rina; Takahashi, Seiichiro; Koyama, Iwao; Matsushita, Makoto; Komoda, Tsugikazu] Saitama Med Univ, Dept Biochem, Saitama, Japan.
[Inoue, Ikuo; Katayama, Shigehiro] Saitama Med Univ, Dept Endocrinol & Diabet, Saitama, Japan.
[Ohshima, Susumu; Akita, Masumi] Saitama Med Univ, Dept Morphol Sci, Biomed Res Ctr, Fac Med, Saitama, Japan.
[Alpers, David H.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
[Akiba, Yasutada; Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
[Nakano, Takanari; Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA.
[Akiba, Yasutada] Brentwood Biomed Res Inst, Los Angeles, CA USA.
RP Nakano, T (reprint author), W Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM nk.takanari@gmail.com
FU Japan Foundation of Applied Enzymology; NIH [DK56341, R01 DK54221];
Department of Veterans Affairs Merit Review Award
FX This work was supported in part by a grant from the Japan Foundation of
Applied Enzymology for T. Nakano, the CNRU grant from NIH, DK56341, for
partial support for D. H. Alpers, and a Department of Veterans Affairs
Merit Review Award and NIH-NIDDK R01 DK54221 for J. D. Kaunitz.
NR 34
TC 23
Z9 24
U1 1
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1857
J9 AM J PHYSIOL-GASTR L
JI Am. J. Physiol.-Gastroint. Liver Physiol.
PD JUL
PY 2009
VL 297
IS 1
BP G207
EP G214
DI 10.1152/ajpgi.90590.2008
PG 8
WC Gastroenterology & Hepatology; Physiology
SC Gastroenterology & Hepatology; Physiology
GA 472RU
UT WOS:000268150500024
PM 19407215
ER
PT J
AU Mu, H
Wang, XW
Wang, H
Lin, P
Yao, QH
Chen, CY
AF Mu, Hong
Wang, Xinwen
Wang, Hao
Lin, Peter
Yao, Qizhi
Chen, Changyi
TI Lactosylceramide promotes cell migration and proliferation through
activation of ERK1/2 in human aortic smooth muscle cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE vascular smooth muscle cell; cell proliferation; oxidative stress;
extracellular signal-regulated kinase 1/2; antioxidant; vascular disease
ID ENDOTHELIAL-CELLS; PROTEIN-KINASES; ATHEROSCLEROSIS; GROWTH;
GLYCOSPHINGOLIPIDS; EXPRESSION; SELENIUM; DISEASE; ACCUMULATION;
ADHESION
AB Mu H, Wang X, Wang H, Lin P, Yao Q, Chen C. Lactosylceramide promotes cell migration and proliferation through activation of ERK1/2 in human aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 297: H400-H408, 2009. First published May 22, 2009; doi: 10.1152/ajpheart.01254.2008.-Increased plasma levels of lactosylceramide (LacCer) have been associated with cardiovascular disease. However, it is largely unknown whether LacCer directly contributes to dysfunction of smooth muscle cells (SMCs), a key event in vascular lesion formation. In the present study, we determined the effects and potential mechanisms of LacCer on cell migration and proliferation in human aortic SMCs (AoSMCs). Cell migration and proliferation were determined by a modified Boyden chamber assay and nonradioactive colorimetric (MTS) assay, respectively. We found that LacCer significantly induced AoSMC migration and proliferation in a concentration- and time-dependent manner. In addition, LacCer significantly upregulated the expression of PDGFR-B, integrins (alpha(v) and beta(3)), and matrix metalloproteinases (matrix metalloproteinase-1 and -2) at both mRNA and protein levels, as determined by real-time PCR and Western blot analyses, respectively. Furthermore, LacCer increased superoxide anion production and the transient phosphorylation of ERK1/2 in AoSMCs, as determined by dihydroethidium staining and immunoassay, respectively. Accordingly, LacCer-induced cell migration and proliferation were effectively blocked by antioxidants (seleno-L-methionine and Mn tetrakis porphyrin) and by a specific ERK1/2 inhibitor. Thus, LacCer promotes cell migration and proliferation through oxidative stress and activation of ERK1/2 in AoSMCs. These findings demonstrate the functional role of LacCer in the vascular disease pathogenesis.
C1 [Mu, Hong; Wang, Xinwen; Wang, Hao; Lin, Peter; Yao, Qizhi; Chen, Changyi] Baylor Coll Med, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, Mol Surg Res Ctr, Houston, TX 77030 USA.
[Lin, Peter; Yao, Qizhi; Chen, Changyi] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
RP Chen, CY (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg MARB413, 1 Baylor Plaza,Mail Stop BCM390, Houston, TX 77030 USA.
EM jchen@bcm.tmc.edu
FU Baylor College of Medicine and Michael E. DeBakey Veterans Affairs
Medical Center
FX This work was partially supported by the Baylor College of Medicine and
Michael E. DeBakey Veterans Affairs Medical Center (Houston, TX).
NR 34
TC 16
Z9 16
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD JUL
PY 2009
VL 297
IS 1
BP H400
EP H408
DI 10.1152/ajpheart.01254.2008
PG 9
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA 464GI
UT WOS:000267492900047
PM 19465542
ER
PT J
AU Tuerk, PW
Grubaugh, AL
Hamner, MB
Foa, EB
AF Tuerk, Peter W.
Grubaugh, Anouk L.
Hamner, Mark B.
Foa, Edna B.
TI Diagnosis and Treatment of PTSD-Related Compulsive Checking Behaviors in
Veterans of the Iraq War: The Influence of Military Context on the
Expression of PTSD Symptoms
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Editorial Material
ID EXPOSURE; DISORDER
AB This case study presents an overview of the conceptualization and treatment of two veterans of the Iraq War who presented for combat-related treatment at a Veterans Administration Medical Center. In addition to posttraumatic stress disorder (PTSD) symptoms of reexperiencing, arousal, and avoidance, the veterans exhibited compulsive checking behaviors that appear to be influenced by theater-specific combat duties and traumatic events. These cases represent what the authors believe to be an increasingly common expression of PTSD in veterans of the Iraq and Afghanistan wars. Both veterans were treated with prolonged exposure therapy, which includes imaginal and in vivo exposure to anxiety-provoking stimuli, processing of traumatic events, and self-assessment of anxiety. Treatment also included in vivo exposure with response prevention techniques borrowed from the literature on obsessive-compulsive disorder to address compulsive checking behaviors within the ecological context of each patient's symptom presentation. Measures related to PTSD and depression were obtained before, during, and after treatment. Treatment was associated with significant declines in symptom severity and improved functioning for both veterans. The unique nature of the conflict in the Middle East represents role challenges for soldiers that affect symptom presentation. Variations in symptom presentation can in turn complicate efforts to identify and appropriately address PTSD-related health concerns in this population. Thus, clinicians and researchers must remain cognizant of how theater-specific duties influence the manifestation and treatment of PTSD in order to provide optimal care to a new generation of veterans.
C1 Ralph H Johnson Vet Affairs Med Ctr, Post Traumat Stress Clin Team, Charleston, SC USA.
Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
Univ Penn, Dept Psychiat, Ctr Treatment & Study Anxiety, Philadelphia, PA 19104 USA.
RP Tuerk, PW (reprint author), Charleston VAMC, Mental Hlth 116,109 Bee St, Charleston, SC 29401 USA.
EM Tuerk@musc.edu
NR 24
TC 15
Z9 17
U1 0
U2 6
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD JUL
PY 2009
VL 166
IS 7
BP 762
EP 767
DI 10.1176/appi.ajp.2009.08091315
PG 6
WC Psychiatry
SC Psychiatry
GA 465RF
UT WOS:000267603800007
PM 19570938
ER
PT J
AU Wilks, JA
Liebig, C
Tasleem, SH
Haderxhanaj, K
Lee, L
Farrow, B
Awad, S
Berger, D
Albo, D
AF Wilks, Jonathan A.
Liebig, Catherine
Tasleem, Syed H.
Haderxhanaj, Kujtim
Lee, Liz
Farrow, Buckminster
Awad, Samir
Berger, David
Albo, Daniel
TI Rectal cancer patients benefit from implementation of a dedicated
colorectal cancer center in a Veterans affairs medical center
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Cancer center; Colorectal cancer; Clinical outcomes; Rectal cancer;
Veterans
ID RANDOMIZED-TRIAL; VOLUME; OUTCOMES; SURGERY; SPECIALIZATION;
RADIOTHERAPY; QUALITY; THERAPY
AB BACKGROUND: A dedicated colorectal cancer (CRC) center was created in a Veterans Affairs Medical Center with the intent of improving quality of patient care and multidisciplinary cooperation.
METHODS: Retrospective and prospective databases before and after creation of the CRC center, respectively, were created. Patients entered in each database included those requiring surgical intervention for CRC treatment. Statistical analyses included Fisher's exact, chi-square, and unpaired Student t tests as well as analysis of variance.
RESULTS: The overall quality of care of CRC patients has improved as evidenced by a larger percentage of complete, margin-negative resections (P <.05) as well as an increase in the number of lymph nodes excised at surgery (P <.0001). Furthermore, a multidisciplinary approach is clearly beneficial as evidenced by the increased number of CRC patients receiving appropriate multidisciplinary therapy (P <.0001).
CONCLUSIONS: A dedicated CRC center has significantly improved quality of care for CRC patients. (C) 2009 Published by Elsevier Inc.
C1 [Wilks, Jonathan A.; Liebig, Catherine; Tasleem, Syed H.; Haderxhanaj, Kujtim; Lee, Liz; Farrow, Buckminster; Awad, Samir; Berger, David; Albo, Daniel] Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, Houston, TX 77030 USA.
[Wilks, Jonathan A.; Liebig, Catherine; Lee, Liz; Farrow, Buckminster; Awad, Samir; Berger, David; Albo, Daniel] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA.
RP Albo, D (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, Houston, TX 77030 USA.
EM dalbo@bcm.edu
NR 15
TC 9
Z9 10
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
J9 AM J SURG
JI Am. J. Surg.
PD JUL
PY 2009
VL 198
IS 1
BP 100
EP 104
DI 10.1016/j.amjsurg.2008.09.020
PG 5
WC Surgery
SC Surgery
GA 467WK
UT WOS:000267773600017
PM 19268899
ER
PT J
AU Sano, Y
Hermsen, JL
Kang, W
Gomez, FE
Lan, J
Maeshima, Y
Kudsk, KA
AF Sano, Yoshifumi
Hermsen, Joshua L.
Kang, Woodae
Gomez, F. Enrique
Lan, Jinggang
Maeshima, Yoshinori
Kudsk, Kenneth A.
TI Parenteral nutrition maintains pulmonary IgA antibody transport
capacity, but not active transport, following injury
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Mucosal immunology; Injury; Enteral nutrition; Parenteral nutrition;
Polymeric immunoglobulin receptor
ID POLYMERIC IMMUNOGLOBULIN RECEPTOR; MAJOR ABDOMINAL-TRAUMA; SECRETORY
COMPONENT; SEPTIC MORBIDITY; MUCOSAL IMMUNITY; ROUTE; EXPRESSION;
RESPONSES; BINDING; INTESTINE
AB BACKGROUND: Parenteral nutrition (PN) increases post-trauma pneumonia versus enteral feeding. PN impairs murine immunoglobulin A (IgA) airway defenses and abrogates a normal IgA increase following injury. This work investigates the effect of type/route of nutrition on lung IgA and its transport protein, polymeric immunoglobulin receptor (pIgR), after injury.
METHODS: Catheterized mice were randomized to Chow or PN for 5 days and sacrificed without injury (Chow: n = 12; PN n = 11), or 8 hours after laparotomy + neck incisions (Chow-injury: n = 11, PN-injury: n = 13). Bronchoalveolar lavage (BAL) and lung IgA levels were analyzed by enzyme-linked immunosorbent assay (ELISA) and lung pIgR by Western blot.
RESULTS: BAL IgA levels increased in Chow-injury versus PN-injury (P <.01) with no differences in pIgR. PN-injury tissue IgA levels decreased versus Chow (P <.01), Chow-injury (P <.01), and PN (P <.05).
CONCLUSIONS: PN impairs the airway IgA response to injury but not due to impaired IgA transport capacity/pIgR level. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Sano, Yoshifumi; Hermsen, Joshua L.; Kang, Woodae; Gomez, F. Enrique; Lan, Jinggang; Maeshima, Yoshinori; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Coll Med, Madison, WI 53706 USA.
[Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA.
RP Kudsk, KA (reprint author), Univ Wisconsin, Dept Surg, Coll Med, Madison, WI 53706 USA.
EM kudsk@surgery.wisc.edu
RI Lan, Jinggang/F-1776-2011
FU National Institutes of Health [R01 GM53439]; Office of Research and
Development, Biomedical Laboratory R&D Service, Department of Veterans
Affairs
FX Supported by Grant No. R01 GM53439 from the National Institutes of
Health and based on work supported in part by the Office of Research and
Development, Biomedical Laboratory R&D Service, Department of Veterans
Affairs.
NR 32
TC 13
Z9 13
U1 0
U2 1
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
J9 AM J SURG
JI Am. J. Surg.
PD JUL
PY 2009
VL 198
IS 1
BP 105
EP 109
DI 10.1016/j.amjsurg.2008.08.018
PG 5
WC Surgery
SC Surgery
GA 467WK
UT WOS:000267773600018
PM 19249732
ER
PT J
AU Moriyama, B
Henning, SA
Neuhauser, MM
Danner, RL
Walsh, TJ
AF Moriyama, Brad
Henning, Stacey A.
Neuhauser, Melinda M.
Danner, Robert L.
Walsh, Thomas J.
TI Continuous-infusion beta-Lactam Antibiotics During Continuous Venovenous
Hemofiltration for the Treatment of Resistant Gram-Negative Bacteria
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Article
DE Acinetobacter baumannii; beta-lactam; continuous infusion; continuous
venovenous hemofiltration; Pseudomonas aeruginosa
ID RENAL REPLACEMENT THERAPY; CRITICALLY-ILL PATIENTS;
PSEUDOMONAS-AERUGINOSA INFECTION; SINGLE-DOSE PHARMACOKINETICS; RABBIT
ENDOCARDITIS MODEL; IN-VITRO; CYSTIC-FIBROSIS; CLAVULANIC ACID;
INTERMITTENT INFUSION; ANTIMICROBIAL AGENTS
AB OBJECTIVE: To describe the rationale, principles, and dosage calculations for continuous-infusion beta-lactam antibiotics to treat multidrug-resistant bacteria in patients undergoing continuous venovenous hemofiltration (CVVH).
DATA SOURCES: A MEDLINE search (1968-November 2008) of the English-language literature was performed using the terms continuous infusion and Pseudomonas or Acinetobacter, hemofiltration or CVVH or hemodiafiltration or CVVHDF or continuous renal replacement therapy or pharmacokinetics; and terms describing different beta-lactam antibiotics.
STUDY SELECTION AND DATA EXTRACTION: In vitro, in vivo, and human studies were evaluated that used continuous-infusion beta-lactam antibiotics to treat Pseudomonas aeruginosa and Acinetobacter baumannii infections. Studies were reviewed that described the pharmacokinetics of beta-lactam antibiotics during CVVH as well as other modalities of continuous renal replacement therapy.
DATA SYNTHESIS: Continuous infusion of beta-lactam antibiotics, maintaining drug concentrations 4-5 times higher than the minimum inhibitory concentration, is a promising approach for managing infections caused by P. aeruginosa and A. baumannii. Safe yet effective continuous infusion therapy is made difficult by the occurrence of acute renal failure and the need for renal replacement therapy. Case series and pharmacokinetic properties indicate that several beta-lactam antimicrobials that have been studied for continuous infusion, such as cefepime, ceftazidime, piperacillin, ticarcillin, clavulanic acid, and tazobactam, are significantly cleared by hemofiltration. Methodology and formulas are provided that allow practitioners to calculate dosage regimens and reach target drug concentrations for continuous beta-lactam antibiotic infusions during CVVH based on a literature review, pharmacokinetic principles, and our experience at the National Institutes of Health Clinical Center.
CONCLUSIONS: Continuous infusion of beta-lactam antibiotics may be a useful treatment strategy for multidrug-resistant gram-negative infections in the intensive care unit. Well-established pharmacokinetic and pharmacodynamic principles can be used to safely reach and maintain steady-state target concentrations of beta-lactam antibiotics in critical illness complicated by acute renal failure requiring CVVH.
C1 [Walsh, Thomas J.] NCI, Immunocompromised Host Sect, Pediat Oncol Branch, Bethesda, MD 20892 USA.
[Moriyama, Brad; Henning, Stacey A.] NIH, Dept Pharm, Ctr Clin, Bethesda, MD 20892 USA.
[Neuhauser, Melinda M.] US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA.
[Danner, Robert L.] NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA.
RP Walsh, TJ (reprint author), CRC 1-5750,10 Ctr Dr, Bethesda, MD 20892 USA.
EM walsht@mail.nih.gov
FU National Institutes of Health
FX This work was supported in part by the intramural research program of
the National Institutes of Health.
NR 87
TC 9
Z9 10
U1 0
U2 1
PU HARVEY WHITNEY BOOKS CO
PI CINCINNATI
PA PO BOX 42696, CINCINNATI, OH 45242 USA
SN 1060-0280
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD JUL-AUG
PY 2009
VL 43
IS 7-8
BP 1324
EP 1337
DI 10.1345/aph.1L638
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 477IM
UT WOS:000268512700020
PM 19584386
ER
PT J
AU Bakaeen, FG
Huh, J
LeMaire, SA
Coselli, JS
Sansgiry, S
Atluri, PV
Chu, DN
AF Bakaeen, Faisal G.
Huh, Joseph
LeMaire, Scott A.
Coselli, Joseph S.
Sansgiry, Shubhada
Atluri, Prasad V.
Chu, Danny
TI The July Effect: Impact of the Beginning of the Academic Cycle on
Cardiac Surgical Outcomes in a Cohort of 70,616 Patients
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID ARTERY-BYPASS SURGERY; TEACHING HOSPITALS; RESIDENT; IMPROVEMENT;
EXPERIENCE; MORTALITY; PROGRAM; SAFETY; LEVEL; RISK
AB Background. Because surgical residents' level of experience may be at its nadir early in the academic year, academic seasonality-or the "July effect"-could affect cardiac surgical outcomes.
Methods. Prospectively collected data from the Department of Veterans Affairs Continuous Improvement in Cardiac Surgery Program were used to identify 70,616 consecutive cardiac surgical procedures performed between October 1997 and October 2007. Morbidity and mortality rates were compared between early (July 1 to August 31, n = 11,975) and late (September 1 to June 30, n = 58,641) periods in the academic year. A prediction model was constructed by using stepwise logistic regression modeling.
Results. The two patient groups had similar demographic and risk variables. Isolated coronary artery bypass grafting accounted for 76.7% of early-period procedures and 75.8% of later-period procedures (p = 0.03). Morbidity rates did not differ significantly between the early (14.0%) and later periods (14.2%; odds ratio [OR], 1.01; 95% confidence interval [CI], 0.96 to 1.07; p = 0.67) and operative mortality was similar, 3.7% vs 3.9% (OR, 0.99; 95% CI, 0.89 to 1.11; p = 0.90). The early portion of the year was associated with longer cardiac ischemia times (84 +/- 40 vs 83 +/- 42 minutes), cardiopulmonary bypass times (126 +/- 52 vs 124 +/- 56 minutes), and total surgical times (295 +/- 90 vs 288 +/- 90 minutes; p < 0.05 for all).
Conclusions. The early part of the academic year was associated with slightly longer operative times; however, risk-adjusted outcomes were similar in both periods. This finding should lessen concerns about the quality of cardiac surgical care at the beginning of the academic year. (Ann Thorac Surg 2009;88:70-5) (C) 2009 by The Society of Thoracic Surgeons
C1 Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA.
RP Bakaeen, FG (reprint author), Michael E DeBakey VAMC, Dept Cardiothorac Surg, OCL 112,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM fbakaeen@bcm.edu
FU Offices of Research and Development; Northport and Eastern Colorado
Health Care System Denver Veterans Affairs Medical Centers
FX Stephen N. Palmer, PhD, ELS, contributed to the editing of this
manuscript. The CICSP-X study was initially funded by VA Health Services
Research and Development Grant #IHY 99214-1 (Dr Shroyer, Principal
Investigator), with ongoing support from the Office of Patient Care
Services, VA Central Office, Washington, DC. This project was supported
in part by the Offices of Research and Development at the Northport and
Eastern Colorado Health Care System Denver Veterans Affairs Medical
Centers. Special acknowledgment is given to Randy Johnson, Lisa Schade,
and Missy Bell, the team members responsible for the CICSP-X access to
care report sections, working under the leadership of Dr Gerald McDonald
(VA Central Office).
NR 19
TC 36
Z9 36
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JUL
PY 2009
VL 88
IS 1
BP 70
EP 75
DI 10.1016/j.athoracsur.2009.04.022
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 464ZV
UT WOS:000267550600011
PM 19559195
ER
PT J
AU Talbert, ML
Ashwood, ER
Brownlee, NA
Clark, JR
Horowitz, RE
Lepoff, RB
Neumann, A
Otis, CN
Powell, SZE
Sodeman, TM
AF Talbert, Michael L.
Ashwood, Edward R.
Brownlee, Noel A.
Clark, Jimmy R.
Horowitz, Richard E.
Lepoff, Ronald B.
Neumann, Ann
Otis, Christopher N.
Powell, Suzanne Zein-Eldin
Sodeman, Thomas M.
TI Resident Preparation for Practice A White Paper From the College of
American Pathologists and Association of Pathology Chairs
SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
LA English
DT Editorial Material
ID SURGICAL-PATHOLOGY; ANATOMIC PATHOLOGY; CURRICULUM CONTENT; COMPETENCE;
PROPOSAL; FUTURE
C1 [Talbert, Michael L.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA.
[Ashwood, Edward R.] Univ Utah, Dept Pathol, Salt Lake City, UT USA.
[Ashwood, Edward R.] ARUP Labs Inc, Salt Lake City, UT USA.
[Brownlee, Noel A.] Greenville Hosp Syst & Pathol Associates & Consul, Dept Pathol, Greenville, SC USA.
[Clark, Jimmy R.] ACL Labs, SC, W Allis, WI USA.
[Horowitz, Richard E.] USC Sch Med, Dept Pathol, Los Angeles, CA USA.
[Horowitz, Richard E.] Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA.
[Lepoff, Ronald B.] Univ Colorado Hosp, Dept Pathol, Aurora, CO USA.
[Neumann, Ann] Coll Amer Pathologists, Northfield, IL USA.
[Otis, Christopher N.] Bayside Med Ctr, Dept Pathol, Springfield, MA USA.
[Powell, Suzanne Zein-Eldin] Methodist Hosp, Dept Pathol, Houston, TX 77030 USA.
RP Talbert, ML (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, 940 Stanton L Young,BMSB 451, Oklahoma City, OK 73104 USA.
EM michael-talbert@ouhsc.edu
NR 18
TC 22
Z9 22
U1 0
U2 0
PU COLLEGE AMER PATHOLOGISTS
PI NORTHFIELD
PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
SN 0003-9985
J9 ARCH PATHOL LAB MED
JI Arch. Pathol. Lab. Med.
PD JUL
PY 2009
VL 133
IS 7
BP 1139
EP 1147
PG 9
WC Medical Laboratory Technology; Medicine, Research & Experimental;
Pathology
SC Medical Laboratory Technology; Research & Experimental Medicine;
Pathology
GA 464DI
UT WOS:000267484900015
PM 19642741
ER
PT J
AU Cowan, RE
Nash, MS
Collinger, JL
Koontz, AM
Boninger, ML
AF Cowan, Rachel E.
Nash, Mark S.
Collinger, Jennifer L.
Koontz, Alicia M.
Boninger, Michael L.
TI Impact of Surface Type, Wheelchair Weight, and Axle Position on
Wheelchair Propulsion by Novice Older Adults
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Aged; Biomechanics; Rehabilitation; Wheelchairs
ID KINETIC-ANALYSIS; SEAT POSITION; ENERGY-COST; SYSTEM TILT; BIOMECHANICS;
SHOULDER; STANDARD; ANGLES
AB Impact of surface type, wheelchair weight, and axle position on wheelchair propulsion by novice older adults.
Objective: To examine the impact of surface type, wheelchair weight, and rear axle position on older adult propulsion biomechanics.
Design: Crossover trial.
Setting: Biomechanics laboratory.
Participants: Convenience sample of 53 ambulatory older adults with minimal wheelchair experience (65-87y); men, n=20; women, n=33.
Intervention: Participants propelled 4 different wheelchair configurations over 4 surfaces: tile, low carpet, high carpet, and an 8% grade ramp (surface, chair order randomized). Chair configurations included (1) unweighted chair with an ante axle position, (2) 9.05kg weighted chair with an anterior axle position, (3) unweighted chair with a posterior axle position (Delta 0.08m), and (4) 9.05kg weighted chair with a posterior axle position (Delta 0.08m). Weight was added to a titanium folding chair, simulating the weight difference between very light and depot wheelchairs. Instrumented wheels measured propulsion kinetics.
Main Outcome Measures: Average self-selected velocity, push frequency, stroke length, peak resultant and tangential force.
Results: Velocity decreased as surface rolling resistance or chair weight increased. Peak resultant and tangential forces increased as chair weight increased, as surface resistance increased, and with a posterior axle position. The effect of a posterior axle position was greater on high carpet and the ramp. The effect of weight was constant, but was more easily observed on high carpet and ramp. The effects of axle position and weight were independent of one another.
Conclusion: Increased surface resistance decreases selfselected velocity and increases peak forces. Increased weight decreases self-selected velocity and increases forces. Anterior axle positions decrease forces, more so on high carpet. The effects of weight and axle position are independent. The greatest reductions in peak forces occur in lighter chairs with anterior axle positions.
C1 [Cowan, Rachel E.; Collinger, Jennifer L.; Koontz, Alicia M.; Boninger, Michael L.] Ctr Excellence Wheelchairs & Related Technol, VA Pittsburgh Hlth Care Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA.
[Collinger, Jennifer L.; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
[Boninger, Michael L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Cowan, Rachel E.; Koontz, Alicia M.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
[Collinger, Jennifer L.; Koontz, Alicia M.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Pittsburgh, PA USA.
[Collinger, Jennifer L.; Koontz, Alicia M.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA.
[Nash, Mark S.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
[Cowan, Rachel E.; Nash, Mark S.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA.
RP Boninger, ML (reprint author), Ctr Excellence Wheelchairs & Related Technol, VA Pittsburgh Hlth Care Syst, Human Engn Res Labs, 5180 Highland Dr 151R-1, Pittsburgh, PA 15206 USA.
EM boninger@pitt.edu
OI Boninger, Michael/0000-0001-6966-919X
FU National Institutes of Health [1 F31 HD053986-01, P30 AG024827,
AG023641]; National Science Foundation [DGE0333420]; Department of
Veterans Affairs Rehabilitation Research and Development [B3142C]
FX Supported by the National Institutes of Health (grant nos. 1 F31
HD053986-01, P30 AG024827, AG023641), the National Science Foundation
(DGE0333420, Graduate Research Fellowship), and the Department of
Veterans Affairs Rehabilitation Research and Development (grant no.
B3142C).
NR 21
TC 33
Z9 33
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD JUL
PY 2009
VL 90
IS 7
BP 1076
EP 1083
DI 10.1016/j.apmr.2008.10.034
PG 8
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 470SA
UT WOS:000267999000002
PM 19577019
ER
PT J
AU Sharpe, AL
Phillips, TJ
AF Sharpe, Amanda L.
Phillips, Tamara J.
TI Central urocortin 3 administration decreases limited-access ethanol
intake in nondependent mice
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Article
DE alcohol drinking; corticotrophin-releasing factor(2); ingestion;
microinjections; mouse; urocortin 3
ID CORTICOTROPIN-RELEASING-FACTOR; MESSENGER-RNA EXPRESSION; IMPAIRED
STRESS-RESPONSE; ANXIETY-LIKE BEHAVIOR; FACTOR-RECEPTOR; DEPENDENT RATS;
CENTRAL NUCLEUS; CRF RECEPTORS; FOOD-INTAKE; BRAIN
AB Stress and alcohol abuse are co-related. Acute alcohol is anxiolytic and stress is cited as a factor in relapse to alcohol use. A primary mediator of the stress response is the neuropeptide corticotropin-releasing factor (CRF). The CRF family of endogenous ligands includes urocortin 3 (Ucn 3), which binds selectively to the CRF type 2 receptor and has been implicated in ethanol consumption in dependent and withdrawing rats. The objective of this study was to examine the effect of Ucn 3, delivered centrally to nondependent mice, on limited-access ethanol consumption. Adult MUM mice were trained to self-administer 10% ethanol during daily, 2-h limited-access sessions, using lickometers to assess drinking patterns for both ethanol and water. Sterile saline or 0.3, 1, or 3 nmol of Ucn 3 was microinjected into the lateral ventricle immediately before the limited-access session in a within-subjects design. There was a significant decrease in ethanol (both ml and g/kg), but not water, intake following Ucn 3 treatment, explained by a change in size of the largest lick run. Food intake at both 2 h and 24 h after injection was statistically unaffected by Ucn 3 administration. These results establish a role for CRF type 2 receptors in a nondependent mouse model of ethanol self-ad ministration. Behavioural Pharmacology 20:346-351 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Sharpe, Amanda L.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Dept Behav Neurosci, Portland, OR 97201 USA.
[Phillips, Tamara J.] Portland VA Med Ctr, Res Serv, Portland, OR USA.
RP Sharpe, AL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol MC7756, 7703 Floyd Curl, San Antonio, TX 78229 USA.
EM sharpea@uthscsa.edu
FU National Institute on Alcohol Abuse and Alcoholism [AA014747, AA013331,
AA010760]; Department of Veterans Affairs
FX This study was supported by NIH grants from the National Institute on
Alcohol Abuse and Alcoholism AA014747 to A.L.S., AA013331 to TJ.P., and
AA010760 to TJ.P, and by the Department of Veterans Affairs.
NR 34
TC 16
Z9 16
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0955-8810
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD JUL
PY 2009
VL 20
IS 4
BP 346
EP 351
DI 10.1097/FBP.0b013e32832f01ba
PG 6
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA 477QW
UT WOS:000268534600007
PM 19581799
ER
PT J
AU Coaxum, SD
Garnovskaya, MN
Gooz, M
Baldys, A
Raymond, JR
AF Coaxum, Sonya D.
Garnovskaya, Maria N.
Gooz, Monika
Baldys, Aleksander
Raymond, John R.
TI Epidermal growth factor activates Na+/H+ exchanger in podocytes through
a mechanism that involves Janus kinase and calmodulin
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
LA English
DT Article
DE Cytosensor microphysiometer; ECAR; Phosphorylation; AG1478
ID RECEPTOR TYROSINE KINASE; NEPHROTIC SYNDROME; EGF-RECEPTOR;
INTRACELLULAR PH; 5-HT1A RECEPTOR; CELL BIOLOGY; PHOSPHORYLATION;
INJURY; INHIBITION; PROTEINS
AB Sodium-proton exchanger type 1 (NHE-1) is ubiquitously expressed, is activated by numerous growth factors, and plays significant roles in regulating intracellular pH and cellular volume, proliferation and cytoskeleton. Despite its importance, little is known about its regulation in renal glomerular podocytes. In the current work, we studied the regulation of NHE-1 activity by the epidermal growth factor receptor (EGFR) in cultured podocytes. RT-PCR demonstrated mRNAs for NHE-1 and NHE-2 in differentiated podocytes, as well as for EGFR subunits EGFR/ErbB1, Erb3, and ErbB4. EGF induced concentration-dependent increases in proton efflux in renal podocytes as assessed using a Cytosensor microphysiometer, were diminished in the presence of 5-(N-methyl-N-isobutyl) amiloride or in a sodium-free solution. Furthermore, pharmacological inhibitors of Janus kinase (Jak2) and calmodulin (CaM) attenuated EGF-induced NHE-1 activity. Co-immunoprecipitation studies determined that EGF induced formation of complexes between Jak2 and CaM, as well as between CaM and NHE-1. In addition, EGF increased levels of tyrosine phosphorylation of Jak2 and CaM. The EGFR kinase inhibitor, AG1478, blocked activation of NHE-1, but did not block EGF-induced phosphorylation of Jak2 or CaM. These results suggest that EGF induces NHE-1 activity in podocytes through two pathways: (1) EGF -> EGFR -> Jak2 activation (independent of EGFR tyrosine kinase activity) -> tyrosine phosphorylation of CaM -> CaM binding to NHE-1 -> conformational change of NHE-1 -> activation of NHE-1; and (2) EGF -> EGFR -> EGFR kinase activation -> association of CaM with NHE-1 (independent of Jak2) -> conformational change of NHE-1 -> activation of NHE-1. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Raymond, John R.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
Ralph H Johnson VA Med Ctr, Med & Res Serv, Charleston, SC USA.
RP Raymond, JR (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, Colcock Hall,Off Provost,179 Ashley Ave, Charleston, SC 29425 USA.
EM raymondj@musc.edu
FU National Institutes of Health [DK52448, GM63909, DK52448-S2]; American
Heart Association [0655445U]
FX The authors want to thank Dr. Peter Mundel for his advice and
assistance, and donation of podocytes. We also would like to thank the
Hollings Cancer Center Molecular Imaging Facility at MUSC. This work was
supported by grants from the Department of Veterans Affairs (Merits
Awards and a REAP award to JRR and MNG), the National Institutes of
Health (DK52448 and GM63909 to JRR, and DK52448-S2 to SDC), the American
Heart Association (GIA 0655445U to MNG), and a laboratory endowment
jointly supported by the M.U.S.C. Division of Nephrology and Dialysis
Clinics, Inc. (JRR). The work also was supported by VA shared equipment
grants (confocal microscope and micro physiometer).
NR 50
TC 28
Z9 28
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-4889
J9 BBA-MOL CELL RES
JI Biochim. Biophys. Acta-Mol. Cell Res.
PD JUL
PY 2009
VL 1793
IS 7
BP 1174
EP 1181
DI 10.1016/j.bbamcr.2009.03.006
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 467VY
UT WOS:000267772400006
PM 19341767
ER
PT J
AU George, MS
AF George, Mark S.
TI From the Editor-in-Chief's desk
SO BRAIN STIMULATION
LA English
DT Editorial Material
C1 [George, Mark S.] Univ S Carolina, Brain Stimulat Basic Translat & Clin Res Neuromod, Charleston, SC USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP George, MS (reprint author), Univ S Carolina, Brain Stimulat Basic Translat & Clin Res Neuromod, Charleston, SC USA.
EM georgem@musc.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
J9 BRAIN STIMUL
JI Brain Stimul.
PD JUL
PY 2009
VL 2
IS 3
BP 121
EP 122
DI 10.1016/j.brs.2009.06.002
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 478UQ
UT WOS:000268614300001
PM 20633410
ER
PT J
AU Castellon, S
Ganz, PA
AF Castellon, Steven
Ganz, Patricia A.
TI Neuropsychological studies in breast cancer: in search of chemobrain
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Editorial Material
ID COGNITIVE DYSFUNCTION; CHEMOTHERAPY; WOMEN; WORKSHOP; ESTROGEN; THERAPY
C1 [Ganz, Patricia A.] Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, Los Angeles, CA 90095 USA.
[Castellon, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Ganz, Patricia A.] Univ Calif Los Angeles, Sch Publ Hlth, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, Los Angeles, CA 90095 USA.
[Castellon, Steven] W Los Angeles Vet Affairs Med Ctr, Dept Mental Hlth & Psychiat, Los Angeles, CA 90073 USA.
RP Ganz, PA (reprint author), Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, 650 Charles Young Dr S,Room A2-125 CHS, Los Angeles, CA 90095 USA.
EM pganz@mednet.ucla.edu
NR 18
TC 15
Z9 15
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUL
PY 2009
VL 116
IS 1
BP 125
EP 127
DI 10.1007/s10549-008-0211-2
PG 3
WC Oncology
SC Oncology
GA 457QH
UT WOS:000266946700011
PM 18923899
ER
PT J
AU Garcia, JA
Casserly, IP
AF Garcia, Joel A.
Casserly, Ivan P.
TI Use of the Boomerang Catalyst (TM) Advantage Closure Device to
Facilitate Complex Multistaged Percutaneous Revascularization Procedures
for the Treatment of Critical Limb Ischemia
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE Boomerang catalyst system; peripheral arterial disease; critical limb
ischemia; complex percutaneous revascularization
ID TRANSLUMINAL ANGIOPLASTY; EXPERIENCE
AB An increasing spectrum of complex peripheral arterial disease may be successfully treated using percutaneous revascularization techniques. A pair of challenging peripheral revascularization procedures in patients with critical limb ischemia is presented, where an array of interventional tools and techniques were required, and the off-label use of the Boomerang catalyst system closure device was important in managing a variety of complex arterial access issues and ultimately allowing procedural success. (C) 2009 Wiley-Liss, Inc.
C1 [Garcia, Joel A.; Casserly, Ivan P.] Univ Colorado Denver, Aurora, CO 80045 USA.
[Garcia, Joel A.] Denver Hlth Med Ctr, Denver, CO USA.
[Casserly, Ivan P.] Denver VA Med Ctr, Denver, CO USA.
RP Casserly, IP (reprint author), Univ Colorado Denver, Anschutz Med Campus,Leprino Off Bldg,12401 E 17th, Aurora, CO 80045 USA.
EM ivan.casserly@ucdenver.edu
NR 10
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1522-1946
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
PD JUL 1
PY 2009
VL 74
IS 1
BP 27
EP 36
DI 10.1002/ccd.21962
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 469VG
UT WOS:000267928200007
PM 19530181
ER
PT J
AU Nihal, M
Ahsan, H
Siddiqui, IA
Mukhtar, H
Ahmad, N
Wood, GS
AF Nihal, Minakshi
Ahsan, Haseeb
Siddiqui, Imtiaz A.
Mukhtar, Hasan
Ahmad, Nihal
Wood, Gary S.
TI (-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to
interferon induced growth inhibition in a mouse model of human melanoma
SO CELL CYCLE
LA English
DT Article
DE melanoma; chemoprevention; green tea; apoptosis; cell cycle; interferon
ID FACTOR-KAPPA-B; GREEN TEA; MALIGNANT-MELANOMA; SIGNALING PATHWAYS;
APOPTOSIS; CANCER; CHEMOPREVENTION; FAS; THERAPY; PROLIFERATION
AB Melanoma incidence has increased over the last few decades and metastatic melanoma is one of the hardest malignancies to treat. Thus, novel approaches are needed for an effective management of melanoma. Interferon-alpha 2b (IFN), an immunomodulatory cytokine commonly used in melanoma treatment, has shown marginal efficacy and often results in discontinuation of therapy due to toxicity. We earlier demonstrated that epigallocatechin-3-gallate (EGCG), the major polyphenolic constituent of green tea, caused cell cycle arrest and apoptosis of human melanoma cells via modulation in cki-cyclin-cdk machinery and Bcl-2 family proteins. This study was undertaken to determine if EGCG could enhance the anti-proliferative effects of IFN. In this study, we demonstrated that EGCG and/or IFN treatments to melanoma cells resulted in a marked (1) decrease in cell proliferation and colony formation ability, and (2) induction of apoptosis. Interestingly, the combination was found to be more effective than either of the agents alone. Further, the anti-proliferative effects of EGCG and/or IFN were accompanied with an increase in Fas protein levels and a decrease in nuclear factor NF kappa B/p65 in the nucleus as well as NF kappa B promoter activity. EGCG and/or IFN also resulted in an increase in Fas-L mediated apoptosis. Further, EGCG and/or IFN treatments resulted in a decrease in melanoma tumor growth and protein levels of proliferation marker PCNA, in athymic nude mice implanted with melanoma tumors. The combination of the two modalities demonstrated a better response than either of them alone. Our data suggest that EGCG could impart therapeutic advantage if used in conjunction with IFN.
C1 [Wood, Gary S.] Univ Wisconsin, Sch Med, Dept Dermatol, Madison, WI 53706 USA.
William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
RP Wood, GS (reprint author), Univ Wisconsin, Sch Med, Dept Dermatol, 1300 Univ Ave,Room B25, Madison, WI 53706 USA.
EM gwood@dermatol-ogy.wisc.edu
RI Ahsan, Haseeb/H-3085-2015
OI Ahsan, Haseeb/0000-0002-5313-5959
FU Department of Veterans Affairs; Dermatology Foundation; NIH [R21
CA116163]
FX This work was supported by Merit Review funding from the Department of
Veterans Affairs (to G. S. W.), a research grant from Dermatology
Foundation (to M.N.) and R21 CA116163 grant from the NIH (to M.N.). We
also thank Caleb Creswell for his help in this project.
NR 31
TC 20
Z9 21
U1 0
U2 0
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD JUL 1
PY 2009
VL 8
IS 13
BP 2057
EP 2063
DI 10.4161/cc.8.13.8862
PG 7
WC Cell Biology
SC Cell Biology
GA 465RG
UT WOS:000267603900023
PM 19502799
ER
PT J
AU Zier, LS
Burack, JH
Micco, G
Chipman, AK
Frank, JA
White, DB
AF Zier, Lucas S.
Burack, Jeffrey H.
Micco, Guy
Chipman, Anne K.
Frank, James A.
White, Douglas B.
TI Surrogate Decision Makers' Responses to Physicians' Predictions of
Medical Futility
SO CHEST
LA English
DT Article
ID CARE; LIFE; RISKS; TEXAS; END
AB Background: Although physicians sometimes use the futility rationale to limit the use of life-sustaining treatments, little is known about how surrogate decision makers view this rationale. We sought to determine the attitudes of surrogates of patients who are critically ill toward whether physicians can predict futility and whether these attitudes predict surrogates' willingness to discontinue life support when faced with predictions of futility.
Methods: This multicenter, mixed qualitative and quantitative study took place at three hospitals in California from 2006 to 2007. We conducted semistructured interviews with surrogate decision makers for 50 patients who were critically ill and incapacitated that addressed their beliefs about medical futility and inductively developed an organizing framework to describe these beliefs. We used a hypothetical scenario with a modified time-trade-off design to examine the relationship between a patient's prognosis and a surrogate's willingness to withdraw life support. We used a mixed-effects regression model to examine the association between surrogates' attitudes about futility and their willingness to limit life support in the face of a very poor prognosis. Validation methods included the use and integration of multiple data sources, multidisciplinary analysis, and member checking.
Results: Sixty-four percent of surrogates (n = 32; 95% confidence interval [CI], 49 to 77%) expressed doubt about the accuracy of physicians' futility predictions, 32% of surrogates (n = 16; 95% CI, 20 to 47%) elected to continue life support with a < 1% survival estimate, and 18% of surrogates (n = 9; 95% CI, 9 to 31%) elected to continue treatment when the physician believed that the patient had no chance of survival. Surrogates with religious objections to the futility rationale (n = 18) were more likely to request continued life support (odds ratio, 4; 95% CI, 1.2 to 14.0; p = 0.03) than those with secular or experiential objections (n = 15; odds ratio, 0.95; 95% CI, 0.3 to 3.4; p = 0.90).
Conclusions: Doubt about physicians' ability to predict medical futility is common among surrogate decision makers. The nature of the doubt may have implications for responding to conflicts about futility in clinical practice. (CHEST 2009,136.-110-117)
C1 [White, Douglas B.] Univ Calif San Francisco, Program Med Eth, Dept Med, San Francisco, CA 94143 USA.
[Frank, James A.; White, Douglas B.] Univ Calif San Francisco, Div Pulm & Crit Care Med, Sch Med, San Francisco, CA 94143 USA.
[Zier, Lucas S.; Burack, Jeffrey H.; Micco, Guy; Chipman, Anne K.] Univ Calif Berkeley, San Francisco Joint Med Program, Berkeley, CA 94720 USA.
[Burack, Jeffrey H.; Micco, Guy] Univ Calif Berkeley, Sch Publ Hlth, Div Community Hlth & Human Dev, Berkeley, CA 94720 USA.
[Burack, Jeffrey H.] Alta Bates Summit Med Ctr, E Bay AIDS Res Inst, Oakland, CA USA.
[Frank, James A.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP White, DB (reprint author), Univ Calif San Francisco, Program Med Eth, Dept Med, 521 Parnassus Ave,Suite C-126,Box 0903, San Francisco, CA 94143 USA.
EM dwhite@medicine.ucsf.edu
FU University of California; Berkeley-Universitv of California, San
Francisco; National Center for Research Resources [KL2 RR0241301];
National Institutes of Health; Greenwall Foundation
FX This project was supported by it grant from the University of
California, Berkeley-Universitv of California, San Francisco joint
Medical Program (Mr. Zier grant from the University of California, San
Francisco Dealt s Office Medical St-tident Besearch Program (1kir.
Zier), and a grant front the National Center for Research Resources [KL2
RR0241301, a component of the National Institute of Health and the
National Institutes of Health Roadmap for Medical Research (Dr. White).
Dr. White is also supported by it grant from the Greenwall Foundation
Facility Scholars Program.
NR 25
TC 33
Z9 33
U1 1
U2 6
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JUL
PY 2009
VL 136
IS 1
BP 110
EP 117
DI 10.1378/chest.08-2753
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 467YG
UT WOS:000267779000017
PM 19318665
ER
PT J
AU Fihn, SD
AF Fihn, Stephan D.
TI Improving Quality Lessons From the Department of Veterans Affairs
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Editorial Material
DE Editorials; hypertension
ID HEALTH-CARE-SYSTEM; TRANSFORMATION
C1 [Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, NW Hlth Serv, Res & Dev Ctr Excellence, Seattle, WA 98101 USA.
[Fihn, Stephan D.] Univ Washington, Dept Med & Hlth Serv, Div Gen Internal Med, Seattle, WA 98195 USA.
RP Fihn, SD (reprint author), VA Puget Sound Hlth Care Syst, NW Hlth Serv, Res & Dev Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM stephan.fihn@va.gov
NR 13
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD JUL
PY 2009
VL 2
IS 4
BP 294
EP 296
DI 10.1161/CIRCOUTCOMES.109.884353
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 575NP
UT WOS:000276074200003
PM 20031853
ER
PT J
AU Mancini, GBJ
Bates, ER
Maron, DJ
Hartigan, P
Dada, M
Gosselin, G
Kostuk, W
Sedlis, SP
Shaw, LJ
Berman, DS
Berger, PB
Spertus, J
Mavromatis, K
Knudtson, M
Chaitman, BR
O'Rourke, RA
Weintraub, WS
Teo, K
Boden, WE
AF Mancini, G. B. John
Bates, Eric R.
Maron, David J.
Hartigan, Pamela
Dada, Marcin
Gosselin, Gilbert
Kostuk, William
Sedlis, Steven P.
Shaw, Leslee J.
Berman, Daniel S.
Berger, Peter B.
Spertus, John
Mavromatis, Kreton
Knudtson, Merril
Chaitman, Bernard R.
O'Rourke, Robert A.
Weintraub, William S.
Teo, Koon
Boden, William E.
CA COURAGE Trial Investigators Coordi
TI Quantitative Results of Baseline Angiography and Percutaneous Coronary
Intervention in the COURAGE Trial
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE coronary angiography; ventricular ejection fraction; gender identity;
delivery of health care; revascularization; stent
ID CONTROLLED CLINICAL-TRIAL; 3 THERAPEUTIC STRATEGIES; ARTERY-DISEASE;
MASS-II; SURGERY; ANGIOPLASTY; MEDICINE; ANGINA; VIVO
AB Background-COURAGE compared outcomes in stable coronary patients randomized to optimal medical therapy plus percutaneous coronary intervention (PCI) versus optimal medical therapy alone.
Methods and Results-Angiographic data were analyzed by treatment arm, health care system (Veterans Administration, US non-Veterans Administration, Canada), and gender. Veterans Administration patients had higher prevalence of coronary artery bypass graft surgery and left ventricular ejection fraction <= 50%. Men had worse diameter stenosis of the most severe lesion, higher prevalence of prior coronary artery bypass graft surgery, lower left ventricular ejection fraction, and more 3-vessel disease that included a proximal left anterior descending lesion (P<0.0001 for all comparisons versus women). Failure to cross rate (3%) and visual angiographic success of stent procedures (97%) were similar to contemporary practice in the National Cardiovascular Data Registry. Quantitative angiographic PCI success was 93% (residual lesion <50% in-segment) and 82% (<20% in-stent), with only minor nonsignificant differences among health care systems and genders. Event rates were higher in patients with higher jeopardy scores and more severe vessel disease, but rates were similar irrespective of treatment strategy. Within the PCI plus optimal medical therapy arm, complete revascularization was associated with a trend toward lower rate of death or nonfatal myocardial infarction. Complete revascularization was similar between genders and among health care systems.
Conclusions-PCI success and completeness of revascularization did not differ significantly by health care system or gender and were similar to contemporary practice. Angiographic burden of disease affected overall event rates but not response to an initial strategy of PCI plus optimal medical therapy or optimal medical therapy alone. (Circ Cardiovasc Qual Outcomes. 2009;2:320-327.)
C1 [Mancini, G. B. John] Univ British Columbia, Vancouver Hosp, Cardiovasc Imaging Res Core Lab, Vancouver, BC V5Z 1M9, Canada.
[Bates, Eric R.] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
[Maron, David J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Hartigan, Pamela] Connecticut VA Healthcare Syst, Vet Affairs Cooperat Studies Program Coordinating, West Haven, CT USA.
[Dada, Marcin] Hartford Hosp, Hartford, CT 06115 USA.
[Gosselin, Gilbert] Univ Montreal, Montreal Heart Inst, Montreal, PQ H3C 3J7, Canada.
[Kostuk, William] Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada.
[Sedlis, Steven P.] NYU, Sch Med, VA New York Harbor Hlth Care Syst New York Campus, New York, NY 10003 USA.
[Shaw, Leslee J.; Mavromatis, Kreton] Emory Univ, Sch Med, Atlanta, GA USA.
[Berman, Daniel S.] Univ Calif Los Angeles, Cedars Sinai Heart Inst, Los Angeles, CA USA.
[Berger, Peter B.] Geisinger Med Ctr, Danville, PA 17822 USA.
[Spertus, John] Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA.
[Knudtson, Merril] Univ Calgary, Calgary, AB T2N 1N4, Canada.
[Chaitman, Bernard R.] St Louis Univ Hosp, St Louis, MO USA.
[O'Rourke, Robert A.] S Texas Vet Healthcare Syst, San Antonio, TX USA.
[O'Rourke, Robert A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA.
[Teo, Koon] McMaster Univ, Med Ctr, Hamilton, ON, Canada.
[Boden, William E.] SUNY, Sch Med & Biomed Sci, Buffalo Gen Hosp, Kaleida Hlth, New York, NY USA.
RP Mancini, GBJ (reprint author), Univ British Columbia, Vancouver Hosp, Cardiovasc Imaging Res Core Lab, 10209-2775 Laurel St, Vancouver, BC V5Z 1M9, Canada.
EM mancini@interchange.ubc.ca
OI Sedlis, Steven/0000-0002-8194-8017
FU Merck Co; Pfizer Pharmaceuticals; Bristol-Myers-Squibb Medical Imaging;
Fujisawa; Kos Pharmaceuticals; Data Scope; AstraZeneca; Key
Pharmaceutical Co Ltd; Sanofi Aventis Inc; First Horizon; Nycomed
Amersham; Department of Veterans Administration; Astellas Healthcare;
Medtronic; GE; Siemens; Molecular Insight Pharma; Sicor; CIHR; Canadian
Cardiovascular Society; Merck
FX This work was supported by the Cooperative Studies Program of the
Department of Veterans Affairs Office of Research and Development, in
collaboration with the Canadian Institute of Health Research;
unrestricted research grants have been obtained from Merck & Co, Pfizer
Pharmaceuticals, Bristol-Myers-Squibb Medical Imaging, Fujisawa, Kos
Pharmaceuticals, Data Scope, AstraZeneca, Key Pharmaceutical Co Ltd,
Sanofi Aventis Inc, First Horizon, and Nycomed Amersham. All industrial
funding in support of the trial has been directed through the Department
of Veterans Administration.; Dr Mancini has received honoraria from
GlaxoSmthKline, Merck, Pfizer, and sanofi-aventis. Dr Berman has
received research grants and honoraria from Astellas Healthcare,
Medtronic, GE, Siemens, and Molecular Insight Pharma; has ownership
interest in Spectrum Dynamics; serves as a consultant for Astellas,
Fluoro Pharma, and Magellan; and has received software royalties from
CSMC. Dr Berger has ownership interest in Lumen and has served on the
consultancy/ad board for PlaCor, Accumetrics, The Medicines Company, and
Eli Lilly/Daiichi-Sankyo. Dr Spertus has received research grants from
Sicor; other research Support from Roche Diagnostics; has ownership
interest in SAQ, KCCQ, and PTQ; and has served as a consultant for
United Healthcare. Dr Knudtson has received research grants from CIHR;
honoraria from the Canadian Cardiovascular Society; and has served as an
expert witness for a defendant in medical civil action suit. Dr Chaitman
has received research grants from Merck; served on the speakers' bureau
for CV Therapeutics; and serves on the consultancy/ad boards for Sanofi
Aventis and Merck. Dr O'Rourke has received research grants from BARI-2D
and has served as a consultant for the PACE-MI Study. Dr Weintraub has
received research grants from Sanofi Aventis, AstraZeneca, Otsuka, and
Bristol Myers Squibb; served as an expert witness for Pfizer nad
AstraZeneca; and served as a consultant for GlaxoSmithKline, Indigo
Pharmaceuticals, Sanofi Aventis, and CV Therapeutics. Dr Teo has
received research grants from CIHR; other research support from
Boehringer-Ingelheim; honoraria from Boehringer-Ingelheim; and has
served as a consultant for Boehringer-Ingelheim.
NR 19
TC 18
Z9 18
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD JUL
PY 2009
VL 2
IS 4
BP 320
EP U97
DI 10.1161/CIRCOUTCOMES.108.830091
PG 48
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 575NP
UT WOS:000276074200007
PM 20031857
ER
PT J
AU Spinale, FG
Escobar, GP
Mukherjee, R
Zavadzkas, JA
Saunders, SM
Jeffords, LB
Leone, AM
Beck, C
Bouges, S
Stroud, RE
AF Spinale, Francis G.
Escobar, G. Patricia
Mukherjee, Rupak
Zavadzkas, Juozas A.
Saunders, Stuart M.
Jeffords, Laura B.
Leone, Allyson M.
Beck, Christy
Bouges, Shenikqua
Stroud, Robert E.
TI Cardiac-Restricted Overexpression of Membrane Type-1 Matrix
Metalloproteinase in Mice Effects on Myocardial Remodeling With Aging
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE matrix; myocardial remodeling; ventricular function; aging
ID TGF-BETA SIGNALS; 1-MATRIX METALLOPROTEINASE; EXTRACELLULAR-MATRIX;
VENTRICULAR-FUNCTION; BINDING-PROTEINS; ACTIVATION; MT1-MMP; CELLS;
CARDIOMYOPATHY; TRAFFICKING
AB Background-The direct consequences of a persistently increased myocardial expression of the unique matrix metallo-proteinase (MMP) membrane type-1 (MT1-MMP) on myocardial remodeling remained unexplored.
Methods and Results-Cardiac-restricted MT1-MMPexp was constructed in mice using the full-length human MT1-MMP gene ligated to the myosin heavy chain promoter, which yielded approximately a 200% increase in MT1-MMP when compared with age/strain-matched wild-type (WT) mice. Left ventricular (LV) function and geometry was assessed by echocardiography in 3-month ("young") WT (n=32) and MT1-MMPexp (n=20) mice and compared with 14-month ("middle-aged") WT (n=58) and MT1-MMPexp (n=35) mice. LV end-diastolic volume was similar between the WT and MT1-MMPexp young groups, as was LV ejection fraction. In the middle-aged WT mice, LV end-diastolic volume and ejection fraction was similar to young WT mice. However, in the MT1-MMPexp middle-aged mice, LV end-diastolic volume was approximate to 43% higher and LV ejection fraction 40% lower (both P<0.05). Moreover, in the middle-aged MT1-MMPexp mice, myocardial fibrillar collagen increased by nearly 2-fold and was associated with approximate to 3-fold increase in the processing of the profibrotic molecule, latency-associated transforming growth factor binding protein. In a second study, 14-day survival after myocardial infarction was significantly lower in middle-aged MT1-MMPexp mice.
Conclusions-Persistently increased myocardial MT1-MMP expression, in and of itself, caused LV remodeling, myocardial fibrosis, dysfunction, and reduced survival after myocardial injury. These findings suggest that MT1-MMP plays a mechanistic role in adverse remodeling within the myocardium. (Circ Heart Fail. 2009;2:351-360.)
C1 [Spinale, Francis G.; Escobar, G. Patricia; Mukherjee, Rupak; Zavadzkas, Juozas A.; Saunders, Stuart M.; Jeffords, Laura B.; Leone, Allyson M.; Beck, Christy; Bouges, Shenikqua; Stroud, Robert E.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA.
[Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Div Cardiothorac Surg, Charleston, SC USA.
RP Spinale, FG (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Room 625,114 Doughty St, Charleston, SC 29425 USA.
EM wilburnm@musc.edu
FU National Institutes of Health [HL059165, PO I HL048788, HL078650];
Veterans' Affairs Health Administration
FX This study was supported by National Institutes of Health grants
HL059165, PO I HL048788, and HL078650 and a Merit Award from the
Veterans' Affairs Health Administration.
NR 30
TC 26
Z9 27
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3289
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD JUL
PY 2009
VL 2
IS 4
BP 351
EP 360
DI 10.1161/CIRCHEARTFAILURE.108.844845
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 477PF
UT WOS:000268530300011
PM 19808359
ER
PT J
AU Carpenter, EL
Mick, R
Rech, AJ
Beatty, GL
Colligon, TA
Rosenfeld, MR
Kaplan, DE
Chang, KM
Domchek, SM
Kanetsky, PA
Fecher, LA
Flaherty, KT
Schuchter, LM
Vonderheide, RH
AF Carpenter, Erica L.
Mick, Rosemarie
Rech, Andrew J.
Beatty, Gregory L.
Colligon, Theresa A.
Rosenfeld, Myrna R.
Kaplan, David E.
Chang, Kyong-Mi
Domchek, Susan M.
Kanetsky, Peter A.
Fecher, Leslie A.
Flaherty, Keith T.
Schuchter, Lynn M.
Vonderheide, Robert H.
TI Collapse of the CD27+B-Cell Compartment Associated with Systemic
Plasmacytosis in Patients with Advanced Melanoma and Other Cancers
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MEMORY B-CELLS; ANTIGEN-PRESENTING CELLS; LUPUS-ERYTHEMATOSUS; T-CELLS;
IMMUNE-RESPONSES; HIV-1 INFECTION; SERUM-LEVELS; LYMPHOCYTES;
POPULATION; EXPRESSION
AB Purpose: Disturbed peripheral blood B-cell homeostasis complicates certain infections and autoimmune diseases, such as HIV and systemic lupus erythematosus, but has not been reported in cancer. This study aimed to investigate whether B-cell physiology was altered in the presence of melanoma and other cancers.
Experimental Design: Flow cytometry was used to identify phenotypic differences in B cells from patients with melanoma and normal donors. In vitro stimulated 8 cells were assessed for responsiveness and also used as stimulators of allogeneic T cells in mixed lymphocyte reactions.
Results: We show B-cell dysregulation in patients with advanced melanoma (n = 26) and other solid tumors (n = 13), marked by a relative and absolute loss of CD27+ (memory) B cells and associated with an aberrant systemic plasmacytosis. Functionally, B cells from patients with melanoma inefficiently up-regulated immunoregulatory molecules and weakly secreted cytokines in response to CD40 and toll-like receptor 9 agonists. Stimulated B cells from patients induced proliferation of alloreactive CD4+ T cells, but these T cells poorly secreted IFN gamma and interleukin-2. These effects were recapitulated by using purified normal donor CD27(neg) B cells in these same assays, linking the predominance of CD27(neg) B cells in patients with the observed functional hyporesponsiveness. Indeed, B-cell dysfunction in patients strongly correlated with the extent of loss of CD27+ B cells in peripheral blood.
Conclusions: Disturbed B-cell homeostasis is a previously unrecognized feature of patients with advanced melanoma and other cancers and may represent an unanticipated mechanism of immune incompetence in cancer.
C1 [Carpenter, Erica L.; Rech, Andrew J.; Beatty, Gregory L.; Colligon, Theresa A.; Vonderheide, Robert H.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
[Mick, Rosemarie; Rosenfeld, Myrna R.; Chang, Kyong-Mi; Domchek, Susan M.; Kanetsky, Peter A.; Fecher, Leslie A.; Flaherty, Keith T.; Schuchter, Lynn M.; Vonderheide, Robert H.] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Kaplan, David E.; Chang, Kyong-Mi] Univ Penn, Sch Med, Gastroenterol Sect, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Beatty, Gregory L.; Domchek, Susan M.; Fecher, Leslie A.; Flaherty, Keith T.; Schuchter, Lynn M.; Vonderheide, Robert H.] Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.
[Kaplan, David E.; Chang, Kyong-Mi] Univ Penn, Sch Med, Div Gastroenterol, Dept Med, Philadelphia, PA 19104 USA.
[Rosenfeld, Myrna R.] Univ Penn, Sch Med, Div Neurooncol, Dept Neurol, Philadelphia, PA 19104 USA.
[Mick, Rosemarie; Kanetsky, Peter A.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
RP Vonderheide, RH (reprint author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, 551 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.
EM rhv@exchange.upenn.edu
OI Kaplan, David E./0000-0002-3839-336X; Rosenfeld,
Myrna/0000-0001-5095-2534
FU NIH [CA093372, CA09140, CA16520, AI47519, RR017625]; Breast Cancer
Research Foundation; VA Career Development Award
FX NIH grants CA093372 (R.H.Vonderheide), CA09140 (E.L. Carpenter), CA16520
(R.H.Vonderheide), AI47519 (K-M. Chang), and RR017625 (D.E. Kaplan);
Breast Cancer Research Foundation (R.H. Vonderheide); VA Career
Development Award (D.E. Kaplan); and a gift from Mark and Paula Solomon
(R.H. Vonderheide).
NR 49
TC 23
Z9 24
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 1
PY 2009
VL 15
IS 13
BP 4277
EP 4287
DI 10.1158/1078-0432.CCR-09-0537
PG 11
WC Oncology
SC Oncology
GA 482SF
UT WOS:000268908300007
PM 19549767
ER
PT J
AU Tan, G
Thornby, J
Hammond, DC
Strehl, U
Canady, B
Arnemann, K
Kaiser, DA
AF Tan, Gabriel
Thornby, John
Hammond, D. Corydon
Strehl, Ute
Canady, Brittany
Arnemann, Kelly
Kaiser, David A.
TI Meta-Analysis of EEG Biofeedback in Treating Epilepsy
SO CLINICAL EEG AND NEUROSCIENCE
LA English
DT Article
DE EEG Biofeedback; Epilepsy; Meta-Analysis; Neurofeedback; Neurotherapy;
Seizure
ID SENSORIMOTOR RHYTHM; SEIZURE PREDICTION; SLEEP EEG; CAT
AB About one third of patients with epilepsy do not benefit from medical treatment. For these patients electroencephalographic (EEG) biofeedback is a viable alternative. EEG biofeedback, or neurofeedback, normalizes or enhances EEG activity by means of operant conditioning. While dozens of scientific reports have been published on neurofeedback for seizure disorder, most have been case series with too few subjects to establish efficacy, The purpose of this paper is to meta-analyze existing research on neurofeedback and epilepsy.
We analyzed every EEG biofeedback study indexed in MedLine, PsychInfo, and PsychLit databases between 1970 and 2005 on epilepsy that provided seizure frequency change in response to feedback. Sixty-three studies have been published, 10 of which provided enough outcome information to be included in a meta-analysis. All studies consisted of patients whose seizures were not controlled by medical therapies, which is a very important factor to keep in mind when interpreting the results. Nine of 10 studies reinforced sensorimotor rhythms (SMR) while 1 study trained slow cortical potentials (SCP). All studies reported an overall mean decreased seizure incidence following treatment and 64 out of 87 patients (74%) reported fewer weekly seizures in response to EEG biofeedback. Treatment effect was mean log (post/pre) where pre and post represent number of seizures per week prior to treatment and at final evaluation, respectively. Due to prevalence of small groups, Hedges's g was computed for effect size, As sample heterogeneity was possible (Q test, p=.18), random effects were assumed and the effect of intervention was -0.233, SE=0.057, z=-4.11, P<.001.
Based on this meta-analysis, EEG operant conditioning was found to produce a significant reduction on seizure frequency. This finding is especially noteworthy given the patient group, individuals who had been unable to control their seizures with medical treatment.
C1 [Tan, Gabriel; Thornby, John] Michael E DeBakey Vet Affairs Hosp, Houston, TX USA.
[Tan, Gabriel; Thornby, John] Baylor Coll Med, Houston, TX 77030 USA.
[Hammond, D. Corydon] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Strehl, Ute] Univ Tubingen, Tubingen, Germany.
[Canady, Brittany] Geisinger Med Ctr, Danville, PA 17822 USA.
[Arnemann, Kelly] Audie L Murphy Vet Affairs Hosp, San Antonio, TX USA.
[Kaiser, David A.] Wavestate Inc, Marina Del Rey, CA USA.
RP Tan, G (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd 145, Houston, TX 77030 USA.
EM tan.gabriel@va.gov
NR 40
TC 64
Z9 65
U1 3
U2 15
PU EEG & CLINICAL NEUROSCIENCE SOC (E C N S)
PI WHEATON
PA 805 W LIBERTY DR, PO BOX 725, WHEATON, IL 60187 USA
SN 1550-0594
J9 CLIN EEG NEUROSCI
JI Clin. EEG Neurosci.
PD JUL
PY 2009
VL 40
IS 3
BP 173
EP 179
PG 7
WC Clinical Neurology; Neurosciences; Neuroimaging; Psychiatry; Psychology
SC Neurosciences & Neurology; Psychiatry; Psychology
GA 477NV
UT WOS:000268526700006
PM 19715180
ER
PT J
AU Kanwal, F
Gralnek, IM
Hays, RD
Zeringue, A
Durazo, F
Han, SB
Saab, S
Bolus, R
Spiegel, BMR
AF Kanwal, Fasiha
Gralnek, Ian M.
Hays, Ron D.
Zeringue, Angelique
Durazo, Francisco
Han, Steven B.
Saab, Sammy
Bolus, Roger
Spiegel, Brennan M. R.
TI Health-Related Quality of Life Predicts Mortality in Patients With
Advanced Chronic Liver Disease
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
ID SERUM SODIUM; HEART-FAILURE; UNITED-STATES; SURVIVAL; TRANSPLANTATION;
MELD; CIRRHOSIS; CANCER; MODEL; POPULATION
AB BACKGROUND & AIMS: It is well-established that cirrhosis negatively impacts health-related quality of life (HRQOL). However, it is less clear how to use this information in everyday clinical practice. If HRQOL predicted survival in cirrhosis, then measuring HRQOL would have important clinical implications. We sought to measure the association between HRQOL and survival in patients with cirrhosis and investigated whether the relationship between HRQOL and Survival is independent of Model for End-Stage Liver Disease (MELD). METHODS: We measured HRQOL in 156 patients with cirrhosis awaiting liver transplantation by using the Short Form Liver Disease Quality of Life instrument. We followed patients prospectively and used Cox proportional hazard models to measure the independent effect of baseline HRQOL on survival, adjusting for MELD and other covariates. RESULTS: During a mean 9-month follow-up, 26 (17%) patients died, and 30 (20%) received liver transplants. In unadjusted analysis, higher baseline HRQOL predicted lower mortality (hazard ratio, 0.96; 95% confidence interval, 0.94-0.99). Specifically, for each 1-point increase in HRQOL, there was a 4% decrease in mortality. These results did not change after adjusting for MELD scores, patient demographics, or psychosocial characteristics; the MELD score accounted for 1% of the variation in HRQOL scores (P=.18). Survival was most strongly predicted by activities of daily living, health distress, sleep disturbance, and perceived disease stigma. CONCLUSIONS: Higher HRQOL predicts lower mortality in patients with cirrhosis. This relationship is independent of MELD; MELD does not capture liver-specific HRQOL. Beyond its use as a secondary outcome in clinical trials, HRQOL could be used to predict survival of patients with advanced liver disease.
C1 [Kanwal, Fasiha; Zeringue, Angelique] John Cochran VA Med Ctr, St Louis, MO USA.
[Kanwal, Fasiha] St Louis Univ, Div Gastroenterol, St Louis, MO 63103 USA.
[Kanwal, Fasiha; Bolus, Roger; Spiegel, Brennan M. R.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA.
[Gralnek, Ian M.] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
[Hays, Ron D.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA.
[Hays, Ron D.] RAND Corp, Santa Monica, CA USA.
[Durazo, Francisco; Han, Steven B.; Saab, Sammy; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
[Han, Steven B.; Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol & Hepatol, Los Angeles, CA USA.
RP Spiegel, BMR (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ucla.edu
RI Zeringue, Angelique/I-1755-2012; Hays, Ronald/D-5629-2013
FU NIA NIH HHS [P30AG021684-07]; NIDDK NIH HHS [2P30 DK 041301-17]
NR 33
TC 49
Z9 49
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD JUL
PY 2009
VL 7
IS 7
BP 793
EP 799
DI 10.1016/j.cgh.2009.03.013
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 476HP
UT WOS:000268430500017
PM 19306949
ER
PT J
AU Palevsky, PM
AF Palevsky, Paul M.
TI Defining Contrast-Induced Nephropathy
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
ID RADIOCONTRAST-INDUCED NEPHROPATHY; ACUTE-RENAL-FAILURE; RANDOMIZED
CONTROLLED-TRIAL; HIGH-RISK PATIENTS; SODIUM-BICARBONATE;
CORONARY-ANGIOGRAPHY; PREVENTION; MEDIA; METAANALYSIS; NEPHROTOXICITY
C1 [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Renal Sect, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
[Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15240 USA.
RP Palevsky, PM (reprint author), Univ Pittsburgh, Sch Med, Renal Sect, VA Pittsburgh Healthcare Syst, Room 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA.
EM palevsky@pitt.edu
OI Palevsky, Paul/0000-0002-7334-5400
NR 29
TC 7
Z9 7
U1 0
U2 0
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JUL
PY 2009
VL 4
IS 7
BP 1151
EP 1153
DI 10.2215/CJN.03410509
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 466WC
UT WOS:000267693400001
PM 19541810
ER
PT J
AU Hinson, VK
Goetz, CG
Leurgans, S
Fan, W
Nguyen, T
Hsu, A
AF Hinson, Vanessa K.
Goetz, Christopher G.
Leurgans, Sue
Fan, Wenqing
Nguyen, Tiffany
Hsu, Ann
TI Reducing Dosing Frequency of Carbidopa/Levodopa: Double-Blind Crossover
Study Comparing Twice-Daily Bilayer Formulation of Carbidopa/Levodopa
(IPX054) Versus 4 Daily Doses of Standard Carbidopa/Levodopa in Stable
Parkinson Disease Patients
SO CLINICAL NEUROPHARMACOLOGY
LA English
DT Review
DE Parkinson disease; levodopa; randomized clinical trials
ID CAPTURE
AB Objective: We compared IPX054, a bilayer tablet of immediate- and extended-release carbidop-/levodopa (CD/LD) given twice daily to standard CD/LD given 4 times daily in patients with stable Parkinson disease (PD).
Methods: Twelve PD patients with no or mild fluctuations oil CD/LD 25/100 mg 4 times daily were randomized to a double-blind crossover comparison with IPX054 (50/200 mg) twice daily. At the end of each 2-week treatment, patients were video recorded while performing a modified Unified Parkinson's Disease Rating Scale motor examination and Rush Dyskinesia Rating Scale at 30-minute intervals over 8.5 hours. The primary Outcome measure was the number of videotape epochs rated as "ON" without troublesome dyskinesia by a blinded observer (Wilcoxon signed rank tests).
Results: The 9 men and 3 women had a mean age of 69 years and mean PD duration of 6 years. IPX054 and CD/LD showed no significant differences in the primary outcome measure (mean number of video epochs rated as ON without troublesome dyskinesia; P = 0.14). The mean time to ON was improved with IPX054 (P = 0.014), and the mean modified Unified Parkinson's Disease Rating Scale scores slightly favored IPX054 (14.4 vs 16.9; P = 0.052.). Mean Rush Dyskinesia Rating Scale scores were not significantly different between IPX054 and CD/LD (0.45 vs 0.69; P = 0.25). No patient developed troublesome dyskinesias.
Conclusions: in stable PD patients, no difference was detected between twice-daily treatment with IPX054 and CD/LD given 4 times daily In this group, substitution with IPX054 reduced closing frequency while maintaining CD/LD efficacy. In clinical practice, this case of administration may offer improved treatment compliance.
C1 [Hinson, Vanessa K.] Med Univ S Carolina, Movement Disorders Program, Dept Neurosci, Charleston, SC 29425 USA.
[Hinson, Vanessa K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Goetz, Christopher G.; Leurgans, Sue; Fan, Wenqing] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
[Nguyen, Tiffany; Hsu, Ann] IMPAX Labs Inc, Hayward, CA USA.
RP Hinson, VK (reprint author), Med Univ S Carolina, Movement Disorders Program, Dept Neurosci, 326 Calhoun St,Suite 308, Charleston, SC 29425 USA.
EM hinsonvk@musc.edu
NR 14
TC 3
Z9 5
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0362-5664
J9 CLIN NEUROPHARMACOL
JI Clin. Neuropharmacol.
PD JUL-AUG
PY 2009
VL 32
IS 4
BP 189
EP 192
DI 10.1097/WNF.0b013e3181a27fae
PG 4
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 481VX
UT WOS:000268841600003
PM 19620848
ER
PT J
AU Kahn, JM
Asch, RJ
Iwashyna, TJ
Haynes, K
Rubenfeld, GD
Angus, DC
Asch, DA
AF Kahn, Jeremy M.
Asch, Rebecca J.
Iwashyna, Theodore J.
Haynes, Kevin
Rubenfeld, Gordon D.
Angus, Derek C.
Asch, David A.
TI Physician attitudes toward regionalization of adult critical care: A
national survey
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE patient transfer; triage; intensive care; mechanical ventilation;
healthcare systems
ID LUNG-PROTECTIVE VENTILATION; PEDIATRIC INTENSIVE-CARE; UNITED-STATES;
HOSPITAL MORTALITY; FAMILY-MEMBERS; RESPONSE RATES; VOLUME; BARRIERS;
ORGANIZATION; OUTCOMES
AB Objective: Regionalization has been proposed as a method to improve outcomes for patients with critical illness. We sought to determine intensivist physician attitudes and potential barriers to the regionalization of adult critical care.
Design: Mail survey.
Setting. United States.
Subjects: Actively practicing physicians specializing in adult critical care, emergency medicine, or internal medicine listed in the 2008 American Medical Association Physician Masterfile (n = 1200).
Interventions: None.
Measurements and Main Results: There were 569 eligible respondents (effective response rate = 53.0%). Respondents were similar to nonrespondents. Fifty-nine percent of respondents thought their hospital would mainly receive patients under a regionalized system, and 30% thought their hospital would mainly send patients. Opinions were split about whether regionalization would improve overall patient survival (52% agreed) and healthcare efficiency (66% agreed). Specialists in anesthesiology and surgery-critical care, academic physicians, and physicians who perceived that they would mainly receive patients were more likely to believe that regionalization would improve outcomes and efficiency (p < 0.001). The most commonly endorsed barriers to regionalization were personal strain on patient's families (66% agreed), current lack of a strong central authority (64% agreed), and the potential to overwhelm capacity at large hospitals (55% agreed). Commonly endorsed strategies to implement regionalization included using objective criteria to determine eligibility for transfer (87% agreed), developing common information technology platforms across hospitals (86% agreed), and demonstrating in a clinical trial that regionalization is beneficial (81% agreed).
Conclusions: Intensivist physicians have mixed opinions about regionalization, with little consensus about whether regionalization will improve outcomes. Most felt that regionalization will improve patient outcomes, but many expressed concerns about unintended adverse consequences. Respondents identified several barriers and potential implementation strategies that can help policymakers design a regionalized system of critical care in the United States. (Crit Care Med 2009; 37:2149-2154)
C1 [Kahn, Jeremy M.; Asch, Rebecca J.] Univ Penn, Sch Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA.
[Kahn, Jeremy M.; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Kahn, Jeremy M.; Haynes, Kevin] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Iwashyna, Theodore J.] Univ Michigan, Div Pulm & Crit Care, Ann Arbor, MI 48109 USA.
[Rubenfeld, Gordon D.] Sunnybrook Hlth Sci Ctr, Program Trauma Crit Care & Emergency Med, Toronto, ON M4N 3M5, Canada.
[Angus, Derek C.] Univ Penn, Lab Clin Res Invest & Syst Modeling Acute Illness, Dept Crit Care Med, Philadelphia, PA 19104 USA.
[Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ & Res & Promot, Philadelphia, PA USA.
RP Kahn, JM (reprint author), Univ Penn, Sch Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA.
EM jmkahn@mail.med.upenn.edu
RI Angus, Derek/E-9671-2012
OI Asch, David/0000-0002-7970-286X; Iwashyna, Theodore/0000-0002-4226-9310
FU Society of Critical Care Medicine; National Institutes of Health
[K23HL082650]
FX This work was funded by a research grant from the Society of Critical
Care Medicine. Dr. Kahn is supported by a career development award from
the National Institutes of Health (K23HL082650).
NR 32
TC 33
Z9 34
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD JUL
PY 2009
VL 37
IS 7
BP 2149
EP 2154
DI 10.1097/CCM.0b013e3181a009d0
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA 461DQ
UT WOS:000267245200001
PM 19455025
ER
PT J
AU Rosendorff, C
Black, HR
AF Rosendorff, Clive
Black, Henry R.
TI Evidence for a lower target blood pressure for people with heart disease
SO CURRENT OPINION IN CARDIOLOGY
LA English
DT Review
DE blood pressure; cardiovascular risk; coronary artery disease;
hypertension
ID ISOLATED SYSTOLIC HYPERTENSION; RANDOMIZED CONTROLLED-TRIAL;
CARDIOVASCULAR OUTCOMES; ACTIVE TREATMENT; PREVENTION; ATHEROSCLEROSIS;
METAANALYSIS; HYPERTROPHY; MANAGEMENT; MORTALITY
AB Purpose of review
The review assesses the evidence for the benefit of lower blood pressure (BP) targets in hypertension management.
Recent findings
The current consensus target for the treatment of hypertension is a BP of below 140/90 mmHg for all patients, and a BP of below 130/80 mmHg for those with diabetes or chronic kidney disease. Recently added to the list of conditions warranting the lower BP target are coronary artery disease and coronary artery disease equivalents (stroke, carotid disease, aortic aneurysm, and peripheral vascular disease), as well as those individuals with a Framingham Risk Score of at least 10%. One theoretical issue with lower BP targets may be the existence of a J-shaped curve of BP versus cardiovascular event rate, implying a greater risk, especially of myocardial ischemia, of lowering diastolic BP, which is also the filling pressure of the coronary arteries, below the lower limit of coronary autoregulation. The evidence that this is not a compelling concern is provided by animal studies, clinical trials with both surrogate and hard endpoints, and epidemiologic data.
Summary
There is at present no proof that more aggressive treatment is harmful and much indirect evidence that it may be beneficial, although the clinical trials that specifically address this question are still in progress.
C1 [Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Rosendorff, Clive] Mt Sinai Sch Med, New York, NY USA.
[Black, Henry R.] NYU, Sch Med, New York, NY USA.
RP Rosendorff, C (reprint author), James J Peters VA Med Ctr, Med 111,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM clive.rosendorff@va.gov
NR 24
TC 8
Z9 11
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0268-4705
J9 CURR OPIN CARDIOL
JI Curr. Opin. Cardiol.
PD JUL
PY 2009
VL 24
IS 4
BP 318
EP 324
DI 10.1097/HCO.0b013e32832bfb48
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 461PE
UT WOS:000267279500008
PM 19395951
ER
PT J
AU Fuller, BE
Loftis, JM
Rodriguez, VL
McQuesten, MJ
Hauser, P
AF Fuller, Bret E.
Loftis, Jennifer M.
Rodriguez, Veronica L.
McQuesten, Matthew J.
Hauser, Peter
TI Psychiatric and substance use disorders comorbidities in veterans with
hepatitis C virus and HIV coinfection
SO CURRENT OPINION IN PSYCHIATRY
LA English
DT Article
DE coinfection; hepatitis C virus; HIV
ID UNITED-STATES VETERANS; SEVERE MENTAL-ILLNESS; INFECTION; CARE;
PREVALENCE; METHAMPHETAMINE; PERFORMANCE; DEPRESSION; DIAGNOSIS; THERAPY
AB Purpose of review
A growing number of veterans in the Veterans Health Administration are coinfected with HIV and hepatitis C virus. This review covers timely research relative to comorbid conditions that are common in this population including psychiatric diagnoses, substance use disorders and neurocognitive problems.
Recent findings
Current literature on the psychiatric, substance use disorders and cognitive problems of the coinfected population show that not only are rates of morbidity higher in the coinfected population but that this affects antiviral treatments as well. There is new evidence that brain injuries and infiltration of the virus into the central nervous system may be responsible for cognitive dysfunction. Cotesting, particularly in hepatitis C infected individuals, is not done routinely despite shared risk factors.
Summary
With this understanding of the comorbidities of the coinfected population, integrated healthcare models involving mental health, internal medicine, substance abuse treatment and internal medicine are crucial to work with these medically and psychologically complex patients.
C1 [Fuller, Bret E.; Hauser, Peter] Portland VA Med Ctr, Div Mental Hlth, Portland, OR 97210 USA.
[Fuller, Bret E.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
[Loftis, Jennifer M.] VA Med Ctr, Res Serv, Portland, OR USA.
[Loftis, Jennifer M.; Hauser, Peter] JENS Lab, Portland, OR USA.
[Hauser, Peter] Oregon Hlth & Sci Univ, Dept Internal Med, Dept Psychiat, Portland, OR 97201 USA.
RP Fuller, BE (reprint author), Portland VA Med Ctr, Div Mental Hlth, 3170 SW US Vet Pk Rd,Mailcode P3MHDC, Portland, OR 97210 USA.
EM bret.fuller@va.gov
NR 46
TC 9
Z9 9
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0951-7367
J9 CURR OPIN PSYCHIATR
JI Curr. Opin. Psychiatr.
PD JUL
PY 2009
VL 22
IS 4
BP 401
EP 408
DI 10.1097/YCO.0b013e32832cadb9
PG 8
WC Psychiatry
SC Psychiatry
GA 460LT
UT WOS:000267189900012
PM 19436202
ER
PT J
AU Asgari, MM
Bertenthal, D
Sen, S
Sahay, A
Chren, MM
AF Asgari, Maryam M.
Bertenthal, Daniel
Sen, Saunak
Sahay, Anju
Chren, Mary-Margaret
TI Patient Satisfaction After Treatment of Nonmelanoma Skin Cancer
SO DERMATOLOGIC SURGERY
LA English
DT Article
ID MOHS MICROGRAPHIC SURGERY; SQUAMOUS-CELL CARCINOMA; CARE; BASAL;
MORBIDITY; VETERANS
AB BACKGROUND Patient satisfaction is an important aspect of patient-centered care but has not been systematically studied after treatment of nonmelanoma skin cancer (NMSC), the most prevalent cancer.
OBJECTIVE To compare patient satisfaction after treatment for NMSC and to determine factors associated with better satisfaction.
METHODS We prospectively measured patient, tumor, and care characteristics in 834 consecutive patients at two centers before and after destruction, excision, and Mohs surgery. We evaluated factors associated with short-term and long-term satisfaction.
RESULTS In all treatment groups, patients were more satisfied with the interpersonal manners of the staff, communication, and financial aspects of their care than with the technical quality, time with the clinician, and accessibility of their care (p<.05). Short-term satisfaction did not differ across treatment groups. In multivariable regression models adjusting for patient, tumor, and care characteristics, higher long-term satisfaction was independently associated with younger age, better pretreatment mental health and skin-related quality of life, and treatment with Mohs surgery (p<.05).
CONCLUSIONS Long-term patient satisfaction after treatment of NMSC is related to pretreatment patient characteristics (mental health, skin-related quality of life) and treatment type (Mohs) but not tumor characteristics. These results can guide informed decision-making for treatment of NMSC.
C1 [Chren, Mary-Margaret] Univ Calif San Francisco, San Francisco VAMC, Dept Dermatol, San Francisco, CA 94121 USA.
[Asgari, Maryam M.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Bertenthal, Daniel; Sen, Saunak; Sahay, Anju; Chren, Mary-Margaret] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA.
[Sen, Saunak] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA.
RP Chren, MM (reprint author), Univ Calif San Francisco, San Francisco VAMC, Dept Dermatol, 4150 Clement St,151 R, San Francisco, CA 94121 USA.
EM chrenm@derm.ucsf.edu
RI Asgari, Maryam/O-4947-2016
FU NIAMS NIH HHS [K23 AR051037, K23 AR051037-03, K24 AR052667, K24
AR052667-01]
NR 27
TC 25
Z9 25
U1 1
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1076-0512
J9 DERMATOL SURG
JI Dermatol. Surg.
PD JUL
PY 2009
VL 35
IS 7
BP 1041
EP 1049
DI 10.1111/j.1524-4725.2009.01181.x
PG 9
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 466JT
UT WOS:000267658700004
PM 19438672
ER
PT J
AU Cadena, J
Thompson, GR
Ho, TT
Medina, E
Hughes, DW
Patterson, TF
AF Cadena, Jose
Thompson, George R., III
Ho, Tony T.
Medina, Edward
Hughes, Darrel W.
Patterson, Thomas F.
TI Immune reconstitution inflammatory syndrome after cessation of the tumor
necrosis factor alpha blocker adalimumab in cryptococcal pneumonia
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
DE Cryptococcus; TNF-alpha inhibitors; Adalimumab; Immune reconstitution
ID PARADOXICAL RESPONSE; THERAPY; TUBERCULOSIS
AB Tumor necrosis factor a antagonists have proven efficacious for a variety of autoimmune-mediated diseases. However, recent data have highlighted the risk of invasive fungal infections with their use. These agents are typically discontinued when infectious complications occur during therapy; however, the immune reconstitution inflammatory syndrome (IRIS) tray be seen after drug cessation. We describe the 1st case of IRIS secondary to cryptococcal pneumonia after cessation of adalimumab. Published by Elsevier Inc.
C1 [Cadena, Jose; Thompson, George R., III; Ho, Tony T.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA.
[Medina, Edward] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Cadena, Jose; Thompson, George R., III; Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Hughes, Darrel W.] Univ Hlth Syst, Dept Pharm, San Antonio, TX 78229 USA.
RP Thompson, GR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA.
EM thompsong2@uthscsa.edu
NR 11
TC 12
Z9 12
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD JUL
PY 2009
VL 64
IS 3
BP 327
EP 330
DI 10.1016/j.diagmicrobio.2009.03.019
PG 4
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 461OL
UT WOS:000267277300014
PM 19501793
ER
PT J
AU Vincent, RK
Odorico, JS
AF Vincent, Robert K.
Odorico, Jon S.
TI Reduced serum concentration is permissive for increased in vitro
endocrine differentiation from murine embryonic stem cells
SO DIFFERENTIATION
LA English
DT Article
DE Embryonic stem cells; Endocrine differentiation; Fetal calf serum; Serum
replacement; Pancreatic duodenal homeobox 1; Neurogenin 3;
Tetracycline-inducible
ID INSULIN-PRODUCING CELLS; PANCREATIC BETA-CELLS; DIRECTED
DIFFERENTIATION; ISLET DIFFERENTIATION; TARGETED EXPRESSION;
GENE-TRANSCRIPTION; EXOCRINE PANCREAS; PROGENITORS; MAFA; PDX-1
AB Embryonic stem cells (ESCs) have been shown to be capable of differentiating into pancreatic progenitors and insulin-producing cells in vitro. However, before ESC derivatives can be used in clinical settings, efficient selective differentiation needs to be achieved. Essential to improving ESC differentiation to islet endocrine cells is an understanding of the influences of extrinsic signals and transcription factors on cell specification. Herein, we investigate the influence of serum-supplemented growth conditions on the differentiation of murine ESCs to endocrine lineages in the context of over-expression of two pancreatic transcription factors, Pdx1 and Ngn3.
To study the effect of different serum formulations and concentrations on the ability of murine ESCs to differentiate into endocrine cells in vitro, cells were grown into embryoid bodies and then differentiated in various serum replacement (SR), fetal calf serum (FCS) and serum-free conditions. Using immunohistochemistry and quantitative real-time RT-PCR (QPCR), we found that, of the conditions tested, 1% SR differentiation medium resulted in the highest levels of insulin-1 mRNA and significantly increased the total number of insulin-expressing cells. Applying this knowledge to cell lines in which Pdx1 or Ngn3 transgene expression could be induced by exposure to doxycycline we differentiated TetPDX1 and TetNgn3 ESCs under conditions of either 10% FCS or 1% SR medium. In the presence of 10% serum, induced expression of either Pdx1 or Ngn3 in differentiating ESCs resulted in modest increases in hormone transcripts and cell counts. However, changing the serum formulation from 10% FCS to 1% SR significantly enhanced the number of insulin+/C-peptide+ cells in parallel with increased insulin-1 transcript levels in both inducible cell lines. In summary, these data demonstrate that induced expression of key pancreatic transcription factors in combination with low serum/SR concentrations increases endocrine cell differentiation from murine ESCs. (C) 2009 International Society of Differentiation. Published by Elsevier Ltd. All rights reserved.
C1 [Vincent, Robert K.; Odorico, Jon S.] Univ Wisconsin, Sch Med & Publ Hlth, Div Transplantat, Dept Surg, Madison, WI 53792 USA.
[Vincent, Robert K.; Odorico, Jon S.] WiCell Res Inst, Madison, WI 53792 USA.
[Vincent, Robert K.; Odorico, Jon S.] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA.
RP Odorico, JS (reprint author), Univ Wisconsin Hosp, Dept Surg, Div Transplantat, H4-756 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA.
EM jon@surgery.wisc.edu
NR 59
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0301-4681
J9 DIFFERENTIATION
JI Differentiation
PD JUL
PY 2009
VL 78
IS 1
BP 24
EP 34
DI 10.1016/j.diff.2009.03.006
PG 11
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA 555RP
UT WOS:000274532000003
PM 19446949
ER
PT J
AU Yermilov, I
Jain, S
Sekeris, E
Bentrem, DJ
Hines, OJ
Reber, HA
Ko, CY
Tomlinson, JS
AF Yermilov, Irina
Jain, Sushma
Sekeris, Evan
Bentrem, David J.
Hines, Oscar J.
Reber, Howard A.
Ko, Clifford Y.
Tomlinson, James S.
TI Utilization of Parenteral Nutrition Following Pancreaticoduodenectomy:
Is Routine Jejunostomy Tube Placement Warranted?
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Pancreaticoduodenectomy; Parenteral nutrition; Enterostomy tube;
Postoperative nutrition
ID SINGLE-INSTITUTION EXPERIENCE; PANCREATIC-CANCER; MORBIDITY; MORTALITY;
RESECTION; LENGTH; TRIAL; COSTS
AB Introduction Complications following pancreaticoduodenectomy (PD) often necessitate nutritional support. This study analyzes the utilization of parenteral nutrition (TPN) during the surgical admission as evidence for or against routine jejunostomy placement. Methods The California Cancer Registry (1994-2003) was linked to the California Inpatient File; PD for adenocarcinoma was performed in 1,873 patients. TPN use and enterostomy tube placement were determined and preoperative characteristics predictive of TPN use during the surgical admission were identified. Results Fourteen percent of patients received TPN, 23% underwent enterostomy tube placement, and 63% received no supplemental nutritional support. TPN was associated with longer hospital stay (18 vs. 13 days, P < 0.0001). The Charlson Comorbidity Index (CCI) a parts per thousand yen 3 had nearly two-fold greater odds of receiving TPN (odds ratio [OR] = 1.85, P < 0.005). Conclusion Approximately 1 in 6 patients undergoing PD received TPN, which was associated with prolonged hospital stay. CCI a parts per thousand yen 3 was associated with increased odds of TPN utilization. Selected jejunostomy placement in patients with high CCI is worthy of consideration.
C1 [Yermilov, Irina; Ko, Clifford Y.; Tomlinson, James S.] VA Greater Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90073 USA.
[Yermilov, Irina; Jain, Sushma; Sekeris, Evan; Hines, Oscar J.; Reber, Howard A.; Ko, Clifford Y.; Tomlinson, James S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Bentrem, David J.] Northwestern Univ, Dept Surg, Chicago, IL 60611 USA.
[Hines, Oscar J.; Reber, Howard A.; Tomlinson, James S.] Univ Calif Los Angeles, Ctr Pancreat Dis, Los Angeles, CA USA.
RP Tomlinson, JS (reprint author), VA Greater Angeles Healthcare Syst, Dept Surg, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM James.Tomlinson@va.gov
NR 24
TC 13
Z9 16
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD JUL
PY 2009
VL 54
IS 7
BP 1582
EP 1588
DI 10.1007/s10620-008-0526-1
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 454AV
UT WOS:000266654900030
PM 18958617
ER
PT J
AU Kahn, R
Biswas, K
Childress, AR
Shoptaw, S
Fudala, PJ
Gorgon, L
Montoya, I
Collins, J
McSherry, F
Li, SH
Chiang, N
Alathari, H
Watson, D
Liberto, J
Beresford, T
Stock, C
Wallace, C
Gruber, V
Elkashef, A
AF Kahn, Roberta
Biswas, Kousick
Childress, Anna-Rose
Shoptaw, Steve
Fudala, Paul J.
Gorgon, Liza
Montoya, Ivan
Collins, Joseph
McSherry, Frances
Li, Shou-Hua
Chiang, Nora
Alathari, Husam
Watson, Donnie
Liberto, Joseph
Beresford, Thomas
Stock, Christopher
Wallace, Christopher
Gruber, Valerie
Elkashef, Ahmed
TI Multi-center trial of baclofen for abstinence initiation in severe
cocaine-dependent individuals
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Cocaine; Dependence; Baclofen
ID RECEPTOR AGONISTS BACLOFEN; LONGITUDINAL DATA-ANALYSIS; HIGH-DOSE
BACLOFEN; GABA(B) RECEPTOR; ALCOHOL-DEPENDENCE; SEEKING BEHAVIOR; RATS;
SYMPTOMS; NICOTINE; REINSTATEMENT
AB Background: Cocaine dependence is a major public health problem for which there is no FDA-approved pharmacological treatment. Baclofen is a GABA(B) receptor agonist that in preclinical and early pilot clinical trials has shown promise for the treatment of cocaine dependence. The purpose of this multi-site, double-blind study, was to compare the safety and efficacy of baclofen (60 mg/day) vs placebo in an 8-week treatment of individuals with severe cocaine dependence. The primary Outcome measure was subjects' self-reported cocaine use substantiated by urine benzoylecgonine (BE). Analysis of the data did not show a significant difference between the groups treated with baclofen and placebo. The current results do not support a role for 60 mg baclofen in treating cocaine dependence in the population studied. The contrast of this result to earlier, preclinical and human pilot data with baclofen may reflect the trial's focus on severe cocaine-dependent users, and/or the need for a higher baclofen dose. Baclofen's potential as a relapse prevention agent was not tested by the current design, but may be a useful target for future studies. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Kahn, Roberta; Gorgon, Liza; Montoya, Ivan; Li, Shou-Hua; Chiang, Nora; Elkashef, Ahmed] NIDA, DPMCDA, Bethesda, MD 20892 USA.
[Biswas, Kousick; Collins, Joseph; McSherry, Frances] Cooperat Studies Program Coordinating Ctr 151E, DVA, Perry Point, MD 21902 USA.
[Fudala, Paul J.] Reckitt Benckiser Pharmaceut Inc, Richmond, VA 23235 USA.
[Shoptaw, Steve; Watson, Donnie] Friends Res Inst Inc, Los Angeles, CA USA.
[Childress, Anna-Rose] Univ Penn, Sch Med, Dept Psychiat, Addict Treatment Res Ctr, Philadelphia, PA 19104 USA.
[Alathari, Husam] Inova Ctr Addict Treatment Serv, Falls Church, VA 22042 USA.
[Watson, Donnie] Univ Calif Los Angeles, Integrated Substance Abuse Program, Torrance, CA 90502 USA.
[Liberto, Joseph] VA Maryland Hlth Care Syst MH 116, Baltimore, MD 21201 USA.
[Beresford, Thomas] Eastern Colorado Vet Affairs Healthcare Syst, Psychiat Serv 116, Denver, CO 80220 USA.
[Stock, Christopher] Vet Affairs Salt Lake City Healthcare Syst, Salt Lake City, UT 84148 USA.
[Wallace, Christopher] S Texas Vet Healthcare Syst, Vet Affairs Med Ctr Psychiat Serv 116A, San Antonio, TX 78229 USA.
[Gruber, Valerie] San Francisco Gen Hosp, San Francisco, CA 94110 USA.
RP Kahn, R (reprint author), NIDA, DPMCDA, 6001 Execut Blvd,Rm 4123,MSC 9551, Bethesda, MD 20892 USA.
EM rkan@nida.nih.gov
FU National Institute on Drug Abuse [Y1-DA4006]
FX This study was Supported by the National Institute on Drug Abuse through
the Department of Veterans Affairs Cooperative Studies Program
(Interagency Agreement No. Y1-DA4006).
NR 35
TC 42
Z9 42
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD JUL 1
PY 2009
VL 103
IS 1-2
BP 59
EP 64
DI 10.1016/j.drugalcdep.2009.03.011
PG 6
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 455LG
UT WOS:000266760700009
PM 19414226
ER
PT J
AU Barnwell, LFS
Lugo, JN
Lee, WL
Willis, SE
Gertz, SJ
Hrachovy, RA
Anderson, AE
AF Barnwell, L. Forbes S.
Lugo, Joaquin N.
Lee, Wai L.
Willis, Sarah E.
Gertz, Shira J.
Hrachovy, Richard A.
Anderson, Anne E.
TI Kv4.2 knockout mice demonstrate increased susceptibility to convulsant
stimulation
SO EPILEPSIA
LA English
DT Article
DE A-type K channel; Channelopathies; Seizures; Status epilepticus; Mouse
ID CA1 PYRAMIDAL NEURONS; POTASSIUM CHANNEL GENE; RAT HIPPOCAMPAL SLICE;
EPILEPTIFORM ACTIVITY; DOWN-REGULATION; HUMAN EPILEPSY; K+ CURRENT;
CURRENTS; SEIZURE; REPOLARIZATION
AB P>Purpose:
Kv4.2 subunits contribute to the pore-forming region of channels that express a transient, A-type K(+) current (A-current) in hippocampal CA1 pyramidal cell dendrites. Here, the A-current plays an important role in signal processing and synaptic integration. Kv4.2 knockout mice show a near elimination of the A-current in area CA1 dendrites, producing increased excitability in this region. In these studies, we evaluated young adult Kv4.2 knockout mice for spontaneous seizures and the response to convulsant stimulation in the whole animal in vivo and in hippocampal slices in vitro.
Methods:
Electroencephalogram electrode-implanted Kv4.2 knockout and wild-type mice were observed for spontaneous behavioral and electrographic seizures. The latency to seizure and status epilepticus onset in Kv4.2 knockout and wild-type mice was assessed following intraperitoneal injection of kainate. Extracellular field potential recordings were performed in hippocampal slices from Kv4.2 knockout and wild-type mice following the bath application of bicuculline.
Results:
No spontaneous behavioral or electrographic seizures were observed in Kv4.2 knockout mice. Following kainate, Kv4.2 knockout mice demonstrated a decreased seizure and status epilepticus latency as well as increased mortality compared to wild-type littermates. The background strain modified the seizure susceptibility phenotype in Kv4.2 knockout mice. In response to bicuculline, slices from Kv4.2 knockout mice exhibited an increase in epileptiform bursting in area CA1 as compared to wild-type littermates.
Discussion:
These studies show that loss of Kv4.2 channels is associated with enhanced susceptibility to convulsant stimulation, supporting the concept that Kv4.2 deficiency may contribute to aberrant network excitability and regulate seizure threshold.
C1 [Anderson, Anne E.] Baylor Coll Med, Feigin Ctr 955, Dept Neurol, Houston, TX 77030 USA.
[Lugo, Joaquin N.; Lee, Wai L.; Anderson, Anne E.] Baylor Coll Med, Dept Pediat, Neurol Sect, Cain Fdn Labs, Houston, TX 77030 USA.
[Gertz, Shira J.] Baylor Coll Med, Dept Pediat, Sect Pediat Crit Care Med, Houston, TX 77030 USA.
[Anderson, Anne E.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA.
[Hrachovy, Richard A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Anderson, AE (reprint author), Baylor Coll Med, Feigin Ctr 955, Dept Neurol, 1102 Bates St,MC 3-6365, Houston, TX 77030 USA.
EM annea@bcm.tmc.edu
FU NIH/NINDS [NS049427, NS039943, K01-NS046328, F32NS056664]; Epilepsy
Foundation Postdoctoral Fellowship; Partnership for Pediatric Research
in Epilepsy/Epilepsy Foundation; Citizens United for Research in
Epilepsy
FX Disclosures: None of the authors has any conflict of interest to
disclose.
NR 42
TC 29
Z9 30
U1 0
U2 5
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD JUL
PY 2009
VL 50
IS 7
BP 1741
EP 1751
DI 10.1111/j.1528-1167.2009.02086.x
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA 466KJ
UT WOS:000267660800008
PM 19453702
ER
PT J
AU Sung, KF
Odinokova, IV
Mareninova, OA
Rakonczay, Z
Hegyi, P
Pandol, SJ
Gukovsky, I
Gukovskaya, AS
AF Sung, Kai-Feng
Odinokova, Irina V.
Mareninova, Olga A.
Rakonczay, Zoltan, Jr.
Hegyi, Peter
Pandol, Stephen J.
Gukovsky, Ilya
Gukovskaya, Anna S.
TI Prosurvival Bcl-2 proteins stabilize pancreatic mitochondria and protect
against necrosis in experimental pancreatitis
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Pancreatic acinar cell; Bcl-xL; CCK; Mitochondrial membrane potential;
Cytochrome c release; Caspase-3
ID MEMBRANE PERMEABILITY TRANSITION; SMALL-MOLECULE INHIBITORS; CELL-DEATH;
ACINAR-CELLS; X-L; CASPASE ACTIVATION; TARGETING BCL-2; KAPPA-B;
APOPTOSIS; CANCER
AB Acinar cells in pancreatitis die through apoptosis and necrosis, the roles of which are different. The severity of experimental pancreatitis correlates directly with the extent of necrosis and inversely, with apoptosis. Apoptosis is mediated by the release of cytochrome c into the cytosol followed by caspase activation, whereas necrosis is associated with the mitochondrial membrane potential (Delta Psi m) loss leading to ATP depletion. Here, we investigate the role of Bcl-2 proteins in apoptosis and necrosis in pancreatitis. We found tip-regulation of prosurvival Bcl-2 proteins in pancreas in various experimental models of acute pancreatitis, most pronounced for Bcl-xL. This up-regulation translated into increased levels of Bcl-xL and Bcl-2 in pancreatic mitochondria. Bcl-xL/Bcl-2 inhibitors induced Delta Psi m loss and cytochrome c release in isolated mitochondria. Corroborating the results On mitochondria, Bcl-xL/Bcl-2 inhibitors induced Delta Psi m loss, NIT depletion and necrosis in pancreatic acinar cells, both untreated and hyperstimulated with CCK-8 (in vitro pancreatitis model). Together Bcl-xL/Bcl-2 inhibitors and CCK induced more necrosis than either treatment alone. Bcl-xL/Bcl-2 inhibitors also stimulated cytochrome c release in acinar cells leading to caspase-3 activation and apoptosis. However, different from their effect on pronecrotic signals, the Stimulation by Bcl-xL/Bcl-2 inhibitors of apoptotic responses was less in CCK-treated than control cells. Therefore, Bcl-xL/Bcl-2 inhibitors potentiated CCK-induced necrosis but not apoptosis. Correspondingly, transfection with Bcl-xL siRNA stimulated necrosis but not apoptosis in the in vitro pancreatitis model. Further, in animal models of pancreatitis Bcl-xL up-regulation inversely correlated with necrosis, but not apoptosis. Results indicate that Bcl-xL and Bcl-2 protect acinar cells from necrosis in pancreatitis by stabilizing mitochondria against death signals. We conclude that Bcl-xL/Bcl-2 inhibition would aggravate acute pancreatitis, whereas Bcl-xL/Bcl-2 up-regulation presents a strategy to prevent or attenuate necrosis in pancreatitis. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Gukovskaya, Anna S.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, Los Angeles, CA 90073 USA.
[Sung, Kai-Feng; Odinokova, Irina V.; Mareninova, Olga A.; Pandol, Stephen J.; Gukovsky, Ilya; Gukovskaya, Anna S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Sung, Kai-Feng] Chang Gung Mem Hosp, Dept Hepatogastroenterol, Taipei 10591, Taiwan.
[Odinokova, Irina V.] Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142292, Moscow Region, Russia.
[Rakonczay, Zoltan, Jr.; Hegyi, Peter] Univ Szeged, Szeged, Hungary.
RP Gukovskaya, AS (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, 11301 Wilshire Blvd,Blg 258,Rm 340, Los Angeles, CA 90073 USA.
EM agukovsk@ucla.edu
FU NIH [DK59936]; American Gastroenterology Association Foundation
Designated Research Scholar Award in Pancreatitis; Department of Veteran
Affairs
FX This study was supported by NIH Grant DK59936 (to A.S.G.), by the
American Gastroenterology Association Foundation Designated Research
Scholar Award in Pancreatitis (to O.A.M.) and by the Department of
Veteran Affairs (to S.J.P.). We thank Dr. A. Lugea for help with animal
models of pancreatitis, and Drs. G. Eibl and E. Angst for help with
using iQ5 real-time PCR detection system.
NR 54
TC 39
Z9 40
U1 0
U2 2
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
J9 EXP CELL RES
JI Exp. Cell Res.
PD JUL 1
PY 2009
VL 315
IS 11
BP 1975
EP 1989
DI 10.1016/j.yexcr.2009.01.009
PG 15
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 454BG
UT WOS:000266656000018
PM 19331832
ER
PT J
AU Saless, N
Litscher, SJ
Franco, GEL
Houlihan, MJ
Sudhakaran, S
Raheem, KA
O'Neil, TK
Vanderby, R
Demant, P
Blank, RD
AF Saless, Neema
Litscher, Suzanne J.
Franco, Gloria E. Lopez
Houlihan, Meghan J.
Sudhakaran, Shaan
Raheem, Khalid Abdul
O'Neil, Tyriina K.
Vanderby, Ray
Demant, Peter
Blank, Robert D.
TI Quantitative trait loci for biomechanical performance and femoral
geometry in an intercross of recombinant congenic mice: restriction of
the Bmd7 candidate interval
SO FASEB JOURNAL
LA English
DT Article
DE osteoporosis; Wnt; modeling and remodeling; linkage; endothelin
ID RECEPTOR-RELATED PROTEIN-5; BONE-MINERAL DENSITY; HETEROGENEOUS
MOUSE-POPULATION; MECHANICAL-PROPERTIES; GENETIC DISSECTION; INBRED
STRAINS; UTAH PARADIGM; MASS; STRENGTH; LRP5
AB Despite steady progress in identifying quantitative trait loci (QTLs) for bone phenotypes, relatively little progress has been made in moving from QTLs to identifying the relevant gene. We exploited the genetic structure of recombinant congenic mouse strains by performing a reciprocal intercross of the strains HcB-8 and HcB-23, phenotyped for body size, femoral biomechanical performance, and femoral diaphyseal geometry and mapped with R/qtl and QTL Cartographer. Significant QTLs are present on chromosomes 1, 2, 3, 4, 6, and 10. We found significant sex x QTL and cross-direction x QTL interactions. The chromosome 4 QTL affects multiple femoral anatomic features and biomechanical properties. The known segregating segment of chromosome 4 contains only 18 genes, among which Ece1, encoding endothelin-converting enzyme 1, stands out as a candidate. Endothelin signaling has been shown to promote the growth of osteoblastic metastases and to potentiate signaling via the Wnt pathway. The colocalizing chromosome 4 QTL Bmd7 (for bone mineral density 7) increases responsiveness to mechanical loading. By exploiting the short informative segment of chromosome 4 and the known biology, we propose that Ece1 is the gene responsible for Bmd7 and that it acts by increasing responsiveness to mechanical loading through modulation of Wnt signaling. Saless, N., Litscher, S. J., Lopez Franco, G. E., Houlihan, M. J., Sudhakaran, S., Raheem, K. A., O'Neil, T. K., Vanderby, R., Demant, P., Blank, R. D. Quantitative trait loci for biomechanical performance and femoral geometry in an intercross of recombinant congenic mice: restriction of the Bmd7 candidate interval. FASEB J. 23, 2142-2154 (2009)
C1 [Saless, Neema; Litscher, Suzanne J.; Franco, Gloria E. Lopez; Houlihan, Meghan J.; Sudhakaran, Shaan; Raheem, Khalid Abdul; O'Neil, Tyriina K.; Vanderby, Ray; Blank, Robert D.] Univ Wisconsin, Madison, WI USA.
[Demant, Peter] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Blank, Robert D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Blank, RD (reprint author), H4-556 CSC 5148,600 Highland Ave, Madison, WI 53705 USA.
EM rdb@medicine.wisc.edu
OI Blank, Robert Daniel/0000-0003-2950-1944
FU Office of Research and Development, Biomedical Laboratory Research and
Development Service, Department of Veterans Affairs
FX We thank Anath Shalev, Marc Drezner, Theresa Guise, and Charles Turner
for helpful discussions. This material is based on work supported by the
Office of Research and Development, Biomedical Laboratory Research and
Development Service, Department of Veterans Affairs, and performed in
the Geriatrics Research, Education, and Clinical Center at the William
S. Middleton Memorial Veterans Hospital. This report is Madison GRECC
manuscript 2008-13.
NR 64
TC 22
Z9 22
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD JUL
PY 2009
VL 23
IS 7
BP 2142
EP 2154
DI 10.1096/fj.08-118679
PG 13
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 481UC
UT WOS:000268836500014
PM 19261723
ER
PT J
AU Salmon, AB
Leonard, S
Masamsetti, V
Pierce, A
Podlutsky, AJ
Podlutskaya, N
Richardson, A
Austad, SN
Chaudhuri, AR
AF Salmon, Adam B.
Leonard, Shanique
Masamsetti, Venkata
Pierce, Anson
Podlutsky, Andrej J.
Podlutskaya, Natalia
Richardson, Arlan
Austad, Steven N.
Chaudhuri, Asish R.
TI The long lifespan of two bat species is correlated with resistance to
protein oxidation and enhanced protein homeostasis
SO FASEB JOURNAL
LA English
DT Article
DE longevity; comparative biology; oxidative stress; ubiquitin-proteasome;
Chiroptera
ID NAKED MOLE-RAT; FREE-RADICAL PRODUCTION; LIVING RODENT; ANTIOXIDANT
DEFENSES; CELLULAR-RESISTANCE; HEART-MITOCHONDRIA; STRESS RESISTANCE;
H2O2 PRODUCTION; MULTIPLE FORMS; METABOLIC-RATE
AB Altered structure, and hence function, of cellular macromolecules caused by oxidation can contribute to loss of physiological function with age. Here, we tested whether the lifespan of bats, which generally live far longer than predicted by their size, could be explained by reduced protein damage relative to short-lived mice. We show significantly lower protein oxidation (carbonylation) in Mexican free-tailed bats (Tadarida brasiliensis) relative to mice, and a trend for lower oxidation in samples from cave myotis bats (Myotis velifer) relative to mice. Both species of bat show in vivo and in vitro resistance to protein oxidation under conditions of acute oxidative stress. These bat species also show low levels of protein ubiquitination in total protein lysates along with reduced proteasome activity, suggesting diminished protein damage and removal in bats. Lastly, we show that bat-derived protein fractions are resistant to urea-induced protein unfolding relative to the level of unfolding detected in fractions from mice. Together, these data suggest that long lifespan in some bat species might be regulated by very efficient maintenance of protein homeostasis.-Salmon, A. B., Leonard, S., Masamsetti, V., Pierce, A., Podlutsky, A. J., Podlutskaya, N., Richardson, A., Austad, S. N., Chaudhuri, A. R. The long lifespan of two bat species is correlated with resistance to protein oxidation and enhanced protein homeostasis. FASEB J. 23, 2317-2326 (2009)
C1 [Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Pierce, Anson; Richardson, Arlan; Chaudhuri, Asish R.] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA.
[Pierce, Anson; Richardson, Arlan; Austad, Steven N.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA.
RP Chaudhuri, AR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM chaudhuria@uthscsa.edu
RI Pierce, Anson/D-1079-2012; Podlutsky, Andrej/F-5421-2015
OI Pierce, Anson/0000-0002-1383-0180;
FU NIH [T32 AG021890-05, AG23843, R37 AG26557, AG022873]; [K07 AG025063
04]
FX The authors thank Bertran Friguet (Universite Paris, Paris, France) for
providing 20S proteasome antibody. We also thank Tom Kunz and Louise
Allen for help in obtaining our bat samples. This work was supported by
K07 AG025063 04 (A. R. C., A. R., S.N.A.); NIH training grant T32
AG021890-05 (A. B. S.); and NIH grants AG23843, R37 AG26557 (A. R.), and
AG022873 (S.N.A.).
NR 48
TC 54
Z9 55
U1 3
U2 16
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JUL
PY 2009
VL 23
IS 7
BP 2317
EP 2326
DI 10.1096/fj.08-122523
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 481UC
UT WOS:000268836500031
PM 19244163
ER
PT J
AU Leung, FW
AF Leung, Felix W.
TI Search for premalignant mucosal lesions: does endoscopic measurement of
oxygen saturation by differential path-length spectroscopy help?
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Editorial Material
ID IN-VIVO; BARRETTS-ESOPHAGUS; TECHNOLOGY; DYSPLASIA
C1 [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA.
[Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gastroenterol, Los Angeles, CA 90095 USA.
RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA.
NR 14
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD JUL
PY 2009
VL 70
IS 1
BP 7
EP 8
DI 10.1016/j.gie.2008.11.015
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 464RI
UT WOS:000267523200002
PM 19559830
ER
PT J
AU Shergill, AK
McQuaid, KR
Rempel, D
AF Shergill, Amandeep K.
McQuaid, Kenneth R.
Rempel, David
TI Ergonomics and GI endoscopy
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Review
ID CUMULATIVE TRAUMA DISORDERS; CARPAL-TUNNEL-SYNDROME; LAPAROSCOPIC
SURGERY; INTERVENTIONAL CARDIOLOGISTS; COLONOSCOPY; PREVALENCE;
INJURIES; OVERUSE; MONITOR; HEIGHT
C1 [Shergill, Amandeep K.; McQuaid, Kenneth R.] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA USA.
[Shergill, Amandeep K.; McQuaid, Kenneth R.] San Francisco VA Med Ctr, Med Serv, Gastroenterol Sect, San Francisco, CA 94121 USA.
[Rempel, David] Univ Calif San Francisco, Dept Med, Div Occupat Med, San Francisco, CA USA.
[Rempel, David] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.
RP Shergill, AK (reprint author), San Francisco VA Med Ctr, GI Sect, 4150 Clement St,Bldg 203 111B1, San Francisco, CA 94121 USA.
RI Rempel, David/E-8424-2013
NR 48
TC 25
Z9 25
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD JUL
PY 2009
VL 70
IS 1
BP 145
EP 153
DI 10.1016/j.gie.2008.12.235
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 464RI
UT WOS:000267523200022
PM 19559836
ER
PT J
AU Scherrer, JF
Virgo, KS
Zeringue, A
Bucholz, KK
Jacob, T
Johnson, RG
True, WR
Carney, RM
Freedland, KE
Xian, H
Caplan, L
McDonald, J
Eisen, SA
AF Scherrer, Jeffrey F.
Virgo, Katherine S.
Zeringue, Angelique
Bucholz, Kathleen K.
Jacob, Theodore
Johnson, Robert G.
True, William R.
Carney, Robert M.
Freedland, Kenneth E.
Xian, Hong
Caplan, Liron
McDonald, Jay
Eisen, Seth A.
TI Depression increases risk of incident myocardial infarction among
Veterans Administration patients with rheumatoid arthritis
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Depression; Myocardial infarction; Rheumatoid arthritis; Veterans
ID CORONARY-HEART-DISEASE; PSYCHIATRIC-DISORDERS; MORTALITY; MEN; AFFAIRS;
COMORBIDITY; POPULATION; PREVALENCE; DIAGNOSIS; SYMPTOMS
AB Objective: This study evaluates whether depression is a risk factor for incident myocardial infarction (MI) in Department of Veterans Affairs (VA) patients with rheumatoid arthritis (RA) between 30 and 79 years of age.
Methods: We used a retrospective cohort study of 15,634 patients with RA. Diagnoses and sociodemographic data were obtained from VA administrative and pharmacy databases between fiscal years 1999 and 2006. Entry into the cohort required 2 years of patient time with no evidence of cardiovascular disease. Cox proportional hazard models with time-dependent covariates were computed to determine whether RA patients with depression as compared to RA patients without depression were at increased risk for MI during the maximum 6-year follow-up period.
Results: Unadjusted analyses indicated depressed RA patients were 1.4 times more likely than nondepressed RA patients to have an MI during follow-up. These results remained significant (HR=1.4; 95% CI: in the adjusted Cox proportional hazards model which included the effects of sociodemographics and known physical risks (e.g., diabetes) for MI.
Conclusions: Depressed RA patients, without a history of cardiovascular disease, are 40% more likely to have a heart attack as compared to those without depression. These data demonstrate a rapid (within 6 years) transition to MI following onset of depression in RA patients. Increased monitoring of depression and heart disease status in this patient population may be warranted which in turn may result in longer duration of life. Published by Elsevier Inc.
C1 [Scherrer, Jeffrey F.; Virgo, Katherine S.; Zeringue, Angelique; Bucholz, Kathleen K.; True, William R.; Xian, Hong; McDonald, Jay] St Louis Vet Affairs Med Ctr, Res Serv, St Louis, MO 63106 USA.
[Scherrer, Jeffrey F.; Bucholz, Kathleen K.] Washington Univ, Dept Psychiat, Midwest Alcoholism Res Ctr, Sch Med, St Louis, MO 63108 USA.
[Virgo, Katherine S.; Johnson, Robert G.] St Louis Univ, Med Ctr, Dept Surg, St Louis, MO 63110 USA.
[Zeringue, Angelique; Xian, Hong; McDonald, Jay] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63108 USA.
[Jacob, Theodore] Vet Affairs Palo Alto Hlth Care Syst, Menlo Pk, CA 94025 USA.
[True, William R.] Washington Univ, George Warren Brown Sch Social Work, St Louis, MO 63110 USA.
[Caplan, Liron] Univ Colorado, Dept Med Rheumatol, Denver Vet Affairs Med Ctr, Denver, CO 80220 USA.
[Eisen, Seth A.] Dept Vet Affairs, Hlth Serv Res & Dev Serv, Washington, DC USA.
RP Scherrer, JF (reprint author), St Louis VAMC 151JC, St Louis, MO 63106 USA.
EM scherrej@psychiatry.wustl.edu
RI Zeringue, Angelique/I-1755-2012
FU VA; CSCP [458]; Career Development Award
FX This study was supported by VA grants, CSCP #458 and Career Development
Award to Jeffrey F. Scherrer.
NR 36
TC 29
Z9 31
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD JUL-AUG
PY 2009
VL 31
IS 4
BP 353
EP 359
DI 10.1016/j.genhosppsych.2009.04.001
PG 7
WC Psychiatry
SC Psychiatry
GA 468DN
UT WOS:000267794500009
PM 19555796
ER
PT J
AU Moser, KL
Kelly, JA
Lessard, CJ
Harley, JB
AF Moser, K. L.
Kelly, J. A.
Lessard, C. J.
Harley, J. B.
TI Recent insights into the genetic basis of systemic lupus erythematosus
SO GENES AND IMMUNITY
LA English
DT Review
DE lupus; genetics; autoimmunity
ID COMPLEMENT DEFICIENCY; RHEUMATOID-ARTHRITIS; FAMILIAL AGGREGATION;
FUNCTIONAL VARIANTS; AFRICAN-AMERICANS; NULL ALLELES; RISK-FACTORS;
ASSOCIATION; SUSCEPTIBILITY; DISEASE
AB Genetic variation was first shown to be important in systemic lupus erythematosus (SLE or lupus) in the 1970s with associations in the human leukocyte antigen region. Almost four decades later, and with the help of increasingly powerful genetic approaches, more than 25 genes are now known to contribute to the mechanisms that predispose individuals to lupus. Over half of these loci have been discovered in the past 2 years, underscoring the extraordinary success of genome-wide association approaches in SLE. Well-established risk factors include alleles in the major histocompatibility complex region ( multiple genes), IRF5, ITGAM, STAT4, BLK, BANK1, PDCD1, PTPN22, TNFSF4, TNFAIP3, SPP1, some of the Fc gamma receptors, and deficiencies in several complement components, including C1q, C4 and C2. As reviewed here, many susceptibility genes fall into key pathways that are consistent with previous studies implicating immune complexes, host immune signal transduction and interferon pathways in the pathogenesis of SLE. Other loci have no known function or apparent immunological role and have the potential to reveal novel disease mechanisms. Certainly, as our understanding of the genetic etiology of SLE continues to mature, important new opportunities will emerge for developing more effective diagnostic and clinical management tools for this complex autoimmune disease. Genes and Immunity (2009) 10, 373-379; doi: 10.1038/gene.2009.39; published online 14 May 2009
C1 [Moser, K. L.; Kelly, J. A.; Lessard, C. J.; Harley, J. B.] Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA.
[Moser, K. L.; Lessard, C. J.; Harley, J. B.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA.
[Harley, J. B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
RP Moser, KL (reprint author), Oklahoma Med Res Fdn, Arthrit & Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.
EM moserk@omrf.org
FU NIH [AR043274, AI24717, AR62277, AR42460, AI31584, DE015223, RR015577,
RR020143, AR48940, AR049084]; Mary Kirkland Scholarship; Barrett
Scholarship Fund; Alliance for Lupus Research; US Department of Veterans
Affairs
FX This work has been supported by the NIH (AR043274, AI24717, AR62277,
AR42460, AI31584, DE015223, RR015577, RR020143, AR48940 and AR049084),
the Mary Kirkland Scholarship, the Barrett Scholarship Fund, the
Alliance for Lupus Research and the US Department of Veterans Affairs.
NR 56
TC 177
Z9 184
U1 2
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUL
PY 2009
VL 10
IS 5
BP 373
EP 379
DI 10.1038/gene.2009.39
PG 7
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 472YH
UT WOS:000268168800001
PM 19440199
ER
PT J
AU Lu, R
Vidal, GS
Kelly, JA
Delgado-Vega, AM
Howard, XK
Macwana, SR
Dominguez, N
Klein, W
Burrell, C
Harley, IT
Kaufman, KM
Bruner, GR
Moser, KL
Gaffney, PM
Gilkeson, GS
Wakeland, EK
Li, QZ
Langefeld, CD
Marion, MC
Divers, J
Alarcon, GS
Brown, EE
Kimberly, RP
Edberg, JC
Ramsey-Goldman, R
Reveille, JD
McGwin, G
Vila, LM
Petri, MA
Bae, SC
Cho, SK
Bang, SY
Kim, I
Choi, CB
Martin, J
Vyse, TJ
Merrill, JT
Harley, JB
Alarcon-Riquelme, ME
Nath, SK
James, JA
Guthridge, JM
AF Lu, R.
Vidal, G. S.
Kelly, J. A.
Delgado-Vega, A. M.
Howard, X. K.
Macwana, S. R.
Dominguez, N.
Klein, W.
Burrell, C.
Harley, I. T.
Kaufman, K. M.
Bruner, G. R.
Moser, K. L.
Gaffney, P. M.
Gilkeson, G. S.
Wakeland, E. K.
Li, Q-Z
Langefeld, C. D.
Marion, M. C.
Divers, J.
Alarcon, G. S.
Brown, E. E.
Kimberly, R. P.
Edberg, J. C.
Ramsey-Goldman, R.
Reveille, J. D.
McGwin, G., Jr.
Vila, L. M.
Petri, M. A.
Bae, S-C
Cho, S-K
Bang, S-Y
Kim, I.
Choi, C-B
Martin, J.
Vyse, T. J.
Merrill, J. T.
Harley, J. B.
Alarcon-Riquelme, M. E.
Nath, S. K.
James, J. A.
Guthridge, J. M.
CA BIOLUPUS Multictr Collaborations
GENLES Multictr Collaboration
TI Genetic associations of LYN with systemic lupus erythematosus
SO GENES AND IMMUNITY
LA English
DT Article
DE systemic lupus erythematosus; association; LYN; SNP
ID GENOME-WIDE ASSOCIATION; B-CELLS; DEFICIENT MICE; AUTOIMMUNE-DISEASE;
KINASE LYN; VARIANTS; PROLIFERATION; LYMPHOCYTES; PREVALENCE; ACTIVATION
AB We targeted LYN, a src-tyosine kinase involved in B-cell activation, in case-control association studies using populations of European-American, African-American and Korean subjects. Our combined European-derived population, consisting of 2463 independent cases and 3131 unrelated controls, shows significant association with rs6983130 in a female-only analysis with 2254 cases and 2228 controls (P = 1.1 x 10(-4), odds ratio (OR) = 0.81 (95% confidence interval: 0.73-0.90)). This single nucleotide polymorphism ( SNP) is located in the 50 untranslated region within the first intron near the transcription initiation site of LYN. In addition, SNPs upstream of the first exon also show weak and sporadic association in subsets of the total European-American population. Multivariate logistic regression analysis implicates rs6983130 as a protective factor for systemic lupus erythematosus (SLE) susceptibility when anti-dsDNA, anti-chromatin, anti-52 kDa Ro or anti-Sm autoantibody status were used as covariates. Subset analysis of the European-American female cases by American College of Rheumatology classification criteria shows a reduction in the risk of hematological disorder with rs6983130 compared with cases without hematological disorders (P = 1.5 x 10(-3), OR = 0.75 (95% CI: 0.62-0.89)). None of the 90 SNPs tested show significant association with SLE in the African American or Korean populations. These results support an association of LYN with European-derived individuals with SLE, especially within autoantibody or clinical subsets. Genes and Immunity (2009) 10, 397-403; doi: 10.1038/gene.2009.19; published online 16 April 2009
C1 [Lu, R.; Vidal, G. S.; Macwana, S. R.; Dominguez, N.; Klein, W.; James, J. A.; Guthridge, J. M.] Oklahoma Med Res Fdn, Clin Immunol Program, Oklahoma City, OK 73104 USA.
[Kelly, J. A.; Howard, X. K.; Burrell, C.; Harley, I. T.; Kaufman, K. M.; Bruner, G. R.; Moser, K. L.; Gaffney, P. M.; Harley, J. B.; Alarcon-Riquelme, M. E.; Nath, S. K.] Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA.
[Delgado-Vega, A. M.; Alarcon-Riquelme, M. E.] Uppsala Univ, Dept Genet & Pathol, Uppsala, Sweden.
[Kaufman, K. M.; Harley, J. B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
[Gilkeson, G. S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA.
[Wakeland, E. K.; Li, Q-Z] Univ Texas SW Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA.
[Langefeld, C. D.; Marion, M. C.; Divers, J.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA.
[Alarcon, G. S.; Brown, E. E.; Kimberly, R. P.; Edberg, J. C.; McGwin, G., Jr.] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Ramsey-Goldman, R.] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Dept Med, Chicago, IL 60611 USA.
[Reveille, J. D.] Univ Texas Houston Hlth Sci Ctr, Div Rheumatol & Clin Immunogenet, Dept Internal Med, Houston, TX USA.
[Vila, L. M.] Univ Puerto Rico, Div Rheumatol, Dept Med, San Juan, PR 00936 USA.
[Petri, M. A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Rheumatol, Baltimore, MD 21205 USA.
[Bae, S-C; Cho, S-K; Bang, S-Y; Kim, I.; Choi, C-B] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul 133791, South Korea.
[Martin, J.] CSIC, Inst Biomed & Parasitol Lopez Neyra, Granada, Spain.
[Vyse, T. J.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Rheumatol Sect, London, England.
[Merrill, J. T.] Oklahoma Med Res Fdn, Dept Clin Pharmacol, Oklahoma City, OK 73104 USA.
[Harley, J. B.; James, J. A.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
[Harley, J. B.; James, J. A.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA.
RP Guthridge, JM (reprint author), 825 NE 13th St,MS 53, Oklahoma City, OK 73104 USA.
EM guthridgej@omrf.org
RI Delgado-Vega, Angelica Maria/A-4318-2009; Vyse, Tim/G-3887-2011; Martin,
Javier/B-8141-2008; D'Alfonso, Sandra/K-7295-2014; Witte,
Torsten/B-5783-2016
OI Delgado-Vega, Angelica Maria/0000-0002-9865-0591; D'Alfonso,
Sandra/0000-0002-3983-9925; Silva, Berta/0000-0001-6579-5068; Kimberly,
Robert/0000-0002-5330-3086; Alarcon Riquelme, Marta
Eugenia/0000-0002-7632-4154
FU National Institutes of Health [RR020143, RR015577,
NIAID-HHSN266200500026C, AI031584, AR053483, AR48940, AI063622,
AR049084, AR42460, AR12253, AR62277, AI24717, AI063274, AR052125,
AR043247, DEO15223]; Kirkland Scholar awards; Alliance for Lupus
Research; US Department of Veterans Affairs; Swedish Research Council;
Korea Healthcare technology RD Project; Ministry for Health, Welfare and
Family Affairs, Republic of Korea; Torsten & Ragnar Soderbergs
Foundation; Swedish Foundation Against Rheumatism; Gustaf
Vth-80th-Year Foundation; Plan Nacional de I+D,
Spain [SAF06-00398]; Junta de Andalucia [CTS-180]; OHRS [HR08-037];
Oklahoma Center for the Advancement of Science Technology; [A010252];
[A080588]
FX We thank the participants, both patients and controls, who graciously
agreed to take part in these studies by donating samples to the various
collections, including the Lupus Family Registry and Repository
(http://lupus.omrf.org), PROFILE, BIOLUPUS and many other individual or
multicenter collaborator initiated collections. We also thank the
recruitment and technical teams at each of the sample procurement sites
for their important contributions. We thank the Wake Forest University
Health Sciences Center for Public Health Genomics for support of the
data analysis efforts of our Wake Forest University collaborators.
Finally, we thank the various funding sources as outlined on the title
page for their continued support for the collection of samples and the
conduct of this research.; Members of BIOLUPUS who have provided samples
to this study are: Peter Junker, Ann Voss and Helle Laustrup (Odense,
Denmark), Bernard Lawerys and Fredric Houssieau (Louvain, Belgium),
Carlos Vasconcelos and Berta Martins Da Silva (Porto, Portugal), Carmen
Gutierrez and Ana Suarez (Oviedo, Spain), Torsten Witte (Hannover,
Germany), Sandra D'Alfonso, Sergio Migliaresi, Mauro Galeazzi and Gian
Domenico Sebastiani (Novara, Naples, Siena and Rome, Italy), Bernardo
Pons-Estel and the members of GENLES (Rosario, Argentina) and Emoke
Endreffy (Szeged, Hungary). Peter K Gregersen from the Feinstein
Institute of Medical Research and Jorge R Oksenberg from the University
of California at San Francisco graciously provided controls used in this
study. Members of PROFILE who have provided samples to this study are
Graciela S Alarcon, Elizabeth E Brown, Robert P Kimberly, Jeffery C
Edberg and Gerald McGwin, Jr (University of Alabama Birmingham,
Birmingham, AL, USA), Rosalind Ramsey-Goldman (Northwestern University
Feinberg School of Medicine, Chicago, IL, USA), John D Reveille
(University Texas Health Science Center, Houston, TX, USA), Luis M Vila
(University of Puerto Rico Medical Sciences Campus, San Juan, PR, USA)
and Michelle A Petri (Johns Hopkins Hospital, Baltimore, MD, USA). This
project was funded by National Institutes of Health RR020143 (JMG and
JBH), RR015577 (JMG, JBH, JAJ), NIAID-HHSN266200500026C (JMG and JAJ),
AI031584 (JBH, JMG, JAJ), AR053483 (JMG, SKN and JAJ), AR48940 (JBH,
JAJ), AI063622 (SKN), Kirkland Scholar awards (JBH and JAJ), AR049084
(SKN, JBH, RPK, RRG, JDR, MAP, LMV, GSA, JCE, GMcG Jr), AR42460 (JBH),
AR12253 (JBH), AR62277 (JBH), AI24717 (JBH), AI063274 (PMG), AR052125
(PMG), AR043247 (KLM), DEO15223 (JBH), Alliance for Lupus Research
(JBH), the US Department of Veterans Affairs (JBH), Swedish Research
Council (MEAR), the Korea Healthcare technology R&D Project, Ministry
for Health, Welfare and Family Affairs, Republic of Korea. (A010252,
A080588) (SCB), the Torsten & Ragnar Soderbergs Foundation (MEAR), the
Swedish Foundation Against Rheumatism (MEAR), the Gustaf
Vth-80th-Year Foundation (MEAR), Plan Nacional de
I+D, Spain (SAF06-00398) (JM), the Junta de Andalucia, grupo CTS-180
(JM) and OHRS award # HR08-037 from the Oklahoma Center for the
Advancement of Science & Technology (JMG). Dr Harley has received
consulting fees, speaking fees and/or director's fees from Bio-Rad
Laboratories, Merck, UCB Inc., ImmunoVision Inc., IVAX Diagnostics and
JK Autoimmunity and owns stock or stock options in IVAX Diagnostics.
NR 29
TC 50
Z9 51
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUL
PY 2009
VL 10
IS 5
BP 397
EP 403
DI 10.1038/gene.2009.19
PG 7
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 472YH
UT WOS:000268168800004
PM 19369946
ER
PT J
AU Douglas, KB
Windels, DC
Zhao, J
Gadeliya, AV
Wu, H
Kaufman, KM
Harley, JB
Merrill, J
Kimberly, RP
Alarcon, GS
Brown, EE
Edberg, JC
Ramsey-Goldman, R
Petri, M
Reveille, JD
Vila, LM
Gaffney, PM
James, JA
Moser, KL
Alarcon-Riquelme, ME
Vyse, TJ
Gilkeson, GS
Jacob, CO
Ziegler, JT
Langefeld, CD
Ulgiati, D
Tsao, BP
Boackle, SA
AF Douglas, K. B.
Windels, D. C.
Zhao, J.
Gadeliya, A. V.
Wu, H.
Kaufman, K. M.
Harley, J. B.
Merrill, J.
Kimberly, R. P.
Alarcon, G. S.
Brown, E. E.
Edberg, J. C.
Ramsey-Goldman, R.
Petri, M.
Reveille, J. D.
Vila, L. M.
Gaffney, P. M.
James, J. A.
Moser, K. L.
Alarcon-Riquelme, M. E.
Vyse, T. J.
Gilkeson, G. S.
Jacob, C. O.
Ziegler, J. T.
Langefeld, C. D.
Ulgiati, D.
Tsao, B. P.
Boackle, S. A.
TI Complement receptor 2 polymorphisms associated with systemic lupus
erythematosus modulate alternative splicing
SO GENES AND IMMUNITY
LA English
DT Article
DE alternative splicing; systemic lupus erythematosus; complement
receptors; single-nucleotide polymorphisms; B cells; follicular
dendritic cells
ID EPSTEIN-BARR-VIRUS; B-LYMPHOCYTES; C3D RECEPTOR; EXON RECOGNITION;
EXPRESSION; CR-2; GENE; CELL; SUSCEPTIBILITY; CD21
AB Genetic factors influence susceptibility to systemic lupus erythematosus (SLE). A recent family-based analysis in Caucasian and Chinese populations provided evidence for association of single-nucleotide polymorphisms (SNPs) in the complement receptor 2 (CR2/CD21) gene with SLE. Here we confirmed this result in a case-control analysis of an independent European-derived population including 2084 patients with SLE and 2853 healthy controls. A haplotype formed by the minor alleles of three CR2 SNPs (rs1048971, rs17615, rs4308977) showed significant association with decreased risk of SLE (30.4% in cases vs 32.6% in controls, P = 0.016, OR = 0.90 (0.82-0.98)). Two of these SNPs are in exon 10, directly 50 of an alternatively spliced exon preferentially expressed in follicular dendritic cells (FDC), and the third is in the alternatively spliced exon. Effects of these SNPs and a fourth SNP in exon 11 (rs17616) on alternative splicing were evaluated. We found that the minor alleles of these SNPs decreased splicing efficiency of exon 11 both in vitro and ex vivo. These findings further implicate CR2 in the pathogenesis of SLE and suggest that CR2 variants alter the maintenance of tolerance and autoantibody production in the secondary lymphoid tissues where B cells and FDCs interact. Genes and Immunity (2009) 10, 457-469; doi: 10.1038/gene.2009.27; published online 23 April 2009
C1 [Boackle, S. A.] Univ Colorado, Denver Sch Med, Div Rheumatol, Aurora, CO 80045 USA.
[Zhao, J.; Wu, H.; Tsao, B. P.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Kaufman, K. M.; Harley, J. B.; Merrill, J.; Gaffney, P. M.; James, J. A.; Moser, K. L.; Alarcon-Riquelme, M. E.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Kaufman, K. M.; Harley, J. B.; Merrill, J.; James, J. A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Kaufman, K. M.; Harley, J. B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
[Kimberly, R. P.; Alarcon, G. S.; Brown, E. E.; Edberg, J. C.] Univ Alabama, Birmingham, AL USA.
[Ramsey-Goldman, R.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Petri, M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Reveille, J. D.] Univ Texas Houston Hlth Sci Ctr, Houston, TX USA.
[Vila, L. M.] Univ Puerto Rico, San Juan, PR 00936 USA.
[Alarcon-Riquelme, M. E.] Uppsala Univ, Uppsala, Sweden.
[Vyse, T. J.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England.
[Gilkeson, G. S.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Jacob, C. O.] Univ So Calif, Los Angeles, CA USA.
[Ziegler, J. T.; Langefeld, C. D.] Wake Forest Univ Hlth Sci, Sect Stat Genet & Bioinformat, Winston Salem, NC USA.
[Ulgiati, D.] Univ Western Australia, Sch Biomed Biomol & Chem Sci, Crawley, WA, Australia.
RP Boackle, SA (reprint author), Univ Colorado, Denver Sch Med, Div Rheumatol, Mail Stop B-115,1775 Aurora Court, Aurora, CO 80045 USA.
EM susan.boackle@ucdenver.edu
RI Vyse, Tim/G-3887-2011; Zhao, Jian/E-6292-2012
OI Kimberly, Robert/0000-0002-5330-3086; Alarcon Riquelme, Marta
Eugenia/0000-0002-7632-4154
FU NIH/NCI Cancer Core [P30 CA046934]; National Institutes of Health (NIH)
[P30 DK57516]; American College of Rheumatology Research and Education
Foundation; Alliance for Lupus Research; US Department of Veterans
Affairs; Kirkland Scholar/Hospital for Special Surgery and
Rheuminations; NIH [NIAID-DAIT-B AA-05-11, N01 AR12253, N01 AR62277, P01
AR049084, P20 RR015577, P20 RR020143, P30 AR053483, P50 AR48940, R01
DE015223, R01 AI31584, R01 AI070983R01 AR42460, R37 AI24717]
FX We thank Dr Raul Torres (National Jewish Health and University of
Colorado Denver School of Medicine) for providing the pL53In vector, Dr
Yong Choi (Ochsner Clinic Foundation) for providing the HK FDC line, and
Carissa Homme and Lauren Kuhlman (University of Colorado Denver School
of Medicine, Aurora, CO, USA) for technical assistance. We also thank Dr
Peter Gregersen (Feinstein Institute for Medical Research, Manhassat,
NY, USA) for contributing DNA samples from control subjects to LLAS, and
the Wake Forest University Health Sciences Center for Public Health
Genomics for assistance with the principal component analysis of the
genotyping data from LLAS1. The pL53In constructs were sequenced by the
University of Colorado Cancer Center DNA Sequencing and Analysis Core
(http://loki.uchsc.edu), which is supported by the NIH/NCI Cancer Core
Support Grant (P30 CA046934). The quality of the RNA samples prepared
from healthy human subjects was evaluated in the University of Colorado
Cancer Center Microarray Core. Quantitative RT-PCR was carried out in
the DERC Molecular Biology Core Facility, which is supported by National
Institutes of Health (NIH) grant P30 DK57516. Other support for this
work included grants from the American College of Rheumatology Research
and Education Foundation, the Alliance for Lupus Research, the US
Department of Veterans Affairs, Kirkland Scholar/Hospital for Special
Surgery and Rheuminations, and NIH (NIAID-DAIT-B AA-05-11, N01 AR12253,
N01 AR62277, P01 AR049084, P20 RR015577, P20 RR020143, P30 AR053483, P50
AR48940, R01 DE015223, R01 AI31584, R01 AI070983R01 AR42460, and R37
AI24717).
NR 44
TC 28
Z9 28
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUL
PY 2009
VL 10
IS 5
BP 457
EP 469
DI 10.1038/gene.2009.27
PG 13
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 472YH
UT WOS:000268168800010
PM 19387458
ER
PT J
AU Namjou, B
Gray-McGuire, C
Sestak, AL
Gilkeson, GS
Jacob, CO
Merrill, JT
James, JA
Wakeland, EK
Li, QZ
Langefeld, CD
Divers, J
Ziegler, J
Moser, KL
Kelly, JA
Kaufman, KM
Harley, JB
AF Namjou, B.
Gray-McGuire, C.
Sestak, A. L.
Gilkeson, G. S.
Jacob, C. O.
Merrill, J. T.
James, J. A.
Wakeland, E. K.
Li, Q-Z
Langefeld, C. D.
Divers, J.
Ziegler, J.
Moser, K. L.
Kelly, J. A.
Kaufman, K. M.
Harley, J. B.
TI Evaluation of C1q genomic region in minority racial groups of lupus
SO GENES AND IMMUNITY
LA English
DT Article
DE C1Q; SLE; genetics
ID COMPLEMENT-SYSTEM; WIDE ASSOCIATION; DISEASE-ACTIVITY; ERYTHEMATOSUS;
POLYMORPHISM; DEFICIENCIES; COMPONENT; MUTATIONS; NEPHRITIS; PATHWAY
AB Complement cascade plasma proteins play a complex role in the etiopathogenesis of systemic lupus erythematosus (SLE). Hereditary C1q deficiency has been strongly related to SLE; however, there are very few published SLE studies that evaluate the polymorphisms of genes encoding for C1q (A, B and C). In this study, we evaluated 17 single nucleotide polymorphisms (SNPs) across 37 kb of C1QA, C1QB and C1QC in a lupus cohort of individuals of the African-American and Hispanic origin. In a case-only analysis, a significant association at multiple SNPs in the C1QA gene was detected in African Americans with kidney nephritis (best P = 4.91 x 10(-6)). In addition, C1QA was associated with SLE in African Americans with a lack of nephritis and accompanying photosensitivity when compared with that in normal controls (P = 6.80 x 10(-6)). A similar trend was observed in the Hispanic subjects (P = 0.003). Quantitative analysis showed that some SNPs in C1q genes might be correlated with C3 complement levels in an additive model among African Americans (best P = 0.0001). The C1QA gene is associated with subphenotypes of lupus in the African-American and Hispanic subjects. Further studies with higher SNP densities in this region and other complement components are necessary to elucidate the complex genetics and phenotypic interactions between complement components and SLE. Genes and Immunity (2009) 10, 517-524; doi: 10.1038/gene.2009.33; published online 14 May 2009
C1 [Namjou, B.; Gray-McGuire, C.; Sestak, A. L.; Merrill, J. T.; James, J. A.; Moser, K. L.; Kelly, J. A.; Kaufman, K. M.; Harley, J. B.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Gilkeson, G. S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA.
[Jacob, C. O.] Univ So Calif, Dept Med, Los Angeles, CA USA.
[Wakeland, E. K.; Li, Q-Z] Univ Texas SW Med Ctr Dallas, Dept Immunol, Dallas, TX USA.
[Langefeld, C. D.; Divers, J.; Ziegler, J.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA.
[Kaufman, K. M.; Harley, J. B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
[James, J. A.; Harley, J. B.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
RP Harley, JB (reprint author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA.
EM john-harley@omrf.org
FU NIH [AR42460, RR015577, AI31584, AR12253, AR48940, DE015223, AR053483,
RR020143, AI062629, AI24717, AR62277, AI50026]; Mary Kirkland
Scholarship; Alliance for Lupus Research; US Department of Veterans
Affairs
FX This work was supported by the NIH (AR42460, RR015577, AI31584, AR12253,
AR48940, DE015223, AR053483, RR020143, AI062629, AI24717, AR62277 and
AI50026, the Mary Kirkland Scholarship, the Alliance for Lupus Research
and the US Department of Veterans Affairs. We thank the participants,
who agreed to take part in this study by donating samples to the various
collections, in particular the Lupus Family Registry and Repository
(LFRR: http://lupus.omrf.org).
NR 29
TC 16
Z9 17
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUL
PY 2009
VL 10
IS 5
BP 517
EP 524
DI 10.1038/gene.2009.33
PG 8
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 472YH
UT WOS:000268168800018
PM 19440201
ER
PT J
AU Guo, L
Deshmukh, H
Lu, R
Vidal, GS
Kelly, JA
Kaufman, KM
Dominguez, N
Klein, W
Kim-Howard, X
Bruner, GR
Scofield, RH
Moser, KL
Gaffney, PM
Dozmorov, IM
Gilkeson, GS
Wakeland, EK
Li, QZ
Langefeld, CD
Marion, MC
Williams, AH
Divers, J
Alarcon, GS
Brown, EE
Kimberly, RP
Edberg, JC
Ramsey-Goldman, R
Reveille, JD
McGwin, G
Vila, LM
Petri, MA
Vyse, TJ
Merrill, JT
James, JA
Nath, SK
Harley, JB
Guthridge, JM
AF Guo, L.
Deshmukh, H.
Lu, R.
Vidal, G. S.
Kelly, J. A.
Kaufman, K. M.
Dominguez, N.
Klein, W.
Kim-Howard, X.
Bruner, G. R.
Scofield, R. H.
Moser, K. L.
Gaffney, P. M.
Dozmorov, I. M.
Gilkeson, G. S.
Wakeland, E. K.
Li, Q-Z
Langefeld, C. D.
Marion, M. C.
Williams, A. H.
Divers, J.
Alarcon, G. S.
Brown, E. E.
Kimberly, R. P.
Edberg, J. C.
Ramsey-Goldman, R.
Reveille, J. D.
McGwin, G., Jr.
Vila, L. M.
Petri, M. A.
Vyse, T. J.
Merrill, J. T.
James, J. A.
Nath, S. K.
Harley, J. B.
Guthridge, J. M.
TI Replication of the BANK1 genetic association with systemic lupus
erythematosus in a European-derived population
SO GENES AND IMMUNITY
LA English
DT Article
DE systemic lupus erythematosus; replication; association; European; BANK1
ID GENOME-WIDE ASSOCIATION; VARIANTS; LINKAGE; ITGAM
AB Systemic lupus erythematosus (SLE) is an autoimmune disease with highly variable clinical presentation. Patients suffer from immunological abnormalities that target T-cell, B-cell and accessory cell functions. B cells are hyperactive in SLE patients. An adapter protein expressed in B cells called BANK1 (B-cell scaffold protein with ankyrin repeats) was reported in a previous study to be associated with SLE in a European population. The objective of this study was to assess the BANK1 genotype phenotype association in an independent replication sample. We genotyped 38 single nucleotide polymorphisms (SNPs) in BANK1 on 1892 European-derived SLE patients and 2652 European-derived controls. The strongest associations with SLE and BANK1 were at rs17266594 (corrected P-value = 1.97 x 10(-5), odds ratio (OR) = 1.22, 95% CI 1.12-1.34) and rs10516487 (corrected P-value = 2.59 x 10(-5), OR = 1.22, 95% CI 1.11-1.34). Our findings suggest that the association is explained by these two SNPs, confirming previous reports that these polymorphisms contribute to the risk of developing lupus. Analysis of patient subsets enriched for hematological, immunological and renal ACR criteria or the levels of autoantibodies, such as anti-RNP A and anti-SmRNP, uncovers additional BANK1 associations. Our results suggest that BANK1 polymorphisms alter immune system development and function to increase the risk for developing lupus. Genes and Immunity (2009) 10, 531-538; doi: 10.1038/gene.2009.18; published online 2 April 2009
C1 [Lu, R.; Vidal, G. S.; Dominguez, N.; Klein, W.; James, J. A.; Guthridge, J. M.] Oklahoma Med Res Fdn, Clin Immunol Program, Oklahoma City, OK 73104 USA.
[Guo, L.; Deshmukh, H.; Kelly, J. A.; Kaufman, K. M.; Kim-Howard, X.; Bruner, G. R.; Scofield, R. H.; Moser, K. L.; Gaffney, P. M.; Dozmorov, I. M.; Nath, S. K.; Harley, J. B.] Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA.
[Guo, L.; James, J. A.; Harley, J. B.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA.
[Kaufman, K. M.; Harley, J. B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
[Gilkeson, G. S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA.
[Wakeland, E. K.; Li, Q-Z] Univ Texas SW Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA.
[Langefeld, C. D.; Marion, M. C.; Williams, A. H.; Divers, J.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA.
[Alarcon, G. S.; Brown, E. E.; Kimberly, R. P.; Edberg, J. C.; McGwin, G., Jr.] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Ramsey-Goldman, R.] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Dept Med, Chicago, IL 60611 USA.
[Reveille, J. D.] Univ Texas Houston Hlth Sci Ctr, Dept Internal Med, Houston, TX USA.
[Vila, L. M.] Univ Puerto Rico, Div Rheumatol, Dept Med, San Juan, PR 00936 USA.
[Petri, M. A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Vyse, T. J.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Rheumatol Sect, London, England.
[Merrill, J. T.] Oklahoma Med Res Fdn, Dept Clin Pharmacol, Oklahoma City, OK 73104 USA.
RP Guthridge, JM (reprint author), Oklahoma Med Res Fdn, Clin Immunol Program, 825 NE 13th St,MS 53, Oklahoma City, OK 73104 USA.
EM guthridgej@omrf.org
RI Vyse, Tim/G-3887-2011
OI Kimberly, Robert/0000-0002-5330-3086
FU National Institutes of Health [RR020143, RR015577, HHSN266200500026C,
AR053483, AI063274, AI031584, AR052125, AR043247]; Kirkland Scholar
awards [AR049084, AR42460, AR12253, AR62277, AI24717, AR48940]; Alliance
for Lupus Research; US Department of Veterans Affairs; OHRS; Oklahoma
Center for the Advancement of Science and Technology [HR08-037]
FX We thank the participants, both patients and controls, who graciously
agreed to take part in these studies by donating samples to the various
collections, including the Lupus Family Registry and Repository (LFRR:
http://lupus.omrf.org), PROFILE, BIOLUPUS, Feinstein Institute for
Medical Research and many other individual or multicenter collaborators.
We also thank the recruitment and technical teams at each of the sample
procurement sites for their important contributions. We acknowledge the
Wake Forest University Health Sciences Center for Public Health Genomics
for support of the data analysis efforts by our Wake Forest University
collaborators. We thank Dr Alarcon-Riquelme for her assistance in
clearly identifying potential overlapping subjects between our
collections to ensure the independence of this study's observed
associations and Dr Peter Gregersen for providing control samples.
Finally, we acknowledge the various funding sources as mentioned below
for their continued support for the collection of samples and the
conduct of this research.; Support: This project was funded by National
Institutes of Health RR020143 (JMG and JBH), RR015577 (JMG, JBH, JAJ),
HHSN266200500026C ( JMG and JAJ), AR053483 ( JMG, SKN and JAJ), AI063274
(PMG), AI031584 ( JBH, JMG, JAJ), AR052125 ( PMG), AR043247 (KLM),
Kirkland Scholar awards ( JBH and JAJ), AR049084 (SKN, JBH, RPK),
AR42460 (JBH), AR12253 (JBH), AR62277 (JBH), AI24717 (JBH), AR48940
(JBH, JAJ), Alliance for Lupus Research (JBH), the US Department of
Veterans Affairs ( JBH) and OHRS award for project number HR08-037 from
the Oklahoma Center for the Advancement of Science and Technology (
JMG). Dr Harley has received consulting fees, speaking fees and/or
director's fees from Bio-Rad Laboratories; Merck; UCB Inc.; ImmunoVision
Inc.; IVAX Diagnostics and JK Autoimmunity and owns stock or stock
options in IVAX Diagnostics.
NR 19
TC 25
Z9 26
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUL
PY 2009
VL 10
IS 5
BP 531
EP 538
DI 10.1038/gene.2009.18
PG 8
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 472YH
UT WOS:000268168800020
PM 19339986
ER
PT J
AU Scheuner, MT
de Vries, H
Kim, B
Meili, RC
Olmstead, SH
Teleki, S
AF Scheuner, Maren T.
de Vries, Han
Kim, Benjamin
Meili, Robin C.
Olmstead, Sarah H.
Teleki, Stephanie
TI Are electronic health records ready for genomic medicine?
SO GENETICS IN MEDICINE
LA English
DT Article
DE electronic health records; family history; genetic tests
ID FAMILY-HISTORY; OPPORTUNITIES; CARE
AB Purpose: The goal of this project was to assess genetic/genomic content in electronic health records. Methods: Semistructured interviews were conducted with key informants. Questions addressed documentation, organization, display, decision support and security of family history and genetic test information, and challenges and opportunities relating to integrating genetic/genomics content in electronic health records. Results: There were 56 participants: 10 electronic health record specialists, 18 primary care clinicians, 16 medical geneticists, and 12 genetic counselors. Few clinicians felt their electronic record met their current genetic/genomic medicine needs. Barriers to integration were mostly related to problems with family history data collection, documentation, and organization. Lack of demand for genetics content and privacy concerns were also mentioned as challenges. Data elements and functionality requirements that clinicians see include: pedigree drawing; clinical decision support for familial risk assessment and genetic testing indications; a patient portal for patient-entered data; and standards for data elements, terminology, structure, interoperability, and clinical decision support rules. Although most said that there is little impact of genetics/genomics on electronic records today, many stated genetics/genomics would be a driver of content in the next 5-10 years. Conclusions: Electronic health records have the potential to enable clinical integration of genetic/genomic medicine and improve delivery of personalized health care; however, structured and standardized data elements and functionality requirements are needed. Genet Med 2009:11(7):510-517.
C1 [Scheuner, Maren T.; de Vries, Han; Kim, Benjamin; Meili, Robin C.; Olmstead, Sarah H.; Teleki, Stephanie] RAND Corp, Santa Monica, CA 90407 USA.
VA Greater Los Angeles Healthcare Syst, Ctrr Excellence Study Healthcare Provider Behav, Sepulveda, CA USA.
Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA.
[Kim, Benjamin] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.
RP Scheuner, MT (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA.
EM Scheuner@rand.org
FU National Institutes of Health [J32 HL 66992]
FX This work was funded by the RAND Corporation through an
investigator-initiated Independent Research & Develo rnent Grant, and
Dr. Kim was supported by a Ruth L. Kirschstein National Research Service
Award from the National Institutes of Health J32 HL 66992). Preliminary
results of this work have been presented at a meeting of the Department
of Health and Human Services American Health Information Community in
February 2008 and a meeting of the American College of Medical Genetics
in March 2008. Dr. Scheuner has a patent pending (US Application No.
20060173717) for a familial risk stratification method and apparatus.
NR 11
TC 28
Z9 29
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1098-3600
J9 GENET MED
JI Genet. Med.
PD JUL
PY 2009
VL 11
IS 7
BP 510
EP 517
DI 10.1097/GIM.0b013e3181a53331
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 472WA
UT WOS:000268162200005
PM 19478682
ER
PT J
AU Lin, AP
Orengo-Nania, S
Braun, UK
AF Lin, Albert P.
Orengo-Nania, Silvia
Braun, Ursula K.
TI Management of chronic open-angle glaucoma in the aging US population
SO GERIATRICS
LA English
DT Article
DE glaucoma; intraocular pressure; optic nerve; prostaglandin analogue;
selective alpha-2 agonist; carbonic anhydrase inhibitor; trabeculectomy;
tube shunt; low vision; blindness
ID PHARMACY CLAIMS DATA; QUALITY-OF-LIFE; INTRAOCULAR-PRESSURE;
UNITED-STATES; ADHERENCE; MEDICATIONS; PERSISTENCE; PREVALENCE; ADULTS
AB Chronic open-angle glaucoma is a leading cause of blindness and visual impairment in older adults. Optic nerve damage and the associated peripheral and subsequent central vision loss are irreversible, but early diagnosis and treatment will give patients the best chance to maintain functional vision and quality of life. Primary care physicians can assist with the diagnosis of glaucoma by making appropriate referrals for routine ophthalmic examinations, especially in patients with risk factors for glaucoma. Medication adherence and persistence may also be enhanced by discussing strategies to improve medication use and efficacy in the primary care setting. Recognition of adverse reactions from glaucoma medications and surgeries will allow proper management of these potentially serious conditions. Patients with advanced visual deficits can still benefit from treatment as well as low-vision and supportive care and should be referred for an ophthalmic evaluation. With an understanding of comprehensive glaucoma management, primary care physicians play an invaluable role in assisting their patients with effective and timely therapy that will result in improved outcomes.
C1 [Lin, Albert P.; Orengo-Nania, Silvia; Braun, Ursula K.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Lin, Albert P.; Orengo-Nania, Silvia; Braun, Ursula K.] Baylor Coll Med, Houston, TX 77030 USA.
RP Lin, AP (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
NR 17
TC 0
Z9 0
U1 0
U2 3
PU ADVANSTAR COMMUNICATIONS INC
PI WOODLAND HILLS
PA 6200 CANOGA AVE, 2ND FLR, WOODLAND HILLS, CA 91367 USA
SN 0016-867X
J9 GERIATRICS
JI Geriatrics
PD JUL
PY 2009
VL 64
IS 7
BP 20
EP +
PG 6
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 470XT
UT WOS:000268016500005
PM 19586087
ER
PT J
AU Oles, D
AF Oles, Deborah
TI Untitled
SO GERIATRICS
LA English
DT Letter
C1 VA Greater LA Hlth Care Syst, Community Living Ctr, Los Angeles, CA USA.
RP Oles, D (reprint author), VA Greater LA Hlth Care Syst, Community Living Ctr, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ADVANSTAR COMMUNICATIONS INC
PI WOODLAND HILLS
PA 6200 CANOGA AVE, 2ND FLR, WOODLAND HILLS, CA 91367 USA
SN 0016-867X
J9 GERIATRICS
JI Geriatrics
PD JUL
PY 2009
VL 64
IS 7
BP 29
EP 29
PG 1
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 470XT
UT WOS:000268016500007
ER
PT J
AU Desai, AA
Nissenson, A
Chertow, GM
Farid, M
Singh, I
Van Oijen, MGH
Esrailian, E
Solomon, MD
Spiegel, BMR
AF Desai, Amar A.
Nissenson, Allen
Chertow, Glenn M.
Farid, Mary
Singh, Inder
Van Oijen, Martijn G. H.
Esrailian, Eric
Solomon, Matthew D.
Spiegel, Brennan M. R.
TI The relationship between laboratory-based outcome measures and mortality
in end-stage renal disease: A systematic review
SO HEMODIALYSIS INTERNATIONAL
LA English
DT Review
DE Hemodialysis; outcomes; end-stage renal disease (ESRD); biomarkers;
systematic review; clinical performance measures
ID CARDIAC TROPONIN-T; C-REACTIVE PROTEIN; CHRONIC-HEMODIALYSIS PATIENTS;
UREA REDUCTION RATIO; PREDICTS ALL-CAUSE; CARDIOVASCULAR MORTALITY;
PRACTICE PATTERNS; DIALYSIS PATIENTS; MAINTENANCE HEMODIALYSIS;
PERITONEAL-DIALYSIS
AB Despite data that traditional laboratory-based outcome measures in dialysis are improving over time, population-based data indicate that mortality rates are not improving in parallel. With increased focus on performance measures based on laboratory-based outcomes (e.g., hematocrit, albumin, and parathyroid hormone), less emphasis has been placed on other markers, some of which may be stronger predictors of mortality. We performed a systematic review to interpret the predictive value of laboratory-based outcome measures in dialysis. We identified studies with data regarding the predictive value of laboratory-based outcomes for mortality in dialysis. We calculated the sample size-weighted pooled relative risk of death with dichotomized "high" vs. "low" levels of each measure. We rank-ordered predictors by scaling the pooled relative risk of each measure by its pooled standard deviation. There were 5171 titles, of which 128 (representing 44 laboratory-based outcomes) were selected. Nine were significantly associated with mortality, in order of decreasing scaled effect size: (1) tumor necrosis factor-alpha, (2) hematocrit, (3) interleukin-6, (4) troponin T, (5) Kt/V(urea), (6) prealbumin, (7) urea reduction ratio, (8) serum albumin, and (9) C-reactive protein. Other oft-cited measures such as calcium phosphate product and parathyroid hormone were not significantly associated with mortality in pooled analysis. Quality improvement efforts to improve traditional laboratory-based outcomes in end-stage renal disease are necessary, but likely insufficient, to improve overall mortality in dialysis. Renewed consideration of cardiovascular, inflammatory, and nutritional markers that are especially strong predictors of mortality may have important implications for risk stratification and targeted therapeutic interventions.
C1 [Farid, Mary; Singh, Inder; Van Oijen, Martijn G. H.; Esrailian, Eric; Solomon, Matthew D.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, VA Ctr Outcomes Res & Educ CORE, Los Angeles, CA 90073 USA.
[Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA.
[Desai, Amar A.] Stanford Univ, Ctr Hlth Policy & Primary Care Outcomes Res, Stanford, CA 94305 USA.
[Nissenson, Allen; Esrailian, Eric; Solomon, Matthew D.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA.
[Desai, Amar A.; Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA.
[Desai, Amar A.; Chertow, Glenn M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Van Oijen, Martijn G. H.] Radboud Univ Nijmegen, Dept Gastroenterol & Hepatol, NL-6525 ED Nijmegen, Netherlands.
RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, VA Ctr Outcomes Res & Educ CORE, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ucla.edu
FU VA HSR&D Research Career Development Award [RCD 03-179-2]; CURE Research
Center (NIH) [2P30 DK 041301-17]; Agency for Healthcare Research and
Quality (AHRQ); Amgen Inc.
FX Dr Spiegel is supported by VA HSR&D Research Career Development Award
RCD 03-179-2 and by the CURE Research Center (NIH 2P30 DK 041301-17). Dr
Desai is supported by a training grant from the Agency for Healthcare
Research and Quality (AHRQ). Support for this investigator-initiated
study was provided by a research grant from Amgen Inc. The principal
investigator, Dr Spiegel, maintained full control over all aspects of
the study design, implementation, data collection, data analysis, data
interpretation, and manuscript preparation. Dr Spiegel had full access
to all of the data in the study and takes responsibility for the
integrity of the data and the accuracy of the data analysis. The
contributions of individual authors is as follows: Amar Desai: Data
collection, data analysis, data interpretation, manuscript preparation,
and manuscript approval. Allen Nissenson: Study design, data
interpretation, manuscript preparation, and manuscript approval. Glenn
Chertow: Data interpretation, manuscript preparation, and manuscript
approval. Mary Farid: Data collection and manuscript approval. Inder
Singh: Data collection and manuscript approval. Martijn van Oijen: Data
collection, manuscript preparation, and manuscript approval. Eric
Esrailian: Study design, data collection, and manuscript approval.
Matthew Solomon: Data interpretation, manuscript preparation, and
manuscript approval. Brennan Spiegel: Study design, study
implementation, data collection, data analysis, data interpretation,
manuscript preparation, manuscript approval, and guarantor of article.
Disclaimer: The opinions and assertions contained herein are the sole
views of the authors and are not to be construed as official or as
reflecting the views of the Department of Veteran Affairs.
NR 117
TC 16
Z9 17
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1492-7535
J9 HEMODIAL INT
JI Hemodial. Int.
PD JUL
PY 2009
VL 13
IS 3
BP 347
EP 359
DI 10.1111/j.1542-4758.2009.00377.x
PG 13
WC Urology & Nephrology
SC Urology & Nephrology
GA 484OZ
UT WOS:000269057200018
PM 19583604
ER
PT J
AU Ioannou, GN
Morrow, OB
Connole, ML
Lee, SP
AF Ioannou, George N.
Morrow, Olivia B.
Connole, Marah L.
Lee, Sum P.
TI Association Between Dietary Nutrient Composition and the Incidence of
Cirrhosis or Liver Cancer in the United States Population
SO HEPATOLOGY
LA English
DT Article
ID FATTY-ACIDS; DISEASE; RISK; HEPATITIS; INJURY; OMEGA-3-FATTY-ACIDS;
STEATOHEPATITIS; CHOLESTEROL; INHIBITION; PREVENTION
AB Little is known about the impact of dietary factors on the progression of liver disease. Our aim was to determine whether dietary intake was associated with the risk of cirrhosis-related or liver cancer-related death or hospitalization in the U.S. population. Participants included 9221 persons aged 25-74 years without evidence of cirrhosis at entry into the study or during the first 5 years of follow-up, who were subsequently followed for a mean of 13.3 years as part of the first National Health and Nutrition Examination Survey. Dietary intake was ascertained at baseline using a 24-hour dietary recall questionnaire. During follow-up, 123 of 9221 participants had a diagnosis of cirrhosis (n = 118) or liver cancer (n = 5) in hospitalization records or death certificates, including 36 who were diagnosed only on the basis of death certificates. Participants who reported a diet high in protein were at a higher risk of hospitalization or death due to cirrhosis or liver cancer (P = 0.001), whereas those who reported a diet high in carbohydrates were at a lower risk (P = 0.003), after adjusting for potential confounders (daily consumption of protein, carbohydrate, fat, tea or coffee, and alcohol, gender, race, age, educational attainment, U.S. geographical region, diabetes, body mass index, and subscapular-to-triceps skinfold ratio). Although total fat consumption was not significantly associated with the risk of cirrhosis or liver cancer, cholesterol consumption was associated with higher risk (P = 0.007), whereas serum cholesterol level was not associated with risk of cirrhosis or liver cancer. Conclusion: Diet may be an important and potentially modifiable determinant of liver disease. (HEPATOLOGY 2009;50:175-184.)
C1 [Ioannou, George N.; Morrow, Olivia B.; Connole, Marah L.; Lee, Sum P.] Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA 98108 USA.
[Ioannou, George N.; Lee, Sum P.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA 98108 USA.
[Ioannou, George N.; Lee, Sum P.] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA.
RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA.
EM georgei@medicine.washington.edu
FU American Liver Foundation and American Association
FX Supported by: American Liver Foundation and American Association for the
Study of Liver Diseases Jan Albrecht Award (to G. N. I).
NR 26
TC 48
Z9 51
U1 0
U2 5
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD JUL
PY 2009
VL 50
IS 1
BP 175
EP 184
DI 10.1002/hep.22941
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 465RW
UT WOS:000267605500020
PM 19441103
ER
PT J
AU Edwards, ER
Spira, AP
Barnes, DE
Yaffe, K
AF Edwards, Emily R.
Spira, Adam P.
Barnes, Deborah E.
Yaffe, Kristine
TI Neuropsychiatric symptoms in mild cognitive impairment: differences by
subtype and progression to dementia
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE mild cognitive impairment; neuropsychiatric symptoms; dementia
ID NURSING-HOME PLACEMENT; ALZHEIMERS-DISEASE; PSYCHIATRIC-SYMPTOMS;
DEPRESSION; MEMORY; PREVALENCE; COMMUNITY; DECLINE; RISK; MCI
AB Background Neuropsychiatric symptoms (NPS) are common in patients with mild cognitive impairment (MCI). Little is known, however, about how NPS vary by MCI subtype (i.e. amnestic, single domain non-memory, and multiple domain). In addition, it is unclear whether NPS increase risk of progression to dementia. We investigated the distribution of NPS across MCI subtypes and determined whether NPS increase risk of progression to dementia.
Method Participants were 521 patients diagnosed with MCI at the Alzheimer's Research Centers of California between 1988 and 1999. At baseline, patients were classified into MCI subtypes and were assessed for NPS.
Results The mean number of NPS was 2.3 (range 0-9.6; 74% had >= 1 NPS). Patients with >= 4 NPS had more medical comorbidities and greater functional impairment (p <= 0.0001 for both). Patients with >= 4 NIPS were more likely than patients with 0-3 NPS to have amnestic MCI (81% vs 71%, respectively, p = 0.03), and patients with amnestic MCI were more likely than those with other subtypes to exhibit depressive symptoms. Patients with >= 4 NPS had nearly 2.5 times the odds of developing dementia at follow-up than patients with 0-3 NPS (adjusted O R= 2.44, 95% CI 1.07, 5.55).
Conclusion NPS are common in MCI patients. Those with an elevated number of NPS may be more likely to have the amnestic subtype of MCI, and depression may be more common in amnestic MCI than in other subtypes. An elevated number of NPS may increase risk of progression to dementia for patients with MCI. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Edwards, Emily R.; Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Barnes, Deborah E.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Spira, Adam P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
RP Spira, AP (reprint author), 624 N Broadway,Hampton House,Rm 794, Baltimore, MD 21205 USA.
EM aspira@jhsph.edu
FU California Department of Health Services [03-75271]; NIH [K24 AG031155,
5 T32 AG000212-15]
FX Supported by ADRCC grant 03-75271 from the California Department of
Health Services, and by NIH grants K24 AG031155, and 5 T32 AG000212-15.
NR 35
TC 25
Z9 27
U1 2
U2 7
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0885-6230
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD JUL
PY 2009
VL 24
IS 7
BP 716
EP 722
DI 10.1002/gps.2187
PG 7
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 466BY
UT WOS:000267636800009
PM 19140134
ER
PT J
AU Conway, B
Miller, RG
Costacou, T
Fried, L
Kelsey, S
Evans, RW
Orchard, TJ
AF Conway, B.
Miller, R. G.
Costacou, T.
Fried, L.
Kelsey, S.
Evans, R. W.
Orchard, T. J.
TI Adiposity and mortality in type 1 diabetes
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
DE type 1 diabetes; mortality; body mass index; underweight; overweight
ID BODY-MASS INDEX; ALL-CAUSE MORTALITY; PROSPECTIVELY STUDIED COHORT;
INTENTIONAL WEIGHT-LOSS; CORONARY-HEART-DISEASE; FAT-FREE MASS;
PITTSBURGH EPIDEMIOLOGY; WAIST CIRCUMFERENCE; FOLLOW-UP; US ADULTS
AB Background: In the general population, adiposity exhibits a J- or U-shaped relationship with mortality; however, in catabolic states this relationship is often inversely linear. We have recently documented an age-independent increase in overweight/obesity in the Pittsburgh Epidemiology of Diabetes Complications Study (EDC) of type 1 diabetes (T1D). As intensified insulin therapy (IIT) may promote weight gain, the impact of weight gain in T1D is of importance. We therefore assessed the association of adiposity with mortality in 655 EDC participants during 20 years of follow-up.
Methods: Individuals were categorized as underweight (body mass index (BMI) <20), normal (20 <= BMI <25), overweight (25 <= BMI <30), or obese (BMI >= 30). Cox models were constructed using BMI and covariates at baseline, updated means during follow-up, time variation (reflecting most recent status), and change during adulthood as predictors of mortality.
Results: The prevalence of IIT (3 + insulin shots daily and/or pump) increased from 7 to 82%. Overweight increased by 47% and obesity increased sevenfold. There were 146 deaths. In unadjusted models, BMI (modeled continuously) showed a quadratic relationship with mortality (P = 0.002, <0.0001 <0.0001 for baseline, updated mean and time-varying models, respectively). However, only in the time-varying model were the obese significantly different from the normal weight, whereas the baseline model showed no differences by BMI category. In both the updated mean and time-varying models, the underweight were at greater risk than were the normal weight (P<0.0001 both models). The nonlinear relationship of adiposity with mortality remained after adjustment for diabetes complications and for biological or socioeconomic/lifestyle risk factors, with the exception of baseline socioeconomic/lifestyle risk factors, in which a linear association emerged. Adjustment for waist circumference eliminated risk in the obese. Finally, weight gain during follow-up was protective.
Conclusion: The relationship of adiposity with mortality in T1D now seems to resemble that of the general population, albeit with a marked increased risk in those who are underweight. International Journal of Obesity (2009) 33, 796-805; doi:10.1038/ijo.2009.75; published online 19 May 2009
C1 [Conway, B.; Miller, R. G.; Costacou, T.; Kelsey, S.; Evans, R. W.; Orchard, T. J.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15217 USA.
[Fried, L.] Univ Dr Div, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Orchard, TJ (reprint author), Univ Pittsburgh, Dept Epidemiol, 3512 5th Ave,2nd Fl, Pittsburgh, PA 15217 USA.
EM OrchardT@edc.pitt.edu
OI orchard, trevor/0000-0001-9552-3215
FU NIDDK NIH HHS [DK34818, R01 DK034818, R01 DK034818-24, R37 DK034818]
NR 56
TC 24
Z9 26
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
J9 INT J OBESITY
JI Int. J. Obes.
PD JUL
PY 2009
VL 33
IS 7
BP 796
EP 805
DI 10.1038/ijo.2009.75
PG 10
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 470BX
UT WOS:000267948800011
PM 19451912
ER
PT J
AU Heinze, E
Baldwin, S
Chan, G
Hansen, J
Song, J
Clements, D
Aragon, R
Nishimura, R
Reeves, M
Weisbart, R
AF Heinze, Emil
Baldwin, Scott
Chan, Grace
Hansen, James
Song, Jason
Clements, Douglas
Aragon, Robert
Nishimura, Robert
Reeves, Mark
Weisbart, Richard
TI Antibody-mediated FOXP3 protein therapy induces apoptosis in cancer
cells in vitro and inhibits metastasis in vivo
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE antibodies; transcription factors; gene regulation; cytotoxicity;
apoptosis
ID REPRESSOR; ENTEROPATHY; ONCOGENE; SCURFIN; MOUSE
AB In addition to its immune suppressive function ill T-regulatory cells, the nuclear transcription factor, FOXP3, has been identified as a tumor suppressor. To evaluate the clinical efficacy of monoclonal antibody (mAb) 31310 Fv antibody-mediated FOXP3 protein therapy of cancer, the Fv-FOXP3 fusion protein produced in Pichia pastoris was tested on breast, ovarian, and colon cancer cells in vitro, and with colon cancer cells in vivo in a mouse model of colon cancer metastasis to liver. Treatment with Fv-FOXP3 resulted in dose-dependent cell death of cancer cells in vitro. Apoptosis was established as a mechanism of cell death by demonstrating increased production of the p17 activated fragment of caspase-3 by cancer cells in response to Fv-FOXP3 and inhibition of cell killing by the caspase inhibitor, Z-VAD-FMK. Fv-FOXP3 treatment resulted in clinically significant reduction in tumor burden in a syngeneic model of colon cancer metastasis to liver in Balb/c mice. These results represent the first demonstration of effective full-length FOXP3 protein therapy and emphasize the clinical potential of mAb 3E10 as an intracellular and intranuclear delivery vehicle of FOXP3 for prevention and treatment of cancer metastasis.
C1 [Heinze, Emil; Chan, Grace; Hansen, James; Song, Jason; Clements, Douglas; Nishimura, Robert; Weisbart, Richard] Vet Affairs Greater Los Angeles Hlth Care Syst, Sepulveda, CA USA.
[Heinze, Emil] Olive View UCLA Med Ctr, Sylmar, CA 91342 USA.
[Baldwin, Scott; Aragon, Robert; Reeves, Mark] Loma Linda Vet Affairs Med Ctr, Loma Linda, CA USA.
RP Weisbart, R (reprint author), Vet Affairs Med Ctr, 111S,16111 Plummer St, Sepulveda, CA 91343 USA.
EM rweisbar@ucla.edu
FU Veterans Affairs; Department of Surgery; Loma Linda University
FX This study was supported by a grant from the Veterans Affairs (R.H.
Weisbart) and a seed grant from the Department of Surgery, Loma Linda
University (M.E. Reeves). We thank Michael Cho for technical assistance
and Dr Joseph Gera for critical reading of the manuscript. E.H. and S.C.
are co-first authors; R.N., M.R., and R.W. are co-senior authors.
NR 12
TC 13
Z9 14
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUL
PY 2009
VL 35
IS 1
BP 167
EP 173
DI 10.3892/ijo_00000325
PG 7
WC Oncology
SC Oncology
GA 460ZH
UT WOS:000267231400019
PM 19513564
ER
PT J
AU Frutkin, AD
Lindsey, JB
Mehta, SK
House, JA
Spertus, JA
Cohen, DJ
Rumsfeld, JS
Marso, SP
AF Frutkin, Andrew D.
Lindsey, Jason B.
Mehta, Sameer K.
House, John A.
Spertus, John A.
Cohen, David J.
Rumsfeld, John S.
Marso, Steven P.
CA NCDR
TI Drug-Eluting Stents and the Use of Percutaneous Coronary Intervention
Among Patients With Class I Indications for Coronary Artery Bypass
Surgery Undergoing Index Revascularization Analysis From the NCDR
(National Cardiovascular Data Registry)
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE percutaneous coronary intervention; coronary artery bypass grafting;
drug-eluting stents
ID UNPROTECTED LEFT MAIN; RANDOMIZED CONTROLLED-TRIAL; OFF-LABEL USE;
2-INSTITUTIONAL COHORT; CLINICAL-PRACTICE; IMPLANTATION; DISEASE;
THROMBOSIS; RESTENOSIS; STENOSIS
AB Objectives Our purpose was to evaluate percutaneous coronary intervention (PCI) attempt rates in patients with class I indications for coronary artery bypass graft (CABG) surgery after the introduction of drug-eluting stents (DES).
Background In patients with severe, multivessel coronary disease, CABG has historically been recommended over PCI. Practice guidelines for CABG were last updated before the emergence of data on DES efficacy.
Methods We analyzed 265,028 procedures from the NCDR (National Cardiovascular Data Registry) meeting American College of Cardiology/American Heart Association class I indications for surgical revascularization. Temporal trends in PCI attempt rates were analyzed during 3 consecutive time periods: pre-DES (before April 1, 2003), DES diffusion (April 1, 2003 to December 31, 2004), and DES (January 1, 2005 to September 30, 2006).
Results The attempted rate of PCI in patients with class I indications for CABG increased over the 3 time periods (pre-DES: 29.4%, DES diffusion: 33.4%, and DES era: 34.7%, p < 0.001). In a hierarchical multivariable logistic model adjusting for patient and PCI site characteristics, PCI attempts were more likely in the DES compared with pre-DES era (odds ratio: 1.44, 95% confidence interval: 1.40 to 1.48) and the DES diffusion era (odds ratio: 1.20, 95% confidence interval: 1.17 to 1.23). PCI attempt rates increased in all 3 time periods, although the average rate of increase during the DES era was 0.6% per quarter compared with 0.3% per quarter for both the DES diffusion and the pre-DES eras (p = 0.03).
Conclusions DES use in clinical practice was associated with a significant overall increase in PCI to treat patients with class I indications for CABG. Long-term follow-up of this cohort of patients is warranted. (J Am Coll Cardiol Intv 2009;2:614-21) (C) 2009 by the American College of Cardiology Foundation
C1 [Frutkin, Andrew D.; Lindsey, Jason B.; Mehta, Sameer K.; House, John A.; Spertus, John A.; Cohen, David J.; Marso, Steven P.] Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64111 USA.
[Rumsfeld, John S.] Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Marso, SP (reprint author), Univ Missouri, Mid Amer Heart Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA.
EM smarso@saint-lukes.org
NR 30
TC 17
Z9 19
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-8798
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD JUL
PY 2009
VL 2
IS 7
BP 614
EP 621
DI 10.1016/j.jcin.2009.05.001
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 613HZ
UT WOS:000278971300006
PM 19628183
ER
PT J
AU Ho, PM
Rumsfeld, JS
Wang, L
AF Ho, P. Michael
Rumsfeld, John S.
Wang, Li
TI Adverse Outcomes Associated With Use of Proton Pump Inhibitors and
Clopidogrel Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Ho, P. Michael; Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
[Wang, Li] Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Ho, PM (reprint author), Denver VA Med Ctr, Denver, CO USA.
EM michael.ho@va.gov
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUL 1
PY 2009
VL 302
IS 1
BP 31
EP 31
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 464GH
UT WOS:000267492800011
ER
PT J
AU Duong, TQ
Muir, ER
AF Duong, Timothy Q.
Muir, Eric R.
TI Magnetic resonance imaging of the retina
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article; Proceedings Paper
CT Closed Symposium on Functional Imaging of the Retina
CY APR 27, 2008
CL Ft Lauderdale, FL
SP Natl Inst Sensory Organs
DE blood flow; blood oxygenation level-dependent (BOLD); fMRI; oxygenation;
retinal diseases
ID CEREBRAL-BLOOD-FLOW; OPTICAL COHERENCE TOMOGRAPHY; HIGH-RESOLUTION;
FUNCTIONAL MRI; RCS RAT; MACAQUE RETINA; SOMATOSENSORY STIMULATION;
QUANTITATIVE PERFUSION; INTRAOCULAR PRESSURES; LAMINAR SPECIFICITY
AB This paper reviews recent developments in high-resolution magnetic resonance imaging (MRI) and its application to image anatomy, physiology, and function in the retina of animals. It describes technical issues and solutions in performing retinal MRI, anatomical MRI, blood oxygenation level-dependent functional MRI (fMRI), and blood-flow MRI both of normal retinas and of retinal degeneration. MRI offers unique advantages over existing retinal imaging techniques, including the ability to image multiple layers without depth limitation and to provide multiple clinically relevant data in a single setting. Retinal MRI has the potential to complement existing retinal imaging techniques.
C1 [Duong, Timothy Q.; Muir, Eric R.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Duong, Timothy Q.] SW Natl Primate Res Ctr, San Antonio, TX USA.
[Muir, Eric R.] Georgia Inst Technol, Grad Program Biomed Engn, Atlanta, GA 30332 USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Ophthalmol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Muir, Eric/H-8830-2013
FU NEI NIH HHS [R01 EY014211-04, R01 EY014211, R01 EY014211-01A1, R01
EY014211-02, R01 EY014211-03, R01 EY014211-05, R01 EY014211-06, R01
EY014211-07, R01 EY014211-08, R01 EY014211-09, R01 EY018855, R01
EY018855-01A1, R01 EY018855-02, R01 EY018855-03]
NR 81
TC 20
Z9 20
U1 0
U2 1
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2009
VL 53
IS 4
BP 352
EP 367
DI 10.1007/s10384-009-0688-1
PG 16
WC Ophthalmology
SC Ophthalmology
GA 496EY
UT WOS:000269953500007
PM 19763752
ER
PT J
AU Thompson, GR
Wiederhold, NP
Sutton, DA
Fothergill, A
Patterson, TF
AF Thompson, George R., III
Wiederhold, Nathan P.
Sutton, Deanna A.
Fothergill, Annette
Patterson, Thomas F.
TI In vitro activity of isavuconazole against Trichosporon, Rhodotorula,
Geotrichum, Saccharomyces and Pichia species
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article; Proceedings Paper
CT 19th Annual Focus on Fungal Infections
CY 2009
CL Ft Myers, FL
DE triazoles; MICs; rare yeasts; Blastoschizomyces capitatum
ID ANTIFUNGAL SUSCEPTIBILITIES; FUNGAL PATHOGENS; ASPERGILLUS; FLUCONAZOLE;
INFECTIONS; CANDIDA
AB Objectives: The emergence of less common, but clinically important, fungal pathogens including the rare yeasts has contributed to the substantial morbidity and mortality observed in immunocompromised patients. These organisms can be resistant or refractory to existing antifungal agents. We sought to evaluate the activity of the new triazole isavuconazole against these difficult pathogens.
Methods: MICs of isavuconazole, voriconazole, posaconazole, fluconazole, amphotericin B and flucytosine were determined for 54 Trichosporon, 7 Geotrichum capitatum, 18 Saccharomyces cerevisiae, 11 Pichia and 14 Rhodotorula species in accordance with the M27-A2 reference method. Minimum fungicidal concentrations were also measured for each agent.
Results: Isavuconazole demonstrated excellent in vitro activity against each species tested. MIC(90) values ranged between 0.125 and 0.25 mg/L against Trichosporon isolates, and between 0.03 and 0.5 mg/L against the other yeast tested. The geometric mean MICs of isavuconazole were similar to those of voriconazole and similar or less than those of posaconazole, fluconazole, amphotericin B and flucytosine for all species tested. This activity was also maintained against one Trichosporon asahii and nine Rhodotorula isolates that were resistant to fluconazole.
Conclusions: Isavuconazole is a welcome addition to the growing antifungal armamentarium with potent in vitro activity against emerging yeast pathogens. Although this agent may be useful in the treatment of the rare yeasts, clinical data are needed to verify these results.
C1 [Thompson, George R., III] UTHSCSA, Med ID, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA.
[Thompson, George R., III; Wiederhold, Nathan P.; Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Wiederhold, Nathan P.] Univ Texas Austin, Coll Pharm, Austin, TX USA.
[Sutton, Deanna A.; Fothergill, Annette] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, Grad Sch Biomed Sci, San Antonio, TX USA.
RP Thompson, GR (reprint author), UTHSCSA, Med ID, Div Infect Dis, Dept Med, 7703 Floyd Curl Dr,MSC 7881, San Antonio, TX 78229 USA.
EM thompsong2@uthscsa.edu
OI Wiederhold, Nathan/0000-0002-2225-5122
NR 10
TC 28
Z9 28
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD JUL
PY 2009
VL 64
IS 1
BP 79
EP 83
DI 10.1093/jac/dkp138
PG 5
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 457VJ
UT WOS:000266962100014
PM 19406849
ER
PT J
AU Darouiche, RO
Mansouri, MD
Gawande, PV
Madhyastha, S
AF Darouiche, Rabih O.
Mansouri, Mohammad D.
Gawande, Purushottam V.
Madhyastha, Srinivasa
TI Antimicrobial and antibiofilm efficacy of triclosan and DispersinB (R)
combination
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
DE infection; catheter; bacteria
ID BIOFILM FORMATION; STAPHYLOCOCCUS-AUREUS; NOSOCOMIAL INFECTIONS;
BACTERIAL BIOFILMS; URINARY CATHETERS; IN-VITRO; DETACHMENT
AB Objectives: The objectives of this study were to examine: (i) synergy of the combination of triclosan and DispersinB (R) (DspB); (ii) in vitro efficacy and durability of triclosan + DspB-coated vascular catheters; and (iii) in vivo efficacy of triclosan + DspB-coated catheters compared with chlorhexidine-silver sulfadiazine (CH-SS)-coated and uncoated (control) vascular catheters in preventing colonization by Staphylococcus aureus.
Methods: We investigated the potential synergistic antimicrobial and antibiofilm activity of triclosan and DspB by biofilm assays. The in vitro antimicrobial efficacy of triclosan + DspB-coated catheters was determined by microbial colonization assays. Antimicrobial durability of the coated catheters was tested by soaking segments in bovine serum for 7 days and determining antimicrobial activity, and by a serial plate transfer method. The in vivo efficacy of triclosan + DspB-coated catheters compared with CH-SS-coated and uncoated catheters was assessed by subcutaneous implantation of segments in a rabbit model of S. aureus infection.
Results: The combination of triclosan and DspB showed synergistic antimicrobial and antibiofilm activity against S. aureus, Staphylococcus epidermidis and Escherichia coli, significantly reduced bacterial colonization (P<0.05) and generally demonstrated a prolonged superior antimicrobial activity against clinical pathogens compared with CH-SS-coated catheters. Triclosan + DspB-coated and CH-SS-coated catheters exhibited equal in vivo efficacy (P <= 0.05) in reducing colonization by S. aureus compared with uncoated catheters.
Conclusions: Catheters coated with the triclosan + DspB combination showed synergistic, broad-spectrum and durable antimicrobial activity. Furthermore, the in vivo efficacy of catheters coated with this unique antimicrobial/antibiofilm composition prompts clinical evaluation of such an innovative approach.
C1 [Darouiche, Rabih O.; Mansouri, Mohammad D.] Michael E Debakey Vet Affairs Med Ctr, Ctr Prostheses Infect, Houston, TX USA.
[Darouiche, Rabih O.; Mansouri, Mohammad D.] Michael E Debakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX USA.
[Darouiche, Rabih O.; Mansouri, Mohammad D.] Baylor Coll Med, Houston, TX 77030 USA.
[Gawande, Purushottam V.; Madhyastha, Srinivasa] Kane Biotech Inc, Winnipeg, MB R3T 6C6, Canada.
RP Darouiche, RO (reprint author), Michael E Debakey Vet Affairs Med Ctr, Ctr Prostheses Infect, Houston, TX USA.
EM rdarouiche@aol.com
RI Gawande, Purushottam/C-5487-2014
OI Gawande, Purushottam/0000-0001-8675-9293
FU Kane Biotech Inc.; Winnipeg, MB, Canada
FX Kane Biotech Inc., Winnipeg, MB, Canada provided funds for conducting
this study.
NR 24
TC 68
Z9 70
U1 5
U2 31
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD JUL
PY 2009
VL 64
IS 1
BP 88
EP 93
DI 10.1093/jac/dkp158
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 457VJ
UT WOS:000266962100016
PM 19447791
ER
PT J
AU Sato, M
Ito, Y
Arima, N
Baba, M
Sobel, M
Wakao, M
Suda, Y
AF Sato, Masaki
Ito, Yuji
Arima, Naomichi
Baba, Masanori
Sobel, Michael
Wakao, Masahiro
Suda, Yasuo
TI High-Sensitivity Analysis of Naturally Occurring Sugar Chains, Using a
Novel Fluorescent Linker Molecule
SO JOURNAL OF BIOCHEMISTRY
LA English
DT Article
DE immobilization; sugar chain; high sensitivity; analysis; fluorescence;
linker molecule; mass spectrometry
ID SURFACE-PLASMON RESONANCE; PERFORMANCE LIQUID-CHROMATOGRAPHY;
MASS-SPECTROMETRY; OLIGOSACCHARIDES; GLYCOMICS; IMMOBILIZATION;
STRATEGY; GLYCANS
AB To analyse the binding of sugar chains to proteins, viruses and cells, the surface plasmon resonance (SPR) technique is very convenient and effective because it is a real-time, non-destructive detection system. Key to this method is linker compounds for immobilization of the sugar chains to the gold-coated chip for SPR. Also, well-designed fluorescent labelling reagents are essential when analysing the structure of trace amounts of sugar chains derived from natural sources, such as glycoproteins on the surface of specific cells. In this report, we developed a novel linker molecule, named 'f-mono', which has both of these properties: simple immobilization chemistry and a fluorescent label. Since the molecule contains a 2,5-diaminopyridyl group and a thioctic acid group, conjugation with sugar chains can be achieved using the well-established reductive amination reaction. This conjugate of sugar chain and fluorescent linker (fluorescent ligand-conjugate, FLC) has fluorescent properties (ex. 335 nm, em. 380 nm), and as little as 1 mu g of FLC can be easily purified using HPLC with a fluorescent detector. MS and MS/MS analysis of the FLC is also possible. As a +2 Da larger MS peak ([M + H + 2](+) ion) was always associated with the theoretical MS peak ([M + H](+)) (due to the reduction of the thioctic acid moiety), the MS peaks of the FLC were easily found, even using unfractionated crude samples. Immobilization of the FLC onto gold-coated chips, and their subsequent SPR analyses were successively accomplished, as had been performed previously using non-fluorescent ligand conjugates.
C1 [Sato, Masaki; Wakao, Masahiro; Suda, Yasuo] Kagoshima Univ, Grad Sch Sci & Engn, Dept Nanostruct & Adv Mat, Kagoshima 8900065, Japan.
[Ito, Yuji] Kagoshima Univ, Grad Sch Sci & Engn, Dept Bioengn, Kagoshima 8900065, Japan.
[Arima, Naomichi; Baba, Masanori] Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Kagoshima 8900065, Japan.
[Sobel, Michael] Univ Washington, Sch Med, Seattle, WA USA.
[Sobel, Michael] VA Puget Sound HCS, Dept Surg, Seattle, WA USA.
[Suda, Yasuo] SUDx Biotec Corp, Kagoshima 8900013, Japan.
RP Suda, Y (reprint author), Kagoshima Univ, Grad Sch Sci & Engn, Dept Nanostruct & Adv Mat, 1-21-40 Kohrimoto, Kagoshima 8900065, Japan.
EM ysuda@eng.kagoshima-u.ac.jp
RI Baba, Masanori/G-3867-2011
FU Frontier Science Research Center (FSRC); Japan Science and Technology
Agency; Japanese Hyogo Prefecture; National Institutes of Health, NHLBI
[HL079182]
FX The Frontier Science Research Center (FSRC) of Kagoshima University (to
Y. S.); Japan Science and Technology Agency (to Y. S.); Japanese Hyogo
Prefecture (to Y. S.); and the National Institutes of Health, NHLBI
(HL079182 to M. S.).
NR 25
TC 7
Z9 7
U1 1
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0021-924X
J9 J BIOCHEM
JI J. Biochem.
PD JUL
PY 2009
VL 146
IS 1
BP 33
EP 41
DI 10.1093/jb/mvp041
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 469IF
UT WOS:000267889000006
PM 19270055
ER
PT J
AU Cusi, K
AF Cusi, Kenneth
TI Thiazolidinediones in NASH An Odd Couple Meant To Be?
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Editorial Material
ID PLACEBO-CONTROLLED TRIAL; NONALCOHOLIC STEATOHEPATITIS; PIOGLITAZONE;
ROSIGLITAZONE; THERAPY
C1 [Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabet, San Antonio, TX 78284 USA.
[Cusi, Kenneth] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
RP Cusi, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabet, Room 3-380S,7703 Floyd Curl Dr, San Antonio, TX 78284 USA.
EM cusi@uthscsa.edu
NR 16
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0192-0790
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD JUL
PY 2009
VL 43
IS 6
BP 503
EP 505
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 461LN
UT WOS:000267268600001
PM 19384246
ER
PT J
AU Shores, MM
Kivlahan, DR
Sadak, TI
Li, EJ
Matsumoto, AM
AF Shores, Molly M.
Kivlahan, Daniel R.
Sadak, Tatiana I.
Li, Ellen J.
Matsumoto, Alvin M.
TI A Randomized, Double-Blind, Placebo-Controlled Study of Testosterone
Treatment in Hypogonadal Older Men With Subthreshold Depression
(Dysthymia or Minor Depression)
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article; Proceedings Paper
CT 6th World Congress on the Aging Male
CY FEB 21-24, 2008
CL Tampa, FL
ID NORMALIZES ANDROGEN LEVELS; CONTROLLED CLINICAL-TRIAL; PRIMARY-CARE
PATIENTS; QUALITY-OF-LIFE; REPLACEMENT THERAPY; SEXUAL FUNCTION; MAJOR
DEPRESSION; BODY-COMPOSITION; BIOAVAILABLE TESTOSTERONE; REFRACTORY
DEPRESSION
AB Objective: Hypogonadism and subthreshold depression are common conditions in elderly men. The objective of this study was to examine the effect of testosterone treatment in older, hypogonadal men with subthreshold depression.
Method: A randomized, double-blind, placebo-controlled study was conducted at a university-affiliated Veterans Affairs Medical Center among men aged 50 years or older (N = 33) with screening total testosterone levels of <= 280 ng/dL and subthreshold depression (dysthymia or minor depression, according to DSM-IV). Recruitment for the study was conducted from November 2002 through May 2005. Participants received either 7.5 g of testosterone gel or placebo gel daily for 12 weeks, followed by a 12-week open-label extension phase during which all subjects received 7.5 g of testosterone gel. The primary outcome measure was the change in the Hamilton Rating Scale for Depression (HAM-D) score from baseline to the end of the double-blind phase. Secondary outcome measures were remission of subthreshold depression (defined a priori as a HAM-D score <= 7) and changes in the Hopkins Symptom Checklist depression scale, the Medical Outcomes Study 36-Item Short-Form Health Survey, and the short-form 16-item Quality of Life Enjoyment and Satisfaction Questionnaire.
Results: At the end of the double-blind phase, testosterone-treated men had a greater reduction in HAM-D scores (p = .024) and a higher remission rate of subthreshold depression (52.9% vs. 18.8%, p = .041) than did placebo-treated men, but there were no differences in other secondary outcome measures between groups. At the end of the open-label phase, the testosterone group had sustained improvement, the control group improved, and there were no differences between groups in any outcome measures.
Conclusion: These results suggest that testosterone replacement may be efficacious treatment for subthreshold depression in older men with hypogonadism. Larger studies are needed to corroborate these findings.
C1 [Shores, Molly M.; Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA.
[Kivlahan, Daniel R.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA.
[Shores, Molly M.; Kivlahan, Daniel R.; Li, Ellen J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Sadak, Tatiana I.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA.
[Matsumoto, Alvin M.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
RP Shores, MM (reprint author), VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, 1660 S Columbian Way,S-182GRECC, Seattle, WA 98108 USA.
EM mxs@u.washington.edu
NR 66
TC 56
Z9 60
U1 2
U2 6
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 240008, MEMPHIS, TN 38124 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUL
PY 2009
VL 70
IS 7
BP 1009
EP 1016
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 477KV
UT WOS:000268518900010
PM 19653976
ER
PT J
AU Kim, TH
Moon, JH
Savard, CE
Kuver, R
Lee, SP
AF Kim, Tae-Hyeon
Moon, Jong Ho
Savard, Christopher E.
Kuver, Rahul
Lee, Sum P.
TI Effects of lipopolysaccharide on platelet-derived growth factor isoform
and receptor expression in cultured rat common bile duct fibroblasts and
cholangiocytes
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE cholangitis; extrahepatic biliary system; fibrosis
ID GALLBLADDER EPITHELIAL-CELLS; PACLITAXEL-INCORPORATED MEMBRANE;
CHOLESTATIC LIVER-INJURY; HEPATIC STELLATE CELLS; PDGF-BETA-RECEPTOR;
LONG-TERM CULTURE; OBSTRUCTIVE-JAUNDICE; BILIARY FIBROSIS; ALPHA;
HEPATOLITHIASIS
AB Background and Aim:
Little is known about the role of platelet-derived growth factor (PDGF) in biliary fibrosis in the setting of bacterial colonization of the biliary tree. We therefore sought to investigate whether exposure to bacterial lipopolysaccharide (LPS) alters PDGF isoform and receptor expression in cultured rat common bile duct fibroblasts (CBDF) and normal rat cholangiocytes (NRC).
Methods:
Collagen content in cells and media was assessed by colorimetric assay and gel electrophoresis. mRNA levels of PDGF-A and -B, and PDGF-Receptors (PDGF-R) alpha and beta were measured by relative quantitative real-time PCR. Protein levels of PDGF-AA, AB and BB were measured by ELISA, and PDGF-R alpha and PDGF-R beta by Western blot.
Results:
In CBDF, LPS increased total soluble collagen synthesis and secretion. PDGF-R alpha and beta mRNA and protein were also increased by LPS treatment in CBDF. Lipopolysaccharide treatment elicited an increase in PDGF-A and -B mRNA levels in CBDF. In NRC, levels of PDGF-A mRNA increased in a dose-dependent fashion following LPS treatment, whereas PDGF-B mRNA showed no response. PDGF-AA secretion was higher by CBDF than by NRC. PDGF-BB levels were also higher in CBDF than in NRC. While PDGF-BB levels did not respond to LPS treatment in CBDF, there was a dose-dependent response of this isoform to LPS in NRC. Intracellular and secreted PDGF-AB increased with LPS treatment in NRC.
Conclusions:
These results support a model in which chronic bacterial colonization of the biliary tree induces fibrosis through PDGF-dependent mechanisms.
C1 [Kuver, Rahul] Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA.
[Kim, Tae-Hyeon; Moon, Jong Ho; Savard, Christopher E.; Kuver, Rahul] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA.
[Lee, Sum P.] Univ Hong Kong, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
RP Kuver, R (reprint author), Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Box 356424,1959 NE Pacific St, Seattle, WA 98195 USA.
EM kuver@u.washington.edu
RI Lee, Sum Ping/C-4333-2009
FU Merit Review Award from the Department of Veterans Affairs; Wonkwang
Institute of Clinical Medicine, Iksan, South Korea
FX We thank J. Donald Ostrow for critical reading of the manuscript. This
work was supported by a Merit Review Award from the Department of
Veterans Affairs. Dr. Tae-Hyeon Kim was supported by the Wonkwang
Institute of Clinical Medicine, Iksan, South Korea.
NR 27
TC 3
Z9 4
U1 0
U2 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0815-9319
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD JUL
PY 2009
VL 24
IS 7
BP 1218
EP 1225
DI 10.1111/j.1440-1746.2008.05729.x
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 476QH
UT WOS:000268456900013
PM 19691150
ER
PT J
AU Kertesz, SG
Hwang, SW
Irwin, J
Ritchey, FJ
LaGory, ME
AF Kertesz, Stefan G.
Hwang, Stephen W.
Irwin, Jay
Ritchey, Ferris J.
LaGory, Mark E.
TI Rising Inability to Obtain Needed Health Care Among Homeless Persons in
Birmingham, Alabama (1995-2005)
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article; Proceedings Paper
CT 31st Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 09-12, 2008
CL Pittsburgh, PA
SP Soc Gen Internal Med
DE homeless persons; access to care; safety net; survey
ID SUBSTANCE-ABUSE SERVICES; SAFETY-NET PROVIDERS; MEDICAL-CARE;
MENTAL-HEALTH; UNMET NEED; URBAN HOMELESS; LOS-ANGELES; NEW-YORK;
DRUG-USE; ADULTS
AB Homeless persons depend disproportionately on the health-care safety net for medical services. National reports identify financial strains to this safety net. Whether this has affected homeless persons is unknown.
We quantified changes in the proportion of homeless persons reporting unmet need for health care in Birmingham, Alabama, comparing two periods, 1995 and 2005. We assessed whether a period effect was independent of characteristics of persons surveyed.
Analysis of two surveys conducted with identical methods among representative samples of homeless persons in 1995 (n = 161) and 2005 (n = 161).
Report of unmet need (inability to obtain care when needed) was the dependent variable. Two survey periods (1995 and 2005) were compared, with multivariable adjustment for sociodemographic and health characteristics. Reasons for unmet need were determined among the subset of persons reporting unmet need.
Unmet need for health care was more common in 2005 (54%) than in 1995 (32%) (p < 0.0001), especially for non-Blacks (64%) and females (65%). Adjusting for individual characteristics, a survey year of 2005 independently predicted unmet need (odds ratio 2.68, 95% CI 1.49-4.83). Among persons reporting unmet need (87 of 161 in 2005; 52 of 161 in 1995), financial barriers were more commonly cited in 2005 (67% of 87) than in 1995 (42% of 52) (p = 0.01).
A rise in unmet health-care needs was reported among Birmingham's homeless from 1995 to 2005. This period effect was independent of population characteristics and may implicate a local safety net inadequacy. Additional data are needed to determine if this represents a national trend.
C1 [Kertesz, Stefan G.] Univ Alabama, Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL 35294 USA.
[Kertesz, Stefan G.] Univ Alabama, Div Prevent Med, Birmingham, AL USA.
[Hwang, Stephen W.] St Michaels Hosp, Ctr Res Inner City Hlth, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada.
[Hwang, Stephen W.] Univ Toronto, Dept Med, Div Gen Internal Med, Toronto, ON, Canada.
[Irwin, Jay; Ritchey, Ferris J.; LaGory, Mark E.] Univ Alabama, Dept Sociol, Birmingham, AL 35294 USA.
RP Kertesz, SG (reprint author), Univ Alabama, Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL 35294 USA.
EM skertesz@uab.edu
RI Hwang, Stephen/D-2297-2011
OI Hwang, Stephen/0000-0002-1276-1101; Kertesz, Stefan/0000-0001-6101-8421
FU NIDA NIH HHS [K23 DA015487, K23-DA-015487]
NR 50
TC 10
Z9 10
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2009
VL 24
IS 7
BP 841
EP 847
DI 10.1007/s11606-009-0990-0
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 457RB
UT WOS:000266948900010
PM 19415393
ER
PT J
AU Bradley, KA
Kivlahan, DR
Williams, EC
AF Bradley, Katharine A.
Kivlahan, Daniel R.
Williams, Emily C.
TI Brief Approaches to Alcohol Screening: Practical Alternatives for
Primary Care
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
ID IDENTIFICATION TEST AUDIT; PROBLEM DRINKING; USE DISORDERS; RISK
DRINKING; CONSUMPTION; QUESTIONNAIRE; VALIDATION; HEALTH; SCORES; MISUSE
C1 [Bradley, Katharine A.; Kivlahan, Daniel R.; Williams, Emily C.] VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA 98101 USA.
[Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA 98101 USA.
[Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA.
[Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Bradley, Katharine A.; Williams, Emily C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
RP Bradley, KA (reprint author), VA Puget Sound Hlth Care Syst, HSR&D, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM Katharine.bradley@va.gov
NR 34
TC 30
Z9 30
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2009
VL 24
IS 7
BP 881
EP 883
DI 10.1007/s11606-009-1014-9
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 457RB
UT WOS:000266948900017
PM 19495888
ER
PT J
AU Sautter, FJ
Glynn, SM
Thompson, KE
Franklin, L
Han, XT
AF Sautter, Frederic J.
Glynn, Shirley M.
Thompson, Karin E.
Franklin, Laurel
Han, Xiaotong
TI A Couple-Based Approach to the Reduction of PTSD Avoidance Symptoms:
Preliminary Findings
SO JOURNAL OF MARITAL AND FAMILY THERAPY
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; MALE VIETNAM VETERANS; LONGITUDINAL
COURSE; YOUNG-ADULTS; RISK-FACTORS; THERAPY; EXPOSURE; BURDEN
AB This study reports preliminary findings regarding the feasibility and efficacy of a novel couple-based treatment, named Strategic Approach Therapy (SAT), for reducing avoidance symptoms of posttraumatic stress disorder (PTSD). Six male Vietnam combat veterans diagnosed with PTSD and their cohabitating marital partners participated in 10 weeks of SAT treatment. Self-report, clinician ratings, and partner ratings of PTSD symptoms were obtained before the first session and after the tenth session of treatment. Veterans reported statistically significant reductions in self-reported, clinician-rated, and partner-rated effortful avoidance, emotional numbing, and overall PTSD severity. These data indicate that SAT offers promise as an effective treatment for PTSD avoidance symptoms.
C1 [Sautter, Frederic J.] Mental Hlth Serv Line, SE Louisiana Vet Hlth Care Syst, New Orleans, LA 70161 USA.
[Glynn, Shirley M.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA.
[Thompson, Karin E.] Vet Affairs Med Ctr, PTSD Program, Memphis, TN USA.
[Franklin, Laurel] SE Louisiana Vet Hlth Care Syst, OEF OIF Trauma Recovery Program, PTSD Program, New Orleans, LA USA.
[Glynn, Shirley M.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA.
[Sautter, Frederic J.; Han, Xiaotong] S Cent Mental Illness Res Educ & Clin Ctr, Little Rock, AR USA.
RP Sautter, FJ (reprint author), Mental Hlth Serv Line, SE Louisiana Vet Hlth Care Syst, POB 61011, New Orleans, LA 70161 USA.
EM fredericsautter@msn.com
NR 27
TC 32
Z9 32
U1 0
U2 2
PU AMER ASSOC MARRIAGE FAMILY THERAPY
PI ALEXANDRIA
PA 112 SOUTH ALFRED ST, ALEXANDRIA, VA 22314 USA
SN 0194-472X
J9 J MARITAL FAM THER
JI J. Marital Fam. Ther.
PD JUL
PY 2009
VL 35
IS 3
BP 343
EP 349
DI 10.1111/j.1752-0606.2009.00125.x
PG 7
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA 456TZ
UT WOS:000266875600006
PM 19522786
ER
PT J
AU Seo, DW
Lopez-Meraz, ML
Allen, S
Wasterlain, CG
Niquet, J
AF Seo, Dae-Won
Lopez-Meraz, Maria-Leonor
Allen, Suni
Wasterlain, Claude Guy
Niquet, Jerome
TI Contribution of a Mitochondrial Pathway to Excitotoxic Neuronal Necrosis
SO JOURNAL OF NEUROSCIENCE RESEARCH
LA English
DT Article
DE glutamate; mitochondrial swelling; cytochrome c; caspase-3; primary
cortical culture
ID TRANSIENT CEREBRAL-ISCHEMIA; GLUTAMATE-INDUCED APOPTOSIS; CYTOCHROME-C
RELEASE; CEREBROCORTICAL NEURONS; EQUINE ESTROGENS; CORTICAL-NEURONS;
INDUCED SEIZURES; CELL-DEATH; CASPASE; ACTIVATION
AB It is traditionally thought that excitotoxic necrosis is a passive mechanism that does not require the activation of a cell death program. In this study, we examined the contribution of the cytochrome c-dependent mitochondrial death pathway to excitotoxic neuronal necrosis, induced by exposing cultured cortical neurons to 1 mM glutamate for 6 hr and blocked by the NMDA antagonist, dizocilpine. Glutamate treatment induced early cytochrome c release, followed by activation of caspase-9 and caspase-3. Preincubation with the caspase-9 inhibitor z-LEHD-fmk, the caspase-3 inhibitor z-DEVD-fmk, or the specific pan-caspase inhibitor Q-VD-oph decreased the percentage of propidium iodide-positive neurons (52.5% +/- 3.1%, 39.4% +/- 3.5%, 44.6% +/- 3%, respectively, vs. 65% +/- 3% in glutamate + vehicle). EM studies showed mitochondrial release of cytochrome c in neurons in the early stages of necrosis and cleaved caspase-3 immunoreactivity in morphologically necrotic neurons. These results suggest that an active mechanism contributes to the demise of a sub-population of excitotoxic necrotic neurons. (C) 2009 Wiley-Liss, Inc.
C1 [Lopez-Meraz, Maria-Leonor; Wasterlain, Claude Guy; Niquet, Jerome] Vet Affairs Greater Los Angeles Healthcare Syst 1, Epilepsy Res Labs, Los Angeles, CA USA.
[Seo, Dae-Won; Lopez-Meraz, Maria-Leonor; Allen, Suni; Wasterlain, Claude Guy; Niquet, Jerome] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Seo, Dae-Won] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea.
[Wasterlain, Claude Guy] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA.
RP Niquet, J (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab 151, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jniquet@ucla.edu
FU Veterans Health Administration; NINDS, National Institutes of Health
[RO1 NS13515]
FX Contract grant sponsor: Research Service of the Veterans Health
Administration; Contract grant sponsor: NINDS, National Institutes of
Health; Contract grant number: RO1 NS13515.
NR 35
TC 11
Z9 11
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0360-4012
J9 J NEUROSCI RES
JI J. Neurosci. Res.
PD JUL
PY 2009
VL 87
IS 9
BP 2087
EP 2094
DI 10.1002/jnr.22035
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 451KE
UT WOS:000266468300013
PM 19235896
ER
PT J
AU Hattori, N
Swan, M
Stobbe, GA
Uomoto, JM
Minoshima, S
Djang, D
Krishnananthan, R
Lewis, DH
AF Hattori, Naoya
Swan, Megan
Stobbe, Gary A.
Uomoto, Jay M.
Minoshima, Satoshi
Djang, David
Krishnananthan, Ruben
Lewis, David H.
TI Differential SPECT Activation Patterns Associated with PASAT Performance
May Indicate Frontocerebellar Functional Dissociation in Chronic Mild
Traumatic Brain Injury
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE traumatic brain injury; cognitive fatigue; SPECT; activation study;
PASAT
ID SERIAL ADDITION TEST; WORKING-MEMORY; HEAD-INJURY; RECOVERY; MODERATE;
FATIGUE; DISEASE; TASK; FMRI
AB Patients with mild traumatic brain injury (TBI) often complain of cognitive fatigue during the chronic recovery phase. The Paced Auditory Serial Addition Test (PASAT) is a complex psychologic measure that may demonstrate subtle deficiencies in higher cognitive functions. The purpose of this study was to investigate the brain activation of regional cerebral blood flow (rCBF) with PASAT in patients with mild TBI to explore mechanisms for the cognitive fatigue. Methods: Two groups consisting of 15 patients with mild TBI and 15 healthy control subjects underwent (99m)Tc-ethylene cysteine dimer SPECT at rest and during PASAT on a separate day. Cortical rCBF was extracted using a 3-dimensional stereotactic surface projection and statistically analyzed to identify areas of activation, which were compared with PASAT performance scores. Results: Image analysis demonstrated a difference in the pattern of activation between patients with mild TBI and healthy control subjects. Healthy control subjects activated the superior temporal cortex (Brodmann area [BA] 22) bilaterally, the precentral gyrus (BA 9) on the left, and the precentral gyrus (BA 6) and cerebellum bilaterally. Patients with mild TBI demonstrated a larger area of supratentorial activation (BAs 9, 10, 13, and 46) but a smaller area of activation in the cerebellum, indicating frontocerebellar dissociation. Conclusion: Patients with mild TBI and cognitive fatigue demonstrated a different pattern of activation during PASAT. Frontocerebellar dissociation may explain cognitive impairment and cognitive fatigue in the chronic recovery phase of mild traumatic brain injury.
C1 [Hattori, Naoya; Minoshima, Satoshi; Krishnananthan, Ruben; Lewis, David H.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA.
[Swan, Megan] Seattle Pacific Univ, Dept Psychol, Seattle, WA 98119 USA.
[Stobbe, Gary A.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA.
[Uomoto, Jay M.] VA Puget Sound Hlth Care Syst, Ctr Polytrauma Care, Dept Neuropsychol, Seattle, WA USA.
[Djang, David] Seattle Nucl Med, Dept Nucl Med, Seattle, WA USA.
RP Hattori, N (reprint author), Univ Washington, Sch Med, Dept Radiol, Box 356113,1959 NE Pacific St, Seattle, WA 98195 USA.
EM nhattori@u.washington.edu
RI Hattori, Naoya/G-2298-2012
NR 28
TC 16
Z9 16
U1 1
U2 3
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
J9 J NUCL MED
JI J. Nucl. Med.
PD JUL
PY 2009
VL 50
IS 7
BP 1054
EP 1061
DI 10.2967/jnumed.108.060368
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 529VO
UT WOS:000272547100015
PM 19525460
ER
PT J
AU Morinelli, TA
Kendall, RT
Luttrell, LM
Walker, LP
Ullian, ME
AF Morinelli, Thomas A.
Kendall, Ryan T.
Luttrell, Louis M.
Walker, Linda P.
Ullian, Michael E.
TI Angiotensin II-Induced Cyclooxygenase 2 Expression in Rat Aorta Vascular
Smooth Muscle Cells Does Not Require Heterotrimeric G Protein Activation
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID SURAMIN ANALOGS; KINASE CASCADE; AT(1) RECEPTOR; TRANSCRIPTION;
ENDOCYTOSIS; MASTOPARAN; BRAIN
AB Angiotensin II (AngII) initiates cellular effects via its G protein-coupled angiotensin 1 (AT(1)) receptor (AT(1)R). Previously, we showed that AngII-induced expression of the prostanoid-producing enzyme cyclooxygenase 2 (COX-2) was dependent upon nuclear trafficking of activated AT(1)R. In the present study, mastoparan (an activator of G proteins), suramin (an inhibitor of G proteins), 1-[6-[[17 beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U73122; a specific inhibitor of phospholipase C), and sarcosine(1)-Ile(4)-Ile(8)-AngII (SII-AngII; a G protein-independent AT(1)R agonist) were used to determine the involvement of G proteins and AT(1A)R trafficking in AngII-stimulated COX-2 protein expression in human embryonic kidney-293 cells stably expressing AT(1A)/green fluorescent protein receptors and cultured vascular smooth muscle cells, respectively. Mastoparan alone stimulated release of intracellular calcium and increased COX-2 expression. Preincubation with mastoparan inhibited AngII-induced calcium signaling without altering AngII-induced AT(1A)R trafficking, p42/44 extracellular signal-regulated kinase (ERK) activation, or COX-2 expression. Suramin or U73122 had no significant effect on their own; they did not inhibit AngII-induced AT(1A)R trafficking, p42/44 ERK activation, or COX-2 expression; but they did inhibit AngII-induced calcium responses. SII-AngII stimulated AT(1A)R trafficking and increased COX-2 protein expression without activating intracellular calcium release. These data suggest that G protein activation results in increased COX-2 protein expression, but AngII-induced COX-2 expression seems to occur independently of G protein activation.
C1 [Morinelli, Thomas A.; Walker, Linda P.; Ullian, Michael E.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
[Kendall, Ryan T.; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Div Endocrinol, Charleston, SC 29425 USA.
[Morinelli, Thomas A.; Luttrell, Louis M.; Ullian, Michael E.] Ralph H Johnson Vet Adm Hosp, Charleston, SC USA.
RP Morinelli, TA (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 829 Clin Sci Bldg,96 Jonathan Lucas St, Charleston, SC 29425 USA.
EM morinelt@musc.edu
FU Dialysis Clinic Incorporated [C-2342A]; Department of Veteran's Affairs
Research Enhancement Award Program [0013]
FX This work was supported by Dialysis Clinic Incorporated [Grant C-2342A]
(research awards); and the Department of Veteran's Affairs Research
Enhancement Award Program [Grant 0013].
NR 23
TC 9
Z9 11
U1 0
U2 0
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD JUL
PY 2009
VL 330
IS 1
BP 118
EP 124
DI 10.1124/jpet.109.151829
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 461PL
UT WOS:000267280300013
PM 19351865
ER
PT J
AU Mohamed, OA
Hamed, HA
Roaiah, MF
Helmy, T
Mahran, A
Bennett, CJ
AF Mohamed, Osama A.
Hamed, Hamed A.
Roaiah, Mohamed Farid
Helmy, Tarek
Mahran, Ali
Bennett, Carol J.
TI Vascular Risk Factors as Predictors of Sexual Function Following
Coronary Artery Bypass Graft
SO JOURNAL OF SEXUAL MEDICINE
LA English
DT Article
DE Cardiovascular Risk Factors; Coronary Artery Bypass Grafting; Sexual
Function Following Coronary Artery Bypass Grafting
ID ERECTILE DYSFUNCTION; OFF-PUMP; DISEASE; EPIDEMIOLOGY; IMPOTENCE;
SURGERY
AB Introduction.
A strong association between cardiovascular risk factors and erectile dysfunction (ED) was suggested. Coronary artery bypass grafting (CABG) is the gold standard for surgical myocardial revascularization.
Aim.
We herein evaluate the impact of vascular risk factors on postoperative sexual functions in patients undergo CABG.
Main Outcome Measures.
ED severity by the International Index of Erectile Function (IIEF-5) and penile duplex study.
Methods.
The present study included 100 patients who underwent CABG. The patients were evaluated by an abridged form of the IIEF-5 questionnaire, followed by CABG. Six months after surgery the erectile function of all patients was revaluated utilizing the IIEF-5.
Results.
Number of risk factors was significantly associated with postoperative change in IIEF-5 score (P = 0.02). A post hoc analysis of the association revealed that patients with one risk factor were significantly more likely to have increased IIEF-5 scores (N = 18), whereas those with two or more risk factors were significantly more likely to have decreased IIEF-5 scores (N = 21, P < 0.05). Furthermore, those with no risk factors were significantly more likely to be stable (N = 8) compared with those with more than two risk factors, who were more likely to have decreased scores (P < 0.05). The hierarchical logistic regression results showed that when examining all risk factors simultaneously, because of multicollinearity, only hyperlipidemia was significantly associated with postoperative ED (odds ratio [OR] = 11.33, confirdence interval [CI] = 1.25, 102.82). Frequency of intercourse was also significantly associated with postoperative ED after controlling for risk factors (OR = 0.71, CI = 0.52, 0.97).
Conclusions.
This data clearly shows that the number of cardiovascular risk factors is an essential predictive factor for sexual function following surgery. Only hyperlipidemia may play a predictive role for the future sexual function of patients undergo CABG. Mohamed OA, Hamed HA, Roaiah MF, Helmy T, Mahran A, and Bennett CJ. Vascular risk factors as predictors of sexual function following coronary artery bypass graft. J Sex Med 2009;6:2017-2023.
C1 [Mohamed, Osama A.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77025 USA.
[Hamed, Hamed A.; Roaiah, Mohamed Farid] Cairo Univ, Fac Med, Androl Dept, Cairo, Egypt.
[Helmy, Tarek] Cairo Univ, Fac Med, Cardiothorac Dept, Cairo, Egypt.
[Mahran, Ali] Asyut Univ, Androl Dept, Fac Med, Asyut, Egypt.
[Bennett, Carol J.] Greater Los Angeles VA Med Syst, Los Angeles, CA USA.
[Bennett, Carol J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Mohamed, OA (reprint author), Baylor Coll Med, Scott Dept Urol, 7490 Bromton Rd, Houston, TX 77025 USA.
EM azimusama@gamil.com
NR 22
TC 4
Z9 5
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1743-6095
J9 J SEX MED
JI J. Sex. Med.
PD JUL
PY 2009
VL 6
IS 7
BP 2017
EP 2023
DI 10.1111/j.1743-6109.2009.01268.x
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 462QA
UT WOS:000267369500025
PM 19453877
ER
PT J
AU Asgari, MA
Tang, J
Epstein, EH
Chren, MM
Warton, EM
Quesenberry, CP
Go, AS
Friedman, GD
AF Asgari, Maryam A.
Tang, Jean
Epstein, Ervin H., Jr.
Chren, Mary-Margaret
Warton, E. Margaret
Quesenberry, Charles P., Jr.
Go, Alan S.
Friedman, Gary D.
TI Statin use and risk of basal cell carcinoma
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE basal cell carcinoma; pharmacoepidemiology; skin cancer; statin
ID NONMELANOMA SKIN-CANCER; FOLLOW-UP; CLINICAL-TRIALS; CHOLESTEROL;
POPULATION; METAANALYSIS; PREVENTION; LOVASTATIN; SIMVASTATIN;
REGRESSION
AB Objective: We examined the association between statin use and basal cell carcinoma (BCC) risk.
Methods: We identified all members of a large integrated health care delivery system with a diagnosis of a histologically proven BCC in 1997. Subsequent BCCs were identified through 2006 from health plan electronic pathology records. Longitudinal exposure to statins and other lipid-lowering agents was determined from automated pharmacy records. We used extended Cox regression to examine the independent association between receipt of statin therapy (ever vs never, cumulative duration) and risk of subsequent BCC. To minimize confounding by indication, we conducted sensitivity analyses in the subset of individuals considered eligible for lipid-lowering therapy based on national guidelines.
Results: Among 12,123 members given a diagnosis of BCC who had no prior statin exposure, 6381 developed a subsequent BCC during follow-up. Neither "ever use of statins" (adjusted hazard ratio 1.02, 95% confidence interval: 0.92-1.12) or Cumulative duration of statin (adjusted hazard ratio 1.02/year, 95% confidence interval: 0.99-1.11) was associated With subsequent BCC after adjustment for age, sex, and health care use. Risk estimates did not change appreciably when the analysis was limited to the Subset of individuals who met eligibility criteria for initiating statin therapy. There was also no significant association between use of non-statin antilipemics and subsequent BCC (adjusted hazard ratio 1.10, 95% confidence interval: 0.76-1-58).
Limitations: No information was available for BCC risk factors, Such as sun sensitivity and sun exposure.
Conclusions: Among a large cohort of individuals with BCC, statin therapy was not significantly associated with risk of subsequent BCC. (J Am Acad Dermatol 2009;61:66-72.)
C1 [Asgari, Maryam A.; Warton, E. Margaret; Quesenberry, Charles P., Jr.; Go, Alan S.; Friedman, Gary D.] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA.
[Asgari, Maryam A.; Tang, Jean; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Biostat Epidemiol & Med, San Francisco, CA 94143 USA.
[Chren, Mary-Margaret] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA.
[Tang, Jean; Epstein, Ervin H., Jr.] Childrens Hosp, Oakland Res Inst, Oakland, CA USA.
[Friedman, Gary D.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA.
RP Asgari, MA (reprint author), Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM maryam.m.asgari@kp.org
RI Asgari, Maryam/O-4947-2016
FU National Institute of Arthritis Musculoskeletal and Skin Diseases [K23
AR 051037, K24 AR 052667]; National Cancer Institute [R01 CA 098838]
FX Supported in part by the National Institute of Arthritis Musculoskeletal
and Skin Diseases (K23 AR 051037 to Dr Asgari, K24 AR 052667 to Dr
Chren) and by the National Cancer Institute (R01 CA 098838 to Dr
Friedman).
NR 31
TC 7
Z9 7
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD JUL
PY 2009
VL 61
IS 1
BP 66
EP 72
DI 10.1016/j.jaad.2009.02.011
PG 7
WC Dermatology
SC Dermatology
GA 462DA
UT WOS:000267325000010
PM 19464071
ER
PT J
AU Parchman, ML
Munoz, A
AF Parchman, Michael L.
Munoz, Abel
TI Risk Factors for Methicillin-Resistant Staphylococcal aureus Skin and
Soft Tissue Infections Presenting in Primary Care: A South Texas
Ambulatory Research Network (STARNet) Study
SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE
LA English
DT Article
ID UNITED-STATES; MRSA
AB Purpose: To examine skin and soft tissue infections presenting at 4 primary care clinics and assess if historical risk factors and examination findings were associated with a positive methicillin-resistant Staphylococcus aureus (MRSA) culture.
Methods: During the 10-month observational study (April 2007 through January 2008), physicians in 5 practices across South Texas collected history, physical examination findings, culture results, and antibiotic( s) prescribed for all patients presenting with a skin or soft tissue infection. Analyses were conducted to determine the relationship between historical indicators, location of lesions, and examination findings with a positive MRSA culture.
Results: Across 4 practices, 164 cases of skin and soft tissue infections were collected during 10 months. Of the 94 with a culture, 63 (67%) were MRSA positive. Patients working in or exposed to a health care setting were more likely to have a culture positive for MRSA, as were those presenting with an abscess. MRSA-positive lesions were also significantly smaller in size.
Conclusions: Because of the high prevalence of MRSA skin and soft tissue infections among patients presenting to family physicians, presumptive treatment for MRSA may be indicated. However, increasing levels of resistance to current antibiotics is concerning and warrants development of alternative management strategies. (J Am Board Fam Med 2009;22:375-9.)
C1 [Parchman, Michael L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA.
[Parchman, Michael L.] S Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res Program, Austin, TX USA.
[Munoz, Abel] Munoz Family Med Clin, Austin, TX USA.
RP Parchman, ML (reprint author), S Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM parchman@uthscsa.edu
OI Parchman, Michael/0000-0001-7129-2889
NR 11
TC 22
Z9 22
U1 0
U2 0
PU AMER BOARD FAMILY MEDICINE
PI LEXINGTON
PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA
SN 1557-2625
J9 J AM BOARD FAM MED
JI J. Am. Board Fam. Med.
PD JUL-AUG
PY 2009
VL 22
IS 4
BP 375
EP 379
DI 10.3122/jabfm.2009.04.090003
PG 5
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 468OK
UT WOS:000267828700008
PM 19587251
ER
PT J
AU Herman, AD
Johnson, TM
Ritchie, CS
Parmelee, PA
AF Herman, Adam D.
Johnson, Theodore M., II
Ritchie, Christine S.
Parmelee, Patricia A.
TI Pain Management Interventions in the Nursing Home: A Structured Review
of the Literature
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE pain management; nursing home; review; healthcare quality
ID RANDOMIZED CONTROLLED-TRIAL; LONG-TERM-CARE; LOW-BACK PAIN;
QUALITY-IMPROVEMENT; NONMALIGNANT PAIN; ELDERLY-PATIENTS; RESIDENTS;
PREVALENCE; DEMENTIA; HEALTH
AB Residents in nursing homes (NHs) experience pain that is underrecognized and undertreated. This pain contributes to a decline in quality of life. Although descriptive studies of pain assessment and management have been conducted, few have been published that critically evaluate interventions to improve pain management. Identification of the strengths and gaps in the current literature is required. A literature search was conducted of clinical trials that evaluated prospective interventions to improve pain management. Information on the intervention type, resident sample and setting, endpoints, and study design were extracted. Studies were classified based on a modification of Donabedian's model of healthcare quality. Four categories of interventions were identified: actor, decision support, treatment, and systems. The search strategy and selection criteria yielded 21 articles. Eleven studies used an actor intervention; of these, eight also employed a systems intervention, and one also used a treatment intervention. Two studies used a decision support intervention, seven used a treatment intervention, and one used a systems intervention. The overall quality of research was uneven in several areas: research design-nine studies were quasi-experimental in nature, endpoints measures were not consistent-three did not perform statistical analysis, and characteristics of the resident samples varied dramatically. In conclusion, the number of high-quality studies of pain management in NHs remains limited. Process endpoints are used as surrogate measures for resident endpoints. Systematic approaches are needed to understand how each type of intervention improves the quality of pain management at the resident level.
C1 [Herman, Adam D.; Johnson, Theodore M., II] Emory Univ, Div Geriatr Med & Gerontol, Atlanta, GA 30322 USA.
[Parmelee, Patricia A.] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA.
[Herman, Adam D.; Johnson, Theodore M., II; Parmelee, Patricia A.] Atlanta Vet Affairs Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Decatur, GA USA.
[Ritchie, Christine S.] Univ Alabama, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA.
[Ritchie, Christine S.] Birmingham Vet Affairs Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA.
RP Herman, AD (reprint author), 1841 Clifton Rd NE, Atlanta, GA 30329 USA.
EM adherma@emory.edu
NR 50
TC 31
Z9 31
U1 3
U2 8
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUL
PY 2009
VL 57
IS 7
BP 1258
EP 1267
DI 10.1111/j.1532-5415.2009.02315.x
PG 10
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 464WI
UT WOS:000267539800017
PM 19558481
ER
PT J
AU Williams, BA
Lindquist, K
Hill, T
Baillargeon, J
Mellow, J
Greifinger, R
Walter, LC
AF Williams, Brie A.
Lindquist, Karla
Hill, Terry
Baillargeon, Jacques
Mellow, Jeff
Greifinger, Robert
Walter, Louise C.
TI Caregiving Behind Bars: Correctional Officer Reports of Disability in
Geriatric Prisoners
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the American-Geriatrics-Society
CY APR 30-MAY 04, 2008
CL Washington, DC
SP Amer Geriatr Soc
DE prisoners; disability; geriatric
ID LIVING OLDER PERSONS; FUNCTIONAL IMPAIRMENT; MENTAL-HEALTH; CARE
AB Despite increasing numbers of geriatric prisoners, little is known about geriatric disability or health care in prison. Although correctional officers often act as a liaison between prisoners and the healthcare system, the role of officers in recognizing geriatric disability has not been characterized. The goals of this study were to assess officers' assessment of disability in their assigned geriatric prisoners and to contrast their views with reports from the California Department of Corrections and Rehabilitation (CDCR). Questionnaires were given to 71 officers assigned to 618 randomly selected geriatric prisoners in 11 prisons. Information about 41 additional prisoners identified by correctional officers as "high risk" was also analyzed. Prisoner disability and health were determined through correctional officer questionnaires (activity of daily living (ADL) impairment, geriatric syndromes, level of care), chart review (medical diagnoses), and CDCR data (demographics, disability designation). Overall, 211 (34.1%) geriatric prisoners were unknown to their officer. Of the 407 known prisoners, officers reported that 5.0% had ADL impairment and 3.1% were unsafe. Discordance between officer and CDCR reports of disability was common, with officers reporting higher disability rates. The 41 high-risk prisoners were more likely to have ADL impairment (22.0% vs 5.2%, P <.01) and geriatric syndromes such as falls and incontinence than the random sample. Overall, nearly one-third of geriatric prisoners were unknown to their assigned officer. Officers identified more disability than the CDCR, and prisoners they identified as high risk had nursing home-level functional impairments. Significant improvement in disability assessment is needed for officers and the CDCR.
C1 [Williams, Brie A.; Lindquist, Karla; Walter, Louise C.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Williams, Brie A.; Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Hill, Terry] Calif Prison Receivership, Sacramento, CA USA.
[Baillargeon, Jacques] Univ Texas Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX USA.
[Mellow, Jeff] CUNY John Jay Coll Criminal Justice, Dept Law Police Sci & Criminal Justice Adm, New York, NY 10019 USA.
[Greifinger, Robert] CUNY John Jay Coll Criminal Justice, Criminal Justice Res & Evaluat Ctr, New York, NY 10019 USA.
RP Williams, BA (reprint author), 4150 Clement St,Box 181-G, San Francisco, CA 94121 USA.
EM brie.williams@ucsf.edu
NR 29
TC 12
Z9 13
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUL
PY 2009
VL 57
IS 7
BP 1286
EP 1292
DI 10.1111/j.1532-5415.2009.02286.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 464WI
UT WOS:000267539800021
PM 19582902
ER
PT J
AU Hazzard, WR
AF Hazzard, William R.
TI BODY WEIGHT AND INCIDENT DEMENTIA
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Letter
C1 Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
RP Hazzard, WR (reprint author), Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUL
PY 2009
VL 57
IS 7
BP 1316
EP 1316
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 464WI
UT WOS:000267539800033
PM 19570170
ER
PT J
AU Ishii, S
Weintraub, N
Mervis, JR
AF Ishii, Shinya
Weintraub, Nancy
Mervis, James R.
TI Apathy: A Common Psychiatric Syndrome in the Elderly
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Review
DE Apathy; dementia; cognition disorders; mood disorders
ID MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; SUBTHALAMIC NUCLEUS
STIMULATION; NURSING-HOME RESIDENTS; PROGRESSIVE SUPRANUCLEAR PALSY;
PARAMETRIC MAPPING ANALYSIS; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE;
NEUROPSYCHIATRIC SYMPTOMS; BEHAVIORAL DISTURBANCES
AB Apathy, or a lack of motivation, has been increasingly recognized as a distinct psychiatric syndrome. Apathy is primarily a dysfunction of the frontal-subcortical circuit and is associated with various neuropsychiatric disorders including Alzheimer's disease. Apathy is associated with a number of adverse outcomes, including apparent cognitive impairment, decreased daily function, poor insight into one's own functional and cognitive impairment, and poor outcome from rehabilitation treatment. Furthermore, the degree of caregiver's burden in these patients is significant. This article reviews the definition of apathy, prevalence and associated adverse outcomes, causation, the approach to patients with apathy, and available treatment options with particular attention to studies conducted in a nursing home setting. The purpose of this article is to increase the recognition of apathy by physicians working in the nursing home. (J Am Med Dir Assoc 2009; 10: 381-393)
C1 [Ishii, Shinya] Vet Affairs Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA 90073 USA.
[Weintraub, Nancy; Mervis, James R.] Sepulveda Campus Greater Los Angeles Vet Affairs, Los Angeles, CA 90073 USA.
[Weintraub, Nancy; Mervis, James R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Ishii, S (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, GRECC, 11301 Wilshire Blvd,Bldg 220,Room 302, Los Angeles, CA 90073 USA.
EM sishii@mednet.ucla.edu
NR 178
TC 48
Z9 52
U1 2
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
EI 1538-9375
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD JUL
PY 2009
VL 10
IS 6
BP 381
EP 393
DI 10.1016/j.jamda.2009.03.007
PG 13
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 477ZL
UT WOS:000268557400005
PM 19560715
ER
PT J
AU Wang, CJ
Patel, MH
Schueth, AJ
Bradley, M
Wu, SY
Crosson, JC
Glassman, PA
Bell, DS
AF Wang, C. Jason
Patel, Mihir H.
Schueth, Anthony J.
Bradley, Melissa
Wu, Shinyi
Crosson, Jesse C.
Glassman, Peter A.
Bell, Douglas S.
TI Perceptions of Standards-based Electronic Prescribing Systems as
Implemented in Outpatient Primary Care: A Physician Survey
SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
LA English
DT Article; Proceedings Paper
CT Annual Conference of the Agency-for-Healthcare-Research-and-Quality
CY SEP 26-28, 2007
CL Bethesda, MD
SP Agcy Healthcare Res & Qual
ID CLINICAL DECISION-SUPPORT; ORDER ENTRY SYSTEMS; AMBULATORY-CARE;
NATIONAL-SURVEY; HEALTH RECORDS; DRUG ALERTS; EXPERIENCES; TECHNOLOGY;
ACCEPTANCE; ADOPTION
AB Objective: To compare the experiences of e-prescribing users and nonusers regarding prescription safety and workload and to assess the use of information from two e-prescribing standards (for medication history and formulary and benefit information), as they are implemented.
Design: Cross-sectional survey of physicians who either had installed or were awaiting installation of one of two commercial e-prescribing systems.
Measurements: Perceptions about medication history and formulary and benefit information among all respondents, and among e-prescribing users, experiences with system usability, job performance impact, and amount of e-prescribing.
Results: Of 395 eligible physicians, 228 (58%) completed the survey. E-prescribers (n = 139) were more likely than non-e-prescribers (n = 89) to perceive that they could identify clinically important drug-drug interactions (83 versus 67%, p = 0.004) but not that they could identify prescriptions from other providers (65 versus 60%, p = 0.49). They also perceived no significant difference in calls about drug coverage problems (76 versus 71% reported getting 10 or fewer such calls per week; p = 0.43). Most e-prescribers reported high satisfaction with their systems, but 17% had stopped using the system and another 46% said they sometimes reverted to handwriting for prescriptions that they could write electronically. The volume of e-prescribing was correlated with perceptions that it enhanced job performance, whereas quitting was associated with perceptions of poor usability.
Conclusions: E-prescribing users reported patient safety benefits but they did not perceive the enhanced benefits expected from using standardized medication history or formulary and benefit information. Additional work is needed for these standards to have the desired effects.
C1 [Wang, C. Jason] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA.
[Wang, C. Jason; Bradley, Melissa; Wu, Shinyi; Glassman, Peter A.; Bell, Douglas S.] RAND Hlth, Santa Monica, CA USA.
[Wang, C. Jason] Boston Univ, Sch Publ Hlth, Dept Maternal & Child Hlth, Boston, MA 02118 USA.
[Patel, Mihir H.] MedImpact Healthcare Syst Inc, Hackensack, NJ USA.
[Schueth, Anthony J.] Point of Care Partners LLC, Boston, MA USA.
[Wu, Shinyi] Univ So Calif, Daniel J Epstein Dept Ind & Syst Engn, Los Angeles, CA USA.
[Crosson, Jesse C.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Family Med, Div Res, New Brunswick, NJ USA.
[Glassman, Peter A.] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Excellence Study Healthcare Provider, Los Angeles, CA USA.
[Glassman, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Bell, Douglas S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA.
RP Wang, CJ (reprint author), Boston Univ, Sch Med, Dept Pediat, 88 E Newto St,Vose 3, Boston, MA 02118 USA.
EM jason.wang@bmc.org
RI Bell, Douglas/G-6702-2013
OI Bell, Douglas/0000-0002-5063-8294
FU AHRQ HHS [1U18HS016391-01, U18 HS016391]; NEI NIH HHS [1K23EY018668-01,
K23 EY018668]
NR 41
TC 35
Z9 35
U1 1
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1067-5027
J9 J AM MED INFORM ASSN
JI J. Am. Med. Inf. Assoc.
PD JUL-AUG
PY 2009
VL 16
IS 4
BP 493
EP 502
DI 10.1197/jamia.M2998
PG 10
WC Computer Science, Information Systems; Computer Science,
Interdisciplinary Applications; Health Care Sciences & Services;
Information Science & Library Science; Medical Informatics
SC Computer Science; Health Care Sciences & Services; Information Science &
Library Science; Medical Informatics
GA 470QZ
UT WOS:000267995500009
PM 19390106
ER
PT J
AU Wang, YX
John, R
Chen, JL
Richardson, JA
Shelton, JM
Bennett, M
Zhou, XJ
Nagami, GT
Zhang, Y
Wu, QQ
Lu, CY
AF Wang, Yanxia
John, Reji
Chen, Jianlin
Richardson, James A.
Shelton, John M.
Bennett, Michael
Zhou, Xin J.
Nagami, Glenn T.
Zhang, Ying
Wu, Qing Qing
Lu, Christopher Y.
TI IRF-1 Promotes Inflammation Early after Ischemic Acute Kidney Injury
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article; Proceedings Paper
CT 41st Annual Meeting of the American-Society-of-Nephrology/Annual Renal
Week
CY NOV 04-09, 2008
CL Philadelphia, PA
SP Amer Soc Nephrol
ID ACUTE-RENAL-FAILURE; REGULATORY FACTOR-I; ACUTE TUBULAR-NECROSIS;
REPERFUSION INJURY; TRANSCRIPTION FACTORS; ISCHEMIA/REPERFUSION INJURY;
DOCOSAHEXAENOIC ACID; EPITHELIAL-CELLS; TNF-ALPHA; T-CELL
AB Acute renal ischemia elicits an inflammatory response that may exacerbate acute kidney injury, but the regulation of the initial signals that recruit leukocytes is not well understood. Here, we found that IFN regulatory factor 1 (IRF-1) was a critical, early proinflammatory signal released during ischemic injury in vitro and in vivo. Within 15 min of reperfusion, proximal tubular cells of the S3 segment produced IRF-1, which is a transcription factor that activates proinflammatory genes. Transgenic knockout of IRF-1 ameliorated the impairment of renal function, morphologic injury, and inflammation after acute ischemia. Bone marrow chimera experiments determined that maximal ischemic injury required IRF-1 expression by both leukocytes and radioresistant renal cells, the latter identified as S3 proximal tubule cells in the outer medulla by in situ hybridization and immunohistochemistry. In vitro, reactive oxygen species, generated during ischemia/reperfusion injury, stimulated expression of IRF-1 in an S3 proximal tubular cell line. Taken together, these data suggest that IRF-1 gene activation by reactive oxygen species is an early signal that promotes inflammation after ischemic renal injury.
C1 [Richardson, James A.; Shelton, John M.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.
[Richardson, James A.; Shelton, John M.; Bennett, Michael; Zhou, Xin J.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
[Lu, Christopher Y.] Univ Texas SW Med Ctr Dallas, Grad Program Immunol, Dallas, TX 75390 USA.
[Nagami, Glenn T.] VA Greater Los Angeles, Nephrol Sect, Los Angeles, CA USA.
[Nagami, Glenn T.] Univ Calif Los Angeles, Los Angeles, CA USA.
RP Lu, CY (reprint author), Univ Texas SW Med Sch, Dept Internal Med Nephrol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM christopher.lu@utsouthwestern.edu
FU NIDDK NIH HHS [R01DK06963303, P30 DK079328, P30DK079328]
NR 62
TC 24
Z9 26
U1 0
U2 0
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD JUL
PY 2009
VL 20
IS 7
BP 1544
EP 1555
DI 10.1681/ASN.2008080843
PG 12
WC Urology & Nephrology
SC Urology & Nephrology
GA 467XC
UT WOS:000267775400019
PM 19443641
ER
PT J
AU Gundiah, N
Ratcliffe, MB
Pruitt, LA
AF Gundiah, Namrata
Ratcliffe, Mark B.
Pruitt, Lisa A.
TI The biomechanics of arterial elastin
SO JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS
LA English
DT Article
ID STRAIN-ENERGY FUNCTION; MECHANICAL-PROPERTIES; CONSTITUTIVE RELATION;
PASSIVE MYOCARDIUM; LAMELLAR UNIT; DEFORMATION; PROTEINS; BEHAVIOR;
SOLIDS
AB Uniaxial mechanical experiments have shown that a neo-Hookean/Gaussian model is suitable to describe the mechanics of arterial elastin networks [Gundiah, N., Ratcliffe, M.B., Pruitt, L.A., 2007. Determination of strain energy function for arterial elastin: Experiments using histology and mechanical tests. J. Biomech. 40, 586-594]. Based on the three-dimensional elastin architecture in arteries, we have proposed an orthotropic material symmetry for arterial elastin consisting of two orthogonally oriented and symmetrically placed families of mechanically equivalent fibers. In this study, we use these results to describe the strain energy function for arterial elastin, with dependence on a reduced subclass of invariants, as W = W(I(1), I(4)). We use previously published equations for this dependence [Humphrey, J.D., Strumpf, R.K., Yin, F.C.P., 1990a. Determination of a constitutive relation for passive myocardium: I. A new functional form. J. Biomech. Eng. 112, 333-339], in combination with a theoretical guided Rivlin-Saunders framework [Rivlin, R.S., Saunders, D.W, 1951. Large elastic deformations of isotropic materials VII. Experiments on the deformation of rubber. Phil. Trans. R. Soc. A 243, 251-288] and biaxial mechanical experiments, to obtain the form of this dependence. Using mechanical equivalence of elastin in the circumferential and longitudinal directions, we add a term in 16 to W that is similar to the form in 14. We propose a semi-empirical model for arterial elastin given by W = c(0) (I(1) - 3) + c(1) (I(4) - 1)(2) + c(2) (I(6) - 1)(2), where c(0), c(1) and c(3) are unknown coefficients. we used the Levenberg-Marquardt algorithm to fit theoretically calculated and experimentally determined stresses from equibiaxial experiments on autoclaved elastin tissues and obtain c(0) = 73.96 +/- 22.51 kPa, c(1) = 1.18 +/- 1.79 kPa and c(2) = 0.8 +/- 1.26 kPa. Thus, the entropic contribution to the strain energy function, represented by c(0), is a dominant feature of elastin mechanics. Because there are no significant differences in the coefficients corresponding to invariants 14 and 16, we surmise that there is an equal distribution of fibers in the circumferential and axial directions. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [Gundiah, Namrata; Pruitt, Lisa A.] Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA.
[Pruitt, Lisa A.] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.
[Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA.
[Ratcliffe, Mark B.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Pruitt, LA (reprint author), Univ Calif Berkeley, Dept Mech Engn, 5134 Etcheverry Hall,Mailstop 1740, Berkeley, CA 94720 USA.
EM lpruitt@me.berkeley.edu
FU NHLBI NIH HHS [2R01 HL06334805, R01 HL063348]
NR 34
TC 24
Z9 24
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1751-6161
J9 J MECH BEHAV BIOMED
JI J. Mech. Behav. Biomed. Mater.
PD JUL
PY 2009
VL 2
IS 3
BP 288
EP 296
DI 10.1016/j.jmbbm.2008.10.007
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 430SO
UT WOS:000265009000008
PM 19627833
ER
PT J
AU Lu, TC
Wang, ZH
Feng, XB
Chuang, PY
Fang, W
Shen, YH
Levy, DE
Xiong, HB
Chen, N
He, JC
AF Lu, Ting-Chi
Wang, Zhao-Hui
Feng, Xiaobei
Chuang, Peter Y.
Fang, Wei
Shen, Yuhong
Levy, David E.
Xiong, Huabao
Chen, Nan
He, John Cijiang
TI Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE collagen IV; diabetic nephropathy; glomerulosclerosis; mesangial cells;
Stat3
ID JAK/STAT-SIGNALING PATHWAY; FACTOR-KAPPA-B; LOW-GRADE INFLAMMATION;
MESANGIAL CELLS; HIGH GLUCOSE; INDUCED ACTIVATION; KIDNEY GLOMERULI;
DB/DB MICE; NEPHROPATHY; GROWTH
AB Recent studies suggest that Stat3, a transcription factor that mediates cytokine signaling, plays a critical role in the pathogenesis of diabetic nephropathy. Complete Stat3 gene knockout is embryonic lethal; therefore, we crossed Stat3+/- mice with Stat3 mutant mice (SA/SA) that lack full Stat3 activity. This strategy generated Stat3SA/- mice (25% activity) and Stat3SA/+ mice (75% activity), which were made diabetic using streptozotocin in order to define the role of Stat3 in diabetic kidney disease. While the glomerular number was not different between these two groups of mice, the diabetic SA/- mice had significantly less proteinuria, mesangial expansion, glomerular cell proliferation, and macrophage infiltration than the diabetic SA/+ mice. The reduction in Stat3 activity did not affect glomerular hyperfiltration seen after the induction of diabetes, as it was increased to the same degree in both groups of mice. Phosphorylation of Stat3 was markedly increased in the glomeruli of diabetic SA/+ mice compared to diabetic SA/- mice. The expression of inflammatory markers, IL-6, MCP-1, and activated NF-kappa B; type IV collagen, TGF-beta, and ICAM-1 mRNA; or type IV collagen and TGF-beta protein, were all found to be significantly less in glomeruli isolated from diabetic SA/- mice, as compared with diabetic SA/+ mice. Our study shows that Stat3 plays a critical role in the regulation of inflammation and abnormal matrix synthesis at an early stage of DN.
C1 [He, John Cijiang] Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA.
[Lu, Ting-Chi; He, John Cijiang] James J Peters VA Med Ctr, Bronx, NY USA.
[Wang, Zhao-Hui; Feng, Xiaobei; Chen, Nan] Shanghai Jiao Tong Univ, Sch Med, RuiJin Hosp, Dept Nephrol, Shanghai 200030, Peoples R China.
[Shen, Yuhong] Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA.
[Levy, David E.] NYU, Dept Pathol, New York, NY 10016 USA.
[Xiong, Huabao] Mt Sinai Sch Med, Immunobiol Ctr, New York, NY USA.
[He, John Cijiang] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY USA.
RP He, JC (reprint author), Mt Sinai Sch Med, Dept Med, Div Nephrol, Box 1243,1 Gustave L Levy Pl, New York, NY 10029 USA.
EM cijiang.he@mssm.edu
OI Levy, David/0000-0002-7320-7788
FU NIH [R01 DK078897, K08 KD082760]
FX JC He was supported by NIH R01 DK078897. PY Chuang was supported by NIH
K08 KD082760.
NR 43
TC 29
Z9 37
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD JUL
PY 2009
VL 76
IS 1
BP 63
EP 71
DI 10.1038/ki.2009.98
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 461KR
UT WOS:000267266200011
PM 19357722
ER
PT J
AU Li, W
Meng, ZH
Liu, YL
Reyes, JD
Lang, JD
AF Li, Wei
Meng, Zihui
Liu, Yuliang
Reyes, Jorge D.
Lang, John D.
TI THE PROTECTIVE EFFECT OF NITRITE ON LIVER COLD ISCHEMIA REPERFUSION
INJURY
SO LIVER TRANSPLANTATION
LA English
DT Meeting Abstract
CT 15th Annual Congress of the International-Liver-Transplantation-Society
CY JUL 08-11, 2009
CL New York, NY
SP Int Liver Transplantat Soc
C1 [Li, Wei; Meng, Zihui; Liu, Yuliang; Reyes, Jorge D.; Lang, John D.] Univ Washington, Seattle, WA 98195 USA.
[Liu, Yuliang; Lang, John D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Reyes, Jorge D.] Childrens Hosp & Reg Med Ctr, Seattle, WA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUL
PY 2009
VL 15
IS 7
BP S236
EP S236
PG 1
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 468CV
UT WOS:000267792300547
ER
PT J
AU Shugarman, LR
Mack, K
Sorbero, MES
Tian, HJ
Jain, AK
Ashwood, JS
Asch, SM
AF Shugarman, Lisa R.
Mack, Katherine
Sorbero, Melony E. S.
Tian, Haijun
Jain, Arvind K.
Ashwood, J. Scott
Asch, Steven M.
TI Race and Sex Differences in the Receipt of Timely and Appropriate Lung
Cancer Treatment
SO MEDICAL CARE
LA English
DT Article
DE Medicare; lung cancer; SEER program; treatment; sex differences; race
differences; disparities
ID AFRICAN-AMERICAN PATIENTS; SEER-MEDICARE DATA; LEUKEMIA GROUP-B;
QUALITY-OF-LIFE; SURGICAL RESECTION; SURVIVAL; DISPARITIES; GENDER;
CARE; CHEMOTHERAPY
AB Background: Previous research suggests that disparities in non-small-cell lung cancer (NSCLC) survival can be explained in part by disparities in the receipt of cancer treatment. Few studies, however, have considered race and sex disparities in the timing and appropriateness of treatment across stages of diagnosis.
Objective: To evaluate the relationship of sex and race with the receipt of timely and clinically appropriate NSCLC treatment for each stage of diagnosis.
Method: Surveillance Epidemiology and End Result data linked to Medicare claims for beneficiaries diagnosed with NSCLC between 1995 and 1999 were used to evaluate the relationship between race and sex with timely and appropriate NSCLC treatment while controlling for other demographic characteristics, comorbidities, socioeconomic status, and provider supply (N = 22,145).
Results: Overall adjusted rates of timely and appropriate treatment are 37.2%, 58.1%, and 29.2% for Medicare beneficiaries diagnosed with stage I or 11, 111, and IV NSCLC, respectively. Among stage I or 11 patients, women were 25% less likely to receive timely Surgical resection relative to men, and blacks were 66% less likely to receive timely and appropriate treatment than whites. Black men were least likely to receive resection (22.2% compared with 43.7% for white men). Blacks were 34% less likely to receive timely surgery, chemotherapy, or radiation for stage III disease and were 51% less likely to receive chemotherapy in a timely fashion for stage IV disease relative to whites.
Conclusion: Significant variations in appropriate timely treatment were found within and across stages of diagnosis, confirming that sex and race differences in NSCLC treatment exist.
C1 [Shugarman, Lisa R.; Mack, Katherine] RAND Corp, Santa Monica, CA 90407 USA.
[Sorbero, Melony E. S.; Ashwood, J. Scott] RAND Corp, Pittsburgh, PA USA.
[Tian, Haijun] MS Hlth, Woodland Hills, CA USA.
[Jain, Arvind K.] RAND Corp, Arlington, VA USA.
[Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, RAND Corp, Vet Adm Greater Los Angeles Healthcare Syst, Santa Monica, CA USA.
RP Shugarman, LR (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA.
EM lisas@rand.org
FU Health Resources and Services Administration (HRSA) Office of Rural
Health Policy [R04-RH03596-01-00]
FX Supported by the Health Resources and Services Administration (HRSA)
Office of Rural Health Policy (R04-RH03596-01-00).
NR 47
TC 41
Z9 41
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD JUL
PY 2009
VL 47
IS 7
BP 774
EP 781
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 463VZ
UT WOS:000267462400009
PM 19536007
ER
PT J
AU Iwashyna, TJ
Christie, JD
Moody, J
Kahn, JM
Asch, DA
AF Iwashyna, Theodore J.
Christie, Jason D.
Moody, James
Kahn, Jeremy M.
Asch, David A.
TI The Structure of Critical Care Transfer Networks
SO MEDICAL CARE
LA English
DT Article
DE networks; critical care; regionalization; Medicare
ID ACUTE MYOCARDIAL-INFARCTION; PERCUTANEOUS CORONARY INTERVENTIONS;
UNITED-STATES; INTENSIVE-CARE; PRIMARY ANGIOPLASTY; HOSPITAL VOLUME;
SOCIAL NETWORK; OUTCOMES; MORTALITY; CENTRALITY
AB Rationale: Moving patients from low-performing hospitals to high-performing hospitals may improve patient outcomes. These transfers may be particularly important in critical care, where small relative improvements can yield substantial absolute changes in survival.
Objective: To characterize the existing critical care network in terms of the pattern of transfers.
Methods: In a retrospective cohort study, the nationwide 2005 Medicare fee-for-service claims were used to identify the interhospital transfer of critically ill patients, defined as instances where patients used critical care services in 2 temporally adjacent hospitalizations.
Measurements: We Measured the characteristics of the interhospital transfer network and the extent to which intensive care unit patients are referred to each hospital in that network-a continuous quantitative measure at the hospital-level known as centrality. We evaluated associations between hospital centrality and organizational, medical, surgical, and radiologic capabilities.
Results: There were 47,820 transfers of critically ill patients among 3308 hospitals. 4.5% of all critical care stays of any length involved an interhospital critical care transfer. Hospitals transferred out to a mean of 4.4 other hospitals. More central hospital positions were associated with multiple indicators of increased capability. Hospital characteristics explained 40.7% of the variance in hospitals' centrality.
Conclusions: Critical care transfers are common, and traverse an informal but structured network. The centrality of a hospital is associated with increased capability in delivery of services, suggesting that existing transfers generally direct patients toward better resourced hospitals. Studies of this network promise further improvements in patient outcomes and efficiency of care.
C1 [Iwashyna, Theodore J.] Univ Michigan, Dept Med, Div Pulm & Crit Care, Ann Arbor, MI 48109 USA.
[Iwashyna, Theodore J.; Kahn, Jeremy M.; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Christie, Jason D.; Kahn, Jeremy M.] Hosp Univ Penn, Dept Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA.
[Christie, Jason D.; Kahn, Jeremy M.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Moody, James] Duke Univ, Dept Sociol, Durham, NC 27706 USA.
[Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Iwashyna, TJ (reprint author), 3A23 300 NIB,SPC 5419,300 N Ingalls Bldg, Ann Arbor, MI 48109 USA.
EM tiwashyna@umich.edu
OI Iwashyna, Theodore/0000-0002-4226-9310
FU NIH [HL07891-09, K08 HL09 1249]; ATS Fellows Career Development Award
FX Supported in part by NIH grants HL07891-09 and K08 HL09 1249 and an ATS
Fellows Career Development Award.
NR 49
TC 65
Z9 65
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD JUL
PY 2009
VL 47
IS 7
BP 787
EP 793
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 463VZ
UT WOS:000267462400011
PM 19536030
ER
PT J
AU Barnett, PG
AF Barnett, Paul G.
TI An Improved Set of Standards for Finding Cost for Cost-Effectiveness
Analysis
SO MEDICAL CARE
LA English
DT Article
DE cost-benefit analysis; costs and cost analysis/methods; hospital costs;
hospital charges; research design
ID ECONOMIC EVALUATIONS; HEALTH-CARE; METHODOLOGIC EVALUATION;
CLINICAL-TRIALS; TASK-FORCE; QUALITY; HOSPITALS; CHARGES
AB Background: Guidelines have helped standardize methods of cost-effectiveness analysis, allowing different interventions to be compared and enhancing the generalizability of study findings. There is agreement that all relevant services be valued from the societal perspective using a long-term time horizon and that more exact methods be used to cost services most affected by the Study intervention. Guidelines are not specific enough with respect to costing methods, however.
Method: The literature was reviewed to identify the problems associated with the 4 principal methods of cost determination.
Findings: Microcosting requires direct measurement and is ordinarily reserved to cost novel interventions. Analysts should include nonwage labor cost, person-level and institutional overhead, and the cost of development, set-up activities, supplies, space, and screening. Activity-based cost systems have promise of finding accurate costs of all services provided, but are not widely adopted. Quality must be evaluated and the generalizability of cost estimates to other settings must be considered. Administrative cost estimates, chiefly cost-adjusted charges, are widely used, but the analyst must consider items excluded from the available system. Gross costing methods determine quantity of services used and employ a unit cost. If the intervention will affect the characteristics of a service, the method should not assume that the service is homogeneous.
Conclusions: Questions are posed for future reviews of the quality of costing methods. The analyst must avoid inappropriate assumptions, especially those that bias the analysis by exclusion of costs that are affected by the intervention under study.
C1 [Barnett, Paul G.] US Dept Vet Affairs, Hlth Econ Resource Ctr, Stanford, CA USA.
[Barnett, Paul G.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA.
RP Barnett, PG (reprint author), Hlth Econ Resource Ctr, 795 Willow Rd 152,Menlo Pk, Menlo Pk, CA 94025 USA.
EM paul.barnett@va.gov
FU US Department of Veterans Affairs Health Services Research and
Development Service [ECN-99-017]; VA Cooperative Studies Program
FX Supported by the US Department of Veterans Affairs Health Services
Research and Development Service (ECN-99-017) and the VA Cooperative
Studies Program.
NR 41
TC 32
Z9 34
U1 3
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD JUL
PY 2009
VL 47
IS 7
BP S82
EP S88
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 463WA
UT WOS:000267462500014
PM 19536018
ER
PT J
AU Huang, AJ
Sawaya, GF
Vittinghoff, E
Lin, F
Grady, D
AF Huang, Alison J.
Sawaya, George F.
Vittinghoff, Eric
Lin, Feng
Grady, Deborah
TI Hot flushes, coronary heart disease, and hormone therapy in
postmenopausal women
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Hot flushes; Coronary heart disease; Hormone therapy; Menopause;
Estrogen
ID ESTROGEN PLUS PROGESTIN; CARDIOVASCULAR-DISEASE; MENOPAUSAL COMPLAINTS;
REPLACEMENT THERAPY; FLASHES; ASSOCIATION; HEALTH; RISK; POLYMORPHISMS;
SYMPTOMS
AB Objective: The aim of this study was to examine interactions between hot flushes, estrogen plus progestogen therapy (EPT), and coronary heart disease (CHD) events in postmenopausal women with CHD.
Methods: We analyzed data from the Heart and Estrogen/Progestin Replacement Study, a randomized, placebo-controlled trial of 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate in 2,763 postmenopausal women with CHD. Hot flushes were assessed at baseline using self-administered questionnaires; women reporting bothersome hot flushes "some" to "all" of the time were considered to have clinically significant flushing. Cox regression models were used to examine the effect of EPT on risk of CHD events among women with and without significant flushing at baseline.
Results: The mean age of participants was 66.7 +/- 6.8 years, and 89% (n = 2,448) were white. Sixteen percent (n = 434) of participants reported clinically significant hot flushes at baseline. Among women with baseline flushing, EPT increased risk of CHD events nine-fold in the first year compared with placebo (hazard ratio = 9.01; 95% CI, 1.15-70.35); among women without baseline flushing, treatment did not significantly affect CHD event risk in the first year (hazard ratio = 1.32; 95% CI, 0.86-2.03; P = 0.07 for interaction of hot flushes with treatment). The trend toward differential effects of EPT on risk for CHD among women with and without baseline flushing did not persist after the first year of treatment.
Conclusions: Among older postmenopausal women with CHD, EPT may increase risk of CHD events substantially in the first year of treatment among women with clinically significant hot flushes but not among those without hot flushes.
C1 [Huang, Alison J.; Grady, Deborah] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Sawaya, George F.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
[Sawaya, George F.; Vittinghoff, Eric; Lin, Feng; Grady, Deborah] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Grady, Deborah] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA.
RP Huang, AJ (reprint author), 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA.
EM ahuang@ucsfmed.org
FU Wyeth-Ayerst Research; National Institutes of Health (NIH); National
Center for Research Resources [KL2RR024130]
FX The Heart and Estrogen/Progestin Replacement Study was funded by
Wyeth-Ayerst Research, but Wyeth-Ayerst Research had no role in the
research described in this manuscript, including management, analysis,
or interpretation of the data, or preparation or revision of this
manuscript. This research was supported by National Institutes of Health
(NIH) and the National Center for Research Resources Grant KL2RR024130
to the University of California San Francisco Clinical and Translational
Science Institute.
NR 24
TC 46
Z9 46
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1072-3714
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD JUL-AUG
PY 2009
VL 16
IS 4
BP 639
EP 643
DI 10.1097/gme.0b013e31819c11c4
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 468RJ
UT WOS:000267837300009
PM 19325499
ER
PT J
AU Hoang, B
Benavides, A
Shi, YJ
Frost, P
Lichtenstein, A
AF Hoang, Bao
Benavides, Angelica
Shi, Yijiang
Frost, Patrick
Lichtenstein, Alan
TI Effect of autophagy on multiple myeloma cell viability
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; PROTEASOME
INHIBITOR PS-341; OVERCOMES DRUG-RESISTANCE; ISOLATED RAT HEPATOCYTES;
MOLECULAR-MECHANISMS; ANTIMYELOMA ACTIVITY; MAMMALIAN TARGET;
DEGRADATION; BORTEZOMIB
AB Because accumulation of potentially toxic malfolded protein may be extensive in immunoglobulin-producing multiple myeloma (MM) cells, we investigated the phenomenon of autophagy in myeloma, a physiologic process that can protect against malfolded protein under some circumstances. Autophagy in MM cell lines that express and secrete immunoglobulin and primary specimens was significantly increased by treatment with the endoplasmic reticulum stress-inducing agent thapsigargin, the mammalian target of rapamycin inhibitor rapamycin, and the proteasome inhibitor bortezomib. Inhibition of basal autophagy in these cell lines and primary cells by use of the inhibitors 3-methyladenine and chloroquine resulted in a cytotoxic effect that was associated with enhanced apoptosis. Use of small interfering RNA to knock down expression of beclin-1, a key protein required for autophagy, also inhibited viable recovery of MM cells. Because the data suggested that autophagy protected MM cell viability, we predicted that autophagy inhibitors would synergize with bortezomib for enhanced antimyeloma effects. However, the combination of these drugs resulted in an antagonistic response. In contrast, the autophagy inhibitor 3-methyladenine did synergize with thapsigargin for an enhanced cytotoxic response. These data suggest that autophagy inhibitors have therapeutic potential in myeloma but caution against combining such drugs with bortezomib. [Mol Cancer Ther 2009;8(7):1974-84]
C1 Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Dept Med,Greater Los Angeles Vet Affairs Healthca, Los Angeles, CA 90024 USA.
Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA.
RP Lichtenstein, A (reprint author), W Los Angeles Vet Affairs Hosp, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM alan.lichtenstein@med.va.gov
OI Frost, Patrick/0000-0003-3348-5983
FU NIH [RO1CA111448, KO1CA111623]; Multiple Myeloma Research Foundation;
Veteran's Administration
FX NIH grants RO1CA111448 and KO1CA111623, Multiple Myeloma Research
Foundation, and research funds of the Veteran's Administration.
NR 46
TC 69
Z9 72
U1 2
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUL
PY 2009
VL 8
IS 7
BP 1974
EP 1984
DI 10.1158/1535-7163.MCT-08-1177
PG 11
WC Oncology
SC Oncology
GA 470UG
UT WOS:000268005700026
PM 19509276
ER
PT J
AU Perrigoue, JG
Saenz, SA
Siracusa, MC
Allenspach, EJ
Taylor, BC
Giacomin, PR
Nair, MG
Du, YR
Zaph, C
van Rooijen, N
Comeau, MR
Pearce, EJ
Laufer, TM
Artis, D
AF Perrigoue, Jacqueline G.
Saenz, Steven A.
Siracusa, Mark C.
Allenspach, Eric J.
Taylor, Betsy C.
Giacomin, Paul R.
Nair, Meera G.
Du, Yurong
Zaph, Colby
van Rooijen, Nico
Comeau, Michael R.
Pearce, Edward J.
Laufer, Terri M.
Artis, David
TI MHC class II-dependent basophil-CD4(+) T cell interactions promote T(H)2
cytokine-dependent immunity
SO NATURE IMMUNOLOGY
LA English
DT Article
ID THYMIC STROMAL LYMPHOPOIETIN; ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS;
IN-VIVO; HELMINTH INFECTION; TYPE-2 IMMUNITY; CUTTING EDGE; MAST-CELLS;
GASTROINTESTINAL-TRACT; EFFECTOR MECHANISMS
AB Dendritic cells can prime naive CD4(+) T cells; however, here we demonstrate that dendritic cell-mediated priming was insufficient for the development of T helper type 2 cell-dependent immunity. We identify basophils as a dominant cell population that coexpressed major histocompatibility complex class II and interleukin 4 message after helminth infection. Basophilia was promoted by thymic stromal lymphopoietin, and depletion of basophils impaired immunity to helminth infection. Basophils promoted antigen-specific CD4(+) T cell proliferation and interleukin 4 production in vitro, and transfer of basophils augmented the population expansion of helminth-responsive CD4(+) T cells in vivo. Collectively, our studies suggest that major histocompatibility complex class II-dependent interactions between basophils and CD4(+) T cells promote T helper type 2 cytokine responses and immunity to helminth infection.
C1 [Perrigoue, Jacqueline G.; Saenz, Steven A.; Siracusa, Mark C.; Taylor, Betsy C.; Giacomin, Paul R.; Nair, Meera G.; Du, Yurong; Pearce, Edward J.; Artis, David] Univ Penn, Dept Pathobiol, Philadelphia, PA 19104 USA.
[Allenspach, Eric J.; Laufer, Terri M.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Zaph, Colby] Univ British Columbia, Biomed Res Ctr, Dept Pathol & Lab Med, Vancouver, BC, Canada.
[van Rooijen, Nico] Vrije Univ Amsterdam, Dept Mol Cell Biol, Amsterdam, Netherlands.
[Comeau, Michael R.] Amgen Inc, Inflammat Res, Seattle, WA USA.
[Laufer, Terri M.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Artis, D (reprint author), Univ Penn, Dept Pathobiol, Philadelphia, PA 19104 USA.
EM dartis@vet.upenn.edu
OI Zaph, Colby/0000-0002-9889-9848
FU NCI NIH HHS [T32 CA009140, T32 CA09140-30]; NIAID NIH HHS [AI074878,
AI32573, AI53825, AI61570, R01 AI032573, R01 AI053825, R01 AI061570, R01
AI061570-05, R01 AI074878, R01 AI074878-02, R56 AI032573, T32 AI007532,
T32 AI007532-08]; NIDDK NIH HHS [DK50306, P30 DK050306]; NIGMS NIH HHS
[F31 GM082187]
NR 59
TC 347
Z9 356
U1 3
U2 20
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD JUL
PY 2009
VL 10
IS 7
BP 697
EP U45
DI 10.1038/ni.1740
PG 10
WC Immunology
SC Immunology
GA 459WF
UT WOS:000267142600008
PM 19465906
ER
PT J
AU Rupnik, M
Wilcox, MH
Gerding, DN
AF Rupnik, Maja
Wilcox, Mark H.
Gerding, Dale N.
TI Clostridium difficile infection: new developments in epidemiology and
pathogenesis
SO NATURE REVIEWS MICROBIOLOGY
LA English
DT Review
ID HUMAN GUT MODEL; SURFACE-LAYER PROTEINS; TERM-CARE FACILITY; TOXIN-B;
BINARY TOXIN; ANTIBODY-RESPONSE; PCR RIBOTYPES; ADP-RIBOSYLTRANSFERASE;
HYPERVIRULENT STRAIN; PATHOGENICITY LOCUS
AB Clostridium difficile is now considered to be one of the most important causes of health care-associated infections. C. difficile infections are also emerging in the community and in animals used for food, and are no longer viewed simply as unpleasant complications that follow antibiotic therapy. Since 2001, the prevalence and severity of C. difficile infection has increased significantly, which has led to increased research interest and the discovery of new virulence factors, and has expanded and focused the development of new treatment and prevention regimens. This Review summarizes the recent epidemiological changes in C. difficile infection, our current knowledge of C. difficile virulence factors and the clinical outcomes of C. difficile infection.
C1 [Rupnik, Maja] Inst Publ Hlth Maribor, Ctr Microbiol, Maribor 2000, Slovenia.
[Rupnik, Maja] Univ Maribor, Fac Med, Maribor 2000, Slovenia.
[Wilcox, Mark H.] Leeds Gen Infirm, Leeds LS1 3EX, W Yorkshire, England.
[Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
[Gerding, Dale N.] Loyola Univ Chicago, Stritch Sch Med, ACOS Res & Dev, Hines, IL 60141 USA.
RP Rupnik, M (reprint author), Inst Publ Hlth Maribor, Ctr Microbiol, Prvomajska 1, Maribor 2000, Slovenia.
EM maja.rupnik@uni-mb.si; mark.wilcox@leedsth.nhs.uk;
dale.gerding2@med.va.gov
FU EU [223585]; ERA NET PathoGenoMics; ARRS [J3-0194-0377-08]
FX M. R. was supported by EU grant 223585, ERA NET PathoGenoMics grant and
ARRS grant J3-0194-0377-08.
NR 129
TC 585
Z9 614
U1 29
U2 207
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1740-1526
J9 NAT REV MICROBIOL
JI Nat. Rev. Microbiol.
PD JUL
PY 2009
VL 7
IS 7
BP 526
EP 536
DI 10.1038/nrmicro2164
PG 11
WC Microbiology
SC Microbiology
GA 458KF
UT WOS:000267016700013
PM 19528959
ER
PT J
AU Stella, SL
Hu, WD
Brecha, NC
AF Stella, Salvatore L., Jr.
Hu, Wanda D.
Brecha, Nicholas C.
TI Adenosine suppresses exocytosis from cone terminals of the salamander
retina
SO NEUROREPORT
LA English
DT Article
DE activity-dependent dye; ATP; Ca(2+) channel; L-glutamate; purines;
Synaptored-C2
ID CALCIUM-CHANNELS; RECEPTORS; PHOTORECEPTORS; RODS; CA2+; SYNAPSES;
SLICES; FM1-43; INFLUX; RAT
AB In the retina, adenosine is released in the dark and has been shown to inhibit Ca(2+) influx through voltage-gated Ca(2+) channels in cones. Therefore, we tested whether adenosine can inhibit exocytosis from isolated cone photoreceptors. Simultaneous measurements of membrane exocytosis and Ca(2+) were made from cones using the activity-dependent dye, Synaptored-C2, and the Ca(2+) indicator dye, Fluo-4. Adenosine suppressed exocytosis in cones, indicating that transmitter release is also reduced from cone terminals, and further supports an inhibitory mechanism for modulating transmitter release onto second-order neurons. Furthermore, this raises the possibility that adenosine might be neuroprotective for photoreceptors and second-order neurons by suppressing Ca(2+) levels in cones and reducing exocytosis of L-glutamate, respectively. NeuroReport 20:923-929 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.
C1 [Stella, Salvatore L., Jr.; Hu, Wanda D.; Brecha, Nicholas C.] Univ Calif Los Angeles, Dept Neurobiol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Stella, SL (reprint author), Univ Calif Los Angeles, Dept Neurobiol, David Geffen Sch Med, 10833 Conte Blvd,Box 951763,CHS 73-323, Los Angeles, CA 90095 USA.
EM sstella@mednet.ucla.edu
OI Stella Jr., Salvatore/0000-0003-1971-2537
FU NIH [04067, 41301]; VA Senior Career Scientist; Fight-For-Sight Student
Fellowship; Jeanette Duval Scholarship; UCLA Undergraduate Research
Scholars Program
FX The authors thank Alejandro Vila and Uyenchi Huynh for providing
technical support, and Arlene Hirano for critically reading earlier
versions of this manuscript and providing insightful comments. This
research was supported by NIH grants EY 04067, and DK 41301 and a VA
Senior Career Scientist to N.C.B., Fight-For-Sight, Grant-in-Aid to
S.L.S., and Fight-For-Sight Student Fellowship, Jeanette Duval
Scholarship, and UCLA Undergraduate Research Scholars Program to W.D.H.
NR 23
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-4965
J9 NEUROREPORT
JI Neuroreport
PD JUL 1
PY 2009
VL 20
IS 10
BP 923
EP 929
DI 10.1097/WNR.0b013e32832ca4b0
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 466AW
UT WOS:000267633600006
PM 19491713
ER
PT J
AU Oh, MC
Lim, DA
AF Oh, Michael C.
Lim, Daniel A.
TI Novel Treatment Strategies for Malignant Gliomas Using Neural Stem Cells
SO NEUROTHERAPEUTICS
LA English
DT Review
DE Neural stem cells; brain tumor stem cells; glioma; gene therapy
ID APOPTOSIS-INDUCING LIGAND; TUMOR-INITIATING CELLS; GENE-THERAPY;
PROGENITOR CELLS; PRECURSOR CELLS; BRAIN-TUMORS;
GLIOBLASTOMA-MULTIFORME; SUBVENTRICULAR ZONE; ADULT BRAIN; IN-VIVO
AB Recent studies in stem cell biology have refined our understanding of the origin and progression of cancer. Identification and characterization of endogenous neural stem cells (NSCs), especially those in the adult human brain, have inspired new ideas for selectively targeting and destroying malignant gliomas. Gliomas consist of a heterogeneous population of cells, and some of these cells have characteristics of cancer stem cells. These brain tumor stem cells (BTSCs) share certain characteristics with normal NSCs. It is still unclear, however, whether malignant gliomas in human patients originate from these aberrant BTSCs. Nonetheless, the cellular and molecular similarities between BTSCs and normal NSCs suggest a common research landscape underlying both normal and cancer stem cell biology, wherein findings of one field are relevant to the other. Furthermore, the natural tropism of NSCs to gliomas has generated the idea that modified NSCs can deliver modified genes to selectively destroy malignant brain tumor cells, and even BTSCs, while leaving healthy surrounding neurons intact. These studies and others on the basic biology of both BTSCs and NSCs will be crucial to expanding our treatment strategies for malignant gliomas.
C1 [Oh, Michael C.; Lim, Daniel A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
[Lim, Daniel A.] San Francisco VA Med Ctr, Surg Serv, Neurosurg Sect, Dept Vet Affairs, San Francisco, CA 94121 USA.
RP Oh, MC (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave, San Francisco, CA 94143 USA.
EM ohmc@neurosurg.ucsf.edu
NR 66
TC 10
Z9 10
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1933-7213
J9 NEUROTHERAPEUTICS
JI Neurotherapeutics
PD JUL
PY 2009
VL 6
IS 3
BP 458
EP 464
PG 7
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 465KE
UT WOS:000267581800005
PM 19560736
ER
PT J
AU Hansen, LK
Brown, M
Johnson, D
Palme, DF
Love, C
Darouiche, R
AF Hansen, Linda K.
Brown, Mary
Johnson, David
Palme, Donald F., II
Love, Charles
Darouiche, Rabih
TI In Vivo Model of Human Pathogen Infection and Demonstration of Efficacy
by an Antimicrobial Pouch for Pacing Devices
SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
LA English
DT Article
DE device infection; pacemaker
ID CENTRAL VENOUS CATHETERS; PACEMAKER IMPLANTATION; PERMANENT PACEMAKER;
COLONIZATION; PREVENTION; GUIDELINES; MANAGEMENT; TRIAL
AB Objective: The purpose of this study was to determine the efficacy of the AIGIS(RX)(TM) antibacterial envelope (TyRx Pharma, Inc., Monmouth Junction, NJ, USA) designed to reduce device-related infections by incorporating minocycline and rifampin in a controlled release polymer.
Methods: An infection was established in a rabbit model by creating bilateral subcutaneous implant pockets, into which a pacing device with or without AIGIS(RX)(TM) was placed. The incisions were closed, and a defined dose of bacteria was infused into each implant pocket. After 7 days, devices were explanted and sampled for viable bacteria by swabbing and sonication.
Results: Initial studies evaluated the ability of the AIGIS(RX) pouch to reduce Staphylococcus epidermidis (S. epi) infection in this model using clinical and quantitative microbial endpoints. Results demonstrate S. epi infection in all control samples, while no pathogens were recovered from samples with the AIGIS(RX)(TM) pouch. Systemic antibiotic levels were undetectable. Additional studies tested the efficacy of the AIGIS(RX)(TM) pouch with additional bacterial strains, Staphylococcus capitis, Escherichia coli, and Acinetobacter Baumannii. In each case, the device and implant pocket with the AIGIS(RX)(TM) pouch was free of any signs of infection. An assessment of biofilm produced by Acinetobacter demonstrated the elimination of biofilm formation on the implanted device.
Conclusion: These results demonstrate that in this animal model, the AIGIS(RX)(TM) device reduces the risk for infection of viable pathogens within implant pockets.
(PACE 2009; 32:898-907).
C1 [Hansen, Linda K.; Brown, Mary; Johnson, David; Palme, Donald F., II] WuXi AppTec Inc, St Paul, MN 55120 USA.
[Love, Charles] Ohio State Univ, Med Ctr, Dept Internal Med, Div Cardiovasc Med, Columbus, OH 43210 USA.
[Darouiche, Rabih] Michael E Debakey Vet Affairs Med Ctr, Houston, TX USA.
RP Hansen, LK (reprint author), WuXi AppTec Inc, St Paul, MN 55120 USA.
EM linda.hansen@wuxiapptec.com
FU TyRx Pharma, Inc.
FX The testing presented in this manuscript was sponsored by TyRx Pharma,
Inc., manufacturer of the AIGISRX(TM) product.
NR 18
TC 19
Z9 19
U1 0
U2 6
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0147-8389
J9 PACE
JI PACE-Pacing Clin. Electrophysiol.
PD JUL
PY 2009
VL 32
IS 7
BP 898
EP 907
PG 10
WC Cardiac & Cardiovascular Systems; Engineering, Biomedical
SC Cardiovascular System & Cardiology; Engineering
GA 462CD
UT WOS:000267322500011
PM 19572866
ER
PT J
AU Gallagher, RM
AF Gallagher, Rollin M.
TI AAPM and Health Care Reform: Your Voice Is Needed
SO PAIN MEDICINE
LA English
DT Editorial Material
C1 [Gallagher, Rollin M.] Univ Penn, Amer Acad Pain Med, Philadelphia, PA 19104 USA.
[Gallagher, Rollin M.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Gallagher, RM (reprint author), Univ Penn, Amer Acad Pain Med, Philadelphia, PA 19104 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1526-2375
J9 PAIN MED
JI Pain Med.
PD JUL-AUG
PY 2009
VL 10
IS 5
BP 781
EP 783
DI 10.1111/j.1526-4637.2009.00674.x
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 476ZI
UT WOS:000268485000003
PM 19682271
ER
PT J
AU Meghani, SH
Wiedemer, NL
Becker, WC
Gracely, EJ
Gallagher, RM
AF Meghani, Salimah H.
Wiedemer, Nancy L.
Becker, William C.
Gracely, Ed J.
Gallagher, Rollin M.
TI Predictors of Resolution of Aberrant Drug Behavior in Chronic Pain
Patients Treated in a Structured Opioid Risk Management Program
SO PAIN MEDICINE
LA English
DT Article
DE Opioids; Chronic Pain; Aberrant Drug Behavior; Substance Abuse; Primary
Care; Opioid Renewal Clinic
ID PRIMARY-CARE PHYSICIANS; CHRONIC NONCANCER PAIN; SOCIAL SUPPORT; ABUSE;
THERAPY; MISUSE; ADJUSTMENT; DEPENDENCE; ADDICTION; NETWORK
AB Objective.
To identify demographic and clinical predictors of the resolution of aberrant drug-related behaviors (ADRBs) in a group of patients referred to the Opioid Renewal Clinic (ORC) by their primary care providers (PCPs). ORC is a program supporting PCPs' use of opioids for chronic pain in patients perceived as at risk for opioid abuse or those with demonstrated ADRBs.
Methods.
A retrospective chart review was conducted for 195 consecutive subjects referred to the ORC from January 17, 2002 to August 27, 2004, for ADRBs. Binary logistic regression was employed to identify independent predictors of aberrant behavior outcome at 1 year.
Results.
Of the 195 referred, 45.6% (N = 89) resolved their ADRB at 1 year. Other outcomes, classified as nonresolution of ADRB, self-discharged or discharged by the ORC for inability to adhere to the opioid treatment agreement (N = 86, 44.1%) and acceptance of referral for addiction treatment (N = 20, 10.2%). A history of cocaine abuse increased the odds of failing the program by five times (odds ratio [OR] = 4.97, P = 0.001). Each additional pain diagnosis reduced the odds of failure by 16% (OR = 0.837, P = 0.008). When compared with singles, married individuals were 62% less likely to fail the ORC program (OR = 0.38, P = 0.028).
Conclusions.
Nearly half of the patients resolved their aberrant behavior within the ORC. Patients with cocaine abuse were at higher risk for failure, suggesting a need for further research into safe and effective ways to manage pain in this complex subset of patients. Aberrant behaviors tended to resolve in patients with multiple pain locations, possibly because of their desire for relief.
C1 [Wiedemer, Nancy L.; Becker, William C.; Gallagher, Rollin M.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Meghani, Salimah H.] Univ Penn, Sch Nursing, NewCourtland Ctr Transit & Hlth, Philadelphia, PA 19104 USA.
[Gracely, Ed J.] Drexel Univ, Coll Med, Philadelphia, PA USA.
[Gallagher, Rollin M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
RP Wiedemer, NL (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM Nancy.Wiedemer@va.gov
OI Becker, William/0000-0002-0788-1467
NR 25
TC 9
Z9 9
U1 1
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1526-2375
J9 PAIN MED
JI Pain Med.
PD JUL-AUG
PY 2009
VL 10
IS 5
BP 858
EP 865
DI 10.1111/j.1526-4637.2009.00643.x
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 476ZI
UT WOS:000268485000015
PM 19523029
ER
PT J
AU Larochelle, MR
Rodriguez, KL
Arnold, RM
Barnato, AE
AF Larochelle, M. R.
Rodriguez, K. L.
Arnold, R. M.
Barnato, A. E.
TI Hospital staff attributions of the causes of physician variation in
end-of-life treatment intensity
SO PALLIATIVE MEDICINE
LA English
DT Article
DE decision making; practice variation; qualitative research; terminal care
ID CARE-UNIT; ADVANCE DIRECTIVES; PREFERENCES; DECISIONS; COMMUNICATION;
PROGNOSES; SUPPORT; PATIENT; DEATH; TRIAL
AB Discrepancies between patient wishes and end-of-life treatment decisions have been documented, and the determinants of end-of-life treatment decisions are not well understood. Our objective was to understand hospital staff perceptions of the role of acute care hospital medical doctors in end-of-life treatment intensity. In 11 purposively sampled Pennsylvania hospitals, we completed 108 audiotaped semistructured interviews with key informants involved in decision making or discharge planning. Using grounded theory, we qualitatively analysed transcripts using constant comparison to identify factors affecting end-of-life treatment decisions. A predominant theme identified was that end-of-life treatment intensity depends on the doctor. Communication with patients and families and collaboration with other care team members also were reported to vary, contributing to treatment variation. Informants attributed physician variation to individual beliefs and attitudes regarding the end-of-life (religion and culture, determination of when a patient is dying, quality-of-life determination and fear of failing) and to socialization by and interaction with the healthcare system (training, role perception, experience and response to incentives). When end-of-life treatment depends on the doctor, patient and family preferences may be neglected. Targeted interventions may reduce variability and align end-of-life treatment with patient wishes. Palliative Medicine (2009); 23: 460-470
C1 [Barnato, A. E.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA.
[Larochelle, M. R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.
[Rodriguez, K. L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Arnold, R. M.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Sect Palliat Care & Med Eth, Pittsburgh, PA 15213 USA.
RP Barnato, AE (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 200 Meyran St,Suite 200, Pittsburgh, PA 15213 USA.
EM aeb2@pitt.edu
FU National Institute on Aging [K08 AG021921, P01 AG19783]
FX Financial support for this research was from National Institute on Aging
grants K08 AG021921 and P01 AG19783. Amber Barnato would like to thank
research mentors Derek Angus and Judith Lave for their intellectual and
personal contributions.
NR 30
TC 30
Z9 30
U1 2
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-2163
J9 PALLIATIVE MED
JI Palliat. Med.
PD JUL
PY 2009
VL 23
IS 5
BP 460
EP 470
DI 10.1177/0269216309103664
PG 11
WC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Medicine, General & Internal
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; General & Internal Medicine
GA 457ON
UT WOS:000266941500011
PM 19324922
ER
PT J
AU Ross, OA
Spanaki, C
Griffith, A
Lin, CH
Kachergus, J
Haugarvoll, K
Latsoudis, H
Plaitakis, A
Ferreira, JJ
Sampaio, C
Bonifati, V
Wu, RM
Zabetian, CP
Farrer, MJ
AF Ross, Owen A.
Spanaki, Cleanthe
Griffith, Alida
Lin, Chin-Hsien
Kachergus, Jennifer
Haugarvoll, Kristoffer
Latsoudis, Helen
Plaitakis, Andreas
Ferreira, Joaquim J.
Sampaio, Cristina
Bonifati, Vincenzo
Wu, Ruey-Meei
Zabetian, Cyrus P.
Farrer, Matthew J.
TI Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Article
DE Parkinson's disease; Leucine-rich repeat kinase 2; R1441H
ID DISEASE; MUTATIONS; RISK; GENE
AB The Roc domain of the Lrrk2 protein harbors two pathogenic mutations which cause autosomal dominant parkinsonism (R1441C and R1441G). A third putatively pathogenic variant (R1441H) has been identified in four probands of diverse ethnicity with parkinsonism. Herein we show that the R1441H substitutions lie on different haplotypes within our patients, confirming this codon as a mutational hotspot. The absence of this variant in control subjects and the presence of two other pathogenic variants at this amino acid position collectively support the contention that 81441 H is a pathogenic substitution. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Ross, Owen A.] Mayo Clin, Morris K Udall Parkinsons Dis Res Ctr Excellence, Dept Neurosci, Jacksonville, FL 32224 USA.
[Spanaki, Cleanthe; Latsoudis, Helen; Plaitakis, Andreas] Univ Crete, Dept Neurol, Sch Med, Iraklion, Crete, Greece.
[Griffith, Alida] Evergreen Hosp, Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA.
[Lin, Chin-Hsien; Wu, Ruey-Meei] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Neurol, Taipei 10764, Taiwan.
[Ferreira, Joaquim J.; Sampaio, Cristina] Lisbon Sch Med, Inst Mol Med, Neurol Clin, Res Unit, Lisbon, Portugal.
[Bonifati, Vincenzo] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
[Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
[Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Geriatr Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA.
[Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
RP Ross, OA (reprint author), Mayo Clin, Morris K Udall Parkinsons Dis Res Ctr Excellence, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
EM ross.owen@mayo.edu
RI Ross, Owen/D-7573-2013; Haugarvoll, Kristoffer/L-1486-2015
OI Haugarvoll, Kristoffer/0000-0001-9381-1109; Wu,
Ruey-Meei/0000-0002-4947-5467; Lin, Chin-Hsien/0000-0001-8566-7573;
Zabetian, Cyrus/0000-0002-7739-4306; Ferreira, Joaquim
J/0000-0003-3950-5113
FU Morris K. Udall Parkinson's Disease Research Center of Excellence
[NS40256]; Department of Veterans Affairs; Taiwan National Science
Council [96-2628-B-002-103-MY2]; Internationaal Parkinson Fonds, The
Netherlands; Parkinson Disease Foundation
FX We would like to thank all those who have contributed to our research.
This work is supported by a Morris K. Udall Parkinson's Disease Research
Center of Excellence (NINDS P50 #NS40256), the Department of Veterans
Affairs (Merit Review Award), the Taiwan National Science Council
(96-2628-B-002-103-MY2), by a grant from the "Internationaal Parkinson
Fonds" (The Netherlands) to VB, and by a research grant from the
"Parkinson Disease Foundation" to CS.
NR 10
TC 20
Z9 21
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD JUL
PY 2009
VL 15
IS 6
BP 466
EP 467
DI 10.1016/j.parkreldis.2008.09.001
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 473MH
UT WOS:000268210500014
PM 18952485
ER
PT J
AU Kennifer, SL
Alexander, SC
Pollak, KI
Jeffreys, AS
Olsen, MK
Rodriguez, KL
Arnold, RM
Tulsky, JA
AF Kennifer, Sarah L.
Alexander, Stewart C.
Pollak, Kathryn I.
Jeffreys, Amy S.
Olsen, Maren K.
Rodriguez, Keri L.
Arnold, Robert M.
Tulsky, James A.
TI Negative emotions in cancer care: Do oncologists' responses depend on
severity and type of emotion?
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Doctor-patient relations; Communication; Cancer; Emotion
ID COMMUNICATION; DOCTOR; NEWS
AB Objective: To examine how type and severity of patients' negative emotions influence oncologists' responses and subsequent conversations.
Methods: We analyzed 264 audio-recorded conversations between advanced cancer patients and their oncologists. Conversations were coded for patients' expressions of negative emotion, which were categorized by type of emotion and severity. Oncologists' responses were coded as using either empathic language or blocking and distancing approaches.
Results: Patients presented fear more often than anger or sadness; severity of disclosures was most often moderate. Oncologists responded to 35% of these negative emotional disclosures with empathic language. They were most empathic when patients presented intense emotions. Responding empathically to patients' emotional disclosures lengthened discussions by an average of only 21 s.
Conclusion: Greater response rates to severe emotions suggest oncologists may recognize negative emotions better when patients express them more intensely. Oncologists were least responsive to patient fear and responded with greatest empathy to sadness.
Practice implications: Oncologists may benefit from additional training to recognize negative emotions, even when displayed without intensity. Teaching cancer patients to better articulate their emotional concerns may also enhance patient-oncologist communication. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Kennifer, Sarah L.; Alexander, Stewart C.; Tulsky, James A.] Duke Univ, Med Ctr, Ctr Palliat Care, Durham, NC 27705 USA.
[Alexander, Stewart C.; Jeffreys, Amy S.; Olsen, Maren K.; Tulsky, James A.] Durham VA Med Ctr, Hlth Serv Res & Dev, Durham, NC USA.
[Pollak, Kathryn I.; Tulsky, James A.] Duke Univ, Med Ctr, Duke Canc Prevent Detect & Control Res Program, Durham, NC 27705 USA.
[Rodriguez, Keri L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Rodriguez, Keri L.; Arnold, Robert M.] Univ Pittsburgh, Sch Med, Dept Gen Internal Med, Pittsburgh, PA 15260 USA.
RP Kennifer, SL (reprint author), Duke Univ, Med Ctr, Ctr Palliat Care, Hock Plaza,Suite 1105,Box 2720,2424 Erwin Rd, Durham, NC 27705 USA.
EM sarah.kennifer@duke.edu
FU National Cancer Institute [R01-CA100387]
FX This work has been funded by a grant from the National Cancer Institute
(R01-CA100387).
NR 24
TC 29
Z9 32
U1 2
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD JUL
PY 2009
VL 76
IS 1
BP 51
EP 56
DI 10.1016/j.pec.2008.10.003
PG 6
WC Public, Environmental & Occupational Health; Social Sciences,
Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
Topics
GA 467HO
UT WOS:000267729500010
PM 19041211
ER
PT J
AU Sittig, DF
Teich, JM
Osheroff, JA
Singh, H
AF Sittig, Dean F.
Teich, Jonathan M.
Osheroff, Jerome A.
Singh, Hardeep
TI Improving Clinical Quality Indicators Through Electronic Health Records:
It Takes More Than Just a Reminder
SO PEDIATRICS
LA English
DT Editorial Material
ID PHYSICIAN ORDER ENTRY; DECISION-SUPPORT; SYSTEM; CARE; OUTCOMES
C1 [Sittig, Dean F.] Univ Texas Houston, Sch Hlth Informat Sci, Houston, TX USA.
[Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA.
[Teich, Jonathan M.] Elsevier Hlth Sci, Philadelphia, PA USA.
[Teich, Jonathan M.] Harvard Univ, Dept Med, Boston, MA 02115 USA.
[Osheroff, Jerome A.] Thomson Reuters, Ann Arbor, MI USA.
[Osheroff, Jerome A.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Singh, Hardeep] Baylor Coll Med, Dept Med, Hlth Policy & Qual Program, Houston Vet Affairs Hlth Serv Res & Dev Ctr Excel, Houston, TX 77030 USA.
[Singh, Hardeep] Baylor Coll Med, Dept Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
RP Sittig, DF (reprint author), Univ Texas Hlth Sci Ctr Houston, Sch Hlth Informat Sci, 6410 Fannin St, Houston, TX 77030 USA.
EM dean.f.sittig@uth.tmc.edu
FU NCI NIH HHS [K23 CA125585, K23 CA125585-04]
NR 16
TC 19
Z9 19
U1 2
U2 4
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD JUL
PY 2009
VL 124
IS 1
BP 375
EP 377
DI 10.1542/peds.2009-0339
PG 3
WC Pediatrics
SC Pediatrics
GA 463QY
UT WOS:000267448100046
PM 19564321
ER
PT J
AU Zeman, RJ
Zhao, JB
Zhang, YF
Zhao, WD
Wen, XL
Wu, Y
Pan, JP
Bauman, WA
Cardozo, C
AF Zeman, Richard J.
Zhao, Jingbo
Zhang, Yuangfei
Zhao, Weidong
Wen, Xialing
Wu, Yong
Pan, Jiangping
Bauman, William A.
Cardozo, Christopher
TI Differential skeletal muscle gene expression after upper or lower motor
neuron transection
SO PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
LA English
DT Article
DE Ubiquitin ligases; Atrogin-1; Paralysis; Muscle atrophy
ID SPINAL-CORD-INJURY; GROWTH-FACTOR-I; FOXO TRANSCRIPTION FACTORS;
NF-KAPPA-B; DENERVATION ATROPHY; UBIQUITIN LIGASES; RAT; TESTOSTERONE;
PROTEIN; SLOW
AB Causes of disuse atrophy include loss of upper motor neurons, which occurs in spinal cord injury (SCI) or lower motor neurons (denervation). Whereas denervation quickly results in muscle fibrillations, SCI causes delayed onset of muscle spasticity. To compare the influence of denervation or SCI on muscle atrophy and atrophy-related gene expression, male rats had transection of either the spinal cord or sciatic nerve and were sacrificed 3, 7, or 14 days later. Rates of atrophy increased gradually over the first week after denervation and then were constant. In contrast, atrophy after SCI peaked at 1 week, then declined sharply. The greater atrophy after SCI compared to denervation was preceded by high levels of ubiquitin ligase genes, MAFbx and MuRF1, which then also markedly declined. After denervation, however, expression of these genes remained elevated at lower levels throughout the 2-week time course. Interestingly, expression of the muscle growth factor, IGF-1 was increased at 3 days after denervation when fibrillation also peaks compared to SCI. Expression of IGF-1R, GADD45, myogenin, and Runx1 were also initially increased after denervation or SCI, with later declines in expression levels which correlated less well with rates of atrophy. Thus, there were significant time-dependent differences in muscle atrophy and MAFbx, MuRF1, and IGF-1 expression following SCI or denervation which may result from distinct temporal patterns of spontaneous muscle contractile activity due to injury to upper versus lower motor neurons.
C1 [Zhao, Jingbo; Zhang, Yuangfei; Zhao, Weidong; Wu, Yong; Pan, Jiangping; Bauman, William A.; Cardozo, Christopher] James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, Dept Vet Affairs, Bronx, NY 10468 USA.
[Zhao, Jingbo; Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
[Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.
[Zeman, Richard J.; Wen, Xialing] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.
RP Zeman, RJ (reprint author), New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.
EM Zeman@nymc.edu
FU Veterans Health Administration, Rehabilitation Research and Development
Service [B4162C, B3347K]; United Spinal Association
FX This work was supported by Veterans Health Administration,
Rehabilitation Research and Development Service (B4162C to WAB, B3347K
to CC), and United Spinal Association (to WAB).
NR 66
TC 29
Z9 31
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0031-6768
EI 1432-2013
J9 PFLUG ARCH EUR J PHY
JI Pflugers Arch.
PD JUL
PY 2009
VL 458
IS 3
BP 525
EP 535
DI 10.1007/s00424-009-0643-5
PG 11
WC Physiology
SC Physiology
GA 455TP
UT WOS:000266789000008
PM 19214561
ER
PT J
AU Anstead, GM
Zhang, Q
Melby, PC
AF Anstead, G. M.
Zhang, Q.
Melby, P. C.
TI Malnutrition promotes prostaglandin over leukotriene production and
dysregulates eicosanoid-cytokine crosstalk in activated resident
macrophages
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
DE Prostaglandin; Leukotriene; Malnutrition; Cytokine; Macrophage; Nitric
oxide; Tumor necrosis factor-alpha; Interleukin-10; Granulocyte
macrophage colony stimulating factor
ID COLONY-STIMULATING FACTOR; PROTEIN-CALORIE MALNUTRITION;
ARACHIDONIC-ACID METABOLITES; RAT ALVEOLAR MACROPHAGES; NITRIC-OXIDE
SYNTHASE; NECROSIS-FACTOR-ALPHA; KAPPA-B ACTIVATION; CELL-LINE J774;
ACUTE-INFLAMMATION; CYCLIC-AMP
AB We previously described a murine model of malnutrition that mimicked features of moderate human malnutrition, and led to increased dissemination of Leishmania donovani. In this study, we investigated the effect of malnutrition on macrophage production of cytokines, prostaglandins (PCs), and leukotrienes (LTs). Using either LPS or calcium ionophore A23187 as a stimulus, macrophages from the malnourished mice produced a 3-fold higher PG/LT ((PGE(2)+6-keto-PGF(1 alpha))/(LTB(4)+cysteinyl leukotrienes)) ratio than macrophages from well-nourished mice. LPS-stimulated macrophages from the malnourished mice produced decreased levels of TNF-alpha, GM-CSF, and IL-10, but similar levels of IL-6 and NO compared to well-nourished mice. A complex crosstalk between the eicosanoids and cytokines in the LPS-stimulated macrophages from the malnourished mice was evident by the following: ( I) high levels of PC secretion despite low levels of TNF-alpha; (2) Supplemental IL-10 modulated the excessive PC production; (3) GM-CSF rectified the PG/LT ratio, but did not correct the abnormal cytokine profile: and (4) inhibitors of cyclooxygenase decreased the PG/LT ratio, but did not affect TNF-alpha. Thus, in this model of malnutrition, there is a relative increase in anti-inflammatory PCs compared to pro-inflammatory LTs, which may contribute to immunodeficiency. Published by Elsevier Ltd.
C1 [Anstead, G. M.; Zhang, Q.; Melby, P. C.] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA.
[Anstead, G. M.; Melby, P. C.] Audie L Murphy Mem Vet Adm Med Ctr, Res Serv, San Antonio, TX 78284 USA.
RP Anstead, GM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM anstead@uthscsa.edu
FU US Department of Veterans Affairs (GMA, PCM); San Antonio Area
Foundation; University of Texas Health Science Center at San Antonio
FX The work was supported by funding from the US Department of Veterans
Affairs (GMA, PCM), the San Antonio Area Foundation, and the University
of Texas Health Science Center at San Antonio (institutional Research
Grant to GMA).
NR 74
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0952-3278
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD JUL
PY 2009
VL 81
IS 1
BP 41
EP 51
DI 10.1016/j.plefa.2009.04.011
PG 11
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
Metabolism
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
Metabolism
GA 475TM
UT WOS:000268384000007
PM 19541468
ER
PT J
AU Wang, R
Kern, JT
Goodfriend, TL
Ball, DL
Luesch, H
AF Wang, Rui
Kern, Jonathan T.
Goodfriend, Theodore L.
Ball, Dennis L.
Luesch, Hendrik
TI Activation of the antioxidant response element by specific oxidized
metabolites of linoleic acid
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
DE Polyunsaturated fatty acids; Fatty acid oxidation; Fatty acid epoxides;
EKODE; Antioxidants; Antioxidant response element
ID HUMAN NEUROBLASTOMA-CELLS; OXIDATIVE STRESS; NAD(P)H-QUINONE
OXIDOREDUCTASE; CYCLOPENTENONE PROSTAGLANDINS; INDUCED APOPTOSIS; HEME
OXYGENASE-1; PALMITIC ACID; INDUCTION; ENZYMES; PROTECTION
AB Linoleic acid is required for normal mammalian health and development, but is also prone to oxidation, yielding metabolites with biological effects. We screened linoleic acid, other fatty acids, and some of their derivatives and found that an epoxy-keto derivative of linoleic acid (but neither linoleic acid itself nor others of its oxidation products) strongly activates the antioxidant response element (ARE) in IMR-32 neuroblastoma cells and cerebro-cortical neurons. The active compound, 12,13-epoxy-9-keto-10(trans)-octadecenoic acid (EKODE), induces the expression of ARE-regulated cytoprotective genes such as NQO1 at the transcript and protein levels. EKODE requires transcription factor NRF2 and PI3-kinase for ARE activity. The results suggest that specific oxidation products of linoleic acid may initiate responses that lessen damage caused by oxidative stress. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Wang, Rui; Luesch, Hendrik] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA.
[Kern, Jonathan T.] Univ Wisconsin, Sch Pharm, Dept Pharmaceut Sci, Madison, WI 53706 USA.
[Goodfriend, Theodore L.; Ball, Dennis L.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA.
[Goodfriend, Theodore L.; Ball, Dennis L.] Univ Wisconsin, Dept Pharmacol, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Goodfriend, Theodore L.; Ball, Dennis L.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI USA.
RP Luesch, H (reprint author), Univ Florida, Dept Med Chem, 1600 SW Archer Rd, Gainesville, FL 32610 USA.
EM luesch@cop.ufl.edu
FU NCI NIH HHS [R21CA133681, R21 CA133681, R21 CA133681-01A1]; NHLBI NIH
HHS [R01 HL076238, HL076238]; NIEHS NIH HHS [F32 ES013463, T32 ES007015,
T32ES07015]; PHS HHS [F32 ESO13463]
NR 36
TC 14
Z9 14
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0952-3278
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD JUL
PY 2009
VL 81
IS 1
BP 53
EP 59
DI 10.1016/j.plefa.2009.04.008
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
Metabolism
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
Metabolism
GA 475TM
UT WOS:000268384000008
PM 19481916
ER
PT J
AU Mohamed, S
Neale, M
Rosenheck, RA
AF Mohamed, Somaia
Neale, Michael
Rosenheck, Robert A.
TI VA Intensive Mental Health Case Management in Urban and Rural Areas:
Veteran Characteristics and Service Delivery
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID ASSERTIVE COMMUNITY TREATMENT; SUBSTANCE-ABUSE; SEVERITY; PROGRAM;
FIDELITY; SCALE; MODEL
AB Objective: The availability of mental health services in rural areas-particularly intensive services such as assertive community treatment (ACT)-has been of increasing concern and was the focus of this study. In recent decades the U. S. Department of Veterans Affairs (VA) has developed a national network of ACT-like programs called mental health intensive case management (MHICM), which have served veterans from diverse locations across the country, including urban and rural areas. Methods: This study used rural-urban commuting area codes and national VA administrative data to compare characteristics of veterans and patterns of MHICM service delivery among veterans with mental illness living in large urban, large rural, small rural, and isolated rural communities. Results: Among veterans enrolled in MHICM from FY 2000 to FY 2005 (N=5,221), 84% (N=4,373) resided in urban areas, 8% (N=421) in large cities, 6% (N=291) in small rural towns, and 3% (N=136) in isolated rural areas. MHICM participants who lived in rural areas had clinical problems broadly similar to those in urban areas, although more rural veterans were unemployed, disabled, received VA disability compensation, and had a payee or fiduciary. MHICM clients in smaller or isolated rural areas received slightly less frequent and less intensive contacts and less recovery-oriented services than those in large urban locations. Conclusions: These data highlight the need for intensive case management services in rural areas and note some challenges in providing them at the intensity and frequency observed in urban areas where travel distances and times are shorter. (Psychiatric Services 60:914-921, 2009)
C1 [Mohamed, Somaia; Neale, Michael; Rosenheck, Robert A.] US Dept Vet Affairs, Vet Integrated Serv Network 1, Mental Illness Res Educ & Clin Ctr, West Haven, CT 06516 USA.
[Mohamed, Somaia; Neale, Michael; Rosenheck, Robert A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
RP Mohamed, S (reprint author), US Dept Vet Affairs, Vet Integrated Serv Network 1, Mental Illness Res Educ & Clin Ctr, 950 Campbell Ave, West Haven, CT 06516 USA.
EM somaia.mohamed@yale.edu
NR 19
TC 17
Z9 17
U1 0
U2 4
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD JUL
PY 2009
VL 60
IS 7
BP 914
EP 921
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 463TU
UT WOS:000267455800008
PM 19564221
ER
PT J
AU Nicolaidis, C
McFarland, B
Curry, M
Gerrity, M
AF Nicolaidis, Christina
McFarland, Bentson
Curry, MaryAnn
Gerrity, Martha
TI Differences in Physical and Mental Health Symptoms and Mental Health
Utilization Associated With Intimate-Partner Violence Versus Childhood
Abuse
SO PSYCHOSOMATICS
LA English
DT Article
ID SELF-REPORTED ABUSE; PRIMARY-CARE; CLINICAL CHARACTERISTICS; DOMESTIC
VIOLENCE; SOMATIC SYMPTOMS; BATTERED WOMEN; CHECKLIST HSCL;
SEXUAL-ABUSE; CONSEQUENCES; EXPERIENCES
AB Background: There is ample evidence that both intimate-partner violence (IPV) and childhood abuse adversely affect the physical and mental health of adult women over the long term. Objective: The authors assessed the associations between abuse, symptoms, and mental health utilization. Method: The authors performed a cross-sectional survey of 380 adult female, internal-medicine patients. Results: Although both IPV and childhood abuse were associated with depressive and physical symptoms, IPV was independently associated with physical symptoms, and childhood abuse was independently associated with depression. Women with a history of childhood abuse had higher odds, whereas women with IPV had lower odds, of receiving care from mental health providers. Conclusion: IPV and childhood abuse may have different effects on women's symptoms and mental health utilization. (Psychosomatics 2009; 50: 340-346)
C1 [Nicolaidis, Christina] Oregon Hlth & Sci Univ, Div Gen Internal Med, Dept Med, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97239 USA.
Portland VA Med Ctr, Portland, OR USA.
RP Nicolaidis, C (reprint author), Oregon Hlth & Sci Univ, Div Gen Internal Med, Dept Med, 3181 SW Sam Jackson Pk Rd,L475, Portland, OR 97239 USA.
EM nicolaid@ohsu.edu
FU Robert Wood Johnson Foundation Depression; National Institute of Mental
Health [K23 MH073008-03]
FX This study was funded by a grant from the Robert Wood Johnson Foundation
Depression in Primary Care Program. Dr. Nicolaidis' time is supported by
a grant from the National Institute of Mental Health (K23 MH073008-03).
NR 31
TC 9
Z9 9
U1 2
U2 5
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD JUL-AUG
PY 2009
VL 50
IS 4
BP 340
EP 346
PG 7
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA 484NJ
UT WOS:000269052200006
PM 19687174
ER
PT J
AU Capasso, P
Weisbord, SD
AF Capasso, Patrizio
Weisbord, Steven D.
TI Comment on Meta-analyses of Trials Comparing Contrast Media
SO RADIOLOGY
LA English
DT Letter
ID INDUCED NEPHROPATHY
C1 [Capasso, Patrizio] Univ Kentucky, Dept Radiol, Lexington, KY 40536 USA.
[Capasso, Patrizio] Univ Kentucky, Dept Surg, Lexington, KY 40536 USA.
[Weisbord, Steven D.] Univ Pittsburgh, Renal Electrolyte Div, Pittsburgh, PA USA.
[Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Capasso, P (reprint author), Univ Kentucky, Dept Radiol, 800 Rose St,HX 319B, Lexington, KY 40536 USA.
EM pcapas777@uky.edu
NR 4
TC 1
Z9 1
U1 0
U2 0
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD JUL
PY 2009
VL 252
IS 1
BP 316
EP 316
DI 10.1148/radiol.2521090443
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 475ME
UT WOS:000268362900042
PM 19561269
ER
PT J
AU Lewis, SL
Miner-Williams, D
Novian, A
Escamilla, MI
Blackwell, PH
Kretzschmar, JH
Arevalo-Flechas, LC
Bonner, PN
AF Lewis, Sharon L.
Miner-Williams, Denise
Novian, Allen
Escamilla, Monica I.
Blackwell, Paula H.
Kretzschmar, Jennifer Hale
Arevalo-Flechas, Lyda C.
Bonner, Peter N.
TI A Stress-Busting Program for Family Caregivers
SO REHABILITATION NURSING
LA English
DT Article
DE Alzheimer's disease; Alzheimer's disease and related dementias;
caregiving.; intervention; stress
ID RELAXATION THERAPY; SYMPTOM QUESTIONNAIRE; HEALTH; DEPRESSION; SPOUSAL;
IMPACT
AB Aging baby boomers, longer life spans, and rising levels of Alzheimer's disease and related dementias (ADRD) will result in a caregiver crisis in the near future. The ways in which caregivers deal with stresses related to caregiving will be critical to both their own well-being and their ability to care for others. The purpose of this article is to describe the Stress-Busting Program (SBP) for family caregivers and its effectiveness. The essential components of the SBP are education, stress management, problem solving, and support delivered in a group setting for 9 weeks. Results of the SBP indicate that throughout the program, caregivers experienced significant improvements in general health, vitality, social function, and mental health scores and decreases in anxiety anger/hostility, depression, perceived stress, and caregiver burden. The SBP is a cost-effective health-promotion strategy for caregivers who have substantial ongoing stress.
C1 [Lewis, Sharon L.] Univ Texas Hlth Sci Ctr San Antonio, Sch Nursing & Med, San Antonio, TX 78229 USA.
[Lewis, Sharon L.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Miner-Williams, Denise; Novian, Allen; Escamilla, Monica I.; Blackwell, Paula H.; Kretzschmar, Jennifer Hale; Arevalo-Flechas, Lyda C.] Univ Texas Hlth Sci Ctr San Antonio, Sch Nursing, San Antonio, TX 78229 USA.
[Bonner, Peter N.] Data & Stat Inc, Boerne, TX USA.
RP Lewis, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sch Nursing & Med, San Antonio, TX 78229 USA.
EM lewissl@uthscsa.edu
NR 32
TC 6
Z9 6
U1 1
U2 17
PU ASSOC REHABILITATION NURSES
PI GLENVIEW
PA 4700 W LAKE AVE, GLENVIEW, IL 60025-1485 USA
SN 0278-4807
J9 REHABIL NURS
JI Rehabil. Nurs.
PD JUL-AUG
PY 2009
VL 34
IS 4
BP 151
EP 159
PG 9
WC Nursing; Rehabilitation
SC Nursing; Rehabilitation
GA 461AK
UT WOS:000267235300004
PM 19583056
ER
PT J
AU Maciejewski, ML
Chen, SY
Au, DH
AF Maciejewski, Matthew L.
Chen, Shih-Yin
Au, David H.
TI Adult Asthma Disease Management: An Analysis of Studies, Approaches,
Outcomes, and Methods
SO RESPIRATORY CARE
LA English
DT Review
DE asthma; disease management; outcomes; study design; study quality
ID GENERAL-PRACTICE; CARE POPULATION; NURSE PRACTICE; MEDICATION USE;
HEALTH-CARE; PROGRAM; MORBIDITY; INTERVENTIONS; REGRESSION; EMERGENCY
AB BACKGROUND: Disease management has been implemented for patients with asthma in various ways. We describe the approaches to and components of adult asthma disease-management interventions, examine the outcomes evaluated, and assess the quality of published studies. METHODS: We searched the MEDLINE, EMBASE, CINAHL, PsychInfo, and Cochrane databases for studies published in 1986 through 2008, on adult asthma management. With the studies that met our inclusion criteria, we examined the clinical, process, medication, economic, and patient-reported outcomes reported, and the study designs, provider collaboration during the studies, and statistical methods. RESULTS: Twenty-nine articles describing 27 studies satisfied our inclusion criteria. There was great variation in the content, extent of collaboration between physician and non-physician providers responsible for intervention delivery, and outcomes examined across the 27 studies. Because of limitations in the design of 22 of the 27 studies, the differences in outcomes assessed, and the lack of rigorous statistical adjustment, we could not draw definitive conclusions about the effectiveness or cost-effectiveness of the asthma disease-management programs or which approach was most effective. CONCLUSIONS: Few well-designed studies with rigorous evaluations have been conducted to evaluate disease-management interventions for adults with asthma. Current evidence is insufficient to recommend any particular intervention.
C1 [Maciejewski, Matthew L.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27701 USA.
[Maciejewski, Matthew L.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[Maciejewski, Matthew L.] Univ N Carolina, Sch Pharm, Div Pharmaceut Outcomes & Policy, Chapel Hill, NC USA.
[Chen, Shih-Yin] Abt Biopharma Solut, Lexington, MA USA.
[Au, David H.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Au, David H.] Univ Washington, Med Ctr, Dept Med, Seattle, WA 98195 USA.
RP Maciejewski, ML (reprint author), Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Legacy Tower,411 W Chapel Hill St, Durham, NC 27701 USA.
EM mlm34@duke.edu
NR 40
TC 9
Z9 9
U1 0
U2 0
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
J9 RESP CARE
JI Respir. Care
PD JUL
PY 2009
VL 54
IS 7
BP 878
EP 886
DI 10.4187/002013209793800385
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 471DX
UT WOS:000268036400008
PM 19558739
ER
PT J
AU Luk, AJ
Levin, GP
Moore, EE
Zhou, XH
Kestenbaum, BR
Choi, HK
AF Luk, Andrew J.
Levin, Gregory P.
Moore, Elya E.
Zhou, Xiao-Hua
Kestenbaum, Bryan R.
Choi, Hyon K.
TI Allopurinol and mortality in hyperuricaemic patients
SO RHEUMATOLOGY
LA English
DT Article
DE Allopurinol; Mortality; Hyperuricaemia; Gout
ID XANTHINE-OXIDASE INHIBITION; CHRONIC HEART-FAILURE; ENDOTHELIAL
DYSFUNCTION; URIC-ACID; CARDIOVASCULAR RISK; HYPERTENSION; GOUT; DISEASE
AB Methods. From a population of hyperuricaemic veterans of [serum urate level 416 mol/l (7.0 mg/dl)] at least 40 years of age, we compared the risk of death between incident allopurinol users (n 2483) and non-users (n 7441). We estimated the multivariate mortality hazard ratio (HR) of allopurinol use with Cox proportional hazards models.
Results. Of the 9924 veterans (males, 98 and mean age 62.7 years), 1021 died during the follow-up. Patients who began treatment with allopurinol had worse prognostic factors for mortality, including higher BMI and comorbidities. After adjusting for baseline urate levels, allopurinol treatment was associated with a lower risk of all-cause mortality (HR 0.78; 95 CI 0.67, 0.91). Further adjustment with other prognostic factors did not appreciably alter this estimate (HR 0.77; 95 CI 0.65, 0.91). The mean change from baseline in serum urate within the allopurinol group was 111 mol/l (1.86 mg/dl). Adjusting for baseline urate level, allopurinol users had a 40 mol/l (0.68 mg/dl) lower follow-up serum urate value than controls (95 CI 0.55, 0.81).
Conclusion. Our findings indicate that allopurinol treatment may provide a survival benefit among patients with hyperuricaemia.
C1 [Choi, Hyon K.] Univ British Columbia, Dept Med, Div Rheumatol, Arthrit Res Ctr Canada, Vancouver, BC V5Z 1L7, Canada.
[Luk, Andrew J.; Zhou, Xiao-Hua] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Levin, Gregory P.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Moore, Elya E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Kestenbaum, Bryan R.] Univ Washington, Dept Med, Seattle, WA USA.
RP Choi, HK (reprint author), Univ British Columbia, Dept Med, Div Rheumatol, Arthrit Res Ctr Canada, 895 W 10th Ave, Vancouver, BC V5Z 1L7, Canada.
EM hchoi@arthritisresearch.ca
FU Takeda Pharmaceuticals North America, Inc
FX Supported by a grant from Takeda Pharmaceuticals North America, Inc.
NR 18
TC 43
Z9 43
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD JUL
PY 2009
VL 48
IS 7
BP 804
EP 806
DI 10.1093/rheumatology/kep069
PG 3
WC Rheumatology
SC Rheumatology
GA 460XY
UT WOS:000267227400018
PM 19447769
ER
PT J
AU Goldstein, KE
Hazlett, EA
New, AS
Haznedar, MM
Newmark, RE
Zelmanova, Y
Passarelli, V
Weinstein, SR
Canfield, EL
Meyerson, DA
Tang, CY
Buchsbaum, MS
Siever, LJ
AF Goldstein, Kim E.
Hazlett, Erin A.
New, Antonia S.
Haznedar, M. Mehmet
Newmark, Randall E.
Zelmanova, Yuliya
Passarelli, Vincent
Weinstein, Shauna R.
Canfield, Emily L.
Meyerson, David A.
Tang, Cheuk Y.
Buchsbaum, Monte S.
Siever, Larry J.
TI Smaller superior temporal gyrus volume specificity in schizotypal
personality disorder
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizotypal personality disorder; Borderline personality disorder;
Schizophrenia; MRI; Brodmann area 22; Auditory cortex
ID VOXEL-BASED MORPHOMETRY; BORDERLINE PERSONALITY; SCHIZOPHRENIA SPECTRUM;
BRAIN ABNORMALITIES; MRI ABNORMALITIES; CINGULATE GYRUS;
AUDITORY-CORTEX; GRAY-MATTER; AMYGDALA; WOMEN
AB Background: Superior temporal gyrus (STG/BA22) volume is reduced in schizophrenia and to a milder degree in schizotypal personality disorder (SPD), representing a less severe disorder in the schizophrenia spectrum. SPD and Borderline personality disorder (BPD) are severe personality disorders characterized by social and cognitive dysfunction. However, while SPD is characterized by social withdrawal/anhedonia, BPD is marked by hyper-reactivity to interpersonal stimuli and hyper-emotionality. This is the first morphometric study to directly compare SPD and BPD patients in temporal lobe volume.
Methods: We compared three age-, sex-, and education-matched groups: 27 unmedicated SPD individuals with no BPD traits, 52 unmedicated BPD individuals with no SPD traits, and 45 healthy controls. We examined gray matter volume of frontal and temporal lobe Brodmann areas (BAs), and dorsal/ventral amygdala from 3-T magnetic resonance imaging.
Results: In the STG, an auditory association area reported to be dysfunctional in SPD and BPD, the SPD patients had significantly smaller volume than healthy controls and BPD patients. No group differences were found between BPD patients and controls. Smaller BA22 volume was associated with greater symptom severity in SPD patients. Reduced STG volume may be an important endophenotype for schizophrenia-spectrum disorders. SPD is distinct from BPD in terms of STG volume abnormalities which may reflect different underlying pathophysiological mechanisms and could help discriminate between them. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Goldstein, Kim E.; Hazlett, Erin A.; New, Antonia S.; Haznedar, M. Mehmet; Newmark, Randall E.; Zelmanova, Yuliya; Passarelli, Vincent; Weinstein, Shauna R.; Canfield, Emily L.; Meyerson, David A.; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[New, Antonia S.; Weinstein, Shauna R.; Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[New, Antonia S.; Weinstein, Shauna R.; Siever, Larry J.] MIRECC, Bronx, NY USA.
[Tang, Cheuk Y.] Mt Sinai Sch Med, Dept Radiol, New York, NY USA.
[Buchsbaum, Monte S.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Buchsbaum, Monte S.] Univ Calif San Diego, Dept Neurol, San Diego, CA 92103 USA.
RP Hazlett, EA (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1505, New York, NY 10029 USA.
EM erin.hazlett@mssm.edu
FU NIMH [MH073911, MH067918]; VA MERIT [7609-28]; National Center for
Research Resources (NCRR) [RR-00071]; NIH; Mental Illness Research
Education and Clinical Center; VISN 3 Veterans Health Administration
FX This work was supported by NIMH grants MH073911 to Dr. Hazlett, MH067918
to Dr. New, and VA MERIT grant 7609-28 to Dr. Siever. Other support came
from Grant Number M01 - Patient Care RR-00071 from the National Center
for Research Resources (NCRR), a component of the NIH and the Mental
Illness Research Education and Clinical Center, VISN 3 Veterans Health
Administration.
NR 60
TC 29
Z9 29
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD JUL
PY 2009
VL 112
IS 1-3
BP 14
EP 23
DI 10.1016/j.schres.2009.04.027
PG 10
WC Psychiatry
SC Psychiatry
GA 472TA
UT WOS:000268153900003
PM 19473820
ER
PT J
AU Chase, MH
AF Chase, Michael H.
TI Factual Errors in Brooks and Peever's Rebuttal to Critiques
SO SLEEP
LA English
DT Letter
ID REM-SLEEP ATONIA; POSTSYNAPTIC INHIBITION; MUSCLE ATONIA; MECHANISMS;
MOTONEURONS
C1 [Chase, Michael H.] WebSci Int, Los Angeles, CA 90024 USA.
[Chase, Michael H.] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90024 USA.
[Chase, Michael H.] Vet Adm Greater Los Angeles Hlth Syst, Los Angeles, CA USA.
RP Chase, MH (reprint author), WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA.
EM mchase@websciences.org
NR 9
TC 1
Z9 1
U1 0
U2 1
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD JUL 1
PY 2009
VL 32
IS 7
BP 845
EP 846
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 472JG
UT WOS:000268126000003
PM 19639746
ER
PT J
AU Prasad, A
Cevallos, ME
Riosa, S
Darouiche, RO
Trautner, BW
AF Prasad, A.
Cevallos, M. E.
Riosa, S.
Darouiche, R. O.
Trautner, B. W.
TI A bacterial interference strategy for prevention of UTI in persons
practicing intermittent catheterization
SO SPINAL CORD
LA English
DT Article
DE urinary tract infection; spinal cord injury; Escherichia coli
ID BLADDER MANAGEMENT; URETHRAL CATHETERS; URINARY CATHETERS;
ESCHERICHIA-COLI; PILOT TRIAL; COLONIZATION; INFECTION; ADHERENCE
AB Study design: Non-randomized pilot trial.
Objectives: To determine whether Escherichia coli 83972-coated urinary catheters in persons with spinal cord injury (SCI) practicing an intermittent catheterization program (ICP) could (1) achieve bladder colonization with this benign organism and (2) decrease the rate of symptomatic urinary tract infection (UTI).
Setting: Outpatient SCI clinic in a Veterans Affairs hospital (USA).
Methods: Participants had neurogenic bladders secondary to SCI, were practicing ICP, had experienced at least one UTI and had documented bacteruria within the past year. All participants received a urinary catheter that had been pre-inoculated with E. coli 83972. The catheter was left in place for 3 days and then removed. Participants were followed with urine cultures and telephone calls weekly for 28 days and then monthly until E. coli 83972 was lost from the urine. Outcome measures were (1) the rate of successful bladder colonization, defined as the detection (>= 10(2) cfu ml(-1)) of E. coli 83972 in urine cultures for >3 days after catheter removal and (2) the rate of symptomatic UTI during colonization with E. coli 83972.
Results: Thirteen participants underwent 19 insertions of study catheters. Eight participants (62%) became successfully colonized for 43 days after catheter removal. In these 8 participants, the rate of UTI during colonization was 0.77 per patient-year, in comparison with the rate of 2.27 UTI per patient-year before enrollment.
Conclusions: E. coli 83972-coated urinary catheters are a viable means of achieving bladder colonization with this potentially protective strain in persons practicing ICP. Spinal Cord (2009) 47, 565-569; doi: 10.1038/sc.2008.166; published online 13 January 2009
C1 [Cevallos, M. E.; Riosa, S.; Darouiche, R. O.; Trautner, B. W.] Baylor Coll Med, Dept Med, Div Infect Dis, Houston, TX 77030 USA.
[Prasad, A.] New York Med Coll, Westchester Med Ctr, Dept Internal Med, Westchester, NY USA.
[Cevallos, M. E.; Riosa, S.; Darouiche, R. O.; Trautner, B. W.] Baylor Coll Med, Ctr Prosthesis Infect, Dept Phys Med & Rehabil, Houston, TX 77030 USA.
[Darouiche, R. O.; Trautner, B. W.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Trautner, BW (reprint author), Baylor Coll Med, Dept Med, Div Infect Dis, 1 Baylor Plaza,BCM 286,N1319, Houston, TX 77030 USA.
EM trautner@bcm.edu
FU Department of Veterans Affairs Rehabilitation Research and Development
Service [B4623R, B4087R, B4387P]; NIH [HD42014, DK77313]
FX This study was supported by Department of Veterans Affairs
Rehabilitation Research and Development Service grants B4623R, B4087R
and B4387P as well as by NIH grants HD42014 and DK77313.
NR 20
TC 17
Z9 18
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
J9 SPINAL CORD
JI Spinal Cord
PD JUL
PY 2009
VL 47
IS 7
BP 565
EP 569
DI 10.1038/sc.2008.166
PG 5
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 465QV
UT WOS:000267602800011
PM 19139758
ER
PT J
AU Subramanian, S
Zhang, B
Kosaka, Y
Burrows, GG
Grafe, MR
Vandenbark, AA
Hurn, PD
Offner, H
AF Subramanian, Sandhya
Zhang, Bing
Kosaka, Yasuharu
Burrows, Gregory G.
Grafe, Marjorie R.
Vandenbark, Arthur A.
Hurn, Patricia D.
Offner, Halina
TI Recombinant T Cell Receptor Ligand Treats Experimental Stroke
SO STROKE
LA English
DT Article
DE autoreactive T cells; immunotherapy; recombinant TCR ligands; stroke
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ISCHEMIC-STROKE;
MULTIPLE-SCLEROSIS; TRANSGENIC MICE; ACTIVATION; INJURY; LYMPHOCYTES;
SYSTEM; ASSOCIATION; INDUCTION
AB Background and Purpose-Experimental stroke induces a biphasic effect on the immune response that involves early activation of peripheral leukocytes followed by severe immunodepression and atrophy of the spleen and thymus. In tandem, the developing infarct is exacerbated by influx of numerous inflammatory cell types, including T and B lymphocytes. These features of stroke prompted our use of recombinant T cell receptor ligands (RTL), partial major histocompatibility complex Class II molecules covalently bound to myelin peptides. We tested the hypothesis that RTL would improve ischemic outcome in the brain without exacerbating defects in the peripheral immune system function.
Methods-Four daily doses of RTL were administered subcutaneously to C57BL/6 mice after middle cerebral artery occlusion, and lesion size and cellular composition were assessed in the brain and cell numbers were assessed in the spleen and thymus.
Results-Treatment with RTL551 (I-A(b) molecule linked to MOG-35-55 peptide) reduced cortical and total stroke lesion size by approximately 50%, inhibited the accumulation of inflammatory cells, particularly macrophages/activated microglial cells and dendritic cells, and mitigated splenic atrophy. Treatment with RTL1000 (HLA-DR2 moiety linked to human MOG-35-55 peptide) similarly reduced the stroke lesion size in HLA-DR2 transgenic mice. In contrast, control RTL with a nonneuroantigen peptide or a mismatched major histocompatibility complex Class II moiety had no effect on stroke lesion size.
Conclusions-These data are the first to demonstrate successful treatment of experimental stroke using a neuroantigen-specific immunomodulatory agent administered after ischemia, suggesting therapeutic potential in human stroke. (Stroke. 2009; 40: 2539-2545.)
C1 [Subramanian, Sandhya; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA.
[Zhang, Bing; Kosaka, Yasuharu; Grafe, Marjorie R.; Hurn, Patricia D.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA.
[Burrows, Gregory G.; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
[Grafe, Marjorie R.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA.
RP Offner, H (reprint author), Portland VA Med Ctr, R&D 31,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM offnerva@ohsu.edu
FU US Public Health Service National Institutes of Health [NS33668,
NRO3521, NS49210, AI43960, NS47661]; National Multiple Sclerosis Society
[RG379-A-4]; The Nancy Davis Center Without Walls; Biomedical Laboratory
R&D Service, Department of Veterans' Affairs
FX This work was supported by US Public Health Service National Institutes
of Health grants NS33668, NRO3521, NS49210, AI43960, and NS47661;
National Multiple Sclerosis Society grant RG379-A-4; The Nancy Davis
Center Without Walls; and the Biomedical Laboratory R&D Service,
Department of Veterans' Affairs.
NR 34
TC 46
Z9 49
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUL
PY 2009
VL 40
IS 7
BP 2539
EP 2545
DI 10.1161/STROKEAHA.108.543991
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 463XR
UT WOS:000267467900041
PM 19443805
ER
PT J
AU Kvale, EA
Murthy, R
Taylor, R
Lee, JY
Nabors, LB
AF Kvale, Elizabeth A.
Murthy, Rashmi
Taylor, Richard
Lee, Jeannette Y.
Nabors, L. B.
TI Distress and quality of life in primary high-grade brain tumor patients
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Glioblastoma multiforme; Brain tumor; Quality of life; Distress
ID FUNCTIONAL OUTCOMES; CANCER-PATIENTS; GLIOMAS; ADULTS; SCALE;
DETERMINANTS; RECOGNITION; DEPRESSION; SURVIVAL; THERAPY
AB We report on the routine use of the NCCN Distress Thermometer and the Functional Assessment of Cancer Therapy-Brain (FACT-Br) to assess patient distress and quality of life in GBM patients. The purpose of this study was to examine the relationship between patient quality of life and distress.
Data from 50 GBM patients presenting to a neuro-oncology clinic were evaluated. Descriptive statistics and correlations between the distress score and the FACT-Br subscale scores were generated.
The mean distress score was 2.15 (std 2.66), and 28.9% of brain tumor patients identified a distress score of 4 or above. The mean FACT-Br total was 127.34 (std 21.29), with patients scoring lowest in the EWB (18.95 std 4.4) and FWB (15.06 std 6.80) subscales. No differences between demographic groups were identified with regard to distress or quality of life. Statistically significant correlations were identified between the distress score and the SWB (R = -0.46, P = 0.001) and EWB (R = -0.56, P = 0.001) subscales of the FACT-Br. Fifty percent of participants who did not complete the FACT-Br reported clinically significant distress, but this did not differ significantly from participants who completed it.
Assessment of distress in brain tumor patients provides clinically relevant information and suggests interventions that may support quality of life. Further research is needed to explore the relationship between distress and quality of life. Current approaches to measuring quality of life in brain tumor patients may systematically undersample patients with advanced illness or significant psychosocial distress.
C1 [Kvale, Elizabeth A.] Univ Alabama, Birmingham VA Med Ctr, Birmingham, AL USA.
[Murthy, Rashmi] Baylor Coll Med, Houston, TX 77030 USA.
[Lee, Jeannette Y.] Univ Arkansas Med Sci, Fayetteville, AR USA.
RP Kvale, EA (reprint author), Univ Alabama, Birmingham VA Med Ctr, Birmingham, AL USA.
EM ekvale@aging.uab.edu
NR 25
TC 24
Z9 24
U1 3
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JUL
PY 2009
VL 17
IS 7
BP 793
EP 799
DI 10.1007/s00520-008-0551-9
PG 7
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 456FK
UT WOS:000266827000006
PM 19421789
ER
PT J
AU Morris, KR
Lutz, RD
Bai, XY
McGibney, MT
Cook, D
Ordway, D
Chan, ED
AF Morris, Kristin R.
Lutz, Ryan D.
Bai, Xiyuan
McGibney, Mischa T.
Cook, Danielle
Ordway, Diane
Chan, Edward D.
TI Suppression of IFN gamma plus mycobacterial lipoarabinomannan-induced NO
by IL-4 is due to decreased IRF-1 expression
SO TUBERCULOSIS
LA English
DT Article
DE Lipoarabinomannan; Nitric oxide; Interleukin-4; Inducible nitric oxide
synthase; Interferon-gamma; Transcriptional regulation
ID NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA;
NF-KAPPA-B; HUMAN PULMONARY TUBERCULOSIS; RAT-LIVER ARGINASE;
INTERFERON-GAMMA; FACTOR-ALPHA; ALTERNATIVE ACTIVATION; MURINE
MACROPHAGES
AB In mice, and possibly in humans, nitric oxide (NO) is an important host-defense molecule against Mycobacterium tuberculosis. Inducible nitric oxide synthase (iNOS) and NO are upregulated in murine macrophages stimulated with interferon-gamma (IFN gamma) and mannose-capped lipoarabinomannan (ManLAM), a major lipoglycan in the cell wall of M. tuberculosis. Interleukin-4 (IL-4) can inhibit NO expression and may impair host immune response to M. tuberculosis. Therefore, we sought to determine the mechanism by which IL-4 inhibits IFN gamma + ManLAM-induced NO production. Since L-arginine is the substrate for both iNOS and arginase, and IL-4 increases arginase activity by inducing its production, a plausible mechanism of IL-4 inhibition of NO expression is via depletion of L-arginine through increased arginase activity. Herein, we show that IL-4 inhibited iNOS gene expression at the transcriptional level, suggesting an inhibitory mechanism that is independent of the competition for L-arginine between iNOS and arginase. Furthermore, pharmacologic inhibition of IL-4-induced arginase activity did not abrogate IL-4 inhibition of IFN gamma + ManLAM-induced NO expression. Instead, inhibition by IL-4 was mediated principally by the ability of IL-4 to inhibit the production of IFN gamma-induced interferon-gamma response factor-1 (IRF-1) protein, a critically important transcriptional element that enhances expression of IFN gamma-inducible genes such as iNOS. Published by Elsevier Ltd.
C1 [Chan, Edward D.] Univ Colorado, Hlth Sci Ctr, Resp Dept, Denver Vet Affairs Med Ctr, Denver, CO USA.
[Morris, Kristin R.; Lutz, Ryan D.; Cook, Danielle; Chan, Edward D.] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA.
[Chan, Edward D.] Univ Colorado, Hlth Sci Ctr, Cell Biol Program, Denver, CO USA.
[Bai, Xiyuan; McGibney, Mischa T.; Chan, Edward D.] Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Denver, CO USA.
[Ordway, Diane] Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.
RP Chan, ED (reprint author), K720,Goodman Bldg,1400 Jackson St, Denver, CO 80206 USA.
EM chane@njhealth.org
FU Department of Veterans Affairs; Veterans Health Administration; Office
of Research and Development (EDC); [N01-Al-75320]
FX This material is based upon work supported in part by the Department of
Veterans Affairs, Veterans Health Administration, Office of Research and
Development (EDC). The authors wish to thank Drs. Patrick Brennan, John
Belisle, and Karen Dobos of Colorado State University in Ft. Collins,
Colorado for the ManLAM, the procurement of which is supported by
N01-Al-75320.
NR 47
TC 11
Z9 11
U1 0
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1472-9792
J9 TUBERCULOSIS
JI Tuberculosis
PD JUL
PY 2009
VL 89
IS 4
BP 294
EP 303
DI 10.1016/j.tube.2009.03.004
PG 10
WC Immunology; Microbiology; Respiratory System
SC Immunology; Microbiology; Respiratory System
GA 484NG
UT WOS:000269051800009
PM 19556165
ER
PT J
AU Kutcher, MA
Klein, LW
Ou, FS
Wharton, TP
Dehmer, GJ
Singh, M
Anderson, HV
Rumsfeld, JS
Weintraub, WS
Shaw, RE
Sacrinty, MT
Woodward, A
Peterson, ED
Brindis, RG
AF Kutcher, Michael A.
Klein, Lloyd W.
Ou, Fang-Shu
Wharton, Thomas P., Jr.
Dehmer, Gregory J.
Singh, Mandeep
Anderson, H. Vernon
Rumsfeld, John S.
Weintraub, William S.
Shaw, Richard E.
Sacrinty, Matthew T.
Woodward, Albert
Peterson, Eric D.
Brindis, Ralph G.
CA NCDR
TI Percutaneous Coronary Interventions in Facilities Without Cardiac
Surgery On Site: A Report From the National Cardiovascular Data Registry
(NCDR)
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE percutaneous coronary intervention; cardiac surgery; outcomes analysis
ID ACUTE MYOCARDIAL-INFARCTION; ARTERY-BYPASS-SURGERY; ON-SITE; PRIMARY
ANGIOPLASTY; AMERICAN-COLLEGE; SURGICAL BACKUP; ACC-NCDR; THROMBOLYTIC
THERAPY; HOSPITALS; COMMUNITY
C1 [Kutcher, Michael A.; Sacrinty, Matthew T.] Wake Forest Univ, Sch Med, Winston Salem, NC 27157 USA.
[Klein, Lloyd W.] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA.
[Ou, Fang-Shu; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA.
[Wharton, Thomas P., Jr.] Royal Devon & Exeter Hosp, Exeter, NH USA.
[Dehmer, Gregory J.] Texas A&M Univ, Coll Med, Scott & White HealthCare, Temple, TX 76508 USA.
[Singh, Mandeep] Mayo Clin, Rochester, MN USA.
[Anderson, H. Vernon] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA.
[Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
[Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA.
[Shaw, Richard E.] Sutter Pacific Heart Ctr, San Francisco, CA USA.
[Woodward, Albert] Natl Cardiovasc Data Registry, Washington, DC USA.
[Brindis, Ralph G.] No Calif Kaiser Permanente, San Francisco, CA USA.
RP Kutcher, MA (reprint author), Wake Forest Univ, Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM mkutcher@wfubmc.edu
NR 30
TC 49
Z9 50
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD JUN 30
PY 2009
VL 54
IS 1
BP 16
EP 24
DI 10.1016/j.jacc.2009.03.038
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 465AJ
UT WOS:000267552000002
PM 19555835
ER
PT J
AU Adelson, D
Lao, L
Zhang, G
Kim, W
Marvizon, JCG
AF Adelson, D.
Lao, L.
Zhang, G.
Kim, W.
Marvizon, J. C. G.
TI SUBSTANCE P RELEASE AND NEUROKININ 1 RECEPTOR ACTIVATION IN THE RAT
SPINAL CORD INCREASE WITH THE FIRING FREQUENCY OF C-FIBERS
SO NEUROSCIENCE
LA English
DT Article
DE A delta-fiber; neurokinin A; neuropeptide; pain; presynaptic terminal;
tachykinins
ID LONG-TERM POTENTIATION; PRIMARY AFFERENT-FIBERS; DORSAL-HORN NEURONS;
METHYL-D-ASPARTATE; PRIMARY SENSORY NEURONS; UNITS IN-VITRO; LAMINA-I;
EVOKED POTENTIALS; CONDUCTION-VELOCITY; NEUROTROPHIC FACTOR
AB Both the firing frequency of primary afferents and neurokinin I receptor (NK1R) internalization in dorsal horn neurons increase with the intensity of noxious stimulus. Accordingly, we studied how the pattern of firing of primary afferent influences NK1R internalization. In rat spinal cord slices, electrical stimulation of the dorsal root evoked NK1R internalization in lamina I neurons by inducing substance P release from primary afferents. The stimulation frequency had pronounced effects on NK1R internalization, which increased up to 100 Hz and then diminished abruptly at 200 Hz. Peptidase inhibitors increased NK1R internalization at frequencies below 30 Hz, indicating that peptidases limit the access of substance P to the receptor at moderate firing rates. NK1R internalization increased with number of pulses at all frequencies, but maximal internalization was substantially lower at 1-10 Hz than at 30 Hz. Pulses organized into bursts produced the same NK1R internalization as sustained 30 Hz stimulation. To determine whether substance P release induced at high stimulation frequencies was from C-fibers, we recorded compound action potentials in the sciatic nerve of anesthetized rats. We observed substantial NK1R internalization when stimulating at intensities evoking a C-elevation, but not at intensities evoking only an A delta-elevation. Each pulse in trains at frequencies up to 100 Hz evoked a C-elevation, demonstrating that C-fibers can follow these high frequencies. C-elevation amplitudes declined progressively with increasing stimulation frequency, which was likely caused by a combination of factors including temporal dispersion. In conclusion, the instantaneous firing frequency in C-fibers determines the amount of substance P released by noxious stimuli. Published by Elsevier Ltd on behalf of IBRO.
C1 [Adelson, D.; Marvizon, J. C. G.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Adelson, D.; Lao, L.; Zhang, G.; Kim, W.; Marvizon, J. C. G.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, CURE Digest Dis Res Ctr,Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA.
RP Marvizon, JCG (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Bldg 115,Room 119,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM marvizon@ucla.edu
OI Adelson, David/0000-0002-4623-6030
FU Rehabilitation Research and Development Service [B47661]; Department of
Veteran Affairs; National Institutes of Health [1R01DA012609]
FX Supported by grants B47661 from the Rehabilitation Research and
Development Service, Department of Veteran Affairs and 1R01DA012609 from
the National Institutes of Health to J.C.G.M. Confocal images were
acquired at Carol Moss Spivak Cell Imaging Facility of the Brain
Research Institute at UCLA, with the assistance of Dr. Matthew J.
Schibler.
NR 59
TC 14
Z9 14
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
J9 NEUROSCIENCE
JI Neuroscience
PD JUN 30
PY 2009
VL 161
IS 2
BP 538
EP 553
DI 10.1016/j.neuroscience.2009.03.058
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA 455VC
UT WOS:000266794100020
PM 19336248
ER
PT J
AU Koenigsberg, HW
Siever, LJ
Lee, H
Pizzarello, S
New, AS
Goodman, M
Cheng, H
Flory, J
Prohovnik, I
AF Koenigsberg, Harold W.
Siever, Larry J.
Lee, Hedok
Pizzarello, Scott
New, Antonia S.
Goodman, Marianne
Cheng, Hu
Flory, Janine
Prohovnik, Isak
TI Neural correlates of emotion processing in borderline personality
disorder
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article
DE Affective instability; Emotion; fMRI; Social-emotional cues; Borderline
personality disorder
ID POSITRON-EMISSION-TOMOGRAPHY; AFFECTIVE INSTABILITY; AMYGDALA;
ACTIVATION; STIMULI; PERCEPTION; WOMEN; FMRI; FACE; CUES
AB Emotional instability is a hallmark feature of borderline personality disorder (BPD), yet its biological underpinnings are poorly understood. We employed functional magnetic resonance imaging (fMRI) to compare patterns of regional brain activation in BPD patients and healthy volunteers as they process positive and negative social emotional stimuli. fMRI images were acquired while 19 BPD patients and 17 healthy controls (HC) viewed emotion-inducing pictures from the International Affective Pictures System set. Activation data were analyzed with SPM5 ANCOVA models to derive the effects of diagnosis and stimulus type. BPD patients demonstrated greater differences in activation than controls, when viewing negative pictures compared with rest, in the amygdala, fusiform gyrus, primary visual areas, superior temporal gyrus (STG), and premotor areas, while healthy controls showed greater differences than BPD patients in the insula, middle temporal gyrus and dorsolateral prefrontal cortex (BA46). When viewing positive pictures compared with rest, BPD patients showed greater differences in the STG, premotor cortex, and ventrolateral prefrontal cortex. These findings suggest that BPD patients show greater amygdala activity and heightened activity of visual processing regions relative to findings for HC subjects in the processing of negative social emotional pictures compared with rest. The patients activate neural networks in emotion processing that are phylogeneticall older and more reflexive than those activated by HC subjects. Published by Elsevier Ireland Ltd.
C1 [Koenigsberg, Harold W.; Siever, Larry J.; Lee, Hedok; New, Antonia S.; Goodman, Marianne; Prohovnik, Isak] Mt Sinai Sch Med, James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Koenigsberg, Harold W.; Siever, Larry J.; New, Antonia S.; Goodman, Marianne; Prohovnik, Isak] Mt Sinai Sch Med, New York, NY USA.
[Cheng, Hu] Indiana Univ, Bloomington, IN 47405 USA.
[Flory, Janine] CUNY Queens Coll, Dept Psychol, Flushing, NY 11367 USA.
[Pizzarello, Scott] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA.
RP Koenigsberg, HW (reprint author), Mt Sinai Sch Med, James J Peters VA Med Ctr, 116A,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM HWarrenK@nyc.rr.com
FU National Center for Research Resources (NCRR) [MO1-RR-00071]; National
Institutes of Health (NIH); Mental Illness Research Education and
Clinical Center; Siemens Medical Systems, Inc
FX This work was supported by Grant Number MO1-RR-00071 from the National
Center for Research Resources (NCRR), a component of the National
Institutes of Health (NIH) and the Mental Illness Research Education and
Clinical Center, VISN 3 Veterans Health Administration, and an
educational grant from the Siemens Medical Systems, Inc. Its contents
are solely the responsibility of the authors and do not necessarily
represent the official views of NCRR, NIH, or the VA. We thank Dr.
Sergei Pakhomov (Institute of the Human Brain, St. Petersburg, Russia)
for the MSU software.
NR 54
TC 96
Z9 96
U1 1
U2 18
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0925-4927
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD JUN 30
PY 2009
VL 172
IS 3
BP 192
EP 199
DI 10.1016/j.pscychresns.2008.07.010
PG 8
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 452ZX
UT WOS:000266580800004
PM 19394205
ER
PT J
AU Pinne, M
Haake, DA
AF Pinne, Marija
Haake, David A.
TI A Comprehensive Approach to Identification of Surface-Exposed, Outer
Membrane-Spanning Proteins of Leptospira interrogans
SO PLOS ONE
LA English
DT Article
AB Leptospirosis is a zoonosis with worldwide distribution caused by pathogenic spirochetes belonging to the genus Leptospira. The leptospiral life cycle involves transmission via fresh water and colonization of the renal tubules of their reservoir hosts or infection of accidental hosts, including humans. Bacterial outer membrane proteins (OMPs), particularly those with surface-exposed regions, play crucial roles in virulence mechanisms of pathogens and the adaptation to various environmental conditions, including those of the mammalian host. Little is known about the surface-exposed OMPs in Leptospira, particularly those with outer membrane-spanning domains. Herein, we describe a comprehensive strategy for identification and characterization of leptospiral transmembrane OMPs. The genomic sequence of L. interrogans serovar Copenhageni strain Fiocruz L1-130 allowed us to employ the beta-barrel prediction programs, PRED-TMBB and TMBETA-NET, to identify potential transmembrane OMPs. Several complementary methods were used to characterize four novel OMPs, designated OmpL36, OmpL37, OmpL47 and OmpL54. In addition to surface immunofluorescence and surface biotinylation, we describe surface proteolysis of intact leptospires as an improved method for determining the surface exposure of leptospiral proteins. Membrane integration was confirmed using techniques for removal of peripheral membrane proteins. We also demonstrate deficiencies in the Triton X-114 fractionation method for assessing the outer membrane localization of transmembrane OMPs. Our results establish a broadly applicable strategy for the elucidation of novel surface-exposed outer membrane-spanning proteins of Leptospira, an essential step in the discovery of potential virulence factors, diagnostic antigens and vaccine candidates.
RP Pinne, M (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
EM mpinne@ucla.edu
FU NIAID NIH HHS [AI-34431, R01 AI034431, R01 AI034431-12, R21 AI034431,
R29 AI034431]
NR 84
TC 38
Z9 38
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 29
PY 2009
VL 4
IS 6
AR e6071
DI 10.1371/journal.pone.0006071
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 463XB
UT WOS:000267465900007
PM 19562037
ER
PT J
AU Scalapino, KJ
Daikh, DI
AF Scalapino, Kenneth J.
Daikh, David I.
TI Suppression of Glomerulonephritis in NZB/NZW Lupus Prone Mice by
Adoptive Transfer of Ex Vivo Expanded Regulatory T Cells
SO PLOS ONE
LA English
DT Article
AB Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown cause characterized by expansion of autoreactive lymphocytes. Regulatory T cells (T(regs)) are a component of the normal immune system and contribute to the maintenance of peripheral tolerance. T(reg) abnormalities have been associated with several autoimmune diseases and there is interest in the role of T(regs) in SLE. We previously demonstrated that transfer of expanded CD4(+)CD25(+)CD62L(HI) T(regs) slows the development of lupus in (NZBxNZW)F(1) (B/W) mice. However in the absence of T(reg) specific surface antigens, cell purification remains a compromise between the breadth and purity of the population isolated. Importantly, purified populations always contain Foxp3(-) effector T cells (T(effs)) that theoretically could exacerbate autoimmunity in the recipient. Here we explore the impact of transferring the more comprehensive, but less pure T(reg) subset defined by CD4(+)CD25(+) expression on development of murine lupus. All cells were FACS sorted and expanded prior to adoptive transfer. Development of proteinuria and survival were measured. We found that exogenous expansion of CD4(+)CD25(+) cells produced a population containing 70-85% CD4(+)Foxp3(+) T(regs). Expanded T(regs) had higher CTLA-4 and Foxp3 expression, increased in vitro suppression capacity, and prolonged in vivo survival as compared to freshly isolated cells. Adoptive transfer of expanded CD4(+)CD25(+) T(regs) inhibited the onset of glomerulonephritis and prolonged survival in mice. Importantly the population of T(eff) contained within the adoptively transferred cells had reduced survival and proliferation capacity as compared to either co-transferred T(regs) or transferred T(effs) expanded in the absence of T(regs). These studies demonstrate that adoptive transfer of expanded CD4(+)CD25(+)Foxp3(+) T(regs) has the capacity to inhibit the onset of murine lupus and that this capacity is significant despite transfer of co-cultured T(eff) cells. These data indicate that when co-expanded with regulatory T cells, exogenously activated T(effs) from autoimmune patients may not pose a significant risk of promoting disease.
RP Scalapino, KJ (reprint author), San Francisco VA Med Ctr, Arthrit Sect, San Francisco, CA USA.
EM daikh@itsa.ucsf.edu
NR 36
TC 21
Z9 23
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 24
PY 2009
VL 4
IS 6
AR e6031
DI 10.1371/journal.pone.0006031
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 462MF
UT WOS:000267356500015
PM 19551149
ER
PT J
AU Goldman, S
McCarren, M
Morkin, E
Ladenson, PW
Edson, R
Warren, S
Ohm, J
Thai, H
Churby, L
Barnhill, J
O'Brien, T
Anand, I
Warner, A
Hattler, B
Dunlap, M
Erikson, J
Shih, MC
Lavori, P
AF Goldman, Steven
McCarren, Madeline
Morkin, Eugene
Ladenson, Paul W.
Edson, Robert
Warren, Stuart
Ohm, Janet
Thai, Hoang
Churby, Lori
Barnhill, Jamie
O'Brien, Terrence
Anand, Inder
Warner, Alberta
Hattler, Brack
Dunlap, Mark
Erikson, John
Shih, Mei-Chiung
Lavori, Phil
TI DITPA (3,5-Diiodothyropropionic Acid), a Thyroid Hormone Analog to Treat
Heart Failure Phase II Trial Veterans Affairs Cooperative Study
SO CIRCULATION
LA English
DT Article
DE cardiac output; hemodynamics; thyroid; heart failure; pharmacology
ID LEFT-VENTRICULAR PERFORMANCE; CHOLESTEROL; ACTIVATION; WEIGHT
AB Background-In animal studies and a pilot trial in patients with congestive heart failure, the thyroid hormone analog 3,5 diiodothyropropionic acid (DITPA) had beneficial hemodynamic effects.
Methods and Results-This was a phase II multicenter, randomized, placebo-controlled, double-blind trial of New York Heart Association class II to IV congestive heart failure patients randomized (2: 1) to DITPA or placebo and treated for 6 months. The study enrolled 86 patients (n = 57 to DITPA, n = 29 to placebo). The primary objective was to assess the effect of DITPA on a composite congestive heart failure end point that classifies patients as improved, worsened, or unchanged based on symptom changes and morbidity/mortality. DITPA was poorly tolerated, which obscured the interpretation of congestive heart failure-specific effects. Fatigue and gastrointestinal complaints, in particular, were more frequent in the DITPA group. DITPA increased cardiac index (by 18%) and decreased systemic vascular resistance (by 11%), serum cholesterol (-20%), low-density lipoprotein cholesterol (-30%), and body weight (-11 lb). Thyroid-stimulating hormone was suppressed in patients given DITPA, which reflects its thyromimetic effect; however, no symptoms or signs of potential hypothyroidism or thyrotoxicosis were seen.
Conclusions-DITPA improved some hemodynamic and metabolic parameters, but there was no evidence for symptomatic benefit in congestive heart failure. (Circulation. 2009; 119: 3093-3100.)
C1 [Goldman, Steven] So Arizona VA Hlth Care Syst, Cardiol Sect 1 111C, Tucson, AZ 85723 USA.
[McCarren, Madeline] VA Pharm Benefits Management, Hines, IL USA.
[Morkin, Eugene] Univ Arizona, Tucson, AZ USA.
[Ladenson, Paul W.] Johns Hopkins Univ, Baltimore, MD USA.
[Edson, Robert; Churby, Lori; Shih, Mei-Chiung; Lavori, Phil] Vet Affairs Med Ctr, R&D Serv, Palo Alto, CA 94304 USA.
[Warren, Stuart; Barnhill, Jamie] Vet Affairs Med Ctr, R&D Serv, Albuquerque, NM USA.
[O'Brien, Terrence] Vet Affairs Med Ctr, Charleston, SC 29403 USA.
[Anand, Inder] Vet Affairs Med Ctr, Minneapolis, MN USA.
[Warner, Alberta] Vet Affairs Med Ctr, Los Angeles, CA USA.
[Hattler, Brack] Vet Affairs Med Ctr, Denver, CO USA.
[Dunlap, Mark] Vet Affairs Med Ctr, Cleveland, OH USA.
[Erikson, John] Vet Affairs Med Ctr, San Antonio, TX USA.
RP Goldman, S (reprint author), So Arizona VA Hlth Care Syst, Cardiol Sect 1 111C, 3601 S 6th Ave, Tucson, AZ 85723 USA.
EM steven.goldman@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Clinical Science Research and Development
Service, Cooperative Studies Program
FX This study was supported by the Department of Veterans Affairs, Veterans
Health Administration, Office of Research and Development, Clinical
Science Research and Development Service, Cooperative Studies Program.
NR 28
TC 50
Z9 52
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JUN 23
PY 2009
VL 119
IS 24
BP 3093
EP U84
DI 10.1161/CIRCULATIONAHA.108.834424
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 461PI
UT WOS:000267279900009
PM 19506112
ER
PT J
AU Bilimoria, KY
Bentrem, DJ
Hansen, NM
Bethke, KP
Rademaker, AW
Ko, CY
Winchester, DP
Winchester, DJ
AF Bilimoria, Karl Y.
Bentrem, David J.
Hansen, Nora M.
Bethke, Kevin P.
Rademaker, Alfred W.
Ko, Clifford Y.
Winchester, David P.
Winchester, David J.
TI Comparison of Sentinel Lymph Node Biopsy Alone and Completion Axillary
Lymph Node Dissection for Node-Positive Breast Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT 94th Annual Clinical Congress of the American-College-of-Surgeons/63rd
Annual Sessions of the Owen H Wangensteen Forum on Fundamental Surgical
Problems
CY OCT 12-16, 2008
CL San Francisco, CA
SP Amer Coll Surg
ID FOLLOW-UP; CONTROLLED-TRIALS; TOTAL MASTECTOMY; ACOSOG Z0011; CARCINOMA;
NOMOGRAM; IRRADIATION; WOMEN
AB Purpose
For women with breast cancer, the role of completion axillary lymph node dissection (ALND) after identification of nodal metastases by sentinel lymph node biopsy (SLNB) has been questioned. Our objectives were to assess national nodal evaluation practice patterns and to examine differences in recurrence and survival for SLNB alone versus SLNB with completion ALND.
Patients and Methods
From the National Cancer Data Base (1998 to 2005), women with clinically node-negative breast cancer who underwent SLNB and who had nodal metastases were identified. Practice patterns and outcomes were examined for patients who underwent SLNB alone versus SLNB with completion ALND (median follow-up, 63 months).
Results
Of 97,314 patients, 20.8% underwent SLNB alone, and 79.2% underwent SLNB with completion ALND. In 2004 to 2005, patients were significantly more likely to undergo SLNB alone if they were older, had smaller tumors, or were treated at non-National Cancer Institute-designated cancer centers. In patients with macroscopic nodal metastases (n = 20,075 during 1998 to 2000), there was a nonsignificant trend toward better outcomes for completion ALND (v SLNB alone) after analysis was adjusted for differences between the two groups: axillary recurrence (hazard ratio [HR], 0.58; 95% CI, 0.32 to 1.06) and overall survival (HR, 0.89; 95% CI, 0.76 to 1.04). In patients with microscopic nodal metastases (n = 2,203 during 1998 to 2000), there were no significant differences in axillary recurrence or survival for patients who underwent SLNB alone versus completion ALND.
Conclusion
Compared with SLNB alone, completion ALND does not appear to improve outcomes for breast cancer patients with microscopic nodal metastases; however, there was a nonsignificant trend toward better outcomes with completion ALND for those with macroscopic disease. J Clin Oncol 27: 2946-2953. (C) 2009 by American Society of Clinical Oncology
C1 [Winchester, David P.] Northwestern Univ, Amer Coll Surg, Canc Programs, Chicago, IL 60611 USA.
Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA.
Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
NorthShore Univ HealthSyst, Dept Surg, Evanston, IL USA.
Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Winchester, DP (reprint author), Northwestern Univ, Amer Coll Surg, Canc Programs, 633 N St Claire, Chicago, IL 60611 USA.
EM dwinchester@facs.org
NR 43
TC 178
Z9 184
U1 0
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 20
PY 2009
VL 27
IS 18
BP 2946
EP 2953
DI 10.1200/JCO.2008.19.5750
PG 8
WC Oncology
SC Oncology
GA 459TP
UT WOS:000267133300013
PM 19364968
ER
PT J
AU Butt, AA
McGinnis, K
Rodriguez-Barradas, MC
Crystal, S
Simberkoff, M
Goetz, MB
Leaf, D
Justice, AC
AF Butt, Adeel A.
McGinnis, Kathleen
Rodriguez-Barradas, Maria C.
Crystal, Stephen
Simberkoff, Michael
Goetz, Matthew Bidwell
Leaf, David
Justice, Amy C.
CA Veterans Aging Cohort Study
TI HIV infection and the risk of diabetes mellitus
SO AIDS
LA English
DT Article
DE antiretroviral therapy; diabetes; HCV; HIV; risk
ID CHRONIC HEPATITIS-C; MULTICENTER AIDS COHORT; INSULIN-RESISTANCE;
VIRUS-INFECTION; ANTIRETROVIRAL THERAPY; POST-HAART; VETERANS;
PREVALENCE; HEALTH; HCV
AB Background: The influence of HIV infection on the risk of diabetes is unclear. We determined the association and predictors of prevalent diabetes mellitus in HIV infected and uninfected veterans.
Methods: We determined baseline prevalence and risk factors for diabetes between HIV infected and uninfected veterans in the Veterans Aging Cohort Study. Logistic regression was used to determine the odds of diabetes in HIV infected and uninfected persons.
Results: We studied 3227 HIV-infected and 3240 HIV-uninfected individuals. HIV-infected individuals were younger, more likely to be black males, have HCV coinfection and a lower BMI. HIV-infected individuals had a lower prevalence of diabetes at baseline (14.9 vs. 21.4%, P < 0.0001). After adjustment for known risk factors, HIV-infected individuals had a lower risk of diabetes (odds ratio = 0.84, 95% confidence interval = 0.72-0.97). Increasing age, male sex, minority race, and BMI were associated with an increased risk. The odds ratio for diabetes associated with increasing age, minority race and BMI were greater among HIV-infected veterans. HCV coinfection and nucleoside and nonnucleoside reverse transcriptase inhibitor therapy were associated with a higher risk of diabetes in HIV-infected veterans.
Conclusion: Although HIV infection itself is not associated with increased risk of diabetes, increasing age; HCV coinfection and BMI have a more profound effect upon the risk of diabetes among HIV-infected persons. Further, long-term ARV treatment also increases risk. Future studies will need to determine whether incidence of diabetes mellitus differs by HIV status. (c) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Butt, Adeel A.; McGinnis, Kathleen] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA.
[Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Crystal, Stephen] Rutgers State Univ, Ctr Pharmacotherapy Dr Crystal Chron Dis Manageme, New Brunswick, NJ 08903 USA.
[Simberkoff, Michael] New York VA Med Ctr, New York, NY USA.
[Goetz, Matthew Bidwell; Leaf, David] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Goetz, Matthew Bidwell; Leaf, David] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Justice, Amy C.] W Haven & Yale Univ, Sch Med & Publ Hlth, VA Connecticut Healthcare Syst, West Haven, CT USA.
RP Butt, AA (reprint author), 3601 5th Ave,Suite 3A, Pittsburgh, PA 15213 USA.
EM butta@dom.pitt.edu
OI Goetz, Matthew/0000-0003-4542-992X
FU National Institute on Alcohol Abuse and Alcoholism [U10 AA 13566]; VHA
Public Health Strategic Health Core Group; National Institutes of Health
/National Institute on Drug Abuse [DA01617501A1]
FX Veterans Aging Cohort Study funded by: National Institute on Alcohol
Abuse and Alcoholism (U10 AA 13566) and VHA Public Health Strategic
Health Core Group. Dr Butt is supported by a Career Developmnt Award
from the National Institutes of Health /National Institute on Drug Abuse
(DA01617501A1).
NR 29
TC 103
Z9 106
U1 2
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JUN 19
PY 2009
VL 23
IS 10
BP 1227
EP 1234
DI 10.1097/QAD.0b013e32832bd7af
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 461PH
UT WOS:000267279800005
PM 19444074
ER
PT J
AU Cha-Molstad, H
Saxena, G
Chen, JQ
Shalev, A
AF Cha-Molstad, Hyunjoo
Saxena, Geetu
Chen, Junqin
Shalev, Anath
TI Glucose-stimulated Expression of Txnip Is Mediated by Carbohydrate
Response Element-binding Protein, p300, and Histone H4 Acetylation in
Pancreatic Beta Cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID THIOREDOXIN-INTERACTING PROTEIN; TRANSCRIPTION FACTOR; ORDERED
RECRUITMENT; MICROARRAY ANALYSIS; GENE-TRANSCRIPTION; APOPTOSIS; MLX;
CHREBP; MONDOA; COACTIVATOR
AB Recently, we identified Txnip (thioredoxin-interacting protein) as a mediator of glucotoxic beta cell death and discovered that lack of Txnip protects against streptozotocin- and obesity-induced diabetes by preventing beta cell apoptosis and preserving endogenous beta cell mass. Txnip has therefore become an attractive target for diabetes therapy, but although we have found that txnip transcription is highly induced by glucose through a unique carbohydrate response element, the factors controlling this effect have remained unknown. Using transient transfection experiments, we now show that overexpression of the carbohydrate response element-binding protein (ChREBP) transactivates the txnip promoter, whereas ChREBP knockdown by small interfering RNA completely blunts glucose-induced txnip transcription. Moreover, chromatin immunoprecipitation demonstrated that glucose leads to a dose- and time-dependent recruitment of ChREBP to the txnip promoter in vivo in INS-1 beta cells as well as human islets. Furthermore, we found that the co-activator and histone acetyltransferase p300 co-immunoprecipitates with ChREBP and also binds to the txnip promoter in response to glucose. Interestingly, this is associated with specific acetylation of histone H4 and recruitment of RNA polymerase II as measured by chromatin immunoprecipitation. Thus, with this study we have identified ChREBP as the transcription factor that mediates glucose-induced txnip expression in human islets and INS-1 beta cells and have characterized the chromatin modification associated with glucose-induced txnip transcription. In addition, the results reveal for the first time that ChREBP interacts with p300. This may explain how ChREBP induces H4 acetylation and sheds new light on glucose-mediated regulation of chromatin structure and transcription.
C1 [Cha-Molstad, Hyunjoo; Saxena, Geetu; Chen, Junqin; Shalev, Anath] Univ Wisconsin, Dept Med, Madison, WI 53792 USA.
[Cha-Molstad, Hyunjoo; Saxena, Geetu; Chen, Junqin; Shalev, Anath] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
RP Shalev, A (reprint author), Univ Wisconsin, Dept Med, H4-526 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA.
EM as7@medicine.wisc.edu
FU National Institutes of Health [R01DK-078752, R21HL-089205]; American
Diabetes Association [7-07-CD-22]; Juvenile Diabetes Research Foundation
[1-2007-790]
FX This work was supported, in whole or in part, by National Institutes of
Health, NIDDK, Grant R01DK-078752 and National Institutes of Health,
NHLBI, Grant R21HL-089205. This work was also supported by American
Diabetes Association Grant 7-07-CD-22 and Juvenile Diabetes Research
Foundation Grant 1-2007-790.
NR 45
TC 83
Z9 87
U1 1
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 19
PY 2009
VL 284
IS 25
BP 16898
EP 16905
DI 10.1074/jbc.M109.010504
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 457VM
UT WOS:000266962400026
PM 19411249
ER
PT J
AU Zeman, RJ
Bauman, WA
Wen, XL
Ouyang, N
Etlinger, JD
Cardozo, CR
AF Zeman, Richard J.
Bauman, William A.
Wen, Xialing
Ouyang, Nengtai
Etlinger, Joseph D.
Cardozo, Christopher R.
TI Improved functional recovery with oxandrolone after spinal cord injury
in rats
SO NEUROREPORT
LA English
DT Article
DE anabolic steroid; axonal sprouting; locomotor function; oxandrolone;
spinal cord injury
ID HISTOLOGICAL OUTCOMES; CONTUSION; LOCOMOTOR; AGONIST
AB At present only the corticosteroid, methylprednisolone, is used for acute spinal cord injury to improve function. However, improvements are modest, and are associated with myopathy and immunosuppression so that alternative treatments are needed. Oxandrolone is an androgenic steroid with potential neuroprotective properties that is used to prevent muscle loss and is not immunosuppressive. Oxandrolone increased locomotor recovery concomitant with reduced loss of cord tissue in a standard weight drop model of spinal cord contusion injury indicating oxandrolone as a possible alternative to methylprednisolone. Oxandrolone also increased axonal sprouting within the ventral horns distal to the injury consistent with formation of relay circuits mediating locomotor recovery. NeuroReport 20:864-868 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Bauman, William A.; Cardozo, Christopher R.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA.
[Zeman, Richard J.; Wen, Xialing; Ouyang, Nengtai; Etlinger, Joseph D.] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.
[Bauman, William A.; Cardozo, Christopher R.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Bauman, William A.; Cardozo, Christopher R.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.
[Zeman, Richard J.; Etlinger, Joseph D.] MotoGen Inc, Mt Kisco, NY USA.
RP Cardozo, CR (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM chris.cardozo@mssm.edu
FU Veterans Health Administration, Rehabilitation Research and Development
Service [B4162C, B3347 K]
FX This study was supported by Veterans Health Administration,
Rehabilitation Research and Development Service (B4162C to WAB, B3347 K
to CC).
NR 19
TC 6
Z9 7
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-4965
J9 NEUROREPORT
JI Neuroreport
PD JUN 17
PY 2009
VL 20
IS 9
BP 864
EP 868
DI 10.1097/WNR.0b013e32832c5cc2
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 457DU
UT WOS:000266908300009
PM 19424096
ER
PT J
AU Petersen, LA
Woodard, LD
Henderson, LM
Urech, TH
Pietz, K
AF Petersen, Laura A.
Woodard, LeChauncy D.
Henderson, Louise M.
Urech, Tracy H.
Pietz, Kenneth
TI Will Hypertension Performance Measures Used for Pay-for-Performance
Programs Penalize Those Who Care for Medically Complex Patients?
SO CIRCULATION
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the
Veterans-Affairs-Health-Services-Research-and-Development-Service
CY FEB 21-23, 2007
CL Arlington, VA
SP Vet Affairs Hlth Serv Res & Dev Serv
DE comorbidity; hypertension; physician incentive plans; process assessment
(health care); quality indicators, health care
ID QUALITY-OF-CARE; DAILY DOSE FREQUENCY; HEALTH-CARE;
MYOCARDIAL-INFARCTION; COMPETING DEMANDS; DEPRESSION CARE;
BLOOD-PRESSURE; DIABETES CARE; MEDICATION; DISEASES
AB Background-There is concern that performance measures, patient ratings of their care, and pay-for-performance programs may penalize healthcare providers of patients with multiple chronic coexisting conditions. We examined the impact of coexisting conditions on the quality of care for hypertension and patient perception of overall quality of their health care.
Methods and Results-We classified 141 609 veterans with hypertension into 4 condition groups: those with hypertension-concordant ( diabetes mellitus, ischemic heart disease, dyslipidemia) and/or -discordant ( arthritis, depression, chronic obstructive pulmonary disease) conditions or neither. We measured blood pressure control at the index visit, overall good quality of care for hypertension, including a follow-up interval, and patient ratings of satisfaction with their care. Associations between condition type and number of coexisting conditions on receipt of overall good quality of care were assessed with logistic regression. The relationship between patient assessment and objective measures of quality was assessed. Of the cohort, 49.5% had concordant-only comorbidities, 8.7% had discordant-only comorbidities, 25.9% had both, and 16.0% had none. Odds of receiving overall good quality after adjustment for age were higher for those with concordant comorbidities ( odds ratio, 1.78; 95% confidence interval, 1.70 to 1.87), discordant comorbidities ( odds ratio, 1.32; 95% confidence interval, 1.23 to 1.41), or both ( odds ratio, 2.25; 95% confidence interval, 2.13 to 2.38) compared with neither. Findings did not change after adjustment for illness severity and/or number of primary care and specialty care visits. Patient assessment of quality did not vary by the presence of coexisting conditions and was not related to objective ratings of quality of care.
Conclusions-Contrary to expectations, patients with greater complexity had higher odds of receiving high-quality care for hypertension. Subjective ratings of care did not vary with the presence or absence of comorbid conditions. Our findings should be reassuring to those who care for the most medically complex patients and are concerned that they will be penalized by performance measures or patient ratings of their care. ( Circulation. 2009; 119: 2978-2985.)
C1 Houston VA Med Ctr, Hlth Serv Res & Dev, Houston Ctr Qual Care & Utilizat Studies, Ctr Excellence,Hlth Policy & Qual Program, Houston, TX 77030 USA.
Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
RP Petersen, LA (reprint author), Houston Vet Affairs Med Ctr, Hlth Serv Res & Dev 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM laurap@bcm.edu
FU NHLBI NIH HHS [R01 HL079173, R01 HL079173-01]
NR 41
TC 31
Z9 31
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JUN 16
PY 2009
VL 119
IS 23
BP 2978
EP 2985
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 458KH
UT WOS:000267016900004
PM 19487595
ER
PT J
AU Ho, PM
Bryson, CL
Rumsfeld, JS
AF Ho, P. Michael
Bryson, Chris L.
Rumsfeld, John S.
TI Medication Adherence Its Importance in Cardiovascular Outcomes
SO CIRCULATION
LA English
DT Article
DE cardiovascular diseases; healthcare quality assessment; medication
adherence; outcomes research
ID ACUTE CORONARY SYNDROMES; ACUTE MYOCARDIAL-INFARCTION; EVIDENCE-BASED
PHARMACOTHERAPY; RANDOMIZED CONTROLLED-TRIALS; CHRONIC HEART-FAILURE;
LONG-TERM MORTALITY; DEPRESSIVE SYMPTOMS; BLOOD-PRESSURE; DRUG-THERAPY;
ANTIHYPERTENSIVE MEDICATION
AB Medication adherence usually refers to whether patients take their medications as prescribed (eg, twice daily), as well as whether they continue to take a prescribed medication. Medication nonadherence is a growing concern to clinicians, healthcare systems, and other stakeholders (eg, payers) because of mounting evidence that it is prevalent and associated with adverse outcomes and higher costs of care. To date, measurement of patient medication adherence and use of interventions to improve adherence are rare in routine clinical practice. The goals of the present report are to address (1) different methods of measuring adherence, (2) the prevalence of medication nonadherence, (3) the association between nonadherence and outcomes, (4) the reasons for nonadherence, and finally, (5) interventions to improve medication adherence. (Circulation. 2009; 119: 3028-3035.)
C1 [Ho, P. Michael; Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
[Ho, P. Michael; Rumsfeld, John S.] Univ Colorado, Denver, CO 80202 USA.
[Ho, P. Michael; Rumsfeld, John S.] Kaiser Permanente, Inst Hlth Res, Aurora, CO USA.
[Bryson, Chris L.] Puget Sound VA Med Ctr, Seattle, WA USA.
[Bryson, Chris L.] Univ Washington, Seattle, WA 98195 USA.
RP Ho, PM (reprint author), 1055 Clermont St 111B, Denver, CO 80220 USA.
EM michael.ho@va.gov
FU Veterans Administration Health Service Research and Career Development
FX Drs Ho and Bryson are supported by Veterans Administration Health
Service Research and Career Development.
NR 79
TC 483
Z9 502
U1 2
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JUN 16
PY 2009
VL 119
IS 23
BP 3028
EP 3035
DI 10.1161/CIRCULATIONAHA.108.768986
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 458KH
UT WOS:000267016900010
PM 19528344
ER
PT J
AU Bilimoria, KY
Bentrem, DJ
Lillemoe, KD
Talamonti, MS
Ko, CY
AF Bilimoria, Karl Y.
Bentrem, David J.
Lillemoe, Keith D.
Talamonti, Mark S.
Ko, Clifford Y.
CA Amer Coll Surg Pancreatic Canc
TI Assessment of Pancreatic Cancer Care in the United States Based on
Formally Developed Quality Indicators
SO JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID NEW-YORK-STATE; HOSPITAL VOLUME; OF-CARE; SURGICAL MORTALITY;
CARDIAC-SURGERY; UNINTENDED CONSEQUENCES; CARDIOTHORACIC SURGEONS;
APPROPRIATENESS METHOD; COLORECTAL-CANCER; HEALTH-CARE
AB Pancreatic cancer outcomes vary considerably among hospitals. Assessing pancreatic cancer care by using quality indicators could help reduce this variability. However, valid quality indicators are not currently available for pancreatic cancer management, and a composite assessment of the quality of pancreatic cancer care in the United States has not been done.
Potential quality indicators were identified from the literature, consensus guidelines, and interviews with experts. A panel of 20 pancreatic cancer experts ranked potential quality indicators for validity based on the RAND/UCLA Appropriateness Methodology. The rankings were rated as valid (high or moderate validity) or not valid. Adherence with valid indicators at both the patient and the hospital levels and a composite measure of adherence at the hospital level were assessed using data from the National Cancer Data Base (2004-2005) for 49 065 patients treated at 1134 hospitals. Summary statistics were calculated for each individual candidate quality indicator to assess the median ranking and distribution.
Of the 50 potential quality indicators identified, 43 were rated as valid (29 as high and 14 as moderate validity). Of the 43 valid indicators, 11 (25.6%) assessed structural factors, 19 (44.2%) assessed clinical processes of care, four (9.3%) assessed treatment appropriateness, four (9.3%) assessed efficiency, and five (11.6%) assessed outcomes. Patient-level adherence with individual indicators ranged from 49.6% to 97.2%, whereas hospital-level adherence with individual indicators ranged from 6.8% to 99.9%. Of the 10 component indicators (contributing 1 point each) that were used to develop the composite score, most hospitals were adherent with fewer than half of the indicators (median score = 4; interquartile range = 3-5).
Based on the quality indicators developed in this study, there is considerable variability in the quality of pancreatic cancer care in the United States. Hospitals can use these indicators to evaluate the pancreatic cancer care they provide and to identify potential quality improvement opportunities.
C1 [Bilimoria, Karl Y.; Ko, Clifford Y.] Amer Coll Surg, Canc Programs, Chicago, IL 60611 USA.
[Bilimoria, Karl Y.; Bentrem, David J.; Talamonti, Mark S.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA.
[Lillemoe, Keith D.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN USA.
[Talamonti, Mark S.] NorthShore Univ Hlth Syst, Dept Surg, Evanston, IL USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
RP Bilimoria, KY (reprint author), Amer Coll Surg, Canc Programs, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA.
EM kbilimoria@facs.org
FU American College of Surgeons, Clinical Scholars in Residence program;
American Cancer Society, Illinois Division; National Cancer Institute
[NCI-60058-NE]
FX American College of Surgeons, Clinical Scholars in Residence program (to
K.Y.B); American Cancer Society, Illinois Division (to D. J. B);
National Cancer Institute (NCI-60058-NE to C.Y.K).
NR 62
TC 49
Z9 51
U1 1
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 J NATL CANCER I
JI J. Natl. Cancer Inst.
PD JUN 16
PY 2009
VL 101
IS 12
BP 848
EP 859
DI 10.1093/jnci/djp107
PG 12
WC Oncology
SC Oncology
GA 460XH
UT WOS:000267225000007
PM 19509366
ER
PT J
AU Gore, JL
Kwan, L
Lee, SP
Reiter, RE
Litwin, MS
AF Gore, John L.
Kwan, Lorna
Lee, Steve P.
Reiter, Robert E.
Litwin, Mark S.
TI Survivorship Beyond Convalescence: 48-Month Quality-of-Life Outcomes
After Treatment for Localized Prostate Cancer
SO JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article; Proceedings Paper
CT 103rd Annual Meeting of the American-Urological-Association
CY MAY 17-22, 2008
CL Orlando, FL
SP Amer Urol Assoc
ID NEOADJUVANT HORMONAL-THERAPY; EXTERNAL-BEAM RADIOTHERAPY; RADICAL
PROSTATECTOMY; CONFORMAL RADIOTHERAPY; BRACHYTHERAPY; RADIATION; BOTHER;
CAPSURE; INDEX
AB Decision making for treatment of localized prostate cancer is often guided by therapeutic side-effect profiles. We sought to assess health-related quality-of-life outcomes for patients 48 months after treatment for localized prostate cancer. Men treated for localized prostate cancer (N = 475) were evaluated before treatment and at 11 intervals during the 48 months after intervention. Changes in mean health-related quality-of-life scores and the probability of regaining baseline levels of health-related quality of life were compared between treatment groups. All statistical tests were two-sided. Urinary incontinence was more common after prostatectomy (n = 307) than after brachytherapy (n = 90) or external beam radiation therapy (n = 78) (both P < .001), whereas voiding and storage urinary symptoms were more prevalent after brachytherapy than after prostatectomy (both P <.001). Sexual dysfunction profoundly affected all three treatment groups, with a lower likelihood of regaining baseline function after prostatectomy than after external beam radiation therapy or brachytherapy (P <.001). Bowel dysfunction was more common after either form of radiation therapy than after prostatectomy. These results may guide decision making for treatment selection and clinical management of patients with health-related quality-of-life impairments after treatment for localized prostate cancer.
C1 [Gore, John L.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res,Dept Med, Los Angeles, CA 90024 USA.
[Gore, John L.] VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, Los Angeles, CA USA.
[Kwan, Lorna; Reiter, Robert E.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
[Gore, John L.; Reiter, Robert E.; Litwin, Mark S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90024 USA.
[Lee, Steve P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90024 USA.
RP Gore, JL (reprint author), Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res,Dept Med, 911 Broxton Ave,3rd Floor, Los Angeles, CA 90024 USA.
EM jgore@mednet.ucla.edu
OI Gore, John/0000-0002-2847-5062
NR 21
TC 76
Z9 81
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 J NATL CANCER I
JI J. Natl. Cancer Inst.
PD JUN 16
PY 2009
VL 101
IS 12
BP 888
EP 892
DI 10.1093/jnci/djp114
PG 5
WC Oncology
SC Oncology
GA 460XH
UT WOS:000267225000011
PM 19509365
ER
PT J
AU Lu, PH
Edland, SD
Teng, E
Tingus, K
Petersen, RC
Cummings, JL
AF Lu, P. H.
Edland, S. D.
Teng, E.
Tingus, K.
Petersen, R. C.
Cummings, J. L.
CA Alzheimer's Dis Cooperative Study
TI Donepezil delays progression to AD in MCI subjects with depressive
symptoms
SO NEUROLOGY
LA English
DT Article
ID MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC
SYMPTOMS; FOLLOW-UP; DEVELOPING DEMENTIA; CONVERSION; APATHY;
GALANTAMINE; HYPOTHESIS; PREDICTION
AB Objective: To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship.
Methods: The study sample was composed of 756 participants with aMCI from the 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study drug trial of donepezil and vitamin E. Beck Depression Inventory (BDI) was used to assess depressive symptoms at baseline and participants were followed either to the end of study or to the primary endpoint of progression to probable or possible AD.
Results: Cox proportional hazards regression, adjusted for age at baseline, gender, apolipoprotein genotype, and NYU paragraph delayed recall score, showed that higher BDI scores were associated with progression to AD (p = 0.03). The sample was stratified into depressed (BDI score >= 10; n = 208) and nondepressed (BDI < 10; n = 548) groups. Kaplan-Meier analysis showed that among the depressed subjects, the proportion progressing to AD was lower for the donepezil group than the combined vitamin E and placebo groups at 1.7 years (p = 0.023), at 2.2 years (p = 0.025), and remained marginally lower at 2.7 years (p = 0.070). The survival curves among the three treatment groups did not differ within the nondepressed participants.
Conclusions: Results suggest that depression is predictive of progression from amnestic mild cognitive impairment (aMCI) to Alzheimer disease (AD) and treatment with donepezil delayed progression to AD among depressed subjects with aMCI. Donepezil appears to modulate the increased risk of AD conferred by the presence of depressive symptoms. Neurology (R) 2009;72:2115-2121
C1 [Lu, P. H.; Teng, E.; Tingus, K.; Cummings, J. L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Cummings, J. L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Edland, S. D.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Teng, E.] Greater Los Angeles VA Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA.
[Petersen, R. C.] Mayo Clin, Coll Med, Dept Neurol, Rochester, MN USA.
RP Lu, PH (reprint author), Mary S Easton Ctr Alzheimers Dis Res, 10911 Weyburn Ave,Suite 200, Los Angeles, CA 90095 USA.
EM plu@mednet.ucla.edu
OI Adler, Lawrence/0000-0002-6619-2493
FU National Institute on Aging [K23-AG028727, P50 AG-16570]; Alzheimer's
Association [NIRG-07-60424]; Alzheimer's Disease Cooperative Study [U01
AG010483]; Alzheimer's Disease Research Center of California, Jim
Easton, and the Sidell Kagan Foundation
FX Supported by grants from the National Institute on Aging (K23-AG028727),
Alzheimer's Association (NIRG-07-60424), the Alzheimer's Disease
Cooperative Study (U01 AG010483), the Alzheimer's Disease Research
Center (P50 AG-16570 from the National Institute on Aging), Alzheimer's
Disease Research Center of California, Jim Easton, and the Sidell Kagan
Foundation.
NR 40
TC 61
Z9 71
U1 3
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUN 16
PY 2009
VL 72
IS 24
BP 2115
EP 2121
DI 10.1212/WNL.0b013e3181aa52d3
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 458KC
UT WOS:000267016300011
PM 19528519
ER
PT J
AU Sawalha, AH
AF Sawalha, Amr H.
TI Xq28 and lupus: IRAK1 or MECP2?
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Letter
ID ERYTHEMATOSUS; RISK
C1 [Sawalha, Amr H.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA.
[Sawalha, Amr H.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK 73104 USA.
[Sawalha, Amr H.] Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA.
RP Sawalha, AH (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA.
EM amr-sawalha@omrf.ouhsc.edu
FU NIAMS NIH HHS [P30 AR053483]
NR 4
TC 5
Z9 5
U1 0
U2 0
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 16
PY 2009
VL 106
IS 24
BP E62
EP E62
DI 10.1073/pnas.0904068106
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 458TD
UT WOS:000267045500075
PM 19506310
ER
PT J
AU Freston, JW
Hisada, M
Peura, DA
Haber, MM
Kovacs, TO
Atkinson, S
Hunt, B
AF Freston, J. W.
Hisada, M.
Peura, D. A.
Haber, M. M.
Kovacs, T. O.
Atkinson, S.
Hunt, B.
TI The clinical safety of long-term lansoprazole for the maintenance of
healed erosive oesophagitis
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID GASTROESOPHAGEAL-REFLUX DISEASE; PROTON PUMP INHIBITORS;
CLOSTRIDIUM-DIFFICILE DIARRHEA; ESOMEPRAZOLE 20 MG; DOSE LANSOPRAZOLE;
COLORECTAL-CANCER; GASTRIC-MUCOSA; DOUBLE-BLIND; RISK; THERAPY
AB The clinical safety of long-term lansoprazole therapy for the maintenance of healed erosive oesophagitis has not been extensively studied in clinical trials.
To assess the long-term clinical safety of dose-titrated lansoprazole as maintenance therapy for up to 82 months in subjects with healed erosive oesophagitis.
Clinical safety was assessed by monitoring adverse events (AEs), laboratory data including serum gastrin levels, and endoscopy.
Mean duration (+/- s.d.) of lansoprazole treatment during the titrated open-label period was 56 +/- 24 months (range < 1-82 months). Overall, 189 of 195 (97%) subjects experienced a total of 2825 treatment-emergent AEs. Most AEs occurred during the first year of treatment, were mild-to-moderate in severity and resolved while on treatment. Of 155 serious AEs (in 74 subjects), only two (colitis and rectal haemorrhage in one subject) were considered treatment-related. Sixty-nine of 195 subjects (35%) experienced 187 treatment-related AEs, with diarrhoea (10%), headache (8%) and abdominal pain (6%) being the most common. Gastrin levels >= 400 pg/mL were seen in 9% of subjects; hypergastrinemia was not associated with gastro-intestinal AEs or nodules/polyps.
Lansoprazole maintenance therapy for up to 6 years is safe and well tolerated in subjects with healed erosive oesophagitis.
C1 [Hisada, M.; Atkinson, S.; Hunt, B.] Takeda Global Res & Dev Ctr Inc, Deerfield, IL 60015 USA.
[Freston, J. W.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA.
[Peura, D. A.] Univ Virginia Hlth Syst, Div Gastroenterol & Hepatol, Charlottesville, VA USA.
[Haber, M. M.] Drexel Univ, Dept Pathol, Coll Med, Philadelphia, PA 19104 USA.
[Kovacs, T. O.] VA Greater LA Healthcare Syst, CURE Clin, Los Angeles, CA USA.
RP Hisada, M (reprint author), Takeda Global Res & Dev Ctr Inc, 1 Takeda Pkwy, Deerfield, IL 60015 USA.
EM michie.hisada@tgrd.com
FU Takeda Global Research & Development Center, Inc [M94-140]; Gillian
Gummer of Rx Communications (UK); Takeda Pharmaceuticals North America,
Inc
FX This study (M94-140) was funded by Takeda Global Research & Development
Center, Inc. Writing support was provided by Gillian Gummer of Rx
Communications (UK) and funded by Takeda Pharmaceuticals North America,
Inc. The authors would like to thank the M94-140 investigators for
participating in the study.
NR 46
TC 15
Z9 15
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD JUN 15
PY 2009
VL 29
IS 12
BP 1249
EP 1260
DI 10.1111/j.1365-2036.2009.03998.x
PG 12
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 448MT
UT WOS:000266267400004
PM 19416133
ER
PT J
AU Thompson, LR
Boudreau, R
Hannon, MJ
Newman, AB
Chu, CR
Jansen, M
Nevitt, MC
Kwoh, CK
AF Thompson, Laura R.
Boudreau, Robert
Hannon, Michael J.
Newman, Anne B.
Chu, Constance R.
Jansen, Mary
Nevitt, Michael C.
Kwoh, C. Kent
CA Osteoarthritis Initiative Inves
TI The Knee Pain Map: Reliability of a Method to Identify Knee Pain
Location and Pattern
SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID BONE-MARROW; OSTEOARTHRITIS; ASSOCIATION
AB Objective. To describe the location and pattern of knee pain in patients with chronic, frequent knee pain using the Knee Pain Map, and to evaluate the inter- and intrarater reliability of the map.
Methods. A cohort of 799 participants from the University of Pittsburgh Osteoarthritis Initiative Clinical Center who had knee pain in the last 12 months were studied. Trained interviewers assessed and recorded participant-reported knee pain patterns into 8 local areas, 4 regional areas, or as diffuse. Inter- and intrarater reliability were assessed using Fleiss' kappa.
Results. Participants most often reported localized (69%) followed by regional (14%) or diffuse (10%) knee pain. In those with localized pain, the most commonly reported locations were the medial (56%) and lateral (43%) joint lines. In those with regional pain, the most commonly reported regions were the patella (44%) and medial region (38%). There was. excellent interrater reliability for the identification of localized and regional pain patterns (kappa = 0.7-0.9 and 0.7-0.8, respectively). The interrater reliability for specific locations was also excellent (kappa = 0.7-1.0) when the number of participants with pain in a location was >4. For regional pain, the kappa for specific regions varied from 0.7-1.0.
Conclusion. The majority of participants could identify the location of their knee pain, and trained interviewers could reliably record those locations. The variation in locations suggests that there are multiple sources of pain in knee OA. Additional studies are needed to determine whether specific knee pain patterns correlate with discrete pathologic findings on radiographs or magnetic resonance images.
C1 [Thompson, Laura R.; Boudreau, Robert; Hannon, Michael J.; Newman, Anne B.; Chu, Constance R.; Jansen, Mary; Kwoh, C. Kent] Univ Pittsburgh, Pittsburgh, PA USA.
[Nevitt, Michael C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Kwoh, C. Kent] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
RP Kwoh, CK (reprint author), S702 BSTWR,200 Lothrop St, Pittsburgh, PA 15261 USA.
EM kwoh@pitt.edu
RI Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150; Boudreau, Robert/0000-0003-0162-5187
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
[AR-12262]; National Institute of Aging Ruth L. Kirschstein National
Research Service Award Institutional Research [AG-021885]; University of
Pittsburgh School of Medicine Clinical Scientist
FX Supported in part by the National Institute of Arthritis and
Musculoskeletal and Skin Diseases (grant AR-12262), the National
Institute of Aging Ruth L. Kirschstein National Research Service Award
Institutional Research Training (grant AG-021885), and the University of
Pittsburgh School of Medicine Clinical Scientist Training Program.
NR 12
TC 26
Z9 27
U1 0
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0004-3591
J9 ARTHRIT RHEUM-ARTHR
JI Arthritis Rheum-Arthritis Care Res.
PD JUN 15
PY 2009
VL 61
IS 6
BP 725
EP 731
DI 10.1002/art.24543
PG 7
WC Rheumatology
SC Rheumatology
GA 459PI
UT WOS:000267115300003
PM 19479703
ER
PT J
AU La Fountaine, MF
Heffernan, KS
Gossett, JD
Bauman, WA
De Meersman, RE
AF La Fountaine, Michael F.
Heffernan, Kevin S.
Gossett, James D.
Bauman, William A.
De Meersman, Ronald E.
TI Transient suppression of heart rate complexity in concussed athletes
SO AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL
LA English
DT Review
DE Mild traumatic brain injury; Concussion; Autonomic nervous system;
Approximate entropy; Heart rate complexity
ID TRAUMATIC BRAIN-INJURY; RATE-VARIABILITY; APPROXIMATE ENTROPY; DYNAMICS
AB Heart rate variability (HRV) and complexity (HRC) were calculated at rest and during an isometric hand grip test (IHGT) within 48-hours (48 h) and two weeks (Week Two) of a concussion in athletes (CG) and control subjects. No differences were present at rest or in HRV during IGHT. HRC was significantly lower in the CG compared to controls at 48 h during IHGT. In CG at Week Two during IHGT, HRC was significantly greater than 48 h observations and not significantly different than controls. The findings suggest that HRC may have utility in detecting efferent cardiac autonomic anomalies within two weeks of concussion. Published by Elsevier B.V.
C1 [La Fountaine, Michael F.; Bauman, William A.] James J Peter VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA.
[De Meersman, Ronald E.] Columbia Univ, Teachers Coll, Dept Biobehav Sci, New York, NY 10027 USA.
[Heffernan, Kevin S.] Tufts Med Ctr, Dept Med, Div Cardiol & Mol Cardiol, Res Inst, Boston, MA USA.
[Bauman, William A.] Mt Sinai Sch Med, Dept Med & Rehabil Med, New York, NY USA.
[Gossett, James D.] Columbia Univ, Dept Sports Med, New York, NY USA.
RP La Fountaine, MF (reprint author), James J Peter VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Michael.LaFountaine@va.gov
FU Department of Veterans Affairs Rehabilitation Research and Development
Center of Excellence for the Medical Consequences of Spinal Cord Injury
[B4162C]; VIDDA Foundation
FX The authors would like to thank the athletes, coaches and administrators
of the Columbia University Athletics Department for their cooperation
during this study. Also, special recognition is warranted for the
Columbia University sports medicine staff for their professionalism and
enthusiasm. The study was conducted in cooperation with the Department
of Veterans Affairs Rehabilitation Research and Development Center of
Excellence for the Medical Consequences of Spinal Cord Injury (# B4162C)
and the VIDDA Foundation.
NR 19
TC 11
Z9 11
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1566-0702
J9 AUTON NEUROSCI-BASIC
JI Auton. Neurosci-Basic Clin.
PD JUN 15
PY 2009
VL 148
IS 1-2
BP 101
EP 103
DI 10.1016/j.autneu.2009.03.001
PG 3
WC Neurosciences
SC Neurosciences & Neurology
GA 455DW
UT WOS:000266738600015
PM 19303821
ER
PT J
AU Dakhova, O
Ozen, M
Creighton, CJ
Li, RL
Ayala, G
Rowley, D
Ittmann, M
AF Dakhova, Olga
Ozen, Mustafa
Creighton, Chad J.
Li, Rile
Ayala, Gustavo
Rowley, David
Ittmann, Michael
TI Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; STEM-CELLS; PERINEURAL
INVASION; BREAST-CANCER; IN-VITRO; PROGRESSION; CARCINOMA; TGF-BETA-1;
LUNG
AB Purpose: Marked reactive stroma formation, designated as grade 3 reactive stroma, is associated with poor outcome in clinically localized prostate cancer. To understand the biological processes and signaling mechanisms underlying the formation of such reactive stroma, we carried out microarray gene expression analysis of laser-captured reactive stroma and matched normal stroma.
Experimental Design: Seventeen cases of reactive stroma grade 3 cancer were used to laser-capture tumor and normal stroma. Expression analysis was carried out using Agilent 44K arrays. Up-regulation of selected genes was confirmed by quantitative reverse transcription-PCR. Expression data was analyzed to identify significantly up- and down-regulated genes, and gene ontology analysis was used to define pathways altered in reactive stroma.
Results: A total of 544 unique genes were significantly higher in the reactive stroma and 606 unique genes were lower. Gene ontology analysis revealed significant alterations in a number of novel processes in prostate cancer reactive stroma, including neurogenesis, axonogenesis, and the DNA damage/repair pathways, as well as evidence of increases in stem cells in prostate cancer reactive stroma.
Conclusions: Formation of reactive stroma in prostate cancer is a dynamic process characterized by significant alterations in growth factor and signal transduction pathways and formation of new structures, including nerves and axons.
C1 [Dakhova, Olga; Ozen, Mustafa; Li, Rile; Ayala, Gustavo; Ittmann, Michael] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.
[Creighton, Chad J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Rowley, David] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
[Dakhova, Olga; Ozen, Mustafa; Ittmann, Michael] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
RP Ittmann, M (reprint author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.
EM mittmann@bcm.tmc.edu
FU National Cancer Institute [1U54CA126568]; P30 Cancer Center [P30
CA125123]; Baylor Prostate Cancer SPORE [P50CA058204]; Department of
Veterans Affairs Merit Review; Diana Helis Henry Medical Research
Foundation
FX Grant support: National Cancer Institute to the Tumor Microenvironment
Network (1U54CA126568; D. Rowley), the P30 Cancer Center support grant
(P30 CA125123), the Baylor Prostate Cancer SPORE (P50CA058204), the
Department of Veterans Affairs Merit Review program (M. Ittmann), the
Diana Helis Henry Medical Research Foundation (M. Ittmann, G. Ayala, D.
Rowley), and by the use of the facilities of the Michael E. DeBakey
Veterans Affairs Medical Center.
NR 54
TC 75
Z9 78
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 15
PY 2009
VL 15
IS 12
BP 3979
EP 3989
DI 10.1158/1078-0432.CCR-08-1899
PG 11
WC Oncology
SC Oncology
GA 459DP
UT WOS:000267080800012
PM 19509179
ER
PT J
AU Betts, RF
Nucci, M
Talwar, D
Gareca, M
Queiroz-Telles, F
Bedimo, RJ
Herbrecht, R
Ruiz-Palacios, G
Young, JAH
Baddley, JW
Strohmaier, KM
Tucker, KA
Taylor, AF
Kartsonis, NA
AF Betts, Robert F.
Nucci, Marcio
Talwar, Deepak
Gareca, Marcelo
Queiroz-Telles, Flavio
Bedimo, Roger J.
Herbrecht, Raoul
Ruiz-Palacios, Guillermo
Young, Jo-Anne H.
Baddley, John W.
Strohmaier, Kim M.
Tucker, Kimberly A.
Taylor, Arlene F.
Kartsonis, Nicholas A.
CA Caspofungin High-Dose Study Grp
TI A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment
Regimen versus a Standard Caspofungin Treatment Regimen for Adult
Patients with Invasive Candidiasis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID HIGH DRUG CONCENTRATIONS; AMPHOTERICIN-B; FUNGAL-INFECTIONS;
RISK-FACTORS; CANDIDEMIA; FLUCONAZOLE; EPIDEMIOLOGY; CANDIDAEMIA;
MICAFUNGIN; MORTALITY
AB Background. The standard caspofungin treatment regimen (50 mg/day after a 70-mg dose on day 1) is effective and well tolerated for the treatment of invasive candidiasis, but experience with higher doses of caspofungin is limited. We evaluated the safety and efficacy of caspofungin at 3 times the standard dosing regimen.
Methods. Patients with proven invasive candidiasis were randomized to receive a standard or high-dose (150 mg/day) caspofungin treatment regimen. Safety was assessed in all patients as treated. Efficacy was assessed as a secondary objective in a full-analysis-set population. A favorable overall response was defined as symptom resolution and microbiological clearance at the end of caspofungin therapy.
Results. A total of 204 patients were included in the safety analysis (104 received the standard regimen, and 100 received the high-dose regimen), and 197 were included in the efficacy analysis (102 and 95 in the standard and high-dose treatment groups, respectively). Patient demographic characteristics, neutropenia status (6.7% and 8.0% had neutropenia, respectively), and Acute Physiology and Chronic Health Evaluation II scores (mean, 16.5 and 17, respectively) were similar between treatment groups. Significant drug-related adverse events occurred in 1.9% of patients receiving the standard regimen and 3.0% of patients receiving the high-dose regimen (difference, 1.1%; 95% confidence interval, -4.1% to 6.8%). The most-common drug-related adverse events in the standard and high-dose treatment groups were phlebitis (3.8% and 2.0%, respectively), increased alkaline phosphatase level (6.9% and 2.0%, respectively), and increased aspartate transaminase level (4.0% and 2.0%, respectively). Overall, 71.6% of patients who received the standard regimen and 77.9% of patients who received the high-dose regimen had favorable overall responses (difference, 6.3%; 95% confidence interval, -5.9% to 18.4%; not statistically significant). Mortality at 8 weeks after therapy was similar between groups.
Conclusions. Both caspofungin dosing regimens were effective and well tolerated in patients with invasive candidiasis. No safety concerns were found for caspofungin at a dosage of 150 mg/day.
C1 [Betts, Robert F.] Univ Rochester, Rochester, NY USA.
[Gareca, Marcelo] Lehigh Valley Hosp, Allentown, PA USA.
[Strohmaier, Kim M.; Tucker, Kimberly A.; Taylor, Arlene F.; Kartsonis, Nicholas A.] Merck Res Labs, West Point, PA USA.
[Young, Jo-Anne H.] Univ Minnesota, Minneapolis, MN USA.
[Bedimo, Roger J.] Vet Affairs N Texas Hlth Care Syst, Dallas, TX USA.
[Baddley, John W.] Univ Alabama, Birmingham, AL USA.
[Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Nucci, Marcio] Univ Fed Rio de Janeiro, Univ Hosp, Rio De Janeiro, Brazil.
[Queiroz-Telles, Flavio] Univ Fed Parana, Hosp Clin, BR-80060000 Curitiba, Parana, Brazil.
[Talwar, Deepak] Metro Hosp, Noida, India.
[Herbrecht, Raoul] Univ Hosp, Strasbourg, France.
[Ruiz-Palacios, Guillermo] Natl Inst Med Sci & Nutr, Mexico City, DF, Mexico.
RP Kartsonis, NA (reprint author), Merck Res Labs, POB 1000,UG3D-56, N Wales, PA 19454 USA.
EM nicholas_kartsonis@merck.com
RI Nucci, Marcio/G-4515-2012; Herbrecht, Raoul/D-3471-2013; Young,
Jo-Anne/G-2617-2013
OI Nucci, Marcio/0000-0003-4867-0014; Young, Jo-Anne/0000-0003-4182-341X;
Streinu-Cercel, Adrian/0000-0001-6382-5067; Herbrecht,
Raoul/0000-0002-9381-4876
FU Merck Co
FX Merck & Co.
NR 20
TC 101
Z9 107
U1 1
U2 4
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 15
PY 2009
VL 48
IS 12
BP 1676
EP 1684
DI 10.1086/598933
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 450YY
UT WOS:000266439100009
PM 19419331
ER
PT J
AU Wolters, PJ
Wray, C
Sutherland, RE
Kim, SS
Koff, J
Mao, Y
Frank, JA
AF Wolters, Paul J.
Wray, Charlie
Sutherland, Rachel E.
Kim, Sophia S.
Koff, Jon
Mao, Ying
Frank, James A.
TI Neutrophil-Derived IL-6 Limits Alveolar Barrier Disruption in
Experimental Ventilator-Induced Lung Injury
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; INTERLEUKIN-6-DEFICIENT MICE;
INFLAMMATION; EXPRESSION; PROTECTION; MECHANISM; RESPONSES; BLOCKADE;
IMMUNE
AB IL-6 is a biological marker of ventilator-associated lung injury that may contribute to alveolar barrier dysfunction in acute respiratory distress syndrome. To determine whether IL-6 affects alveolar barrier disruption in a model of ventilator-induced lung injury, we examined alveolar barrier albumin flux in wild-type (WT) mice given an IL-6-blocking Ab (IL6AB) and mice deficient in IL-6 (LL6KO). Albumin flux was significantly higher in mice given IL6AB compared with mice given a control Ab. Unexpectedly, albumin flux was similar in WT and IL6KO mice. To examine the mechanisms for these findings, lung neutrophil accumulation (myeloperoxidase activity) was compared, revealing a correlation between lung neutrophil accumulation and albumin flux. IL6AB mice had significantly more lung neutrophils than WT and IL6KO mice, which were similar. Therefore, to determine whether the cellular source of IL-6 influences neutrophil accumulation and alveolar barrier function, chimeric mice were compared. WT/KO chimeras (WT mice with IL6KO hematopoietic cells) showed significantly greater albumin flux and neutrophil accumulation with mechanical ventilation than WT/WT mice. Neutrophil depletion decreased albumin flux in WT and WT/KO mice. IL6KO neutrophils were more adherent in an in vitro assay compared with WT neutrophils. IL-6 from a hematopoietic cell source limits alveolar barrier disruption potentially by reducing neutrophil contact with the endothelium. Modulation of IL-6 signaling in a cell type-specific fashion may be a therapeutic target for patients with acute lung injury. The Journal of Immunology, 2009, 182: 8056-8062.
C1 [Frank, James A.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
[Wolters, Paul J.; Sutherland, Rachel E.; Kim, Sophia S.; Koff, Jon; Frank, James A.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA 94121 USA.
[Wray, Charlie; Mao, Ying; Frank, James A.] Vet Hlth Res Inst, No Calif Inst Res & Educ, San Francisco, CA 94121 USA.
[Frank, James A.] San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA.
RP Frank, JA (reprint author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco Vet Affairs Med Ctr, 4150 Clement St,Box 111D, San Francisco, CA 94121 USA.
EM james.frank@ucsf.edu
RI Wolters, Paul/A-7181-2009
FU National Institutes of Health and National Heart, Lung and Blood
Institute [HL088440, HL075026]
FX This work was supported by funding from the National Institutes of
Health and National Heart, Lung and Blood Institute Grants HL088440 (to
J.A.F.) and HL075026 (to P.J.W.).
NR 23
TC 36
Z9 38
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUN 15
PY 2009
VL 182
IS 12
BP 8056
EP 8062
PG 7
WC Immunology
SC Immunology
GA 456HD
UT WOS:000266833900078
PM 19494331
ER
PT J
AU Camargo, JF
Kulkarni, H
Agan, BK
Gaitan, AA
Beachy, LA
Srinivas, S
He, WJ
Anderson, S
Marconi, VC
Dolan, MJ
Ahuja, SK
AF Camargo, Jose F.
Kulkarni, Hemant
Agan, Brian K.
Gaitan, Alvaro A.
Beachy, Lisa A.
Srinivas, Sowmya
He, Weijing
Anderson, Stephanie
Marconi, Vincent C.
Dolan, Matthew J.
Ahuja, Sunil K.
TI Responsiveness of T Cells to Interleukin-7 Is Associated with Higher
CD4(+) T Cell Counts in HIV-1-Positive Individuals with Highly Active
Antiretroviral Therapy-Induced Viral Load Suppression
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SURFACE CCR5 DENSITY; IL-7
RECEPTOR-ALPHA; DISEASE PROGRESSION; SINGLE-CELL; IN-VIVO; HOMEOSTATIC
PROLIFERATION; HIV-1-INFECTED PATIENTS; LYMPHOID HOMEOSTASIS; INFECTED
PATIENTS
AB Background. Despite suppression of the human immunodeficiency virus type 1 (HIV-1) load by highly active antiretroviral therapy (HAART), recovery of CD4(+) T cell counts can be impaired. We investigated whether this impairment may be associated with hyporesponsiveness of T cells to gamma-chain (gamma c) cytokines known to influence T cell homeostasis.
Methods. The responsiveness of T cells to interleukin (IL)-2, IL-7, and IL-15 was determined by assessing cytokine-induced phosphorylation of the signal transducer and activator of transcription 5 (STAT5) in peripheral T cells obtained from 118 HIV-positive subjects and 13 HIV-negative subjects.
Results. The responsiveness of T cells to interleukin (IL)-7 but not to IL-2 or IL-15 was lower among HIV-positive subjects than among HIV-negative subjects. Among subjects with viral load suppression, the degree of IL-7 responsiveness (1) correlated with naive CD4(+) T cell counts and was a better immune correlate of the prevailing CD4(+) T cell count than were levels of human leukocyte antigen-DR1 or programmed death-1, which are predictors of T cell homeostasis during HIV infection; and (2) was greater in subjects with complete (i.e., attainment of >= 500 CD4(+) T cells/mm(3) >= 5 years after initiation of HAART) versus incomplete immunologic responses. The correlation between plasma levels of IL-7 and CD4(+) T cell counts during HAART was maximal in subjects with increased IL-7 responsiveness.
Conclusions. Responsiveness of T cells to IL-7 is associated with higher CD4(+) T cell counts during HAART and thus may be a determinant of the extent of immune reconstitution.
C1 [Camargo, Jose F.; Kulkarni, Hemant; Gaitan, Alvaro A.; Beachy, Lisa A.; Srinivas, Sowmya; He, Weijing; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol, San Antonio, TX 78229 USA.
[Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Immunol, San Antonio, TX 78229 USA.
[Camargo, Jose F.; Kulkarni, Hemant; Gaitan, Alvaro A.; Beachy, Lisa A.; Srinivas, Sowmya; He, Weijing; Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX 78229 USA.
[Anderson, Stephanie; Marconi, Vincent C.; Dolan, Matthew J.] Wilford Hall USAF Med Ctr, Infect Dis Serv, Lackland AFB, TX 78236 USA.
[Anderson, Stephanie; Dolan, Matthew J.] Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX 78236 USA.
[Anderson, Stephanie; Marconi, Vincent C.; Dolan, Matthew J.] San Antonio Mil Med Ctr, Ft Sam Houston, TX USA.
[Anderson, Stephanie; Marconi, Vincent C.; Dolan, Matthew J.] San Antonio Mil Med Ctr, Lackland AFB, TX USA.
[Agan, Brian K.; Anderson, Stephanie; Marconi, Vincent C.] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA.
RP Ahuja, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,Rm 5-009R, San Antonio, TX 78229 USA.
EM mdolan@hjf.org; ahujas@uthscsa.edu
RI Marconi, Vincent/N-3210-2014
OI Marconi, Vincent/0000-0001-8409-4689; Agan, Brian/0000-0002-5114-1669
FU Veterans Administration Center on AIDS and HIV Infection, South Texas
Veterans Health Care System; National Institutes of Health (NIH)
[R37046326, HU0001-05-2-0011]; Elizabeth Glaser Scientist Award;
Burroughs Wellcome Clinical Scientist Award in Translational Research;
Uniformed Services University of the Health Sciences (USUHS)
FX Veterans Administration Center on AIDS and HIV Infection, South Texas
Veterans Health Care System; National Institutes of Health (NIH; MERIT
award R37046326 to S. K. A.). S. K. A. is a recipient of the Elizabeth
Glaser Scientist Award and the Burroughs Wellcome Clinical Scientist
Award in Translational Research. Support for the Wilford Hall Medical
Center cohort was provided by the Infectious Disease Clinical Research
Program (IDCRP) of the Uniformed Services University of the Health
Sciences (USUHS). The IDCRP is a Department of Defense triservice
program executed through the USUHS and the Henry M. Jackson Foundation
for the Advancement of Military Medicine, in collaboration with the
Department of Health and Human Services/ NIH/National Institute of
Allergy and Infectious Diseases/Division of Clinical Research through
Interagency Agreement HU0001-05-2-0011.
NR 43
TC 36
Z9 37
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 15
PY 2009
VL 199
IS 12
BP 1872
EP 1882
DI 10.1086/598858
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 448BM
UT WOS:000266236500021
PM 19432535
ER
PT J
AU Raval, MV
Bilimoria, KY
Stewart, AK
Bentrem, DJ
Ko, CY
AF Raval, Mehul V.
Bilimoria, Karl Y.
Stewart, Andrew K.
Bentrem, David J.
Ko, Clifford Y.
TI Using the NCDB for Cancer Care Improvement: An Introduction to Available
Quality Assessment Tools
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Review
DE quality of health care; Health Care Quality Assessment; National Cancer
Database
ID UNITED-STATES; DATA-BASE
AB Improving the quality of cancer care requires high-quality data, mechanisms to feed back information to hospitals, systems to act on the data, and participation of providers. The purpose of this review is to describe how the National Cancer Database (NCDB) can be utilized to improve the quality of cancer care in the United States through a variety of benchmarking reports and data feedback mechanisms available to hospitals approved by the Commission on Cancer (CoC). J. Surg. Oncol. 2009;99:485-490. (C) 2009 Wiley-Liss, Inc.
C1 [Raval, Mehul V.; Bilimoria, Karl Y.; Stewart, Andrew K.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, Chicago, IL 60611 USA.
[Raval, Mehul V.; Bilimoria, Karl Y.; Bentrem, David J.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Ko, CY (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, 636 N St Clair St,22nd Floor, Chicago, IL 60611 USA.
EM CKo@mednet.ucla.edu
OI Raval, Mehul/0000-0002-1527-2661
NR 16
TC 58
Z9 58
U1 1
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0022-4790
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD JUN 15
PY 2009
VL 99
IS 8
BP 488
EP 490
DI 10.1002/jso.21173
PG 3
WC Oncology; Surgery
SC Oncology; Surgery
GA 455DS
UT WOS:000266738200008
PM 19466738
ER
PT J
AU Rodrigues, GR
Walker, RH
Bader, B
Danek, A
Marques, W
Tumas, V
AF Rodrigues, Guilherme R.
Walker, Ruth H.
Bader, Benedikt
Danek, Adrian
Marques, Wilson, Jr.
Tumas, Vitor
TI Reply: Chorea-Acanthocytosis: Report of Two Brazilian Cases
SO MOVEMENT DISORDERS
LA English
DT Letter
C1 [Rodrigues, Guilherme R.; Marques, Wilson, Jr.; Tumas, Vitor] Univ Sao Paulo, Dept Neurol, Ribeirao Preto Sch Med, BR-14049 Ribeirao Preto, Brazil.
[Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA.
[Bader, Benedikt; Danek, Adrian] Univ Munich, Dept Neurol, D-8000 Munich, Germany.
RP Rodrigues, GR (reprint author), Univ Sao Paulo, Dept Neurol, Ribeirao Preto Sch Med, BR-14049 Ribeirao Preto, Brazil.
RI Rodrigues, Guilherme/D-3547-2009; Marques, Wilson/G-4240-2012; Danek,
Adrian/G-7339-2011; Tumas, Vitor/C-9949-2014
OI Rodrigues, Guilherme/0000-0002-4296-1016; Marques,
Wilson/0000-0002-4589-2749; Danek, Adrian/0000-0001-8857-5383;
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD JUN 15
PY 2009
VL 24
IS 8
BP 1254
EP 1254
DI 10.1002/mds.22501
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 464NE
UT WOS:000267511000031
ER
PT J
AU Galie, N
Brundage, BH
Ghofrani, HA
Oudiz, RJ
Simonneau, G
Safdar, Z
Shapiro, S
White, RJ
Chan, M
Beardsworth, A
Frumkin, L
Barst, RJ
AF Galie, Nazzareno
Brundage, Bruce H.
Ghofrani, Hossein A.
Oudiz, Ronald J.
Simonneau, Gerald
Safdar, Zeenat
Shapiro, Shelley
White, R. James
Chan, Melanie
Beardsworth, Anthony
Frumkin, Lyn
Barst, Robyn J.
CA Pulm Arterial Hypertension & Resp
TI Tadalafil Therapy for Pulmonary Arterial Hypertension
SO CIRCULATION
LA English
DT Article
DE hypertension, pulmonary; phosphodiesterase inhibitors; tadalafil
ID DOUBLE-BLIND; NITRIC-OXIDE; INHALED ILOPROST; CONTROLLED-TRIAL;
SILDENAFIL; BOSENTAN; EFFICACY; PROSTACYCLIN; SITAXSENTAN; AMBRISENTAN
AB Background-Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway.
Methods and Results-In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or associated), either treatment-naive or on background therapy with the endothelin receptor antagonist bosentan, were randomized to placebo or tadalafil 2.5, 10, 20, or 40 mg orally once daily. The primary end point was the change from baseline to week 16 in the distance walked in 6 minutes. Changes in World Health Organization functional class, clinical worsening, and health-related quality of life were also assessed. Patients completing the 16-week study could enter a long-term extension study. Tadalafil increased the distance walked in 6 minutes in a dose-dependent manner; only the 40-mg dose met the prespecified level of statistical significance (P<0.01). Overall, the mean placebo-corrected treatment effect was 33 m (95% confidence interval, 15 to 50 m). In the bosentan-naive group, the treatment effect was 44 m (95% confidence interval, 20 to 69 m) compared with 23 m (95% confidence interval, -2 to 48 m) in patients on background bosentan therapy. Tadalafil 40 mg improved the time to clinical worsening (P=0.041), incidence of clinical worsening (68% relative risk reduction; P=0.038), and health-related quality of life. The changes in World Health Organization functional class were not statistically significant. The most common treatment-related adverse events reported with tadalafil were headache, myalgia, and flushing.
Conclusions-In patients with pulmonary arterial hypertension, tadalafil 40 mg was well tolerated and improved exercise capacity and quality of life measures and reduced clinical worsening. (Circulation. 2009; 119: 2894-2903.)
C1 [Galie, Nazzareno] Univ Bologna, Inst Cardiol, I-40138 Bologna, Italy.
[Brundage, Bruce H.] Heart Inst Cascades, Bend, OR USA.
[Ghofrani, Hossein A.] Univ Giessen, Univ Hosp, Giessen, Germany.
[Oudiz, Ronald J.] Univ Calif Los Angeles, Los Angeles Biomed Res Inst Harbor, Torrance, CA USA.
[Simonneau, Gerald] Antoine Beclere Univ Hosp, Clamart, France.
[Safdar, Zeenat] Baylor Coll Med, Div Pulm & Crit Care Med, Houston, TX 77030 USA.
[Shapiro, Shelley] Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90095 USA.
[White, R. James] Univ Rochester, Div Pulm & Crit Care Med, Rochester, NY USA.
[Chan, Melanie] Eli Lilly & Co, Toronto, ON, Canada.
[Frumkin, Lyn] ICOS Corp, Bothell, WA USA.
[Barst, Robyn J.] Schneider Childrens Hosp N Shore Long Isl Jewish, New Hyde Pk, NY USA.
RP Galie, N (reprint author), Univ Bologna, Inst Cardiol, Via Massarenti 9, I-40138 Bologna, Italy.
EM nazzareno.galie@unibo.it
RI Reynaud-Gaubert, Martine/P-6958-2016
OI Galie, Nazzareno/0000-0003-4271-8670
FU Eli Lilly and Company
FX The study was funded by Eli Lilly and Company.
NR 42
TC 433
Z9 466
U1 1
U2 23
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JUN 9
PY 2009
VL 119
IS 22
BP 2894
EP U65
DI 10.1161/CIRCULATIONAHA.108.839274
PG 12
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 455QM
UT WOS:000266777900006
PM 19470885
ER
PT J
AU Yaffe, K
Fiocco, AJ
Lindquist, K
Vittinghoff, E
Simonsick, EM
Newman, AB
Satterfield, S
Rosano, C
Rubin, SM
Ayonayon, HN
Harris, TB
AF Yaffe, K.
Fiocco, A. J.
Lindquist, K.
Vittinghoff, E.
Simonsick, E. M.
Newman, A. B.
Satterfield, S.
Rosano, C.
Rubin, S. M.
Ayonayon, H. N.
Harris, T. B.
CA Hlth ABC Study
TI Predictors of maintaining cognitive function in older adults The Health
ABC Study
SO NEUROLOGY
LA English
DT Article
ID ATTENTIONAL CONTROL; ALZHEIMERS-DISEASE; GLUCOSE-TOLERANCE; LIFE-STYLE;
WOMEN; PLASTICITY; EXERCISE; DECLINE; BRAIN; AGE
AB Background: Although several risk factors for cognitive decline have been identified, much less is known about factors that predict maintenance of cognitive function in advanced age.
Methods: We studied 2,509 well-functioning black and white elders enrolled in a prospective study. Cognitive function was measured using the Modified Mini-Mental State Examination at baseline and years 3, 5, and 8. Random effects models were used to classify participants as cognitive maintainers (cognitive change slope >= 0), minor decliners (slope <0 and >1 SD below mean), or major decliners (slope <= 1 SD below mean). Logistic regression was used to identify domain-specific factors associated with being a maintainer vs a minor decliner.
Results: Over 8 years, 30% of the participants maintained cognitive function, 53% showed minor decline, and 16% had major cognitive decline. In the multivariate model, baseline variables significantly associated with being a maintainer vs a minor decliner were age (odds ratio [OR] = 0.65, 95% confidence interval [CI] 0.55-0.77 per 5 years), white race (OR = 1.72, 95% CI 1.30-2.28), high school education level or greater (OR = 2.75, 95% CI 1.78-4.26), ninth grade literacy level or greater (OR = 4.85, 95% CI 3.00-7.87), weekly moderate/vigorous exercise (OR = 1.31, 95% CI 1.06-1.62), and not smoking (OR = 1.84, 95% CI 1.14-2.97). Variables associated with major cognitive decline compared to minor cognitive decline are reported.
Conclusion: Elders who maintain cognitive function have a unique profile that differentiates them from those with minor decline. Importantly, some of these factors are modifiable and thus may be implemented in prevention programs to promote successful cognitive aging. Further, factors associated with maintenance may differ from factors associated with major cognitive decline, which may impact prevention vs treatment strategies. Neurology (R) 2009; 72: 2029-2035
C1 [Yaffe, K.; Fiocco, A. J.] Univ San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94117 USA.
[Yaffe, K.; Vittinghoff, E.; Rubin, S. M.; Ayonayon, H. N.] Univ San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94117 USA.
[Yaffe, K.] Univ San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94117 USA.
[Lindquist, K.] Univ San Francisco, Sch Med, Dept Med, San Francisco, CA 94117 USA.
[Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Simonsick, E. M.] NIA, Clin Res Branch, Baltimore, MD 21224 USA.
[Harris, T. B.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Baltimore, MD 21224 USA.
[Newman, A. B.; Rosano, C.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Satterfield, S.] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA.
RP Fiocco, AJ (reprint author), Univ San Francisco, Sch Med, Dept Psychiat, 4150 Clement St, San Francisco, CA 94117 USA.
EM jazzfiocco@hotmail.com
RI Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150; Rosano, Caterina/0000-0002-0909-1506;
Rosano, Caterina/0000-0002-4271-6010
FU Intramural NIH HHS; NIA NIH HHS [N01-AG-6-2106, AG 031155, AG021918,
N01-AG-6-2101, N01-AG-6-2103]
NR 36
TC 113
Z9 119
U1 1
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUN 9
PY 2009
VL 72
IS 23
BP 2029
EP 2035
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 455QI
UT WOS:000266777500012
PM 19506226
ER
PT J
AU Raskind, WH
Matsushita, M
Peter, B
Biberston, J
Wolff, J
Lipe, H
Burbank, R
Bird, TD
AF Raskind, Wendy H.
Matsushita, Mark
Peter, Beate
Biberston, Jeffrey
Wolff, John
Lipe, Hillary
Burbank, Ruben
Bird, Thomas D.
TI Familial Dyskinesia and Facial Myokymia (FDFM): Follow-Up of a Large
Family and Linkage to Chromosome 3p21-3q21
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE chorea; movement disorder; episodic disorder
ID EPISODIC ATAXIA; CHANNEL; MUTATION; GENE; EPILEPSY; PROTEIN; KCNA1
AB We previously reported a five-generation family manifesting an autosomal dominant disorder of facial myokymia and dystonic/choreic movements (FDFM). The dyskinetic episodes are initially paroxysmal but may become constant. With increasing age they may lessen or even disappear. The previous study excluded nine candidate genes chosen for their association with myokymia or chorea and two regions containing single or clustered ion channel genes. We now report identification by whole genome linkage analysis of a broad region on chromosome 3p21-3q21 that segregates with the disease in all 10 affected members in three generations who participated in the study. GENEHUNTER-MODSCORE Version 2.0.1 provided a maximum multipoint LOD score of 3.099. No other disorders primarily characterized by myokymia, dystonia, or chorea are known to map to this region. Identification of additional families with FDFM may narrow the critical region and facilitate the choice of candidate genes for further analysis. (C) 2008 Wiley-Liss, Inc.
C1 [Raskind, Wendy H.; Matsushita, Mark; Biberston, Jeffrey; Wolff, John; Burbank, Ruben] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Raskind, Wendy H.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Raskind, Wendy H.; Matsushita, Mark] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
[Peter, Beate] Univ Washington, Sch Med, Dept Speech & Hearing Sci, Seattle, WA 98195 USA.
[Wolff, John; Lipe, Hillary; Bird, Thomas D.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
[Bird, Thomas D.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA.
RP Raskind, WH (reprint author), Univ Washington, Sch Med, Dept Med, Box 35-7720, Seattle, WA 98195 USA.
EM wendyrun@u.washington.edu
FU Department of Veterans Affairs; NIH [2 T32 DC000033]
FX The authors wish to thank the members of the family whose cooperation
with, and interest in, the research is essential. The research was
supported in part by funds from the Department of Veterans Affairs
(W.H.R., M.M., J.W., H.L., and T.D.B.) and NIH 2 T32 DC000033 (B.P.).
NR 25
TC 8
Z9 8
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1552-4841
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD JUN 5
PY 2009
VL 150B
IS 4
BP 570
EP 574
DI 10.1002/ajmg.b.30879
PG 5
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA 452CD
UT WOS:000266516400016
PM 18980218
ER
PT J
AU Mortensen, EM
Copeland, LA
Pugh, MJV
Restrepo, MI
de Molina, RM
Nakashima, B
Anzueto, A
AF Mortensen, Eric M.
Copeland, Laurel A.
Pugh, Mary Jo V.
Restrepo, Marcos I.
de Molina, Rosa Malo
Nakashima, Brandy
Anzueto, Antonio
TI Impact of statins and ACE inhibitors on mortality after COPD
exacerbations
SO RESPIRATORY RESEARCH
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; C-REACTIVE PROTEIN; AIRWAY INFLAMMATION;
PROPENSITY SCORE; HEALTH-STATUS; VALIDATION; PROTECTION; PNEUMONIA;
MORBIDITY; INFLUENZA
AB Background: The purpose of our study was to examine the association of prior outpatient use of statins and angiotensin converting enzyme (ACE) inhibitors on mortality for subjects >= 65 years of age hospitalized with acute COPD exacerbations.
Methods: We conducted a retrospective national cohort study using Veterans Affairs administrative data including subjects >= 65 years of age hospitalized with a COPD exacerbation. Our primary analysis was a multilevel model with the dependent variable of 90-day mortality and hospital as a random effect, controlling for preexisting comorbid conditions, demographics, and other medications prescribed.
Results: We identified 11,212 subjects with a mean age of 74.0 years, 98% were male, and 12.4% of subjects died within 90-days of hospital presentation. In this cohort, 20.3% of subjects were using statins, 32.0% were using ACE inhibitors or angiotensin II receptor blockers (ARB). After adjusting for potential confounders, current statin use (odds ratio 0.51, 95% confidence interval 0.40-0.64) and ACE inhibitor/ARB use (0.55, 0.46-0.66) were significantly associated with decreased 90-day mortality.
Conclusion: Use of statins and ACE inhibitors prior to admission is associated with decreased mortality in subjects hospitalized with a COPD exacerbation. Randomized controlled trials are needed to examine whether the use of these medications are protective for those patients with COPD exacerbations.
C1 [Mortensen, Eric M.; Copeland, Laurel A.; Pugh, Mary Jo V.; Restrepo, Marcos I.; de Molina, Rosa Malo; Nakashima, Brandy; Anzueto, Antonio] S Texas Vet Hlth Care Syst, VERDICT Res Unit, San Antonio, TX USA.
[Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Gen Internal Med, San Antonio, TX 78229 USA.
[Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Restrepo, Marcos I.; de Molina, Rosa Malo; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA.
RP Mortensen, EM (reprint author), S Texas Vet Hlth Care Syst, VERDICT Res Unit, San Antonio, TX USA.
EM mortensene@uthscsa.edu; copelandl@uthscsa.edu; pughm@uthsca.edu;
restrepom@uthscsa.edu; rmm02004@yahoo.es; nakashima@uthscsa.edu;
anzueto@uthsa.edu
RI Restrepo, Marcos/H-4442-2014
OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563;
Copeland, Laurel/0000-0002-9478-0209
FU Department of Veterans Affairs [IIR 02-076, MREP 02-267, MREP 05-145]
FX Dr. Pugh received funding from the Department of Veterans Affairs IIR
02-076 and MREP 02-267. Dr. Copeland was supported by Department of
Veterans Affairs MREP 05-145. This material is the result of work
supported with resources and the use of facilities at the South Texas
Veterans Health Care System. The funding agencies had no role in
conducting the study, or role in the preparation, review, or approval of
the manuscript.
NR 38
TC 62
Z9 65
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
4LB, ENGLAND
SN 1465-9921
J9 RESP RES
JI Respir. Res.
PD JUN 3
PY 2009
VL 10
AR 45
DI 10.1186/1465-9921-10-45
PG 9
WC Respiratory System
SC Respiratory System
GA 462BR
UT WOS:000267320800001
PM 19493329
ER
PT J
AU Chirinos, JA
Segers, P
Gupta, AK
Swillens, A
Rietzschel, ER
De Buyzere, ML
Kirkpatrick, JN
Gillebert, TC
Wang, Y
Keane, MG
Townsend, R
Ferrari, VA
Wiegers, SE
Sutton, MSJ
AF Chirinos, Julio A.
Segers, Patrick
Gupta, Amit Kumar
Swillens, Abigail
Rietzschel, Ernst R.
De Buyzere, Marc L.
Kirkpatrick, James N.
Gillebert, Thierry C.
Wang, Yan
Keane, Martin G.
Townsend, Raymond
Ferrari, Victor A.
Wiegers, Susan E.
Sutton, Martin St John
TI Time-Varying Myocardial Stress and Systolic Pressure-Stress Relationship
Role in Myocardial-Arterial Coupling in Hypertension
SO CIRCULATION
LA English
DT Article
DE hypertension; myocardium; hemodynamics
ID LEFT-VENTRICULAR GEOMETRY; WAVE REFLECTION; HEART-FAILURE; WALL STRESS;
HYPERTROPHY; ECHOCARDIOGRAPHY; QUANTIFICATION; DISEASE
AB Background-Myocardial afterload depends on left ventricular (LV) cavity size, pressure, and wall thickness, all of which change markedly throughout ejection. We assessed the relationship between instantaneous ejection-phase pressure and myocardial stress and the effect of arterial wave reflections on myocardial stress in hypertensive and normotensive adults.
Methods and Results-We studied 42 untreated hypertensive, 42 treated hypertensive, and 42 normotensive adults with normal LV ejection fraction. Time-resolved central pressure, flow, and LV geometry were measured with carotid tonometry, Doppler, and speckle-tracking echocardiography for computation of arterial load and time-varying circumferential and longitudinal myocardial stress. In all 3 groups, peak myocardial stress typically occurred in early systole (within the first 100 milliseconds of ejection), followed by a marked midsystolic shift in the pressure-stress relationship, which favored lower late systolic stress values (P < 0.001) relative to pressure. The mean magnitude of this midsystolic shift was quantitatively important in all 3 groups (circumferential stress, 144 to 148 kdynes/cm(2)) and was independently predicted by a higher LV ejection fraction and ratio of LV end-diastolic cavity to wall volume. Time of peak myocardial stress independently correlated with time of the first systolic but not with time of the second systolic central pressure peak.
Conclusions-Peak myocardial stress occurs in early systole, before important contributions of reflected waves to central pressure. In the presence of normal LV ejection fraction, a midsystolic shift in the pressure-stress relationship protects cardiomyocytes against excessive late systolic stress (despite pressure augmentation associated with wave reflections), a coupling mechanism that may be altered in various disease states. (Circulation. 2009; 119:2798-2807.)
C1 [Chirinos, Julio A.; Gupta, Amit Kumar; Kirkpatrick, James N.; Wang, Yan; Keane, Martin G.; Townsend, Raymond; Ferrari, Victor A.; Wiegers, Susan E.; Sutton, Martin St John] Univ Penn, Philadelphia, PA 19104 USA.
[Chirinos, Julio A.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Segers, Patrick; Swillens, Abigail] Univ Ghent, Cardiovasc Mech & Biofluid Dynam Res Unit, IBiTech, B-9000 Ghent, Belgium.
[Rietzschel, Ernst R.; De Buyzere, Marc L.; Gillebert, Thierry C.] Ghent Univ Hosp, Dept Cardiovasc Dis, B-9000 Ghent, Belgium.
RP Chirinos, JA (reprint author), Childrens Hosp Philadelphia, Div Cardiol, Room 8B111,3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM julio.chirinos@uphs.upenn.edu
RI Gupta, amit/B-3831-2012
OI Gillebert, Thierry/0000-0002-3832-919X
NR 19
TC 35
Z9 35
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JUN 2
PY 2009
VL 119
IS 21
BP 2798
EP U100
DI 10.1161/CIRCULATIONAHA.108.829366
PG 20
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 452DY
UT WOS:000266521400008
PM 19451350
ER
PT J
AU Breitner, JCS
Haneuse, SJPA
Walker, R
Dublin, S
Crane, PK
Gray, SL
Larson, EB
AF Breitner, J. C. S.
Haneuse, S. J. P. A.
Walker, R.
Dublin, S.
Crane, P. K.
Gray, S. L.
Larson, E. B.
TI Risk of dementia and AD with prior exposure to NSAIDs in an elderly
community-based cohort
SO NEUROLOGY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E;
ANTIINFLAMMATORY DRUGS; CACHE COUNTY; ONSET; AGE; ROFECOXIB; NAPROXEN
AB Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) may prevent Alzheimer dementia (AD).
Methods: We analyzed the association of prior NSAID exposure with incident dementia and AD in the Adult Changes in Thought population-based cohort aged >= 65 years (median 74.8) at enrollment. Participants were members of Group Health, which provided computerized pharmacy dispensing records from 1977 onward. We studied 2,736 dementia-free enrollees with extensive prior pharmacy data, following them biennially for up to 12 years to identify dementia and AD. Cox proportional hazards regression assessed association of dementia or AD with NSAID use graded in standard daily doses (SDD) dispensed over 2 years (e.g., heavy use = 500 + SDD), with some analyses also adding consecutive biennial self-reports of NSAID use.
Results: Pharmacy records identified 351 participants (12.8%) with history of heavy NSAID use at enrollment. Another 107 became heavy users during follow-up. Some 476 individuals developed incident dementia, 356 with AD (median onset ages 83.5 and 83.8 years). Contrary to the hypothesis that NSAIDs protect against AD, pharmacy-defined heavy NSAID users showed increased incidence of dementia and AD, with adjusted hazard ratios of 1.66 (95% confidence interval, 1.24-2.24) and 1.57 (95% confidence interval, 1.10-2.23). Addition of self-reported exposure data did not alter these results.
Conclusions: These findings differ from those of other studies with younger cohorts. The results observed elsewhere may reflect delayed onset of Alzheimer dementia (AD) in nonsteroidal anti-inflammatory drug (NSAID) users. Conceivably, such delay could result in increased AD incidence in late old age. The relation of NSAID use and AD pathogenesis needs further investigation. Neurology (R) 2009; 72: 1899-1905
C1 [Breitner, J. C. S.] Geriatr Res Educ & Clin Ctr, Dept Vet Affairs Med Ctr, Seattle, WA USA.
[Breitner, J. C. S.; Crane, P. K.] Univ Washington, Sch Med, Seattle, WA USA.
[Haneuse, S. J. P. A.; Walker, R.; Dublin, S.; Larson, E. B.] Ctr Hlth Studies, Grp Hlth Cooperat, Seattle, WA USA.
[Dublin, S.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA.
[Gray, S. L.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA.
RP Breitner, JCS (reprint author), VA Puget Sound Hlth Care Syst, GRECC S182, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM jcsb@u.washington.edu
RI Crane, Paul/C-8623-2014
OI Crane, Paul/0000-0003-4278-7465
FU NIA NIH HHS [U01 AG006781, K23 AG028954, K23 AG028954-01A1,
K23-AG-28954, R01-AG-24010, U01 AG006781-13, U01-AG-06781, U01-AG-15477]
NR 28
TC 99
Z9 102
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUN 2
PY 2009
VL 72
IS 22
BP 1899
EP 1905
DI 10.1212/WNL.0b013e3181a18691
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 452FD
UT WOS:000266524600005
PM 19386997
ER
PT J
AU Grudzen, CR
Timmermans, S
Koenig, WJ
Torres, JM
Hoffman, JR
Lorenz, KA
Asch, SM
AF Grudzen, Corita R.
Timmermans, Stefan
Koenig, William J.
Torres, Jacqueline M.
Hoffman, Jerome R.
Lorenz, Karl A.
Asch, Steven M.
TI Paramedic and Emergency Medical Technicians Views on Opportunities and
Challenges When Forgoing and Halting Resuscitation in the Field
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article
DE resuscitation; ethics; emergency medical services; prehospital care;
cardiac arrest
ID CARDIAC-ARREST; QUALITY; DEATH
AB The objective was to assess paramedic and emergency medical technicians (EMT) perspectives and decision-making after a policy change that allows forgoing or halting resuscitation in prehospital atraumatic cardiac arrest.
Five semistructured focus groups were conducted with 34 paramedics and 2 EMTs from emergency medical services (EMS) agencies within Los Angeles County (LAC), 6 months after a policy change that allowed paramedics to forgo or halt resuscitation in the field under certain circumstances.
Participants had an overwhelmingly positive view of the policy; felt it empowered their decision-making abilities; and thought the benefits to patients, family, EMS, and the public outweighed the risks. Except under certain circumstances, such as when the body was in public view or when family members did not appear emotionally prepared to have the body left on scene, they felt the policy improved care. Assuming that certain patient characteristics were present, decisions by paramedics about implementing the policy in the field involve many factors, including knowledge and comfort with the new policy, family characteristics (e.g., agreement), and logistics regarding the place of arrest (e.g., size of space). Paramedic and EMT experiences with and attitudes toward forgoing resuscitation, as well as group dynamics among EMS leadership, providers, police, and ED staff, also play a role.
Participants view the ability to forgo or halt resuscitation in the field as empowering and do not believe it presents harm to patients or families under most circumstances. Factors other than patient clinical characteristics, such as knowledge and attitudes toward the policy, family emotional preparedness, and location of arrest, affect whether paramedics will implement it.
C1 [Grudzen, Corita R.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA.
[Timmermans, Stefan] Univ Calif Los Angeles, Dept Sociol, Los Angeles, CA 90024 USA.
[Koenig, William J.] Los Angeles Cty, Emergency Med Serv Agcy, Los Angeles, CA USA.
[Torres, Jacqueline M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Hoffman, Jerome R.] Univ Calif Los Angeles, Dept Emergency Med, Los Angeles, CA USA.
[Lorenz, Karl A.] Vet Integrated Palliat Care Program, Los Angeles, CA USA.
[Lorenz, Karl A.; Asch, Steven M.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
[Grudzen, Corita R.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA.
RP Grudzen, CR (reprint author), Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA.
EM corita.grudzen@mountsinai.org
OI Grudzen, Corita/0000-0003-3039-8497
FU California Health Care Foundation [07-1155]
FX This study was funded with a grant from the California Health Care
Foundation, Grant 07-1155.
NR 14
TC 10
Z9 10
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1069-6563
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD JUN
PY 2009
VL 16
IS 6
BP 532
EP 538
DI 10.1111/j.1553-2712.2009.00427.x
PG 7
WC Emergency Medicine
SC Emergency Medicine
GA 453FB
UT WOS:000266594600009
PM 19438412
ER
PT J
AU Lee, S
Van Remmen, H
Csete, M
AF Lee, Sukkyoo
Van Remmen, Holly
Csete, Marie
TI Sod2 overexpression preserves myoblast mitochondrial mass and function,
but not muscle mass with aging
SO AGING CELL
LA English
DT Article
DE hydrogen peroxide; mitochondria; muscle aging; myoblast; PI3 kinase-Akt
signaling; superoxide
ID MANGANESE SUPEROXIDE-DISMUTASE; FOXO TRANSCRIPTION FACTORS;
PROTEIN-KINASE B; DNA COPY NUMBER; SKELETAL-MUSCLE; SATELLITE-CELL;
MUTANT MICE; DILATED CARDIOMYOPATHY; OXIDATIVE STRESS; COMPLEX I
AB Mice lacking superoxide dismutase-2 (SOD2 or MnSOD) die during embryonic or early neonatal development, with diffuse superoxide-induced mitochondrial damage. Although stem and progenitor cells are exquisitely sensitive to oxidant stress, they have not been well studied in MnSOD2-manipulated mouse models. Patterns of proliferation and differentiation of cultured myoblasts (muscle progenitor cells), PI3-Akt signaling during differentiation, and the maintenance of mitochondrial mass with aging using myoblasts from young (3-4 week old) and aged (27-29 months old) MnSOD2-overexpressing (Sod2-Tg) and heterozygote (Sod2(+/-)) mice were characterized by us. Overexpression of MnSOD2 in myoblasts had a protective effect on mitochondrial DNA abundance and some aspects of mitochondrial function with aging, and preservation of differentiation potential. Sod2 deficiency resulted in defective signaling in the PI3-Akt pathway, specifically impaired phosphorylation of Akt at Ser473 and Thr308 in young myoblasts, and decreased differentiation potential. Compared with young myoblasts, aged myoblast Akt was constitutively phosphorylated, unresponsive to mitogen signaling, and indifferent to MnSOD2 levels. These data suggest that specific sites in the PI3K-Akt pathway are more sensitive to increased superoxide levels than to the increased hydrogen peroxide levels generated in Sod2-transgenic myoblasts. In wild-type myoblasts, aging was associated with significant loss of mitochondrial DNA relative to chromosomal DNA, but MnSOD2 overexpression was associated with maintained myoblast mitochondrial DNA with aging.
C1 [Lee, Sukkyoo; Csete, Marie] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA.
[Lee, Sukkyoo; Csete, Marie] Emory Univ, Sch Med, Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA.
[Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Csete, M (reprint author), Calif Inst Regenerat Med, 210 King St, San Francisco, CA 94107 USA.
EM mcsete@cirm.ca.gov
FU Emory Anesthesiology; [PO1 NIA 1-386003609]
FX The authors thank Dr Charles Epstein for supplying mice for these
studies. The authors acknowledge Drs Russ Price (Emory), David Lambeth
(Emory), Tom Burkholder (GaTech) and Karl Saxe (American Cancer Society)
for helpful discussions. This work was supported by PO1 NIA 1-386003609
(MC, HVR), and Emory Anesthesiology.
NR 63
TC 10
Z9 10
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1474-9718
J9 AGING CELL
JI Aging Cell
PD JUN
PY 2009
VL 8
IS 3
BP 296
EP 310
DI 10.1111/j.1474-9726.2009.00477.x
PG 15
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 450RE
UT WOS:000266417700009
PM 19627269
ER
PT J
AU Crothers, K
Goulet, JL
Rodriguez-Barradas, MC
Gibert, CL
Oursler, KAK
Goetz, MB
Crystal, S
Leaf, DA
Butt, AA
Braithwaite, RS
Peck, R
Justice, AC
AF Crothers, Kristina
Goulet, Joseph L.
Rodriguez-Barradas, Maria C.
Gibert, Cynthia L.
Oursler, Kris Ann K.
Goetz, Matthew Bidwell
Crystal, Stephen
Leaf, David A.
Butt, Adeel A.
Braithwaite, R. Scott
Peck, Robin
Justice, Amy C.
TI IMPACT OF CIGARETTE SMOKING ON MORTALITY IN HIV-POSITIVE AND
HIV-NEGATIVE VETERANS
SO AIDS EDUCATION AND PREVENTION
LA English
DT Article; Proceedings Paper
CT Workshop on Current Issues in Cigarette Smoking and HIV/AIDS
CY OCT 08, 2007
CL Bethesda, MD
SP Natl Inst Hlth
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE-SYSTEM; QUALITY-OF-LIFE;
BACTERIAL PNEUMONIA; RANDOMIZED-TRIAL; ALCOHOL-USE; INFECTION;
CESSATION; OUTCOMES; DISEASE
AB It is unknown whether smoking confers similar mortality risk in HIV-positive as in HIV-negative patients. We compared overall mortality stratified by HIV and smoking of 1,034 HIV-positive block-matched to 739 HIV-negative veterans, enrolled 2001-2002 in the Veterans Aging Cohort 5 Site Study. Adjusted incidence rate ratios (IRR) for mortality were calculated using Poisson regression. Mortality was significantly increased in HIV-positive veterans according to both smoking status and pack-years in unadjusted and adjusted analyses (adjusted IRR 2.31, 95% confidence interval [CI] 1.53-3.49 for HIV-positive current smokers and IRR 1.32, 95% CI 0.67-2.61 for HIV-negative current smokers). Comorbid diseases were also significantly increased according to smoking status and pack-years. Current smoking is associated with poor outcomes; even lower levels of exposure appear to be detrimental in HIV-infected veterans. These findings support the need for improvements in smoking cessation and for studies of mechanisms and diseases underlying increased mortality in smokers with HIV.
C1 [Crothers, Kristina; Goulet, Joseph L.; Rodriguez-Barradas, Maria C.; Justice, Amy C.] VA Connecticut Healthcare Syst, Dept Internal Med, New Haven, CT USA.
[Crothers, Kristina; Goulet, Joseph L.; Rodriguez-Barradas, Maria C.; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA.
[Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Med Serv, Houston, TX USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Gibert, Cynthia L.; Peck, Robin] George Washington Univ, Dept Med, Washington, DC USA.
[Gibert, Cynthia L.; Peck, Robin] VA Med Ctr, Washington, DC USA.
[Oursler, Kris Ann K.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Oursler, Kris Ann K.] Baltimore VA Med Ctr, Ctr Geriatr Res Educ & Clin, Baltimore, MD USA.
[Goetz, Matthew Bidwell; Leaf, David A.] VA Greater Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA.
[Goetz, Matthew Bidwell; Leaf, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Crystal, Stephen] Rutgers State Univ, Ctr Pharmacotherapy Chron Dis Management & Outcom, New Brunswick, NJ 08903 USA.
[Crystal, Stephen] Rutgers State Univ, Inst Hlth, New Brunswick, NJ 08903 USA.
[Crystal, Stephen] Rutgers State Univ, Sch Social Work, New Brunswick, NJ 08903 USA.
[Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Dept Internal Med, Pittsburgh, PA USA.
[Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
RP Crothers, K (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave,11 ACSLG, West Haven, CT 06516 USA.
EM kristina.crothers@yale.edu
OI Goetz, Matthew/0000-0003-4542-992X; Goulet, Joseph/0000-0002-0842-804X;
Crothers, Kristina/0000-0001-9702-0371
FU AHRQ HHS [U18 HS016097, U18-HS016097]; NCRR NIH HHS [1KL2 RR024138, KL2
RR024138]; NHLBI NIH HHS [1R01 HL090342, R01 HL090342]; NIAAA NIH HHS
[3U01AA13566, U01 AA013566, U10 AA013566, U10 AA013566-08]; NIMH NIH HHS
[MH058984, R01 MH058984]
NR 37
TC 54
Z9 55
U1 0
U2 1
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0899-9546
J9 AIDS EDUC PREV
JI Aids Educ. Prev.
PD JUN
PY 2009
VL 21
IS 3
BP 40
EP 53
PG 14
WC Education & Educational Research; Public, Environmental & Occupational
Health
SC Education & Educational Research; Public, Environmental & Occupational
Health
GA 456XT
UT WOS:000266888500005
PM 19537953
ER
PT J
AU Denmark, DL
Buck, KJ
AF Denmark, D. L.
Buck, K. J.
TI A POSSIBLE ROLE FOR THE MITOCHONDRIAL RESPIRATORY CHAIN IN GENETIC
VULNERABILITY TO SEVERE ALCOHOL WITHDRAWAL
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 20-24, 2009
CL San Diego, CA
SP Res Soc Alcoholism
C1 Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97239 USA.
Portland VA Med Ctr, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2009
VL 33
IS 6
BP 18A
EP 18A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 449MQ
UT WOS:000266335100030
ER
PT J
AU Hashimoto, JG
Forquer, MR
Wiren, KM
AF Hashimoto, J. G.
Forquer, M. R.
Wiren, K. M.
TI SEXUALLY DIMORPHIC HORMONE PROFILES AFTER CHRONIC ALCOHOL EXPOSURE IN
WSP AND WSR MICE: TESTOSTERONE LEVELS DROP IN MALES BUT INCREASE IN
FEMALES
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 20-24, 2009
CL San Diego, CA
SP Res Soc Alcoholism
C1 Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2009
VL 33
IS 6
BP 32A
EP 32A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 449MQ
UT WOS:000266335100086
ER
PT J
AU Hawkins, EH
Malte, CA
Baer, JS
Kivlahan, DR
AF Hawkins, E. H.
Malte, C. A.
Baer, J. S.
Kivlahan, D. R.
TI PREVALENCE AND CHARACTERISTICS OF PATIENTS WITH MULTIPLE ALCOHOL USE
DISORDER TREATMENT EPISODES
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 20-24, 2009
CL San Diego, CA
SP Res Soc Alcoholism
C1 [Hawkins, E. H.; Malte, C. A.; Baer, J. S.; Kivlahan, D. R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2009
VL 33
IS 6
BP 57A
EP 57A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 449MQ
UT WOS:000266335100188
ER
PT J
AU Gazdzinski, S
Mon, A
Durazzo, TC
Meyerhoff, DJ
AF Gazdzinski, S.
Mon, A.
Durazzo, T. C.
Meyerhoff, D. J.
TI ELEVATED BODY MASS INDEX IS ASSOCIATED WITH BRAIN INJURY IN ALCOHOL
DEPENDENCE - A MAGNETIC RESONANCE STUDY
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 20-24, 2009
CL San Diego, CA
SP Res Soc Alcoholism
C1 Univ Calif San Francisco, San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2009
VL 33
IS 6
BP 90A
EP 90A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 449MQ
UT WOS:000266335100321
ER
PT J
AU Batki, SL
Dimmock, JA
Ploutz-Snyder, R
Meszaros, ZS
Canfield, K
AF Batki, S. L.
Dimmock, J. A.
Ploutz-Snyder, R.
Meszaros, Z. S.
Canfield, K.
TI DIRECTLY MONITORED NALTREXONE REDUCES HEAVY DRINKING IN SCHIZOPHRENIA:
PRELIMINARY ANALYSIS OF A CONTROLLED TRIAL
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 20-24, 2009
CL San Diego, CA
SP Res Soc Alcoholism
C1 UCSF, Dept Psychiat, San Francisco, CA 94121 USA.
San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2009
VL 33
IS 6
BP 113A
EP 113A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 449MQ
UT WOS:000266335100412
ER
PT J
AU Milner, LC
Giardino, W
Buck, KJ
AF Milner, L. C.
Giardino, W.
Buck, K. J.
TI DEVELOPMENT OF A NOVEL MURINE BEHAVIORAL BATTERY: EFFECTS OF ETHANOL
WITHDRAWAL AND KCNJ9 ALLELIC STATUS
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 20-24, 2009
CL San Diego, CA
SP Res Soc Alcoholism
C1 Portland VA Med Ctr, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Dept Behav Neurosci, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2009
VL 33
IS 6
BP 141A
EP 141A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 449MQ
UT WOS:000266335100525
ER
PT J
AU Rasmussen, DD
Federoff, D
Froehlich, JC
AF Rasmussen, D. D.
Federoff, D.
Froehlich, J. C.
TI PRAZOSIN REDUCES ALCOHOL DRINKING IN AN ANIMAL MODEL OF ALCOHOL RELAPSE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 20-24, 2009
CL San Diego, CA
SP Res Soc Alcoholism
C1 [Rasmussen, D. D.] VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Rasmussen, D. D.] Univ Washington, Seattle, WA 98195 USA.
[Federoff, D.; Froehlich, J. C.] Indiana Univ, Sch Med, Indianapolis, IN 46202 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2009
VL 33
IS 6
BP 146A
EP 146A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 449MQ
UT WOS:000266335100543
ER
PT J
AU Mckay, JR
Lynch, KG
Van Horn, D
Ivey, M
Oslin, D
Drapkin, M
AF McKay, J. R.
Lynch, K. G.
Van Horn, D.
Ivey, M.
Oslin, D.
Drapkin, M.
TI EFFECTIVENESS OF EXTENDED TELEPHONE CONTINUING CARE: 18 MONTH OUTCOMES
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 20-24, 2009
CL San Diego, CA
SP Res Soc Alcoholism
C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2009
VL 33
IS 6
BP 197A
EP 197A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 449MQ
UT WOS:000266335100747
ER
PT J
AU Durazzo, TC
Pathik, V
Gazdzinski, S
Mon, A
Meyerhoff, DJ
AF Durazzo, T. C.
Pathik, V.
Gazdzinski, S.
Mon, A.
Meyerhoff, D. J.
TI METABOLITE LEVELS IN THE BRAIN REWARD PATHWAY AT TREATMENT ENTRY
DIFFERENTIATE FUTURE ABSTAINERS AND RELAPERS
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 20-24, 2009
CL San Diego, CA
SP Res Soc Alcoholism
C1 [Durazzo, T. C.; Pathik, V.; Gazdzinski, S.; Mon, A.; Meyerhoff, D. J.] Univ Calif San Francisco, San Francisco VA Med Ctr, Ctr Neuroimaging Neurodegenerat Dis, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2009
VL 33
IS 6
BP 231A
EP 231A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 449MQ
UT WOS:000266335100883
ER
PT J
AU Raskind, MA
AF Raskind, M. A.
TI SUSTAINED RECOVERY FROM CHRONIC ALCOHOL DEPENDENCE WITH PRAZOSIN
TREATMENT OF PTSD
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 20-24, 2009
CL San Diego, CA
SP Res Soc Alcoholism
C1 [Raskind, M. A.] Univ Washington, Mental Hlth Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Raskind, M. A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA.
NR 0
TC 2
Z9 2
U1 3
U2 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2009
VL 33
IS 6
BP 311A
EP 311A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 449MQ
UT WOS:000266335101195
ER
PT J
AU Walker, B
Rasmussen, D
Raskind, M
Koob, G
AF Walker, B.
Rasmussen, D.
Raskind, M.
Koob, G.
TI THE EFFECT OF ALPHA-1 ADRENERGIC RECEPTOR ANTAGONISM ON EXCESSIVE
ALCOHOL SELF-ADMINISTRATION DURING ACUTE WITHDRAWAL IN DEPENDENT
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 20-24, 2009
CL San Diego, CA
SP Res Soc Alcoholism
C1 [Walker, B.] Washington State Univ, Pullman, WA 99164 USA.
[Rasmussen, D.; Raskind, M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Rasmussen, D.; Raskind, M.] Univ Washington, Seattle, WA 98195 USA.
[Koob, G.] Scripps Res Inst, La Jolla, CA 92037 USA.
RI koob, george/P-8791-2016
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2009
VL 33
IS 6
BP 311A
EP 311A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 449MQ
UT WOS:000266335101196
ER
PT J
AU Rasmussen, DD
Federoff, D
Froehlich, JC
AF Rasmussen, D. D.
Federoff, D.
Froehlich, J. C.
TI PRAZOSIN REDUCES VOLUNTARY ALCOHOL DRINKING IN BOTH NON-DEPRIVED AND
ALCOHOL-DEPRIVED RATS SELECTIVELY BRED FOR ALCOHOL PREFERENCE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 20-24, 2009
CL San Diego, CA
SP Res Soc Alcoholism
C1 [Rasmussen, D. D.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Federoff, D.; Froehlich, J. C.] Indiana Univ, Sch Med, Indianapolis, IN 46202 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2009
VL 33
IS 6
BP 312A
EP 312A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 449MQ
UT WOS:000266335101197
ER
PT J
AU Simpson, TL
Saxon, AJ
Meredith, CW
Malte, CA
McBride, B
Ferguson, LC
Gross, CA
Hart, KL
Raskind, M
AF Simpson, T. L.
Saxon, A. J.
Meredith, C. W.
Malte, C. A.
McBride, B.
Ferguson, L. C.
Gross, C. A.
Hart, K. L.
Raskind, M.
TI A PILOT TRIAL OF THE ALPHA-1 ADRENERGIC ANTAGONIST, PRAZOSIN, FOR
ALCOHOL DEPENDENCE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 32nd Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 20-24, 2009
CL San Diego, CA
SP Res Soc Alcoholism
C1 [Simpson, T. L.; Saxon, A. J.; Meredith, C. W.; Malte, C. A.; McBride, B.; Ferguson, L. C.; Gross, C. A.; Hart, K. L.; Raskind, M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2009
VL 33
IS 6
BP 312A
EP 312A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 449MQ
UT WOS:000266335101198
ER
PT J
AU Gheorghiade, M
Adams, KF
Cleland, JGF
Cotter, G
Felker, GM
Filippatos, GS
Fonarow, GC
Greenberg, BH
Hernandez, AF
Khan, S
Komajda, M
Konstam, MA
Liu, PP
Maggioni, AP
Massie, BM
McMurray, JJ
Mehra, M
Metra, M
O'Connell, J
O'Connor, CM
Pang, PS
Pina, IL
Sabbah, HN
Teerlink, JR
Udelson, JE
Yancy, CW
Zannad, F
Stockbridge, N
AF Gheorghiade, Mihai
Adams, Kirkwood F.
Cleland, John G. F.
Cotter, Gad
Felker, G. Michael
Filippatos, Gerasimos S.
Fonarow, Gregg C.
Greenberg, Barry H.
Hernandez, Adrian F.
Khan, Sadiya
Komajda, Michel
Konstam, Marvin A.
Liu, Peter P.
Maggioni, Aldo P.
Massie, Barry M.
McMurray, John J.
Mehra, Mandeep
Metra, Marco
O'Connell, John
O'Connor, Christopher M.
Pang, Peter S.
Pina, Ileana L.
Sabbah, Hani N.
Teerlink, John R.
Udelson, James E.
Yancy, Clyde W.
Zannad, Faiez
Stockbridge, Norman
CA Acute Heart Failure Syndromes Int
TI Phase III clinical trial end points in acute heart failure syndromes: A
virtual roundtable with the acute heart failure syndromes international
working group
SO AMERICAN HEART JOURNAL
LA English
DT Editorial Material
C1 [Gheorghiade, Mihai; Khan, Sadiya; O'Connell, John; Pang, Peter S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Adams, Kirkwood F.] Univ N Carolina, Chapel Hill, NC USA.
[Cleland, John G. F.] Univ Hull, Castle Hill Hosp, Kingston Upon Hull, Yorks, England.
[Cotter, Gad] Momentum Res Inc, Durham, NC USA.
[Felker, G. Michael; Hernandez, Adrian F.; O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA.
[Filippatos, Gerasimos S.] Univ Athens, Athens, Greece.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles Med Ctr, Los Angeles, CA USA.
[Greenberg, Barry H.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Komajda, Michel] Univ Paris 06, Paris, France.
[Komajda, Michel] Hosp Pitie Salpetriere, Paris, France.
[Konstam, Marvin A.] Tufts Med Ctr, Boston, MA USA.
[Liu, Peter P.] UHN, Toronto Gen Hosp, Toronto, ON, Canada.
[Maggioni, Aldo P.] Assoc Nazl Med Cardiol Osped, Florence, Italy.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[McMurray, John J.] Univ Glasgow, British Heart Fdn, Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.
[Mehra, Mandeep] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA.
[Metra, Marco] Univ Brescia, Brescia, Italy.
[Pina, Ileana L.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Sabbah, Hani N.] Henry Ford Hosp, Henry Ford Heart & Vasc Inst, Detroit, MI 48202 USA.
[Teerlink, John R.] Univ Calif San Francisco, Vet Adm Med Ctr, San Francisco, CA USA.
[Yancy, Clyde W.] Baylor Heart & Vasc Inst, Dallas, TX USA.
[Zannad, Faiez] INSERM, Nancy, France.
[Stockbridge, Norman] US FDA, Silver Spring, MD USA.
RP Gheorghiade, M (reprint author), Northwestern Univ, Feinberg Sch Med, 676 N St Clair St,Suite 600, Chicago, IL 60611 USA.
EM m-gheorghiade@northwestern.edu
RI Teerlink, John/D-2986-2012; Lainscak, Mitja/F-3237-2015; Hernandez,
Adrian F./A-7818-2016
OI Mehra, Mandeep/0000-0001-8683-7044; Hernandez, Adrian
F./0000-0003-3387-9616; Cleland, John/0000-0002-1471-7016; Metra,
Marco/0000-0001-6691-8568; mcmurray, john/0000-0002-6317-3975
NR 0
TC 37
Z9 37
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD JUN
PY 2009
VL 157
IS 6
BP 957
EP 970
DI 10.1016/j.ahj.2009.04.010
PG 14
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 454GD
UT WOS:000266669500002
PM 19464405
ER
PT J
AU Mendez, MF
McMurtray, AM
Licht, EA
Saul, RE
AF Mendez, Mario F.
McMurtray, Aaron M.
Licht, Eliot A.
Saul, Ronald E.
TI Frontal-executive Versus Posterior-perceptual Mental Status Deficits in
Early-onset Dementias
SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS
LA English
DT Article
DE dementia; Alzheimer's disease; vascular dementia; frontotemporal
dementia; frontal-executive functions; perceptual disturbances
ID FRONTOTEMPORAL LOBAR DEGENERATION; DIAGNOSED PRESENILE-DEMENTIA;
ISCHEMIC VASCULAR DEMENTIA; ALZHEIMERS-DISEASE; ASSESSMENT BATTERY;
NEUROPSYCHOLOGICAL FEATURES; CLINICAL CHARACTERISTICS; COGNITIVE
IMPAIRMENT; PREVALENCE; MEMORY
AB Background: Compared to late-onset dementias, early-onset dementias (EODs) may have greater focal cognitive involvement with differences in frontal-executive compared to posterior-perceptual deficits. Objective: This study evaluated whether mental status screening based on this frontal-posterior axis can distinguish EODs. Methods: Twenty-three patients each with early-onset Alzheimer's disease (eAD), frontotemporal dementia (FTD), or subcortical ischemic vascular disease (SIVD), and 20 normal controls underwent the Frontal Assessment Battery (FAB) and the Perceptual Assessment Battery (PAB). Results: Compared to controls, SIVD and FTD groups were impaired on the FAB whereas eAD and SIVD groups were impaired on the PAB. The FAB/PAB ratio further differentiated the groups (F(3,85) = 26.49, P < .001). For sensitivities and specificities of 93%, a cut-off score of 1.25 on the FAB/PAB distinguished eAD, and a cut-off of 0.83 distinguishing FTD. Conclusion: Although preliminary, this study indicates that mental status screening based on frontal versus posterior cortical functions may help clinicians diagnose EODs.
C1 [Mendez, Mario F.; McMurtray, Aaron M.; Licht, Eliot A.] VA Greater Los Angeles Healthcare Syst, Dept Neurol, Neurobehav Unit, Los Angeles, CA 90073 USA.
[Mendez, Mario F.; McMurtray, Aaron M.; Saul, Ronald E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Syst, Neurobehav Unit 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mmendez@ucla.edu
NR 56
TC 5
Z9 5
U1 1
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-3175
J9 AM J ALZHEIMERS DIS
JI Am. J. Alzheimers Dis. Other Dement.
PD JUN-JUL
PY 2009
VL 24
IS 3
BP 220
EP 227
DI 10.1177/1533317509332626
PG 8
WC Geriatrics & Gerontology; Clinical Neurology
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 464NL
UT WOS:000267511700005
PM 19329784
ER
PT J
AU Baruch, L
Agarwal, S
Gupta, B
Haynos, A
Eng, C
AF Baruch, Lawrence
Agarwal, Sanjay
Gupta, Bhanu
Haynos, Ann
Eng, Calvin
TI Effect on Serum Lipid Levels of Switching Dose of Ezetimibe from 10 to 5
mg
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID CHOLESTEROL ABSORPTION INHIBITOR; TREATMENT PANEL-III; PRIMARY
HYPERCHOLESTEROLEMIA; CLINICAL-TRIALS; TOLERABILITY
AB Although during its initial development, lower doses of ezetimibe reduced low-density lipoprotein (LDL) significantly, ezetimibe is available only in 10-mg form. Compliant patients receiving ezetimibe 10 mg were randomized in a blinded fashion to continue therapy with ezetimibe 10 mg or to convert to a split-tablet 5-mg dose. Lipid panels were collected at baseline and after 4 weeks of therapy. The impact of the 2 ezetimibe dosing strategies on LDL and the achievement of the Adult Treatment Panel III LDL goal was evaluated. One hundred thirty patients receiving ezetimibe 10 mg were screened for eligibility. Thirty-nine of the 130 patients were randomized; 36 patients successfully completed the study. All patients who had achieved their Adult Treatment Panel III LDL goals at baseline remained at their LDL goals after conversion to 5 mg. In conclusion, conversion to the lower dose of ezetimibe did not result in any clinically meaningful or statistically significant changes in any lipid parameter. (C) 2009 Published by Elsevier Inc. (Am J Cardiol 2009;103:1568-1571)
C1 [Baruch, Lawrence; Agarwal, Sanjay; Gupta, Bhanu; Haynos, Ann; Eng, Calvin] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Baruch, Lawrence; Agarwal, Sanjay; Gupta, Bhanu; Eng, Calvin] Mt Sinai Sch Med, New York, NY USA.
RP Baruch, L (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
EM lawrence.baruch@va.gov
NR 10
TC 1
Z9 1
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD JUN 1
PY 2009
VL 103
IS 11
BP 1568
EP 1571
DI 10.1016/j.amjcard.2009.01.365
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 456ZR
UT WOS:000266894300015
PM 19463517
ER
PT J
AU Aspinall, SL
Good, CB
Metlay, JP
Mor, MK
Fine, MJ
AF Aspinall, Sherrie L.
Good, Chester B.
Metlay, Joshua P.
Mor, Maria K.
Fine, Michael J.
TI Antibiotic prescribing for presumed nonbacterial acute respiratory tract
infections
SO AMERICAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
CT National Annual Meeting of the
US-Department-of-Veterans-Affairs-Health-Services-Research-and-Developme
nt-Service
CY FEB, 2005
CL Baltimore, MD
SP US Dept Vet Affairs Hlth Serv Res & Dev Serv
ID ACUTE BRONCHITIS; STREPTOCOCCUS-PNEUMONIAE; EMERGENCY-DEPARTMENTS;
AMBULATORY PRACTICE; CARE PHYSICIANS; UNITED-STATES; ADULTS; TRENDS;
PREDICTORS; MANAGEMENT
AB Objective: The objective of the study was to identify patient and provider factors associated with prescribing antibiotics for outpatients with acute respiratory tract infections of likely nonbacterial etiology.
Methods: We identified outpatients who were diagnosed in the emergency department with nonspecific upper respiratory tract infections (URIs) and acute bronchitis at the VA Pittsburgh Healthcare System from June 15, 2003, to June 14, 2004, and the Philadelphia VA Medical Center from November 30, 2003, to March 31, 2004. Stepwise logistic regression was used to identify factors independently associated with antibiotic prescribing.
Results: Overall, 26% of the 667 eligible patients with URIs and/or acute bronchitis received antibiotics. Antibiotics were prescribed significantly more frequently for acute bronchitis at one site (97% vs 65%, P < .001). Using multivariable analysis, the following factors were independently associated with antibiotic prescribing (odds ratio, 95% confidence interval): presence of I or more comorbidities (2.1, 1.2-3.5), fever (2.5, 1.4-4.4), purulent sputum (2.5, 1.5-4.4), shortness of breath (2.8, 1.4-5.4), altered breath sounds (4.6, 2.4-8.6), diagnosis of acute bronchitis (15.9, 8.0-31.8), provider age >= 30 years (2.6, 1.1-6.3), and noninternal medicine specialty (2.7, 1.2-6.0).
Conclusions: Antibiotic use was high and varied substantially for URN and acute bronchitis. Specific signs and symptoms, a diagnosis of acute bronchitis, and provider age and specialty were associated with antibiotic prescribing. Interventions to decrease inappropriate prescribing should address the perceived utility of antibiotics in acute bronchitis and the accuracy of signs and symptoms in diagnosing a bacterial respiratory infection. Published by Elsevier Inc.
C1 [Aspinall, Sherrie L.; Good, Chester B.; Mor, Maria K.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Aspinall, Sherrie L.; Good, Chester B.] VA Ctr Medicat Safety, Hines VA, Hines, IL 60141 USA.
[Aspinall, Sherrie L.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA 15261 USA.
[Good, Chester B.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA.
[Metlay, Joshua P.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 19104 USA.
[Metlay, Joshua P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
RP Aspinall, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151C-H, Pittsburgh, PA 15206 USA.
EM sherrie.aspinall@va.gov
FU PHS HHS [5K24 A101769]
NR 31
TC 12
Z9 12
U1 2
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0735-6757
J9 AM J EMERG MED
JI Am. J. Emerg. Med.
PD JUN
PY 2009
VL 27
IS 5
BP 544
EP 551
DI 10.1016/j.ajem.2008.04.015
PG 8
WC Emergency Medicine
SC Emergency Medicine
GA 457OH
UT WOS:000266940800005
PM 19497459
ER
PT J
AU Freedland, SJ
Aronson, WJ
AF Freedland, Stephen J.
Aronson, William J.
TI Invited Commentary: Lower Urinary Tract Symptoms and Inflammation -
Weighing the Evidence
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material
DE inflammation; prostate; urinary tract physiological phenomena
ID MEN
AB Lower urinary tract symptoms (LUTS) are a common condition, particularly among older men. The etiology of these symptoms is often obscure and not always clearly related to prostatic enlargement or benign prostatic hyperplasia. St. Sauver et al. (Am J Epidemiol. 2009;169(11):1281-1290) hypothesized that systemic inflammation may be associated with LUTS and benign prostatic hyperplasia. Using a well-defined cohort, they found that, in general, inflammation was not related to LUTS or to benign prostatic hyperplasia progression. However, men with the highest amount of systemic inflammation, as measured by C-reactive protein levels, were at increased risk of a rapid change in irritative voiding symptoms and decreased urinary flow but not obstructive voiding symptoms or prostate size. To what degree systemic inflammation relates to inflammation within the urinary system and specifically the bladder and/or prostate is unclear. Furthermore, to what degree inflammation within the urinary system contributes to LUTS is unclear. Given that clinical trials of antiinflammatory drugs for LUTS have been largely unsuccessful, the role of inflammation as a contributor to LUTS remains an interesting hypothesis that requires further study.
C1 [Freedland, Stephen J.] Durham VA Med Ctr, Dept Surg, Durham, NC USA.
[Freedland, Stephen J.] Duke Prostate Ctr, Durham, NC USA.
[Freedland, Stephen J.] Duke Univ, Med Ctr, Div Urol Surg, Dept Surg, Durham, NC 27710 USA.
[Freedland, Stephen J.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
[Aronson, William J.] Greater Los Angeles VA Hlth Syst, Dept Surg, Los Angeles, CA USA.
[Aronson, William J.] Univ Calif Los Angeles, Med Ctr, Dept Urol, Los Angeles, CA 90024 USA.
RP Freedland, SJ (reprint author), Duke Univ, Med Ctr, Div Urol Surg, Dept Surg, Box 2626, Durham, NC 27710 USA.
EM steve.freedland@duke.edu
NR 8
TC 4
Z9 4
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 1
PY 2009
VL 169
IS 11
BP 1291
EP 1293
DI 10.1093/aje/kwp084
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 446GF
UT WOS:000266109400002
PM 19395692
ER
PT J
AU Hassanein, T
Blei, AT
Perry, W
Hilsabeck, R
Stange, J
Larsen, FS
Brown, RS
Caldwell, S
McGuire, B
Nevens, F
Fontana, R
AF Hassanein, Tarek
Blei, Andres T.
Perry, William
Hilsabeck, Robin
Stange, Jan
Larsen, Fin S.
Brown, Robert S., Jr.
Caldwell, Stephen
McGuire, Brendan
Nevens, Frederik
Fontana, Robert
TI Performance of the Hepatic Encephalopathy Scoring Algorithm in a
Clinical Trial of Patients With Cirrhosis and Severe Hepatic
Encephalopathy
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID PORTAL-SYSTEMIC ENCEPHALOPATHY; DOUBLE-BLIND; ALBUMIN DIALYSIS;
FLUMAZENIL; PLACEBO; MULTICENTER; LACTULOSE; NEOMYCIN; COMA
AB OBJECTIVES: The grading of hepatic encephalopathy (HE) is based on a combination of indicators that reflect the state of consciousness, intellectual function, changes in behavior, and neuromuscular alterations seen in patients with liver failure.
METHODS: We modified the traditional West Haven criteria (WHC) to provide an objective assessment of the cognitive parameters to complement the subjective clinical ratings for the performance of extracorporeal albumin dialysis (ECAD) using a molecular adsorption recirculating system in patients with cirrhosis and severe (grade III/IV) encephalopathy. The HE Scoring Algorithm (HESA) combined clinical indicators with those derived from simple neuropsychological tests, the latter more often used in milder grades of HE (I/II). The performance of each indicator was compared across grades and sites.
RESULTS: Results of HESA were also compared with the Glasgow Coma Scale. A total of 597 evaluations were performed in patients randomized to ECAD plus standard medical therapy or the latter only. Most parameters exhibited significant separation between grades; the most effective indicators were lack of verbal, eye, and motor response (grade IV), somnolence and disorientation to place (grade III), and lethargy and disorientation to time (grade II). Two clinical and four neuropsychological indicators were useful to classify patients as grade I. The Glasgow Coma Scale differed among the four stages of the WHC, but the differences between grades I and II were small and not clinically useful.
CONCLUSION: HESA extends the traditional WHC for grading HE. In the absence of a "gold" standard, the most useful indicators noted in this trial should be further validated.
C1 [Hassanein, Tarek] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
[Blei, Andres T.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA.
[Perry, William; Hilsabeck, Robin] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Hilsabeck, Robin] S Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA.
[Hilsabeck, Robin] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Stange, Jan] Univ Rostock, Dept Internal Med, D-2500 Rostock, Germany.
[Larsen, Fin S.] Univ Copenhagen Hosp, Rigshosp, Dept Hepatol, DK-2100 Copenhagen, Denmark.
[Brown, Robert S., Jr.] Columbia Univ, Dept Med, New York, NY USA.
[Caldwell, Stephen] Univ Virginia, Dept Med, Charlottesville, VA USA.
[McGuire, Brendan] Univ Alabama, Dept Med, Birmingham, AL 35294 USA.
[Nevens, Frederik] Univ Hosp Gasthuisberg, Dept Hepatol, B-3000 Louvain, Belgium.
[Fontana, Robert] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
RP Hassanein, T (reprint author), Univ Calif San Diego, Dept Med, 200 W Arbor Dr,MC 8423, San Diego, CA 92103 USA.
EM thassanein@ucsd.edu
OI Larsen, Fin Stolze/0000-0003-2205-8265
FU Teraklin
FX The authors acknowledge Dr Je C Gornbein from the Department of
Biostatistics at the University of California at Los Angeles for
invaluable statistical assistance. The authors also thank Fatma Barakat
and Deanna L. Oliver for their support in preparation of the manuscript.
This study was supported by research grants from Teraklin.
NR 29
TC 28
Z9 29
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JUN
PY 2009
VL 104
IS 6
BP 1392
EP 1400
DI 10.1038/ajg.2009.160
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 457DR
UT WOS:000266906900017
PM 19455117
ER
PT J
AU Khandwalla, HE
Fasakin, Y
El-Serag, HB
AF Khandwalla, Hashim E.
Fasakin, Yemi
El-Serag, Hashem B.
TI The Utility of Evaluating Low Serum Albumin Gradient Ascites in Patients
With Cirrhosis
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID PERITONITIS; DIAGNOSIS; PROTEIN; FLUID
AB OBJECTIVES: Serum-ascites albumin gradient (SAAG) has been used extensively in the diagnostic workup of patients with ascites. A SAAG level of <1.1 g/dl is usually thought of as a result of nonportal hypertension etiologies, including malignancies, tuberculous peritonitis, and nephrotic syndrome. However, the predictive value of a low SAAG in patients with existing cirrhosis in whom the pretest probability of portal hypertension is high is not clear.
METHODS: We identified all patients with a SAAG of <1.1 g/dl during a 5-year period at a single large veterans affairs medical center. Cirrhosis was defined by clinical, histological, and radiological features. Nonportal hypertension causes of low SAAG were identified, including bacterial peritonitis, peritoneal carcinomatosis, nephrogenous ascites, tuberculous peritonitis, chylous ascites, and pancreatic ascites.
RESULTS: We identified 92 patients (76 with cirrhosis and 16 with no cirrhosis) with ascites and a SAAG of <1.1 g/dl. Of the 76 patients with cirrhosis, only 29 (38%) had an identifiable cause, most commonly primary bacterial peritonitis (11, 38%), followed by peritoneal carcinomatosis or malignant ascites (8, 28%) and nephrotic syndrome (5, 17%). There were 47 patients with cirrhosis and a low SAAG for whom no etiology was identified. Thirty-three patients underwent a repeat paracentesis, 24 (73%) of whom changed to a high SAAG. On the other hand, the 16 patients with no cirrhosis had significantly lower SAAG (0.66 vs. 0.81), and most (12, 75 %) had an identifiable cause of ascites.
CONCLUSIONS: Evaluation of a SAAG <1.1 g/dl in patients with known cirrhosis has low yield and is less likely to be helpful than that in patients without cirrhosis. A repeat paracentesis as part of the workup is recommended. Further studies of low SAAG cutoffs are needed.
C1 [El-Serag, Hashem B.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA.
[Khandwalla, Hashim E.; Fasakin, Yemi; El-Serag, Hashem B.] Michael E DeBakey Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA.
RP El-Serag, HB (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Gastroenterol Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hasheme@bcm.tmc.edu
FU Houston VA HSR&D Center of Excellence [HFP90-020]; NIH/NIDDK Center [P30
DK56338]; Dr El-Serag [K24DK078154-03]
FX This is work was supported in part by the Houston VA HSR&D Center of
Excellence (HFP90-020) and NIH/NIDDK Center Grant P30 DK56338. Dr
El-Serag is supported by NIH K24DK078154-03.
NR 15
TC 7
Z9 8
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JUN
PY 2009
VL 104
IS 6
BP 1401
EP 1405
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 457DR
UT WOS:000266906900018
PM 19491852
ER
PT J
AU Castle, NG
Hanlon, JT
Handler, SM
AF Castle, Nicholas G.
Hanlon, Joseph T.
Handler, Steven M.
TI Results of a Longitudinal Analysis of National Data to Examine
Relationships Between Organizational and Market Characteristics and
Changes in Antipsychotic Prescribing in US Nursing Homes From 1996
Through 2006
SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY
LA English
DT Article
DE aged; antipsychotics; elderly; nursing homes; prescribing patterns
ID QUALITY-OF-CARE; RANDOMIZED-TRIAL; DRUG-USE; DEMENTIA; RESIDENTS;
PLACEBO; RISK; REGULATIONS; MEDICATIONS; RISPERIDONE
AB Objective: The aim of this work was to examine the association between organizational characteristics, market characteristics, and changes in antipsychotic medication use in US nursing homes over time.
Methods: This was a longitudinal study comparing antipsychotic use in US nursing homes from 1996 through 2006 using Medicare and Medicaid data (the Online Survey Certification And Reporting system) and US Department of Health and Human Resources Health Resources and Services Administration data (the Area Resource File). The 3 outcomes of interest were increasing, decreasing, or stable use of antipsychotic medications. The primary independent variables were organizational characteristics (eg, for-profit status, chain membership) and market characteristics (eg, Medicaid reimbursement, levels of competition).
Results: Antipsychotic use increased from 16.4% in 1996 to 25.9% in 2006 (P < 0.05). A multinomial generalized estimating equations model, controlling for facility, staffing, and resident factors, suggested that increased antipsychotic use was associated with for-profit facilities (adjusted odds ratio [AOR], 1.58; 95% CI, 1.51-1.65; P <= 0.001). Decreased antipsychotic use was associated with chain membership (AOR, 0.82; 95% CI, 0.79-0.85; P <= 0.001), higher levels of competition (AOR, 1.22; 95% CI, 1.16-1.29; P <= 0.001), and a higher Medicaid reimbursement rate (AOR, 0.88; 95% CI, 0.85-0.92; P <= 0.001).
Conclusions: Antipsychotic use increased in US nursing homes from 1996 through 2006 and was associated with certain organizational characteristics and market characteristics. Future interventions to reduce antipsychotic use in nursing homes will have to focus Oil these factors. (Am J Geriatr Pharmacother. 2009;7:143-150) (C) 2009 Excerpta Medica Inc.
C1 [Castle, Nicholas G.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.; Handler, Steven M.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA.
[Handler, Steven M.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Castle, NG (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15213 USA.
EM castlen@pitt.edu
OI Handler, Steven/0000-0002-3940-3224
FU National Institute of Aging [R01AG027896, R01AG027017, P30AG024827,
5KL2RR024154]; Agency for Health Care Research and Quality grants
[R01HS016808, R03HS016547]; Veterans Administration Health Services
Research grant [IIR-06-062]
FX This study was supported by National Institute of Aging grants (R01
AG027896,R01AG027017,P30AG024827, 5KL2RR024154), Agency for Health Care
Research and Quality grants (R01HS016808, R03HS016547), and a Veterans
Administration Health Services Research grant (IIR-06-062).
NR 36
TC 17
Z9 17
U1 2
U2 3
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 1543-5946
J9 AM J GERIATR PHARMAC
JI Am. J. Geriatr. Pharmacother.
PD JUN
PY 2009
VL 7
IS 3
BP 143
EP 150
DI 10.1016/j.amjopharm.2009.05.001
PG 8
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 470MF
UT WOS:000267978100001
PM 19616182
ER
PT J
AU LoboPrabhu, SM
Molinari, VA
Hamilton, JD
Lomax, JW
AF LoboPrabhu, Sheila M.
Molinari, Victor A.
Hamilton, Joseph D.
Lomax, James W.
TI The Aging Physician With Cognitive Impairment: Approaches to Oversight,
Prevention, and Remediation
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Aging; physician; dementia; dyscompetence; impairment
AB There are many important unanswered issues regarding the occurrence of cognitive impairment in physicians, such as detection of deficits, remediation efforts, policy implications for safe medical practice, and the need to safeguard quality patient care. The authors review existing literature on these complex issues and derive heuristic formulations regarding how to help manage the professional needs of the aging physician with dementia. To ensure safe standards of medical care while also protecting the needs of physicians and their families, state regulatory or licensing agencies in collaboration with state medical associations and academic medical centers should generate evaluation guidelines to assure continued high levels of functioning. The authors also raise the question of whether age should be considered as a risk factor that merits special screening for adequate functioning. Either age-related screening for cognitive impairment should be initiated or rigorous evaluation after lapses in standard of care should be the norm regardless of age. Ultimately, competence rather than mandatory retirement due to age per se should be the deciding factor regarding whether physicians should be able to continue their practice. Finally, the authors issue a call for an expert consensus panel to convene to make recommendations concerning aging physicians with cognitive impairment who are at risk for medical errors. (Am J Geriatr Psychiatry 2009; 17: 445-454)
C1 [LoboPrabhu, Sheila M.] Michael E DeBakey Dept Vet Affairs Med Ctr, Mental Hlth Care Line & MIRECC, Houston, TX 77030 USA.
[LoboPrabhu, Sheila M.; Hamilton, Joseph D.; Lomax, James W.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Molinari, Victor A.] Univ S Florida, Dept Aging & Mental Hlth Dispar, Louis de la Parte Florida Mental Hlth Inst, Tampa, FL USA.
RP LoboPrabhu, SM (reprint author), Michael E DeBakey Dept Vet Affairs Med Ctr, Mental Hlth Care Line & MIRECC, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM SheilaM.Loboprabhu@med.va.gov
NR 37
TC 7
Z9 7
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2009
VL 17
IS 6
BP 445
EP 454
DI 10.1097/JGP.0b013e31819e2d7e
PG 10
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA V21XU
UT WOS:000208241100001
PM 19461256
ER
PT J
AU Wetherell, JL
Ayers, CR
Sorrell, JT
Thorp, SR
Nuevo, R
Belding, W
Gray, E
Stanley, MA
Arean, PA
Donohue, M
Unutzer, J
Ramsdell, J
Xu, RH
Patterson, TL
AF Wetherell, Julie Loebach
Ayers, Catherine R.
Sorrell, John T.
Thorp, Steven R.
Nuevo, Roberto
Belding, Wendy
Gray, Emily
Stanley, Melinda A.
Arean, Patricia A.
Donohue, Michael
Unutzer, Jurgen
Ramsdell, Joe
Xu, Ronghui
Patterson, Thomas L.
TI Modular Psychotherapy for Anxiety in Older Primary Care Patients
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Aged; elderly; generalized anxiety disorder; cognitive-behavioral
therapy
ID LATE-LIFE ANXIETY; COGNITIVE-BEHAVIORAL TREATMENT; GENERALIZED ANXIETY;
ELDERLY-PATIENTS; INVENTORY-II; OPEN TRIAL; DISORDER; ADULTS;
DEPRESSION; HEALTH
AB Objective: To develop and test a modular psychotherapy protocol in older primary care patients with anxiety disorders. Design: Randomized, controlled pilot study. Setting: University-based geriatric medicine clinics. Participants: Thirty-one elderly primary care patients with generalized anxiety disorder or anxiety disorder not otherwise specified. Intervention: Modular form of psychotherapy compared with enhanced community treatment. Measurements: Self-reported, interviewer-rated, and qualitative assessments of anxiety, worry, depression, and mental health-related quality of life. Results: Both groups showed substantial improvements in anxiety symptoms, worry, depressive symptoms, and mental health-related quality of life. Most individuals in the enhanced community treatment condition reported receiving medications or some other form of professional treatment for anxiety. Across both conditions, individuals who reported major life events or stressors and those who used involvement in activities as a coping strategy made smaller gains than those who did not. Conclusions: Results suggest that modular psychotherapy and other treatments can be effective for anxiety in older primary care patients. Results further suggest that life events and coping through increased activity may play a role in the maintenance of anxiety in older adults. (Am J Geriatr Psychiatry 2009; 17:483-492)
C1 [Wetherell, Julie Loebach; Ayers, Catherine R.; Thorp, Steven R.; Belding, Wendy; Gray, Emily; Patterson, Thomas L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Wetherell, Julie Loebach; Ayers, Catherine R.; Thorp, Steven R.; Belding, Wendy; Gray, Emily] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA USA.
[Sorrell, John T.] San Mateo Med Ctr, San Mateo, CA USA.
[Nuevo, Roberto] Hosp Univ Princesa, Dept Psychiat, Madrid, Spain.
[Stanley, Melinda A.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Stanley, Melinda A.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Arean, Patricia A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Donohue, Michael; Xu, Ronghui] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA.
[Unutzer, Jurgen] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Ramsdell, Joe] Univ Calif San Diego, Dept Internal Med, San Diego, CA 92103 USA.
RP Wetherell, JL (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr,Dept 9116B, La Jolla, CA 92093 USA.
EM jwetherell@ucsd.edu
OI Nuevo, Roberto/0000-0003-3385-2747
FU NIMH [MH067643]
FX The authors gratefully acknowledge the contributions of Georgia
Birchler, Debora Goodman, Dilip V. Jeste, M. D., Laura Otis, Ph. D., and
Murray B. Stein, M. D., M. P. H. This research was supported by NIMH
grant MH067643.
NR 41
TC 33
Z9 33
U1 2
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2009
VL 17
IS 6
BP 483
EP 492
DI 10.1097/JGP.0b013e3181a31fb5
PG 10
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 451YC
UT WOS:000266505800005
PM 19461257
ER
PT J
AU Coca, SG
Yusuf, B
Shlipak, MG
Garg, AX
Parikh, CR
AF Coca, Steven G.
Yusuf, Bushra
Shlipak, Michael G.
Garg, Amit X.
Parikh, Chirag R.
TI Long-term Risk of Mortality and Other Adverse Outcomes After Acute
Kidney Injury: A Systematic Review and Meta-analysis
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Acute renal failure; chronic kidney disease; prognosis
ID ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; QUALITY-OF-LIFE;
PERCUTANEOUS CORONARY INTERVENTION; INTENSIVE-CARE-UNIT; CONTINUOUS
VENOVENOUS HEMODIALYSIS; ACUTE TUBULAR-NECROSIS; REPLACEMENT THERAPY;
HOSPITAL MORTALITY; PERITUBULAR CAPILLARIES
AB Background: Acute kidney injury (AKI) is common in hospitalized patients. The impact of AKI on long-term outcomes is controversial.
Study Design: Systematic review and meta-analysis.
Setting & Participants: Persons with AKI.
Selection Criteria for Studies: MEDLINE and EMBASE databases were searched from 1985 through October 2007. Original studies describing outcomes of AKI for patients who survived hospital discharge were included. Studies were excluded from review when participants were followed up for less than 6 months.
Predictor: AKI, defined as acute changes in serum creatinine level or acute need for renal replacement therapy.
Outcomes: Chronic kidney disease (CKD), cardiovascular disease, and mortality.
Results: 48 studies that contained a total of 47,017 participants were reviewed; 15 studies reported long-term data for patients without AKI. The incidence rate of mortality was 8.9 deaths/100 person-years in survivors of AKI and 4.3 deaths/100 patient-years in survivors without AKI (rate ratio [RR], 2.59; 95% confidence interval, 1.97 to 3.42). AKI was associated independently with mortality risk in 6 of 6 studies that performed multivariate adjustment (adjusted RR, 1.6 to 3.9) and with myocardial infarction in 2 of 2 studies (RR, 2.05; 95% confidence interval, 1.61 to 2.61). The incidence rate of CKD after an episode of AKI was 7.8 events/100 patient-years, and the rate of end-stage renal disease was 4.9 events/100 patient-years.
Limitations: The relative risk for CKD and end-stage renal disease after AKI was unattainable because of lack of follow-up of appropriate controls without AKI.
Conclusions: The development of AKI, defined as acute changes in serum creatinine level, characterizes hospitalized patients at increased risk of long-term adverse outcomes. Am J Kidney Dis 53:961-973. Published by Elsevier Inc on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.
C1 [Coca, Steven G.; Yusuf, Bushra; Parikh, Chirag R.] Yale Univ, Nephrol Sect, West Haven, CT 06516 USA.
[Coca, Steven G.; Yusuf, Bushra; Parikh, Chirag R.] Vet Affairs Med Ctr, West Haven, CT USA.
[Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Garg, Amit X.] Univ Western Ontario, London, ON, Canada.
RP Parikh, CR (reprint author), Yale Univ, Nephrol Sect, 950 Campbell Ave,Mail Code 151B,Bldg 35 A,Rm 219, West Haven, CT 06516 USA.
EM chirag.parikh@yale.edu
FU National Institutes of Health [K23DK08013, DK082185]; Canadian
Institutes of Health Research; AKI [RO1 HL085757]
FX Support: Dr Coca is funded by the career development grant K23DK08013
from the National Institutes of Health and is Supported by the American
Heart Association's Established investigator Award. Dr Garg is funded by
the Clinical Scientist Award from the Canadian Institutes of Health
Research. Dr Parikh is Supported by the AKI grants RO1 HL085757 and
UOI-DK082185 from the National Institutes of Health.
NR 77
TC 362
Z9 393
U1 3
U2 17
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD JUN
PY 2009
VL 53
IS 6
BP 961
EP 973
DI 10.1053/j.ajkd.2008.11.034
PG 13
WC Urology & Nephrology
SC Urology & Nephrology
GA 456RY
UT WOS:000266866600011
PM 19346042
ER
PT J
AU Brown, AS
Vinogradov, S
Kremen, WS
Poole, JH
Deicken, RF
Penner, JD
McKeague, IW
Kochetkova, A
Kern, D
Schaefer, CA
AF Brown, Alan S.
Vinogradov, Sophia
Kremen, William S.
Poole, John H.
Deicken, Raymond F.
Penner, Justin D.
McKeague, Ian W.
Kochetkova, Anna
Kern, David
Schaefer, Catherine A.
TI Prenatal Exposure to Maternal Infection and Executive Dysfunction in
Adult Schizophrenia
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article; Proceedings Paper
CT 62nd Annual Meeting of the Society-of-Biological-Psychiatry
CY MAY 17-20, 2007
CL San Diego, CA
SP Soc Biol Psychiat
ID OBSTETRIC COMPLICATIONS; RISK; DEFICITS; PERFORMANCE; TOXOPLASMOSIS;
DETERMINANTS; INFLUENZA; PATTERNS; SIBLINGS
AB Objective: Executive dysfunction is one of the most prominent and functionally important cognitive deficits in schizophrenia. Although strong associations have been identified between executive impairments and structural and functional prefrontal cortical deficits, the etiological factors that contribute to disruption of this important cognitive domain remain unclear. Increasing evidence suggests that schizophrenia has a neurodevelopmental etiology, and several prenatal infections have been associated with risk of this disorder. The authors examined whether prenatal infection is associated with executive dysfunction in patients with schizophrenia.
Method: The authors assessed the relationship between serologically documented prenatal exposure to influenza and toxoplasmosis and performance on the Wisconsin Card Sorting Test and the Trail Making Test, part B (Trails B), as well as other measures of executive function, in 26 patients with schizophrenia from a large and well-characterized birth cohort.
Results: Patients who were exposed to infection in utero committed significantly more total errors on the Wisconsin Card Sorting Test and took significantly more time to complete the Trails B than unexposed patients. Exposed patients also exhibited deficits on figural fluency, letter-number sequencing, and backward digit span.
Conclusions: Prenatal infections previously associated with schizophrenia are related to impaired performance on the Wisconsin Card Sorting Test and Trails B. The pattern of results suggests that cognitive set-shifting ability may be particularly vulnerable to this gestational exposure. Further work is needed to elucidate the specificity of prenatal infection to these executive function measures and to examine correlates with neuroanatomic and neurophysiologic anomalies.
C1 Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, New York, NY 10032 USA.
Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
Kaiser Permanente, Div Res, Oakland, CA USA.
RP Brown, AS (reprint author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, 1051 Riverside Dr,Unit 23, New York, NY 10032 USA.
EM asb11@columbia.edu
OI Kern, David/0000-0001-5417-3925
FU NIA NIH HHS [1 R01 AG18386, 1 R01 AG22381, 1 R01 AG22982, R01 AG018386,
R01 AG018386-05, R01 AG022381, R01 AG022381-08, R01 AG022982, R01
AG022982-04]; NICHD NIH HHS [N01-HD-1-3334, N01-HD-6-3258]; NIMH NIH HHS
[K02 MH065422-08, 1R01MH-60249, K02 MH065422, R01 MH060249, R01
MH060249-03, R01 MH060249-03S2]
NR 31
TC 77
Z9 78
U1 1
U2 12
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD JUN
PY 2009
VL 166
IS 6
BP 683
EP 690
DI 10.1176/appi.ajp.2008.08010089
PG 8
WC Psychiatry
SC Psychiatry
GA 452KQ
UT WOS:000266539300011
PM 19369317
ER
PT J
AU Wolfe, WR
Weiser, SD
Steward, WT
Iacopino, V
Heisler, M
AF Wolfe, William R.
Weiser, Sheri D.
Steward, Wayne T.
Iacopino, Vincent
Heisler, Michele
TI UNIVERSAL ACCESS TO ANTIRETROVIRAL THERAPY AND HIV STIGMA IN BOTSWANA
RESPONSE
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Letter
C1 [Wolfe, William R.; Weiser, Sheri D.; Iacopino, Vincent; Heisler, Michele] Phys Human Rights, Cambridge, MA USA.
[Wolfe, William R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Weiser, Sheri D.; Steward, Wayne T.] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA.
[Iacopino, Vincent] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Heisler, Michele] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
[Heisler, Michele] Ann Arbor Vet Affairs Hlth Syst, Ann Arbor, MI USA.
RP Wolfe, WR (reprint author), San Francisco VA Med Ctr, Posttraumat Stress Disorder Program, 4150 Clement St,Mail Stop 116P, San Francisco, CA 94121 USA.
EM william.wolfe@ucsf.edu
RI Heisler, Michele/B-5774-2015
OI Heisler, Michele/0000-0002-6889-2063
NR 2
TC 0
Z9 0
U1 0
U2 1
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2009
VL 99
IS 6
BP 969
EP 969
DI 10.2105/AJPH.2009.159939
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 448VE
UT WOS:000266289300004
ER
PT J
AU Basile, J
AF Basile, Jan
TI New Therapeutic Options in Patients Prone to Hypertension: A Focus on
Direct Renin Inhibition and Aldosterone Blockade
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Review
DE Hypertension; Renin inhibition; Aldosterone blockade
ID HIGH-BLOOD-PRESSURE; RESISTANT HYPERTENSION; DIABETIC-NEPHROPATHY;
SYSTOLIC HYPERTENSION; ANGIOTENSIN-II; RENAL-DISEASE; RECEPTOR BLOCKERS;
UNITED-STATES; ALISKIREN; SPIRONOLACTONE
AB Certain patient Populations have a high prevalence of hypertension, including black, elderly, or obese patients patients with metabolic syndrome, or frank diabetes; and patients with chronic kidney disease. Many of these patients experience renin-angiotensin-aldosterone system (RAAS) dysregulation, which is important because the RAAS plays a pivotal role in the pathogenesis of hypertension, cardiovascular disease, and renal dysfunction. Data available regarding newer approaches that target the RAAS, including direct renin inhibition and aldosterone receptor antagonism, in patients who often have hypertension are reviewed. Aliskiren. the first direct renin inhibitor, is effective in a number of these patient groups, including those who are black or obese or who have metabolic syndrome, renal impairment, or diabetes. In addition, in the setting of long-term angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, aldosterone receptor antagonists (spironolactone and eplerenone) provide another rational therapeutic approach for patients whose blood pressure is not controlled by standard therapies.
C1 [Basile, Jan] Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC 29403 USA.
[Basile, Jan] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
RP Basile, J (reprint author), Ralph H Johnson VA Med Ctr, Primary Care Serv Line, 109 Bee St, Charleston, SC 29403 USA.
EM jan.basile@va.gov
FU Novartis Pharmaceuticals Corp
FX Editorial Support was provided by Apothecom and Funded by Novartis
Pharmaceuticals Corp.
NR 63
TC 9
Z9 11
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-9629
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD JUN
PY 2009
VL 337
IS 6
BP 438
EP 444
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 459TD
UT WOS:000267131900010
PM 19390429
ER
PT J
AU Conway, WC
Faries, MB
Nicholl, MB
Terando, AM
Glass, EC
Sim, M
Morton, DL
AF Conway, W. Charles
Faries, Mark B.
Nicholl, Michael B.
Terando, Alicia M.
Glass, Edwin C.
Sim, MyungShin
Morton, Donald L.
TI Age-Related Lymphatic Dysfunction in Melanoma Patients
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT 6th Biennial International-Sentinel-Node-Society Meeting
CY FEB 18-20, 2008
CL Sydney, AUSTRALIA
SP Int Sentinel Node Soc
ID EARLY-STAGE MELANOMA; SENTINEL LYMPHADENECTOMY; PROGNOSTIC-FACTORS;
BREAST-CANCER; AGING SKIN; NODE; LYMPHOSCINTIGRAPHY; LYMPHANGIOGENESIS;
VISUALIZATION; VALIDATION
AB Age-related outcomes have become increasingly common in evaluating patients with melanoma. For instance, as age increases, sentinel node (SN) nonidentification increases and SN positivity decreases. Furthermore, advanced age is a risk factor for in-transit disease. We hypothesized that increasing age is accompanied by alterations in lymphatic function, possibly explaining these findings.
Our center's melanoma database was queried to identify patients who underwent successful sentinel node biopsy after lymphoscintigraphy. Records of those treated between 2000 and 2005 were reviewed for age, sex, drainage basin, intraoperative radioactivity, and SN pathology.
The 858 patients had a mean age of 55 years; 59% were men. Mean radioactivity in the hottest SN was 5232 counts per second; 179 patients (21%) had SN metastases. SN count rates were significantly and inversely related to age (P < .001 by Pearson correlation, analysis of variance, and chi(2) test). Mean counts per second were 6105, 5883, and 2720 for axillary, inguinal, and cervical basins, respectively (P < .01), and count rates in these basins were consistently lower with increasing age (neck and axilla, P < .001; groin, P = .060; Pearson correlation). Multivariate analysis confirmed an independent inverse association between age and count rates (P < .001), overall and within each primary tumor site.
Lymphatic function, as assessed by radiocolloid transit to and uptake within the SN, declines with age. Altered lymphatic function in older patients may modify metastatic patterns; knowledge of this may help clarify findings of reduced nodal positivity and increased in-transit disease in this population.
C1 [Conway, W. Charles; Faries, Mark B.; Nicholl, Michael B.; Terando, Alicia M.; Morton, Donald L.] St Johns Hlth Ctr, Dept Surg Oncol, John Wayne Canc Inst, Santa Monica, CA USA.
[Glass, Edwin C.] W Los Angeles Vet Affairs Med Ctr, Dept Nucl Med, Los Angeles, CA 90073 USA.
[Sim, MyungShin] St Johns Hlth Ctr, Dept Biostat, John Wayne Canc Inst, Santa Monica, CA USA.
RP Conway, WC (reprint author), St Johns Hlth Ctr, Dept Surg Oncol, John Wayne Canc Inst, Santa Monica, CA USA.
EM FariesM@JWCI.ORG
RI Conway, William/A-5804-2011; Terando, Alicia/E-4186-2011
FU NCI NIH HHS [CA29605, P01 CA029605, P01 CA029605-27, P01
CA029605-278051]
NR 24
TC 46
Z9 46
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD JUN
PY 2009
VL 16
IS 6
BP 1548
EP 1552
DI 10.1245/s10434-009-0420-x
PG 5
WC Oncology; Surgery
SC Oncology; Surgery
GA 441RD
UT WOS:000265787200018
PM 19277787
ER
PT J
AU Chu, D
Bakaeen, FG
AF Chu, Danny
Bakaeen, Faisal G.
TI Coronary Bypass Grafting in Patients With Concomitant Peripheral
Arterial Disease: Do Not Underestimate Asymptomatic Disease Reply
SO ANNALS OF THORACIC SURGERY
LA English
DT Letter
ID VETERANS-AFFAIRS; CARDIAC-SURGERY; IMPROVEMENT; QUALITY
C1 [Chu, Danny; Bakaeen, Faisal G.] Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Chu, D (reprint author), Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
EM dchu@bcm.tmc.edu
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JUN
PY 2009
VL 87
IS 6
BP 2004
EP 2004
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 448BA
UT WOS:000266234900075
ER
PT J
AU Tolman, JA
Wiederhold, NP
McConville, JT
Najvar, LK
Bocanegra, R
Peters, JI
Coalson, JJ
Graybill, JR
Patterson, TF
Williams, RO
AF Tolman, Justin A.
Wiederhold, Nathan P.
McConville, Jason T.
Najvar, Laura K.
Bocanegra, Rosie
Peters, Jay I.
Coalson, Jacqueline J.
Graybill, John R.
Patterson, Thomas F.
Williams, Robert O., III
TI Inhaled Voriconazole for Prevention of Invasive Pulmonary Aspergillosis
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID MURINE MODEL; AMPHOTERICIN-B; TRANSPLANTATION; BURDEN
AB Targeted airway delivery of antifungals as prophylaxis against invasive aspergillosis may lead to high lung drug concentrations while avoiding toxicities associated with systemically administered agents. We evaluated the effectiveness of aerosolizing the intravenous formulation of voriconazole as prophylaxis against invasive pulmonary aspergillosis caused by Aspergillus fumigatus in an established murine model. Inhaled voriconazole significantly improved survival and limited the extent of invasive disease, as assessed by histopathology, compared to control and amphotericin B treatments.
C1 [Tolman, Justin A.; Wiederhold, Nathan P.; McConville, Jason T.; Williams, Robert O., III] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA.
[Wiederhold, Nathan P.] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA.
[Najvar, Laura K.; Bocanegra, Rosie; Graybill, John R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA.
[Najvar, Laura K.; Bocanegra, Rosie; Peters, Jay I.; Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Peters, Jay I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78229 USA.
[Coalson, Jacqueline J.] Univ Texas Hlth Sci Ctr San Antonio, Grad Sch Biomed Sci, Dept Pathol, San Antonio, TX 78229 USA.
RP Wiederhold, NP (reprint author), UTHSCSA, PERC MSC 6220,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM wiederholdn@uthscsa.edu; williro@mail.utexas.edu
OI Williams III, Robert/0000-0003-4993-6427; Wiederhold,
Nathan/0000-0002-2225-5122
FU CyDex Pharmaceuticals Inc.; Pfizer; Schering-Plough
FX We thank CyDex Pharmaceuticals Inc. for their financial support. N. P.
W. has received research support from CyDex Pharmaceuticals, Pfizer, and
Schering-Plough. J. I. P. has served on the speaker's bureau for Merck
and Boehringer-Ingelheim. J. R. G. has received research support from
Pfizer, Schering-Plough, Merck, and Astellas and has served on the
speaker's bureau for Merck and Schering-Plough and as a consultant for
Merck, Schering-Plough, Indevus, Vicuron, Nektar, and F2G. T. F. P. has
received research support from Merck, Pfizer, Schering-Plough, and
Nektar Therapeutics and has served on the speaker's bureau for Merck and
Pfizer and as a consultant for Astellas, Basilea, Merck, Nektar, Pfizer,
Schering-Plough, and Stiefel Laboratories. R. O. W. has received
research support from CyDex Pharmaceuticals. J. A. T., J. T. M., L. K.
N., R. B., and J. J. C. have no disclosures to report.
NR 12
TC 17
Z9 18
U1 1
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2009
VL 53
IS 6
BP 2613
EP 2615
DI 10.1128/AAC.01657-08
PG 3
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 448DY
UT WOS:000266244500053
PM 19289523
ER
PT J
AU Darouiche, RO
Mansouri, MD
Schneidkraut, MJ
AF Darouiche, Rabih O.
Mansouri, Mohammad D.
Schneidkraut, Marlowe J.
TI Comparative Efficacies of Telavancin and Vancomycin in Preventing
Device-Associated Colonization and Infection by Staphylococcus aureus in
Rabbits
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID GRAM-POSITIVE BACTERIA; IN-VITRO ACTIVITY; COMPLICATED SKIN; STANDARD
THERAPY; VIVO EFFICACY; TD-6424; MODEL
AB Telavancin is an investigational lipoglycopeptide antibiotic that is active against gram-positive pathogens. In an in vivo rabbit model, subtherapeutic (15-mg/kg) and therapeutic (30- or 45-mg/kg) doses of telavancin were demonstrated to be noninferior and superior to vancomycin (20 mg/kg), respectively, for preventing subcutaneous implant colonization and infection by Staphylococcus aureus.
C1 [Darouiche, Rabih O.] Baylor Coll Med, Ctr Prostheses Infect, Michael E Debakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Darouiche, Rabih O.; Mansouri, Mohammad D.] Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA.
[Schneidkraut, Marlowe J.] Astellas Pharma US Inc, Deerfield, IL USA.
RP Darouiche, RO (reprint author), Baylor Coll Med, Ctr Prostheses Infect, Michael E Debakey Vet Affairs Med Ctr, 1333 Moursund Ave,Suite A221, Houston, TX 77030 USA.
EM rdarouiche@aol.com
FU Astellas Pharma US, Inc.; Deerfield, IL.
FX This study was supported by Astellas Pharma US, Inc., Deerfield, IL.
Astellas Pharma has a collaboration agreement with Theravance, Inc., for
the commercialization and development of telavancin.
NR 20
TC 15
Z9 16
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2009
VL 53
IS 6
BP 2626
EP 2628
DI 10.1128/AAC.01101-08
PG 3
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 448DY
UT WOS:000266244500056
PM 19364874
ER
PT J
AU Eggers, SL
Myaskovsky, L
Burkitt, KH
Tolerico, M
Switzer, GE
Fine, MJ
Boninger, ML
AF Eggers, Sara L.
Myaskovsky, Larissa
Burkitt, Kelly H.
Tolerico, Michelle
Switzer, Galen E.
Fine, Michael J.
Boninger, Michael L.
TI A Preliminary Model of Wheelchair Service Delivery
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Health care disparities; Models, theoretical; Rehabilitation;
Wheelchairs
ID SPINAL-CORD-INJURY; TECHNOLOGY OUTCOMES RESEARCH; QUALITY-OF-LIFE;
ASSISTIVE TECHNOLOGY; MANUAL WHEELCHAIRS; DECISION-MAKING;
REHABILITATION; PARTICIPATION; SATISFACTION; INDIVIDUALS
AB Objective: To integrate and expand on previously published models of wheelchair service delivery, and provide a preliminary framework for developing more comprehensive, descriptive models of wheelchair service delivery for adults with spinal cord injury within the U.S. health care system.
Design: Literature review and a qualitative analysis of in-depth interviews.
Setting: Not applicable.
Participants: Ten academic, clinical, regulatory. and industry experts (Department of Veterans Affairs [VA] and non-VA) in wheelchair service delivery.
Interventions: Not applicable.
Main Outcome Measures: Interviewees were asked to discuss the full range of variables and stakeholders involved in wheelchair service delivery, and to limit their scope to the provision of primary subsequent or replacement chains (not backup chairs) to adults within the United States.
Results: Most experts we interviewed stressed that clients who require a wheelchair play a central role in the wheelchair service delivery process. Providers (including clinicians. rehabilitation engineers, and rehabilitation counselors) are also critical stakeholders. More so than in other health care settings, Suppliers play ail integral role in the provision of wheelchairs to clients and may significantly influence the appropriateness of the wheelchair provided. Suppliers often have a direct role in wheelchair service delivery through their interactions with the clinician and/or client. This model also identified a number of, system-level factors (including facility administration and Standards. policies, and regulations) that influence wheelchair service delivery and ultimately the appropriateness of the wheelchair provided.
Conclusions: We developed a detailed, descriptive model of wheelchair service delivery that integrates the delivery process and device outcomes, and includes the patient-level, provider-level. and system-level factors that may directly influence those processes and outcomes. We believe that this detailed model can help clinicians and researchers describe and consider the complexities of wheelchair service delivery. It can be used to identify factors that may be related to disparities in wheelchair service delivery and in the appropriateness of the wheelchair prescribed. Further, this model can help researchers and clinicians identify factors that may be related to disparities in wheelchair service delivery, and intervene to reduce such disparities.
C1 [Eggers, Sara L.; Myaskovsky, Larissa; Burkitt, Kelly H.; Switzer, Galen E.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Tolerico, Michelle; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA.
[Eggers, Sara L.] Decis Partners LLC, Pittsburgh, PA USA.
[Myaskovsky, Larissa; Switzer, Galen E.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA.
[Myaskovsky, Larissa; Switzer, Galen E.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Tolerico, Michelle; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
[Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn Rehabil Sci & Technol, Pittsburgh, PA USA.
RP Myaskovsky, L (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA.
EM Larissa.Myaskovsky@va.gov
RI IB/USP, Genetica e Biologia /G-1755-2017
OI Boninger, Michael/0000-0001-6966-919X
NR 51
TC 14
Z9 14
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD JUN
PY 2009
VL 90
IS 6
BP 1030
EP 1038
DI 10.1016/j.apmr.2008.12.007
PG 9
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 455SW
UT WOS:000266787000019
PM 19480881
ER
PT J
AU Barrett-Connor, E
Cox, D
Song, J
Mitlak, B
Mosca, L
Grady, D
AF Barrett-Connor, E.
Cox, D.
Song, J.
Mitlak, B.
Mosca, L.
Grady, D.
TI RALOXIFENE AND STROKE RISK BASED ON THE FRAMINGHAM STROKE RISK SCORE
SO ATHEROSCLEROSIS SUPPLEMENTS
LA English
DT Meeting Abstract
C1 [Barrett-Connor, E.] Univ Calif San Diego, Dept Family & Prevent Med & Med, La Jolla, CA 92093 USA.
[Cox, D.; Song, J.; Mitlak, B.] Lilly Res Labs, Indianapolis, IN USA.
[Mosca, L.] Columbia Univ, Med Ctr, New York, NY USA.
[Grady, D.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Grady, D.] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 1567-5688
J9 ATHEROSCLEROSIS SUPP
JI Atheroscler. Suppl.
PD JUN
PY 2009
VL 10
IS 2
PG 1
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA V17SO
UT WOS:000207957101058
ER
PT J
AU Boyd, JE
Kanas, NA
Salnitskiy, VP
Gushin, VI
Saylor, SA
Weiss, DS
Marmar, CR
AF Boyd, Jennifer E.
Kanas, Nick A.
Salnitskiy, Vyacheslav P.
Gushin, Vadim I.
Saylor, Stephanie A.
Weiss, Daniel S.
Marmar, Charles R.
TI Cultural Differences in Crewmembers and Mission Control Personnel During
Two Space Station Programs
SO AVIATION SPACE AND ENVIRONMENTAL MEDICINE
LA English
DT Article
DE culture; spaceflight; mental health
ID LESSONS
AB BOYD JE, KANAS NA, SALNITSKIY VP, GUSHIN VI, SAYLOR SA, WEISS DS, MARMAR CR. Cultural differences in crewmembers and mission control personnel during two space station programs. Aviat Space Environ Med 2009; 80:532-40.
Introduction: Cultural differences among crewmembers and mission control personnel can affect long-duration space missions. We examine three cultural contrasts: national (American vs. Russian); occupational (crewmembers vs. mission control personnel); and organizational [Mir space station vs. International Space Station (ISS)]. Methods: The Mir sample included 5 American astronauts, 8 Russian cosmonauts, and 42 American and 16 Russian mission control personnel. The ISS sample included 8 astronauts, 9 cosmonauts, and 108 American and 20 Russian mission control personnel. Subjects responded to mood and group climate questions on a weekly basis. The ISS sample also completed a culture and language questionnaire. Results: Crewmembers had higher scores on cultural sophistication than mission control personnel, especially American mission control. Cultural sophistication was not related to mood or social climate. Russian subjects reported greater language flexibility than Americans. Crewmembers reported better mood states than mission control, but both were in the healthy range. There were several Russian-American differences in social climate, with the most robust being higher work pressure among Americans. Russian-American social climate differences were also found in analyses of crew only. Analyses showed Mir-ISS differences in social climate among crew but not in the full sample. Discussion: We found evidence for national, occupational, and organizational cultural differences. The findings from the Mir space station were essentially replicated on the ISS. Alterations to the ISS to make it a more user-friendly environment have still not resolved the issue of high levels of work pressure among the American crew.
C1 [Boyd, Jennifer E.; Kanas, Nick A.; Weiss, Daniel S.; Marmar, Charles R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Boyd, Jennifer E.; Kanas, Nick A.; Weiss, Daniel S.; Marmar, Charles R.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Salnitskiy, Vyacheslav P.; Gushin, Vadim I.] Minist Publ Hlth Russia, Inst Biomed Problems, Moscow, Russia.
[Saylor, Stephanie A.] No Calif Inst Res & Educ, San Francisco, CA USA.
RP Boyd, JE (reprint author), Univ Calif San Francisco, Dept Psychiat, VAMC 116A,4150 Clement St, San Francisco, CA 94121 USA.
EM jennifer.boyd@ucsf.edu
FU National Aeronautics and Space Administration [NAS9-19411, NAS9-98093,
NCC-0161]
FX This work was supported by National Aeronautics and Space Administration
contracts # NAS9-19411, # NAS9-98093, and # NCC-0161. Statistical
consultation was provided by Alan Bostrom, Ph.D.
NR 18
TC 8
Z9 9
U1 1
U2 6
PU AEROSPACE MEDICAL ASSOC
PI ALEXANDRIA
PA 320 S HENRY ST, ALEXANDRIA, VA 22314-3579 USA
SN 0095-6562
J9 AVIAT SPACE ENVIR MD
JI Aviat. Space Environ. Med.
PD JUN
PY 2009
VL 80
IS 6
BP 532
EP 540
DI 10.3357/ASEM.2430.2009
PG 9
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Sport Sciences
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Sport Sciences
GA 454LM
UT WOS:000266683400004
PM 19522363
ER
PT J
AU Hallahan, B
Newell, J
Soares, JC
Brambilla, P
Strakowski, SM
Fleck, DE
Kieseppa, T
Altshuler, LL
Fornito, A
Malhi, GS
McIntosh, AM
Yurgelun-Todd, DA
Labar, KS
Densmore, M
MacQueen, GM
Murray, RM
McDonald, C
AF Hallahan, B.
Newell, J.
Soares, J. C.
Brambilla, P.
Strakowski, S. M.
Fleck, D. E.
Kieseppa, T.
Altshuler, L. L.
Fornito, A.
Malhi, G. S.
McIntosh, A. M.
Yurgelun-Todd, D. A.
LaBar, K. S.
Densmore, M.
MacQueen, G. M.
Murray, R. M.
McDonald, C.
TI Structural MRI in bipolar disorder: An international collaborative
mega-analysis of individual patient data
SO BIPOLAR DISORDERS
LA English
DT Meeting Abstract
CT 8th International Conference on Bipolar Disorder
CY JUN 25-27, 2009
CL Pittsburgh, PA
DE bipolar; MRI; lithium
C1 [Hallahan, B.; Newell, J.; McDonald, C.] Natl Univ Ireland Galway, Galway, Ireland.
[Soares, J. C.; Brambilla, P.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
[Brambilla, P.] Univ Udine, Italy & Sci Inst, I-33100 Udine, Italy.
[Strakowski, S. M.; Fleck, D. E.] Univ Cincinnati, Coll Med, Cincinnati, OH USA.
[Kieseppa, T.] HUCS, Helsinki, Finland.
[Altshuler, L. L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Fornito, A.] Univ Cambridge, Cambridge, England.
[Malhi, G. S.] Royal N Shore Hosp, St Leonards, NSW 2065, Australia.
[McIntosh, A. M.] Univ Edinburgh, Royal Edinburgh Hosp, Edinburgh, Midlothian, Scotland.
[Yurgelun-Todd, D. A.] Harvard Univ, Sch Med, Boston, MA USA.
[Yurgelun-Todd, D. A.] McLean Hosp, Belmont, MA 02178 USA.
[LaBar, K. S.] Duke Univ, Med Ctr, Durham, NC USA.
[Densmore, M.] Univ Western Ontario, London, ON, Canada.
[MacQueen, G. M.] Univ Calgary, Calgary, AB, Canada.
[Murray, R. M.] Inst Psychiat, London, England.
[Fornito, A.] Univ Melbourne, Melbourne Neuropsychiat Ctr, Melbourne, Vic 3010, Australia.
RI brambilla, paolo/B-4184-2010; McIntosh, Andrew/B-9379-2008; Alex,
Fornito/N-8214-2013
OI brambilla, paolo/0000-0002-4021-8456; McIntosh,
Andrew/0000-0002-0198-4588; Alex, Fornito/0000-0001-9134-480X
NR 0
TC 4
Z9 4
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1398-5647
J9 BIPOLAR DISORD
JI Bipolar Disord.
PD JUN
PY 2009
VL 11
BP 10
EP 11
PG 2
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 483KH
UT WOS:000268963500027
ER
PT J
AU Altshuler, LL
Kupka, RW
Hellemann, G
Frye, MA
Grunze, H
Keck, PE
Leverich, GS
McElroy, SL
Nolen, WA
Sugar, CA
Zermeno, M
Post, RM
Suppes, T
AF Altshuler, L. L.
Kupka, R. W.
Hellemann, G.
Frye, M. A.
Grunze, H.
Keck, P. E., Jr.
Leverich, G. S.
McElroy, S. L.
Nolen, W. A.
Sugar, C. A.
Zermeno, M.
Post, R. M.
Suppes, T.
TI Gender and depressive symptoms in 711 patients with bipolar disorder
evaluated prospectively in the Stanley Foundation Bipolar Treatment
Network
SO BIPOLAR DISORDERS
LA English
DT Meeting Abstract
CT 8th International Conference on Bipolar Disorder
CY JUN 25-27, 2009
CL Pittsburgh, PA
DE bipolar; gender; longitudinal; prospective
C1 [Altshuler, L. L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, W Los Angeles Healthcare Ctr, Los Angeles, CA USA.
[Altshuler, L. L.; Hellemann, G.; Zermeno, M.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA.
[Leverich, G. S.; Post, R. M.] Bipolar Collaborat Network, Bethesda, MD USA.
[Post, R. M.] George Washington Sch Med, Washington, DC USA.
[Nolen, W. A.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands.
[Frye, M. A.] Mayo Coll Med, Mayo Mood Disorder Clin, Rochester, MN USA.
[Frye, M. A.] Mayo Coll Med, Res Program, Genom Express & Neuropsychiat Evaluat Unit, Rochester, MN USA.
[Keck, P. E., Jr.; McElroy, S. L.] Univ Cincinnati, Coll Med, Dept Psychiat, Psychopharmacol Res Program, Cincinnati, OH USA.
[Keck, P. E., Jr.; McElroy, S. L.] Craig & Frances Lindner Ctr HOPE, Cincinnati, OH USA.
[Kupka, R. W.] Altrech Inst Mental Hlth Care, Utrecht, Netherlands.
[Grunze, H.] Ludwig Maximilians Univ Munchen, Dept Psychiat, Munich, Germany.
[Sugar, C. A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
[Sugar, C. A.; Suppes, T.] Univ Calif Los Angeles, Dept Psychiat, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA USA.
RI Nolen, Willem/E-9006-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1398-5647
J9 BIPOLAR DISORD
JI Bipolar Disord.
PD JUN
PY 2009
VL 11
BP 15
EP 16
PG 2
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 483KH
UT WOS:000268963500040
ER
PT J
AU Matthews, AM
Mitchell, SH
AF Matthews, A. M.
Mitchell, S. H.
TI Smoking characteristics of veterans enrolled in a multicenter study of
bipolar disorder
SO BIPOLAR DISORDERS
LA English
DT Meeting Abstract
CT 8th International Conference on Bipolar Disorder
CY JUN 25-27, 2009
CL Pittsburgh, PA
DE smoking; veterans; bipolar disorder
C1 [Matthews, A. M.] Portland VA Med Ctr, Portland, OR USA.
[Matthews, A. M.; Mitchell, S. H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1398-5647
J9 BIPOLAR DISORD
JI Bipolar Disord.
PD JUN
PY 2009
VL 11
BP 60
EP 60
PG 1
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 483KH
UT WOS:000268963500163
ER
PT J
AU Hiatt, EL
Collins, RL
Pastorek, NJ
Bellows, CF
AF Hiatt, Emily L.
Collins, Robert L.
Pastorek, Nicholas J.
Bellows, Charles F.
TI Body image and health locus of control among male patients with
incisional hernias
SO BODY IMAGE
LA English
DT Article
DE Body image; Disfigurement; Health locus of control; Incisional hernias;
Men
ID DISSATISFACTION; ADJUSTMENT; SURVIVAL; INJURY; WOMEN
AB Incisional hernias form after surgery through incision sites and can enlarge over time. Relations between body image (BI) and health locus of control (HLC) were investigated in male patients undergoing evaluation for incisional hernia repair (n = 32) and non-hernia controls (n = 34). Analyses revealed that patients with incisional hernias reported significantly less satisfaction with general appearance and appearance of the mid-torso than non-hernia controls. Although HLC beliefs did not vary by group, post hoc analyses revealed several significant relations between BI factors and HLC beliefs. Results suggest that poor BI is a significant area of concern among patients with incisional hernias. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Hiatt, Emily L.] Univ Houston, Dept Educ Psychol, EPSY, Houston, TX 77004 USA.
[Collins, Robert L.; Pastorek, Nicholas J.; Bellows, Charles F.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Hiatt, EL (reprint author), Univ Houston, Dept Educ Psychol, EPSY, 4800 Calhoun Rd,Farish Hall, Houston, TX 77004 USA.
EM elhiatt@uh.edu
NR 23
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1740-1445
J9 BODY IMAGE
JI Body Image
PD JUN
PY 2009
VL 6
IS 3
BP 242
EP 245
DI 10.1016/j.bodyim.2009.04.006
PG 4
WC Psychology, Clinical; Psychiatry; Psychology, Multidisciplinary
SC Psychology; Psychiatry
GA 465ZB
UT WOS:000267628300013
PM 19482569
ER
PT J
AU Gruenewald, DA
Ezeji-Okoye, SC
Kuschner, WG
Beal, A
AF Gruenewald, David A.
Ezeji-Okoye, Stephen C.
Kuschner, Ware G.
Beal, Alice
TI Clinical Guidelines and Clinicians' Intentions in End-Of-Life Care
Response
SO CHEST
LA English
DT Letter
C1 [Gruenewald, David A.] VA Puget Sound Hlth Care Syst, Geriatr & Extended Care Serv, Seattle, WA 98108 USA.
[Ezeji-Okoye, Stephen C.; Kuschner, Ware G.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Beal, Alice] Vet Affairs New York Harbor Hlth Care Syst, New York, NY USA.
RP Gruenewald, DA (reprint author), VA Puget Sound Hlth Care Syst, Geriatr & Extended Care Serv, 1660 S Columbian Way,S-182-GEC, Seattle, WA 98108 USA.
EM david.gruenewald@va.gov
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JUN
PY 2009
VL 135
IS 6
BP 1697
EP 1697
DI 10.1378/chest.09-0392
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 455UE
UT WOS:000266791100048
ER
PT J
AU Sun, HY
Wagener, MM
Singh, N
AF Sun, Hsin-Yun
Wagener, Marilyn M.
Singh, Nina
TI Cryptococcosis in Solid-Organ, Hematopoietic Stem Cell, and Tissue
Transplant Recipients: Evidence-Based Evolving Trends
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Review
ID INVASIVE FUNGAL-INFECTIONS; VERSUS-HOST-DISEASE; PRIMARY CUTANEOUS
CRYPTOCOCCOSIS; BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION;
LIVER-TRANSPLANTATION; RENAL-TRANSPLANTATION; AMPHOTERICIN-B; ALLOGRAFT
RECIPIENT; RISK-FACTORS
AB The impact of current transplantation practices on the characteristics of cryptococcosis in solid-organ transplant recipients is not well defined. The incidence of cryptococcal disease among solid-organ transplant recipients has remained unchanged; however, patients are less likely to present with central nervous system or disseminated disease and are more likely to have cryptococcosis limited to the lungs. Additionally, lipid formulations of amphotericin B are now used more frequently, whereas their use in combination with flucytosine has decreased. The overall mortality of cryptococcosis has significantly improved in the current era. Renal failure remains associated with poor outcome, whereas use of lipid formulations of amphotericin B is associated with a higher survival rate. Despite rare infectious complication, certain peculiar attributes of cryptococcal disease in hematopoietic stem cell recipients and tissue transplant recipients warrant recognition.
C1 [Sun, Hsin-Yun; Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Wagener, Marilyn M.; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA.
[Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
[Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan.
RP Singh, N (reprint author), Vet Adm Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA.
EM nis5@pitt.edu
OI SUN, HSIN-YUN/0000-0003-0074-7721
FU National Institutes of Health; National Institute of Allergy and
Infectious Diseases [R01 AI 054719-01]; Schering-Plough, Enzon, Pfizer,
and Astellas
FX Potential conflicts of interest. N. S. has received grant support from
Schering-Plough, Enzon, Pfizer, and Astellas. H.-Y.S. and M.M.W.: no
conflicts.
NR 123
TC 38
Z9 39
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 1
PY 2009
VL 48
IS 11
BP 1566
EP 1576
DI 10.1086/598936
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 441DL
UT WOS:000265749400011
PM 19402789
ER
PT J
AU Abdel-Kader, K
Unruh, ML
Weisbord, SD
AF Abdel-Kader, Khaled
Unruh, Mark L.
Weisbord, Steven D.
TI Symptom Burden, Depression, and Quality of Life in Chronic and End-Stage
Kidney Disease
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC-HEMODIALYSIS PATIENTS; RENAL-DISEASE; DIALYSIS PATIENTS;
ASSESSMENT SYSTEM; UNITED-STATES; HEALTH-STATUS; PREVALENCE; MORTALITY;
SEVERITY; HOSPITALIZATION
AB Background and objectives: While many patients with end-stage renal disease (ESRD) have impaired physical and psychologic well-being, less is known about these health domains in patients with advanced chronic kidney disease (CKD). The authors sought to compare symptoms, depression, and quality of life in patients with ESRD and those with CKD.
Design, setting, participants, & measurements: Patients with ESRD and subjects with advanced CKD were enrolled. Patients' symptoms, depression, and quality of life were assessed using the Dialysis Symptom Index (DSI), Patient Health Questionnaire-9 (PHQ-9), and Short Form 36 (SF-36), respectively, and these health domains were compared between patient groups.
Results: Ninety patients with ESRD and 87 with CKD were enrolled. There were no differences in the overall number of symptoms or in the total DSI symptom-severity score. Median scores on the PHQ-9 were similar, as was the proportion of patients with PHQ-9 scores >9. SF-36 Physical Component Summary scores were comparable, as were SF-36 Mental Component Summary scores.
Conclusions: The burden of symptoms, prevalence of depression, and low quality of life are comparable in patients with ESRD and advanced CKD. Given the widely recognized impairments in these domains in ESRD, findings of this study underscore the substantial decrements in the physical and psychologic well-being of patients with CKD. Clin J Am Soc Nephrol 4: 1057-1064, 2009. doi: 10.2215/CJN.00430109
C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA.
[Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA.
[Abdel-Kader, Khaled; Unruh, Mark L.; Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA.
RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Mailstop 111F-U,7E Room 120, Pittsburgh, PA 15240 USA.
EM veisbordsd@upmc.edu
OI Abdel-Kader, Khaled/0000-0002-6412-8498
FU National Kidney Foundation Young Investigator; Paul Teschan Research
[DK66006, DK77785]; National Research Service Award Institutional
Research Training [T32-DK061296]
FX This work was supported by Fresenius National Kidney Foundation Young
Investigator Grant, Paul Teschan Research Grant, NIH DK66006 and DK77785
(Unruh); Ruth L. Kirschstein National Research Service Award
Institutional Research Training Grants, T32-DK061296 (Abdel-Kader). The
views expressed in this manuscript do not represent those of the
Department of Veterans Affairs or the United States government.
NR 36
TC 102
Z9 107
U1 4
U2 18
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JUN
PY 2009
VL 4
IS 6
BP 1057
EP 1064
DI 10.2215/CJN.00430109
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 451OD
UT WOS:000266478600007
PM 19423570
ER
PT J
AU Thase, ME
AF Thase, Michael E.
TI A Commentary on "Sleep Disturbance in Bipolar Disorder"
SO CLINICAL PSYCHOLOGY-SCIENCE AND PRACTICE
LA English
DT Editorial Material
DE behavioral sleep medicine; bipolar affective disorder; bipolar disorder;
sleep disturbance
ID DEPRESSION; COMORBIDITY; DIAGNOSIS; LIFETIME
AB Sleep disturbances are among the most common clinical features of bipolar affective disorder and are typically present in manic, hypomanic, mixed, and depressive episodes. The processes that regulate sleep are relevant to the pathophysiology of bipolar illness and further study of these processes may help to elucidate fundamental associations with central nervous system arousal and cerebral metabolism. Among the various therapeutic interventions that are used to treat insomnia associated with bipolar affective disorder, the strategies and approaches of behavioral sleep medicine warrant greater attention.
C1 [Thase, Michael E.] Univ Penn, Dept Psychiat, Sch Med, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA.
RP Thase, ME (reprint author), Univ Penn, Dept Psychiat, Sch Med, 3535 Market St,Suite 670, Philadelphia, PA 19104 USA.
EM thase@mail.med.upenn.edu
NR 16
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0969-5893
J9 CLIN PSYCHOL-SCI PR
JI Clin. Psychol.-Sci. Pract.
PD JUN
PY 2009
VL 16
IS 2
BP 278
EP 280
PG 3
WC Psychology, Clinical
SC Psychology
GA 457IT
UT WOS:000266922400016
ER
PT J
AU Magruder, KM
Ouyang, B
Miller, S
Tilley, BC
AF Magruder, Kathryn M.
Ouyang, Bichun
Miller, Scott
Tilley, Barbara C.
TI Retention of Under-represented Minorities in Drug Abuse Treatment
Studies
SO CLINICAL TRIALS
LA English
DT Article
ID CLINICAL-TRIALS-NETWORK; SUBSTANCE-ABUSE; BUPRENORPHINE-NALOXONE;
TREATMENT PROGRAMS; BREAST-CANCER; STRATEGIES; DETOXIFICATION;
PARTICIPANTS; RECRUITMENT; INCENTIVES
AB Background Differential attrition by minority participants can be as limiting to interpreting final results as poor initial recruitment of minority participants. This is especially important in drug abuse treatment studies, as minorities are over-represented in substance abuse clinical treatment programs.
Purpose The specific aims of this secondary data analysis were to: (1) determine if there are differences in study retention rates by race/ethnicity and age, and (2) explore other client characteristics, as well as protocol and treatment program factors, that could account for differential retention rates.
Methods We conducted a secondary analysis using data from 1737 participants in the first six clinical trials whose databases were locked in the NIDA Clinical Trials Network. Protocol level characteristics were also abstracted from these studies, and we used data from a study which assessed characteristics of community treatment programs that participated in these studies. Logistic regression was used to study the effect on retention of: client, protocol, and program characteristics.
Results In the model of client characteristics, a significant age by race/ethnicity interaction term was detected based on a threshold of 0.1, with younger African Americans having the lowest odds of retention. Primary drug of abuse was also a significant factor in determining study retention, with heroin, methadone, and opiate users having the greatest odds of retention and polydrug users the lowest. Similar analyses testing treatment program characteristics found that only the presence of HIV risk screening and decreasing levels of female admissions (as a percent of total admissions) were related to study retention. In our final model, there was an effect of age, but not race/ethnicity, with younger participants having lower odds of retention. A multivariable model including protocol variables could not be developed due to the high correlation among protocol variables.
Limitations We excluded those of multi-race/ethnicity and those from minority groups other than Hispanic or African American due to small numbers. Additionally, only three therapy types were represented among the six studies. Some potential variables that would influence retention, such as client housing, and client comorbidities, the race/ethnicity and gender of the staff who conducted study follow-up assessments, and reasons for loss to follow-up, were not collected by the CTN.
Conclusions Although in our client model older African Americans and Caucasians had the greatest odds of retention and younger African Americans the lowest, in our final model, only age was significantly related to study retention. Additionally, primary drug of abuse, having HIV risk screening as a program benefit, and lower percentages of female admissions were significantly related to study retention. Efforts should be made to increase the study retention of younger participants to improve the validity and generalizability of drug abuse treatment study results. Clinical Trials 2009; 6: 252-260. http://ctj.sagepub.com
C1 [Magruder, Kathryn M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Magruder, Kathryn M.; Ouyang, Bichun; Miller, Scott; Tilley, Barbara C.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA.
[Magruder, Kathryn M.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA.
RP Magruder, KM (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St, Charleston, SC 29425 USA.
EM magrudkm@musc.edu
FU Southern Consortium; National Institute on Drug Abuse Clinical Trials
Network [5 U010 DA013727]; SC Cooperative for Healthy Aging in Minority
Populations - Resource Center for Minority Aging Research [5 P30
AG021677]; Medical University of South Carolina (MUSC)
FX Support provided by the Southern Consortium, National Institute on Drug
Abuse Clinical Trials Network (5 U010 DA013727) and the SC Cooperative
for Healthy Aging in Minority Populations - Resource Center for Minority
Aging Research (SC CHAMP/RCMAR) (5 P30 AG021677) at the Medical
University of South Carolina (MUSC).
NR 29
TC 23
Z9 23
U1 2
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
EI 1740-7753
J9 CLIN TRIALS
JI Clin. Trials
PD JUN
PY 2009
VL 6
IS 3
BP 252
EP 260
DI 10.1177/1740774509105224
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 465WI
UT WOS:000267619600006
PM 19528134
ER
PT J
AU Thompson, GR
Cadena, J
Patterson, TF
AF Thompson, George R.
Cadena, Jose
Patterson, Thomas F.
TI Overview of Antifungal Agents
SO CLINICS IN CHEST MEDICINE
LA English
DT Article
DE Fungal infection; Invasive mycoses; Triazoles; Echinocandins;
Amphotericin; Flucytosine
ID LIPOSOMAL AMPHOTERICIN-B; INVASIVE FUNGAL-INFECTIONS; CLINICAL-PRACTICE
GUIDELINES; PLACEBO-CONTROLLED TRIAL; CRYPTOCOCCAL MENINGITIS;
HEALTHY-VOLUNTEERS; RANDOMIZED-TRIAL; DOUBLE-BLIND; IN-VITRO;
POSACONAZOLE PHARMACOKINETICS
AB This article is a comprehensive clinically focused review of currently available anti-fungals administered by way of the intravenous or inhalational route: amphotericin B and its lipid formulations, fluconazole, itraconazole, posaconazole, voriconazole, caspofungin, micafungin, anidulafungin, and flucytosine. Emphasis is placed on pharmacodynamics and kinetics, drug interactions, adverse events, and evidence for their use. Selected clinical trials demonstrating the efficacy of these agents are also reviewed.
C1 [Thompson, George R.; Cadena, Jose; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Infect Dis, San Antonio, TX 78229 USA.
[Thompson, George R.; Cadena, Jose; Patterson, Thomas F.] S Texas Vet Hlth Care Syst, Dept Internal Med, Div Infect Dis, San Antonio, TX 78229 USA.
RP Thompson, GR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM thompsong2@uthscsa.edu
NR 95
TC 43
Z9 45
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-5231
J9 CLIN CHEST MED
JI Clin. Chest Med.
PD JUN
PY 2009
VL 30
IS 2
BP 203
EP +
DI 10.1016/j.ccm.2009.02.001
PG 14
WC Respiratory System
SC Respiratory System
GA 450DE
UT WOS:000266380400002
PM 19375628
ER
PT J
AU Darouiche, RO
AF Darouiche, Rabih O.
TI Candida in the ICU
SO CLINICS IN CHEST MEDICINE
LA English
DT Article
DE Candida; Candidemia; Invasive infection; Deep-seated infection;
Candidiasis; ICU
ID INTENSIVE-CARE-UNIT; BLOOD-STREAM INFECTIONS; COST-EFFECTIVENESS
ANALYSIS; LIPOSOMAL AMPHOTERICIN-B; NON-ALBICANS-CANDIDA; INVASIVE
CANDIDIASIS; RISK-FACTORS; FLUCONAZOLE THERAPY; EMPIRIC TREATMENT;
RANDOMIZED-TRIAL
AB Invasive Candida infections are becoming increasingly recognized in critically ill patients. These infections result in serious morbidity, can be life threatening, and are expensive to manage. Early suspicion of Candida infection and the use of timely and proper antifungal treatment can improve outcome. Although treatment of documented, deep-seated Candida infections in nonneutropenic patients has been studied extensively, guidelines for the management of suspected but undocumented cases of invasive Candida infections in critically ill patients have not been clearly established. Future work should focus on better delineation of the sector of critically ill patients who have suspected invasive Candida infection and who could benefit from the use of empiric antifungal therapy, and on the investigation of novel approaches for the potential salvage of devices infected with Candida species.
C1 [Darouiche, Rabih O.] Michael E Debakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA.
[Darouiche, Rabih O.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA.
[Darouiche, Rabih O.] Baylor Coll Med, Ctr Prostheses Infect, Dept Phys Med & Rehabil, Houston, TX 77030 USA.
RP Darouiche, RO (reprint author), Michael E Debakey Vet Affairs Med Ctr, Infect Dis Sect, Room 4B-370,2002 Holcome Blvd, Houston, TX 77030 USA.
EM rdarouiche@aol.com
NR 41
TC 10
Z9 10
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-5231
J9 CLIN CHEST MED
JI Clin. Chest Med.
PD JUN
PY 2009
VL 30
IS 2
BP 287
EP +
DI 10.1016/j.ccm.2009.02.013
PG 9
WC Respiratory System
SC Respiratory System
GA 450DE
UT WOS:000266380400009
PM 19375635
ER
PT J
AU Moghissi, ES
Korytkowski, MT
DiNardo, M
Einhorn, D
Hellman, R
Hirsch, IB
Inzucchi, SE
Ismail-Beigi, F
Kirkman, MS
Umpierrez, GE
AF Moghissi, Etie S.
Korytkowski, Mary T.
DiNardo, Monica
Einhorn, Daniel
Hellman, Richard
Hirsch, Irl B.
Inzucchi, Silvio E.
Ismail-Beigi, Faramarz
Kirkman, M. Sue
Umpierrez, Guillermo E.
TI American Association of Clinical Endocrinologists and American Diabetes
Association Consensus Statement on Inpatient Glycemic Control
SO DIABETES CARE
LA English
DT Editorial Material
ID ACUTE MYOCARDIAL-INFARCTION; INTENSIVE-CARE-UNIT; CRITICALLY-ILL
PATIENTS; INSULIN INFUSION PROTOCOL; SLIDING-SCALE INSULIN; RANDOMIZED
CONTROLLED-TRIAL; ENTERAL NUTRITION THERAPY; TRAUMATIC BRAIN-INJURY;
TIGHT GLUCOSE CONTROL; SHORT-TERM MORTALITY
C1 [Moghissi, Etie S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Korytkowski, Mary T.] Univ Pittsburgh, Dept Med, Div Endocrinol & Metab, Pittsburgh, PA USA.
[DiNardo, Monica] Vet Affairs Pittsburgh Hlth Ctr, Div Endocrinol & Metab, Pittsburgh, PA USA.
[DiNardo, Monica] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA.
[Einhorn, Daniel] Scripps Whittier Diabet Inst, La Jolla, CA USA.
[Einhorn, Daniel] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA.
[Einhorn, Daniel] Diabet & Endocrine Associates, La Jolla, CA USA.
[Hellman, Richard] Univ Missouri, Kansas City Sch Med, Dept Med, Kansas City, MO USA.
[Hellman, Richard] Hellman & Rosen Endocrine Associates, Kansas City, MO USA.
[Hirsch, Irl B.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Inzucchi, Silvio E.] Yale Univ, Sch Med, Dept Med, Endocrinol Sect, New Haven, CT 06510 USA.
[Inzucchi, Silvio E.] Yale New Haven Med Ctr, Yale Diabet Ctr, New Haven, CT 06504 USA.
[Ismail-Beigi, Faramarz] Case Western Reserve Univ, Dept Physiol & Med Biophys, Div Clin & Mol Endocrinol, Cleveland, OH 44106 USA.
[Kirkman, M. Sue] Amer Diabet Assoc, Alexandria, VA USA.
[Umpierrez, Guillermo E.] Emory Univ, Dept Med Endocrinol, Atlanta, GA 30322 USA.
RP Moghissi, ES (reprint author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
EM emoghissi@pol.net
NR 159
TC 399
Z9 439
U1 2
U2 21
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD JUN
PY 2009
VL 32
IS 6
BP 1119
EP 1131
DI 10.2337/dc09-9029
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 452EG
UT WOS:000266522200030
PM 19429873
ER
PT J
AU White, R
Cotton, SM
Hind, J
Robbins, J
Perry, A
AF White, Ruth
Cotton, Susan M.
Hind, Jackie
Robbins, JoAnne
Perry, Alison
TI A Comparison of the Reliability and Stability of Oro-lingual Swallowing
Pressures in Patients with Head and Neck Cancer and Healthy Adults
SO DYSPHAGIA
LA English
DT Article
DE Reliability; Oro-lingual swallowing pressures; Head and neck cancer;
Dysphagia; Deglutition; Deglutition disorders
ID TONGUE STRENGTH; STROKE PATIENTS; DYSPHAGIA; VOLUME; VISCOSITY;
ENDURANCE; EXERCISE; FORCE
AB The ability to measure normality and abnormality and to accurately assess true changes in swallowing function over time, is important for the management of dysphagia. Despite this, there is a paucity of information regarding the stability and reliability of measurements tools used for dysphagia research. As both head and neck (H&N) cancer and its treatment(s) have been shown to significantly affect deglutitive tongue function, it is important that we have a reliable method to measure swallowing tongue function in this population. In this study we evaluate the reliability and stability of oro-lingual swallowing pressures captured from H&N cancer patients and from healthy, age- and gender-matched controls using the Kay Swallowing Workstation (KSW) fixed, three-transducer tongue pressure array. Significant differences between the two samples (H&N cancer and controls), with respect to mean peak oro-lingual pressures were recorded during swallowing. Furthermore, reliability of these measures was lower in H&N cancer patients. These differences highlight the importance of obtaining information about the reliability of dysphagia assessment tools with the specific population with whom they will be used.
C1 [Perry, Alison] La Trobe Univ, Fac Hlth Sci, Sch Human Commun Sci, Bundoora, Vic 3086, Australia.
[Hind, Jackie; Robbins, JoAnne] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53705 USA.
[Hind, Jackie; Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
[Cotton, Susan M.] Univ Melbourne, ORYGEN Res Ctr, Dept Psychiat, Melbourne, Vic 3010, Australia.
[White, Ruth] ABM Univ, NHS Trust, Speech & Language Therapy Dept, Swansea, W Glam, Wales.
RP Perry, A (reprint author), La Trobe Univ, Fac Hlth Sci, Sch Human Commun Sci, Bundoora, Vic 3086, Australia.
EM A.Perry@latrobe.edu.au
OI Cotton, Sue/0000-0002-9386-8348
FU GRECC [2007-21]
FX GRECC Manuscript # 2007-21 (Joanne Robbins).
NR 44
TC 7
Z9 8
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0179-051X
J9 DYSPHAGIA
JI Dysphagia
PD JUN
PY 2009
VL 24
IS 2
BP 137
EP 144
DI 10.1007/s00455-008-9181-0
PG 8
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 451CM
UT WOS:000266448300002
PM 18956230
ER
PT J
AU Wilkinson, CW
AF Wilkinson, Charles W.
TI Adrenocortical Responsiveness to Adrenocorticotropin: StAR Is Ascendant
SO ENDOCRINOLOGY
LA English
DT Editorial Material
ID ACUTE REGULATORY PROTEIN; ADRENAL GLUCOCORTICOID SYNTHESIS; MULTIPLE
SIGNALING PATHWAYS; CORTISOL SECRETION; DIURNAL-VARIATION;
GENE-EXPRESSION; ACTH; CELLS; MELATONIN; RECEPTOR
C1 [Wilkinson, Charles W.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Wilkinson, Charles W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA.
RP Wilkinson, CW (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, S-182 GRECC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM wilkinso@u.washington.edu
NR 34
TC 1
Z9 1
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD JUN
PY 2009
VL 150
IS 6
BP 2509
EP 2511
DI 10.1210/en.2009-0303
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 448IQ
UT WOS:000266256700005
PM 19458248
ER
PT J
AU Thaler, JP
Cummings, DE
AF Thaler, Joshua P.
Cummings, David E.
TI Hormonal and Metabolic Mechanisms of Diabetes Remission after
Gastrointestinal Surgery
SO ENDOCRINOLOGY
LA English
DT Review
ID GASTRIC-BYPASS-SURGERY; ROUX-EN-Y; DUODENAL-JEJUNAL BYPASS;
GLUCAGON-LIKE PEPTIDE-1; MORBIDLY OBESE-PATIENTS; PLASMA GHRELIN LEVELS;
GOTO-KAKIZAKI RATS; BETA-CELL FUNCTION; WEIGHT-LOSS; BARIATRIC SURGERY
AB Bariatric surgery is the most effective available treatment for obesity. The most frequently performed operation, Roux-en-Y gastric bypass (RYGB), causes profound weight loss and ameliorates obesity-related comorbid conditions, especially type 2 diabetes mellitus (T2DM). Approximately 84% of diabetic patients experience complete remission of T2DM after undergoing RYGB, often before significant weight reduction. The rapid time course and disproportional degree of T2DM improvement after RYGB compared with equivalent weight loss from other interventions suggest surgery-specific, weight-independent effects on glucose homeostasis. Potential mechanisms underlying the direct antidiabetic impact of RYGB include enhanced nutrient stimulation of lower intestinal hormones (e. g. glucagon-like peptide-1), altered physiology from excluding ingested nutrients from the upper intestine, compromised ghrelin secretion, modulations of intestinal nutrient sensing and regulation of insulin sensitivity, and other changes yet to be fully characterized. Research aimed at determining the relative importance of these effects and identifying additional mechanisms promises not only to improve surgical design but also to identify novel targets for diabetes medications. (Endocrinology 150: 2518-2525, 2009)
C1 [Cummings, David E.] Univ Washington, Diabet Endocrinol Res Ctr, Diabet & Obes Ctr Excellence, Div Metab Endocrinol & Nutr,Dept Med, Seattle, WA 98195 USA.
Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
RP Cummings, DE (reprint author), Univ Washington, Diabet Endocrinol Res Ctr, Diabet & Obes Ctr Excellence, Div Metab Endocrinol & Nutr,Dept Med, Box 358280 Mail Stop 111, Seattle, WA 98195 USA.
EM davidec@u.washington.edu
NR 79
TC 217
Z9 232
U1 3
U2 31
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD JUN
PY 2009
VL 150
IS 6
BP 2518
EP 2525
DI 10.1210/en.2009-0367
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 448IQ
UT WOS:000266256700007
PM 19372197
ER
PT J
AU Latif, R
Morshed, SA
Zaidi, M
Davies, TF
AF Latif, Rauf
Morshed, Syed A.
Zaidi, Mone
Davies, Terry F.
TI The Thyroid-Stimulating Hormone Receptor: Impact of Thyroid-Stimulating
Hormone and Thyroid-Stimulating Hormone Receptor Antibodies on
Multimerization, Cleavage, and Signaling
SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
LA English
DT Review
DE TSH receptor; Multimerization; Oligomerization; Signaling; TSHR
antibodies; Autoimmune thyroid disease
ID HUMAN THYROTROPIN RECEPTOR; G-PROTEIN ACTIVATION; EMBRYONIC STEM-CELLS;
HUMAN TSH RECEPTOR; GRAVES-DISEASE; MONOCLONAL-ANTIBODIES; EXTRACELLULAR
DOMAIN; LIGAND-BINDING; STRUCTURAL DETERMINANTS; DEOXYRIBONUCLEIC-ACID
AB The thyroid-stimulating hormone receptor (TSHR) has a central role in thyrocyte function and is also one of the major autoantigens for the autoimmune thyroid diseases. We review the post-translational processing, multimerization, and intramolecular cleavage of TSHR, all of which may modulate its signal transduction. The recent characterization of monoclonal antibodies to the TSHR, including stimulating, blocking, and neutral antibodies, have also revealed unique biologic insights into receptor activation and the variety of these TSHR antibodies may help explain the multiple clinical phenotypes seen in autoimmune thyroid diseases. Knowledge of the structure/function relationship of the TSHR is beginning to provide a greater understanding of thyroid physiology and thyroid autoimmunity.
C1 [Latif, Rauf; Morshed, Syed A.; Davies, Terry F.] Mt Sinai Sch Med, Thyroid Res Unit, Bronx, NY 10468 USA.
[Latif, Rauf; Morshed, Syed A.; Davies, Terry F.] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Zaidi, Mone] Mt Sinai Sch Med, Thyroid Res Unit, New York, NY 10029 USA.
[Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
RP Latif, R (reprint author), 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM rauf.latif@mssm.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
[DK069713, DK052464]; David Owen Segal Endowment
FX Supported in part by DK069713 and DK052464 from National Institute of
Diabetes and Digestive and Kidney Diseases, the VA Merit Award Program,
and the David Owen Segal Endowment.
NR 126
TC 32
Z9 34
U1 0
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8529
J9 ENDOCRIN METAB CLIN
JI Endocrinol. Metabol. Clin. North Amer.
PD JUN
PY 2009
VL 38
IS 2
BP 319
EP +
DI 10.1016/j.ecl.2009.01.006
PG 24
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 438PN
UT WOS:000265567800007
PM 19328414
ER
PT J
AU Price, DA
Martinez, AA
Seillier, A
Koek, W
Acosta, Y
Fernandez, E
Strong, R
Lutz, B
Marsicano, G
Roberts, JL
Giuffrida, A
AF Price, David A.
Martinez, Alex A.
Seillier, Alexandre
Koek, Wouter
Acosta, Yolanda
Fernandez, Elizabeth
Strong, Randy
Lutz, Beat
Marsicano, Giovanni
Roberts, James L.
Giuffrida, Andrea
TI WIN55,212-2, a cannabinoid receptor agonist, protects against
nigrostriatal cell loss in the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's
disease
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE cannabinoid receptors; neuroinflammation; neurotoxicity; striatum;
substantia nigra
ID LEVODOPA-INDUCED DYSKINESIA; MPTP-TREATED-MOUSE; TOXICITY IN-VIVO;
SUBSTANTIA-NIGRA; KNOCKOUT MICE; NITRIC-OXIDE; ENDOCANNABINOID SYSTEM;
MICROGLIAL ACTIVATION; INDUCED NEUROTOXICITY; MULTIPLE-SCLEROSIS
AB Parkinson's disease (PD) is characterized by the progressive loss of nigrostriatal dopamine neurons leading to motor disturbances and cognitive impairment. Current pharmacotherapies relieve PD symptoms temporarily but fail to prevent or slow down the disease progression. In this study, we investigated the molecular mechanisms by which the non-selective cannabinoid receptor agonist WIN55,212-2 (WIN) protects mouse nigrostriatal neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity and neuroinflammation. Stereological analyses showed that chronic treatment with WIN (4 mg/kg, intraperitoneal), initiated 24 h after MPTP administration, protected against MPTP-induced loss of tyrosine hydroxylase-positive neurons in the substantia nigra pars compacta independently of CB(1) cannabinoid receptor activation. The neuroprotective effect of WIN was accompanied by increased dopamine and 3,4-dihydroxyphenylacetic acid levels in the substantia nigra pars compacta and dorsal striatum of MPTP-treated mice. At 3 days post-MPTP, we found significant microglial activation and up-regulation of CB(2) cannabinoid receptors in the ventral midbrain. Treatment with WIN or the CB(2) receptor agonist JWH015 (4 mg/kg, intraperitoneal) reduced MPTP-induced microglial activation, whereas genetic ablation of CB(2) receptors exacerbated MPTP systemic toxicity. Furthermore, chronic WIN reversed MPTP-associated motor deficits, as revealed by the analysis of forepaw step width and percentage of faults using the inverted grid test. In conclusion, our data indicate that agonism at CB(2) cannabinoid receptors protects against MPTP-induced nigrostriatal degeneration by inhibiting microglial activation/infiltration and suggest that CB(2) receptors represent a new therapeutic target to slow the degenerative process occurring in PD.
C1 [Price, David A.; Martinez, Alex A.; Seillier, Alexandre; Koek, Wouter; Acosta, Yolanda; Fernandez, Elizabeth; Strong, Randy; Roberts, James L.; Giuffrida, Andrea] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Koek, Wouter] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Fernandez, Elizabeth; Strong, Randy] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
[Lutz, Beat] Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-6500 Mainz, Germany.
[Marsicano, Giovanni] Univ Bordeaux 2, INSERM, U682, Neuroctr Magendie,Avenir Grp, F-33076 Bordeaux, France.
[Roberts, James L.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
RP Giuffrida, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,MC 6205, San Antonio, TX 78229 USA.
EM giuffrida@uthscsa.edu
RI Fernandez-Espejo, Emilio/F-9205-2015
OI Fernandez-Espejo, Emilio/0000-0003-0724-6049
FU NIH [NS050401-05, T32 AG021890]; American Parkinson's Disease
Association
FX This work was supported by NIH grants NS050401-05 (A.G.) and T32
AG021890 (D.A.P.) and by a grant from the American Parkinson's Disease
Association (A.G.). We would like to thank Dr Rebecca L. Cunningham
(UTHSCSA) for her technical assistance and Dr Nephi Stella (University
of Washington) for generously providing spleen tissue from
CB2-/- mice and wild-type littermates.
NR 85
TC 85
Z9 86
U1 1
U2 5
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0953-816X
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD JUN
PY 2009
VL 29
IS 11
BP 2177
EP 2186
DI 10.1111/j.1460-9568.2009.06764.x
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 453FY
UT WOS:000266597000008
PM 19490092
ER
PT J
AU Tache, Y
Bernstein, CN
AF Tache, Yvette
Bernstein, Charles N.
TI Evidence for the Role of the Brain-Gut Axis in Inflammatory Bowel
Disease: Depression as Cause and Effect?
SO GASTROENTEROLOGY
LA English
DT Editorial Material
ID PRIMARY-CARE; RISK-FACTOR; DISORDERS; ANXIETY; ANTIDEPRESSANTS; IMPACT;
MODEL; MOOD
C1 [Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, CURE Digest Dis Res Ctr,Dept Med, Los Angeles, CA 90073 USA.
[Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Ctr Neurobiol Stress,Dept Med, Los Angeles, CA 90073 USA.
[Tache, Yvette] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Bernstein, Charles N.] Univ Manitoba, IBD Clin & Res Ctr, Winnipeg, MB, Canada.
[Bernstein, Charles N.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada.
RP Tache, Y (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, CURE Digest Dis Res Ctr,Dept Med, 11301 Wilshire Blvd,CURE Bldg 115,Room 117, Los Angeles, CA 90073 USA.
EM ytache@mednet.ucla.edu
FU NIDDK NIH HHS [P30 DK041301]
NR 27
TC 10
Z9 10
U1 2
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUN
PY 2009
VL 136
IS 7
BP 2058
EP 2061
DI 10.1053/j.gastro.2009.04.032
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 454CK
UT WOS:000266659100009
PM 19406133
ER
PT J
AU Leung, FW
AF Leung, Felix W.
TI The case of unsedated screening colonoscopy in the United States
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; NITROUS-OXIDE; FLEXIBLE SIGMOIDOSCOPY;
CECAL INTUBATION; US VETERANS; SEDATION; COMPLICATIONS; ENDOSCOPY;
OPTIONS
C1 [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Res & Med Serv, Sepulveda Ambulatory Care Ctr, North Hills, CA USA.
[Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res & Med Serv, Sepulveda Ambulatory Care Ctr, North Hills, CA USA.
NR 34
TC 7
Z9 8
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD JUN
PY 2009
VL 69
IS 7
BP 1354
EP 1356
DI 10.1016/j.gie.2008.12.234
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 455WU
UT WOS:000266800000024
PM 19249764
ER
PT J
AU Garcia, JM
Polvino, WJ
AF Garcia, Jose M.
Polvino, William J.
TI Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin
mimetic and growth hormone secretagogue in healthy volunteers
SO GROWTH HORMONE & IGF RESEARCH
LA English
DT Article
DE Ghrelin; Anorexia; Growth hormone secretagogues; IGF-1; Growth hormone
ID CANCER-PATIENTS; OBESE SUBJECTS; FOOD-INTAKE; FACTOR-I; SECRETION;
PEPTIDE; DEFICIENCY; RECEPTOR; RELEASE; MK-677
AB Objective: Activation of ghrelin receptors Stimulates GH secretion and appetite, increasing lean body mass and body weight. However, clinical use of ghrelin is limited because it has a short half-life and must be administered parenterally. Anamorelin is a novel, orally active, non-peptidic ghrelin mimetic and growth hormone secretagogue. Our objective was to evaluate its hormonal effects in healthy subjects.
Design: A double-blind, randomized, placebo-controlled study evaluated the short-term effects of anamorelin on GH, insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3), prolactin, ACTH, LH, FSH, TSH, cortisol, insulin and glucose. Normal healthy volunteers (n = 32) recruited from the general population were administered escalating doses of anamorelin (25, 50, and 75 mg daily) vs. placebo.
Results: Anamorelin significantly increased CH levels at all doses (p <= 0.01). Effects on the somatotropic axis were maintained, as evidenced by sustained increases in IGF-1 and IGFBP-3 compared to placebo following 5-6 days of treatment. Negligible effects on other anterior pituitary hormone profiles and on fasting glucose were noted and all mean hormone levels remained within normal range. Some degree of insulin resistance as assessed by HOMA-IR was evident after treatment with 75 mg dose but not with the 25 or the 50 mg doses. Significant dose-related increases in body weight were recorded. Changes in body weight directly correlated with changes in IGF-1 levels. Anamorelin was well tolerated.
Conclusions: Anamorelin increases GH, IGF-1, IGFBP-3 and body weight with good tolerability and selectivity, without affecting other anterior pituitary axes or fasting glucose levels. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Garcia, Jose M.] Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA.
[Polvino, William J.] Sapphire Therapeut Inc, Bridgewater, NJ USA.
RP Garcia, JM (reprint author), Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM jgarcia1@bcm.tmc.edu
NR 34
TC 39
Z9 40
U1 0
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1096-6374
EI 1532-2238
J9 GROWTH HORM IGF RES
JI Growth Horm. IGF Res.
PD JUN
PY 2009
VL 19
IS 3
BP 267
EP 273
DI 10.1016/j.ghir.2008.12.003
PG 7
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 464UN
UT WOS:000267533400014
PM 19196529
ER
PT J
AU Ettner, SL
Cadwell, BL
Russell, LB
Brown, A
Karter, AJ
Safford, M
Mangione, C
Beckles, G
Herman, WH
Thompson, TJ
AF Ettner, Susan L.
Cadwell, Betsy L.
Russell, Louise B.
Brown, Arleen
Karter, Andrew J.
Safford, Monika
Mangione, Carol
Beckles, Gloria
Herman, William H.
Thompson, Theodore J.
CA TRIAD Study Grp
TI INVESTING TIME IN HEALTH: DO SOCIOECONOMICALLY DISADVANTAGED PATIENTS
SPEND MORE OR LESS EXTRA TIME ON DIABETES SELF-CARE?
SO HEALTH ECONOMICS
LA English
DT Article
DE self-care; opportunity costs of time; diabetes; disparities;
socioeconomic status
ID QUALITY-OF-CARE; MANAGED CARE; TRANSLATING RESEARCH; RACIAL DISPARITIES;
ETHNIC-DIFFERENCES; POPULATION; COMPLICATIONS; MELLITUS; PEOPLE; ADULTS
AB Background: Research on self-care for chronic disease has not examined time requirements. Translating Research into Action for Diabetes (TRIAD), a multi-site study of managed care patients with diabetes, is among the first to assess self-care time.
Objective: To examine associations between socioeconomic position and extra time patients spend on foot care, shopping/cooking, and exercise due to diabetes.
Data: Eleven thousand nine hundred and twenty-seven patient surveys from 2000 to 2001.
Methods: Bayesian two-part models were used to estimate associations of self-reported extra time spent on self-care with race/ethnicity, education, and income, controlling for demographic and clinical characteristics.
Results: Proportions of patients spending no extra time on foot care, shopping/cooking, and exercise were, respectively, 37, 52, and 31%. Extra time spent on foot care and shopping/cooking was greater among racial/ethnic minorities, less-educated and lower-income patients. For example, African-Americans were about 10 percentage points more likely to report spending extra time on foot care than whites and extra time spent was about 3 min more per day.
Discussion: Extra time spent on self-care was greater for socioeconomically disadvantaged patients than for advantaged patients, perhaps because their perceived opportunity cost of time is lower or they cannot afford Substitutes. Our findings suggest that poorly controlled diabetes risk factors among disadvantaged populations may not be attributable to self-care practices. Copyright (C) 2008 John Wiley & Sons, Ltd.
C1 [Ettner, Susan L.; Brown, Arleen; Mangione, Carol] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Dept Med, Los Angeles, CA 90095 USA.
[Cadwell, Betsy L.; Beckles, Gloria; Thompson, Theodore J.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Russell, Louise B.] Rutgers State Univ, Dept Econ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA.
[Karter, Andrew J.] Kaiser Permanente, Div Res, Oakland, CA USA.
[Safford, Monika] Univ Alabama Birmingham, Deep S Ctr Effectiveness, Birmingham VA Med Ctr, Birmingham, AL USA.
[Herman, William H.] Univ Michigan Hlth Syst, Ann Arbor, MI USA.
RP Ettner, SL (reprint author), Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Dept Med, 911 Broxton Plaza,Room 106, Los Angeles, CA 90095 USA.
EM settner@mednet.ucla.edu
OI Ferrara, Assiamira/0000-0002-7505-4826
FU Centers for Disease Control and Prevention (Division of Diabetes
Translation); National Institute of Diabetes and Digestive and Kidney
Diseases
FX The authors are grateful for the significant contributions to this study
made by members of the Translating Research into Action for Diabetes
(TRIAD) Study Group, including TRIAD participants, other TRIAD
investigators, and staff who made this study possible. The authors also
acknowledge the participation of our health plan partners. This study
was jointly funded by Program Announcement number 04005 from the Centers
for Disease Control and Prevention (Division of Diabetes Translation)
and the National Institute of Diabetes and Digestive and Kidney
Diseases.
NR 45
TC 15
Z9 15
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9230
EI 1099-1050
J9 HEALTH ECON
JI Health Econ.
PD JUN
PY 2009
VL 18
IS 6
BP 645
EP 663
DI 10.1002/hec.1394
PG 19
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 449TT
UT WOS:000266353700003
PM 18709636
ER
PT J
AU Hussey, PS
de Vries, H
Romley, J
Wang, MC
Chen, SS
Shekelle, PG
McGlynn, EA
AF Hussey, Peter S.
de Vries, Han
Romley, John
Wang, Margaret C.
Chen, Susan S.
Shekelle, Paul G.
McGlynn, Elizabeth A.
TI A Systematic Review of Health Care Efficiency Measures
SO HEALTH SERVICES RESEARCH
LA English
DT Review
DE Efficiency; provider profiling; performance measurement; systematic
review
ID HOSPITAL EFFICIENCY; REGIONAL-VARIATIONS; QUALITY; PRODUCTIVITY;
PHYSICIANS; INEFFICIENCIES; INCENTIVES
AB To review and characterize existing health care efficiency measures in order to facilitate a common understanding about the adequacy of these methods.
Review of the MedLine and EconLit databases for articles published from 1990 to 2008, as well as search of the "gray" literature for additional measures developed by private organizations.
We performed a systematic review for existing efficiency measures. We classified the efficiency measures by perspective, outputs, inputs, methods used, and reporting of scientific soundness.
We identified 265 measures in the peer-reviewed literature and eight measures in the gray literature, with little overlap between the two sets of measures. Almost all of the measures did not explicitly consider the quality of care. Thus, if quality varies substantially across groups, which is likely in some cases, the measures reflect only the costs of care, not efficiency. Evidence on the measures' scientific soundness was mostly lacking: evidence on reliability or validity was reported for six measures (2.3 percent) and sensitivity analyses were reported for 67 measures (25.3 percent).
Efficiency measures have been subjected to few rigorous evaluations of reliability and validity, and methods of accounting for quality of care in efficiency measurement are not well developed at this time. Use of these measures without greater understanding of these issues is likely to engender resistance from providers and could lead to unintended consequences.
C1 [de Vries, Han] Westbrook Ctr, RAND, Cambridge, England.
[Shekelle, Paul G.] RAND Corp, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA.
[Romley, John] Occidental Coll, Los Angeles, CA 90041 USA.
[Chen, Susan S.] Michigan State Univ, Coll Agr & Nat Resources, E Lansing, MI 48824 USA.
[Shekelle, Paul G.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
RP Hussey, PS (reprint author), 1200 S Hayes St, Arlington, VA 22202 USA.
EM hussey@rand.org
FU Agency for Healthcare Research and Quality (AHRQ), Rockville, MD
[282-00-0005-21]
FX Disclosures: None.
NR 48
TC 60
Z9 62
U1 4
U2 22
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0017-9124
J9 HEALTH SERV RES
JI Health Serv. Res.
PD JUN
PY 2009
VL 44
IS 3
BP 784
EP 805
DI 10.1111/j.1475-6773.2008.00942.x
PG 22
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 446HB
UT WOS:000266111600002
PM 19187184
ER
PT J
AU Mulligan, JK
Day, TA
Gillespie, MB
Rosenzweig, SA
Young, MRI
AF Mulligan, Jennifer K.
Day, Terry A.
Gillespie, M. Boyd
Rosenzweig, Steven A.
Young, M. Rita I.
TI Secretion of vascular endothelial growth factor by oral squamous cell
carcinoma cells skews endothelial cells to suppress T-cell functions
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE Oral squamous cell carcinoma (OSCC); Vascular endothelial growth factor
(VEGF); Endothelial cell; T-cell; Immune suppression
ID NECK-CANCER; DENDRITIC CELLS; IMMUNE SUPPRESSION; FACTOR VEGF; HEAD;
TUMOR; ANGIOGENESIS; CYTOKINES; SURVIVAL; DIFFERENTIATION
AB Patients with oral squamous cell carcinoma (OSCC) have severe defects in antitumor immune function. Endothelial cells are potential regulators of immune cell function and have therefore been examined to determine their role in tumor-induced immune suppression. The present Studies demonstrated that supernatants from endothelial cells exposed to OSCC-conditioned media (endo(OSCC-sup)) exhibited elevated levels of the immune suppressive products prostaglandin E(2) (PGE(2)) and Vascular endothelial growth factor (VEGF) compared with supernatants from endothelial cells treated with medium alone (endo(medium)) or with keratinocyte-conditioned medium (endo(ker-sup)). Antibody neutralization of OSCC-derived VEGF prevented tumor-conditioned media from inducing endothelial cells to increase production of PGE(2) and VEGF. Furthermore, treatment of T-cells with supernatants from endo(OSCC-sup) resulted in diminished T-cell proliferation and decreased interferon-gamma (IFN-gamma) production compared with T-cells treated with medium or supernatants from endo(medium) or endo(ker-sup) controls. T-cell levels of granzyme B and perform were reduced after treatment with Supernatant from endo(OSCC-sup) Compared with control treatments. The addition of VEGF neutralizing antibody to the OSCC-conditioned medium prevented endothelial cells from being skewed to downregulate T-cell proliferation and production of IFN-gamma, perform, and granzyme B. Taken together, these studies provide support for the use of VEGF-targeting therapies as an immunotherapeutic agent to block induction of immune Suppressive endothelial cells in patients with OSCC. (C) 2009 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
C1 [Mulligan, Jennifer K.; Gillespie, M. Boyd; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.
[Mulligan, Jennifer K.; Day, Terry A.; Gillespie, M. Boyd; Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA.
[Rosenzweig, Steven A.] Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA.
[Rosenzweig, Steven A.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
[Young, M. Rita I.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.
EM rita.young@va.gov
FU Research Service of the Department of Veterans Affairs; National
Institutes of Health [R01CA85266, R01CA97813]
FX This work was supported by the Research Service of the Department of
Veterans Affairs and by Grants R01CA85266 and R01CA97813 from the
National Institutes of Health to MRIY. The authors thank Bridgette
Ransom and Kiki Gibbs for their assistance in preparing OSCC samples and
Andrea Selmer for her technical assistance.
NR 32
TC 24
Z9 24
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD JUN
PY 2009
VL 70
IS 6
BP 375
EP 382
DI 10.1016/j.humimm.2009.01.014
PG 8
WC Immunology
SC Immunology
GA 455ZF
UT WOS:000266806900001
PM 19480853
ER
PT J
AU Ceylan-Isik, AF
Guo, KK
Carlson, EC
Privratsky, JR
Liao, SJ
Cai, L
Chen, AF
Ren, J
AF Ceylan-Isik, Asli F.
Guo, Kelly K.
Carlson, Edward C.
Privratsky, Jamie R.
Liao, Song-Jie
Cai, Lu
Chen, Alex F.
Ren, Jun
TI Metallothionein Abrogates GTP Cyclohydrolase I Inhibition-Induced
Cardiac Contractile and Morphological Defects Role of Mitochondrial
Biogenesis
SO HYPERTENSION
LA English
DT Article
DE BH4; eNOS uncoupling; cardiomyocyte mechanics; metallothionein;
superoxide
ID NITRIC-OXIDE SYNTHASE; LOW-RENIN HYPERTENSION; ENDOTHELIAL DYSFUNCTION;
VASCULAR-DISEASE; BLOOD-PRESSURE; GENE-TRANSFER; TETRAHYDROBIOPTERIN;
PHOSPHORYLATION; OVEREXPRESSION; MICE
AB One key mechanism for endothelial dysfunction is endothelial NO synthase (eNOS) uncoupling, whereby eNOS generates O(2)(center dot-) rather than NO because of deficient eNOS cofactor tetrahydrobiopterin (BH4). This study was designed to examine the effect of BH4 deficiency on cardiac morphology and function, as well as the impact of metallothionein (MT) on BH4 deficiency induced abnormalities, if any. Friend virus B (FVB) and cardiac specific MT transgenic mice were exposed to 2,4-diamino-6-hydroxypyrimidine (DAHP; 10 mmol/L, 3 weeks), an inhibitor of the BH4 synthetic enzyme GTP cyclohydrolase I. DAHP reduced plasma BH4 levels by 85% and elevated blood pressure in both FVB and MT mice. Echocardiography found decreased fractional shortening and increased end systolic diameter in DAHPtreated FVB mice. Cardiomyocytes from DAHP treated FVB mice displayed enhanced O(2)(center dot-) production, contractile and intracellular Ca(2+) defects including depressed peak shortening and maximal velocity of shortening/relengthening, prolonged duration of relengthening, reduced intracellular Ca(2+) rise, and clearance. DAHP triggered mitochondrial swelling/myocardial filament aberrations and mitochondrial O(2)(center dot-) accumulation, assessed by transmission electron microscopy and MitoSOX Red fluorescence, respectively. DAHP also promoted the N(G-)nitro-L-arginine methyl ester inhibitable O(2)(center dot-) production and eNOS phosphorylation at Thr497. Although MT had little effect on cardiac mechanics and ultrastructure, it attenuated DAHP induced defects in cardiac function, morphology,O(2)(center dot) production, and eNOS phosphorylation (Thr497). The DAHP induced cardiomyocyte mechanical responses were alleviated by in vitro BH4 treatment. DAHP inhibited mitochondrial biogenesis, mitochondrial uncoupling protein 2, and chaperone heat shock protein 90, and all but uncoupling protein 2 were rescued by MT. Our data suggest a role for BH4 deficiency in cardiac dysfunction and the therapeutic potential of antioxidants against eNOS uncoupling in the heart. (Hypertension. 2009; 53: 10231031.)
C1 [Ceylan-Isik, Asli F.; Guo, Kelly K.; Ren, Jun] Univ Wyoming, Coll Hlth Sci, Ctr Cardiovasc Res & Alternat Med, Laramie, WY 82071 USA.
[Carlson, Edward C.; Privratsky, Jamie R.; Ren, Jun] Univ N Dakota, Sch Med & Hlth Sci, Grand Forks, ND 58203 USA.
[Cai, Lu] Univ Louisville, Dept Pediat, Louisville, KY 40202 USA.
[Liao, Song-Jie; Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA.
[Liao, Song-Jie; Chen, Alex F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
RP Ren, J (reprint author), Univ Wyoming, Coll Hlth Sci, Ctr Cardiovasc Res & Alternat Med, Laramie, WY 82071 USA.
EM jren@uwyo.edu
FU NCRR NIH HHS [P20 RR016474, P20 RR016474-08, P20 RR016474-086660]; NIGMS
NIH HHS [R01 GM077352]
NR 35
TC 30
Z9 31
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD JUN
PY 2009
VL 53
IS 6
BP 1023
EP U243
DI 10.1161/HYPERTENSIONAHA.108.123422
PG 16
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 448CG
UT WOS:000266239300025
PM 19398661
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI Seasonal Variation of Enteric Infections and Inflammatory Bowel Disease
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Letter
C1 Portland VA Med Ctr, Portland, OR USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-G1, Portland, OR USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1078-0998
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD JUN
PY 2009
VL 15
IS 6
BP 809
EP 809
DI 10.1002/ibd.20770
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 454HT
UT WOS:000266673700004
PM 18942760
ER
PT J
AU Johnson, E
Ricketts, T
Hornsby, B
AF Johnson, Earl
Ricketts, Todd
Hornsby, Benjamin
TI The effect of extending high-frequency bandwidth on the Acceptable Noise
Level (ANL) of hearing-impaired listeners
SO INTERNATIONAL JOURNAL OF AUDIOLOGY
LA English
DT Article
CT Annual Meeting of the American-Auditory-Society
CY MAR 04-06, 2007
CL Scottsdale, AZ
SP Amer Auditory Soc
DE Acceptable noise level; Background noise; Bandwidth; Reverberation;
Hearing aid outcome; Hearing aid usage
ID BINAURAL SPEECH-PERCEPTION; BACKGROUND-NOISE; SOUND QUALITY; MEDIAN
PLANE; AID USE; REVERBERATION; INTELLIGIBILITY; AMPLIFICATION;
LOCALIZATION; CANCELLATION
AB This study examined the effects of extending high-frequency bandwidth, for both a speech signal and a background noise, on the acceptable signal-to-noise ratio (SNR) of listeners with mild sensorineural hearing loss through utilization of the Acceptable Noise Level (ANL) procedure. In addition to extending high-frequency bandwidth. the effects of reverberation time and background noise type and shape were also examined. The study results showed a significant increase in the mean ANL (i.e, participants requested a better SNR for an acceptable listening situation) when high-frequency bandwidth was extended from 3 to 9 kHz and from 6 to 9 kHz. No change in the ANL of study participants was observed as a result of isolated modification to reverberation time or background noise stimulus. An interaction effect. however, of reverberation time and background noise Stimulus was demonstrated, These Findings may have implications for future design of hearing aid memory programs for listening to speech in the presence of broadband background noise.
C1 [Johnson, Earl] US Dept Vet Affairs, Tennessee Med Ctr, Mountain Home, TN 37684 USA.
[Johnson, Earl] E Tennessee State Univ, Johnson City, TN 37614 USA.
[Ricketts, Todd; Hornsby, Benjamin] Vanderbilt Univ, Vanderbilt Bill Wilkerson Ctr, Nashville, TN USA.
RP Johnson, E (reprint author), US Dept Vet Affairs, Tennessee Med Ctr, POB 4000,Audiol 126, Mountain Home, TN 37684 USA.
EM earl.johnson@va.gov
NR 56
TC 9
Z9 9
U1 1
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1499-2027
J9 INT J AUDIOL
JI Int. J. Audiol.
PD JUN
PY 2009
VL 48
IS 6
BP 353
EP 362
DI 10.1080/14992020802662964
PG 10
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 478GT
UT WOS:000268576500005
PM 19925343
ER
PT J
AU Garcia, JA
Movassaghi, B
Casserly, IP
Klein, AJ
Chen, SYJ
Messenger, JC
Hansgen, A
Wink, O
Groves, BM
Carroll, JD
AF Garcia, Joel A.
Movassaghi, Babak
Casserly, Ivan P.
Klein, Andrew J.
Chen, S. -Y. James
Messenger, John C.
Hansgen, Adam
Wink, Onno
Groves, Bertron M.
Carroll, John D.
TI Determination of optimal viewing regions for X-ray coronary angiography
based on a quantitative analysis of 3D reconstructed models
SO INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING
LA English
DT Article
DE Angiography; Imaging; Radiography; Optimal view map, coronary;
Three-dimensional
ID ARTERIAL TREE
AB Current expert-recommended views for coronary angiography are based on heuristic experience and have not been scientifically studied. We sought to identify optimal viewing regions for first and second order vessel segments of the coronary arteries that provide optimal diagnostic value in terms of minimizing vessel foreshortening and overlap. Using orthogonal 2D images of the coronary tree, 3D models were created from which patient-specific optimal view maps (OVM) allowing quantitative assessment of vessel foreshortening and overlap were generated. Using a novel methodology that averages 3D-based optimal projection geometries, a universal OVM was created for each individual coronary vessel segment that minimized both vessel foreshortening and overlap. A universal OVM model for each coronary segment was generated based on data from 137 patients undergoing coronary angiography. We identified viewing regions for each vessel segment achieving a mean vessel foreshortening value of 5.8 +/- A 3.9% for the left coronary artery (LCA) and 5.6 +/- A 3.6% for the right coronary artery (RCA). The overall mean overlap values achieved were 8.7 +/- A 7.9% for the LCA and 4.6 +/- A 3.2% for the RCA. This scientifically-based OVM evaluation of coronary vessel segments provides the means to facilitate acquisitions during coronary angiography and interventions that minimize imaging inaccuracies related to foreshortening and overlap, improving the accuracy, efficiency, and safety of diagnostic and interventional coronary procedures.
C1 [Garcia, Joel A.; Casserly, Ivan P.; Klein, Andrew J.; Chen, S. -Y. James; Messenger, John C.; Hansgen, Adam; Groves, Bertron M.; Carroll, John D.] Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA.
[Garcia, Joel A.] Denver Hlth Med Ctr, Denver, CO 80204 USA.
[Movassaghi, Babak; Wink, Onno] PMS, Clin Res, Denver, CO USA.
[Casserly, Ivan P.] Denver VA Med Ctr, Div Cardiol, Denver, CO 80220 USA.
RP Garcia, JA (reprint author), Univ Colorado, Hlth Sci Ctr, Div Cardiol, 4200 E 9th Ave,Box B-132, Denver, CO 80262 USA.
EM joel.garcia@dhha.org
FU Philips Medical Systems
FX John D. Carroll, M. D and S.-Y. James Chen, Ph. D. are Co-inventor of
patented 3-D vascular reconstruction and analysis software. The patents
have been assigned to the University of Chicago and the University of
Colorado. They both received Research grants from Philips Medical
Systems.
NR 17
TC 11
Z9 11
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1569-5794
J9 INT J CARDIOVAS IMAG
JI Int. J. Cardiovasc. Imaging
PD JUN
PY 2009
VL 25
IS 5
BP 455
EP 462
DI 10.1007/s10554-008-9402-5
PG 8
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 446TV
UT WOS:000266145000002
PM 19101820
ER
PT J
AU Von Zee, CL
Richards, MP
Bu, P
Perlman, JI
Stubbs, EB
AF Von Zee, Cynthia L.
Richards, Michael P.
Bu, Ping
Perlman, Jay I.
Stubbs, Evan B., Jr.
TI Increased RhoA and RhoB Protein Accumulation in Cultured Human
Trabecular Meshwork Cells by Lovastatin
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COENZYME-A REDUCTASE; GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; OUTFLOW
FACILITY; MEVALONATE PATHWAY; FOCAL ADHESIONS; ANIMAL-MODEL; RAS;
GTPASES; PRENYLATION
AB PURPOSE. This study aimed to determine the effect of lovastatin on Rho G-protein expression and activation in human trabecular meshwork (TM) cells.
METHODS. Confluent cultures of low-passage (primary) or transformed (GTM3) human TM cells were incubated overnight with vehicle (0.01% ethanol) or activated lovastatin (10 mu M). Changes in Rho mRNA, protein content, and activation were quantified by qRT-PCR, immunoblotting, and ELISA, respectively. F-actin organization was determined using Alexa Fluor 488- conjugated phalloidin.
RESULTS. Low-passage or transformed TM cells treated with lovastatin exhibited marked increases in RhoA and RhoB mRNA and protein content. Actinomycin D prevented lovastatin-dependent increases in RhoB, but not RhoA, protein accumulation. In contrast, cycloheximide prevented lovastatin from increasing both RhoA and RhoB. Supplementation with mevalonate or geranylgeranyl pyrophosphate prevented, whereas inhibition of geranylgeranyl transferase mimicked, the effects of lovastatin on RhoA and RhoB accumulation. The effect of lovastatin was dose dependent, with newly synthesized protein accumulating in the cytosol. The amount of functionally active (GTP-bound) RhoA in cell lysates was significantly reduced by lovastatin. Lovastatin altered the morphology of TM cells by disrupting F-actin organization.
CONCLUSIONS. Lovastatin enhances the accumulation of RhoA and RhoB in human TM cells, in part, by limiting geranylgeranyl isoprenylation of these G-proteins. We propose that post-translational geranylgeranylation serves as a regulator of both RhoA and RhoB protein expression and processing in human TM cells. Increased accumulation of unprenylated forms of RhoA and RhoB may disrupt Rho-dependent regulation of TM cell cytoskeletal organization. (Invest Ophthalmol Vis Sci. 2009; 50: 2816-2823) DOI: 10.1167/iovs.08-2466
C1 [Von Zee, Cynthia L.; Richards, Michael P.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA.
[Perlman, Jay I.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Surg Serv, Hines, IL 60141 USA.
[Stubbs, Evan B., Jr.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Hines, IL 60141 USA.
[Bu, Ping; Perlman, Jay I.; Stubbs, Evan B., Jr.] Loyola Univ Chicago, Stritch Sch Med, Dept Ophthalmol, Maywood, IL USA.
[Perlman, Jay I.] Loyola Univ Chicago, Stritch Sch Med, Dept Pathol, Maywood, IL USA.
[Von Zee, Cynthia L.; Stubbs, Evan B., Jr.] Loyola Univ Chicago, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL USA.
RP Stubbs, EB (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv 151, 5th & Roosevelt, Hines, IL 60141 USA.
EM evan.stubbs@med.va.gov
FU Department of Veterans Affairs [C3638R]; Illinois Society for the
Prevention of Blindness; Richard A. Peritt Charitable Foundation
FX Supported in part by grants from the Department of Veterans Affairs
(C3638R), the Illinois Society for the Prevention of Blindness, and the
Richard A. Peritt Charitable Foundation. CVZ is a recipient of a
Pre-Doctoral Associated Health Rehabilitation Research Fellowship from
the Department of Veterans Affairs.
NR 39
TC 9
Z9 9
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2009
VL 50
IS 6
BP 2816
EP 2823
DI 10.1167/iovs.08-2466
PG 8
WC Ophthalmology
SC Ophthalmology
GA 450ME
UT WOS:000266403800040
PM 19151402
ER
PT J
AU Meredith, CW
Jaffe, C
Cherrier, M
Robinson, JP
Malte, CA
Yanasak, EV
Kennedy, A
Ferguson, LC
Tapp, AM
Saxon, AJ
AF Meredith, Charles W.
Jaffe, Craig
Cherrier, Monique
Robinson, Joseph P.
Malte, Carol A.
Yanasak, Elisia V.
Kennedy, Annette
Ferguson, Laura C.
tapp, Andre M.
Saxon, Andrew J.
TI Open Trial of Injectable Risperidone for Methamphetamine Dependence
SO JOURNAL OF ADDICTION MEDICINE
LA English
DT Article
DE methamphetamine; risperidone; injection; neuropsychological function;
psychiatric symptoms; addiction severity
ID PLACEBO-CONTROLLED TRIAL; RATING-SCALE; D-AMPHETAMINE; DRUG-SEEKING;
OPEN-LABEL; COCAINE; ANTIPSYCHOTICS; DISORDER; RELAPSE; ABUSERS
AB We tested acceptability and tolerability of long-acting injectable risperidone for methamphetamine (MA) dependence in all open trial with the hypothesis that participants would reduce MA use. Participants were also evaluated for changes in neurocognitive function and psychiatric symptomology. Participants with MA dependence (n = 34) entered a 7-day open-label run-in with oral risperidone. Participants who tolerated oral risperidone (n = 22) were begun on long-acting injectable risperidone 25 mg intramuscular medication with subsequent injections q 2 weeks to a total of 4 injections. Participants remained on oral risperidone during the first 3 weeks after initial injection. Participants were offered 8 weekly individual sessions of relapse prevention counseling. At baseline, participants reported using MA an average of 4.1 days per week (SD = 1.9). Estimated mean days of MA use per week while on injections was 1.0 (95% confidence interval = 0.6-1.4), with days of use decreasing significantly from baseline through week 8 (beta = -0.27; 95% confidence interval: -0.38--0.16; P < 0.001). Mean week 6 risperidone + 9-OH risperidone plasma levels for participants abstinent from MA from weeks 5 to 8 (n = 7, 63.6%) were 18.8 ng/mL (SD = 6.6) compared with 12.3 (SD = 4.0) for those not abstinent n = 4; P = 0.075). No serious adverse events Occurred. Verbal memory improved at week 4 compared with baseline (P < 0.05). Participation in this trial of injectable risperidone was associated with reductions in MA use as well as some positive benefits on verbal memory. However, these results are limited by the use of an open trial design with a high dropout rate. Risperidone deserves further study in controlled trials as a pharmacotherapy for MA dependence.
C1 [Meredith, Charles W.; Robinson, Joseph P.; Malte, Carol A.; Yanasak, Elisia V.; Kennedy, Annette; Ferguson, Laura C.; tapp, Andre M.; Saxon, Andrew J.] VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA USA.
[Malte, Carol A.; Ferguson, Laura C.; Saxon, Andrew J.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
[Meredith, Charles W.; Jaffe, Craig; Cherrier, Monique; Ferguson, Laura C.; tapp, Andre M.; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Meredith, CW (reprint author), VA Puget Sound Hlth Care Syst, Mental Hlth Serv, S-116A,1660 S Columbian Wy, Seattle, WA USA.
EM Charles.meredith@va.gov
FU Ortho-McNeil Janssen Scientific Affairs LLC; Center of Excellence in
Substance Abuse Treatment and Education, VA Puget Sound Health Care
System; AstraZeneca; Eli Lilly
FX Supported by a grant from Ortho-McNeil Janssen Scientific Affairs LLC
and by the Center of Excellence in Substance Abuse Treatment and
Education, VA Puget Sound Health Care System.; Dr. Cherrier has provided
consultation to Solvay, file. and Merck, Inc.; Dr. Tapp has been on the
speaker's bureau and has received honoraria from AstraZeneca, Eli Lilly,
and Janssen and has received research support front AstraZeneca and Eli
Lilly.
NR 63
TC 6
Z9 6
U1 3
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1932-0620
EI 1935-3227
J9 J ADDICT MED
JI J. Addict. Med.
PD JUN
PY 2009
VL 3
IS 2
BP 55
EP 65
PG 11
WC Substance Abuse
SC Substance Abuse
GA 452BT
UT WOS:000266515300002
PM 21769001
ER
PT J
AU Gupta, RS
Zhang, XY
Sharp, LK
Shannon, JJ
Weiss, KB
AF Gupta, Ruchi S.
Zhang, Xingyou
Sharp, Lisa K.
Shannon, John J.
Weiss, Kevin B.
TI The protective effect of community factors on childhood asthma
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Asthma; prevalence; community; neighborhood; childhood; environment;
social capital; disparity
ID INNER-CITY ASTHMA; SCHOOL-AGE-CHILDREN; HOUSE-DUST MITE;
SOCIOECONOMIC-STATUS; AIR-POLLUTION; BIRTH-COHORT; ENVIRONMENTAL
INTERVENTION; PSYCHOSOCIAL FACTORS; COCKROACH ALLERGEN; NITROGEN-DIOXIDE
AB Background: Asthma burden in the US is not evenly distributed. Although asthma prevalence varies widely across urban neighborhoods, little attention has been paid to the community as a key contributor.
Objective: To determine the effect of positive socio-environmental community factors on childhood asthma prevalence in Chicago.
Methods: From 2003 to 2005, an asthma screening survey was conducted among children attending Chicago Public/Catholic schools from kindergarten through eighth grade. One hundred five schools participated, yielding a stratified representation of 4 race-income groups. Positive community factors, such as social capital, economic potential, and community amenities, were assessed by using the Metro Chicago Information Center's Community Vitality Index.
Results: Of the surveys returned, 45,177 (92%) were geocoded into 287 neighborhoods. Neighborhoods were divided into quartile groups by asthma prevalence (mean, 8%, 12%, 17%, 25%). Community vitality (54% vs 44%; P < .0001) and economic potential (64% vs 38%; P < .0001) were significantly higher in neighborhoods with low asthma prevalence. Neighborhood interaction (36% vs 73%; P < .0001) and stability (40% vs 53%; P < .0001) were significantly higher in neighborhoods with high asthma prevalence. Overall, positive factors explained 21% of asthma variation. Childhood asthma increased as the black population increased in a community (P < .0001). Accordingly, race/ethnicity was controlled. In black neighborhoods, these factors remained significantly higher in neighborhoods with low asthma prevalence. When considered alongside socio-demographic/individual characteristics, overall community vitality as well as social capital continued to contribute significantly to asthma variation.
Conclusion: Asthma prevalence in Chicago is strongly associated with socio-environmental factors thought to enrich a community. A deeper understanding of this impact may lend insight into interventions to reduce childhood asthma. (J Allergy Clin Immunol 2009;123:1297-304.)
C1 [Gupta, Ruchi S.] Childrens Mem Hosp, Chicago, IL 60614 USA.
[Gupta, Ruchi S.; Weiss, Kevin B.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA.
[Weiss, Kevin B.] Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL 60611 USA.
[Zhang, Xingyou] Amer Acad Family Physicians, Robert Graham Ctr Policy Studies Family Med & Pri, Washington, DC USA.
[Sharp, Lisa K.] Univ Illinois, Dept Med, Sect Hlth Promot, Chicago, IL USA.
[Shannon, John J.] Cook Cty Hosp, Dept Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA.
[Weiss, Kevin B.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA.
RP Gupta, RS (reprint author), Childrens Mem Hosp, 2300 Childrens Plaza,Box 157, Chicago, IL 60614 USA.
EM rugupta@childrensmemorial.org
FU National Heart, Lung, and Blood Institute [5U01 HL072478-05]; National
Institute of Child Health and Human Development [K 12 HD052902]
FX Supported by National Heart, Lung, and Blood Institute grant 5U01
HL072478-05 and National Institute of Child Health and Human Development
grant K 12 HD052902.
NR 59
TC 21
Z9 21
U1 7
U2 14
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JUN
PY 2009
VL 123
IS 6
BP 1297
EP 1304
DI 10.1016/j.jaci.2009.03.039
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA 455WO
UT WOS:000266799100020
PM 19450873
ER
PT J
AU Frueh, BC
Grubaugh, AL
Cusack, KJ
Kimble, MO
Elhai, JD
Knapp, RG
AF Frueh, B. Christopher
Grubaugh, Anoluk L.
Cusack, Karen J.
Kimble, Matthew O.
Elhai, Jon D.
Knapp, Rebecca G.
TI Exposure-based cognitive-behavioral treatment of PTSD in adults with
schizophrenia or schizoaffective disorder: A pilot study
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE PTSD; Trauma; Severe mental illness (SMI); Schizophrenia; Exposure
therapy; Cognitive-behavioral therapy
ID POSTTRAUMATIC-STRESS-DISORDER; SEVERE MENTAL-ILLNESS; RANDOMIZED
CONTROLLED-TRIAL; TRAUMA MANAGEMENT THERAPY; COMBAT-RELATED PTSD;
SOUTH-CAROLINA; HEALTH; VICTIMS; SCALE; VETERANS
AB In an open trial design, adults (n = 20) with posttraumatic stress disorder (PTSD) and either schizophrenia or schizoaffective disorder were treated via an 11-week cognitive-behavioral intervention for PTSD that consisted of education, anxiety management therapy, social skills training and exposure, therapy, provided at Community mental health centers. Results offer preliminary hope for effective treatment of PTSD among adults with schizophrenia or schizoaffective disorder, especially among treatment completers (n = 13). Data showed significant PTSD symptom improvement maintained at 3, month follow-tip. Further, 12 of 13 completers no longer met criteria for PTSD or were considered treatment responders. Clinical Outcomes for other targeted domains (e.g., anger, general mental health) also improved and were maintained at 3-month follow-up. Participants evidenced high treatment satisfaction, with no adverse events. Significant improvements were not noted on depression, general anxiety,or physical health status. Future directions include the need for randomized controlled trials and dissemination efforts. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Frueh, B. Christopher] Baylor Coll Med, Menninger Clin, Houston, TX 77080 USA.
[Frueh, B. Christopher] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77080 USA.
[Grubaugh, Anoluk L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Grubaugh, Anoluk L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Cusack, Karen J.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA.
[Kimble, Matthew O.] Middlebury Coll, Dept Psychol, Middlebury, VT 05753 USA.
[Elhai, Jon D.] Univ S Dakota, Disaster Mental Hlth Inst, Vermillion, SD 57069 USA.
[Knapp, Rebecca G.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA.
RP Frueh, BC (reprint author), Baylor Coll Med, Menninger Clin, 2801 Gessner Dr, Houston, TX 77080 USA.
EM frueh@hawaii.edu
FU NIMH NIH HHS [K24 MH074468, K24 MH074468-01A1, K24 MH074468-02, K24
MH074468-03, MH065248, MH074468, R21 MH065248, R21 MH065248-01A1, R21
MH065248-02, R21 MH065248-02S1, R21 MH065248-03]
NR 82
TC 65
Z9 65
U1 7
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD JUN
PY 2009
VL 23
IS 5
BP 665
EP 675
DI 10.1016/j.janxdis.2009.02.005
PG 11
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 439WG
UT WOS:000265657700015
PM 19342194
ER
PT J
AU Bensing, BA
Sullam, PM
AF Bensing, Barbara A.
Sullam, Paul M.
TI Characterization of Streptococcus gordonii SecA2 as a Paralogue of SecA
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article
ID BINDING-PROTEIN-GSPB; SURFACE GLYCOPROTEINS GSPB; ESCHERICHIA-COLI SECA;
MYCOBACTERIUM-TUBERCULOSIS; TRANSLOCASE MOTOR; HUMAN PLATELETS; ATPASE
ACTIVITY; IB-ALPHA; SECRETION; EXPORT
AB The accessory Sec system of Streptococcus gordonii is essential for transport of the glycoprotein GspB to the bacterial cell surface. A key component of this dedicated transport system is SecA2. The SecA2 proteins of streptococci and staphylococci are paralogues of SecA and are presumed to have an analogous role in protein transport, but they may be specifically adapted for the transport of large, serine-rich glycoproteins. We used a combination of genetic and biochemical methods to assess whether the S. gordonii SecA2 functions similarly to SecA. Although mutational analyses demonstrated that conserved amino acids are essential for the function of SecA2, replacing such residues in one of two nucleotide binding folds had only minor effects on SecA2 function. SecA2-mediated transport is highly sensitive to azide, as is SecA-mediated transport. Comparison of the S. gordonii SecA and SecA2 proteins in vitro revealed that SecA2 can hydrolyze ATP at a rate similar to that of SecA and is comparably sensitive to azide but that the biochemical properties of these enzymes are subtly different. That is, SecA2 has a lower solubility in aqueous solutions and requires higher Mg(2+) concentrations for maximal activity. In spite of the high degree of similarity between the S. gordonii paralogues, analysis of SecA-SecA2 chimeras indicates that the domains are not readily interchangeable. This suggests that specific, unique contacts between SecA2 and other components of the accessory Sec system may preclude cross-functioning with the canonical Sec system.
C1 San Francisco VA Med Ctr, San Francisco, CA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Sullam, PM (reprint author), Vet Adm Med Ctr, Div Infect Dis, 111W,4150 Clement St, San Francisco, CA 94121 USA.
EM paul.sullam@ucsf.edu
FU National Institutes of Health [RO1AI41513, RO1AI057433]
FX We thank R. Seepersaud for critical reading of the manuscript.
NR 57
TC 20
Z9 20
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD JUN
PY 2009
VL 191
IS 11
BP 3482
EP 3491
DI 10.1128/JB.00365-09
PG 10
WC Microbiology
SC Microbiology
GA 445HG
UT WOS:000266041300007
PM 19363114
ER
PT J
AU Spokas, M
Luterek, JA
Heimberg, RG
AF Spokas, Megan
Luterek, Jane A.
Heimberg, Richard G.
TI Social anxiety and emotional suppression: The mediating role of beliefs
SO JOURNAL OF BEHAVIOR THERAPY AND EXPERIMENTAL PSYCHIATRY
LA English
DT Article
DE Social anxiety; Emotion; Emotional suppression; Beliefs
ID PHOBIA SCALE; PSYCHOLOGICAL-RESEARCH; POSITIVE EMOTIONS; PANIC DISORDER;
EXPRESSION; ALEXITHYMIA; VALIDATION; ATTITUDES; VALIDITY; MODEL
AB There is mounting evidence to suggest that social anxiety is associated with the suppression of emotional expression. The current study examined self-reported emotional suppression and beliefs about expressing emotions among undergraduate students (n = 95). Socially anxious undergraduates reported greater use of emotional suppression compared to their non-socially anxious peers. They also reported greater ambivalence about emotional expression, more difficulties in emotional responding, more fears of emotional experiences, and more negative beliefs about emotional expression. Believing that emotional expression must be kept in control and is a sign of weakness partially mediated the association between social anxiety and emotional suppression. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Spokas, Megan] Univ Penn, Dept Psychiat, Psychopathol Res Unit, Philadelphia, PA 19104 USA.
[Luterek, Jane A.] Mental Illness Res Educ & Clin Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Luterek, Jane A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Heimberg, Richard G.] Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA.
RP Spokas, M (reprint author), Univ Penn, Dept Psychiat, Psychopathol Res Unit, 3535 Market St,Room 2029, Philadelphia, PA 19104 USA.
EM mspokas@mail.med.upenn.edu; jane.luterek@va.gov; heimberg@temple.edu
NR 40
TC 42
Z9 43
U1 4
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0005-7916
J9 J BEHAV THER EXP PSY
JI J. Behav. Ther. Exp. Psychiatry
PD JUN
PY 2009
VL 40
IS 2
BP 283
EP 291
DI 10.1016/j.jbtep.2008.12.004
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 443EI
UT WOS:000265892600011
PM 19135648
ER
PT J
AU Matioc, AA
AF Matioc, Adrian A.
TI The adult ergonomic face mask concept: historical and theoretical
perspectives
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Article
DE Airway management; Airway obstruction; Face mask: Ergonomic face mask
ID UNCONSCIOUS PATIENT; UNPROTECTED AIRWAY; GENERAL-ANESTHESIA;
VENTILATION; RESUSCITATION; DIFFICULT; OBSTRUCTION; GUIDELINES;
MANAGEMENT; POSITION
AB The fundamental skill required of the anesthesiologist and rescuer is to treat upper airway obstruction and maintain adequate ventilation. Adult one-hand face mask ventilation is a complex technique, often applied with suboptimal results. The adult face mask in use today was not designed for one-handed ventilation but inherited its features from the 19(th) century face piece. The airway maneuver used with one-handed ventilation is not standardized. An ergonomic face mask has an asymmetrical dome that accommodates the hand grip required for chin lift and may be better for one-hand ventilation. The historical and theoretical considerations patent to the design and technique of the ergonomic face mask are reviewed. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Matioc, Adrian A.] William S Middleton Mem Vet Adm Med Ctr, Dept Anesthesiol, VA Med Ctr, Madison, WI 53705 USA.
[Matioc, Adrian A.] Univ Wisconsin, Hosp & Clin, Dept Anesthesiol, Madison, WI 53792 USA.
RP Matioc, AA (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Anesthesiol, VA Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM adrian.matioc@va.gov
NR 40
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0952-8180
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD JUN
PY 2009
VL 21
IS 4
BP 300
EP 304
DI 10.1016/j.jclinane.2008.08.018
PG 5
WC Anesthesiology
SC Anesthesiology
GA 464JP
UT WOS:000267501500014
PM 19502042
ER
PT J
AU Calleo, J
Stanley, MA
Greisinger, A
Wehmanen, O
Johnson, M
Novy, D
Wilson, N
Kunik, M
AF Calleo, Jessica
Stanley, Melinda A.
Greisinger, Anthony
Wehmanen, Oscar
Johnson, Michael
Novy, Diane
Wilson, Nancy
Kunik, Mark
TI Generalized Anxiety Disorder in Older Medical Patients: Diagnostic
Recognition, Mental Health Management and Service Utilization
SO JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS
LA English
DT Article
DE Generalized anxiety disorder; Primary care; Older patients; Database
study; Medical record review
ID PRIMARY-CARE PATIENTS; UNITED-STATES; PREVALENCE; SYMPTOMS; QUALITY;
ISSUES; COST
AB Background Primary care physicians often treat older adults with Generalized Anxiety Disorder. Objective To estimate physician diagnosis and recognition of anxiety and compare health service use among older adults with GAD with two comparison samples with and without other DSM diagnoses. Methods Participants were 60+ patients of a multi-specialty medical organization. Administrative database and medical records were reviewed for a year. Differences in frequency of health service use were analyzed with logistic regression and between-subjects analysis of covariance. Results Physician diagnosis of GAD was 1.5% and any anxiety was 9%, and recognition of anxiety symptoms was 34% in older adults with GAD. After controlling for medical comorbidity, radiology appointments were increased in the GAD group relative to those with and without other psychiatric diagnoses, chi(2) (2, N = 225) = 4.75, p < .05. Conclusions Most patients with anxiety do not have anxiety or symptoms documented in their medical records.
C1 [Stanley, Melinda A.; Johnson, Michael; Wilson, Nancy; Kunik, Mark] Michael E DeBakey VAMC 152, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA.
[Calleo, Jessica; Stanley, Melinda A.; Wilson, Nancy; Kunik, Mark] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Greisinger, Anthony; Wehmanen, Oscar] Kelsey Res Fdn, Houston, TX USA.
[Johnson, Michael] Univ Houston, Coll Pharm, Dept Clin Sci & Adm, Houston, TX 77030 USA.
[Novy, Diane] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Pain Med, Houston, TX 77030 USA.
[Kunik, Mark] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Kunik, Mark] Educ & Clin Ctr, VA S Cent Mental Illness Res, N Little Rock, AR USA.
[Kunik, Mark] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
RP Kunik, M (reprint author), Michael E DeBakey VAMC 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe, Houston, TX 77030 USA.
EM mkunik@bcm.tmc.edu
FU NIMH NIH HHS [R01 MH053932, R01 MH053932-09, R01MH053932]
NR 28
TC 25
Z9 26
U1 1
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9583
J9 J CLIN PSYCHOL MED S
JI J. Clin. Psychol. Med. Settings
PD JUN
PY 2009
VL 16
IS 2
BP 178
EP 185
DI 10.1007/s10880-008-9144-5
PG 8
WC Psychology, Clinical
SC Psychology
GA 443NZ
UT WOS:000265918300005
PM 19152056
ER
PT J
AU Tatum, RP
Pellegrini, CA
AF Tatum, Roger P.
Pellegrini, Carlos A.
TI How I Do It: Laparoscopic Heller Myotomy with Toupet Fundoplication for
Achalasia
SO JOURNAL OF GASTROINTESTINAL SURGERY
LA English
DT Article
DE Achalasia; Heller myotomy; Antireflux procedure
ID MINIMALLY INVASIVE SURGERY; 8-YEAR EXPERIENCE
AB Achalasia, an esophageal motility disorder characterized by aperistalsis and failure of lower esophageal sphincter (LES) relaxation, is most effectively treated by surgical ablation of the LES. In this report, we describe our technique of laparoscopic extended Heller myotomy with Toupet partial posterior fundoplication. The technical details of this procedure include careful division of the longitudinal and circular muscle fibers of the LES anteriorly, including extension of the myotomy 3 cm distal to the esophagogastric junction onto the gastric cardia. The Toupet procedure, involving a posterior wrap of the gastric fundus which is secured to both edges of the myotomy as well as to the crura of the hiatus, is added to prevent post-myotomy gastroesophageal reflux. From a recently published report, mean dysphagia scores remained low (3 out of 10 severity on a visual analog scale) and symptoms of reflux were reported minimally in a series of 63 patients followed for a median of 45 months. This technique provides excellent and durable relief of dysphagia associated with achalasia while minimizing post-myotomy acid reflux symptoms.
C1 [Tatum, Roger P.; Pellegrini, Carlos A.] Univ Washington, Dept Surg, VA Puget Sound HCS, Seattle, WA 98108 USA.
RP Tatum, RP (reprint author), Univ Washington, Dept Surg, VA Puget Sound HCS, 1660 S Columbian Way,S-112 Gs, Seattle, WA 98108 USA.
EM rtatum@u.washington.edu
NR 13
TC 9
Z9 9
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1091-255X
J9 J GASTROINTEST SURG
JI J. Gastrointest. Surg.
PD JUN
PY 2009
VL 13
IS 6
BP 1120
EP 1124
DI 10.1007/s11605-008-0585-9
PG 5
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 440FM
UT WOS:000265686200019
PM 18622657
ER
PT J
AU Krebs, EE
Lorenz, KA
Bair, MJ
Damush, TM
Wu, JW
Sutherland, JM
Asch, SM
Kroenke, K
AF Krebs, Erin E.
Lorenz, Karl A.
Bair, Matthew J.
Damush, Teresa M.
Wu, Jingwei
Sutherland, Jason M.
Asch, Steven M.
Kroenke, Kurt
TI Development and Initial Validation of the PEG, a Three-item Scale
Assessing Pain Intensity and Interference
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE pain; measurement; primary care
ID LOW-BACK-PAIN; PRIMARY-CARE; IMMPACT RECOMMENDATIONS; CLINICAL-TRIALS;
HEALTH-STATUS; SHORT-FORM; VALIDITY; OUTCOMES; RESPONSIVENESS;
RELIABILITY
AB Inadequate pain assessment is a barrier to appropriate pain management, but single-item "pain screening" provides limited information about chronic pain. Multidimensional pain measures such as the Brief Pain Inventory (BPI) are widely used in pain specialty and research settings, but are impractical for primary care. A brief and straightforward multidimensional pain measure could potentially improve initial assessment and follow-up of chronic pain in primary care.
To develop an ultra-brief pain measure derived from the BPI.
Development of a shortened three-item pain measure and initial assessment of its reliability, validity, and responsiveness.
We used data from 1) a longitudinal study of 500 primary care patients with chronic pain and 2) a cross-sectional study of 646 veterans recruited from ambulatory care.
Selected items assess average pain intensity (P), interference with enjoyment of life (E), and interference with general activity (G). Reliability of the three-item scale (PEG) was alpha = 0.73 and 0.89 in the two study samples. Overall, construct validity of the PEG was good for various pain-specific measures (r = 0.60-0.89 in Study 1 and r = 0.77-0.95 in Study 2), and comparable to that of the BPI. The PEG was sensitive to change and differentiated between patients with and without pain improvement at 6 months.
We provide strong initial evidence for reliability, construct validity, and responsiveness of the PEG among primary care and other ambulatory clinic patients. The PEG may be a practical and useful tool to improve assessment and monitoring of chronic pain in primary care.
C1 [Krebs, Erin E.; Bair, Matthew J.; Damush, Teresa M.; Kroenke, Kurt] Regenstrief Inst Inc, Indianapolis, IN USA.
[Krebs, Erin E.; Bair, Matthew J.; Damush, Teresa M.; Wu, Jingwei; Kroenke, Kurt] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA.
[Sutherland, Jason M.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH 03756 USA.
[Lorenz, Karl A.; Asch, Steven M.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Lorenz, Karl A.; Asch, Steven M.] RAND Corp, Santa Monica, CA USA.
[Lorenz, Karl A.; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Krebs, Erin E.; Bair, Matthew J.; Damush, Teresa M.; Kroenke, Kurt] Roudebush VAMC, Ctr Implementing Evidence Based Practice, Indianapolis, IN 46202 USA.
RP Krebs, EE (reprint author), Roudebush VAMC, Ctr Implementing Evidence Based Practice, 11H,1481 W 10th St, Indianapolis, IN 46202 USA.
EM krebse@iupui.edu
FU National Institute of Mental Health [MH-071268]; Health Services
Research & Development (HSRD); US Department of Veterans Affairs
[IIR-03-150]; VA HSRD
FX SCAMP was supported by a grant from the National Institute of Mental
Health to Dr. Kroenke (MH-071268). HELP-Vets was supported by the Health
Services Research & Development (HSR&D) service of the US Department of
Veterans Affairs (IIR-03-150). Drs. Krebs, Lorenz, and Bair were
supported by VA HSR&D Research Career Development Awards.
NR 41
TC 68
Z9 68
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2009
VL 24
IS 6
BP 733
EP 738
DI 10.1007/s11606-009-0981-1
PG 6
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 448CV
UT WOS:000266241300007
PM 19418100
ER
PT J
AU Kramer, BJ
Vivrette, RL
Satter, DE
Jouldjian, S
McDonald, LR
AF Kramer, B. Josea
Vivrette, Rebecca L.
Satter, Delight E.
Jouldjian, Stella
McDonald, Leander Russell
TI Dual Use of Veterans Health Administration and Indian Health Service:
Healthcare Provider and Patient Perspectives
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE veterans; rural health; qualitative research; patient preferences;
health services research
ID AMERICAN-INDIANS; AMBULATORY-CARE; AFFAIRS; ACCESS; MEDICARE; VA;
NATIVES; POLICY
AB Many American Indian and Alaska Native veterans are eligible for healthcare from Veterans Health Administration (VHA) and from Indian Health Service (IHS). These organizations executed a Memorandum of Understanding in 2003 to share resources, but little was known about how they collaborated to deliver healthcare.
To describe dual use from the stakeholders' perspectives, including incentives that encourage cross-use, which organization's primary care is "primary," and the potential problems and opportunities for care coordination across VHA and IHS.
VHA healthcare staff, IHS healthcare staff and American Indian and Alaska Native veterans.
Focus groups were conducted using a semi-structured guide. A software-assisted text analysis was performed using grounded theory to develop analytic categories.
Dual use was driven by variation in institutional resources, leading patients to actively manage health-seeking behaviors and IHS providers to make ad hoc recommendations for veterans to seek care at VHA. IHS was the "primary" primary care for dual users. There was little coordination between VHA and IHS resulting in delays and treatment conflicts, but all stakeholder groups welcomed future collaboration.
Fostering closer alignment between VHA and IHS would reduce care fragmentation and improve accountability for patient care.
C1 [Kramer, B. Josea; Vivrette, Rebecca L.; Jouldjian, Stella] VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA 91343 USA.
[Kramer, B. Josea] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Satter, Delight E.] Univ Calif Los Angeles, Ctr Healthcare Policy & Res, Los Angeles, CA 90024 USA.
[McDonald, Leander Russell] Cankdeska Cikana Community Coll, Ft Totten, ND 58335 USA.
RP Kramer, BJ (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, 16111 Plummer St, Sepulveda, CA 91343 USA.
EM Josea.Kramer@va.gov
FU VA Health Services Research and Development Service [ACC 03-304]
FX This study, "VA and Indian Health Service: Access for American Indian
Veterans," was funded by the VA Health Services Research and Development
Service, ACC 03-304. We gratefully acknowledge the advice of the study's
national VHA-IHS Advisory Committee and Elizabeth M. Yano, PhD, MSPH, of
the VA Center for the Study of Healthcare Provider Behavior, for their
comments and suggestions on this article. The project also benefited
from technical assistance in developing the moderator discussion guide
from Melissa Scherwinski, MSW of the VA Employee Education System,
Steven P. Wallace, PhD of UCLA Center for Healthcare Policy and Diane
Weiner, PhD, consulting anthropologist. We also acknowledge the
assistance of local site principle investigators at the participating
Veterans Health Administration (VHA) and Indian Health Service (IHS)
facilities, and thank the Tribal Councils for allowing us to conduct
focus groups with stakeholders in their respective communities. This
report presents findings and conclusions of the authors; it does not
necessarily reflect the opinions or policies of the Department of
Veterans Affairs or the Indian Health Service.
NR 38
TC 12
Z9 12
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2009
VL 24
IS 6
BP 758
EP 764
DI 10.1007/s11606-009-0962-4
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 448CV
UT WOS:000266241300012
PM 19381730
ER
PT J
AU Dhaliwal, G
AF Dhaliwal, Gurpreet
TI Teaching Medicine to Non-English Speaking Background Learners in a
Foreign Country
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE Non-English speaking background; English as a second language; Medical
education; International teaching
ID EDUCATION; REFORM; JAPAN
AB Teaching abroad exposes medical educators to unfamiliar teaching methods and learning styles that can enhance their overall teaching repertoire. Based on the author's experience teaching residents for one month at a community hospital in Japan and a review of the non-English speaking background (NESB) educational literature, pedagogical principles and lessons for successful international NESB instruction are outlined. These methods include understanding the dissimilar linguistic, cultural, and academic backgrounds of the learners, emphasizing pace and clarity of speech, presenting a conceptual framework instead of detailed discourse on subjects, and regular visual reinforcement of spoken words. The limitations introduced by the language barrier and the use of interpreters are briefly discussed. As society and institutions of higher learning become more global and multicultural, clinician-educators may benefit from teaching in other countries in order to enhance their teaching skills with NESB learners, both abroad and in their own institutions.
C1 [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Dhaliwal, Gurpreet] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Dhaliwal, G (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111, San Francisco, CA 94121 USA.
EM gurpreet.dhaliwal@va.gov
NR 15
TC 2
Z9 2
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2009
VL 24
IS 6
BP 771
EP 773
DI 10.1007/s11606-009-0967-z
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 448CV
UT WOS:000266241300014
PM 19381729
ER
PT J
AU Andersson, A
Yang, SC
Huang, M
Zhu, L
Kar, UK
Batra, RK
Elashoff, D
Strieter, RM
Dubinett, SM
Sharma, S
AF Andersson, Asa
Yang, Seok-Chul
Huang, Min
Zhu, Li
Kar, Upendra K.
Batra, Rai K.
Elashoff, David
Strieter, Robert M.
Dubinett, Steven M.
Sharma, Sherven
TI IL-7 Promotes CXCR3 Ligand-Dependent T Cell Antitumor Reactivity in Lung
Cancer
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID REGULATORY CELLS; OVARIAN-CANCER; CUTTING EDGE; INTERLEUKIN-7; FOXP3;
EXPRESSION; CARCINOMA; LYMPHOCYTES; HOMEOSTASIS; PROGNOSIS
AB We are evaluating the immune enhancing activities of cytokines for their optimum utility in augmenting cellular immune responses against lung cancer. In this study, we evaluated the mechanism of antitumor responses following IL-7 administration to mice bearing established Lewis lung cancer. IL-7 decreased tumor burden with concomitant increases in the frequency of CD4 and CD8 T lymphocyte subsets, T cell activation markers CXCR3, CD69, and CD127(low), effector memory T cells, and T cell cytolytic activity against parental tumor cells. Accompanying the antitumor responses were increases in IFN-gamma, CXCL9, CXCL10, and IL-12. Individual neutralization of CD4, CD8 T lymphocytes, or the CXCR3 ligands CXCL9 and CXCL10 reversed the antitumor benefit of IL-7, indicating their importance for optimal responses in vivo. Furthermore, IL-7 decreased the tumor-induced apoptosis of T cells with subsequent decrease of the proapoptotic marker Bim. We assessed the impact of IL-7 treatment on regulatory T cells that negatively impact antitumor immune responses. IL-7 decreased regulatory T Foxp3 as well as cell suppressive activity with a reciprocal increase in SMAD7. These results indicate that IL-7 induces CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. The Journal of Immunology, 2009, 182: 6951-6958.
C1 [Andersson, Asa; Huang, Min; Zhu, Li; Kar, Upendra K.; Batra, Rai K.; Elashoff, David; Dubinett, Steven M.; Sharma, Sherven] Univ Calif Los Angeles, Lung Canc Program, Div Pulm & Crit Care Med, Dept Med, Los Angeles, CA 90095 USA.
[Huang, Min; Zhu, Li; Batra, Rai K.; Dubinett, Steven M.; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Yang, Seok-Chul] Seoul Natl Univ Hosp, Dept Med, Div Pulm & Crit Care Med, Seoul 110744, South Korea.
[Huang, Min; Zhu, Li; Batra, Rai K.; Dubinett, Steven M.; Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Gene Med Lab, Los Angeles, CA 90073 USA.
[Strieter, Robert M.] Univ Virginia, Dept Med, Div Cardiol, Charlottesville, VA 22903 USA.
[Strieter, Robert M.] Univ Virginia, Div Pulm & Crit Care Med, Charlottesville, VA 22903 USA.
RP Sharma, S (reprint author), Univ Calif Los Angeles, Lung Canc Program, Div Pulm & Crit Care Med, Dept Med, 10833 Conte Ave, Los Angeles, CA 90095 USA.
EM ssharma@mednet.ucla.edu
OI Batra, Raj K./0000-0002-1126-543X
FU National Institutes of Health [R01 CA85686, R01 CA 126944]; University
of California Los Angeles Lung Cancer SPORE [P50 CA90388]; Department of
Veteran Affairs Medical Research Funds; Tobacco Related Disease Program
Award Program of the University of California
FX This work was supported by National Institutes of Health Grants R01
CA85686 and R01 CA 126944 and University of California Los Angeles Lung
Cancer SPORE P50 CA90388, Department of Veteran Affairs Medical Research
Funds, and Tobacco Related Disease Program Award Program of the
University of California.
NR 47
TC 41
Z9 45
U1 2
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUN 1
PY 2009
VL 182
IS 11
BP 6951
EP 6958
DI 10.4049/jimmunol.0803340
PG 8
WC Immunology
SC Immunology
GA 448JG
UT WOS:000266258300039
PM 19454692
ER
PT J
AU Johnson, S
AF Johnson, Stuart
TI Recurrent Clostridium difficile infection: A review of risk factors,
treatments, and outcomes
SO JOURNAL OF INFECTION
LA English
DT Review
DE Clostridum difficile; Vancomycin; Metronidazole; Diarrhea
ID PLACEBO-CONTROLLED TRIAL; IN-VITRO ACTIVITY; SACCHAROMYCES-BOULARDII;
MULTIPLE RELAPSES; ANTIBODY-RESPONSE; TOXIN-A; DIARRHEA; DISEASE;
COLITIS; METRONIDAZOLE
AB Episodes of recurrent Clostridium difficile infection (CDI) are difficult to treat for several reasons. Foremost, data are tacking to support any particular treatment strategy. In addition, treatment of recurrent episodes is not always successful, and repeated, prolonged treatment is often necessary. Identification of subgroups at risk for recurrent CDI may aid in diagnosing and treating these patients. Two likely mechanistic factors increasing the risk of recurrent CDI are an inadequate immune response to C. difficile toxins and persistent disruption of the normal colonic flora. Important epidemiologic risk factors include advanced age, continuation of other antibiotics, and prolonged hospital stays. Current guidelines recommend that the first recurrent episode be treated with the same agent (i.e., metronidazole or vancomycin) used for the index episode. However, if the first recurrence is characterized as severe, vancomycin should be used. A reasonable strategy for managing a subsequent episode involves tapering followed by pulsed doses of vancomycin. Other potentially effective strategies for recurrent CDI include vancomycin with adjunctive treatments, such as Socchoromyces boulardii, rifaximin "chaser" therapy after vancomycin, nitazoxanide, fecal transplantation, and intravenous immunoglobutin. New treatment agents that are active against C. difficile, but spare critical components of the normal flora, may decrease the incidence of recurrent CDI. Published by Elsevier Ltd on behalf of The British Infection Society.
C1 [Johnson, Stuart] Loyola Univ, Med Ctr, Infect Dis Sect, Stritch Sch Med, Maywood, IL 60153 USA.
[Johnson, Stuart] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
RP Johnson, S (reprint author), Loyola Univ, Med Ctr, Infect Dis Sect, Stritch Sch Med, 2160 S 1st Ave,Fahey Ctr Bldg 54,Room 149, Maywood, IL 60153 USA.
EM sjohnson@lumc.edu
FU ViroPharma Incorporated
FX The author thanks Marie Bialek, PharmD, and Robert Michael Healthcare
Alliance LLC for assistance in preparing this article. This work was
supported by a grant from ViroPharma Incorporated.
NR 59
TC 165
Z9 171
U1 3
U2 24
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
J9 J INFECTION
JI J. Infect.
PD JUN
PY 2009
VL 58
IS 6
BP 403
EP 410
DI 10.1016/j.jinf.2009.03.010
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 461UK
UT WOS:000267297400001
PM 19394704
ER
PT J
AU Doolittle, MH
Ben-Zeev, O
Bassilian, S
Whitelegge, JP
Peterfy, M
Wong, H
AF Doolittle, Mark H.
Ben-Zeev, Osnat
Bassilian, Sara
Whitelegge, Julian P.
Peterfy, Miklos
Wong, Howard
TI Hepatic lipase maturation: a partial proteome of interacting factors
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE protein folding; endoplasmic reticulum; chaperones; calnexin; tandem
affinity purification; mass spectrometry
ID COLLAGEN TRIPLE-HELIX; TANDEM AFFINITY PURIFICATION; ER QUALITY-CONTROL;
MULTIPLE EF-HAND; ENDOPLASMIC-RETICULUM; LIPOPROTEIN-LIPASE; SECRETORY
PATHWAY; MAMMALIAN-CELLS; CHAPERONE HSP47; MULTIPROTEIN COMPLEXES
AB Tandem affinity purification (TAP) has been used to isolate proteins that interact with human hepatic lipase (HL) during its maturation in Chinese hamster ovary cells. Using mass spectrometry and Western blotting, we identified 28 proteins in HL-TAP isolated complexes, 16 of which localized to the endoplasmic reticulum (ER), the site of HL folding and assembly. Of the 12 remaining proteins located outside the ER, five function in protein translation or ER-associated degradation (ERAD). Components of the two major ER chaperone systems were identified, the BiP/Grp94 and the calnexin (CNX)/calreticulin (CRT) systems. All factors involved in CNX/CRT chaperone cycling were identified, including UDP-glucose: glycoprotein glucosyltransferase 1 (UGGT), glucosidase II, and the 57 kDa oxidoreductase (ERp57). We also show that CNX, and not CRT, is the lectin chaperone of choice during HL maturation. Along with the 78 kDa glucose-regulated protein (Grp78; BiP) and the 94 kDa glucose-regulated protein (Grp94), an associated peptidyl-prolyl cis-trans isomerase and protein disulfide isomerase were also detected. Finally, several factors in ERAD were identified, and we provide evidence that terminally misfolded HL is degraded by the ubiquitin-mediated proteasomal pathway. We propose that newly synthesized HL emerging from the translocon first associates with CNX, ERp57, and glucosidase II, followed by repeated posttranslational cycles of CNX binding that is mediated by UGGT. BiP/Grp94 may stabilize misfolded HL during its transition between cycles of CNX binding and may help direct its eventual degradation.-Doolittle, M. H., O. Ben-Zeev, S. Bassilian, J. P. Whitelegge, M. Peterfy, and H. Wong. Hepatic lipase maturation: a partial proteome of interacting factors. J. Lipid Res. 2009. 50: 1173-1184.
C1 [Doolittle, Mark H.; Ben-Zeev, Osnat; Bassilian, Sara; Whitelegge, Julian P.; Peterfy, Miklos; Wong, Howard] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Doolittle, Mark H.; Ben-Zeev, Osnat; Peterfy, Miklos; Wong, Howard] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Bassilian, Sara; Whitelegge, Julian P.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA.
[Peterfy, Miklos] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
RP Doolittle, MH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
EM markdool@ucla.edu
FU Cedars-Sinai Medical Center; Department of Veterans Affairs; National
Institutes of Health [HL-24841]
FX This work was supported by the Cedars-Sinai Medical Center, the
Department of Veterans Affairs, and Grant HL-24841 from the National
Institutes of Health.
NR 69
TC 15
Z9 15
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
J9 J LIPID RES
JI J. Lipid Res.
PD JUN
PY 2009
VL 50
IS 6
BP 1173
EP 1184
DI 10.1194/jlr.M800603-JLR200
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 446IE
UT WOS:000266114500015
PM 19136429
ER
PT J
AU Mendez, MF
Chen, JWY
AF Mendez, Mario F.
Chen, James W. Y.
TI Epilepsy partialis continua with visual allesthesia
SO JOURNAL OF NEUROLOGY
LA English
DT Letter
C1 [Mendez, Mario F.; Chen, James W. Y.] VA Greater Angeles Healthcare Syst, Dept Neurol, Neurobehav Unit 116AF, Los Angeles, CA 90073 USA.
[Mendez, Mario F.; Chen, James W. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Mendez, MF (reprint author), VA Greater Angeles Healthcare Syst, Dept Neurol, Neurobehav Unit 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mmendez@ucla.edu
NR 9
TC 2
Z9 2
U1 0
U2 0
PU DR DIETRICH STEINKOPFF VERLAG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, 69121 HEIDELBERG, GERMANY
SN 0340-5354
J9 J NEUROL
JI J. Neurol.
PD JUN
PY 2009
VL 256
IS 6
BP 1009
EP 1011
DI 10.1007/s00415-009-5031-8
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 460WT
UT WOS:000267223100025
PM 19240953
ER
PT J
AU Kinkel, RP
Simon, J
O'Connor, PW
Kollman, C
AF Kinkel, R. P.
Simon, J.
O'Connor, P. W.
Kollman, C.
TI Long-term study of high-risk patients after a clinically isolated
syndrome: 10-year follow-up from CHAMPIONS
SO JOURNAL OF NEUROLOGY
LA English
DT Meeting Abstract
CT 19th Meeting of the European-Neurological-Society
CY JUN 20-24, 2009
CL Milan, ITALY
SP European Neurol Soc
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Portland VA Med Ctr, Portland, OR USA.
St Michaels Hosp, Toronto, ON M5B 1W8, Canada.
Hlth Res Fdn Inc, Jaeb Ctr, Tampa, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU DR DIETRICH STEINKOPFF VERLAG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, 69121 HEIDELBERG, GERMANY
SN 0340-5354
J9 J NEUROL
JI J. Neurol.
PD JUN
PY 2009
VL 256
BP S10
EP S10
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 473YO
UT WOS:000268248700022
ER
PT J
AU Lopez, OL
Becker, JT
Wahed, AS
Saxton, J
Sweet, RA
Wolk, DA
Klunk, W
DeKosky, ST
AF Lopez, O. L.
Becker, J. T.
Wahed, A. S.
Saxton, J.
Sweet, R. A.
Wolk, D. A.
Klunk, W.
DeKosky, S. T.
TI Long-term effects of the concomitant use of memantine with
cholinesterase inhibition in Alzheimer disease
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; LAST 2 DECADES;
RATING-SCALE; DOUBLE-BLIND; RECEIVING DONEPEZIL; NATURAL-HISTORY;
OPEN-LABEL; DEMENTIA; EFFICACY
AB Background: Patients using cholinesterase inhibitors (ChEIs) have a delay in nursing home (NH) admission compared with those who were not using the medication. There are no long-term studies of the effects of memantine in combination with ChEIs use in Alzheimer disease (AD). This study was conducted to examine the effects of ChEIs and memantine on time to death and time to NH admission.
Methods: Time to NH admission and death was examined in 943 probable AD patients who had at least a 1-year follow-up evaluation. Of these patients, 140 (14.9%) used both ChEIs and memantine, 387 (45.0%) used only ChEIs, and 416 (40.1%) used neither. The mean (SD) follow-up time was 62.3 (35.8) months. The analysis was conducted with multivariable Cox proportional hazard models controlling for critical covariates (ie, age, education level, gender, severity of the dementia, hypertension, diabetes mellitus, heart disease, psychiatric symptoms and use of psychotropic medications).
Results: Compared with those who never used cognitive enhancers, patients who used ChEIs had a significant delay in NH admission (HR: 0.37, 95% CI 0.27 to 0.49); this effect was significantly augmented with the addition of memantine (HR: 0.29, 95% CI 0.11 to 0.72) (memantine+ChEI vs ChEI alone). ChEIs alone, or in combination with memantine had no significant association on time to death.
Conclusions: This observational study revealed that the addition of the NMDA receptor antagonist memantine to the treatment of AD with ChEI significantly altered the treated history of AD by extending time to nursing home admission.
C1 [Lopez, O. L.; Becker, J. T.; Saxton, J.; Sweet, R. A.; Wolk, D. A.; Klunk, W.; DeKosky, S. T.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Lopez, O. L.; Becker, J. T.; Saxton, J.; Sweet, R. A.; Klunk, W.; DeKosky, S. T.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA.
[Lopez, O. L.; Becker, J. T.; Saxton, J.; Sweet, R. A.; Wolk, D. A.; Klunk, W.; DeKosky, S. T.] Univ Pittsburgh, Sch Med, Alzheimers Dis Res Ctr, Pittsburgh, PA 15261 USA.
[Becker, J. T.] Univ Pittsburgh, Sch Med, Dept Psychol, Pittsburgh, PA 15261 USA.
[Wahed, A. S.] Univ Pittsburgh, Sch Med, Dept Biostat, Pittsburgh, PA 15261 USA.
[Sweet, R. A.] VA Pittsburgh Hlth Care Syst, MIRECC, VISN 4, Pittsburgh, PA USA.
RP Lopez, OL (reprint author), 3501 Forbers Ave,Oxford Bldg,Suite 830, Pittsburgh, PA 15213 USA.
EM lopezol@upmc.edu
OI Klunk, William/0000-0001-5512-0251; Wahed, Abdus/0000-0001-6911-7221
FU National Institute on Aging [AG03705, AG05133, AG16976, AG20098,
AG027224]; VISN 4 Mental Illness Research Education and Clinical Center
(MIRECC); VA Pittsburgh Health Care System, Pittsburgh, Pennsylvania
FX This study was fully supported by grants AG03705, AG05133, AG16976,
AG20098 and AG027224 from the National Institute on Aging, and by VISN 4
Mental Illness Research Education and Clinical Center (MIRECC), VA
Pittsburgh Health Care System, Pittsburgh, Pennsylvania.
NR 55
TC 124
Z9 127
U1 2
U2 10
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD JUN
PY 2009
VL 80
IS 6
BP 600
EP 607
DI 10.1136/jnnp.2008.158964
PG 8
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 446HU
UT WOS:000266113500008
PM 19204022
ER
PT J
AU Arjomandi, M
Haight, T
Redberg, R
Gold, WM
AF Arjomandi, Mehrdad
Haight, Thaddeus
Redberg, Rita
Gold, Warren M.
TI Pulmonary Function Abnormalities in Never-Smoking Flight Attendants
Exposed to Secondhand Tobacco Smoke in the Aircraft Cabin
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID ACUTE CORONARY SYNDROMES; CARDIO2000 CASE-CONTROL; INDOOR AIR-POLLUTION;
TOTAL LUNG CAPACITY; PASSIVE SMOKING; HEART-DISEASE; CARBON-MONOXIDE;
HEALTH; ASSOCIATION; RISK
AB Objective: To determine whether the flight attendants who were exposed to secondhand tobacco smoke in the aircraft cabin have abnormal pulmonary function. Methods: We administered questionnaires and performed pulmonary function testing in 61 never-smoking female flight attendants who worked in active air crews before the smoking ban on commercial aircraft (preban). Results: Although the preban flight attendants had normal FVC, FEV(1) and FEV(1)/FVC ratio, they had significantly decreased flow at mid- and low-lung volumes, curvilinear flow-volume curves, and evidence of air trapping Furthermore, the flight attendants had significantly decreased diffusing capacity (77.5% +/- 11.2% predicted normal) with 51% having a diffusing copacity below their 95% normal prediction limit. Conclusions. This cohort of healthy never-smoking flight attendants who were exposed. to secondhand tobacco smoke in the aircraft cabin showed pulmonary function abnormalities suggestive of airway obstruction and impaired diffusion. (J Occup Environ Med. 2009;5.1:639-646)
C1 [Gold, Warren M.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, San Francisco, CA 94143 USA.
[Arjomandi, Mehrdad; Redberg, Rita; Gold, Warren M.] Univ Calif San Francisco, FAMRI Ctr Excellence, San Francisco, CA 94143 USA.
[Gold, Warren M.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.
[Arjomandi, Mehrdad] San Francisco VA Med Ctr, San Francisco, CA USA.
[Haight, Thaddeus] Univ Calif San Francisco, Sch Publ Hlth, San Francisco, CA 94143 USA.
RP Gold, WM (reprint author), Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, Box 0111, San Francisco, CA 94143 USA.
EM warren.gold@ucsf.edu
FU Flight Attendants Medical Research Institute (FAMRI); National
Institutes of Health [K23 HL083099]
FX Supported by the Flight Attendants Medical Research Institute (FAMRI),
and the National Institutes of Health (K23 HL083099).
NR 53
TC 13
Z9 13
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1076-2752
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD JUN
PY 2009
VL 51
IS 6
BP 639
EP 646
DI 10.1097/JOM.0b013e3181a7f048
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 456YO
UT WOS:000266890800002
PM 19448573
ER
PT J
AU Lorenz, KA
Dy, SM
Naeim, A
Walling, AM
Sanati, H
Smith, P
Shanman, R
Roth, CP
Asch, SM
AF Lorenz, Karl A.
Dy, Sydney M.
Naeim, Arash
Walling, Anne M.
Sanati, Homayoon
Smith, Patricia
Shanman, Roberta
Roth, Carol P.
Asch, Steven M.
TI Quality Measures for Supportive Cancer Care: The Cancer Quality-ASSIST
Project
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
CT Conference of the Australia-New-Zealand-Health-Services-Association
CY DEC, 2007
CL Auckland, NEW ZEALAND
SP Australia New Zealand Hlth Serv Assoc
DE Quality of care; supportive care; palliative care; cancer
ID EVIDENCE-BASED RECOMMENDATIONS; OF-LIFE CARE; END; INDICATORS; DELIRIUM;
PERFORMANCE
AB Patients and physicians often cite symptom control as one of their most important goals in cancer care. Despite this, a previous systematic review found few tools for evaluating the quality of supportive cancer management. We developed a comprehensive set of quality indicators for evaluating pain and nonpain symptom management as well as care planning needs in cancer patients. Based on the prevalence and quality-of-life data, clinician-researchers prioritized pain, psychosocial distress, dyspnea, nausea and vomiting, fatigue and anorexia, treatment-associated toxicities, and information and care planning for quality-indicator development. Using search terms and selection criteria, we identified English-language documents from Medline (1997-2007) and Internet-based searches. Based on this evidence, clinician-reviewers Proposed process quality indicators. We then used the VA Health Services Research and Development (VA HSR & D) appropriateness methods to compile the ratings of a multidisciplinary, international expert panel of the validity and feasibility of each indicator The panel judged 92 out of 133 (69%) proposed quality indicators valid and feasible (15 out of 23 pain, 5 out of 6 depression, 8 out of 11 dyspnea, 15 out of 19 nausea and vomiting, 13 out of 26 fatigue and anorexia, 23 out of 32 other treatment-associated toxicities, and 13 out of 16 information and care planning). Of the final indicators, 67 are potentially useful for inpatient and 81 for outpatient evaluation, and 26 address screening, 12 diagnostic evaluation, 20 management, and 21 follow-up. These quality indicators provide evidence explicit tools for measuring processes critical to ensuring high-quality supportive cancer care. Research is needed to characterize adherence to recommended practices and to evaluate the use of these measures in quality improvement efforts. J Pain Symptom Manage 2009;37:943-964. (C) 2009 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [Lorenz, Karl A.; Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Lorenz, Karl A.; Smith, Patricia; Shanman, Roberta; Roth, Carol P.; Asch, Steven M.] RAND Corp, Santa Monica, CA USA.
[Lorenz, Karl A.; Naeim, Arash; Walling, Anne M.; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Dy, Sydney M.] Johns Hopkins Univ, Sydney Kimmel Canc Ctr, Baltimore, MD USA.
[Sanati, Homayoon] Univ Calif Irvine, Dept Oncol, Irvine, CA USA.
RP Lorenz, KA (reprint author), VA Greater Los Angeles Healthcare Syst, 11301,Wilshire Blvd,Code 3-G, Los Angeles, CA 90073 USA.
EM karl.lorenz@med.va.gov
FU NCI NIH HHS [K07-CA096783]
NR 27
TC 34
Z9 34
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JUN
PY 2009
VL 37
IS 6
BP 943
EP 964
DI 10.1016/j.jpainsymman.2008.05.018
PG 22
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 460JG
UT WOS:000267183400001
PM 19359135
ER
PT J
AU Downey, L
Diehr, P
Standish, LJ
Patrick, DL
Kozak, L
Fisher, D
Congdon, S
Lafferty, WE
AF Downey, Lois
Diehr, Paula
Standish, Leanna J.
Patrick, Donald L.
Kozak, Leila
Fisher, Douglass
Congdon, Sean
Lafferty, William E.
TI Might Massage or Guided Meditation Provide "Means to a Better End"?
Primary outcomes from an efficacy trial with patients at the end of life
SO JOURNAL OF PALLIATIVE CARE
LA English
DT Article
ID QUALITY-OF-LIFE; ALTERNATIVE MEDICINE; AROMATHERAPY MASSAGE; PALLIATIVE
CARE; CLINICAL-TRIALS; COMPLEMENTARY; TRENDS; PREFERENCES; DEPRESSION;
CANCER
AB This article reports findings from a randomized controlled trial of massage and guided meditation with patients at the end of life. Using data from 167 randomized patients, the authors considered patient outcomes through 10 weeks post-enrolment, as well as next-of-kin ratings of the quality of the final week of life for 106 patients who died during study participation. Multiple regression models demonstrated no significant treatment effects of either massage or guided meditation, delivered up to twice a week, when compared with outcomes of an active control group that received visits from hospice-trained volunteers on a schedule similar to that of the active treatment arms. The authors discuss the implications of their findings for integration of these complementary and alternative
C1 [Downey, Lois] Univ Washington, Sch Med, Harborview Med Ctr, Div Pulm & Crit Care Med,Dept Med, Seattle, WA 98104 USA.
[Diehr, Paula; Patrick, Donald L.] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA.
[Diehr, Paula] Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Seattle, WA 98195 USA.
[Standish, Leanna J.] Bastyr Univ, Sch Naturopath Med, Kenmore, WA 98028 USA.
[Kozak, Leila] Vet Affairs Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Serv Ctr Excellence, Seattle, WA 98101 USA.
[Fisher, Douglass] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
[Congdon, Sean] Bastyr Univ Res Ctr, Kenmore, WA 98028 USA.
[Lafferty, William E.] Univ Missouri, Sch Med, Dept Informat, Off Hlth Serv & Publ Hlth Outcomes Res, Kansas City, MO 64108 USA.
RP Downey, L (reprint author), Univ Washington, Sch Med, Harborview Med Ctr, Div Pulm & Crit Care Med,Dept Med, Box 359765,325 9th Ave, Seattle, WA 98104 USA.
FU NCI NIH HHS [5R01-CA106204, R01 CA106204, R01 CA106204-04]
NR 30
TC 9
Z9 10
U1 5
U2 7
PU CENTER BIOETHICS CLIN RES INST MONTREAL
PI MONTREAL
PA 110 PINE AVE W, MONTREAL, QUEBEC H2W 1R7, CANADA
SN 0825-8597
J9 J PALLIAT CARE
JI J. Palliative Care
PD SUM
PY 2009
VL 25
IS 2
BP 100
EP 108
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 461UR
UT WOS:000267298200004
PM 19678461
ER
PT J
AU Yehuda, R
Bierer, LM
Andrew, R
Schmeidler, J
Seckl, JR
AF Yehuda, Rachel
Bierer, Linda M.
Andrew, Ruth
Schmeidler, James
Seckl, Jonathan R.
TI Enduring effects of severe developmental adversity, including
nutritional deprivation, on cortisol metabolism in aging Holocaust
survivors
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Posttraumatic stress disorder; Glucocorticoid metabolism; Biological
markers; 5 alpha-Tetrahydrocortisol; 11 beta-hydroxysteroid
dehydrogenase; Child psychiatry
ID POSTTRAUMATIC-STRESS-DISORDER; PITUITARY-ADRENAL AXIS;
11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; BETA-HYDROXYSTEROID
DEHYDROGENASE; PRENATAL EXPOSURE; BLOOD-PRESSURE; PTSD SCALE; LIVER;
ENZYMES; 5-ALPHA-REDUCTASE
AB Objective: In animal models, early life exposure to major environmental challenges such as malnutrition and stress results in persisting cardiometabolic, neuroendocrine and affective effects. While such effects have been associated with pathogenesis, the widespread occurrence of 'developmental programming' suggests it has adaptive function. Glucocorticoids may mediate 'programming' and their metabolism is known to be affected by early life events in rodents. To examine these relationships in humans, cortisol metabolism and cardiometabolic disease manifestations were examined in Holocaust survivors in relation to age at exposure and affective dysfunction, notably lifetime posttraumatic stress disorder (PTSD).
Methods: Fifty-one Holocaust survivors and 22 controls without Axis I disorder collected 24-h urine samples and were evaluated for psychiatric disorders and cardiometabolic diagnoses. Corticosteroids and their metabolites were assayed by gas chromatography-mass spectroscopy (GC-MS); cortisol was also measured by radioimmunoassay (RIA).
Results: Holocaust survivors showed reduced cortisol by RIA, and decreased levels of 5 alpha-tetrahydrocortisol (5 alpha-THF) and total glucocorticoid production by GC-MS. The latter was associated with lower cortisol metabolism by 5 alpha-reductase and 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) type-2. The greatest decrements were associated with earliest age of Holocaust exposure and less severe PTSD symptomatology. Cardiometabolic manifestations were associated with decreased 11 beta-HSD-2 activity. In controls, 5 alpha-reductase was positively associated with trauma-related symptoms (i.e., to traumatic exposures unrelated to the Holocaust).
Conclusion: Extreme malnutrition and related stress during development is associated with long-lived alterations in specific pathways of glucocorticoid metabolism. These effects may be adaptive and link with lower risks of cardiometabolic and stress-related disorders in later life. Published by Elsevier Ltd.
C1 [Yehuda, Rachel; Bierer, Linda M.; Schmeidler, James] Mt Sinai Sch Med, Traumat Stress Studies Div, Bronx, NY 10468 USA.
[Yehuda, Rachel; Bierer, Linda M.; Schmeidler, James] James J Peters Bronx Vet Affairs Med Ctr, Bronx, NY 10468 USA.
[Andrew, Ruth; Seckl, Jonathan R.] Univ Edinburgh, Queens Med Res Inst, Endocrinol Unit, Edinburgh EH16 4TJ, Midlothian, Scotland.
RP Yehuda, R (reprint author), Mt Sinai Sch Med, Traumat Stress Studies Div, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM rachel.yehuda@va.gov
RI Seckl, Jonathan/C-3555-2013; Andrew, Ruth/C-2727-2008
FU NIMH [5 R01 MH064675-02]; Wellcome Trust
FX This work was supported by NIMH 5 R01 MH064675-02 to Rachel Yehuda and
by grants from the Wellcome Trust to Ruth Andrew and Jonathan R. Seckl.
Neither the NIMH nor the Wellcome Trust had any further role in study
design; in the collection, analysis or interpretation of data; in
manuscript preparation; or in the decision to submit the paper for
publication.
NR 44
TC 41
Z9 43
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD JUN
PY 2009
VL 43
IS 9
BP 877
EP 883
DI 10.1016/j.jpsychires.2008.12.003
PG 7
WC Psychiatry
SC Psychiatry
GA 452XC
UT WOS:000266573500009
PM 19162277
ER
PT J
AU Beigi, RH
Switzer, GE
Meyn, LA
AF Beigi, Richard H.
Switzer, Galen E.
Meyn, Leslie A.
TI Acceptance of a Pandemic Avian Influenza Vaccine in Pregnancy
SO JOURNAL OF REPRODUCTIVE MEDICINE
LA English
DT Article; Proceedings Paper
CT 34th Annual Scientific Meeting of the
Infectious-Diseases-Society-for-Obstetrics-and-Gynecology
CY AUG 09-11, 2007
CL Boston, MA
SP Infect Dis Soc Obstet & Gynecol
DE avian influenza; pandemics; pregnancy; vaccination
ID ASIAN INFLUENZA; WOMEN; HOSPITALIZATIONS; EPIDEMIC; ILLNESS; H5N1
AB OBJECTIVE: To evaluate acceptance of a pandemic avian influenza vaccine among obstetric patients and nonphysician obstetric office personnel.
STUDY DESIGN: Two separate office-based questionnaires were administered to patients and nonphysician personnel. Questions included demographics, vaccine beliefs and acceptance of a potential pandemic avian influenza vaccine in pregnancy.
RESULTS: Questionnaires were completed by 394 of 600 (65.7%) eligible patients and 101 of 134 (75.3%) eligible office personnel. Only 15.4% of the patients stated they would definitely accept a pandemic influenza vaccine in pregnancy despite most (68%) reporting they would first consult their obstetrician for information. Fifty percent of the office personnel would not recommend a pandemic influenza vaccine to pregnant women and 40% reported unwillingness to accept the same vaccine if they were pregnant.
CONCLUSION: Barriers exist that may hinder mass vaccination efforts among the pregnant population during the next influenza pandemic. Preemptive educational efforts may assist in the acceptance of a pandemic vaccine among pregnant women and enable obstetricians to better provide disease prevention during the next influenza pandemic. (J Reprod Med 2009;54:341-346)
C1 [Beigi, Richard H.] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci,Div Reprod Infec, Pittsburgh, PA 15213 USA.
Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA.
VA Pittsburgh Healthcare Syst, Ctr Hlth Equ & Promot, Pittsburgh, PA USA.
Magee Womens Res Inst, Pittsburgh, PA USA.
RP Beigi, RH (reprint author), Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci,Div Reprod Infec, 300 Halket St, Pittsburgh, PA 15213 USA.
EM rbeigi@mail.magee.edu
NR 22
TC 22
Z9 22
U1 1
U2 5
PU SCI PRINTERS & PUBL INC
PI ST LOUIS
PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA
SN 0024-7758
J9 J REPROD MED
JI J. Reprod. Med.
PD JUN
PY 2009
VL 54
IS 6
BP 341
EP 346
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 461EW
UT WOS:000267248400003
PM 19639922
ER
PT J
AU Becker, MA
Schumacher, HR
MacDonald, PA
Lloyd, E
Lademacher, C
AF Becker, Michael A.
Schumacher, H. Ralph
MacDonald, Patricia A.
Lloyd, Eric
Lademacher, Christopher
TI Clinical Efficacy and Safety of Successful Longterm Urate Lowering with
Febuxostat or Allopurinol in Subjects with Gout
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE GOUT; HYPERURICEMIA; FEBUXOSTAT; ALLOPURINOL; SERUM URATE
ID SERUM URIC-ACID; HYPERURICEMIA; ARTHRITIS; MANAGEMENT; REDUCTION;
THERAPY; ATTACKS; CARE
AB Objective. To determine longterm urate-lowering efficacy and clinical benefits and safety of therapy with febuxostat or allopurinol in subjects with gout.
Methods. Subjects (n = 1086) in this open-label extension Study were assigned to fixed-dose daily Urate-lowering treatment (ULT) with febuxostat (80 mg or 120 mg) or allopurinol (300 tug). ULT reassignment was permitted during months I to 6 to achieve serum urate (SUA) concentrations between 3.0 and < 6.0 mg/dl. Flares requiring treatment, tophus size, safety, and SUA levels were monitored during up to 40 months of ULT maintenance. C,
Results. After 1 month initial treatment, > 80% of Subjects receiving either febuxostat close, but Only 46% of subjects receiving allopurinol, achieved SUA < 6.0 mg/dl. After ULT reassignment, > 80% of all remaining subjects maintained the primary efficacy endpoint of SUA < 6.0 mg/dl at each visit. More Subjects initially randomized to allopurinol required ULT reassignment to achieve SUA < 6.0 mg/dl compared with subjects receiving febuxostat. Maintenance of SUA < 6.0 mg/dl resulted in progressive reduction to nearly 0 in proportion of subjects requiring gout flare treatment. Baseline tophus resolution was achieved by 46% 36%, and 29% of subjects maintained on febuxostat 80 mg, febuxostat 120 mg, and allopurinol, respectively. Overall adverse event rates (including cardiovascular adverse event rates), adjusted for 10-fold greater febuxostat than allopurinol exposure, did not differ significantly among treatment groups.
Conclusion. Durable maintenance of goal range SUA level with either dose of febuxostat or in smaller numbers of subjects with allopurinol resulted in near elimination of gout flares and improved tophus status over time. Registered as NCT00175019. (First Release March 15 2009; J Rheumatol 2009;36:1273-82; doi: 10.3899/jrheum.080814)
C1 [Becker, Michael A.] Univ Chicago, Med Ctr, Pritzker Sch Med, Chicago, IL 60637 USA.
[Schumacher, H. Ralph] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
Vet Affairs Med Ctr, Philadelphia, PA USA.
[Lloyd, Eric; Lademacher, Christopher] Takeda Global Res & Dev Ctr Inc, Deerfield, IL USA.
RP Becker, MA (reprint author), Univ Chicago, Med Ctr, Pritzker Sch Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM mbecker@medicine.bsd.uchicago.edu
FU Takeda Global Research & Development Center, Inc.
FX Supported by Takeda Global Research & Development Center, Inc. (TAP
Pharmaceutical Products Inc. is now a part of Takeda Global Research &
Development Center, Inc.). Dr Becker and Dr. Schumacher are consultants
for Takeda Global Research & Development Center, Inc.
NR 23
TC 99
Z9 104
U1 2
U2 9
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD JUN
PY 2009
VL 36
IS 6
BP 1273
EP 1282
DI 10.3899/jrheum.080814
PG 10
WC Rheumatology
SC Rheumatology
GA 456YU
UT WOS:000266891500030
PM 19286847
ER
PT J
AU Malik, A
Dinnella, JE
Kwoh, CK
Schumacher, HR
AF Malik, Aarti
Dinnella, Janet E.
Kwoh, C. Kent
Schumacher, H. Ralph
TI Poor Validation of Medical Record ICD-9 Diagnoses of Gout in a Veterans
Affairs Database
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE DIAGNOSES; GOUT; EPIDEMIOLOGIC STUDIES
ID POSITIVE PREDICTIVE-VALUE; EPIDEMIOLOGY; PREVALENCE; ARTHRITIS;
ACCURACY; CRITERIA; CLAIMS
AB Objective. Diagnostic codes based on medical records or claims data have been used to identify patient Populations with gout For important epidemiologic and Clinical Studies. We evaluated whether we can document the accuracy Of Such diagnoses by review of medical records and then on direct interviews with a Subset of patients.
Methods. Electronic medical records of 289 patients with 2 visits with ICD-9 codes for gout were extensively reviewed to search for documentation of features that Would classify patients as having gout by 3 sets of proposed criteria, the American College of Rheumatology (ACR), New York, or Rome criteria. Records of patients who had been seen by rheumatologists were compared with all others. A subset of patients seen in clinic were directly interviewed for comparison with the results front the records.
Results. Based on medical records review there was documentation of gout by the ACR criteria in only 36%, Rome criteria in 30%, and New York criteria in 33%. Records of patients who had seen rheumatologists had better documentation of classification features. Interview in clinic of 37 patients also improved documentation of the 3 sets of criteria features of gout in 65%-81% of those with ICD-9 codes for gout.
Conclusion. We found it difficult to confirm ICD-9 coded diagnoses of gout using currently available proposed criteria from details recorded in medical records. This may reflect a problem with available criteria and with documentation. Direct interview of patients may be needed to confirm the presence of typical features when high specificity is desired. (First Release May 15 2009: J Rheumatol 2009;36:1283-6: doi: 10.3899/jrheum.081195)
C1 [Malik, Aarti; Dinnella, Janet E.; Schumacher, H. Ralph] Univ Penn, Philadelphia, PA 19104 USA.
[Malik, Aarti; Dinnella, Janet E.; Schumacher, H. Ralph] Vet Affairs Med Ctr, Philadelphia, PA USA.
[Kwoh, C. Kent] Univ Pittsburgh, Pittsburgh, PA USA.
[Kwoh, C. Kent] Vet Affairs Med Ctr, Pittsburgh, PA USA.
RP Malik, A (reprint author), Evanston NW Healthcare, Div Rheumatol, 2650 Ridge Ave,Room 5313, Evanston, IL 60201 USA.
FU TAP Pharmaceuticals
FX Supported in part by an Investigator Initiated grant from TAP
Pharmaceuticals.
NR 13
TC 20
Z9 20
U1 0
U2 0
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD JUN
PY 2009
VL 36
IS 6
BP 1283
EP 1286
DI 10.3899/jrheum.081195
PG 4
WC Rheumatology
SC Rheumatology
GA 456YU
UT WOS:000266891500031
PM 19447931
ER
PT J
AU Cohen, ME
Bilimoria, KY
Ko, CY
Hall, BL
AF Cohen, Mark E.
Bilimoria, Karl Y.
Ko, Clifford Y.
Hall, Bruce Lee
TI Development of an American College of Surgeons National Surgery Quality
Improvement Program: Morbidity and Mortality Risk Calculator for
Colorectal Surgery
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID POSSUM SCORING SYSTEMS; POSTOPERATIVE MORTALITY; CANCER SURGERY;
P-POSSUM; OPERATIVE RISK; RESECTION; VALIDATION; SCORES; SCALE
AB BACKGROUND: Surgical decision-making and informed patient consent both benefit from having accurate information about risk. But currently available risk estimating systems have one or more limitations associated with lack of specificity to operation type, size of sample (reliability), range of outcomes predicted, and appreciation of hospital effects.
STUDY DESIGN: Data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) patients who underwent colorectal surgery in 2006 to 2007 were used to generate logistic prediction models for 30-day morbidity, serious morbidity, and mortality. Results for these three models were then used to construct a universal multivariable model to predict risk for all three outcomes. Model performance was externally validated against 2005 data.
RESULTS: For 2006 to 2007, 28,863 patients were identified who underwent major colorectal operations at 182 hospitals. A single 15-variable predictor model exhibited discrimination (c-statistic) close to that observed for the separate models on all three outcomes. Similar discrimination was found when the 2006 to 2007 universal model was applied to 3,037 operations conducted in 2005 at 37 hospitals.
CONCLUSIONS: The ACS NSQIP colorectal risk calculator allows surgeons to preoperatively provide patients with detailed information about their personal risks of overall morbidity, serious morbidity, and mortality. Because ACS NSQIP can also categorize hospitals as performing better or worse than expected (or as expected), surgeons have the opportunity to adjust risk probabilities for patients at their institutions accordingly. (J Am Coll Surg 2009;208:1009-1016. (C) 2009 by the American College of Surgeons)
C1 [Cohen, Mark E.; Bilimoria, Karl Y.; Ko, Clifford Y.] Northwestern Univ, Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
[Bilimoria, Karl Y.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Hall, Bruce Lee] Washington Univ, John Cochran Vet Affairs Med Ctr, St Louis, MO USA.
[Hall, Bruce Lee] Washington Univ, Sch Med, St Louis, MO USA.
[Hall, Bruce Lee] Washington Univ, Barnes Jewish Hosp, Ctr Hlth Policy, St Louis, MO USA.
[Hall, Bruce Lee] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA.
RP Cohen, ME (reprint author), Northwestern Univ, Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA.
EM markcohen@facs.org
NR 24
TC 148
Z9 150
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2009
VL 208
IS 6
BP 1009
EP 1016
DI 10.1016/j.jamcollsurg.2009.01.043
PG 8
WC Surgery
SC Surgery
GA 459TY
UT WOS:000267134300002
PM 19476884
ER
PT J
AU Alvord, LA
Henderson, WG
Benton, K
Buchwald, D
AF Alvord, Lori Arviso
Henderson, William G.
Benton, Kathryn
Buchwald, Dedra
TI Surgical Outcomes in American Indian Veterans: A Closer Look
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID RISK ADJUSTMENT; GALLBLADDER DISEASE; PIMA INDIANS; QUALITY; CARE;
MISCLASSIFICATION; PREVALENCE; MORBIDITY; MORTALITY; RATES
AB BACKGROUND: American Indian/Alaska Native (AI/ANs) male veterans have considerably higher postoperative mortality rates than their Caucasian Counterparts, but similar postoperative morbidity rates even after adjusting for major preoperative risk factors. This Study seeks to explain the discrepancy in morbidity and mortality.
STUDY DESIGN: We obtained data from the Veterans Affairs National Surgical Quality Improvement Program on major, noncardiac, surgical procedures performed from 1991 to 2002 for all AI/AN men (n = 2,155), and a random sample of Caucasian men (n = 2,264), matched by site. We compared the number and types of postoperative complications and mortality rates for those patients in whom complications developed. We also examined complication and mortality rates by whether they Occurred after hospital discharge, or by specific type of surgical procedure. Preoperative risk factors were assessed in patients who died. Chi-square or Fisher's exact tests were used for all comparisons.
RESULTS: AI/ANs and Caucasians did not differ by number of complications but Caucasian patients had considerably higher rates for three specific complications. There was no difference in deaths after discharge or in mortality rates after specific surgical procedures. The groups differed considerably in the types of procedures performed. Among patients who died, three preoperative risk factors, ie, hemiplegia, diabetes, and wound infection, occurred more frequently among AI/AN than Caucasian veterans.
CONCLUSIONS: We cannot fully explain higher postoperative mortality rates experienced by AI/AN relative to Caucasian veterans after examining complications, types of procedures, and other relevant factors. AI/ANs with certain preoperative risk factors can be Vulnerable to 30-day postoperative mortality and benefit from closer postoperative surveillance. (J Am Coll Surg 2009;208:, 1085-1092. (C) 2009 by the American College of Surgeons)
C1 [Alvord, Lori Arviso] Dartmouth Med Sch, Dept Surg, Lebanon, NH USA.
[Alvord, Lori Arviso] White River Junct VA Med Ctr, White River Jct, VT USA.
[Henderson, William G.] Univ Colorado Denver, Dept Prevent Med & Biometr, Denver, CO USA.
[Henderson, William G.] Univ Colorado Denver, Hlth Outcomes Program, Denver, CO USA.
[Henderson, William G.] Denver VA Med Ctr, Denver, CO USA.
[Benton, Kathryn] Univ Colorado Denver, Colorado Hlth Outcomes Program, Denver, CO USA.
[Buchwald, Dedra] Univ Washington, Dept Med, Seattle, WA USA.
RP Alvord, LA (reprint author), Dartmouth Med Sch, Dept Surg, Hinman Box 7010, Hanover, NH 03755 USA.
EM lori.arivso.alvord@dartmouth.edu
FU University of Washington; University of Colorado Denver
FX We wish to thank Spero Manson, PhD, and the Native Elder Research Center
at the University of Colorado Denver and the University of Washington
for grant and statistical support. We also thank Shukri F Khuri, MD, and
the NSQIP for the data used in this study.
NR 27
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2009
VL 208
IS 6
BP 1085
EP 1092
DI 10.1016/j.jamcollsurg.2009.02.058
PG 8
WC Surgery
SC Surgery
GA 459TY
UT WOS:000267134300014
PM 19476896
ER
PT J
AU Friedlander, AH
Mahler, M
Norman, KM
Ettinger, RL
AF Friedlander, Arthur H.
Mahler, Michael
Norman, Keith M.
Ettinger, Ronald L.
TI Parkinson disease Systemic and orofacial manifestations, medical and
dental management
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Review
DE Parkinson disease; local anesthetics; saliva
ID BOTULINUM-TOXIN-A; ORAL-HEALTH; NONMOTOR SYMPTOMS; FOLLOW-UP; DIAGNOSIS;
DYSFUNCTION; DOPAMINE; DEMENTIA; LEVODOPA; THERAPY
AB Background. More than 1.5 million Americans have Parkinson disease (PD), and this figure is expected to rise as the population ages. However, the dental literature offers little information about the illness.
Types of Studies Reviewed. The authors conducted a MEDLINE search using the key terms "Parkinson's disease, "medical management" and "dentistry." They selected contemporaneous articles published in peer-reviewed journals and gave preference to articles reporting randomized controlled trials.
Results. PD is a progressive neurodegenerative disorder caused by loss of dopaminergic and nondopaminergic neurons in the brain. These deficits result in tremor, slowness of movement, rigidity, postural instability and autonomic and behavioral dysfunction. Treatment consists of administering medications that replace dopamine, stimulate dopamine receptors and modulate other neurotransmitter systems.
Clinical Implications. Oral health may decline because of tremors, muscle rigidity and cognitive deficits. The dentist should consult with the patient's physician to establish the patient's competence to provide informed consent and to determine the presence of comorbid illnesses. Scheduling short morning appointments that begin 90 minutes after administration of PD medication enhances the patient's ability to cooperate with care. Inclination of the dental chair at 45 degrees, placement of a bite prop, use of a rubber dam and high-volume oral evacuation enhance airway protection. To avoid adverse drug interactions with levodopa and entacapone, the dentist should limit administration of local anesthetic agents to three cartridges of 2 percent lidocaine with 1:100,000 epinephrine per half hour, and patients receiving selegiline should not be given agents containing epinephrine or levonordefrin. The dentist should instruct the patient and the caregiver in good oral hygiene techniques.
C1 [Friedlander, Arthur H.] VA Greater Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA 90073 USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
[Mahler, Michael] VA Greater Angeles Healthcare Syst, Neurobehav Clin, Los Angeles, CA 90073 USA.
[Mahler, Michael] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Ettinger, Ronald L.] Univ Iowa, Dept Prosthodont, Iowa City, IA USA.
[Ettinger, Ronald L.] Univ Iowa, Dows Inst Dent Res, Iowa City, IA USA.
RP Friedlander, AH (reprint author), VA Greater Angeles Healthcare Syst, Dept Vet Affairs, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM arthur.friedlander@med.va.gov
NR 102
TC 13
Z9 16
U1 3
U2 10
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD JUN
PY 2009
VL 140
IS 6
BP 658
EP 669
PG 12
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 456KQ
UT WOS:000266845300014
PM 19491161
ER
PT J
AU Lee, SJ
Sudore, RL
Williams, BA
Lindquist, K
Chen, HL
Covinsky, KE
AF Lee, Sei J.
Sudore, Rebecca L.
Williams, Brie A.
Lindquist, Karla
Chen, Helen L.
Covinsky, Kenneth E.
TI Functional Limitations, Socioeconomic Status, and All-Cause Mortality in
Moderate Alcohol Drinkers
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article; Proceedings Paper
CT 31st Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 09-12, 2008
CL Pittsburgh, PA
SP Soc Gen Internal Med
DE alcohol; function; socioeconomic status; risk adjustment
ID CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED TRIAL; ESTROGEN PLUS
PROGESTIN; POSTMENOPAUSAL WOMEN; SOCIAL INTEGRATION; PROPENSITY SCORE;
ELDERLY-PEOPLE; RISK-FACTORS; BRITISH MEN; US ADULTS
AB To determine whether the survival benefit associated with moderate alcohol use remains after accounting for nontraditional risk factors such as socioeconomic status (SES) and functional limitations.
Prospective cohort.
The Health and Retirement Study (HRS), a nationally representative study of U.S. adults aged 55 and older.
Twelve thousand five hundred nineteen participants were enrolled in the 2002 wave of the HRS.
Participants were asked about their alcohol use, functional limitations (activities of daily living, instrumental activities of daily living, and mobility), SES (education, income, and wealth), psychosocial factors (depressive symptoms, social support, and the importance of religion), age, sex, race and ethnicity, smoking, obesity, and comorbidities. Death by December 31, 2006, was the outcome measure.
Moderate drinkers (1 drink/d) had a markedly more-favorable risk factor profile, with higher SES and fewer functional limitations. After adjusting for demographic factors, moderate drinking (vs no drinking) was strongly associated with less mortality (odds ratio (OR)=0.50, 95% confidence interval (CI)=0.40-0.62). When traditional risk factors (smoking, obesity, and comorbidities) were also adjusted for, the protective effect was slightly attenuated (OR=0.57, 95% CI=0.46-0.72). When all risk factors including functional status and SES were adjusted for, the protective effect was markedly attenuated but still statistically significant (OR=0.72, 95% CI=0.57-0.91).
Moderate drinkers have better risk factor profiles than nondrinkers, including higher SES and fewer functional limitations. Although these factors explain much of the survival advantage associated with moderate alcohol use, moderate drinkers maintain their survival advantage even after adjustment for these factors.
C1 [Lee, Sei J.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA.
[Lee, Sei J.; Sudore, Rebecca L.; Williams, Brie A.; Lindquist, Karla; Chen, Helen L.; Covinsky, Kenneth E.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
RP Lee, SJ (reprint author), San Francisco VA Med Ctr, Div Geriatr, Bldg 1,Room 306,Box 181G,4150 Clement St, San Francisco, CA 94121 USA.
EM seijlee@gmail.com
FU NCRR NIH HHS [KL2 RR024130, KL2 RR024130-04, KL2RR024130]; NIA NIH HHS
[R01 AG023626, K24 AG029812, K24-AG029812, L30 AG030755, L30
AG030755-02, R01-AG023626, U01 AG009740, U01AG09740]
NR 58
TC 31
Z9 31
U1 1
U2 5
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2009
VL 57
IS 6
BP 955
EP 962
DI 10.1111/j.1532-5415.2009.02184.x
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 451SM
UT WOS:000266490500001
PM 19473456
ER
PT J
AU Anderson, S
Halter, JB
Hazzard, WR
Himmelfarb, J
Horne, FM
Kaysen, GA
Kusek, JW
Nayfield, SG
Schmader, K
Tian, Y
Ashworth, JR
Clayton, CP
Parker, RP
Tarver, ED
Woolard, NF
High, KP
AF Anderson, Sharon
Halter, Jeffrey B.
Hazzard, William R.
Himmelfarb, Jonathan
Horne, Frances McFarland
Kaysen, George A.
Kusek, John W.
Nayfield, Susan G.
Schmader, Kenneth
Tian, Ying
Ashworth, John R.
Clayton, Charles P.
Parker, Ryan P.
Tarver, Erika D.
Woolard, Nancy F.
High, Kevin P.
TI Prediction, Progression, and Outcomes of Chronic Kidney Disease in Older
Adults
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Review
ID STAGE RENAL-DISEASE; GLOMERULAR-FILTRATION-RATE; CYCLE INHIBITOR
P16(INK4A); CARDIOVASCULAR RISK-FACTOR; URINARY ALBUMIN EXCRETION;
CHRONIC-HEMODIALYSIS PATIENTS; POLYUNSATURATED FATTY-ACIDS; TYPE-2
DIABETES-MELLITUS; LOW-DENSITY-LIPOPROTEIN; COGNITIVE FUNCTION
AB Chronic kidney disease is a large and growing problem among aging populations. Although progression of chronic kidney disease to end-stage renal disease (ESRD) is a costly and important clinical event with substantial morbidity, it appears less frequently in aging people compared with cardiovascular mortality. The measurement of kidney function and management of kidney disease in older individuals remain challenging, partly because the pathophysiologic mechanisms underlying age-related decline in kidney function, the interactions between age and other risk factors in renal progression, and the associations of chronic kidney disease with other comorbidities in older people are understudied and poorly understood. The Association of Specialty Professors, the American Society of Nephrology, the American Geriatrics Society, the National Institute on Aging, and the National Institute of Diabetes and Digestive and Kidney Diseases held a workshop, summarized in this article, to review what is known about chronic kidney disease, identify research gaps and resources available to address them, and identify priority areas for future research. Answers to emerging research questions will support the integration of geriatrics and nephrology and thus improve care for older patients at risk for chronic kidney disease.
C1 [High, Kevin P.] Wake Forest Univ, Sch Med, Dept Internal Med, Infect Dis Sect, Winston Salem, NC 27157 USA.
[Anderson, Sharon] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Halter, Jeffrey B.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
[Hazzard, William R.] Univ Washington, Dept Med, Seattle, WA USA.
[Hazzard, William R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Himmelfarb, Jonathan] Maine Med Ctr, Dept Med, Portland, ME 04102 USA.
[Horne, Frances McFarland; Ashworth, John R.; Clayton, Charles P.; Parker, Ryan P.; Tarver, Erika D.] Assoc Specialty Professors, Washington, DC USA.
[Kaysen, George A.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA.
[Kusek, John W.] NIDDKD, Kidney & Urol Branch, Bethesda, MD 20892 USA.
[Nayfield, Susan G.; Tian, Ying] NIA, Geriatr & Clin Gerontol Branch, Bethesda, MD 20892 USA.
[Schmader, Kenneth] Duke Univ, Dept Med, Durham, NC USA.
[Schmader, Kenneth] Durham VA Med Ctr, Durham, NC USA.
RP High, KP (reprint author), Wake Forest Univ, Sch Med, Dept Internal Med, Infect Dis Sect, 100 Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM khigh@wfubmc.edu
OI Clayton, Charles/0000-0003-1945-0477
FU John A. Hartford Foundation
FX This workshop was supported by a generous grant from the John A.
Hartford Foundation to the Association of Specialty Professors. For a
list of the planning cornmittee and attendees of the conference, please
visit http:// www.im.org/CarcerDevelopinent/Grantsand
Scholarships/IGP/ExpandingResearch Efforts/
Pages/Workshoponprediction,Progression and Outcomes of Chronic Kidney
Diseasein OlderAdults.aspx.
NR 146
TC 78
Z9 85
U1 0
U2 9
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD JUN
PY 2009
VL 20
IS 6
BP 1199
EP 1209
DI 10.1681/ASN.2008080860
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA 453NK
UT WOS:000266617200012
PM 19470680
ER
PT J
AU Amstadter, AB
Acierno, R
Richardson, LK
Kilpatrick, DG
Gros, DF
Gaboury, MT
Trinh, LT
Lam, TT
Nguyen, TT
Tran, T
La, TB
Tran, TH
Tran, DT
Galea, S
AF Amstadter, Ananda B.
Acierno, Ron
Richardson, Lisa K.
Kilpatrick, Dean G.
Gros, Daniel F.
Gaboury, Mario T.
Trinh Luong Tran
Lam Tu Trung
Nguyen Thanh Tam
Tran Tuan
La Thi Buoi
Tran Thu Ha
Tran Duc Thach
Galea, Sandro
TI Posttyphoon Prevalence of Posttraumatic Stress Disorder, Major
Depressive Disorder, Panic Disorder, and Generalized Anxiety Disorder in
a Vietnamese Sample
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID DISASTER VICTIMS SPEAK; HURRICANE-KATRINA; MENTAL-HEALTH; NATURAL
DISASTER; COMORBIDITY; POPULATION; SEQUELAE; EXPOSURE; TRAUMA; IMPACT
AB In 2006 typhoon Xangsane disrupted a multiagency health needs study of 4,982 individuals in Vietnam. Following this disaster, 798 of the original participants were reinterviewed to determine prevalence and risk factors associated with posmaumatic stress disorder (PTSD), major depressive disorder (MDD), panic disorder (PD), and generalized anxiety disorder (GAD). Posttyphoon prevalences were PTSD 2.6%, MDD 5.9%, PD 9.3%, and GAD 2.2%. Of those meeting criteria for a disorder, 70% reported only one disorder 15% had two, 14% had three, and 1% met criteria for all four disorders. Risk factors for posttyphoon psychopathology differed among disorders, but generally were related to high typhoon exposure, prior trauma exposure, and in contrast to Western populations, higher age, but not gender.
C1 [Amstadter, Ananda B.; Acierno, Ron; Richardson, Lisa K.; Kilpatrick, Dean G.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Gros, Daniel F.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
[Gaboury, Mario T.] Univ New Haven, New Haven, CT USA.
[Gaboury, Mario T.] Oskar Schindler Humanities Fdn, New Haven, CT USA.
[Trinh Luong Tran] Hlth Dept Da Nang City, Da Nang City, Vietnam.
[Lam Tu Trung] Da Nang Mental Hlth Hosp, Da Nang City, Vietnam.
[Nguyen Thanh Tam] Vietnam Vet Amer Fdn, Hanoi, Vietnam.
[Tran Tuan; La Thi Buoi; Tran Thu Ha; Tran Duc Thach] Res & Training Ctr Community Dev, Hanoi, Vietnam.
[Galea, Sandro] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
RP Amstadter, AB (reprint author), Natl Crime Victims Res & Treatment Ctr, POB 250852, Charleston, SC 29425 USA.
EM amstadt@musc.edu
RI Tran, Thach/H-7734-2014
OI Tran, Thach/0000-0002-4686-8601
FU NIMH NIH HHS [F32 MH083469, F32 MH083469-01]
NR 31
TC 31
Z9 31
U1 2
U2 5
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2009
VL 22
IS 3
BP 180
EP 188
DI 10.1002/jts.20404
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 468JR
UT WOS:000267814300003
PM 19455707
ER
PT J
AU Lu, M
Wagner, A
Van Male, L
Whitehead, A
Boehnlein, J
AF Lu, Mary
Wagner, Amy
Van Male, Lynn
Whitehead, Ashlee
Boehnlein, James
TI Imagery Rehearsal Therapy for Posttraumatic Nightmares in US Veterans
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID SEXUAL ASSAULT SURVIVORS; COMBAT-RELATED PTSD; STRESS-DISORDER
AB Imagery rehearsal therapy (IRT) may help reduce residual nightmares and posttraumatic stress disorder (PTSD) symptoms in veterans after trauma-focused PTSD treatment. Fifteen male U. S. veterans with PTSD and trauma-related nightmares, who had not previously completed trauma-focused PTSD treatment, attended 6 IRT group sessions. No benefits were observed immediately posttreatment. At 3- and 6-month follow-up, however, trauma related nightmare frequency (nights/week) decreased (p < .01). The number of trauma-related nightmares/week (P < .01), number of total nightmares/week (p < .05), and PTSD symptoms (p <. 05) also decreased at 3 months. The overall F test for time was significant (p < .05) for nightmare severity and fear of sleep. No effects were found on measures of the impact of nightmares, sleep quality, or depression. Clinical and research implications are discussed.
C1 [Lu, Mary; Wagner, Amy; Van Male, Lynn; Boehnlein, James] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Lu, Mary; Wagner, Amy; Van Male, Lynn; Whitehead, Ashlee; Boehnlein, James] Portland VA Med Ctr, Div Mental Hlth, Portland, OR USA.
RP Lu, M (reprint author), 3710 SW US Vet Hosp Rd,POB 1035,V3SATP, Portland, OR 97239 USA.
EM Mary.Lu@va.gov
FU NCRR NIH HHS [UL1 RR024140]
NR 16
TC 27
Z9 27
U1 0
U2 6
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2009
VL 22
IS 3
BP 236
EP 239
DI 10.1002/jts.20407
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 468JR
UT WOS:000267814300010
PM 19444882
ER
PT J
AU Gavin, AR
Chae, DH
Mustillo, S
Kiefe, CI
AF Gavin, Amelia R.
Chae, David H.
Mustillo, Sarah
Kiefe, Catarina I.
TI Prepregnancy Depressive Mood and Preterm Birth in Black and White Women:
Findings from the CARDIA Study
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID CORTICOTROPIN-RELEASING HORMONE; PITUITARY-ADRENAL-FUNCTION;
AFRICAN-AMERICAN WOMEN; PREGNANCY OUTCOMES; MATERNAL STRESS;
PSYCHOSOCIAL FACTORS; BACTERIAL VAGINOSIS; ETHNIC-DIFFERENCES; SOCIAL
SUPPORT; FETAL-GROWTH
AB Objectives: We examine associations among race, prepregnancy depressive mood, and preterm birth (<37 weeks gestation) in a cohort study of black and white women.
Methods: We tested for mediation of the association between race and preterm birth by prepregnancy depressive mood among 555 women enrolled in the Coronary Artery Risk Development in Young Adults (CARDIA) Study.
Results: Black women had significantly higher levels of prepregnancy depressive mood ( modified CES-D score 13.0 vs. 9.5, t=-4.64, p<0.001). After adjustment for covariates, black women had 2.70 times the odds of preterm birth as white women (95% confidence interval [CI] 1.41, 5.17). When adding prepregnancy depressive mood to this model, higher depressive mood was associated with greater odds of preterm birth (odds ratio [ OR] 1.04; 95% CI 1.01, 1.07), and the effect of black race was attenuated (OR 2.47, 95% CI 1.28, 4.77).
Conclusions: Our data suggest that prepregnancy depressive mood may be a risk factor for preterm birth among black and white women.
C1 [Gavin, Amelia R.] Univ Washington, Sch Social Work, Seattle, WA 98105 USA.
[Chae, David H.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA.
[Mustillo, Sarah] Purdue Univ, Dept Sociol, E Lafeyette, IN USA.
[Kiefe, Catarina I.] Univ Alabama, Sch Med, Birmingham, AL USA.
[Kiefe, Catarina I.] Univ Alabama, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Gavin, AR (reprint author), Univ Washington, Sch Social Work, 4101 15th Ave NE, Seattle, WA 98105 USA.
EM gavina@u.washington.edu
RI Chae, David/F-6956-2015
FU Robert Wood Johnson Health and Society Scholars program; W. K. Kellogg
Doctoral Fellowship in Health Policy
FX D. H. C. was supported by the Robert Wood Johnson Health and Society
Scholars program and was also supported by the W. K. Kellogg Doctoral
Fellowship in Health Policy.
NR 77
TC 13
Z9 13
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUN
PY 2009
VL 18
IS 6
BP 803
EP 811
DI 10.1089/jwh.2008.0984
PG 9
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA 457BW
UT WOS:000266901200006
PM 19445645
ER
PT J
AU Sugimoto, M
Yamaoka, Y
AF Sugimoto, Mitsushige
Yamaoka, Yoshio
TI Helicobacter pylori infection and hypertension in end-stage renal
disease Response
SO KIDNEY INTERNATIONAL
LA English
DT Letter
C1 [Sugimoto, Mitsushige; Yamaoka, Yoshio] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA.
RP Sugimoto, M (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, 2002 Holcombe Blvd,Rm 3A-320B, Houston, TX 77030 USA.
EM sugimoto@bcm.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD JUN
PY 2009
VL 75
IS 11
BP 1235
EP 1235
DI 10.1038/ki.2009.39
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA 447YK
UT WOS:000266227800018
ER
PT J
AU Sevick, MA
Millers, GD
Loeser, RF
Williamson, JD
Messier, SP
AF Sevick, Mary A.
Millers, Gary D.
Loeser, Richard F.
Williamson, Jeff D.
Messier, Stephen P.
TI Cost-Effectiveness of Exercise and Diet in Overweight and Obese Adults
with Knee Osteoarthritis
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Article
DE OSTEOARTHRITIS; OBESITY; WEIGHT LOSS; INTERVENTION STUDIES; RANDOMIZED
CONTROLLED TRIAL
ID ACTIVITY PROMOTION TRIAL; RHEUMATOID-ARTHRITIS; PHYSICAL-ACTIVITY;
SELF-MANAGEMENT; OLDER-ADULTS; WEIGHT-LOSS; RESISTANCE EXERCISE;
ECONOMIC-EVALUATION; WESTERN ONTARIO; OSTEO-ARTHRITIS
AB SEVICK. M. A., G. D. MILLER, R. F. LOESER, J. D. WILLIAMSON, and S. P. MESSIER. Cost-Effectiveness of Exercise and Diet in Overweight and Obese Adults with Knee Osteoarthritis. riled. Sci. Spoils Exerc., Vol. 41, No. 6, pp. 1167-1174, 2009. Purpose: The purpose of this study was to compare the cost-effectiveness of dietary and exercise interventions in overweight or obese elderly patients with knee osteoarthritis (OA) enrolled in the Arthritis. Diet, and Physical Activity Promotion Trial (ADAPT). Methods: ADAPT was a single-blinded, controlled trial of 316 adults with knee OA, randomized to one of four groups: Healthy Lifestyle Control group, Diet group, Exercise group, or Exercise and Diet group. A cost analysis was performed from a payer perspective, incorporating those costs and benefits that would be realized by a managed care organization interested in maintaining the health and satisfaction of its enrollees while reducing unnecessary utilization of health care services. Results: The Diet intervention was most cost-effective for reducing weight, at $35 for each percentage point reduction in baseline body weight. The Exercise intervention was most cost-effective for improving mobility, costing $10 for each percentage point improvement in a 6-min walking distance and $9 for each percentage point improvement in the timed stair climbing task. The Exercise and Diet intervention was most cost-effective for improving self-reported function and symptoms of arthritis, costing $24 for each percentage point improvement in subjective function, $20 for each percentage point improvement in self-reported pain, and $56 for each percentage point improvement in self-reported stiffness. Conclusions: The Exercise and Diet intervention consistently yielded the greatest improvements in weight, physical performance, and symptoms of knee OA. However, it was also the most expensive and was the most cost-effective approach only for the subjective outcomes of knee OA (self-reported function, pain, and stiffness). Perceived function and symptoms of knee OA are likely to be stronger drivers of downstream health service utilization than weight, or objective performance measures and may be the most cost-effective in the long term.
C1 [Sevick, Mary A.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
[Sevick, Mary A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Sevick, Mary A.] Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
[Sevick, Mary A.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Millers, Gary D.; Messier, Stephen P.] Wake Forest Univ, Dept Hlth & Exercise Sci, Winston Salem, NC 27109 USA.
[Loeser, Richard F.; Williamson, Jeff D.] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27103 USA.
RP Sevick, MA (reprint author), Univ Pittsburgh, Sch Med, Dept Med, 230 McKee Pl, Pittsburgh, PA 15213 USA.
EM sevick@pitt.edu
FU National Institutes of Health; Claude D. Pepper Older Americans
Independence Center [5P60 AG10484-07, M01-RR00211]
FX Support for this study was provided by the following grants from the
National Institutes of Health: Claude D. Pepper Older Americans
Independence Center 5P60 AG10484-07 and M01-RR00211. The results of this
study as presented in this report do not constitute endorsement by the
ACSM.
NR 46
TC 16
Z9 17
U1 1
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD JUN
PY 2009
VL 41
IS 6
BP 1167
EP 1174
DI 10.1249/MSS.0b013e318197ece7
PG 8
WC Sport Sciences
SC Sport Sciences
GA 450JY
UT WOS:000266398000001
PM 19461553
ER
PT J
AU McEllistrem, MC
Scott, JR
Zuniga-Castillo, J
Khan, SA
AF McEllistrem, M. Catherine
Scott, Jennifer R.
Zuniga-Castillo, Jacobo
Khan, Saleem A.
TI Marked Increase in Biofilm-Derived Rough Pneumococcal Variants and
Rifampin-Resistant Strains Not Due to hex Gene Mutations
SO MICROBIAL DRUG RESISTANCE
LA English
DT Article
ID STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; CAPSULAR POLYSACCHARIDE;
COLONY MORPHOLOGY; MISMATCH REPAIR; PHASE VARIATION; OTITIS-MEDIA;
TRANSFORMATION; DISEASE; COMPETENCE
AB Otitis, pneumonia, and meningitis are tissue-based pneumococcal infections that can be associated with biofilms. The emergence of phenotypic rough variants, also known as acapsular small-colony variants, is essential for pneumococcal biofilm formation. These rough variants can increase nearly 100-fold in biofilms over time and can arise through single nucleotide polymorphisms (SNPs), deletions, or tandem duplications in the first gene of the capsular operon, cps3D. We detected a 100-fold increase in rifampin-resistant (Rif(r)) mutants in biofilms compared to planktonic cultures using a nonvaccine serotype 3 strain, which is causing an increasing number of cases of otitis in the 7-valent pneumococcal conjugate vaccine era. Since both rough variants and Rif(r) strains can arise through SNPs, they could emerge due to alteration of the mismatch repair (MMR) system. The Hex system, a pneumococcal MMR system, repairs mismatches during replication and transformation. In this study, no mutations were detected in the hexAB gene sequences among several rough variants with unique mutations in the cps3D gene. Within a hexA null mutant grown in broth, we detected only a 17.5-fold increase in rough variants compared to the wild-type parental strain. Taken together, these data suggest that mutations in the hex genes and modulation of hexA activity are unlikely to account for the generation of biofilm-derived rough variants.
C1 [McEllistrem, M. Catherine] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
[McEllistrem, M. Catherine] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Scott, Jennifer R.] Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD USA.
[Zuniga-Castillo, Jacobo; Khan, Saleem A.] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA USA.
RP McEllistrem, MC (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Univ Dr C,Mailstop 130-U, Pittsburgh, PA 15240 USA.
EM mary.mcellistrem@va.gov
NR 27
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1076-6294
J9 MICROB DRUG RESIST
JI Microb. Drug Resist.
PD JUN
PY 2009
VL 15
IS 2
BP 85
EP 90
DI 10.1089/mdr.2009.0866
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 453VE
UT WOS:000266640200003
PM 19496673
ER
PT J
AU Kertesz, SG
Crouch, K
Milby, JB
Cusimano, RE
Schumacher, JE
AF Kertesz, Stefan G.
Crouch, Kimberly
Milby, Jesse B.
Cusimano, Robert E.
Schumacher, Joseph E.
TI Housing First for Homeless Persons with Active Addiction: Are We
Overreaching ?
SO MILBANK QUARTERLY
LA English
DT Review
DE Homeless persons; housing; addiction treatment; review literature;
public policy
ID SEVERE MENTAL-ILLNESS; MODIFIED THERAPEUTIC-COMMUNITY; SUBSTANCE-ABUSING
HOMELESS; TREATMENT OUTCOMES; HEALTH-CARE; PSYCHIATRIC DISABILITIES;
CONTINGENCY-MANAGEMENT; SEVERITY INDEX; ADULTS; COCAINE
AB Context: More than 350 communities in the United States have committed to ending chronic homelessness. One nationally prominent approach, Housing First, offers early access to permanent housing without requiring completion of treatment or, for clients with addiction, proof of sobriety.
Methods: This article reviews studies of Housing First and more traditional rehabilitative (e.g., "linear") recovery interventions, focusing on the outcomes obtained by both approaches for homeless individuals with addictive disorders.
Findings: According to reviews of comparative trials and case series reports, Housing First reports document excellent housing retention, despite the limited amount of data pertaining to homeless clients with active and severe addiction. Several linear programs cite reductions in addiction severity but have shortcomings in long-term housing success and retention.
Conclusions: This article suggests that the current research data are not sufficient to identify an optimal housing and rehabilitation approach for an important homeless subgroup. The research regarding Housing First and linear approaches can be strengthened in several ways, and policymakers should be cautious about generalizing the results of available Housing First studies to persons with active addiction when they enter housing programs.
C1 [Kertesz, Stefan G.; Milby, Jesse B.] Univ Alabama, Sch Med, Div Prevent Med, Dept Psychol, Birmingham, AL 35294 USA.
[Kertesz, Stefan G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Milby, Jesse B.] Univ Alabama, Sch Publ Hlth, Dept Hlth Behav, Birmingham, AL 35294 USA.
[Schumacher, Joseph E.] Univ Alabama, Ctr AIDS Res, Birmingham, AL 35294 USA.
RP Kertesz, SG (reprint author), Univ Alabama, Sch Med, Div Prevent Med, Dept Psychol, 1530 3rd Ave S,MT608, Birmingham, AL 35294 USA.
EM skertesz@uab.edu
OI Kertesz, Stefan/0000-0001-6101-8421
FU National Institute on Drug Abuse [K23-DA-15487]
FX We thank the National Institute on Drug Abuse (K23-DA-15487) for its
support for this work. The opinions expressed in this article do not
reflect formal positions of the National Institute on Drug Abuse or the
Department of Veterans Affairs.
NR 101
TC 88
Z9 88
U1 3
U2 33
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0887-378X
J9 MILBANK Q
JI Milbank Q.
PD JUN
PY 2009
VL 87
IS 2
BP 495
EP 534
DI 10.1111/j.1468-0009.2009.00565.x
PG 40
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 454VM
UT WOS:000266711000007
PM 19523126
ER
PT J
AU Kumar, P
Kamat, A
Mendelson, CR
AF Kumar, Premlata
Kamat, Amrita
Mendelson, Carole R.
TI Estrogen Receptor alpha (ER alpha) Mediates Stimulatory Effects of
Estrogen on Aromatase (CYP19) Gene Expression in Human Placenta
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID HUMAN TROPHOBLAST DIFFERENTIATION; BREAST-CANCER CELLS; FACTOR-KAPPA-B;
TRANSCRIPTION FACTOR; IN-VITRO; CYTOTROPHOBLAST DIFFERENTIATION; HISTONE
ACETYLATION; TRANSGENIC MICE; UP-REGULATION; ACTIVATION
AB A 246-bp region upstream of placenta-specific exon L1 of the human aromatase (hCYP19) gene mediates placenta-specific, developmental, and O(2) regulation of expression. In this study, trophoblast differentiation and associated induction of CYP19 expression were prevented when cytotrophoblasts were cultured in phenol red-free medium containing charcoal-stripped serum or with the estrogen receptor (ER) antagonist, ICI 182,780, suggesting a stimulatory role of estrogen/ER. ER alpha protein was expressed in human trophoblasts and increased during syncytiotrophoblast differentiation, whereas ER beta was undetectable. Mutational analysis revealed that an estrogen response element-like sequence (ERE-LS) at -208 bp is required for inductive effects of estradiol/ER alpha on hCYP19L1 promoter activity in transfected COS-7 cells. Increased binding of syncytiotrophoblast compared with cytotrophoblast nuclear proteins to the ERE-LS was observed in vitro; however, ER alpha antibodies failed to supershift the complex and in vitro-transcribed/translated ER alpha did not bind. Nonetheless, chromatin immunoprecipitation assays in cultured trophoblasts revealed recruitment of endogenous ER alpha to the -255- to -155- bp region containing the ERE-LS before induction of hCYP19 expression; this was inhibited by ICI 182,780. Chromatin immunoprecipitation also revealed increased acetylated histone H3(K9/14) and decreased methylated histone H3(K9) associated with this region during trophoblast differentiation. These modifications were prevented when trophoblasts were incubated with ICI 182,780, suggesting that ER alpha recruitment to the -255- to -155-bp region promotes histone modifications leading to increased hCYP19 transcription. Thus, during trophoblast differentiation, estrogen/ER alpha exerts a positive feedback role, which promotes permissive histone modifications that are associated with induction of hCYP19 gene transcription. (Molecular Endocrinology 23: 784-793, 2009)
C1 [Kumar, Premlata; Mendelson, Carole R.] Univ Texas SW Med Ctr Dallas, Dept Biochem, N Texas March Dimes Birth Defects Ctr, Dallas, TX 75390 USA.
[Kumar, Premlata; Mendelson, Carole R.] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, N Texas March Dimes Birth Defects Ctr, Dallas, TX 75390 USA.
[Kamat, Amrita] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Div, Ctr Geriatr Res Educ & Clin, S Texas Vet Hlth Care Syst,Dept Med, San Antonio, TX 78229 USA.
RP Mendelson, CR (reprint author), Univ Texas SW Med Ctr Dallas, Dept Biochem, N Texas March Dimes Birth Defects Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM carole.mendelson@utsouthwestern.edu
OI Mendelson, Carole/0000-0003-1696-9791
FU National Institutes of Health [5 R01 DK031206]
FX This work was supported by National Institutes of Health Grant 5 R01
DK031206 (C. R. M.).
NR 47
TC 32
Z9 35
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD JUN
PY 2009
VL 23
IS 6
BP 784
EP 793
DI 10.1210/me.2008-0371
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 450MC
UT WOS:000266403600006
PM 19299445
ER
PT J
AU Kottgen, A
Glazer, NL
Dehghan, A
Hwang, SJ
Katz, R
Li, M
Yang, Q
Gudnason, V
Launer, LJ
Harris, TB
Smith, AV
Arking, DE
Astor, BC
Boerwinkle, E
Ehret, GB
Ruczinski, I
Scharpf, RB
Chen, YDI
de Boer, IH
Haritunians, T
Lumley, T
Sarnak, M
Siscovick, D
Benjamin, EJ
Levy, D
Upadhyay, A
Aulchenko, YS
Hofman, A
Rivadeneira, F
Uitterlinden, AG
van Duijn, CM
Chasman, DI
Pare, G
Ridker, PM
Kao, WHL
Witteman, JC
Coresh, J
Shlipak, MG
Fox, CS
AF Koettgen, Anna
Glazer, Nicole L.
Dehghan, Abbas
Hwang, Shih-Jen
Katz, Ronit
Li, Man
Yang, Qiong
Gudnason, Vilmundur
Launer, Lenore J.
Harris, Tamara B.
Smith, Albert V.
Arking, Dan E.
Astor, Brad C.
Boerwinkle, Eric
Ehret, Georg B.
Ruczinski, Ingo
Scharpf, Robert B.
Chen, Yii-Der Ida
de Boer, Ian H.
Haritunians, Talin
Lumley, Thomas
Sarnak, Mark
Siscovick, David
Benjamin, Emelia J.
Levy, Daniel
Upadhyay, Ashish
Aulchenko, Yurii S.
Hofman, Albert
Rivadeneira, Fernando
Uitterlinden, Andre G.
van Duijn, Cornelia M.
Chasman, Daniel I.
Pare, Guillaume
Ridker, Paul M.
Kao, W. H. Linda
Witteman, Jacqueline C.
Coresh, Josef
Shlipak, Michael G.
Fox, Caroline S.
TI Multiple loci associated with indices of renal function and chronic
kidney disease
SO NATURE GENETICS
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; SERUM CREATININE; CARDIOVASCULAR-DISEASE;
POOLED ANALYSIS; RISK-FACTOR; STANNIOCALCIN-1; HERITABILITY; PREVALENCE;
STATEMENT; BIOLOGY
AB Chronic kidney disease (CKD) has a heritable component and is an important global public health problem because of its high prevalence and morbidity(1). We conducted genome-wide association studies (GWAS) to identify susceptibility loci for glomerular filtration rate, estimated by serum creatinine (eGFRcrea) and cystatin C (eGFRcys), and CKD (eGFRcrea < 60ml/min/1.73 m(2)) in European-ancestry participants of four population-based cohorts (ARIC, CHS, FHS, RS; n = 19,877; 2,388 CKD cases), and tested for replication in 21,466 participants (1,932 CKD cases). We identified significant SNP associations (P < 5 x 10(-8)) with CKD at the UMOD locus, with eGFRcrea at UMOD, SHROOM3 and GATM-SPATA5L1, and with eGFRcys at CST and STC1. UMOD encodes the most common protein in human urine, Tamm-Horsfall protein(2), and rare mutations in UMOD cause mendelian forms of kidney disease(3). Our findings provide new insights into CKD pathogenesis and underscore the importance of common genetic variants influencing renal function and disease.
C1 [Hwang, Shih-Jen; Levy, Daniel; Fox, Caroline S.] Natl Heart Lung & Blood Inst Framingham Heart Stu, Framingham, MA USA.
[Hwang, Shih-Jen; Levy, Daniel; Fox, Caroline S.] Ctr Populat Studies, Framingham, MA USA.
[Koettgen, Anna; Li, Man; Astor, Brad C.; Kao, W. H. Linda; Coresh, Josef] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA.
[Glazer, Nicole L.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, DC USA.
[Siscovick, David] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Dehghan, Abbas; Aulchenko, Yurii S.; Hofman, Albert; van Duijn, Cornelia M.; Witteman, Jacqueline C.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
[Katz, Ronit; Lumley, Thomas] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Yang, Qiong] Boston Univ, Dept Biostat, Boston, MA 02215 USA.
[Gudnason, Vilmundur; Smith, Albert V.] Iceland Heart Assoc Res Inst, Kopavogur, Iceland.
[Gudnason, Vilmundur] Univ Iceland, Reykjavik, Iceland.
[Launer, Lenore J.; Harris, Tamara B.] NIA, Intramural Res Program, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA.
[Arking, Dan E.; Ehret, Georg B.] Johns Hopkins Med Inst, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA.
[Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX USA.
[Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Div Epidemiol, Houston, TX USA.
[Ehret, Georg B.] Univ Hosp Geneva, Div Cardiol, Geneva, Switzerland.
[Ruczinski, Ingo; Scharpf, Robert B.; Coresh, Josef] Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21205 USA.
[Chen, Yii-Der Ida; Haritunians, Talin] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
[de Boer, Ian H.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA.
[Sarnak, Mark] Tufts Univ New England Med Ctr, Boston, MA USA.
[Siscovick, David] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Upadhyay, Ashish] Boston Med Ctr, Renal Sect, Boston, MA USA.
[Rivadeneira, Fernando; Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
[Chasman, Daniel I.; Pare, Guillaume; Ridker, Paul M.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, San Francisco VA Med Ctr, Gen Internal Med Div, San Francisco, CA 94143 USA.
[Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, Boston, MA 02115 USA.
[Fox, Caroline S.] Harvard Univ, Sch Med, Boston, MA USA.
RP Fox, CS (reprint author), Natl Heart Lung & Blood Inst Framingham Heart Stu, Framingham, MA USA.
EM j.witteman@erasmusmc.nl; coresh@jhu.edu; michael.shlipak@ucsf.edu;
foxca@nhlbi.nih.gov
RI Aulchenko, Yurii/M-8270-2013; Yang, Qiong/G-5438-2014; Gudnason,
Vilmundur/K-6885-2015; Rivadeneira, Fernando/O-5385-2015; EHRET,
Georg/A-9532-2009; Kottgen, Anna/D-2920-2012; Smith, Albert/K-5150-2015
OI Aulchenko, Yurii/0000-0002-7899-1575; Gudnason,
Vilmundur/0000-0001-5696-0084; Rivadeneira,
Fernando/0000-0001-9435-9441; EHRET, Georg/0000-0002-5730-0675; Smith,
Albert/0000-0003-1942-5845; Upadhyay, Ashish/0000-0002-0536-5776;
Benjamin, Emelia/0000-0003-4076-2336; Dehghan, Abbas/0000-0001-6403-016X
FU Intramural NIH HHS; NCATS NIH HHS [UL1 TR000423]; NCI NIH HHS [CA
047988, R01 CA047988]; NCRR NIH HHS [KL2 RR025015, KL2 RR025015-03, M01
RR000069, M01RR00069, UL1 RR025005, UL1 RR025005-01, UL1RR025005]; NHGRI
NIH HHS [U01 HG004402, U01 HG004402-01, U01HG004402]; NHLBI NIH HHS [N01
HC055018, HL 043851, N01 HC015103, N01 HC025195, N01 HC035129, N01
HC045133, N01 HC055015, N01 HC055016, N01 HC055019, N01 HC055020, N01
HC055021, N01 HC055022, N01 HC055222, N01 HC075150, N01 HC085079, N01
HC085086, N01-HC-25195, N01-HC-55015, N01-HC-55016, N01-HC-55018,
N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, N01-HC-55222,
N01-HC-75150, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082,
N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01HC25195,
N01HC55015, N01HC55016, N01HC55018, N01HC55019, N01HC55020, N01HC55021,
N01HC55022, N01HC55222, N01HC75150, N01HC85079, N01HC85086, N02 HL64278,
N02-HL-6-4278, R01 HL043851, R01 HL043851-09, R01 HL059367, R01
HL059367-02, R01 HL086694, R01 HL086694-01A1, R01 HL087641, R01
HL087641-01, R01 HL087652, R01 HL087652-01, R01HL086694, R01HL087641,
R01HL59367, U01 HL080295, U01 HL080295-01]; NIA NIH HHS [N01 AG012100,
N01AG12100, R01 AG027002, R01 AG027002-01]; NIDDK NIH HHS [DK063491, K01
DK067207, K01 DK067207-01A1, K01DK067207, P30 DK063491, P30
DK063491-019004, P30 DK063491-05, R01 DK076770]; PHS HHS
[HHSN268200625226C]
NR 30
TC 251
Z9 258
U1 1
U2 19
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD JUN
PY 2009
VL 41
IS 6
BP 712
EP 717
DI 10.1038/ng.377
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 450OW
UT WOS:000266411700021
PM 19430482
ER
PT J
AU Gorman, AA
Foley, JM
Ettenhofer, ML
Hinkin, CH
van Gorp, WG
AF Gorman, Ashley A.
Foley, Jessica M.
Ettenhofer, Mark L.
Hinkin, Charles H.
van Gorp, Wilfred G.
TI Functional Consequences of HIV-Associated Neuropsychological Impairment
SO NEUROPSYCHOLOGY REVIEW
LA English
DT Review
DE HIV/AIDS; Neuropsychology; Medication adherence; Employment; Driving
ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; OLDER-ADULT
DRIVERS; QUALITY-OF-LIFE; MEDICATION ADHERENCE; INFECTED ADULTS;
DRUG-USERS; DRIVING SIMULATOR; SOCIAL SUPPORT; PSYCHIATRIC-DISORDERS
AB This review focuses on the "real world" implications of infection with HIV/AIDS from a neuropsychological perspective. Relevant literature is reviewed which examines the relationships between HIV-associated neuropsychological impairment and employment, driving, medication adherence, mood, fatigue, and interpersonal functioning. Specifically, the relative contributions of medical, cognitive, psychosocial, and psychiatric issues on whether someone with HIV/AIDS will be able to return to work, adhere to a complicated medication regimen, or safely drive a vehicle will be discussed. Methodological issues that arise in the context of measuring medication adherence or driving capacity are also explored. Finally, the impact of HIV/AIDS on mood state, fatigue, and interpersonal relationships are addressed, with particular emphasis on how these variables interact with cognition and independent functioning. The purpose of this review is to integrate neuropsychological findings with their real world correlates of functional behavior in the HIV/AIDS population.
C1 [Gorman, Ashley A.; van Gorp, Wilfred G.] Columbia Univ, Dept Psychiat, Med Ctr, New York, NY 10027 USA.
[Foley, Jessica M.; Ettenhofer, Mark L.; Hinkin, Charles H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Hinkin, Charles H.] VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA.
RP Gorman, AA (reprint author), Columbia Univ, Dept Psychiat, Med Ctr, New York, NY 10027 USA.
EM ashleyanngorman@yahoo.com
FU NIMH NIH HHS [R01 MH058552, T32 MH019535, R01 MH058552-02]
NR 126
TC 65
Z9 66
U1 5
U2 8
PU CONSULTANTS BUREAU/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1040-7308
J9 NEUROPSYCHOL REV
JI Neuropsychol. Rev.
PD JUN
PY 2009
VL 19
IS 2
BP 186
EP 203
DI 10.1007/s11065-009-9095-0
PG 18
WC Psychology, Clinical; Neurosciences
SC Psychology; Neurosciences & Neurology
GA 454EQ
UT WOS:000266665400005
PM 19472057
ER
PT J
AU Martin, LF
Davalos, DB
Kisley, MA
AF Martin, Laura F.
Davalos, Deana B.
Kisley, Michael A.
TI Nicotine enhances automatic temporal processing as measured by the
mismatch negativity waveform
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID AUDITORY SENSORY MEMORY; EVENT-RELATED POTENTIALS; ELECTROPHYSIOLOGICAL
INDEXES; SCHIZOPHRENIC-PATIENTS; COGNITIVE PERFORMANCE; SELECTIVE
ATTENTION; RECEPTOR ACTIVATION; INTERVAL DURATION; PREFRONTAL CORTEX;
DOPAMINE
AB Cholinergic agonists and, more specifically, nicotine, have been found to enhance a number of cognitive processes. The effect of nicotine on temporal processing is not known. The use of behavioral measures of temporal processing to measure its effect could be confounded by the general effects of nicotine on attention. Mismatch negativity (MMN) has been used as a physiological measure of automatic temporal processing to avoid this potential confound.
A total of 20 subjects (11 nonsmokers and 9 smokers following 2 hr of abstinence) participated in a two-visit single-blind, placebo-controlled crossover study of the effect of nicotine on MMN indices in response to an interstimulus interval deviant.
Nicotine-enhanced MMN amplitudes from baseline recording to postdrug recording greater than did the placebo condition. This enhancement was seen in both nonsmokers and smokers. Nicotine had no significant effect on MMN latency or N100 amplitude or latency.
This is the first study to demonstrate a nicotine-related enhancement of MMN amplitude to an interstimulus interval duration deviant and confirms our hypothesis that nicotine enhances preattentive temporal processing. Nicotinic agonists may represent a potential therapeutic option for individuals with abnormalities in early sensory or temporal processing related to cholinergic system abnormalities. Methodologically, our paradigm of nicotine administration in abstinent smokers is important because it resulted in both minimal withdrawal symptoms and meaningful data that are not attributable solely to relief of withdrawal.
C1 [Martin, Laura F.; Davalos, Deana B.] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA.
[Martin, Laura F.; Davalos, Deana B.] Denver Vet Affairs Med Ctr, Res Serv, Denver, CO USA.
[Davalos, Deana B.] Colorado State Univ, Dept Psychol, Ft Collins, CO 80523 USA.
[Kisley, Michael A.] Univ Colorado, Dept Psychol, Colorado Springs, CO 80933 USA.
RP Martin, LF (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Psychiat, 4200 E 9th Ave,C268-71, Denver, CO 80262 USA.
EM laura.martin@uchsc.edu
FU The Veterans Affairs Medical Research Service
FX The Veterans Affairs Medical Research Service
NR 60
TC 21
Z9 21
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD JUN
PY 2009
VL 11
IS 6
BP 698
EP 706
DI 10.1093/ntr/ntp052
PG 9
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA 454QX
UT WOS:000266698600017
PM 19436039
ER
PT J
AU Ney, DM
Weiss, JM
Kind, AJH
Robbins, J
AF Ney, Denise M.
Weiss, Jennifer M.
Kind, Amy J. H.
Robbins, JoAnne
TI Senescent Swallowing: Impact, Strategies, and Interventions
SO NUTRITION IN CLINICAL PRACTICE
LA English
DT Review
DE aging; deglutition disorders; enteral nutrition; pneumonia;
malnutrition; dehydration
ID PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; ACUTE ISCHEMIC-STROKE; QOL OUTCOMES
TOOL; OF-THE-LITERATURE; OLDER-ADULTS; SKELETAL-MUSCLE; OROPHARYNGEAL
DYSPHAGIA; DIETARY-PROTEIN; BOUNCING-BACK; SWAL-QOL
AB The risk for disordered oropharyngeal swallowing (dysphagia) increases with age. Loss of swallowing function can have devastating health implications, including dehydration, malnutrition, pneumonia, and reduced quality of life. Age-related changes increase risk for dysphagia. First, natural, healthy aging takes its toll on head and neck anatomy and physiologic and neural mechanisms underpinning swallowing function. This progression of change contributes to alterations in the swallowing in healthy older adults and is termed presbyphagia, naturally diminishing functional reserve. Second, disease prevalence increases with age, and dysphagia is a comorbidity of many age-related diseases and/or their treatments. Sensory changes, medication, sarcopenia, and age-related diseases are discussed herein. Recent findings that health complications are associated with dysphagia are presented. Nutrient requirements, fluid intake, and nutrition assessment for older adults are reviewed relative to dysphagia. Dysphagia screening and the pros and Coils Of tube feeding as a solution are discussed. Optimal intervention strategies for elders with dysphagia ranging from compensatory interventions to more rigorous exercise approaches are presented. Compelling evidence of improved functional swallowing and eating Outcomes resulting from active rehabilitation focusing on increasing strength of head and neck Musculature is provided. In summary, although oropharyngeal dysphagia may be life threatening, so are some of the traditional alternatives, particularly for frail, elderly patients. Although the state of the evidence calls for more research, this review indicates that the behavioral, dietary, and environmental modifications emerging in this past decade are compassionate, promising, and, in many cases, preferred alternatives to the always present option of tube feuding. (Nutr Clin Pract. 2009;24:395-413)
C1 Univ Wisconsin, Dept Nutr Sci, Madison, WI 53705 USA.
Univ Wisconsin, Dept Med, Madison, WI 53705 USA.
Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA.
RP Robbins, J (reprint author), Univ Wisconsin, VA Hosp GRECC, 2500 Overlook Terrace,GRECC 11G, Madison, WI 53705 USA.
EM jrobbin2@wisc.edu
FU AHRQ HHS [HS000083, HS000083-12, T32 HS000083]; NCRR NIH HHS [UL1
RR025011-03, UL1 RR025011, UL1 RR025011-01, UL1 RR025011-02]; None [T32
HS000083-12]
NR 105
TC 85
Z9 96
U1 6
U2 30
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0884-5336
J9 NUTR CLIN PRACT
JI Nutr. Clin. Pract.
PD JUN-JUL
PY 2009
VL 24
IS 3
BP 395
EP 413
DI 10.1177/0884533609332005
PG 19
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 454YA
UT WOS:000266719000011
PM 19483069
ER
PT J
AU Berman, P
Collins, M
Baumgarten, I
Seoighe, C
Jennings, CL
Joffe, Y
Lambert, EV
Levitt, NS
Faulenbach, MV
Kahn, SE
Goedecke, JH
AF Berman, Peter
Collins, Malcolm
Baumgarten, Ingrid
Seoighe, Cathal
Jennings, Courtney L.
Joffe, Yael
Lambert, Estelle V.
Levitt, Naomi S.
Faulenbach, Mirjam V.
Kahn, Steven E.
Goedecke, Julia H.
TI Association Between the 4 bp Proinsulin Gene Insertion Polymorphism
(IVS-69) and Body Composition in Black South African Women
SO OBESITY
LA English
DT Article
ID SPLICE-VARIANT; OBESITY; TRANSLATION
AB The objective of the study was to examine the association between a functional 4 bp proinsulin gene insertion polymorphism (IVS-69), fasting insulin concentrations, and body composition in black South African women. Body composition, body fat distribution, fasting glucose and insulin concentrations, and IVS-69 genotype were measured in 115 normal-weight (BMI < 25 kg/ m(2)) and 138 obese (BMI >= 30 kg/m(2)) premenopausal women. The frequency of the insertion allele was significantly higher in the class 2 obese (BMI >= 35kg/m(2)) compared with the normal-weight group (P = 0.029). Obese subjects with the insertion allele had greater fat mass (42.3 +/- 0.9 vs. 38.9 +/- 0.9 kg, P = 0.034) and fat-free soft tissue mass (47.4 +/- 0.6 vs. 45.1 +/- 0.6 kg, P = 0.014), and more abdominal subcutaneous adipose tissue (SAT, 595 +/- 17 vs. 531 +/- 17 cm(2), P = 0.025) but not visceral fat (P = 0.739), than obese homozygotes for the wild-type allele. Only SAT was greater in normal-weight subjects with the insertion allele (P = 0.048). There were no differences in fasting insulin or glucose levels between subjects with the insertion allele or homozygotes for the wild-type allele in the normal-weight or obese groups. In conclusion, the 4 bp proinsulin gene insertion allele is associated with extreme obesity, reflected by greater fat-free soft tissue mass and fat mass, particularly SAT, in obese black South African women.
C1 [Berman, Peter; Baumgarten, Ingrid] Univ Cape Town, Div Chem Pathol, ZA-7925 Cape Town, South Africa.
[Collins, Malcolm; Jennings, Courtney L.; Joffe, Yael; Lambert, Estelle V.; Goedecke, Julia H.] Univ Cape Town, MRC Res Unit Exercise Sci & Sports Med, Dept Human Biol, ZA-7925 Cape Town, South Africa.
[Collins, Malcolm; Goedecke, Julia H.] S African MRC, Cape Town, South Africa.
[Seoighe, Cathal] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
[Seoighe, Cathal] Natl Univ Ireland, Dept Math Stat & Appl Math, Galway, Ireland.
[Levitt, Naomi S.] Univ Cape Town, Dept Med, Endocrine Unit, ZA-7925 Cape Town, South Africa.
[Faulenbach, Mirjam V.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Faulenbach, Mirjam V.; Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA.
RP Berman, P (reprint author), Univ Cape Town, Div Chem Pathol, ZA-7925 Cape Town, South Africa.
EM peter.berman@uct.ac.za
RI Collins, Malcolm/G-4046-2011; Goedecke, Julia/J-8628-2013; Goedecke,
Julia/E-1820-2016
OI Collins, Malcolm/0000-0002-2564-0480; Goedecke,
Julia/0000-0001-6795-4771; Goedecke, Julia/0000-0001-6795-4771; Kahn,
Steven/0000-0001-7307-9002
FU National Research Foundation of South Africa; South African Medical
Research Council; International Atomic Energy Agency; University of Cape
Town; United States Department of Veterans Affairs
FX We are grateful to Hendriena Victor and Judy Belonje for their technical
assistance. We also thank Jack Bergman, Naomi Fenton, and Linda
Bewerunge for performing the scans. This study was funded by the
National Research Foundation of South Africa, the South African Medical
Research Council, the International Atomic Energy Agency, the University
of Cape Town and the United States Department of Veterans Affairs.
NR 11
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1930-7381
J9 OBESITY
JI Obesity
PD JUN
PY 2009
VL 17
IS 6
BP 1298
EP 1300
DI 10.1038/oby.2009.40
PG 3
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 450EG
UT WOS:000266383200032
PM 19247282
ER
PT J
AU Mata, IF
Cosentino, C
Marca, V
Torres, L
Mazzetti, P
Ortega, O
Raggio, V
Aljanati, R
Buzo, R
Yearout, D
Dieguez, E
Zabetian, CP
AF Mata, Ignacio F.
Cosentino, Carlos
Marca, Victoria
Torres, Luis
Mazzetti, Pilar
Ortega, Olimpio
Raggio, Victor
Aljanati, Ruth
Buzo, Ricardo
Yearout, Dora
Dieguez, Elena
Zabetian, Cyrus P.
TI LRRK2 mutations in patients with Parkinson's disease from Peru and
Uruguay
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Article
DE Parkinson's disease; LRRK2; Mutation; Haplotype
ID SPANISH PATIENTS; COMMON MUTATION; G2019S; IDENTIFICATION; PENETRANCE;
FREQUENCY; PHENOTYPE; GENETICS; FOUNDER; EUROPE
AB Variation in the leucine-rich repeat kinase 2 (LRRK2) gene represents the most common genetic determinant of Parkinson's disease (PD) identified to date. While the frequency and distribution of LRRK2 mutations have been well-studied in Europe and North America, few data are available from South America. To address this gap in knowledge, we screened two cohorts of patients with PD from Peru (n = 240) and Uruguay (n = 125) for the three most common LRRK2 mutations (R1441C, R1441G, G2019S). We identified at total of seven patients with mutations, one with R1441G, and six with G2019S. The carrier frequency was significantly greater in the Uruguayan cohort (4.8%) than in the Peruvian cohort (0.4%; p = 0.007). This likely resulted from a greater admixture proportion in the Peruvian sample. Haplotype analyses suggested that G2019S was probably brought to Peru and Uruguay by European settlers. In contrast, the origin of R1441G in our cohort was not clear, as the patient with this mutation had a background haplotype that was clearly distinct from that reported in carriers from Europe and North America. Our data add to a growing body of evidence indicating that LRRK2 mutations are widely distributed across South America but might differ by region in prevalence. Published by Elsevier Ltd.
C1 [Mata, Ignacio F.; Yearout, Dora; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Mata, Ignacio F.; Yearout, Dora; Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Cosentino, Carlos; Torres, Luis] Inst Ciencias Neurol, Movement Disorders Unit, Lima, Peru.
[Marca, Victoria; Mazzetti, Pilar; Ortega, Olimpio] Inst Ciencias Neurol, Neurogenet Unit, Lima, Peru.
[Raggio, Victor] Univ Republica, Fac Med, Dept Genet, Montevideo, Uruguay.
[Aljanati, Ruth; Buzo, Ricardo] Univ Republica, Fac Med, Dept PD & Movement Disorders, Montevideo, Uruguay.
[Dieguez, Elena] Univ Republica, Fac Med, Dept Neurol, Montevideo, Uruguay.
RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, S-182,1660 S Columbia Way, Seattle, WA 98108 USA.
EM zabetian@u.washington.edu
OI Fernandez Mata, Ignacio/0000-0003-1198-0633; Zabetian,
Cyrus/0000-0002-7739-4306
FU Department of Veterans Affairs, Office of Research and Development
Medical Research Service; American Parkinson Disease Association;
Parkinson's Disease Foundation
FX We thank the individuals who participated in the study, and Giovanna
Ramos, Amalia Avila and Luis Delgado for technical support and
assistance with subject recruitment. This work was supported by grants
from the Department of Veterans Affairs, Office of Research and
Development Medical Research Service (Merit Review Award, C.P.Z.), the
American Parkinson Disease Association (C.P.Z.), and the Parkinson's
Disease Foundation (Postdoctoral Research Fellowship, I.FM.).
NR 28
TC 17
Z9 18
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD JUN
PY 2009
VL 15
IS 5
BP 370
EP 373
DI 10.1016/j.parkreldis.2008.09.002
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 460OD
UT WOS:000267196100008
PM 18980856
ER
PT J
AU Davis, JM
Haake, DA
Ramakrishnan, L
AF Davis, J. Muse
Haake, David A.
Ramakrishnan, Lalita
TI Leptospira interrogans Stably Infects Zebrafish Embryos, Altering
Phagocyte Behavior and Homing to Specific Tissues
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID MYCOBACTERIUM-MARINUM INFECTION; RENAL-DISEASE; GUINEA-PIGS; IN-VIVO;
PATHOGENESIS; MACROPHAGES; MODEL; CELLS; ICTEROHAEMORRHAGIAE;
LIPOPOLYSACCHARIDE
AB Leptospirosis is an extremely widespread zoonotic infection with outcomes ranging from subclinical infection to fatal Weil's syndrome. Despite the global impact of the disease, key aspects of its pathogenesis remain unclear. To examine in detail the earliest steps in the host response to leptospires, we used fluorescently labelled Leptospira interrogans serovar Copenhageni to infect 30 hour post fertilization zebrafish embryos by either the caudal vein or hindbrain ventricle. These embryos have functional innate immunity but have not yet developed an adaptive immune system. Furthermore, they are optically transparent, allowing direct visualization of host-pathogen interactions from the moment of infection. We observed rapid uptake of leptospires by phagocytes, followed by persistent, intracellular infection over the first 48 hours. Phagocytosis of leptospires occasionally resulted in formation of large cellular vesicles consistent with apoptotic bodies. By 24 hours, clusters of infected phagocytes were accumulating lateral to the dorsal artery, presumably in early hematopoietic tissue. Our observations suggest that phagocytosis may be a key defense mechanism in the early stages of leptospirosis, and that phagocytic cells play roles in immunopathogenesis and likely in the dissemination of leptospires to specific target tissues.
C1 [Davis, J. Muse] Emory Univ, Immunol & Mol Pathogenesis Grad Program, Atlanta, GA 30322 USA.
[Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.
[Ramakrishnan, Lalita] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
[Ramakrishnan, Lalita] Univ Washington, Dept Med & Immunol, Seattle, WA 98195 USA.
RP Davis, JM (reprint author), Emory Univ, Immunol & Mol Pathogenesis Grad Program, Atlanta, GA 30322 USA.
EM dhaake@ucla.edu; lalitar@u.washington.edu
FU American Society for Engineering Education; NIH/NIAID [AI-34431]; NIH
[R01 AI-54503]
FX M. D. was supported by an American Society for Engineering Education
predoctoral fellowship. D. A. H. was supported by VA Medical Research
Funds, and by NIH/NIAID grant AI-34431. L. R. was supported by NIH R01
AI-54503 and the Burroughs Wellcome Foundation. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 44
TC 30
Z9 34
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2009
VL 3
IS 6
AR e463
DI 10.1371/journal.pntd.0000463
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 475XS
UT WOS:000268401000005
PM 19547748
ER
PT J
AU Nielsen, SL
Okiishi, J
Nielsen, DL
Hawkins, EJ
Harmon, SC
Pedersen, T
Worthen, VE
Isakson, RL
Lambert, MJ
Lawson, J
Whipple, JL
Gleave, RL
Hansen, NB
Dougher, MK
Smart, DW
Rice, ML
Chapman, RK
Jackson, AP
AF Nielsen, Stevan Lars
Okiishi, John
Nielsen, Dianne L.
Hawkins, Eric J.
Harmon, S. Cory
Pedersen, Tyler
Worthen, Vaughn E.
Isakson, Richard L.
Lambert, Michael J.
Lawson, Jane
Whipple, Jason L.
Gleave, Robert L.
Hansen, Nathan B.
Dougher, M. Kirk
Smart, David W.
Rice, Maureen L.
Chapman, Ronald K.
Jackson, Aaron P.
TI Termination, Appointment Use, and Outcome Patterns Associated With
Intake Therapist Discontinuity
SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE
LA English
DT Article
DE intake; continuity of care; outpatient psychotherapy
ID DOSE-EFFECT RELATIONS; PSYCHOTHERAPY; CONTINUITY; CARE
AB Psychotherapy clients often experience intake therapist discontinuity: meeting first with an intake therapist, then entering therapy with a different treating therapist. The authors compared such discontinuity clients at a university's counseling center (55.6% of 15,137 clients) with continuity clients, who continued therapy with their intake therapists. Discontinuity clients were twice as likely as continuity clients to terminate by missing the appointment after intake. Improvement among discontinuity clients lagged behind improvement among continuity clients at Sessions 2 and 3. Though more likely to terminate by missing Session 2, discontinuity clients attended 2 sessions more than continuity clients, on average, making treatment of discontinuity clients 19% more expensive than treatment of continuity clients in terms of sessions attended. The extra sessions attended by discontinuity clients did not yield overall better outcomes. Intake therapist discontinuity appeared to disrupt the beginning of psychotherapy, dissuading some clients from returning after intake, slowing early improvement among those who did return, and unproductively lengthening their treatment.
C1 [Nielsen, Stevan Lars; Nielsen, Dianne L.; Pedersen, Tyler; Worthen, Vaughn E.; Isakson, Richard L.; Lawson, Jane; Gleave, Robert L.; Smart, David W.; Rice, Maureen L.] Brigham Young Univ, CCC, Provo, UT 84602 USA.
[Jackson, Aaron P.] Brigham Young Univ, APA Accredited Doctoral Counseling Psychol Progra, Provo, UT 84602 USA.
[Hawkins, Eric J.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
[Harmon, S. Cory] New York Presbyterian Hosp, White Plains, NY USA.
[Whipple, Jason L.] Bassett Army Community Hosp, Community Mental Hlth Serv, Ft Wainwright, AK USA.
[Hansen, Nathan B.] Yale Univ, Sch Med, Dept Psychiat, Consultat Ctr, New Haven, CT 06520 USA.
[Hansen, Nathan B.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT 06520 USA.
RP Nielsen, SL (reprint author), Brigham Young Univ, CCC, 1526 WSC, Provo, UT 84602 USA.
EM stevan.lars.nielsen@byu.edu
RI Hansen, Nathan/F-2074-2016
OI Nielsen, Stevan Lars/0000-0003-2877-262X
NR 17
TC 0
Z9 0
U1 0
U2 3
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0735-7028
J9 PROF PSYCHOL-RES PR
JI Prof. Psychol.-Res. Pract.
PD JUN
PY 2009
VL 40
IS 3
BP 272
EP 278
DI 10.1037/a0013286
PG 7
WC Psychology, Multidisciplinary
SC Psychology
GA 458BD
UT WOS:000266984700008
ER
PT J
AU Nelles, JL
Freedland, SJ
Presti, JC
Terris, MK
Aronson, WJ
Amling, CL
Kane, CJ
AF Nelles, J. L.
Freedland, S. J.
Presti, J. C., Jr.
Terris, M. K.
Aronson, W. J.
Amling, C. L.
Kane, C. J.
TI Impact of nerve sparing on surgical margins and biochemical recurrence:
results from the SEARCH database
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Article
DE radical prostatectomy; biochemical recurrence; nerve sparing
ID PROSTATE-SPECIFIC ANTIGEN; RADICAL RETROPUBIC PROSTATECTOMY; POSITIVE
MARGINS; CANCER; PRESERVATION; FAILURE; PREDICT
AB The effects of nerve sparing on the risk of positive surgical margins (PSMs) and biochemical recurrence after radical prostatectomy (RP) remain controversial. We examined data from 1018 men treated by RP between 1988 and 2006 at five centers in the Shared Equal Access Regional Cancer Hospital database. Neither bilateral nor unilateral nerve-sparing techniques were associated with a higher risk of PSM; on multivariate analysis of individual sides, the risk of PSM on either side was not increased by nerve sparing on either side. The risk for biochemical recurrence was not affected by bilateral or unilateral nerve sparing. When used on appropriately selected patients, nerve sparing does not increase the probability of PSM or biochemical recurrence after RP. Prostate Cancer and Prostatic Diseases (2009) 12, 172-176; doi:10.1038/pcan.2008.40; published online 15 July 2008
C1 [Kane, C. J.] Univ Calif San Diego, San Diego Med Ctr, Dept Surg, Div Urol, San Diego, CA 92103 USA.
[Nelles, J. L.] Univ Calif San Francisco, San Francisco Sch Med, Dept Urol, San Francisco, CA 94143 USA.
[Freedland, S. J.] Vet Adm Med Ctr, Dept Surg, Durham, NC USA.
[Freedland, S. J.] Duke Univ, Sch Med, Dept Surg, Div Urol Surg, Durham, NC USA.
[Freedland, S. J.] Duke Univ, Sch Med, Duke Prostate Ctr, Durham, NC USA.
[Freedland, S. J.] Duke Univ, Sch Med, Dept Pathol, Durham, NC USA.
[Presti, J. C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA.
[Presti, J. C., Jr.] Vet Adm Med Ctr, Dept Surg, Urol Sect, Palo Alto, CA 94304 USA.
[Terris, M. K.] Vet Adm Med Ctr, Dept Surg, Augusta, GA 30904 USA.
[Terris, M. K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA.
[Aronson, W. J.] Vet Adm Greater Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA.
[Aronson, W. J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
[Amling, C. L.] Univ Alabama, Dept Surg, Div Urol, Birmingham, AL 35294 USA.
[Kane, C. J.] Moores UCSD Canc Ctr, La Jolla, CA USA.
RP Kane, CJ (reprint author), Univ Calif San Diego, San Diego Med Ctr, Dept Surg, Div Urol, 200 W Arbor Dr 8897, San Diego, CA 92103 USA.
EM ckane@ucsd.edu
OI Terris, Martha/0000-0002-3843-7270
FU Department of Veterans Affairs; National Institute of Health [T32
DK0779001, R01CA100938, P50 CA92131-01A1]; American Urological
Association Foundation
FX This work was supported by the Department of Veterans Affairs, National
Institute of Health T32 Grant DK0779001 (JLN, CJK), National Institute
of Health R01CA100938 (WJA), NIH Specialized Programs of Research
Excellence Grant P50 CA92131-01A1 (WJA), the Georgia Cancer Coalition
(MKT), the Department of Defense, Prostate Cancer Research Program,
(SJF), and the American Urological Association Foundation Astellas
Rising Star in Urology Award (SJF).
NR 18
TC 10
Z9 10
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1365-7852
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD JUN
PY 2009
VL 12
IS 2
BP 172
EP 176
DI 10.1038/pcan.2008.40
PG 5
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 444KT
UT WOS:000265980600012
PM 18626507
ER
PT J
AU Barry, LK
AF Barry, Liliana Kalogjera
TI Ethical Issues in Psychiatric Research
SO PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Ethics; Psychiatric research; Informed consent; Human subjects; Mental
illness research
ID MENTAL-HEALTH PROBLEMS; CONFLICTS-OF-INTEREST; CLINICAL-RESEARCH;
GENETIC EXCEPTIONALISM; INFORMED-CONSENT; AFGHANISTAN; SAFEGUARDS; IRAQ;
SCHIZOPHRENIA; ATTITUDES
AB The psychiatric research imperative remains strong, as investigators strive for greater understanding of mental illness, which affects millions of people in the United States alone. With the need for research, however, comes an obligation to conduct such research in a manner that protects and respects participants. Accordingly, the field of psychiatric research ethics continues to grow in depth and breadth. Initial debates, which focused on the ethical permissibility of research involving participants who have mental illness, have evolved into more nuanced inquiries, both theoretical and empirical. These inquiries can provide a greater understanding of the imperatives and boundaries for psychiatric research.
C1 [Barry, Liliana Kalogjera] US Dept Vet Affairs, Off Reg Counsel, Reg Off, Milwaukee, WI 53214 USA.
[Barry, Liliana Kalogjera] Med Coll Wisconsin, Dept Psychiat & Behav Med, Milwaukee, WI 53226 USA.
RP Barry, LK (reprint author), US Dept Vet Affairs, Off Reg Counsel, Reg Off, 5400 W Natl Ave, Milwaukee, WI 53214 USA.
EM liliana.kalogjera@va.gov
NR 41
TC 4
Z9 4
U1 3
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0193-953X
J9 PSYCHIAT CLIN N AM
JI Psychiatr. Clin. North Amer.
PD JUN
PY 2009
VL 32
IS 2
BP 381
EP +
DI 10.1016/j.psc.2009.02.003
PG 16
WC Psychiatry
SC Psychiatry
GA 463EC
UT WOS:000267411000011
PM 19486820
ER
PT J
AU Qureshi, SU
Pyne, JM
Magruder, KM
Schulz, PE
Kunik, ME
AF Qureshi, Salah U.
Pyne, Jeffrey M.
Magruder, Kathy M.
Schulz, Paul E.
Kunik, Mark E.
TI The Link Between Post-traumatic Stress Disorder and Physical
Comorbidities: A Systematic Review
SO PSYCHIATRIC QUARTERLY
LA English
DT Article
DE Post-traumatic stress disorder; Physical comorbidities; Specific
physical disorders
ID PRIMARY-CARE; VIETNAM VETERANS; HEART-DISEASE; HEALTH; ILLNESS; WOMEN;
PTSD; WAR; PREVALENCE; HISTORIES
AB Context Returning veterans from Afghanistan and Iraq will increase frequency of post-traumatic stress disorder (PTSD). Little is known about its impact on physical health. Objective Systematic literature review focusing on the association between PTSD and specific physical disorders. Data Sources An electronic search using PUBMED and hand search of four journals with an anxiety focus for studies published between January 1981 and July 2008, plus a manual search of article bibliographies. Study Selection Original research reports focusing on PTSD and its association with physical health. Studies investigating only PTSD symptoms, trauma and physical disorders classified at the organ-system level were excluded. Eighty studies were reviewed and seven selected for final analysis. Data Extraction Specific physical-health diagnoses were organized by system and tabulated. They were considered positive only if results were statistically significant. Total number of positive and negative studies for each diagnosis was then calculated for review. Results Seven studies examined the relationship between PTSD and specific physical disorders. Arthritis was associated with PTSD in most studies. Data conflicted regarding diabetes, coronary heart disease, and stroke. Conclusions Few studies have examined the relationship between PTSD and physical health. Large, prospective epidemiological trials are needed.
C1 [Qureshi, Salah U.; Kunik, Mark E.] Michael E DeBakey Vet Affairs Med Ctr 152, Hlth Serv Res & Dev Serv, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA.
[Qureshi, Salah U.; Schulz, Paul E.] Baylor Coll Med, Neurosensory Ctr, Houston, TX 77030 USA.
[Pyne, Jeffrey M.] Cent Arkansas Vet Healthcare Syst, Ctr Mental Hlth & Outcomes Res, N Little Rock, AR USA.
[Pyne, Jeffrey M.] Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Little Rock, AR 72205 USA.
[Magruder, Kathy M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Magruder, Kathy M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Qureshi, Salah U.; Schulz, Paul E.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Qureshi, Salah U.; Schulz, Paul E.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Kunik, Mark E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Kunik, Mark E.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Kunik, Mark E.] Vet Affairs S Cent Mental Illness Res Educ & Clin, N Little Rock, AR USA.
RP Kunik, ME (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, Hlth Serv Res & Dev Serv, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe, Houston, TX 77030 USA.
EM mkunik@bcm.tmc.edu
NR 21
TC 61
Z9 62
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-2720
J9 PSYCHIAT QUART
JI Psychiatr. Q.
PD JUN
PY 2009
VL 80
IS 2
BP 87
EP 97
DI 10.1007/s11126-009-9096-4
PG 11
WC Psychiatry
SC Psychiatry
GA 444WL
UT WOS:000266011000003
PM 19291401
ER
PT J
AU Szymusiak, R
AF Szymusiak, Ronald
TI Sleepy Synapses
SO SLEEP
LA English
DT Editorial Material
ID LONG-TERM POTENTIATION; MOTOR CORTEX; RAT
C1 [Szymusiak, Ronald] VA Greater Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
[Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
RP Szymusiak, R (reprint author), VA Greater Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91344 USA.
EM rszym@ucla.edu
NR 11
TC 0
Z9 0
U1 0
U2 0
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD JUN 1
PY 2009
VL 32
IS 6
BP 713
EP 714
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 452WE
UT WOS:000266571100001
PM 19544744
ER
PT J
AU Platt, AB
Field, SH
Asch, DA
Chen, Z
Patel, NP
Gupta, R
Roche, DF
Gurubhagavatula, I
Christie, JD
Kuna, ST
AF Platt, Alec B.
Field, Samuel H.
Asch, David A.
Chen, Zhen
Patel, Nirav P.
Gupta, Rajesh
Roche, Dominic F.
Gurubhagavatula, Indira
Christie, Jason D.
Kuna, Samuel T.
TI Neighborhood of Residence is Associated with Daily Adherence to CPAP
Therapy
SO SLEEP
LA English
DT Article
DE Obstructive sleep apnea; continuous positive airway pressure; adherence;
socioeconomic status
ID POSITIVE AIRWAY PRESSURE; OBSTRUCTIVE SLEEP-APNEA; CORONARY
HEART-DISEASE; CHARLSON COMORBIDITY INDEX; SOCIOECONOMIC-STATUS;
ADMINISTRATIVE DATABASES; PRACTICE PARAMETERS; NASAL CPAP; HEALTH; RISK
AB Study Objectives: Adherence to continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea is poor. Risk factors for nonadherence are not well understood but may reflect individual or neighborhood socioeconomic factors. We sought to determine the association of socioeconomic status and initial CPAP adherence.
Design: Retrospective cohort study, 2005 to 2006.
Setting: Philadelphia VA Medical Center.
Participants: Of 330 consecutive veterans who met study criteria for initiation of CPAP therapy for newly diagnosed sleep apnea, 266 had complete data for study inclusion.
Interventions: N/A.
Measurements: Through a multivariable logistic regression model, using an outcome of objectively measured CPAP use ! 4 h daily during the first week of treatment, we tested whether patients from higher socioeconomic neighborhoods had higher CPAP adherence. We measured neighborhood socioeconomic status with an index derived from the 2000 U.S. Census at the block group-level composed of median household income, male and female employment, adult high school completion, married households, and minority composition.
Results: CPAP adherence : >= 4 h occurred on 48.9% of 1,805 patient-days observed for the 266 subjects. After adjustment for individual sociodemographic characteristics and medical comorbidity, the probability of daily CPAP use >= 4 h ranged from 34.1% (95% CI, 26.4-42.7) for subjects from a low socioeconomic neighborhood (5th percentile) to 62.3% (95% CI, 53.8-70.1) for subjects from a high (95th percentile) neighborhood.
Conclusions: In a retrospective cohort of veterans, initial CPAP adherence was closely associated with higher neighborhood socioeconomic factors. Future investigation should target specific impediments to adherence in the home and neighborhood environment.
C1 [Platt, Alec B.; Field, Samuel H.; Asch, David A.; Roche, Dominic F.; Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Platt, Alec B.] Reading Hosp Med Ctr, Reading, PA USA.
[Field, Samuel H.] Univ N Carolina, Frank Porter Graham Child Dev Inst, Chapel Hill, NC USA.
[Asch, David A.; Patel, Nirav P.; Gurubhagavatula, Indira; Christie, Jason D.; Kuna, Samuel T.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Asch, David A.; Christie, Jason D.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Chen, Zhen] NICHHD, Div Epidemiol Stat & Prevent Res, Bethesda, MD 20892 USA.
[Patel, Nirav P.; Gupta, Rajesh; Gurubhagavatula, Indira; Kuna, Samuel T.] Philadelphia VA Med Ctr, Pulm Crit Care & Sleep Sect, Philadelphia, PA USA.
RP Platt, AB (reprint author), 2608 Keiser Blvd, Wyomissing, PA 19610 USA.
EM alecplatt@gmail.com
FU NHLBI NIH HHS [T-32 HL07713-14, T32 HL007713]; NIOSH CDC HHS
[R01-OH-009149-01, R01 OH009149]
NR 52
TC 53
Z9 53
U1 0
U2 6
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD JUN 1
PY 2009
VL 32
IS 6
BP 799
EP 806
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 452WE
UT WOS:000266571100014
PM 19544757
ER
PT J
AU Conrad, AK
Jacoby, AM
Jobes, DA
Lineberry, TW
Shea, CE
Ewing, TDA
Schmid, PJ
Ellenbecker, SM
Lee, JL
Fritsche, K
Grenell, JA
Gehin, JM
Kung, S
AF Conrad, Amy K.
Jacoby, Aaron M.
Jobes, David A.
Lineberry, Timothy W.
Shea, Catherine E.
Ewing, Theresa D. Arnold
Schmid, Phyllis J.
Ellenbecker, Susan M.
Lee, Joy L.
Fritsche, Kathryn
Grenell, Jennifer A.
Gehin, Jessica M.
Kung, Simon
TI A Psychometric Investigation of the Suicide Status Form II with a
Psychiatric Inpatient Sample
SO SUICIDE AND LIFE-THREATENING BEHAVIOR
LA English
DT Article
ID SOMATIC ANXIETY STICSA; CLINICAL PREDICTORS; LIVING INVENTORY; TRAIT
INVENTORY; SCALE; HOPELESSNESS; IDEATION; REASONS; OUTPATIENTS; RISK
AB We investigated the psychometric validity and reliability of the Suicide Status Form-II (SSF-II) developed by Jobes, Jacoby, Cimbolic, and Hustead (1997). Participants were 149 psychiatric inpatients (108 suicidal; 41 nonsuicidal) at the Mayo Clinic. Each participant completed assessment measures within 24 hours of admission and 48-72 hours later. Factor analyses of the SSF core assessment produced a robust two-factor solution reflecting chronic and acute response styles. The SSF core assessment had good to excellent convergent and criterion validity; pre-post SSF ratings also demonstrated moderate test-retest reliability. The results replicated previous research and show that the SSF-II is psychometrically sound with a high-risk suicidal inpatient sample.
C1 [Jobes, David A.] Catholic Univ Amer, Dept Psychol, Washington, DC 20064 USA.
[Conrad, Amy K.] Walter Reed Army Med Ctr, Silver Spring, MD USA.
[Jacoby, Aaron M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Lineberry, Timothy W.; Shea, Catherine E.; Ewing, Theresa D. Arnold; Schmid, Phyllis J.; Ellenbecker, Susan M.; Lee, Joy L.; Fritsche, Kathryn; Grenell, Jennifer A.; Gehin, Jessica M.; Kung, Simon] Mayo Clin, Rochester, MN USA.
RP Jobes, DA (reprint author), Catholic Univ Amer, Dept Psychol, 314 OBoyle Hall, Washington, DC 20064 USA.
EM Jobes@cua.edu
NR 45
TC 32
Z9 32
U1 1
U2 3
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0363-0234
J9 SUICIDE LIFE-THREAT
JI Suicide Life-Threat. Behav.
PD JUN
PY 2009
VL 39
IS 3
BP 307
EP 320
PG 14
WC Psychiatry; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 470CY
UT WOS:000267952900006
PM 19606922
ER
PT J
AU Walker, RH
Koch, RJ
Sweeney, JE
Moore, C
Meshul, CK
AF Walker, Ruth H.
Koch, Rick J.
Sweeney, John E.
Moore, Cynthia
Meshul, Charles K.
TI Effects of subthalamic nucleus lesions and stimulation upon glutamate
levels in the dopamine-depleted rat striatum
SO NEUROREPORT
LA English
DT Article
DE deep brain stimulation; glutamate; 6-hydroxydopamine; microdialysis;
Parkinson's disease; rat; striatum; subthalamic nucleus
ID HIGH-FREQUENCY STIMULATION; PARKINSONS-DISEASE; BASAL GANGLIA;
SUBSTANTIA-NIGRA; NEURONS; TRANSMISSION; OVERACTIVITY; RETICULATA;
INCREASE
AB It is not known how neurosurgical interventions benefit patients with Parkinson's disease. We compared the effects of electrical stimulation and electrolytic lesions of the subthalamic nucleus upon striatal extracellular glutamate levels in awake rats, either intact or which had undergone unilateral 6-hydroxydopamine lesions. Two hours of subthalamic nucleus stimulation had no effect in either group. Subthalamic nucleus lesions of intact animals increased striatal glutamate levels. Subthalamic nucleus lesions of 6-hydroxydopamine-lesioned rats decreased striatal glutamate levels. As dopamine depletion alone increased striatal glutamate, subthalamic nucleus lesioning decreased levels to normal. Thus, subthalamic nucleus lesions and short-term stimulation have different effects upon striatal glutamate. The effects of lesions differed depending upon the presence of dopamine. These results suggest that short-term electrical stimulation does not result in a direct inhibitory effect upon the subthalamic nucleus. NeuroReport 20:770-775 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Walker, Ruth H.; Koch, Rick J.] James J Peters Vet Adm Med Ctr, Dept Neurol, Bronx, NY 10468 USA.
[Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA.
[Sweeney, John E.; Moore, Cynthia; Meshul, Charles K.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Neurocytol Lab, Res Serv, Portland, OR 97201 USA.
[Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci & Pathol, Portland, OR 97201 USA.
RP Walker, RH (reprint author), James J Peters Vet Adm Med Ctr, Dept Neurol, 130 W Kingsbridge Rd 127, Bronx, NY 10468 USA.
EM ruth.walker@mssm.edu
FU Parkinson's Disease Foundation International Research Grant; Veterans
Affairs Merit awards
FX This study was supported by a Parkinson's Disease Foundation
International Research Grant to R.H.W and by Veterans Affairs Merit
awards to R.H.W and C.K.M.
NR 25
TC 19
Z9 20
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-4965
J9 NEUROREPORT
JI Neuroreport
PD MAY 27
PY 2009
VL 20
IS 8
BP 770
EP 775
DI 10.1097/WNR.0b013e32832ad556
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 446UP
UT WOS:000266147100007
PM 19373115
ER
PT J
AU Ebrahimi, R
Dyke, C
Mehran, R
Manoukian, SV
Feit, F
Cox, DA
Gersh, BJ
Ohman, EM
White, HD
Moses, JW
Ware, JH
Lincoff, AM
Stone, GW
AF Ebrahimi, Ramin
Dyke, Cornelius
Mehran, Roxana
Manoukian, Steven V.
Feit, Frederick
Cox, David A.
Gersh, Bernard J.
Ohman, E. Magnus
White, Harvey D.
Moses, Jeffrey W.
Ware, James H.
Lincoff, A. Michael
Stone, Gregg W.
TI Outcomes Following Pre-Operative Clopidogrel Administration in Patients
With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery
The ACUITY (Acute Catheterization and Urgent Intervention Triage
strategY) Trial
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE coronary artery bypass surgery; clopidogrel; acute coronary syndromes
ID ST-SEGMENT ELEVATION; UNSTABLE ANGINA; MYOCARDIAL-INFARCTION; ASPIRIN;
REVASCULARIZATION; COMBINATION; MANAGEMENT; BENEFITS; IMPACT; CURE
AB Objectives This study sought to evaluate the impact of upstream clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) requiring coronary artery bypass grafting (CABG) from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Background Despite benefits of clopidogrel in patients with NSTE-ACS undergoing percutaneous coronary intervention, this agent is often not administered upstream (before angiography) as recommended by the American College of Cardiology/American Heart Association guidelines because of potential bleeding in the minority of patients who require CABG.
Methods The ACUITY trial enrolled 13,819 patients with NSTE-ACS undergoing early invasive management. The timing of clopidogrel initiation was per investigator discretion. A 5-day washout period before CABG was recommended for patients having received clopidogrel.
Results Of 13,819 patients enrolled, 1,539 (11.1%) underwent CABG before discharge. Clopidogrel-exposed patients had a longer median duration of hospitalization (12.0 days vs. 8.9 days, p < 0.0001), but fewer adverse composite ischemic events (death, myocardial infarction, or unplanned revascularization) at 30 days; 12.7% vs. 17.3%, p = 0.01), with nonsignificantly different rates of non-CABG-related major bleeding (3.4% vs. 3.2%, p = 0.87) and post-CABG major bleeding (50.3% vs. 50.9%, p = 0.83) compared with those patients not administered clopidogrel. By multivariable analysis, clopidogrel use before CABG was an independent predictor of reduced 30-day composite ischemia (odds ratio: 0.67, 95% confidence interval: 0.48 to 0.92, p = 0.001) but not of increased post-CABG major bleeding (odds ratio: 0.98, 95% confidence interval: 0.80 to 1.19, p = 0.80).
Conclusions Clopidogrel administration before catheterization in patients with NSTE-ACS requiring CABG is associated with significantly fewer 30-day adverse ischemic events without significantly increasing major bleeding, compared to withholding clopidogrel until after angiography. These findings support the American College of Cardiology/American Heart Association guidelines for upstream clopidogrel administration in all NSTE-ACS patients, including those who subsequently undergo CABG. (Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes [ACS]; NCT00093158). (J Am Coll Cardiol 2009; 53: 1965-72) c 2009 by the American College of Cardiology Foundation
C1 [Ebrahimi, Ramin] Greater Los Angeles VA Med Ctr, Dept Med, Cardiol Sect 111E, Los Angeles, CA 90073 USA.
[Ebrahimi, Ramin] Univ Calif Los Angeles, Los Angeles, CA 90073 USA.
[Dyke, Cornelius] Gaston Mem Hosp, Gastonia, NC USA.
[Mehran, Roxana; Moses, Jeffrey W.; Stone, Gregg W.] Columbia Univ, Med Ctr, New York, NY USA.
[Mehran, Roxana; Stone, Gregg W.] Cardiovas Res Fdn, New York, NY USA.
[Manoukian, Steven V.] Sarah Cannon Res Inst, Nashville, TN USA.
[Manoukian, Steven V.] Centennial Heart Ctr, Nashville, TN USA.
[Feit, Frederick] NYU, Sch Med, New York, NY USA.
[Cox, David A.] Lehigh Valley Hosp, Allentown, PA USA.
[Gersh, Bernard J.] Mayo Clin, Rochester, MN USA.
[Ohman, E. Magnus] Duke Univ, Med Ctr, Durham, NC USA.
[White, Harvey D.] Auckland City Hosp, Auckland, New Zealand.
[Ware, James H.] Harvard Univ, Boston, MA 02115 USA.
[Lincoff, A. Michael] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
RP Ebrahimi, R (reprint author), Greater Los Angeles VA Med Ctr, Dept Med, Cardiol Sect 111E, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM ebrahimi@UCLA.edu
NR 19
TC 86
Z9 94
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAY 26
PY 2009
VL 53
IS 21
BP 1965
EP 1972
DI 10.1016/j.jacc.2009.03.006
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 448BP
UT WOS:000266236800005
PM 19460609
ER
PT J
AU Tyner, JW
Deininger, MW
Loriaux, MM
Chang, BH
Gotlib, JR
Willis, SG
Erickson, H
Kovacsovics, T
O'Hare, T
Heinrich, MC
Druker, BJ
AF Tyner, Jeffrey W.
Deininger, Michael W.
Loriaux, Marc M.
Chang, Bill H.
Gotlib, Jason R.
Willis, Stephanie G.
Erickson, Heidi
Kovacsovics, Tibor
O'Hare, Thomas
Heinrich, Michael C.
Druker, Brian J.
TI RNAi screen for rapid therapeutic target identification in leukemia
patients
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE acute lymphoblastic leukemia; acute myeloid leukemia; chronic
myelomonocytic leukemia; molecular diagnosis; personalized medicine
ID ACUTE MYELOID-LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE
LYMPHOBLASTIC-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; GROWTH-FACTOR
RECEPTOR; TYROSINE KINASE ROR1; CELL LUNG-CANCER; ACTIVATING MUTATION;
SOMATIC MUTATIONS; FOLLOW-UP
AB Targeted therapy has vastly improved outcomes in certain types of cancer. Extension of this paradigm across a broad spectrum of malignancies will require an efficient method to determine the molecular vulnerabilities of cancerous cells. Improvements in sequencing technology will soon enable high-throughput sequencing of entire genomes of cancer patients; however, determining the relevance of identified sequence variants will require complementary functional analyses. Here, we report an RNAi-assisted protein target identification (RAPID) technology that individually assesses targeting of each member of the tyrosine kinase gene family. We demonstrate that RAPID screening of primary leukemia cells from 30 patients identifies targets that are critical to survival of the malignant cells from 10 of these individuals. We identify known, activating mutations in JAK2 and K-RAS, as well as patient-specific sensitivity to down-regulation of FLT1, CSF1R, PDGFR, ROR1, EPHA4/5, JAK1/3, LMTK3, LYN, FYN, PTK2B, and N-RAS. We also describe a previously undescribed, somatic, activating mutation in the thrombopoietin receptor that is sensitive to downstream pharmacologic inhibition. Hence, the RAPID technique can quickly identify molecular vulnerabilities in malignant cells. Combination of this technique with whole-genome sequencing will represent an ideal tool for oncogenic target identification such that specific therapies can be matched with individual patients.
C1 [Tyner, Jeffrey W.; Deininger, Michael W.; Loriaux, Marc M.; Willis, Stephanie G.; Erickson, Heidi; Kovacsovics, Tibor; O'Hare, Thomas; Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97239 USA.
[Loriaux, Marc M.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA.
[Chang, Bill H.] Oregon Hlth & Sci Univ, Dept Pediat, Div Pediat Hematol & Oncol, Portland, OR 97239 USA.
[Gotlib, Jason R.] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA.
[O'Hare, Thomas; Druker, Brian J.] Howard Hughes Med Inst, Portland, OR 97239 USA.
[Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Druker, BJ (reprint author), Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97239 USA.
EM drukerb@ohsu.edu
OI Chang, Bill/0000-0003-3783-1820; Tyner, Jeffrey/0000-0002-2133-0960
FU Leukemia and Lymphoma Society; T.J. Martell Foundation; Doris Duke
Charitable Foundation; National Institutes of Health Roadmap for Medical
Research; National Institutes of Health Cancer Biology Training; William
Lawrence and Blanche Hughes Fund; Oregon Clinical and Translational
Research Institute; National Center for Research Resources [UL1
RR024140]; Veterans Affairs Merit Review grant; Oregon Health & Science
University (OHSU) [5 p30 CA069533]
FX This work is supported in part by The Leukemia and Lymphoma Society, the
T.J. Martell Foundation, and the Doris Duke Charitable Foundation. J. W.
T. is supported by the National Institutes of Health Roadmap for Medical
Research, by grants from the National Institutes of Health Cancer
Biology Training, and from the William Lawrence and Blanche Hughes Fund,
and by the Oregon Clinical and Translational Research Institute Grant
UL1 RR024140 from the National Center for Research Resources. M. C. H.
is supported in part by a Veterans Affairs Merit Review grant. B. J. D.
is an investigator of the Howard Hughes Medical Institute and prinicipal
investigator of the Oregon Health & Science University (OHSU) Cancer
Center Support Grant 5 p30 CA069533.
NR 42
TC 58
Z9 59
U1 0
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 26
PY 2009
VL 106
IS 21
BP 8695
EP 8700
DI 10.1073/pnas.0903233106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 450WS
UT WOS:000266432700052
PM 19433805
ER
PT J
AU Pollack, CE
Armstrong, K
AF Pollack, Craig Evan
Armstrong, Katrina
TI The Geographic Accessibility of Retail Clinics for Underserved
Populations
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID CARE
AB Background: The extent to which retail clinics provide access to care for underserved populations remains largely unknown. The purpose of this study was to determine whether retail clinics tend to be located in census tracts with higher medical need.
Methods: The locations of retail clinics as of July 1, 2008, were mapped and linked to the 2000 US Census and 2008 Health Resources and Services Administration data. Bi-variate analyses and logistic regression models with random effects were used to compare the characteristics of census tracts with and without retail clinics. To determine whether retail clinics followed the underlying distribution of chain stores, the location of clinics conditional on there being a chain store was analyzed in 6 counties.
Results: Of the 932 retail clinics, 930 were successfully mapped. Eighteen states had no retail clinics, and 17 states had 25 or more clinics. Within counties with at least 1 retail clinic, census tracts with retail clinics had a lower black population percentage, lower poverty rates, and higher median incomes and were less likely to be medically underserved areas/populations compared with census tracts without retail clinics. Similarly, stores with retail clinics were less likely to be located in medically underserved areas compared with stores without retail clinics.
Conclusion: Retail clinics are currently located in more advantaged neighborhoods, which may make them less accessible for those most in need. Arch Intern Med. 2009; 169(10): 945-949
C1 [Pollack, Craig Evan] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA.
[Pollack, Craig Evan; Armstrong, Katrina] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Armstrong, Katrina] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Armstrong, Katrina] Univ Penn, Div Gen Internal Med, Sch Med, Philadelphia, PA 19104 USA.
[Pollack, Craig Evan] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Pollack, CE (reprint author), Univ Penn, Robert Wood Johnson Clin Scholars Program, 1303B Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM craige@mail.med.upenn.edu
FU Robert Wood Johnson Foundation Clinical Scholars Program
FX Funding/Support: The Robert Wood Johnson Foundation Clinical Scholars
Program at the University of Pennsylvania provided funding for this
research.
NR 20
TC 29
Z9 29
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAY 25
PY 2009
VL 169
IS 10
BP 945
EP 949
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 449AZ
UT WOS:000266304500006
PM 19468086
ER
PT J
AU Singh, H
Mani, S
Espadas, D
Petersen, N
Franklin, V
Petersen, LA
AF Singh, Hardeep
Mani, Shrinidi
Espadas, Donna
Petersen, Nancy
Franklin, Veronica
Petersen, Laura A.
TI Prescription Errors and Outcomes Related to Inconsistent Information
Transmitted Through Computerized Order Entry A Prospective Study
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID ADVERSE DRUG EVENTS; HEALTH-CARE; UNINTENDED CONSEQUENCES; MEDICATION
ERRORS; SYSTEMS; TECHNOLOGY; PREVENTION; CPOE
AB Background: Although several types of computerized provider order entry (CPOE)-related errors may occur, errors related to inconsistent information within the same prescription (ie, mismatch between the structured template and the associated free-text field) have not been described, to our knowledge. We determined the nature and frequency of such errors and identified their potential predictive variables.
Methods: In this prospective study, we enrolled pharmacists to report prescriptions containing inconsistent communication over a 4-month period at a tertiary care facility. We also electronically retrieved all prescriptions written during the study period containing any comments in the free-text field and then randomly selected 500 for manual review to determine inconsistencies between free-text and structured fields. Of these, prescriptions without inconsistencies were categorized as controls. Data on potentially predictive variables from reported and unreported errors and controls were collected. For all inconsistencies, we determined their nature (eg, drug dosage or administration schedule) and potential harm and used multivariate logistic regression models to identify factors associated with errors and harm.
Results: Of 55 992 new prescriptions, 532 (0.95%) were reported to contain inconsistent communication, a rate comparable to that obtained from the unreported group. Drug dosage was the most common inconsistent element among both groups. Certain medications were more likely associated with errors, as was the inpatient setting (odds ratio, 3.30; 95% confidence interval, 2.18-5.00) and surgical subspecialty (odds ratio, 2.45; 95% confidence interval, 1.57-3.82). About 20% of errors could have resulted in moderate to severe harm, for which significant independent predictors were found.
Conclusions: Despite standardization of data entry, inconsistent communication in CPOE poses a significant risk to safety. Improving the usability of the CPOE interface and integrating it with workflow may reduce this risk. Arch Intern Med. 2009; 169(10): 982-989
C1 [Singh, Hardeep; Mani, Shrinidi; Espadas, Donna; Petersen, Nancy; Petersen, Laura A.] Baylor Coll Med, Houston Vet Affairs Hlth Serv Res & Dev VA HSR&D, Houston, TX 77030 USA.
[Singh, Hardeep; Mani, Shrinidi; Espadas, Donna; Petersen, Nancy; Petersen, Laura A.] Baylor Coll Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Houston, TX 77030 USA.
[Franklin, Veronica] Baylor Coll Med, Pharm Sect, Houston, TX 77030 USA.
[Singh, Hardeep; Petersen, Nancy; Petersen, Laura A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Singh, Hardeep; Petersen, Nancy; Petersen, Laura A.] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA.
RP Singh, H (reprint author), Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.tmc.edu
FU Veterans Affairs National Center for Patient Safety; National Institutes
of Health [K23CA125585]; Houston VA HSR&D Center of Excellence
[HFP90-020]
FX Funding/Support: This study was supported by the Veterans Affairs
National Center for Patient Safety; National Institutes of Health K23
career development award K23CA125585 (Dr Singh); and in part by grant
HFP90-020 from the Houston VA HSR&D Center of Excellence (Dr L. A.
Petersen).
NR 32
TC 45
Z9 49
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAY 25
PY 2009
VL 169
IS 10
BP 982
EP 989
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 449AZ
UT WOS:000266304500012
PM 19468092
ER
PT J
AU Jones, CCB
Kreklywich, CN
Messaoudi, I
Vomaske, J
McCartney, E
Orloff, SL
Nelson, JA
Streblow, DN
AF Jones, Carmen C. Baca
Kreklywich, Craig N.
Messaoudi, Illhem
Vomaske, Jennifer
McCartney, Erin
Orloff, Susan L.
Nelson, Jay A.
Streblow, Daniel N.
TI Rat cytomegalovirus infection depletes MHC II in bone marrow derived
dendritic cells
SO VIROLOGY
LA English
DT Article
DE Dendritic cells; Viral; MHC; Antigen presentation/processing;
Cytomegalovirus
ID MURINE CYTOMEGALOVIRUS; MOUSE CYTOMEGALOVIRUS; ANTIGEN PRESENTATION;
ENCODED INTERLEUKIN-10; INHIBITS MATURATION; T-CELLS; HLA-DR;
GLYCOPROTEIN; EXPRESSION; MOLECULES
AB While cytomegalovirus (CMV) infects and replicates in a Multitude of cell types, the ability of the virus to replicate in antigen presenting cells (APCs) is believed to play a critical role in the viral dissemination and latency. CMV infection of APCs and manipulation of their function are important areas of investigation. CMV down regulation of MHC 11 is reportedly mediated by the HCMV proteins US2, US3, UL83, UL111a (vIL10) or through the induction of cellular IL10. In this study, we demonstrate that rat CMV (RCMV) significantly reduces MHC 11 expression neither by mechanisms that do not involve orthologues of the known HCMV genes nor by an increase in cellular IL10. Rat bone marrow derived dendritic cells (BMDC) were highly Susceptible to infection with RCMV and a recombinant RCMV expressing eGFP. RCMV infection of BMDCs depleted both Surface and intracellular MHC 11 to nearly undetectable levels as well as reduced surface expression of MHC 1. The effect on MHC If only occurred in the infected GFP positive cells and is mediated by an immediate early or early viral gene product. Furthermore, treatment of uninfected immature DCs with virus-free conditioned supernatants from infected cells failed to down regulate MHC II. RCMV depletion of MHC II was sensitive to treatment with lysosomal inhibitors but not proteasomal inhibitors Suggesting that the mechanism of RCMV-mediated down regulation of MHC II Occurs through endocytic degradation. Since RCMV does not encode homologues of US2, US3, UL83 or UL111a, these data indicate a novel mechanism for RCMV depletion of MHC II. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Jones, Carmen C. Baca; Messaoudi, Illhem; Vomaske, Jennifer; McCartney, Erin; Orloff, Susan L.; Nelson, Jay A.; Streblow, Daniel N.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA.
[Jones, Carmen C. Baca; Messaoudi, Illhem; Vomaske, Jennifer; McCartney, Erin; Orloff, Susan L.; Nelson, Jay A.; Streblow, Daniel N.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
[Kreklywich, Craig N.; Orloff, Susan L.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97239 USA.
[Orloff, Susan L.] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Streblow, DN (reprint author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 SW 185th, Beaverton, OR 97006 USA.
EM streblow@ohsu.edu
NR 45
TC 3
Z9 3
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAY 25
PY 2009
VL 388
IS 1
BP 78
EP 90
DI 10.1016/j.virol.2009.02.050
PG 13
WC Virology
SC Virology
GA 448UY
UT WOS:000266288700010
ER
PT J
AU Venkatachalam, K
Venkatesan, B
Valente, AJ
Melby, PC
Nandish, S
Reusch, JEB
Clark, RA
Chandrasekar, B
AF Venkatachalam, Kaliyamurthi
Venkatesan, Balachandar
Valente, Anthony J.
Melby, Peter C.
Nandish, Sailesh
Reusch, Jane E. B.
Clark, Robert A.
Chandrasekar, Bysani
TI WISP1, a Pro-mitogenic, Pro-survival Factor, Mediates Tumor Necrosis
Factor-alpha (TNF-alpha)-stimulated Cardiac Fibroblast Proliferation but
Inhibits TNF-alpha-induced Cardiomyocyte Death
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ELEMENT-BINDING PROTEIN; NF-KAPPA-B; ACUTE MYOCARDIAL-INFARCTION;
MUSCLE-CELL MIGRATION; TISSUE GROWTH-FACTOR; INFLAMMATORY CYTOKINES;
CREB PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ACTIVATED PROTEIN;
HEART-FAILURE
AB WNT1-inducible signaling pathway protein-1 (WISP1), a member of the CYR61/CTGF/Nov family of growth factors, can mediate cell growth, transformation, and survival. Previously we demonstrated that WISP1 is up-regulated in post-infarct heart, stimulates cardiac fibroblast proliferation, and is induced by the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Here we investigated (i) the localization of TNF-alpha and WISP1 in post-infarct heart, (ii) the mechanism of TNF-alpha-mediated WISP1 induction in primary human cardiac fibroblasts (CF), (iii) the role of WISP1 in TNF-alpha-mediated CF proliferation and collagen production, and (iv) the effects of WISP1 on TNF-alpha-mediated cardiomyocyte death. TNF-alpha and WISP1 expressions were increased in the border zones and non-ischemic remote regions of the post-ischemic heart. In CF, TNF-alpha potently induced WISP1 expression in cyclic AMP response element-binding protein (CREB)-dependent manner. TNF-alpha induced CREB phosphorylation in vitro and DNA binding and reporter gene activities in vivo. TNF-alpha induced CREB activation via ERK1/2, and inhibition of ERK1/2 and CREB blunted TNF-alpha-mediated WISP1 induction. Most importantly, WISP1 knockdown attenuated TNF-alpha stimulated collagen production and CF proliferation. Furthermore, WISP1 attenuated TNF-alpha-mediated cardiomyocyte death, thus demonstrating pro-mitogenic and pro-survival effects for WISP1 in myocardial constituent cells. Our results suggest that a TNF-alpha/WISP1 signaling pathway may contribute to post-infarct cardiac remodeling, a condition characterized by fibrosis and progressive cardiomyocyte loss.
C1 [Valente, Anthony J.; Melby, Peter C.; Nandish, Sailesh; Clark, Robert A.; Chandrasekar, Bysani] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Venkatachalam, Kaliyamurthi; Venkatesan, Balachandar; Melby, Peter C.; Clark, Robert A.; Chandrasekar, Bysani] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA.
[Reusch, Jane E. B.] Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol Metab & Diabet, Aurora, CO 80110 USA.
[Reusch, Jane E. B.] Denver Vet Affairs Med Ctr, Vet Affairs Res Serv, Denver, CO 80220 USA.
RP Chandrasekar, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM chandraseka@uthscsa.edu
FU Research Service of the Department of Veterans Affairs
FX This work was supported in part by the Research Service of the
Department of Veterans Affairs.
NR 66
TC 53
Z9 56
U1 1
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 22
PY 2009
VL 284
IS 21
BP 14414
EP 14427
DI 10.1074/jbc.M809757200
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 448TY
UT WOS:000266286100048
PM 19339243
ER
PT J
AU He, WJ
Marconi, VC
Castiblanco, J
Kulkarni, H
Clark, RA
Dolan, MJ
Weiss, RA
Ahuja, SK
AF He, Weijing
Marconi, Vincent C.
Castiblanco, John
Kulkarni, Hemant
Clark, Robert A.
Dolan, Matthew J.
Weiss, Robin A.
Ahuja, Sunil K.
TI Response: Association of Duffy Antigen Genotypes with HIV-AIDS
Susceptibility
SO CELL HOST & MICROBE
LA English
DT Letter
ID INFECTION
C1 [Marconi, Vincent C.; Dolan, Matthew J.] USAF, Infect Dis Serv, Med Ctr, Lackland AFB, TX 78236 USA.
[He, Weijing; Castiblanco, John; Kulkarni, Hemant; Clark, Robert A.; Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX 78229 USA.
[He, Weijing; Castiblanco, John; Kulkarni, Hemant; Clark, Robert A.; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Marconi, Vincent C.] Uniformed Serv Univ Hlth Sci, IDCRP, Bethesda, MD 20814 USA.
[Marconi, Vincent C.; Dolan, Matthew J.] SAMMC, Ft Sam Houston, TX 78234 USA.
[Marconi, Vincent C.; Dolan, Matthew J.] SAMMC, Lackland AFB, TX 78234 USA.
[Dolan, Matthew J.] USAF, Henry M Jackson Fdn, Med Ctr, Lackland AFB, TX 78236 USA.
[Weiss, Robin A.] UCL, Div Infect & Immun, London W1T 4JF, England.
RP Dolan, MJ (reprint author), USAF, Infect Dis Serv, Med Ctr, Wilford Hall, Lackland AFB, TX 78236 USA.
EM matthew.dolan@lackland.af.mil; r.weiss@ucl.ac.uk; ahujas@uthscsa.edu
RI CASTIBLANCO, JOHN/B-6599-2009; Marconi, Vincent/N-3210-2014
OI CASTIBLANCO, JOHN/0000-0002-7965-9822; Marconi,
Vincent/0000-0001-8409-4689; CASTIBLANCO, JOHN/0000-0003-2556-3697
NR 10
TC 7
Z9 7
U1 0
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1931-3128
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD MAY 21
PY 2009
VL 5
IS 5
BP 418
EP 419
DI 10.1016/j.chom.2009.05.007
PG 2
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 450RZ
UT WOS:000266419800006
ER
PT J
AU Weaver, FM
Rothlind, J
Stern, M
AF Weaver, Frances M.
Rothlind, Johannes
Stern, Matthew
TI Deep Brain Stimulation for Patients With Advanced Parkinson Disease
Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID DEMENTIA; PD
C1 [Rothlind, Johannes] San Francisco VA Med Ctr, San Francisco, CA USA.
[Stern, Matthew] Univ Penn, Philadelphia, PA 19104 USA.
EM frances.weaver@va.gov
NR 5
TC 0
Z9 0
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 20
PY 2009
VL 301
IS 19
BP 1985
EP 1986
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 446YU
UT WOS:000266159600012
ER
PT J
AU Bergman, J
Saigal, CS
Miller, DC
Hanley, J
Gore, JL
Lorenz, K
Litwin, MS
AF Bergman, J.
Saigal, C. S.
Miller, D. C.
Hanley, J.
Gore, J. L.
Lorenz, K.
Litwin, M. S.
CA Urol Dis Amer Project
TI Hospice utilization by men dying of prostate cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Univ Calif Los Angeles, Los Angeles, CA USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
RAND Corp, Santa Monica, CA USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 9501
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606121
PM 27964452
ER
PT J
AU Heinrich, MC
Carden, R
Griffith, D
Liang, C
Marino-Enriquez, A
McKinley, A
Presnell, A
Fletcher, JA
AF Heinrich, M. C.
Carden, R.
Griffith, D.
Liang, C.
Marino-Enriquez, A.
McKinley, A.
Presnell, A.
Fletcher, J. A.
TI In vitro activity of sorafenib against imatinib- and sunitinib-resistant
kinase mutations associated with drug-resistant GI stromal tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Portland VA Med Ctr, Portland, OR USA.
OHSU, Knight Canc Inst, Portland, OR USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 2
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 10500
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606606563
PM 27963686
ER
PT J
AU Scher, K
Tisnado, DM
Rose-Ash, D
Rastegar, A
Adams, J
Ko, CY
Ganz, PA
Kahn, KL
AF Scher, K.
Tisnado, D. M.
Rose-Ash, D.
Rastegar, A.
Adams, J.
Ko, C. Y.
Ganz, P. A.
Kahn, K. L.
TI Physician and practice characteristics influencing tumor board
attendance: Results from the provider survey of the Los Angeles Women's
Health Study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 Vet Affairs Greater Los Angeles, Los Angeles, CA USA.
RAND Corp, Santa Monica, CA USA.
Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA e17501
PG 2
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606604482
PM 27963245
ER
PT J
AU Wasif, N
Tomlinson, JS
Maggard, MA
Giuliano, AE
Ko, CY
AF Wasif, N.
Tomlinson, J. S.
Maggard, M. A.
Giuliano, A. E.
Ko, C. Y.
TI Polypectomy or surgery for malignant colonic polyps: Do we need to
change the NCCN guidelines?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 29-JUN 02, 2009
CL Orlando, FL
SP Amer Soc Clin Oncol
C1 [Wasif, N.; Tomlinson, J. S.; Maggard, M. A.; Giuliano, A. E.; Ko, C. Y.] John Wayne Canc Inst, Santa Monica, CA USA.
[Wasif, N.; Tomlinson, J. S.; Maggard, M. A.; Giuliano, A. E.; Ko, C. Y.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
SU S
MA 4031
PG 1
WC Oncology
SC Oncology
GA 582OF
UT WOS:000276606600271
PM 27961549
ER
PT J
AU Hicks, GE
Morone, N
Weiner, DK
AF Hicks, Gregory E.
Morone, Natalia
Weiner, Debra K.
TI Degenerative Lumbar Disc and Facet Disease in Older Adults Prevalence
and Clinical Correlates
SO SPINE
LA English
DT Article
DE chronic low back pain; aging; degenerative disc disease; degenerative
facet disease
ID LOW-BACK-PAIN; TRUNK MUSCLE COMPOSITION; PHYSICAL FUNCTION;
BODY-COMPOSITION; DISABILITY; SPINE; HEALTH; ARTHROSIS; OSTEOARTHRITIS;
QUESTIONNAIRE
AB Study Design. A case-control study of older adults with and without chronic low back pain (CLBP).
Objective. Compare and describe the radiographic severity of degenerative disc and facet disease in the lumbosacral spine of community-dwelling older adults with and without CLBP and to examine the relationship between spinal pathology and pain.
Summary of Background Data. Degenerative spinal pathology is often implicated as the primary reason for CLBP in older adults. Despite evidence that spinal pathology may be ubiquitous in older adults regardless of pain status, radiography continues to be heavily used in the diagnostic process.
Methods. Participants in this case-control study included 162 older adults (>= 65) with CLBP and an age and gender matched pain-free group of 158 people. CLBP was characterized as pain of at least moderate intensity occurring daily or almost everyday for at least 3 months. Radiographic severity of disc and facet disease was graded using a reliable and valid system.
Results. Results demonstrated that the presence of degenerative disc and facet pathology in older adults is ubiquitous, regardless of clinical status, with greater than 90% demonstrating some level of degeneration. Higher radiographic severity scores were associated with the presence of CLBP. In fact, presence of severe disc pathology was associated with 2-fold greater odds of having CLBP. But, radiographic severity of disc and facet disease was not associated with pain severity among those with CLBP.
Conclusion. From a research perspective, radiographic evaluation of spinal pathology provides additional information about older adults with CLBP compared to pain-free individuals, but its clinical utility for diagnostic purposes is still in question.
C1 [Hicks, Gregory E.] Univ Delaware, Dept Phys Therapy, Newark, DE 19716 USA.
[Morone, Natalia] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA.
[Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
RP Hicks, GE (reprint author), Univ Delaware, Dept Phys Therapy, 303 McKinly Lab, Newark, DE 19716 USA.
EM ghicks@udel.edu
FU National Institute on Aging, National Institutes of Health
[R01AG018299]; NICHD [1K12HD055931-01]; National Center for Research
Resources (NCRR) [KL2 RR024154-03]
FX Supported by the National Institute on Aging, National Institutes of
Health with a research grant (R01AG018299). Supported by grant number
1K12HD055931-01 (NICHD) (to G. H.) and grant number KL2 RR024154-03 (to
N. M.) from the National Center for Research Resources (NCRR), a
component of the NIH and NIH Roadmap for Medical Research.
NR 35
TC 57
Z9 60
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0362-2436
J9 SPINE
JI SPINE
PD MAY 20
PY 2009
VL 34
IS 12
BP 1301
EP 1306
DI 10.1097/BRS.0b013e3181a18263
PG 6
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 447VQ
UT WOS:000266220500011
PM 19455005
ER
PT J
AU O'Hare, AM
Kaufman, JS
Covinsky, KE
Landefeld, CS
McFarland, LV
Larson, EB
AF O'Hare, Ann M.
Kaufman, James S.
Covinsky, Kenneth E.
Landefeld, C. Seth
McFarland, Lynne V.
Larson, Eric B.
TI Current Guidelines for Using Angiotensin-Converting Enzyme Inhibitors
and Angiotensin II-Receptor Antagonists in Chronic Kidney Disease: Is
the Evidence Base Relevant to Older Adults?
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; RANDOMIZED CONTROLLED TRIAL;
LEFT-VENTRICULAR HYPERTROPHY; DEPENDENT DIABETES-MELLITUS; CHRONIC
RENAL-INSUFFICIENCY; URINARY ALBUMIN EXCRETION; PLACEBO-CONTROLLED
TRIAL; NONDIABETIC NEPHROPATHIES; CARDIOVASCULAR OUTCOMES; HYPERTENSIVE
PATIENTS
AB Angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists are recommended for patients with chronic kidney disease because these drugs can slow disease progression. Older adults account for a large and growing number of patients with chronic kidney disease. The authors evaluated the relevance to adults older than 70 years of the evidence base for major U. S. practice guidelines for the use of these agents in chronic kidney disease. The authors first examined the representation of older adults in randomized trials that underpin these guidelines, then compared the characteristics of participants in these trials with those of a representative sample of older adults with chronic kidney disease in the general population. The authors found that current guidelines for the use of angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease are based on evidence with limited relevance to most persons older than 70 years with this condition.
C1 [O'Hare, Ann M.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98108 USA.
Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
Grp Hlth Ctr Hlth Studies, Seattle, WA USA.
Boston Univ, Sch Med, Boston, MA 02118 USA.
Vet Affairs Boston Healthcare Syst, Boston, MA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
RP O'Hare, AM (reprint author), Univ Washington, Dept Med, Div Nephrol, Bldg 100,Room 5B113,1660 S Columbian Way, Seattle, WA 98108 USA.
EM ann.ohare@va.gov
FU National Institute on Aging [K 1K23AG28980]
FX By a Beeson Career Development Award from the National Institute on
Aging to Dr. O'Hare (K 1K23AG28980).
NR 72
TC 70
Z9 78
U1 0
U2 0
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAY 19
PY 2009
VL 150
IS 10
BP 717
EP U12
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 448TQ
UT WOS:000266285300008
PM 19451579
ER
PT J
AU Hannibal, MC
Ruzzo, EK
Miller, LR
Betz, B
Buchan, JG
Knutzen, DM
Barnett, K
Landsverk, ML
Brice, A
LeGuern, E
Bedford, HM
Worrall, BB
Lovitt, S
Appel, SH
Andermann, E
Bird, TD
Chance, PF
AF Hannibal, M. C.
Ruzzo, E. K.
Miller, L. R.
Betz, B.
Buchan, J. G.
Knutzen, D. M.
Barnett, K.
Landsverk, M. L.
Brice, A.
LeGuern, E.
Bedford, H. M.
Worrall, B. B.
Lovitt, S.
Appel, S. H.
Andermann, E.
Bird, T. D.
Chance, P. F.
TI SEPT9 gene sequencing analysis reveals recurrent mutations in hereditary
neuralgic amyotrophy
SO NEUROLOGY
LA English
DT Article
ID MAMMALIAN SEPTIN; HEREDOFAMILIAL NEURITIS; BRACHIAL PREDILECTION;
CHROMOSOME 17Q; HNA LOCUS; NEUROPATHY; DATABASE; COMPLEX; REFINEMENT;
EXPRESSION
AB Background: Hereditary neuralgic amyotrophy (HNA) is an autosomal dominant disorder that manifests as recurrent, episodic, painful brachial neuropathies. A gene for HNA maps to chromosome 17q25.3 where mutations in SEPT9, encoding the septin-9 protein, have been identified.
Objective: To determine the frequency and type of mutations in the SEPT9 gene in a new cohort of 42 unrelated HNA pedigrees.
Methods: DNA sequencing of all exons and intron-exon boundaries for SEPT9 was carried out in an affected individual in each pedigree from our HNA cohort. Genotyping using microsatellite markers spanning the SEPT9 gene was also used to identify pedigrees with a previously reported founder haplotype.
Results: Two missense mutations were found: c.262C > T (p.Arg88Trp) in seven HNA pedigrees and c.278C > T (p.Ser93Phe) in one HNA pedigree. Sequencing of other known exons in SEPT9 detected no additional disease-associated mutations. A founder haplotype, without defined mutations in SEPT9, was present in seven pedigrees.
Conclusions: We provide further evidence that mutation of the SEPT9 gene is the molecular basis of some cases of hereditary neuralgic amyotrophy (HNA). DNA sequencing of SEPT9 demonstrates a restricted set of mutations in this cohort of HNA pedigrees. Nonetheless, sequence analysis will have an important role in mutation detection in HNA. Additional techniques will be required to find SEPT9 mutations in an HNA founder haplotype and other pedigrees. Neurology (R) 2009; 72: 1755-1759
C1 [Hannibal, M. C.] Univ Washington, Sch Med, Dept Pediat, Div Genet & Dev Med,Neurogenet Lab,Hlth Sci RR236, Seattle, WA 98195 USA.
[Bird, T. D.; Chance, P. F.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA.
[Bird, T. D.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Hannibal, M. C.; Chance, P. F.] Seattle Childrens Hosp, Seattle, WA USA.
[Bird, T. D.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Brice, A.; LeGuern, E.] Univ Paris 06, Pitie Salpetriere Hosp, AP HP,Pitie Salpetriere Med Sch, Dept Genet & Cytogenet,INSERM,UMR S679, Paris, France.
[Bedford, H. M.] N York Gen Hosp, Genet Programme, Toronto, ON, Canada.
[Worrall, B. B.] Univ Virginia Hlth Syst, Dept Neurol, Charlottesville, VA USA.
[Worrall, B. B.] Univ Virginia Hlth Syst, Dept Publ Hlth Sci, Charlottesville, VA USA.
[Lovitt, S.] Methodist Neurol Inst, Houston, TX USA.
[Andermann, E.] McGill Univ, Dept Neurol & Neurosurg, Neurogenet Unit, Montreal Neurol Hosp & Inst, Montreal, PQ H3A 2T5, Canada.
[Andermann, E.] McGill Univ, Dept Human Genet, Neurogenet Unit, Montreal Neurol Hosp & Inst, Montreal, PQ H3A 2T5, Canada.
[Appel, S. H.] Dept Neurol, Houston, TX USA.
RP Hannibal, MC (reprint author), Univ Washington, Sch Med, Dept Pediat, Div Genet & Dev Med,Neurogenet Lab,Hlth Sci RR236, 1959 NE Pacific St,Box 356320, Seattle, WA 98195 USA.
EM mhanni@u.washington.edu
FU NIH ( National Institute of Neurological Disorders and Stroke)
[NS38181]; The Neuropathy Association, New York, NY; Allan and Phyllis
Treuer Endowed Chair for Genetics and Development
FX Supported by funds from the NIH ( National Institute of Neurological
Disorders and Stroke), NS38181 ( P. F. C. and M. C. H.); The Neuropathy
Association, New York, NY ( M. C. H. and P. F. C.); and the Allan and
Phyllis Treuer Endowed Chair for Genetics and Development ( P. F. C.).
NR 36
TC 21
Z9 23
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD MAY 19
PY 2009
VL 72
IS 20
BP 1755
EP 1759
DI 10.1212/WNL.0b013e3181a609e3
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 447EB
UT WOS:000266173300008
PM 19451530
ER
PT J
AU Brousseau, KM
Filley, CM
Kaye, K
Kiser, JJ
Adler, LE
Connick, E
AF Brousseau, Kristin M.
Filley, Christopher M.
Kaye, Kathryn
Kiser, Jennifer J.
Adler, Lawrence E.
Connick, Elizabeth
TI Dementia with features of Alzheimer's disease and HIV-associated
dementia in an elderly man with AIDS
SO AIDS
LA English
DT Letter
C1 [Brousseau, Kristin M.; Filley, Christopher M.; Adler, Lawrence E.] Denver Vet Affairs Med Ctr, VISN 19, MIR ECC, Aurora, CO USA.
[Brousseau, Kristin M.; Filley, Christopher M.; Kaye, Kathryn; Adler, Lawrence E.; Connick, Elizabeth] Univ Colorado, Denver Sch Med, Aurora, CO USA.
[Kiser, Jennifer J.] Univ Colorado, Denver Sch Pharm, Aurora, CO USA.
[Brousseau, Kristin M.; Kiser, Jennifer J.; Connick, Elizabeth] Colorado Ctr AIDS Res, Aurora, CO USA.
RP Brousseau, KM (reprint author), Univ Colorado Hosp, Infect Dis Grp Practice, 1635 N Ursula St,Mail Stop B163, Aurora, CO 80045 USA.
EM Kristin.Brousseau@ucdenver.edu
NR 11
TC 3
Z9 3
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAY 15
PY 2009
VL 23
IS 8
BP 1029
EP 1031
DI 10.1097/QAD.0b013e32832ac380
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 446MH
UT WOS:000266125200021
PM 19414994
ER
PT J
AU McDonald, JR
Zeringue, AL
Caplan, L
Ranganathan, P
Xian, H
Burroughs, TE
Fraser, VJ
Cunningham, F
Eisen, SA
AF McDonald, Jay R.
Zeringue, Angelique L.
Caplan, Liron
Ranganathan, Prabha
Xian, Hong
Burroughs, Thomas E.
Fraser, Victoria J.
Cunningham, Fran
Eisen, Seth A.
TI Herpes Zoster Risk Factors in a National Cohort of Veterans with
Rheumatoid Arthritis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID ADVERSE DRUG-REACTIONS; ADMINISTRATIVE DATA; UNITED-STATES; INFECTION;
GUIDELINES; MANAGEMENT; AGREEMENT; ACCURACY; UPDATE; AGENTS
AB Background. Herpes zoster occurs more commonly in patients taking immunosuppressive medications, although the risk associated with different medications is poorly understood.
Methods. We conducted a retrospective cohort study involving 20,357 patients who were followed in the Veterans Affairs healthcare system and treated for rheumatoid arthritis from October 1998 through June 2005. Cox proportional hazards regression was used to determine risk factors for herpes zoster and herpes zoster-free survival. Chart review was performed to validate the diagnosis of herpes zoster.
Results. The incidence of herpes zoster was 9.96 episodes per 1000 patient-years. In time-to-event analysis, patients receiving medications used to treat mild rheumatoid arthritis were less likely to have an episode of herpes zoster than patients receiving medications used to treat moderate and severe rheumatoid arthritis (P < .001). Independent risk factors for herpes zoster included older age, prednisone use, medications used to treat moderate and severe rheumatoid arthritis, malignancy, chronic lung disease, renal failure, and liver disease. Among patients receiving tumor necrosis factor-alpha antagonists, etanercept (hazard ratio, 0.62) and adalimumab (hazard ratio, 0.53) were associated with a lower risk of herpes zoster. There was excellent agreement between the International Classification of Diseases, Version 9, Clinical Modification diagnosis of herpes zoster and diagnosis by chart review (kappa = 0.92).
Conclusions. Risk factors for herpes zoster included older age, prednisone use, medications used to treat moderate and severe rheumatoid arthritis, and several comorbid medical conditions. These results demonstrate that the Department of Veterans Affairs' national administrative databases can be used to study rare adverse drug events.
C1 [McDonald, Jay R.; Zeringue, Angelique L.; Xian, Hong; Eisen, Seth A.] St Louis Vet Affairs Med Ctr, St Louis, MO 63106 USA.
[McDonald, Jay R.; Zeringue, Angelique L.; Ranganathan, Prabha; Xian, Hong; Fraser, Victoria J.; Eisen, Seth A.] Washington Univ, St Louis, MO USA.
[Burroughs, Thomas E.] St Louis Univ, St Louis, MO 63103 USA.
[Caplan, Liron] Univ Colorado, Hlth Sci Ctr, Denver, CO USA.
[Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Cunningham, Fran] Vet Affairs Pharm Benefits Management, Hines, IL USA.
RP McDonald, JR (reprint author), St Louis Vet Affairs Med Ctr, Mail Code 111-JC,915 N Grand Blvd, St Louis, MO 63106 USA.
EM Jay.McDonald1@va.gov
RI Zeringue, Angelique/I-1755-2012
FU US Department of Veterans Affairs; Veterans Health Administration [IAF
06-026]; National Institutes of Health [K12RR023249, KL2RR024994]
FX Financial support. US Department of Veterans Affairs, Veterans Health
Administration (Health Services Research and Development Service project
IAF 06-026); and National Institutes of Health (K12RR023249 and
KL2RR024994).
NR 32
TC 105
Z9 109
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2009
VL 48
IS 10
BP 1364
EP 1371
DI 10.1086/598331
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 441DK
UT WOS:000265749300006
PM 19368499
ER
PT J
AU Schwartz, BS
Graber, CJ
Diep, BA
Basuino, L
Perdreau-Remington, F
Chambers, HF
AF Schwartz, Brian S.
Graber, Christopher J.
Diep, Binh A.
Basuino, Li
Perdreau-Remington, Francoise
Chambers, Henry F.
TI Doxycycline, Not Minocycline, Induces Its Own Resistance in
Multidrug-Resistant, Community-Associated Methicillin-Resistant
Staphylococcus aureus Clone USA300
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
ID TETRACYCLINE RESISTANCE; SKIN
C1 [Schwartz, Brian S.; Perdreau-Remington, Francoise; Chambers, Henry F.] Univ Calif San Francisco, Div Infect Dis, San Francisco, CA 94143 USA.
[Schwartz, Brian S.; Diep, Binh A.; Basuino, Li; Perdreau-Remington, Francoise; Chambers, Henry F.] San Francisco Gen Hosp, Div Infect Dis, San Francisco, CA USA.
[Graber, Christopher J.] Vet Affairs Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA.
RP Schwartz, BS (reprint author), Univ Calif San Francisco, Div Infect Dis, 513 Parnassus Ave,S-380, San Francisco, CA 94143 USA.
NR 6
TC 23
Z9 23
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2009
VL 48
IS 10
BP 1483
EP 1484
DI 10.1086/598510
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 441DK
UT WOS:000265749300026
PM 19374563
ER
PT J
AU Guthrie, CR
Schellenberg, GD
Kraemer, BC
AF Guthrie, Chris R.
Schellenberg, Gerard D.
Kraemer, Brian C.
TI SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PUROMYCIN-SENSITIVE AMINOPEPTIDASE; C-ELEGANS; FRONTOTEMPORAL DEMENTIA;
AGGRESOME FORMATION; MISFOLDED PROTEINS; ALZHEIMERS-DISEASE; PRION
PROTEIN; MUTATIONS; GENE; TAUOPATHY
AB Expression of human tau in Caenorhabditis elegans neurons causes accumulation of aggregated tau leading to neurodegeneration and uncoordinated movement. We used this model of human tauopathy disorders to screen for genes required for tau neurotoxicity. Recessive loss-of-function mutations in the sut-2 locus suppress the Unc phenotype, tau aggregation and neurodegenerative changes caused by human tau. We cloned the sut-2 gene and found it encodes a novel sub-type of CCCH zinc finger protein conserved across animal phyla. SUT-2 shares significant identity with the mammalian SUT-2 (MSUT-2). To identify SUT-2 interacting proteins, we conducted a yeast two hybrid screen and found SUT-2 binds to ZYG-12, the sole C. elegans HOOK protein family member. Likewise, SUT-2 binds ZYG-12 in in vitro protein binding assays. Furthermore, loss of ZYG-12 leads to a marked upregulation of SUT-2 protein supporting the connection between SUT-2 and ZYG-12. The human genome encodes three homologs of ZYG-12: HOOK1, HOOK2 and HOOK3. Of these, the human ortholog of SUT-2 (MSUT-2) binds only to HOOK2 suggesting the interaction between SUT-2 and HOOK family proteins is conserved across animal phyla. The identification of sut-2 as a gene required for tau neurotoxicity in C. elegans may suggest new neuroprotective strategies capable of arresting tau pathogenesis in tauopathy disorders.
C1 [Guthrie, Chris R.; Schellenberg, Gerard D.; Kraemer, Brian C.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Guthrie, Chris R.; Schellenberg, Gerard D.; Kraemer, Brian C.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA.
[Schellenberg, Gerard D.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
RP Kraemer, BC (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, S182,1660 S Columbian Way, Seattle, WA 98108 USA.
EM kraemerb@u.washington.edu
FU Department of Veterans Affairs Merit Review; NIA [PO1 AG17586]
FX This work was supported by Department of Veterans Affairs Merit Review
Grant ( B. C. K.) and by NIA grant PO1 AG17586 ( G. D. S.).
NR 57
TC 47
Z9 54
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 15
PY 2009
VL 18
IS 10
BP 1825
EP 1838
DI 10.1093/hmg/ddp099
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 437ZJ
UT WOS:000265525400009
PM 19273536
ER
PT J
AU Sundararaj, KP
Samuvel, DJ
Li, YC
Sanders, JJ
Lopes-Virella, MF
Huang, Y
AF Sundararaj, Kamala P.
Samuvel, Devadoss J.
Li, Yanchun
Sanders, John J.
Lopes-Virella, Maria F.
Huang, Yan
TI Interleukin-6 Released from Fibroblasts Is Essential for Up-regulation
of Matrix Metalloproteinase-1 Expression by U937 Macrophages in
Coculture CROSS-TALKING BETWEEN FIBROBLASTS AND U937 MACROPHAGES EXPOSED
TO HIGH GLUCOSE
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PERIODONTAL-DISEASE; GINGIVAL FIBROBLASTS; TISSUE INHIBITOR;
GENE-EXPRESSION; KAPPA-B; COLLAGENASE; CELLS; HISTIOCYTES; INVOLVEMENT;
ACTIVATION
AB Matrix metalloproteinases (MMPs) play a key role in periodontal disease. Although it is known that macrophages and fibroblasts are co-localized and express MMPs in the diseased periodontal tissue, the effect of interaction between these two cell types on MMP expression has not been well elucidated. Furthermore although it is known that diabetes is associated with accelerated periodontal tissue destruction, it remains unknown whether hyperglycemia, a major metabolic abnormality in diabetes, regulates MMP expression by affecting the cross-talking between fibroblasts and macrophages. In this study, human gingival fibroblasts and U937 macrophages were cocultured in a two-compartment transwell culture system, and the cells were treated with normal or high glucose. We found that coculture of fibroblasts and U937 macrophages led to an augmentation of MMP-1 expression by U937 macrophages, and high glucose further enhanced this augmentation. Similar observations were also made in the coculture of fibroblasts and human primary monocytes. We also found that interleukin 6 (IL-6) released by fibroblasts was essential for the augmentation of MMP-1 expression by U937 macrophages. Furthermore our results showed that high glucose, IL-6, and lipopolysaccharide had a synergistic effect on MMP-1 expression. Finally our study indicated that MAPK pathways and activator protein-1 transcription factor were involved in the coculture- and high glucose-augmented MMP-1 expression. In conclusion, this study demonstrates that IL-6 derived from fibroblasts is essential for MMP-1 up-regulation by cross-talking between fibroblasts and U937 macrophages exposed to high glucose, revealing an IL-6-dependent mechanism in MMP-1 up-regulation.
C1 [Li, Yanchun; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29403 USA.
[Sundararaj, Kamala P.; Samuvel, Devadoss J.; Lopes-Virella, Maria F.; Huang, Yan] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA.
[Sanders, John J.] Med Univ S Carolina, Coll Dent Med, Dept Stomatol, Charleston, SC 29403 USA.
RP Huang, Y (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 114 Doughty St, Charleston, SC 29403 USA.
EM huangyan@musc.edu
FU National Institutes of Health [DE16353]; Department of Veterans Affairs
FX This work was supported, in whole or in part, by National Institutes of
Health Grant DE16353 (to Y. H.). This work was also supported by a merit
review grant from the Department of Veterans Affairs (to Y. H.).
NR 35
TC 41
Z9 41
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 15
PY 2009
VL 284
IS 20
BP 13714
EP 13724
DI 10.1074/jbc.M806573200
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 442YL
UT WOS:000265877300049
PM 19307187
ER
PT J
AU Dagda, RK
Cherra, SJ
Kulich, SM
Tandon, A
Park, D
Chu, CT
AF Dagda, Ruben K.
Cherra, Salvatore J., III
Kulich, Scott M.
Tandon, Anurag
Park, David
Chu, Charleen T.
TI Loss of PINK1 Function Promotes Mitophagy through Effects on Oxidative
Stress and Mitochondrial Fission
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DEPENDENT PROTEIN-KINASE; PARKINSONS-DISEASE; CELL-DEATH; RECESSIVE
PARKINSONISM; DOPAMINERGIC-NEURONS; ALZHEIMERS-DISEASE; MAMMALIAN-CELLS;
SH-SY5Y CELLS; AUTOPHAGY; MUTATIONS
AB Mitochondrial dysregulation is strongly implicated in Parkinson disease. Mutations in PTEN-induced kinase 1 (PINK1) are associated with familial parkinsonism and neuropsychiatric disorders. Although overexpressed PINK1 is neuroprotective, less is known about neuronal responses to loss of PINK1 function. We found that stable knockdown of PINK1 induced mitochondrial fragmentation and autophagy in SH-SY5Y cells, which was reversed by the reintroduction of an RNA interference (RNAi)-resistant plasmid for PINK1. Moreover, stable or transient overexpression of wild-type PINK1 increased mitochondrial interconnectivity and suppressed toxin-induced autophagy/mitophagy. Mitochondrial oxidant production played an essential role in triggering mitochondrial fragmentation and autophagy in PINK1 shRNA lines. Autophagy/mitophagy served a protective role in limiting cell death, and overexpressing Parkin further enhanced this protective mitophagic response. The dominant negative Drp1 mutant inhibited both fission and mitophagy in PINK1-deficient cells. Interestingly, RNAi knockdown of autophagy proteins Atg7 and LC3/Atg8 also decreased mitochondrial fragmentation without affecting oxidative stress, suggesting active involvement of autophagy in morphologic remodeling of mitochondria for clearance. To summarize, loss of PINK1 function elicits oxidative stress and mitochondrial turnover coordinated by the autophagic and fission/fusion machineries. Furthermore, PINK1 and Parkin may cooperate through different mechanisms to maintain mitochondrial homeostasis.
C1 [Dagda, Ruben K.; Cherra, Salvatore J., III; Kulich, Scott M.; Chu, Charleen T.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA.
[Chu, Charleen T.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA.
[Kulich, Scott M.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
[Tandon, Anurag] Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M55 3H2, Canada.
[Park, David] Univ Ottawa, Neurosci Grp, Ottawa Hlth Res Inst, Ottawa, ON K1H 8M5, Canada.
RP Chu, CT (reprint author), Univ Pittsburgh, Dept Pathol, 200 Lothrop St, Pittsburgh, PA 15261 USA.
EM ctc4@pitt.edu
RI Chu, Charleen/B-1601-2008
OI Chu, Charleen/0000-0002-5052-8271; Dagda, Ruben/0000-0002-9946-9591
FU National Institutes of Health [AG026389, DC009120, NS053777, F32
AG030821]; Pittsburgh Foundation, Emmerling Fund; American Parkinson
Disease Association; Veterans Administration Advanced Career Development
Award
FX Supported in part by National Institutes of Health Grant F32 AG030821.
NR 60
TC 397
Z9 403
U1 7
U2 52
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 15
PY 2009
VL 284
IS 20
BP 13843
EP 13855
DI 10.1074/jbc.M808515200
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 442YL
UT WOS:000265877300061
PM 19279012
ER
PT J
AU Brooks-Worrell, B
Warsen, A
Palmer, JP
AF Brooks-Worrell, Barbara
Warsen, Adelaide
Palmer, Jerfy P.
TI Improved T cell assay for identification of type 1 diabetes patients
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE Type 1 diabetes; Islet proteins; T cells; Immune monitoring; T cell
assay
ID IMMUNE-RESPONSES; ISLET PROTEINS; ANTIGENS; ANTIBODIES; MELLITUS;
LYMPHOCYTES; ONSET; PANCREAS; DISEASE; LYT-2+
AB Diabetes mellitus is comprised primarily of two clinically separate diseases: type 1 (T1D) and type 2 diabetes (T2D). T1D is a cell-mediated autoimmune disease directed against the beta cells and characterized by autoantibody (Ab) and T cell reactivity to islet proteins whereas, T2D is non-autoimmune. Despite the fact that the pathological process in autoimmune diabetes involves T cells, immune markers of diabetes have primarily centered on the presence of circulating serum islet autoantibodies. In two masked NIH sponsored workshops, our cellular immunoblotting T cell assay. which uses isolated human islets separated into 18 molecular weight fractions, has been validated to be able to distinguish T1D patients from controls with excellent specificity and sensitivity. In this study. we utilized the first workshop to select eight molecular weight fractions of human islets that were the most discriminatory between T1D patients and controls. Using these eight molecular weight fractions identified in the first workshop, we validated the preferential recognition of these 8 blot sections in a second workshop. We then re-calculated the sensitivity and specificity of the cellular immunoblotting assay for both workshops using only the data from these 8 blot sections. We observed increases in both sensitivity and specificity compared to the original workshop data for both workshops. The use of 8 instead of 18 molecular weight regions allows for a significant reduction in the amount of blood needed from patients, thus allowing cellular immunoblotting to be performed on pediatric patients participating in immunomodulatory studies. This improved T cell assay, which directly measures islet reactive T cell responses in autoimmune diabetes patients with excellent sensitivity and specificity, will likely improve patient follow-up during intervention studies. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Brooks-Worrell, Barbara; Warsen, Adelaide; Palmer, Jerfy P.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA.
RP Brooks-Worrell, B (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way,Bldg 1,Room 609, Seattle, WA 98108 USA.
EM bbrooks@u.washington.edu
FU National Institute of Health [P01-DK053004, P30-DK17047, M01-RR00037]
FX The following National Institute of Health grants provided partial
support: P01-DK053004, P30-DK17047, and M01-RR00037.
NR 28
TC 13
Z9 14
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD MAY 15
PY 2009
VL 344
IS 1
BP 79
EP 83
DI 10.1016/j.jim.2009.03.004
PG 5
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 452WW
UT WOS:000266572900010
PM 19328805
ER
PT J
AU Beckham, JD
Tuttle, K
Tyler, KL
AF Beckham, J. David
Tuttle, Kathryn
Tyler, Kenneth L.
TI Reovirus Activates Transforming Growth Factor beta and Bone
Morphogenetic Protein Signaling Pathways in the Central Nervous System
That Contribute to Neuronal Survival following Infection
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID WEST-NILE-VIRUS; INDUCED APOPTOSIS REQUIRES; NF-KAPPA-B; CELL-DEATH;
TGF-BETA; TISSUE-INJURY; JC VIRUS; IN-VITRO; REPLICATION; EXPRESSION
AB Viral infections of the central nervous system (CNS) are important causes of worldwide morbidity and mortality, and understanding how viruses perturb host cell signaling pathways will facilitate identification of novel antiviral therapies. We now show that reovirus infection activates transforming growth factor beta (TGF-beta) and bone morphogenetic protein (BMP) signaling in a murine model of encephalitis in vivo. TGF-beta receptor I (TGF-beta RI) expression is increased and its downstream signaling factor, SMAD3, is activated in the brains of reovirus-infected mice. TGF-beta signaling is neuroprotective, as inhibition with a TGF-beta RI inhibitor increases death of infected neurons. Similarly, BMP receptor I expression is increased and its downstream signaling factor, SMAD1, is activated in reovirus-infected neurons in the brains of infected mice in vivo. Activated SMAD1 and SMAD3 were both detected in regions of brain infected by reovirus, but activated SMAD1 was found predominantly in uninfected neurons in close proximity to infected neurons. Treatment of reovirus-infected primary mouse cortical neurons with a BMP agonist reduced apoptosis. These data provide the first evidence for the activation of TGF-beta and BMP signaling pathways following neurotropic viral infection and suggest that these signaling pathways normally function as part of the host's protective innate immune response against CNS viral infection.
C1 [Beckham, J. David; Tyler, Kenneth L.] Univ Colorado, Dept Med, Denver, CO 80045 USA.
[Tuttle, Kathryn; Tyler, Kenneth L.] Univ Colorado, Dept Neurol, Denver, CO 80045 USA.
[Tyler, Kenneth L.] Univ Colorado, Dept Microbiol, Denver, CO 80045 USA.
[Beckham, J. David; Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA.
RP Tyler, KL (reprint author), Univ Colorado Denver, Dept Neurol B182, 12700 E 19th Ave,Res Complex 2-5th Floor, Aurora, CO 80045 USA.
EM Ken.Tyler@uchsc.edu
OI Tyler, Kenneth/0000-0003-3294-5888
FU VA Career Development Award-2; NIH [5K08AI076518, 5R01NS050138,
1R01NS051403]
FX We express our thanks to Jennifer Smith Leser for technical support.
This work was supported in part by VA Career Development Award-2, VA
Merit funding, NIH 5K08AI076518, NIH 5R01NS050138, NIH 1R01NS051403, and
ASCI Young Investigator Award.
NR 45
TC 10
Z9 11
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAY 15
PY 2009
VL 83
IS 10
BP 5035
EP 5045
DI 10.1128/JVI.02433-08
PG 11
WC Virology
SC Virology
GA 436IS
UT WOS:000265407700030
PM 19279118
ER
EF